id	sid	tid	token	lemma	pos
chd-169	1	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	1	2	e1	e1	NOUN
chd-169	1	3	cancer	cancer	NOUN
chd-169	1	4	health	health	NOUN
chd-169	1	5	disparities	disparity	NOUN
chd-169	1	6	research	research	VERB
chd-169	1	7	psychosocial	psychosocial	ADJ
chd-169	1	8	stress	stress	NOUN
chd-169	1	9	,	,	PUNCT
chd-169	1	10	glucocorticoid	glucocorticoid	ADJ
chd-169	1	11	signaling	signaling	NOUN
chd-169	1	12	and	and	CCONJ
chd-169	1	13	prostate	prostate	NOUN
chd-169	1	14	cancer	cancer	NOUN
chd-169	1	15	health	health	NOUN
chd-169	1	16	disparities	disparity	NOUN
chd-169	1	17	in	in	ADP
chd-169	1	18	african	african	ADJ
chd-169	1	19	american	american	ADJ
chd-169	1	20	men	man	NOUN
chd-169	1	21	leanne	leanne	PROPN
chd-169	1	22	woods	wood	NOUN
chd-169	1	23	-	-	PUNCT
chd-169	1	24	burnham1	burnham1	PROPN
chd-169	1	25	,	,	PUNCT
chd-169	1	26	#	#	X
chd-169	1	27	,	,	PUNCT
chd-169	1	28	laura	laura	PROPN
chd-169	1	29	stiel2	stiel2	PROPN
chd-169	1	30	,	,	PUNCT
chd-169	1	31	shannalee	shannalee	PROPN
chd-169	1	32	r.	r.	PROPN
chd-169	1	33	martinez1	martinez1	PROPN
chd-169	1	34	,	,	PUNCT
chd-169	1	35	evelyn	evelyn	PROPN
chd-169	1	36	s.	s.	PROPN
chd-169	1	37	sanchez	sanchez	PROPN
chd-169	1	38	-	-	PUNCT
chd-169	1	39	hernandez1	hernandez1	PROPN
chd-169	1	40	,	,	PUNCT
chd-169	1	41	herbert	herbert	PROPN
chd-169	1	42	c.	c.	PROPN
chd-169	1	43	ruckle3	ruckle3	PROPN
chd-169	1	44	,	,	PUNCT
chd-169	1	45	frankis	frankis	PROPN
chd-169	1	46	g.	g.	PROPN
chd-169	1	47	almaguel1,4	almaguel1,4	PROPN
chd-169	1	48	,	,	PUNCT
chd-169	1	49	mariana	mariana	PROPN
chd-169	1	50	c.	c.	PROPN
chd-169	1	51	stern5	stern5	PROPN
chd-169	1	52	,	,	PUNCT
chd-169	1	53	lisa	lisa	PROPN
chd-169	1	54	r.	r.	PROPN
chd-169	1	55	roberts6	roberts6	PROPN
chd-169	1	56	,	,	PUNCT
chd-169	1	57	david	david	PROPN
chd-169	1	58	r.	r.	PROPN
chd-169	1	59	williams7	williams7	PROPN
chd-169	1	60	,	,	PUNCT
chd-169	1	61	susanne	susanne	PROPN
chd-169	1	62	montgomery1,,2	montgomery1,,2	PROPN
chd-169	1	63	,	,	PUNCT
chd-169	1	64	carlos	carlos	PROPN
chd-169	1	65	a.	a.	PROPN
chd-169	1	66	casiano1.8	casiano1.8	PROPN
chd-169	1	67	*	*	PROPN
chd-169	1	68	1center	1center	NUM
chd-169	1	69	for	for	ADP
chd-169	1	70	health	health	NOUN
chd-169	1	71	disparities	disparity	NOUN
chd-169	1	72	and	and	CCONJ
chd-169	1	73	molecular	molecular	ADJ
chd-169	1	74	medicine	medicine	NOUN
chd-169	1	75	and	and	CCONJ
chd-169	1	76	department	department	NOUN
chd-169	1	77	of	of	ADP
chd-169	1	78	basic	basic	ADJ
chd-169	1	79	sciences	science	NOUN
chd-169	1	80	,	,	PUNCT
chd-169	1	81	loma	loma	PROPN
chd-169	1	82	linda	linda	PROPN
chd-169	1	83	university	university	PROPN
chd-169	1	84	school	school	NOUN
chd-169	1	85	of	of	ADP
chd-169	1	86	medicine	medicine	NOUN
chd-169	1	87	,	,	PUNCT
chd-169	1	88	loma	loma	PROPN
chd-169	1	89	linda	linda	PROPN
chd-169	1	90	,	,	PUNCT
chd-169	1	91	ca	ca	PROPN
chd-169	1	92	,	,	PUNCT
chd-169	1	93	usa	usa	PROPN
chd-169	1	94	;	;	PUNCT
chd-169	1	95	2loma	2loma	NUM
chd-169	1	96	linda	linda	PROPN
chd-169	1	97	university	university	NOUN
chd-169	1	98	school	school	NOUN
chd-169	1	99	of	of	ADP
chd-169	1	100	behavioral	behavioral	ADJ
chd-169	1	101	health	health	NOUN
chd-169	1	102	,	,	PUNCT
chd-169	1	103	loma	loma	PROPN
chd-169	1	104	linda	linda	PROPN
chd-169	1	105	,	,	PUNCT
chd-169	1	106	ca	ca	PROPN
chd-169	1	107	,	,	PUNCT
chd-169	1	108	usa	usa	PROPN
chd-169	1	109	;	;	PUNCT
chd-169	1	110	3department	3department	NUM
chd-169	1	111	of	of	ADP
chd-169	1	112	surgical	surgical	ADJ
chd-169	1	113	urology	urology	NOUN
chd-169	1	114	,	,	PUNCT
chd-169	1	115	loma	loma	PROPN
chd-169	1	116	linda	linda	PROPN
chd-169	1	117	university	university	PROPN
chd-169	1	118	school	school	NOUN
chd-169	1	119	of	of	ADP
chd-169	1	120	medicine	medicine	NOUN
chd-169	1	121	,	,	PUNCT
chd-169	1	122	loma	loma	PROPN
chd-169	1	123	linda	linda	PROPN
chd-169	1	124	,	,	PUNCT
chd-169	1	125	ca	ca	PROPN
chd-169	1	126	,	,	PUNCT
chd-169	1	127	usa	usa	PROPN
chd-169	1	128	;	;	PUNCT
chd-169	1	129	4loma	4loma	NUM
chd-169	1	130	linda	linda	PROPN
chd-169	1	131	university	university	NOUN
chd-169	1	132	cancer	cancer	NOUN
chd-169	1	133	center	center	NOUN
chd-169	1	134	,	,	PUNCT
chd-169	1	135	loma	loma	PROPN
chd-169	1	136	linda	linda	PROPN
chd-169	1	137	,	,	PUNCT
chd-169	1	138	ca	ca	PROPN
chd-169	1	139	,	,	PUNCT
chd-169	1	140	usa	usa	PROPN
chd-169	1	141	;	;	PUNCT
chd-169	1	142	5departments	5departments	NUM
chd-169	1	143	of	of	ADP
chd-169	1	144	preventive	preventive	ADJ
chd-169	1	145	medicine	medicine	NOUN
chd-169	1	146	and	and	CCONJ
chd-169	1	147	urology	urology	NOUN
chd-169	1	148	,	,	PUNCT
chd-169	1	149	university	university	NOUN
chd-169	1	150	of	of	ADP
chd-169	1	151	southern	southern	PROPN
chd-169	1	152	california	california	PROPN
chd-169	1	153	keck	keck	PROPN
chd-169	1	154	school	school	PROPN
chd-169	1	155	of	of	ADP
chd-169	1	156	medicine	medicine	NOUN
chd-169	1	157	,	,	PUNCT
chd-169	1	158	los	los	PROPN
chd-169	1	159	angeles	angeles	PROPN
chd-169	1	160	,	,	PUNCT
chd-169	1	161	ca	ca	NOUN
chd-169	1	162	;	;	PUNCT
chd-169	1	163	6loma	6loma	NUM
chd-169	1	164	linda	linda	PROPN
chd-169	1	165	university	university	PROPN
chd-169	1	166	school	school	NOUN
chd-169	1	167	of	of	ADP
chd-169	1	168	nursing	nursing	NOUN
chd-169	1	169	,	,	PUNCT
chd-169	1	170	loma	loma	PROPN
chd-169	1	171	linda	linda	PROPN
chd-169	1	172	,	,	PUNCT
chd-169	1	173	ca	ca	PROPN
chd-169	1	174	,	,	PUNCT
chd-169	1	175	usa	usa	PROPN
chd-169	1	176	;	;	PUNCT
chd-169	1	177	7department	7department	NUM
chd-169	1	178	of	of	ADP
chd-169	1	179	social	social	ADJ
chd-169	1	180	and	and	CCONJ
chd-169	1	181	behavioral	behavioral	ADJ
chd-169	1	182	sciences	science	NOUN
chd-169	1	183	,	,	PUNCT
chd-169	1	184	harvard	harvard	PROPN
chd-169	1	185	university	university	PROPN
chd-169	1	186	school	school	NOUN
chd-169	1	187	of	of	ADP
chd-169	1	188	public	public	ADJ
chd-169	1	189	health	health	NOUN
chd-169	1	190	;	;	PUNCT
chd-169	1	191	8department	8department	NUM
chd-169	1	192	of	of	ADP
chd-169	1	193	medicine	medicine	NOUN
chd-169	1	194	,	,	PUNCT
chd-169	1	195	loma	loma	PROPN
chd-169	1	196	linda	linda	PROPN
chd-169	1	197	university	university	PROPN
chd-169	1	198	school	school	NOUN
chd-169	1	199	of	of	ADP
chd-169	1	200	medicine	medicine	NOUN
chd-169	1	201	,	,	PUNCT
chd-169	1	202	loma	loma	PROPN
chd-169	1	203	linda	linda	PROPN
chd-169	1	204	,	,	PUNCT
chd-169	1	205	ca	ca	PROPN
chd-169	1	206	,	,	PUNCT
chd-169	1	207	usa	usa	PROPN
chd-169	1	208	.	.	PROPN
chd-169	2	1	#	#	DET
chd-169	2	2	current	current	ADJ
chd-169	2	3	address	address	NOUN
chd-169	2	4	:	:	PUNCT
chd-169	2	5	city	city	NOUN
chd-169	2	6	of	of	ADP
chd-169	2	7	hope	hope	PROPN
chd-169	2	8	comprehensive	comprehensive	ADJ
chd-169	2	9	cancer	cancer	NOUN
chd-169	2	10	center	center	NOUN
chd-169	2	11	,	,	PUNCT
chd-169	2	12	department	department	NOUN
chd-169	2	13	of	of	ADP
chd-169	2	14	population	population	NOUN
chd-169	2	15	sciences	sciences	PROPN
chd-169	2	16	,	,	PUNCT
chd-169	2	17	division	division	NOUN
chd-169	2	18	of	of	ADP
chd-169	2	19	health	health	NOUN
chd-169	2	20	equities	equity	NOUN
chd-169	2	21	,	,	PUNCT
chd-169	2	22	1500	1500	NUM
chd-169	2	23	east	east	PROPN
chd-169	2	24	duarte	duarte	PROPN
chd-169	2	25	rd	rd	PROPN
chd-169	2	26	,	,	PUNCT
chd-169	2	27	duarte	duarte	PROPN
chd-169	2	28	ca	ca	PROPN
chd-169	2	29	91010	91010	NUM
chd-169	2	30	*	*	PUNCT
chd-169	2	31	corresponding	correspond	VERB
chd-169	2	32	author	author	NOUN
chd-169	2	33	:	:	PUNCT
chd-169	2	34	carlos	carlos	PROPN
chd-169	2	35	a.	a.	PROPN
chd-169	2	36	casiano	casiano	PROPN
chd-169	2	37	,	,	PUNCT
chd-169	2	38	email	email	NOUN
chd-169	2	39	:	:	PUNCT
chd-169	2	40	ccasiano@llu.edu	ccasiano@llu.edu	PROPN
chd-169	2	41	.	.	PUNCT
chd-169	3	1	abstract	abstract	ADJ
chd-169	3	2	:	:	PUNCT
chd-169	3	3	recent	recent	ADJ
chd-169	3	4	advances	advance	NOUN
chd-169	3	5	in	in	ADP
chd-169	3	6	our	our	PRON
chd-169	3	7	understanding	understanding	NOUN
chd-169	3	8	of	of	ADP
chd-169	3	9	racial	racial	ADJ
chd-169	3	10	disparities	disparity	NOUN
chd-169	3	11	in	in	ADP
chd-169	3	12	prostate	prostate	NOUN
chd-169	3	13	cancer	cancer	NOUN
chd-169	3	14	(	(	PUNCT
chd-169	3	15	pca	pca	NOUN
chd-169	3	16	)	)	PUNCT
chd-169	3	17	incidence	incidence	NOUN
chd-169	3	18	and	and	CCONJ
chd-169	3	19	mortality	mortality	NOUN
chd-169	3	20	that	that	PRON
chd-169	3	21	disproportionately	disproportionately	ADV
chd-169	3	22	affect	affect	VERB
chd-169	3	23	african	african	ADJ
chd-169	3	24	american	american	PROPN
chd-169	3	25	(	(	PUNCT
chd-169	3	26	aa	aa	NOUN
chd-169	3	27	)	)	PUNCT
chd-169	3	28	men	man	NOUN
chd-169	3	29	have	have	AUX
chd-169	3	30	provided	provide	VERB
chd-169	3	31	important	important	ADJ
chd-169	3	32	insights	insight	NOUN
chd-169	3	33	into	into	ADP
chd-169	3	34	the	the	DET
chd-169	3	35	psychosocial	psychosocial	ADJ
chd-169	3	36	,	,	PUNCT
chd-169	3	37	socioeconomic	socioeconomic	ADJ
chd-169	3	38	,	,	PUNCT
chd-169	3	39	environmental	environmental	ADJ
chd-169	3	40	,	,	PUNCT
chd-169	3	41	and	and	CCONJ
chd-169	3	42	molecular	molecular	ADJ
chd-169	3	43	contributors	contributor	NOUN
chd-169	3	44	.	.	PUNCT
chd-169	4	1	there	there	PRON
chd-169	4	2	is	be	VERB
chd-169	4	3	,	,	PUNCT
chd-169	4	4	however	however	ADV
chd-169	4	5	,	,	PUNCT
chd-169	4	6	limited	limited	ADJ
chd-169	4	7	mechanistic	mechanistic	ADJ
chd-169	4	8	knowledge	knowledge	NOUN
chd-169	4	9	of	of	ADP
chd-169	4	10	how	how	SCONJ
chd-169	4	11	the	the	DET
chd-169	4	12	interplay	interplay	NOUN
chd-169	4	13	between	between	ADP
chd-169	4	14	these	these	DET
chd-169	4	15	determinants	determinant	NOUN
chd-169	4	16	influences	influence	VERB
chd-169	4	17	prostate	prostate	NOUN
chd-169	4	18	tumor	tumor	NOUN
chd-169	4	19	aggressiveness	aggressiveness	NOUN
chd-169	4	20	in	in	ADP
chd-169	4	21	aa	aa	PROPN
chd-169	4	22	men	man	NOUN
chd-169	4	23	and	and	CCONJ
chd-169	4	24	other	other	ADJ
chd-169	4	25	men	man	NOUN
chd-169	4	26	of	of	ADP
chd-169	4	27	african	african	ADJ
chd-169	4	28	ancestry	ancestry	NOUN
chd-169	4	29	.	.	PUNCT
chd-169	5	1	growing	grow	VERB
chd-169	5	2	evidence	evidence	NOUN
chd-169	5	3	indicates	indicate	VERB
chd-169	5	4	that	that	SCONJ
chd-169	5	5	chronic	chronic	ADJ
chd-169	5	6	psychosocial	psychosocial	ADJ
chd-169	5	7	stress	stress	NOUN
chd-169	5	8	in	in	ADP
chd-169	5	9	aa	aa	PROPN
chd-169	5	10	populations	population	NOUN
chd-169	5	11	leads	lead	VERB
chd-169	5	12	to	to	ADP
chd-169	5	13	sustained	sustained	ADJ
chd-169	5	14	glucocorticoid	glucocorticoid	NOUN
chd-169	5	15	signaling	signal	VERB
chd-169	5	16	through	through	ADP
chd-169	5	17	the	the	DET
chd-169	5	18	glucocorticoid	glucocorticoid	ADJ
chd-169	5	19	receptor	receptor	NOUN
chd-169	5	20	(	(	PUNCT
chd-169	5	21	gr	gr	NOUN
chd-169	5	22	)	)	PUNCT
chd-169	5	23	,	,	PUNCT
chd-169	5	24	with	with	ADP
chd-169	5	25	negative	negative	ADJ
chd-169	5	26	physiological	physiological	ADJ
chd-169	5	27	and	and	CCONJ
chd-169	5	28	pathological	pathological	ADJ
chd-169	5	29	consequences	consequence	NOUN
chd-169	5	30	.	.	PUNCT
chd-169	6	1	compelling	compelling	ADJ
chd-169	6	2	evidence	evidence	NOUN
chd-169	6	3	indicates	indicate	VERB
chd-169	6	4	that	that	SCONJ
chd-169	6	5	treatment	treatment	NOUN
chd-169	6	6	of	of	ADP
chd-169	6	7	castration	castration	NOUN
chd-169	6	8	-	-	PUNCT
chd-169	6	9	resistant	resistant	ADJ
chd-169	6	10	prostate	prostate	NOUN
chd-169	6	11	cancer	cancer	NOUN
chd-169	6	12	(	(	PUNCT
chd-169	6	13	crpc	crpc	PROPN
chd-169	6	14	)	)	PUNCT
chd-169	6	15	with	with	ADP
chd-169	6	16	anti	anti	ADJ
chd-169	6	17	-	-	ADJ
chd-169	6	18	androgen	androgen	ADJ
chd-169	6	19	therapy	therapy	NOUN
chd-169	6	20	activates	activate	VERB
chd-169	6	21	gr	gr	NOUN
chd-169	6	22	signaling	signal	VERB
chd-169	6	23	.	.	PUNCT
chd-169	7	1	this	this	PRON
chd-169	7	2	enhanced	enhance	VERB
chd-169	7	3	gr	gr	NOUN
chd-169	7	4	signaling	signal	VERB
chd-169	7	5	bypasses	bypass	NOUN
chd-169	7	6	androgen	androgen	NOUN
chd-169	7	7	receptor	receptor	NOUN
chd-169	7	8	(	(	PUNCT
chd-169	7	9	ar	ar	NOUN
chd-169	7	10	)	)	PUNCT
chd-169	7	11	signaling	signal	VERB
chd-169	7	12	and	and	CCONJ
chd-169	7	13	transcriptionally	transcriptionally	ADV
chd-169	7	14	activates	activate	VERB
chd-169	7	15	both	both	DET
chd-169	7	16	ar	ar	NOUN
chd-169	7	17	-	-	NOUN
chd-169	7	18	target	target	NOUN
chd-169	7	19	genes	gene	NOUN
chd-169	7	20	and	and	CCONJ
chd-169	7	21	gr	gr	ADJ
chd-169	7	22	-	-	PUNCT
chd-169	7	23	target	target	NOUN
chd-169	7	24	genes	gene	NOUN
chd-169	7	25	,	,	PUNCT
chd-169	7	26	resulting	result	VERB
chd-169	7	27	in	in	ADP
chd-169	7	28	increased	increase	VERB
chd-169	7	29	prostate	prostate	NOUN
chd-169	7	30	tumor	tumor	NOUN
chd-169	7	31	resistance	resistance	NOUN
chd-169	7	32	to	to	ADP
chd-169	7	33	anti	anti	ADJ
chd-169	7	34	-	-	ADJ
chd-169	7	35	androgen	androgen	ADJ
chd-169	7	36	therapy	therapy	NOUN
chd-169	7	37	,	,	PUNCT
chd-169	7	38	chemotherapy	chemotherapy	NOUN
chd-169	7	39	,	,	PUNCT
chd-169	7	40	and	and	CCONJ
chd-169	7	41	radiotherapy	radiotherapy	NOUN
chd-169	7	42	.	.	PUNCT
chd-169	8	1	given	give	VERB
chd-169	8	2	its	its	PRON
chd-169	8	3	enhanced	enhanced	ADJ
chd-169	8	4	signaling	signal	VERB
chd-169	8	5	in	in	ADP
chd-169	8	6	aa	aa	PROPN
chd-169	8	7	men	man	NOUN
chd-169	8	8	,	,	PUNCT
chd-169	8	9	gr	gr	PROPN
chd-169	8	10	—	—	PUNCT
chd-169	8	11	together	together	ADV
chd-169	8	12	with	with	ADP
chd-169	8	13	specific	specific	ADJ
chd-169	8	14	genetic	genetic	ADJ
chd-169	8	15	drivers	driver	NOUN
chd-169	8	16	—	—	PUNCT
chd-169	8	17	may	may	AUX
chd-169	8	18	promote	promote	VERB
chd-169	8	19	crpc	crpc	ADJ
chd-169	8	20	progression	progression	NOUN
chd-169	8	21	and	and	CCONJ
chd-169	8	22	exacerbate	exacerbate	VERB
chd-169	8	23	tumor	tumor	NOUN
chd-169	8	24	aggressiveness	aggressiveness	NOUN
chd-169	8	25	in	in	ADP
chd-169	8	26	this	this	DET
chd-169	8	27	population	population	NOUN
chd-169	8	28	,	,	PUNCT
chd-169	8	29	potentially	potentially	ADV
chd-169	8	30	contributing	contribute	VERB
chd-169	8	31	to	to	ADP
chd-169	8	32	pca	pca	NOUN
chd-169	8	33	mortality	mortality	NOUN
chd-169	8	34	disparities	disparity	NOUN
chd-169	8	35	.	.	PUNCT
chd-169	9	1	ongoing	ongoing	ADJ
chd-169	9	2	and	and	CCONJ
chd-169	9	3	future	future	ADJ
chd-169	9	4	crpc	crpc	ADJ
chd-169	9	5	clinical	clinical	ADJ
chd-169	9	6	trials	trial	NOUN
chd-169	9	7	that	that	PRON
chd-169	9	8	combine	combine	VERB
chd-169	9	9	standard	standard	NOUN
chd-169	9	10	of	of	ADP
chd-169	9	11	care	care	NOUN
chd-169	9	12	therapies	therapy	NOUN
chd-169	9	13	with	with	ADP
chd-169	9	14	gr	gr	NOUN
chd-169	9	15	modulators	modulator	NOUN
chd-169	9	16	should	should	AUX
chd-169	9	17	assess	assess	VERB
chd-169	9	18	racial	racial	ADJ
chd-169	9	19	differences	difference	NOUN
chd-169	9	20	in	in	ADP
chd-169	9	21	therapy	therapy	NOUN
chd-169	9	22	response	response	NOUN
chd-169	9	23	and	and	CCONJ
chd-169	9	24	clinical	clinical	ADJ
chd-169	9	25	outcomes	outcome	NOUN
chd-169	9	26	in	in	ADP
chd-169	9	27	order	order	NOUN
chd-169	9	28	to	to	PART
chd-169	9	29	improve	improve	VERB
chd-169	9	30	pca	pca	NOUN
chd-169	9	31	health	health	NOUN
chd-169	9	32	disparities	disparity	NOUN
chd-169	9	33	that	that	PRON
chd-169	9	34	continue	continue	VERB
chd-169	9	35	to	to	PART
chd-169	9	36	exist	exist	VERB
chd-169	9	37	for	for	ADP
chd-169	9	38	aa	aa	NOUN
chd-169	9	39	men	man	NOUN
chd-169	9	40	.	.	PUNCT
chd-169	10	1	keywords	keyword	NOUN
chd-169	10	2	:	:	PUNCT
chd-169	10	3	african	african	PROPN
chd-169	10	4	american	american	PROPN
chd-169	10	5	,	,	PUNCT
chd-169	10	6	african	african	ADJ
chd-169	10	7	ancestry	ancestry	NOUN
chd-169	10	8	,	,	PUNCT
chd-169	10	9	clinical	clinical	ADJ
chd-169	10	10	trials	trial	NOUN
chd-169	10	11	,	,	PUNCT
chd-169	10	12	glucocorticoid	glucocorticoid	ADJ
chd-169	10	13	receptor	receptor	NOUN
chd-169	10	14	,	,	PUNCT
chd-169	10	15	glucocorticoid	glucocorticoid	ADJ
chd-169	10	16	signaling	signaling	NOUN
chd-169	10	17	,	,	PUNCT
chd-169	10	18	health	health	NOUN
chd-169	10	19	disparities	disparity	NOUN
chd-169	10	20	,	,	PUNCT
chd-169	10	21	prostate	prostate	NOUN
chd-169	10	22	cancer	cancer	NOUN
chd-169	10	23	,	,	PUNCT
chd-169	10	24	psychosocial	psychosocial	ADJ
chd-169	10	25	stress	stress	NOUN
chd-169	10	26	citation	citation	NOUN
chd-169	10	27	:	:	PUNCT
chd-169	10	28	woods	woods	PROPN
chd-169	10	29	-	-	PUNCT
chd-169	10	30	burnham	burnham	NOUN
chd-169	10	31	l	l	NOUN
chd-169	10	32	et	et	PROPN
chd-169	10	33	al	al	PROPN
chd-169	10	34	(	(	PUNCT
chd-169	10	35	2020	2020	NUM
chd-169	10	36	)	)	PUNCT
chd-169	10	37	psychosocial	psychosocial	ADJ
chd-169	10	38	stress	stress	NOUN
chd-169	10	39	,	,	PUNCT
chd-169	10	40	glucocorticoid	glucocorticoid	ADJ
chd-169	10	41	signaling	signaling	NOUN
chd-169	10	42	,	,	PUNCT
chd-169	10	43	and	and	CCONJ
chd-169	10	44	prostate	prostate	NOUN
chd-169	10	45	cancer	cancer	NOUN
chd-169	10	46	health	health	NOUN
chd-169	10	47	disparities	disparity	NOUN
chd-169	10	48	in	in	ADP
chd-169	10	49	african	african	ADJ
chd-169	10	50	american	american	ADJ
chd-169	10	51	men	man	NOUN
chd-169	10	52	.	.	PUNCT
chd-169	11	1	cancer	cancer	NOUN
chd-169	11	2	health	health	NOUN
chd-169	11	3	disparities	disparity	NOUN
chd-169	11	4	4	4	NUM
chd-169	11	5	:	:	PUNCT
chd-169	11	6	e1	e1	NOUN
chd-169	11	7	-	-	PUNCT
chd-169	11	8	e30	e30	NOUN
chd-169	11	9	.	.	PUNCT
chd-169	12	1	doi:10.9777	doi:10.9777	VERB
chd-169	12	2	/	/	SYM
chd-169	12	3	chd.2020.1005	chd.2020.1005	PROPN
chd-169	12	4	.	.	PUNCT
chd-169	13	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	13	2	e2	e2	PROPN
chd-169	13	3	cancer	cancer	NOUN
chd-169	13	4	health	health	NOUN
chd-169	13	5	disparities	disparity	NOUN
chd-169	13	6	research	research	NOUN
chd-169	13	7	introduction	introduction	NOUN
chd-169	13	8	prostate	prostate	NOUN
chd-169	13	9	cancer	cancer	NOUN
chd-169	13	10	(	(	PUNCT
chd-169	13	11	pca	pca	PROPN
chd-169	13	12	)	)	PUNCT
chd-169	13	13	is	be	AUX
chd-169	13	14	the	the	DET
chd-169	13	15	most	most	ADV
chd-169	13	16	commonly	commonly	ADV
chd-169	13	17	diagnosed	diagnose	VERB
chd-169	13	18	cancer	cancer	NOUN
chd-169	13	19	and	and	CCONJ
chd-169	13	20	the	the	DET
chd-169	13	21	second	second	ADJ
chd-169	13	22	leading	leading	ADJ
chd-169	13	23	cause	cause	NOUN
chd-169	13	24	of	of	ADP
chd-169	13	25	cancer	cancer	NOUN
chd-169	13	26	mortality	mortality	NOUN
chd-169	13	27	in	in	ADP
chd-169	13	28	men	man	NOUN
chd-169	13	29	in	in	ADP
chd-169	13	30	the	the	DET
chd-169	13	31	united	united	PROPN
chd-169	13	32	states	states	PROPN
chd-169	13	33	(	(	PUNCT
chd-169	13	34	u.s	u.s	PROPN
chd-169	13	35	.	.	PROPN
chd-169	13	36	)	)	PUNCT
chd-169	14	1	(	(	PUNCT
chd-169	14	2	siegel	siegel	NOUN
chd-169	14	3	et	et	PROPN
chd-169	14	4	al	al	PROPN
chd-169	14	5	.	.	PROPN
chd-169	14	6	,	,	PUNCT
chd-169	14	7	2020	2020	NUM
chd-169	14	8	)	)	PUNCT
chd-169	14	9	.	.	PUNCT
chd-169	15	1	approximately	approximately	ADV
chd-169	15	2	191,930	191,930	NUM
chd-169	15	3	men	man	NOUN
chd-169	15	4	will	will	AUX
chd-169	15	5	be	be	AUX
chd-169	15	6	diagnosed	diagnose	VERB
chd-169	15	7	with	with	ADP
chd-169	15	8	pca	pca	PROPN
chd-169	15	9	and	and	CCONJ
chd-169	15	10	33,330	33,330	NUM
chd-169	15	11	will	will	AUX
chd-169	15	12	die	die	VERB
chd-169	15	13	from	from	ADP
chd-169	15	14	this	this	DET
chd-169	15	15	malignancy	malignancy	NOUN
chd-169	15	16	in	in	ADP
chd-169	15	17	the	the	DET
chd-169	15	18	u.s	u.s	PROPN
chd-169	15	19	.	.	PROPN
chd-169	15	20	in	in	ADP
chd-169	15	21	2020	2020	NUM
chd-169	15	22	(	(	PUNCT
chd-169	15	23	siegel	siegel	PROPN
chd-169	15	24	et	et	PROPN
chd-169	15	25	al	al	PROPN
chd-169	15	26	.	.	PROPN
chd-169	15	27	,	,	PUNCT
chd-169	15	28	2020	2020	NUM
chd-169	15	29	)	)	PUNCT
chd-169	15	30	.	.	PUNCT
chd-169	16	1	african	african	PROPN
chd-169	16	2	-	-	PUNCT
chd-169	16	3	american	american	ADJ
chd-169	16	4	(	(	PUNCT
chd-169	16	5	aa	aa	NOUN
chd-169	16	6	)	)	PUNCT
chd-169	16	7	men	man	NOUN
chd-169	16	8	have	have	VERB
chd-169	16	9	the	the	DET
chd-169	16	10	highest	high	ADJ
chd-169	16	11	rates	rate	NOUN
chd-169	16	12	of	of	ADP
chd-169	16	13	pca	pca	NOUN
chd-169	16	14	incidence	incidence	NOUN
chd-169	16	15	and	and	CCONJ
chd-169	16	16	mortality	mortality	NOUN
chd-169	16	17	compared	compare	VERB
chd-169	16	18	to	to	ADP
chd-169	16	19	men	man	NOUN
chd-169	16	20	of	of	ADP
chd-169	16	21	other	other	ADJ
chd-169	16	22	races	race	NOUN
chd-169	16	23	and	and	CCONJ
chd-169	16	24	ethnicities	ethnicity	NOUN
chd-169	16	25	in	in	ADP
chd-169	16	26	the	the	DET
chd-169	16	27	u.s	u.s	PROPN
chd-169	16	28	.	.	PROPN
chd-169	16	29	(	(	PUNCT
chd-169	16	30	siegel	siegel	PROPN
chd-169	16	31	et	et	PROPN
chd-169	16	32	al	al	PROPN
chd-169	16	33	.	.	PROPN
chd-169	16	34	,	,	PUNCT
chd-169	16	35	2020	2020	NUM
chd-169	16	36	)	)	PUNCT
chd-169	16	37	.	.	PUNCT
chd-169	17	1	these	these	DET
chd-169	17	2	disparities	disparity	NOUN
chd-169	17	3	have	have	AUX
chd-169	17	4	also	also	ADV
chd-169	17	5	been	be	AUX
chd-169	17	6	reported	report	VERB
chd-169	17	7	in	in	ADP
chd-169	17	8	other	other	ADJ
chd-169	17	9	populations	population	NOUN
chd-169	17	10	of	of	ADP
chd-169	17	11	men	man	NOUN
chd-169	17	12	with	with	ADP
chd-169	17	13	african	african	ADJ
chd-169	17	14	ancestry	ancestry	NOUN
chd-169	17	15	(	(	PUNCT
chd-169	17	16	petersen	petersen	PROPN
chd-169	17	17	et	et	PROPN
chd-169	17	18	al	al	PROPN
chd-169	17	19	.	.	PROPN
chd-169	17	20	,	,	PUNCT
chd-169	17	21	2019	2019	NUM
chd-169	17	22	;	;	PUNCT
chd-169	17	23	rebbeck	rebbeck	NOUN
chd-169	17	24	,	,	PUNCT
chd-169	17	25	2017	2017	NUM
chd-169	17	26	)	)	PUNCT
chd-169	17	27	.	.	PUNCT
chd-169	18	1	at	at	ADP
chd-169	18	2	time	time	NOUN
chd-169	18	3	of	of	ADP
chd-169	18	4	diagnosis	diagnosis	NOUN
chd-169	18	5	,	,	PUNCT
chd-169	18	6	aa	aa	NOUN
chd-169	18	7	men	man	NOUN
chd-169	18	8	and	and	CCONJ
chd-169	18	9	african	african	ADJ
chd-169	18	10	men	man	NOUN
chd-169	18	11	show	show	VERB
chd-169	18	12	a	a	DET
chd-169	18	13	greater	great	ADJ
chd-169	18	14	frequency	frequency	NOUN
chd-169	18	15	of	of	ADP
chd-169	18	16	high	high	ADJ
chd-169	18	17	-	-	PUNCT
chd-169	18	18	risk	risk	NOUN
chd-169	18	19	prostate	prostate	NOUN
chd-169	18	20	tumors	tumor	NOUN
chd-169	18	21	compared	compare	VERB
chd-169	18	22	to	to	ADP
chd-169	18	23	men	man	NOUN
chd-169	18	24	from	from	ADP
chd-169	18	25	other	other	ADJ
chd-169	18	26	racial	racial	ADJ
chd-169	18	27	groups	group	NOUN
chd-169	18	28	,	,	PUNCT
chd-169	18	29	ultimately	ultimately	ADV
chd-169	18	30	resulting	result	VERB
chd-169	18	31	in	in	ADP
chd-169	18	32	increased	increase	VERB
chd-169	18	33	mortality	mortality	NOUN
chd-169	18	34	(	(	PUNCT
chd-169	18	35	cuevas	cuevas	PROPN
chd-169	18	36	et	et	PROPN
chd-169	18	37	al	al	PROPN
chd-169	18	38	.	.	PROPN
chd-169	18	39	,	,	PUNCT
chd-169	18	40	2019	2019	NUM
chd-169	18	41	;	;	PUNCT
chd-169	18	42	petersen	petersen	PROPN
chd-169	18	43	et	et	PROPN
chd-169	18	44	al	al	PROPN
chd-169	18	45	.	.	PROPN
chd-169	18	46	,	,	PUNCT
chd-169	18	47	2019	2019	NUM
chd-169	18	48	;	;	PUNCT
chd-169	18	49	rebbeck	rebbeck	NOUN
chd-169	18	50	,	,	PUNCT
chd-169	18	51	2017	2017	NUM
chd-169	18	52	;	;	PUNCT
chd-169	18	53	woods	wood	NOUN
chd-169	18	54	-	-	PUNCT
chd-169	18	55	burnham	burnham	PROPN
chd-169	18	56	et	et	NOUN
chd-169	18	57	al	al	PROPN
chd-169	18	58	.	.	PROPN
chd-169	18	59	,	,	PUNCT
chd-169	18	60	2018a	2018a	NUM
chd-169	18	61	)	)	PUNCT
chd-169	18	62	.	.	PUNCT
chd-169	19	1	emerging	emerge	VERB
chd-169	19	2	evidence	evidence	NOUN
chd-169	19	3	supports	support	VERB
chd-169	19	4	the	the	DET
chd-169	19	5	notion	notion	NOUN
chd-169	19	6	that	that	SCONJ
chd-169	19	7	these	these	DET
chd-169	19	8	disparities	disparity	NOUN
chd-169	19	9	stem	stem	VERB
chd-169	19	10	from	from	ADP
chd-169	19	11	the	the	DET
chd-169	19	12	interplay	interplay	NOUN
chd-169	19	13	between	between	ADP
chd-169	19	14	multiple	multiple	ADJ
chd-169	19	15	factors	factor	NOUN
chd-169	19	16	including	include	VERB
chd-169	19	17	socioeconomic	socioeconomic	ADJ
chd-169	19	18	status	status	NOUN
chd-169	19	19	(	(	PUNCT
chd-169	19	20	ses	ses	PROPN
chd-169	19	21	)	)	PUNCT
chd-169	19	22	,	,	PUNCT
chd-169	19	23	environment	environment	NOUN
chd-169	19	24	,	,	PUNCT
chd-169	19	25	and	and	CCONJ
chd-169	19	26	biology	biology	NOUN
chd-169	19	27	(	(	PUNCT
chd-169	19	28	abdalla	abdalla	X
chd-169	19	29	et	et	PROPN
chd-169	19	30	al	al	PROPN
chd-169	19	31	.	.	PROPN
chd-169	19	32	,	,	PUNCT
chd-169	19	33	1999	1999	NUM
chd-169	19	34	;	;	PUNCT
chd-169	19	35	chornokur	chornokur	NOUN
chd-169	19	36	et	et	PROPN
chd-169	19	37	al	al	PROPN
chd-169	19	38	.	.	PROPN
chd-169	19	39	,	,	PUNCT
chd-169	19	40	2011	2011	NUM
chd-169	19	41	;	;	PUNCT
chd-169	19	42	desantis	desantis	PROPN
chd-169	19	43	et	et	PROPN
chd-169	19	44	al	al	PROPN
chd-169	19	45	.	.	PROPN
chd-169	19	46	,	,	PUNCT
chd-169	19	47	2019	2019	NUM
chd-169	19	48	;	;	PUNCT
chd-169	19	49	moul	moul	X
chd-169	19	50	et	et	PROPN
chd-169	19	51	al	al	PROPN
chd-169	19	52	.	.	PROPN
chd-169	19	53	,	,	PUNCT
chd-169	19	54	1995	1995	NUM
chd-169	19	55	)	)	PUNCT
chd-169	19	56	.	.	PUNCT
chd-169	20	1	an	an	DET
chd-169	20	2	emerging	emerge	VERB
chd-169	20	3	area	area	NOUN
chd-169	20	4	in	in	ADP
chd-169	20	5	the	the	DET
chd-169	20	6	field	field	NOUN
chd-169	20	7	of	of	ADP
chd-169	20	8	pca	pca	PROPN
chd-169	20	9	health	health	NOUN
chd-169	20	10	disparities	disparity	NOUN
chd-169	20	11	research	research	NOUN
chd-169	20	12	is	be	AUX
chd-169	20	13	the	the	DET
chd-169	20	14	contribution	contribution	NOUN
chd-169	20	15	of	of	ADP
chd-169	20	16	psychosocial	psychosocial	ADJ
chd-169	20	17	stress	stress	NOUN
chd-169	20	18	or	or	CCONJ
chd-169	20	19	socioenvironmental	socioenvironmental	ADJ
chd-169	20	20	adversity	adversity	NOUN
chd-169	20	21	to	to	ADP
chd-169	20	22	an	an	DET
chd-169	20	23	increased	increase	VERB
chd-169	20	24	risk	risk	NOUN
chd-169	20	25	of	of	ADP
chd-169	20	26	tumor	tumor	NOUN
chd-169	20	27	aggressiveness	aggressiveness	NOUN
chd-169	20	28	,	,	PUNCT
chd-169	20	29	particularly	particularly	ADV
chd-169	20	30	in	in	ADP
chd-169	20	31	aa	aa	PROPN
chd-169	20	32	men	man	NOUN
chd-169	20	33	(	(	PUNCT
chd-169	20	34	cuevas	cuevas	PROPN
chd-169	20	35	et	et	PROPN
chd-169	20	36	al	al	PROPN
chd-169	20	37	.	.	PROPN
chd-169	20	38	,	,	PUNCT
chd-169	20	39	2019	2019	NUM
chd-169	20	40	;	;	PUNCT
chd-169	20	41	kantor	kantor	PROPN
chd-169	20	42	et	et	PROPN
chd-169	20	43	al	al	PROPN
chd-169	20	44	.	.	PROPN
chd-169	20	45	,	,	PUNCT
chd-169	20	46	2019	2019	NUM
chd-169	20	47	;	;	PUNCT
chd-169	20	48	woods	wood	NOUN
chd-169	20	49	-	-	PUNCT
chd-169	20	50	burnham	burnham	PROPN
chd-169	20	51	et	et	NOUN
chd-169	20	52	al	al	PROPN
chd-169	20	53	.	.	PROPN
chd-169	20	54	,	,	PUNCT
chd-169	20	55	2018a	2018a	NUM
chd-169	20	56	)	)	PUNCT
chd-169	20	57	.	.	PUNCT
chd-169	21	1	in	in	ADP
chd-169	21	2	this	this	DET
chd-169	21	3	review	review	NOUN
chd-169	21	4	we	we	PRON
chd-169	21	5	discuss	discuss	VERB
chd-169	21	6	recent	recent	ADJ
chd-169	21	7	studies	study	NOUN
chd-169	21	8	linking	link	VERB
chd-169	21	9	psychosocial	psychosocial	ADJ
chd-169	21	10	stress	stress	NOUN
chd-169	21	11	with	with	ADP
chd-169	21	12	increased	increase	VERB
chd-169	21	13	glucocorticoid	glucocorticoid	NOUN
chd-169	21	14	signaling	signal	VERB
chd-169	21	15	in	in	ADP
chd-169	21	16	aa	aa	PROPN
chd-169	21	17	populations	population	NOUN
chd-169	21	18	.	.	PUNCT
chd-169	22	1	we	we	PRON
chd-169	22	2	also	also	ADV
chd-169	22	3	discuss	discuss	VERB
chd-169	22	4	emerging	emerge	VERB
chd-169	22	5	evidence	evidence	NOUN
chd-169	22	6	pointing	point	VERB
chd-169	22	7	to	to	ADP
chd-169	22	8	glucocorticoid	glucocorticoid	NOUN
chd-169	22	9	signaling	signal	VERB
chd-169	22	10	through	through	ADP
chd-169	22	11	the	the	DET
chd-169	22	12	glucocorticoid	glucocorticoid	ADJ
chd-169	22	13	receptor	receptor	NOUN
chd-169	22	14	(	(	PUNCT
chd-169	22	15	gr	gr	NOUN
chd-169	22	16	)	)	PUNCT
chd-169	22	17	as	as	ADV
chd-169	22	18	critical	critical	ADJ
chd-169	22	19	for	for	ADP
chd-169	22	20	pca	pca	NOUN
chd-169	22	21	progression	progression	NOUN
chd-169	22	22	into	into	ADP
chd-169	22	23	the	the	DET
chd-169	22	24	therapy	therapy	NOUN
chd-169	22	25	-	-	PUNCT
chd-169	22	26	resistant	resistant	ADJ
chd-169	22	27	advanced	advanced	ADJ
chd-169	22	28	stage	stage	NOUN
chd-169	22	29	.	.	PUNCT
chd-169	23	1	we	we	PRON
chd-169	23	2	propose	propose	VERB
chd-169	23	3	a	a	DET
chd-169	23	4	model	model	NOUN
chd-169	23	5	(	(	PUNCT
chd-169	23	6	fig	fig	NOUN
chd-169	23	7	.	.	NOUN
chd-169	23	8	1	1	NUM
chd-169	23	9	)	)	PUNCT
chd-169	23	10	that	that	PRON
chd-169	23	11	integrates	integrate	VERB
chd-169	23	12	psychosocial	psychosocial	ADJ
chd-169	23	13	stress	stress	NOUN
chd-169	23	14	,	,	PUNCT
chd-169	23	15	glucocorticoid	glucocorticoid	ADJ
chd-169	23	16	signaling	signaling	NOUN
chd-169	23	17	,	,	PUNCT
chd-169	23	18	and	and	CCONJ
chd-169	23	19	pca	pca	NOUN
chd-169	23	20	progression	progression	NOUN
chd-169	23	21	in	in	ADP
chd-169	23	22	the	the	DET
chd-169	23	23	context	context	NOUN
chd-169	23	24	of	of	ADP
chd-169	23	25	pca	pca	PROPN
chd-169	23	26	health	health	NOUN
chd-169	23	27	disparities	disparity	NOUN
chd-169	23	28	.	.	PUNCT
chd-169	24	1	in	in	ADP
chd-169	24	2	this	this	DET
chd-169	24	3	model	model	NOUN
chd-169	24	4	,	,	PUNCT
chd-169	24	5	cumulative	cumulative	ADJ
chd-169	24	6	exposure	exposure	NOUN
chd-169	24	7	to	to	ADP
chd-169	24	8	psychosocial	psychosocial	ADJ
chd-169	24	9	stressors	stressor	NOUN
chd-169	24	10	(	(	PUNCT
chd-169	24	11	e.g.	e.g.	ADV
chd-169	24	12	discrimination	discrimination	NOUN
chd-169	24	13	,	,	PUNCT
chd-169	24	14	negative	negative	ADJ
chd-169	24	15	neighborhood	neighborhood	NOUN
chd-169	24	16	effects	effect	NOUN
chd-169	24	17	,	,	PUNCT
chd-169	24	18	low	low	ADJ
chd-169	24	19	ses	se	NOUN
chd-169	24	20	,	,	PUNCT
chd-169	24	21	limited	limited	ADJ
chd-169	24	22	access	access	NOUN
chd-169	24	23	to	to	ADP
chd-169	24	24	health	health	NOUN
chd-169	24	25	care	care	NOUN
chd-169	24	26	)	)	PUNCT
chd-169	24	27	contributes	contribute	VERB
chd-169	24	28	to	to	ADP
chd-169	24	29	sustained	sustained	ADJ
chd-169	24	30	elevated	elevated	ADJ
chd-169	24	31	levels	level	NOUN
chd-169	24	32	of	of	ADP
chd-169	24	33	cortisol	cortisol	NOUN
chd-169	24	34	resulting	result	VERB
chd-169	24	35	in	in	ADP
chd-169	24	36	amplified	amplify	VERB
chd-169	24	37	gr	gr	NOUN
chd-169	24	38	signaling	signal	VERB
chd-169	24	39	.	.	PUNCT
chd-169	25	1	this	this	PRON
chd-169	25	2	amplified	amplify	VERB
chd-169	25	3	gr	gr	NOUN
chd-169	25	4	signaling	signal	VERB
chd-169	25	5	is	be	AUX
chd-169	25	6	further	far	ADV
chd-169	25	7	increased	increase	VERB
chd-169	25	8	by	by	ADP
chd-169	25	9	anti	anti	ADJ
chd-169	25	10	-	-	ADJ
chd-169	25	11	androgen	androgen	ADJ
chd-169	25	12	therapy	therapy	NOUN
chd-169	25	13	during	during	ADP
chd-169	25	14	pca	pca	PROPN
chd-169	25	15	treatment	treatment	NOUN
chd-169	25	16	,	,	PUNCT
chd-169	25	17	leading	lead	VERB
chd-169	25	18	to	to	ADP
chd-169	25	19	the	the	DET
chd-169	25	20	activation	activation	NOUN
chd-169	25	21	of	of	ADP
chd-169	25	22	molecular	molecular	ADJ
chd-169	25	23	mechanisms	mechanism	NOUN
chd-169	25	24	associated	associate	VERB
chd-169	25	25	with	with	ADP
chd-169	25	26	pca	pca	NOUN
chd-169	25	27	aggressiveness	aggressiveness	NOUN
chd-169	25	28	and	and	CCONJ
chd-169	25	29	therapy	therapy	NOUN
chd-169	25	30	resistance	resistance	NOUN
chd-169	25	31	.	.	PUNCT
chd-169	26	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	26	2	e3	e3	NOUN
chd-169	26	3	cancer	cancer	NOUN
chd-169	26	4	health	health	NOUN
chd-169	26	5	disparities	disparity	NOUN
chd-169	26	6	research	research	VERB
chd-169	26	7	fig	fig	NOUN
chd-169	26	8	.	.	PUNCT
chd-169	27	1	1	1	NUM
chd-169	27	2	psychosocial	psychosocial	ADJ
chd-169	27	3	stress	stress	NOUN
chd-169	27	4	,	,	PUNCT
chd-169	27	5	glucocorticoid	glucocorticoid	ADJ
chd-169	27	6	signaling	signaling	NOUN
chd-169	27	7	,	,	PUNCT
chd-169	27	8	and	and	CCONJ
chd-169	27	9	prostate	prostate	NOUN
chd-169	27	10	cancer	cancer	NOUN
chd-169	27	11	progression	progression	NOUN
chd-169	27	12	in	in	ADP
chd-169	27	13	the	the	DET
chd-169	27	14	context	context	NOUN
chd-169	27	15	of	of	ADP
chd-169	27	16	health	health	NOUN
chd-169	27	17	disparities	disparity	NOUN
chd-169	27	18	.	.	PUNCT
chd-169	28	1	chronic	chronic	ADJ
chd-169	28	2	or	or	CCONJ
chd-169	28	3	cumulative	cumulative	ADJ
chd-169	28	4	exposure	exposure	NOUN
chd-169	28	5	of	of	ADP
chd-169	28	6	aa	aa	PROPN
chd-169	28	7	men	man	NOUN
chd-169	28	8	to	to	ADP
chd-169	28	9	psychosocial	psychosocial	ADJ
chd-169	28	10	stressors	stressor	NOUN
chd-169	28	11	(	(	PUNCT
chd-169	28	12	e.g.	e.g.	ADV
chd-169	28	13	discrimination	discrimination	NOUN
chd-169	28	14	,	,	PUNCT
chd-169	28	15	negative	negative	ADJ
chd-169	28	16	neighborhood	neighborhood	NOUN
chd-169	28	17	effects	effect	NOUN
chd-169	28	18	,	,	PUNCT
chd-169	28	19	low	low	ADJ
chd-169	28	20	ses	se	NOUN
chd-169	28	21	,	,	PUNCT
chd-169	28	22	limited	limited	ADJ
chd-169	28	23	access	access	NOUN
chd-169	28	24	to	to	ADP
chd-169	28	25	health	health	NOUN
chd-169	28	26	care	care	NOUN
chd-169	28	27	)	)	PUNCT
chd-169	28	28	contributes	contribute	VERB
chd-169	28	29	to	to	ADP
chd-169	28	30	sustained	sustained	ADJ
chd-169	28	31	elevated	elevated	ADJ
chd-169	28	32	levels	level	NOUN
chd-169	28	33	of	of	ADP
chd-169	28	34	cortisol	cortisol	NOUN
chd-169	28	35	resulting	result	VERB
chd-169	28	36	in	in	ADP
chd-169	28	37	amplified	amplify	VERB
chd-169	28	38	gr	gr	NOUN
chd-169	28	39	signaling	signal	VERB
chd-169	28	40	leading	lead	VERB
chd-169	28	41	to	to	ADP
chd-169	28	42	the	the	DET
chd-169	28	43	activation	activation	NOUN
chd-169	28	44	of	of	ADP
chd-169	28	45	molecular	molecular	ADJ
chd-169	28	46	mechanisms	mechanism	NOUN
chd-169	28	47	associated	associate	VERB
chd-169	28	48	with	with	ADP
chd-169	28	49	prostate	prostate	NOUN
chd-169	28	50	tumor	tumor	NOUN
chd-169	28	51	aggressiveness	aggressiveness	NOUN
chd-169	28	52	and	and	CCONJ
chd-169	28	53	therapy	therapy	NOUN
chd-169	28	54	resistance	resistance	NOUN
chd-169	28	55	.	.	PUNCT
chd-169	29	1	aa	aa	PROPN
chd-169	29	2	,	,	PUNCT
chd-169	29	3	african	african	PROPN
chd-169	29	4	american	american	PROPN
chd-169	29	5	;	;	PUNCT
chd-169	29	6	gr	gr	NUM
chd-169	29	7	,	,	PUNCT
chd-169	29	8	glucocorticoid	glucocorticoid	ADJ
chd-169	29	9	receptor	receptor	NOUN
chd-169	29	10	;	;	PUNCT
chd-169	29	11	ses	se	NOUN
chd-169	29	12	,	,	PUNCT
chd-169	29	13	socioeconomic	socioeconomic	ADJ
chd-169	29	14	status	status	NOUN
chd-169	29	15	.	.	PUNCT
chd-169	30	1	prostate	prostate	NOUN
chd-169	30	2	cancer	cancer	NOUN
chd-169	30	3	health	health	NOUN
chd-169	30	4	disparities	disparity	NOUN
chd-169	30	5	aa	aa	NOUN
chd-169	30	6	men	man	NOUN
chd-169	30	7	are	be	AUX
chd-169	30	8	more	more	ADV
chd-169	30	9	likely	likely	ADJ
chd-169	30	10	to	to	PART
chd-169	30	11	be	be	AUX
chd-169	30	12	diagnosed	diagnose	VERB
chd-169	30	13	and	and	CCONJ
chd-169	30	14	die	die	VERB
chd-169	30	15	from	from	ADP
chd-169	30	16	pca	pca	PROPN
chd-169	30	17	than	than	ADP
chd-169	30	18	european	european	PROPN
chd-169	30	19	american	american	PROPN
chd-169	30	20	(	(	PUNCT
chd-169	30	21	ea	ea	NOUN
chd-169	30	22	)	)	PUNCT
chd-169	30	23	men	man	NOUN
chd-169	30	24	(	(	PUNCT
chd-169	30	25	siegel	siegel	PROPN
chd-169	30	26	et	et	PROPN
chd-169	30	27	al	al	PROPN
chd-169	30	28	.	.	PROPN
chd-169	30	29	,	,	PUNCT
chd-169	30	30	2020	2020	NUM
chd-169	30	31	)	)	PUNCT
chd-169	30	32	.	.	PUNCT
chd-169	31	1	while	while	SCONJ
chd-169	31	2	it	it	PRON
chd-169	31	3	is	be	AUX
chd-169	31	4	estimated	estimate	VERB
chd-169	31	5	that	that	SCONJ
chd-169	31	6	1	1	NUM
chd-169	31	7	in	in	ADP
chd-169	31	8	9	9	NUM
chd-169	31	9	ea	ea	NOUN
chd-169	31	10	men	man	NOUN
chd-169	31	11	will	will	AUX
chd-169	31	12	be	be	AUX
chd-169	31	13	diagnosed	diagnose	VERB
chd-169	31	14	with	with	ADP
chd-169	31	15	pca	pca	PROPN
chd-169	31	16	in	in	ADP
chd-169	31	17	their	their	PRON
chd-169	31	18	lifetime	lifetime	NOUN
chd-169	31	19	,	,	PUNCT
chd-169	31	20	the	the	DET
chd-169	31	21	estimation	estimation	NOUN
chd-169	31	22	rate	rate	NOUN
chd-169	31	23	in	in	ADP
chd-169	31	24	aa	aa	PROPN
chd-169	31	25	men	man	NOUN
chd-169	31	26	is	be	AUX
chd-169	31	27	1	1	NUM
chd-169	31	28	in	in	ADP
chd-169	31	29	7	7	NUM
chd-169	31	30	(	(	PUNCT
chd-169	31	31	desantis	desantis	PROPN
chd-169	31	32	et	et	PROPN
chd-169	31	33	al	al	PROPN
chd-169	31	34	.	.	PROPN
chd-169	31	35	,	,	PUNCT
chd-169	31	36	2019	2019	NUM
chd-169	31	37	)	)	PUNCT
chd-169	31	38	.	.	PUNCT
chd-169	32	1	we	we	PRON
chd-169	32	2	recently	recently	ADV
chd-169	32	3	reported	report	VERB
chd-169	32	4	that	that	SCONJ
chd-169	32	5	1	1	NUM
chd-169	32	6	in	in	ADP
chd-169	32	7	3	3	NUM
chd-169	32	8	aa	aa	NOUN
chd-169	32	9	men	man	NOUN
chd-169	32	10	had	have	VERB
chd-169	32	11	elevated	elevate	VERB
chd-169	32	12	circulating	circulate	VERB
chd-169	32	13	psa	psa	NOUN
chd-169	32	14	in	in	ADP
chd-169	32	15	a	a	DET
chd-169	32	16	random	random	ADJ
chd-169	32	17	sample	sample	NOUN
chd-169	32	18	of	of	ADP
chd-169	32	19	414	414	NUM
chd-169	32	20	adult	adult	NOUN
chd-169	32	21	aa	aa	NOUN
chd-169	32	22	men	man	NOUN
chd-169	32	23	from	from	ADP
chd-169	32	24	the	the	DET
chd-169	32	25	community	community	NOUN
chd-169	32	26	(	(	PUNCT
chd-169	32	27	woods	woods	PROPN
chd-169	32	28	-	-	PUNCT
chd-169	32	29	burnham	burnham	NOUN
chd-169	32	30	et	et	NOUN
chd-169	32	31	al	al	PROPN
chd-169	32	32	.	.	PROPN
chd-169	32	33	,	,	PUNCT
chd-169	32	34	2018b	2018b	NUM
chd-169	32	35	)	)	PUNCT
chd-169	32	36	.	.	PUNCT
chd-169	33	1	the	the	DET
chd-169	33	2	biological	biological	ADJ
chd-169	33	3	characteristics	characteristic	NOUN
chd-169	33	4	of	of	ADP
chd-169	33	5	prostate	prostate	NOUN
chd-169	33	6	tumors	tumor	NOUN
chd-169	33	7	are	be	AUX
chd-169	33	8	exaggerated	exaggerated	ADJ
chd-169	33	9	in	in	ADP
chd-169	33	10	aa	aa	PROPN
chd-169	33	11	men	man	NOUN
chd-169	33	12	compared	compare	VERB
chd-169	33	13	to	to	ADP
chd-169	33	14	ea	ea	NOUN
chd-169	33	15	men	man	NOUN
chd-169	33	16	at	at	ADP
chd-169	33	17	time	time	NOUN
chd-169	33	18	of	of	ADP
chd-169	33	19	diagnosis	diagnosis	NOUN
chd-169	33	20	,	,	PUNCT
chd-169	33	21	including	include	VERB
chd-169	33	22	higher	high	ADJ
chd-169	33	23	psa	psa	NOUN
chd-169	33	24	levels	level	NOUN
chd-169	33	25	,	,	PUNCT
chd-169	33	26	higher	high	ADJ
chd-169	33	27	gleason	gleason	PROPN
chd-169	33	28	scores	score	NOUN
chd-169	33	29	,	,	PUNCT
chd-169	33	30	differential	differential	ADJ
chd-169	33	31	anatomical	anatomical	ADJ
chd-169	33	32	localization	localization	NOUN
chd-169	33	33	of	of	ADP
chd-169	33	34	the	the	DET
chd-169	33	35	tumors	tumor	NOUN
chd-169	33	36	,	,	PUNCT
chd-169	33	37	and	and	CCONJ
chd-169	33	38	advanced	advanced	ADJ
chd-169	33	39	tumor	tumor	NOUN
chd-169	33	40	stage	stage	NOUN
chd-169	33	41	(	(	PUNCT
chd-169	33	42	abdalla	abdalla	X
chd-169	33	43	et	et	PROPN
chd-169	33	44	al	al	PROPN
chd-169	33	45	.	.	PROPN
chd-169	33	46	,	,	PUNCT
chd-169	33	47	1999	1999	NUM
chd-169	33	48	;	;	PUNCT
chd-169	33	49	chornokur	chornokur	NOUN
chd-169	33	50	et	et	PROPN
chd-169	33	51	al	al	PROPN
chd-169	33	52	.	.	PROPN
chd-169	33	53	,	,	PUNCT
chd-169	33	54	2011	2011	NUM
chd-169	33	55	;	;	PUNCT
chd-169	33	56	moul	moul	X
chd-169	33	57	et	et	PROPN
chd-169	33	58	al	al	PROPN
chd-169	33	59	.	.	PROPN
chd-169	33	60	,	,	PUNCT
chd-169	33	61	1995	1995	NUM
chd-169	33	62	)	)	PUNCT
chd-169	33	63	.	.	PUNCT
chd-169	34	1	moreover	moreover	ADV
chd-169	34	2	,	,	PUNCT
chd-169	34	3	aa	aa	PROPN
chd-169	34	4	men	man	NOUN
chd-169	34	5	show	show	VERB
chd-169	34	6	a	a	DET
chd-169	34	7	higher	high	ADJ
chd-169	34	8	rate	rate	NOUN
chd-169	34	9	of	of	ADP
chd-169	34	10	errors	error	NOUN
chd-169	34	11	at	at	ADP
chd-169	34	12	the	the	DET
chd-169	34	13	time	time	NOUN
chd-169	34	14	of	of	ADP
chd-169	34	15	biopsy	biopsy	NOUN
chd-169	34	16	,	,	PUNCT
chd-169	34	17	leading	lead	VERB
chd-169	34	18	to	to	ADP
chd-169	34	19	under	under	ADP
chd-169	34	20	-	-	PUNCT
chd-169	34	21	detection	detection	NOUN
chd-169	34	22	of	of	ADP
chd-169	34	23	higher	high	ADJ
chd-169	34	24	grade	grade	NOUN
chd-169	34	25	disease	disease	NOUN
chd-169	34	26	at	at	ADP
chd-169	34	27	the	the	DET
chd-169	34	28	time	time	NOUN
chd-169	34	29	of	of	ADP
chd-169	34	30	diagnosis	diagnosis	NOUN
chd-169	34	31	,	,	PUNCT
chd-169	34	32	which	which	PRON
chd-169	34	33	may	may	AUX
chd-169	34	34	compromise	compromise	VERB
chd-169	34	35	their	their	PRON
chd-169	34	36	outcomes	outcome	NOUN
chd-169	34	37	(	(	PUNCT
chd-169	34	38	sanchez	sanchez	NOUN
chd-169	34	39	-	-	PUNCT
chd-169	34	40	ortiz	ortiz	PROPN
chd-169	34	41	et	et	PROPN
chd-169	34	42	al	al	PROPN
chd-169	34	43	.	.	PROPN
chd-169	34	44	,	,	PUNCT
chd-169	34	45	2006	2006	NUM
chd-169	34	46	;	;	PUNCT
chd-169	34	47	sundi	sundi	PROPN
chd-169	34	48	et	et	PROPN
chd-169	34	49	al	al	PROPN
chd-169	34	50	.	.	PROPN
chd-169	34	51	,	,	PUNCT
chd-169	34	52	2013	2013	NUM
chd-169	34	53	)	)	PUNCT
chd-169	34	54	.	.	PUNCT
chd-169	35	1	multifactorial	multifactorial	ADJ
chd-169	35	2	causes	cause	NOUN
chd-169	35	3	of	of	ADP
chd-169	35	4	pca	pca	NOUN
chd-169	35	5	health	health	NOUN
chd-169	35	6	disparities	disparity	NOUN
chd-169	35	7	.	.	PUNCT
chd-169	36	1	the	the	DET
chd-169	36	2	causes	cause	NOUN
chd-169	36	3	of	of	ADP
chd-169	36	4	these	these	DET
chd-169	36	5	racial	racial	ADJ
chd-169	36	6	disparities	disparity	NOUN
chd-169	36	7	are	be	AUX
chd-169	36	8	complex	complex	ADJ
chd-169	36	9	and	and	CCONJ
chd-169	36	10	include	include	VERB
chd-169	36	11	the	the	DET
chd-169	36	12	interplay	interplay	NOUN
chd-169	36	13	between	between	ADP
chd-169	36	14	multiple	multiple	ADJ
chd-169	36	15	factors	factor	NOUN
chd-169	36	16	such	such	ADJ
chd-169	36	17	as	as	ADP
chd-169	36	18	ses	se	NOUN
chd-169	36	19	,	,	PUNCT
chd-169	36	20	biological	biological	ADJ
chd-169	36	21	and	and	CCONJ
chd-169	36	22	genetic	genetic	ADJ
chd-169	36	23	determinants	determinant	NOUN
chd-169	36	24	,	,	PUNCT
chd-169	36	25	stress	stress	NOUN
chd-169	36	26	,	,	PUNCT
chd-169	36	27	diet	diet	NOUN
chd-169	36	28	,	,	PUNCT
chd-169	36	29	lifestyle	lifestyle	NOUN
chd-169	36	30	,	,	PUNCT
chd-169	36	31	and	and	CCONJ
chd-169	36	32	access	access	NOUN
chd-169	36	33	to	to	ADP
chd-169	36	34	healthcare	healthcare	NOUN
chd-169	36	35	(	(	PUNCT
chd-169	36	36	derouen	derouen	PROPN
chd-169	36	37	et	et	PROPN
chd-169	36	38	al	al	PROPN
chd-169	36	39	.	.	PROPN
chd-169	36	40	,	,	PUNCT
chd-169	36	41	2018	2018	NUM
chd-169	36	42	;	;	PUNCT
chd-169	36	43	desantis	desantis	PROPN
chd-169	36	44	et	et	PROPN
chd-169	36	45	al	al	PROPN
chd-169	36	46	.	.	PROPN
chd-169	36	47	,	,	PUNCT
chd-169	36	48	2019	2019	NUM
chd-169	36	49	;	;	PUNCT
chd-169	36	50	deshmukh	deshmukh	PROPN
chd-169	36	51	et	et	PROPN
chd-169	36	52	al	al	PROPN
chd-169	36	53	.	.	PROPN
chd-169	36	54	,	,	PUNCT
chd-169	36	55	2017	2017	NUM
chd-169	36	56	;	;	PUNCT
chd-169	36	57	kelly	kelly	PROPN
chd-169	36	58	et	et	PROPN
chd-169	36	59	al	al	PROPN
chd-169	36	60	.	.	PROPN
chd-169	36	61	,	,	PUNCT
chd-169	36	62	2017	2017	NUM
chd-169	36	63	;	;	PUNCT
chd-169	36	64	kinlock	kinlock	PROPN
chd-169	36	65	et	et	PROPN
chd-169	36	66	al	al	PROPN
chd-169	36	67	.	.	PROPN
chd-169	36	68	,	,	PUNCT
chd-169	36	69	2016	2016	NUM
chd-169	36	70	;	;	PUNCT
chd-169	36	71	krokschoen	krokschoen	PROPN
chd-169	36	72	et	et	PROPN
chd-169	36	73	al	al	PROPN
chd-169	36	74	.	.	PROPN
chd-169	36	75	,	,	PUNCT
chd-169	36	76	2017	2017	NUM
chd-169	36	77	;	;	PUNCT
chd-169	36	78	mahal	mahal	PROPN
chd-169	36	79	et	et	PROPN
chd-169	36	80	al	al	PROPN
chd-169	36	81	.	.	PROPN
chd-169	36	82	,	,	PUNCT
chd-169	36	83	2017	2017	NUM
chd-169	36	84	;	;	PUNCT
chd-169	36	85	singh	singh	PROPN
chd-169	36	86	and	and	CCONJ
chd-169	36	87	jemal	jemal	ADJ
chd-169	36	88	,	,	PUNCT
chd-169	36	89	2017	2017	NUM
chd-169	36	90	;	;	PUNCT
chd-169	36	91	tsodikov	tsodikov	PROPN
chd-169	36	92	et	et	PROPN
chd-169	36	93	al	al	PROPN
chd-169	36	94	.	.	PROPN
chd-169	36	95	,	,	PUNCT
chd-169	36	96	2017	2017	NUM
chd-169	36	97	;	;	PUNCT
chd-169	36	98	weprin	weprin	NOUN
chd-169	36	99	et	et	PROPN
chd-169	36	100	al	al	PROPN
chd-169	36	101	.	.	PROPN
chd-169	36	102	,	,	PUNCT
chd-169	36	103	2019	2019	NUM
chd-169	36	104	)	)	PUNCT
chd-169	36	105	.	.	PUNCT
chd-169	37	1	low	low	ADJ
chd-169	37	2	ses	se	NOUN
chd-169	37	3	directly	directly	ADV
chd-169	37	4	affects	affect	VERB
chd-169	37	5	diet	diet	NOUN
chd-169	37	6	,	,	PUNCT
chd-169	37	7	lifestyle	lifestyle	NOUN
chd-169	37	8	,	,	PUNCT
chd-169	37	9	and	and	CCONJ
chd-169	37	10	access	access	NOUN
chd-169	37	11	to	to	ADP
chd-169	37	12	healthcare	healthcare	PROPN
chd-169	37	13	,	,	PUNCT
chd-169	37	14	and	and	CCONJ
chd-169	37	15	therefore	therefore	ADV
chd-169	37	16	contributes	contribute	VERB
chd-169	37	17	significantly	significantly	ADV
chd-169	37	18	to	to	ADP
chd-169	37	19	cancer	cancer	NOUN
chd-169	37	20	health	health	NOUN
chd-169	37	21	disparities	disparity	NOUN
chd-169	37	22	(	(	PUNCT
chd-169	37	23	bach	bach	PROPN
chd-169	37	24	et	et	PROPN
chd-169	37	25	al	al	PROPN
chd-169	37	26	.	.	PROPN
chd-169	37	27	,	,	PUNCT
chd-169	37	28	2002	2002	NUM
chd-169	37	29	;	;	PUNCT
chd-169	37	30	benjamins	benjamin	NOUN
chd-169	37	31	et	et	PROPN
chd-169	37	32	al	al	PROPN
chd-169	37	33	.	.	PROPN
chd-169	37	34	,	,	PUNCT
chd-169	37	35	2016	2016	NUM
chd-169	37	36	;	;	PUNCT
chd-169	37	37	desantis	desantis	PROPN
chd-169	37	38	et	et	PROPN
chd-169	37	39	al	al	PROPN
chd-169	37	40	.	.	PROPN
chd-169	37	41	,	,	PUNCT
chd-169	37	42	2019	2019	NUM
chd-169	37	43	;	;	PUNCT
chd-169	37	44	ward	ward	NOUN
chd-169	37	45	et	et	PROPN
chd-169	37	46	al	al	PROPN
chd-169	37	47	.	.	PROPN
chd-169	37	48	,	,	PUNCT
chd-169	37	49	2004	2004	NUM
chd-169	37	50	)	)	PUNCT
chd-169	37	51	.	.	PUNCT
chd-169	38	1	aas	aas	PROPN
chd-169	38	2	have	have	AUX
chd-169	38	3	been	be	AUX
chd-169	38	4	reported	report	VERB
chd-169	38	5	to	to	PART
chd-169	38	6	suffer	suffer	VERB
chd-169	38	7	disparities	disparity	NOUN
chd-169	38	8	for	for	ADP
chd-169	38	9	many	many	ADJ
chd-169	38	10	cancer	cancer	NOUN
chd-169	38	11	risk	risk	NOUN
chd-169	38	12	factors	factor	NOUN
chd-169	38	13	,	,	PUNCT
chd-169	38	14	such	such	ADJ
chd-169	38	15	as	as	ADP
chd-169	38	16	lower	low	ADJ
chd-169	38	17	dietary	dietary	ADJ
chd-169	38	18	quality	quality	NOUN
chd-169	38	19	,	,	PUNCT
chd-169	38	20	greater	great	ADJ
chd-169	38	21	rates	rate	NOUN
chd-169	38	22	of	of	ADP
chd-169	38	23	obesity	obesity	NOUN
chd-169	38	24	,	,	PUNCT
chd-169	38	25	lower	low	ADJ
chd-169	38	26	rates	rate	NOUN
chd-169	38	27	of	of	ADP
chd-169	38	28	physical	physical	ADJ
chd-169	38	29	activity	activity	NOUN
chd-169	38	30	,	,	PUNCT
chd-169	38	31	higher	high	ADJ
chd-169	38	32	rates	rate	NOUN
chd-169	38	33	of	of	ADP
chd-169	38	34	exposure	exposure	NOUN
chd-169	38	35	to	to	PART
chd-169	38	36	endocrine	endocrine	VERB
chd-169	38	37	disruptive	disruptive	ADJ
chd-169	38	38	chemicals	chemical	NOUN
chd-169	38	39	,	,	PUNCT
chd-169	38	40	and	and	CCONJ
chd-169	38	41	higher	high	ADJ
chd-169	38	42	prevalence	prevalence	NOUN
chd-169	38	43	of	of	ADP
chd-169	38	44	night	night	NOUN
chd-169	38	45	-	-	PUNCT
chd-169	38	46	shift	shift	NOUN
chd-169	38	47	work	work	NOUN
chd-169	38	48	(	(	PUNCT
chd-169	38	49	wang	wang	PROPN
chd-169	38	50	and	and	CCONJ
chd-169	38	51	chen	chen	PROPN
chd-169	38	52	,	,	PUNCT
chd-169	38	53	2011	2011	NUM
chd-169	38	54	)	)	PUNCT
chd-169	38	55	.	.	PUNCT
chd-169	39	1	income	income	NOUN
chd-169	39	2	inequalities	inequality	NOUN
chd-169	39	3	also	also	ADV
chd-169	39	4	contribute	contribute	VERB
chd-169	39	5	to	to	ADP
chd-169	39	6	increased	increase	VERB
chd-169	39	7	exposure	exposure	NOUN
chd-169	39	8	to	to	ADP
chd-169	39	9	risk	risk	NOUN
chd-169	39	10	factors	factor	NOUN
chd-169	39	11	such	such	ADJ
chd-169	39	12	as	as	ADP
chd-169	39	13	barriers	barrier	NOUN
chd-169	39	14	to	to	ADP
chd-169	39	15	highquality	highquality	NOUN
chd-169	39	16	cancer	cancer	NOUN
chd-169	39	17	prevention	prevention	NOUN
chd-169	39	18	,	,	PUNCT
chd-169	39	19	early	early	ADJ
chd-169	39	20	detection	detection	NOUN
chd-169	39	21	,	,	PUNCT
chd-169	39	22	and	and	CCONJ
chd-169	39	23	cutting	cut	VERB
chd-169	39	24	-	-	PUNCT
chd-169	39	25	edge	edge	NOUN
chd-169	39	26	treatment	treatment	NOUN
chd-169	39	27	options	option	NOUN
chd-169	39	28	(	(	PUNCT
chd-169	39	29	bach	bach	PROPN
chd-169	39	30	et	et	PROPN
chd-169	39	31	al	al	PROPN
chd-169	39	32	.	.	PROPN
chd-169	39	33	,	,	PUNCT
chd-169	39	34	2002	2002	NUM
chd-169	39	35	;	;	PUNCT
chd-169	39	36	benjamins	benjamin	NOUN
chd-169	39	37	et	et	PROPN
chd-169	39	38	al	al	PROPN
chd-169	39	39	.	.	PROPN
chd-169	39	40	,	,	PUNCT
chd-169	39	41	2016	2016	NUM
chd-169	39	42	;	;	PUNCT
chd-169	39	43	desantis	desantis	PROPN
chd-169	39	44	et	et	PROPN
chd-169	39	45	al	al	PROPN
chd-169	39	46	.	.	PROPN
chd-169	39	47	,	,	PUNCT
chd-169	39	48	2019	2019	NUM
chd-169	39	49	;	;	PUNCT
chd-169	39	50	ward	ward	NOUN
chd-169	39	51	et	et	PROPN
chd-169	39	52	al	al	PROPN
chd-169	39	53	.	.	PROPN
chd-169	39	54	,	,	PUNCT
chd-169	39	55	2004	2004	NUM
chd-169	39	56	)	)	PUNCT
chd-169	39	57	.	.	PUNCT
chd-169	40	1	the	the	DET
chd-169	40	2	level	level	NOUN
chd-169	40	3	of	of	ADP
chd-169	40	4	education	education	NOUN
chd-169	40	5	affects	affect	VERB
chd-169	40	6	potential	potential	ADJ
chd-169	40	7	income	income	NOUN
chd-169	40	8	,	,	PUNCT
chd-169	40	9	and	and	CCONJ
chd-169	40	10	aas	aas	NOUN
chd-169	40	11	have	have	VERB
chd-169	40	12	lower	low	ADJ
chd-169	40	13	percentages	percentage	NOUN
chd-169	40	14	of	of	ADP
chd-169	40	15	college	college	NOUN
chd-169	40	16	degrees	degree	NOUN
chd-169	40	17	and	and	CCONJ
chd-169	40	18	higher	high	ADJ
chd-169	40	19	rates	rate	NOUN
chd-169	40	20	of	of	ADP
chd-169	40	21	poverty	poverty	NOUN
chd-169	40	22	than	than	ADP
chd-169	40	23	eas	ea	NOUN
chd-169	40	24	(	(	PUNCT
chd-169	40	25	desantis	desantis	PROPN
chd-169	40	26	et	et	PROPN
chd-169	40	27	al	al	PROPN
chd-169	40	28	.	.	PROPN
chd-169	40	29	,	,	PUNCT
chd-169	40	30	2019	2019	NUM
chd-169	40	31	)	)	PUNCT
chd-169	40	32	.	.	PUNCT
chd-169	41	1	less	less	ADJ
chd-169	41	2	education	education	NOUN
chd-169	41	3	leading	lead	VERB
chd-169	41	4	to	to	ADP
chd-169	41	5	lower	low	ADJ
chd-169	41	6	income	income	NOUN
chd-169	41	7	also	also	ADV
chd-169	41	8	affects	affect	VERB
chd-169	41	9	neighborhood	neighborhood	NOUN
chd-169	41	10	placement	placement	NOUN
chd-169	41	11	,	,	PUNCT
chd-169	41	12	and	and	CCONJ
chd-169	41	13	low	low	ADJ
chd-169	41	14	ses	se	NOUN
chd-169	41	15	neighborhoods	neighborhood	NOUN
chd-169	41	16	are	be	AUX
chd-169	41	17	more	more	ADV
chd-169	41	18	likely	likely	ADJ
chd-169	41	19	to	to	PART
chd-169	41	20	be	be	AUX
chd-169	41	21	targeted	target	VERB
chd-169	41	22	by	by	ADP
chd-169	41	23	marketing	marketing	NOUN
chd-169	41	24	that	that	PRON
chd-169	41	25	promotes	promote	VERB
chd-169	41	26	behaviors	behavior	NOUN
chd-169	41	27	known	know	VERB
chd-169	41	28	to	to	PART
chd-169	41	29	increase	increase	VERB
chd-169	41	30	cancer	cancer	NOUN
chd-169	41	31	risk	risk	NOUN
chd-169	41	32	(	(	PUNCT
chd-169	41	33	desantis	desantis	PROPN
chd-169	41	34	et	et	PROPN
chd-169	41	35	al	al	PROPN
chd-169	41	36	.	.	PROPN
chd-169	41	37	,	,	PUNCT
chd-169	41	38	2016	2016	NUM
chd-169	41	39	)	)	PUNCT
chd-169	41	40	.	.	PUNCT
chd-169	42	1	lower	low	ADJ
chd-169	42	2	ses	se	NOUN
chd-169	42	3	also	also	ADV
chd-169	42	4	translates	translate	VERB
chd-169	42	5	to	to	ADP
chd-169	42	6	worse	bad	ADJ
chd-169	42	7	overall	overall	ADJ
chd-169	42	8	cancer	cancer	NOUN
chd-169	42	9	survival	survival	NOUN
chd-169	42	10	rates	rate	NOUN
chd-169	42	11	for	for	ADP
chd-169	42	12	several	several	ADJ
chd-169	42	13	reasons	reason	NOUN
chd-169	42	14	that	that	PRON
chd-169	42	15	include	include	VERB
chd-169	42	16	limited	limited	ADJ
chd-169	42	17	access	access	NOUN
chd-169	42	18	to	to	ADP
chd-169	42	19	high	high	ADJ
chd-169	42	20	-	-	PUNCT
chd-169	42	21	quality	quality	NOUN
chd-169	42	22	health	health	NOUN
chd-169	42	23	care	care	NOUN
chd-169	42	24	(	(	PUNCT
chd-169	42	25	bach	bach	PROPN
chd-169	42	26	et	et	PROPN
chd-169	42	27	al	al	PROPN
chd-169	42	28	.	.	PROPN
chd-169	42	29	,	,	PUNCT
chd-169	42	30	2002	2002	NUM
chd-169	42	31	;	;	PUNCT
chd-169	42	32	shavers	shaver	NOUN
chd-169	42	33	and	and	CCONJ
chd-169	42	34	brown	brown	ADJ
chd-169	42	35	,	,	PUNCT
chd-169	42	36	2002	2002	NUM
chd-169	42	37	;	;	PUNCT
chd-169	42	38	ward	ward	NOUN
chd-169	42	39	et	et	PROPN
chd-169	42	40	al	al	PROPN
chd-169	42	41	.	.	PROPN
chd-169	42	42	,	,	PUNCT
chd-169	42	43	2008	2008	NUM
chd-169	42	44	;	;	PUNCT
chd-169	42	45	zeng	zeng	PROPN
chd-169	42	46	et	et	PROPN
chd-169	42	47	al	al	PROPN
chd-169	42	48	.	.	PROPN
chd-169	42	49	,	,	PUNCT
chd-169	42	50	2015	2015	NUM
chd-169	42	51	)	)	PUNCT
chd-169	42	52	.	.	PUNCT
chd-169	43	1	worse	bad	ADJ
chd-169	43	2	overall	overall	ADJ
chd-169	43	3	survival	survival	NOUN
chd-169	43	4	is	be	AUX
chd-169	43	5	also	also	ADV
chd-169	43	6	influenced	influence	VERB
chd-169	43	7	by	by	ADP
chd-169	43	8	the	the	DET
chd-169	43	9	fact	fact	NOUN
chd-169	43	10	that	that	SCONJ
chd-169	43	11	aas	aas	PROPN
chd-169	43	12	are	be	AUX
chd-169	43	13	more	more	ADV
chd-169	43	14	likely	likely	ADJ
chd-169	43	15	to	to	PART
chd-169	43	16	be	be	AUX
chd-169	43	17	diagnosed	diagnose	VERB
chd-169	43	18	with	with	ADP
chd-169	43	19	pca	pca	PROPN
chd-169	43	20	at	at	ADP
chd-169	43	21	advanced	advanced	ADJ
chd-169	43	22	tumor	tumor	NOUN
chd-169	43	23	stage	stage	NOUN
chd-169	43	24	,	,	PUNCT
chd-169	43	25	which	which	PRON
chd-169	43	26	limits	limit	VERB
chd-169	43	27	treatment	treatment	NOUN
chd-169	43	28	options	option	NOUN
chd-169	43	29	and	and	CCONJ
chd-169	43	30	reduces	reduce	VERB
chd-169	43	31	their	their	PRON
chd-169	43	32	efficacy	efficacy	NOUN
chd-169	43	33	(	(	PUNCT
chd-169	43	34	arace	arace	NOUN
chd-169	43	35	et	et	PROPN
chd-169	43	36	al	al	PROPN
chd-169	43	37	.	.	PROPN
chd-169	43	38	,	,	PUNCT
chd-169	43	39	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	43	40	e4	e4	PROPN
chd-169	43	41	cancer	cancer	NOUN
chd-169	43	42	health	health	NOUN
chd-169	43	43	disparities	disparity	NOUN
chd-169	43	44	research	research	VERB
chd-169	43	45	2020	2020	NUM
chd-169	43	46	;	;	PUNCT
chd-169	44	1	desantis	desantis	PROPN
chd-169	44	2	et	et	PROPN
chd-169	44	3	al	al	PROPN
chd-169	44	4	.	.	PROPN
chd-169	44	5	,	,	PUNCT
chd-169	44	6	2016	2016	NUM
chd-169	44	7	)	)	PUNCT
chd-169	44	8	.	.	PUNCT
chd-169	45	1	aa	aa	PROPN
chd-169	45	2	men	man	NOUN
chd-169	45	3	also	also	ADV
chd-169	45	4	experience	experience	VERB
chd-169	45	5	lower	low	ADJ
chd-169	45	6	pca	pca	NOUN
chd-169	45	7	screening	screen	VERB
chd-169	45	8	rates	rate	NOUN
chd-169	45	9	compared	compare	VERB
chd-169	45	10	to	to	ADP
chd-169	45	11	non	non	ADJ
chd-169	45	12	-	-	ADJ
chd-169	45	13	aa	aa	ADJ
chd-169	45	14	men	man	NOUN
chd-169	45	15	(	(	PUNCT
chd-169	45	16	misra	misra	ADJ
chd-169	45	17	-	-	PUNCT
chd-169	45	18	hebert	hebert	NOUN
chd-169	45	19	et	et	NOUN
chd-169	45	20	al	al	PROPN
chd-169	45	21	.	.	PROPN
chd-169	45	22	,	,	PUNCT
chd-169	45	23	2017	2017	NUM
chd-169	45	24	)	)	PUNCT
chd-169	45	25	.	.	PUNCT
chd-169	46	1	we	we	PRON
chd-169	46	2	recently	recently	ADV
chd-169	46	3	reported	report	VERB
chd-169	46	4	that	that	SCONJ
chd-169	46	5	in	in	ADP
chd-169	46	6	a	a	DET
chd-169	46	7	sample	sample	NOUN
chd-169	46	8	of	of	ADP
chd-169	46	9	264	264	NUM
chd-169	46	10	aa	aa	NOUN
chd-169	46	11	/	/	SYM
chd-169	46	12	black	black	ADJ
chd-169	46	13	men	man	NOUN
chd-169	46	14	over	over	ADP
chd-169	46	15	45	45	NUM
chd-169	46	16	years	year	NOUN
chd-169	46	17	old	old	ADJ
chd-169	46	18	living	live	VERB
chd-169	46	19	in	in	ADP
chd-169	46	20	the	the	DET
chd-169	46	21	u.s	u.s	PROPN
chd-169	46	22	.	.	PROPN
chd-169	46	23	who	who	PRON
chd-169	46	24	met	meet	VERB
chd-169	46	25	the	the	DET
chd-169	46	26	american	american	PROPN
chd-169	46	27	cancer	cancer	PROPN
chd-169	46	28	society	society	PROPN
chd-169	46	29	criteria	criterion	NOUN
chd-169	46	30	for	for	ADP
chd-169	46	31	screening	screen	VERB
chd-169	46	32	,	,	PUNCT
chd-169	46	33	only	only	ADV
chd-169	46	34	49.6	49.6	NUM
chd-169	46	35	%	%	NOUN
chd-169	46	36	had	have	AUX
chd-169	46	37	ever	ever	ADV
chd-169	46	38	been	be	AUX
chd-169	46	39	screened	screen	VERB
chd-169	46	40	and	and	CCONJ
chd-169	46	41	only	only	ADV
chd-169	46	42	29.2	29.2	NUM
chd-169	46	43	%	%	NOUN
chd-169	46	44	had	have	VERB
chd-169	46	45	a	a	DET
chd-169	46	46	psa	psa	NOUN
chd-169	46	47	test	test	NOUN
chd-169	46	48	within	within	ADP
chd-169	46	49	the	the	DET
chd-169	46	50	last	last	ADJ
chd-169	46	51	year	year	NOUN
chd-169	46	52	,	,	PUNCT
chd-169	46	53	consistent	consistent	ADJ
chd-169	46	54	with	with	ADP
chd-169	46	55	other	other	ADJ
chd-169	46	56	reports	report	NOUN
chd-169	46	57	of	of	ADP
chd-169	46	58	lower	low	ADJ
chd-169	46	59	rates	rate	NOUN
chd-169	46	60	of	of	ADP
chd-169	46	61	screening	screen	VERB
chd-169	46	62	among	among	ADP
chd-169	46	63	aa	aa	PROPN
chd-169	46	64	men	man	NOUN
chd-169	46	65	(	(	PUNCT
chd-169	46	66	roberts	roberts	PROPN
chd-169	46	67	et	et	PROPN
chd-169	46	68	al	al	PROPN
chd-169	46	69	.	.	PROPN
chd-169	46	70	,	,	PUNCT
chd-169	46	71	2018	2018	NUM
chd-169	46	72	)	)	PUNCT
chd-169	46	73	.	.	PUNCT
chd-169	47	1	in	in	ADP
chd-169	47	2	another	another	DET
chd-169	47	3	study	study	NOUN
chd-169	47	4	of	of	ADP
chd-169	47	5	414	414	NUM
chd-169	47	6	aa	aa	ADJ
chd-169	47	7	/	/	SYM
chd-169	47	8	black	black	ADJ
chd-169	47	9	men	man	NOUN
chd-169	47	10	(	(	PUNCT
chd-169	47	11	mean	mean	VERB
chd-169	47	12	age	age	NOUN
chd-169	47	13	48.9	48.9	NUM
chd-169	47	14	years	year	NOUN
chd-169	47	15	)	)	PUNCT
chd-169	47	16	living	live	VERB
chd-169	47	17	in	in	ADP
chd-169	47	18	the	the	DET
chd-169	47	19	u.s	u.s	PROPN
chd-169	47	20	.	.	PROPN
chd-169	47	21	,	,	PUNCT
chd-169	47	22	we	we	PRON
chd-169	47	23	found	find	VERB
chd-169	47	24	that	that	SCONJ
chd-169	47	25	less	less	ADJ
chd-169	47	26	than	than	ADP
chd-169	47	27	half	half	NOUN
chd-169	47	28	(	(	PUNCT
chd-169	47	29	45.2	45.2	NUM
chd-169	47	30	%	%	NOUN
chd-169	47	31	)	)	PUNCT
chd-169	47	32	of	of	ADP
chd-169	47	33	the	the	DET
chd-169	47	34	participants	participant	NOUN
chd-169	47	35	had	have	AUX
chd-169	47	36	discussed	discuss	VERB
chd-169	47	37	pca	pca	NOUN
chd-169	47	38	screening	screening	NOUN
chd-169	47	39	with	with	ADP
chd-169	47	40	their	their	PRON
chd-169	47	41	physicians	physician	NOUN
chd-169	47	42	,	,	PUNCT
chd-169	47	43	and	and	CCONJ
chd-169	47	44	detected	detect	VERB
chd-169	47	45	higher	high	ADJ
chd-169	47	46	-	-	PUNCT
chd-169	47	47	than	than	ADP
chd-169	47	48	-	-	PUNCT
chd-169	47	49	normal	normal	ADJ
chd-169	47	50	psa	psa	NOUN
chd-169	47	51	values	value	NOUN
chd-169	47	52	in	in	ADP
chd-169	47	53	29.1	29.1	NUM
chd-169	47	54	%	%	NOUN
chd-169	47	55	of	of	ADP
chd-169	47	56	the	the	DET
chd-169	47	57	men	man	NOUN
chd-169	47	58	who	who	PRON
chd-169	47	59	had	have	AUX
chd-169	47	60	not	not	PART
chd-169	47	61	discussed	discuss	VERB
chd-169	47	62	pca	pca	NOUN
chd-169	47	63	screening	screening	NOUN
chd-169	47	64	(	(	PUNCT
chd-169	47	65	woods	wood	NOUN
chd-169	47	66	-	-	PUNCT
chd-169	47	67	burnham	burnham	NOUN
chd-169	47	68	et	et	NOUN
chd-169	47	69	al	al	PROPN
chd-169	47	70	.	.	PROPN
chd-169	47	71	,	,	PUNCT
chd-169	47	72	2018b	2018b	NUM
chd-169	47	73	)	)	PUNCT
chd-169	47	74	.	.	PUNCT
chd-169	48	1	even	even	ADV
chd-169	48	2	when	when	SCONJ
chd-169	48	3	provided	provide	VERB
chd-169	48	4	the	the	DET
chd-169	48	5	same	same	ADJ
chd-169	48	6	pca	pca	NOUN
chd-169	48	7	treatment	treatment	NOUN
chd-169	48	8	as	as	ADP
chd-169	48	9	ea	ea	NUM
chd-169	48	10	men	man	NOUN
chd-169	48	11	,	,	PUNCT
chd-169	48	12	aa	aa	ADJ
chd-169	48	13	men	man	NOUN
chd-169	48	14	are	be	AUX
chd-169	48	15	more	more	ADV
chd-169	48	16	likely	likely	ADJ
chd-169	48	17	to	to	PART
chd-169	48	18	experience	experience	VERB
chd-169	48	19	delay	delay	NOUN
chd-169	48	20	in	in	ADP
chd-169	48	21	treatment	treatment	NOUN
chd-169	48	22	administration	administration	NOUN
chd-169	48	23	and	and	CCONJ
chd-169	48	24	suffer	suffer	VERB
chd-169	48	25	greater	great	ADJ
chd-169	48	26	postoperative	postoperative	ADJ
chd-169	48	27	complications	complication	NOUN
chd-169	48	28	(	(	PUNCT
chd-169	48	29	schmid	schmid	PROPN
chd-169	48	30	et	et	PROPN
chd-169	48	31	al	al	PROPN
chd-169	48	32	.	.	PROPN
chd-169	48	33	,	,	PUNCT
chd-169	48	34	2016	2016	NUM
chd-169	48	35	)	)	PUNCT
chd-169	48	36	.	.	PUNCT
chd-169	49	1	in	in	ADP
chd-169	49	2	addition	addition	NOUN
chd-169	49	3	,	,	PUNCT
chd-169	49	4	aas	aas	PROPN
chd-169	49	5	are	be	AUX
chd-169	49	6	less	less	ADV
chd-169	49	7	likely	likely	ADJ
chd-169	49	8	to	to	PART
chd-169	49	9	enroll	enroll	VERB
chd-169	49	10	in	in	ADP
chd-169	49	11	clinical	clinical	ADJ
chd-169	49	12	trials	trial	NOUN
chd-169	49	13	,	,	PUNCT
chd-169	49	14	preventing	prevent	VERB
chd-169	49	15	them	they	PRON
chd-169	49	16	from	from	ADP
chd-169	49	17	exposure	exposure	NOUN
chd-169	49	18	to	to	ADP
chd-169	49	19	cutting	cut	VERB
chd-169	49	20	-	-	PUNCT
chd-169	49	21	edge	edge	NOUN
chd-169	49	22	treatment	treatment	NOUN
chd-169	49	23	options	option	NOUN
chd-169	49	24	(	(	PUNCT
chd-169	49	25	murthy	murthy	PROPN
chd-169	49	26	et	et	PROPN
chd-169	49	27	al	al	PROPN
chd-169	49	28	.	.	PROPN
chd-169	49	29	,	,	PUNCT
chd-169	49	30	2004	2004	NUM
chd-169	49	31	;	;	PUNCT
chd-169	49	32	wallace	wallace	PROPN
chd-169	49	33	et	et	PROPN
chd-169	49	34	al	al	PROPN
chd-169	49	35	.	.	PROPN
chd-169	49	36	,	,	PUNCT
chd-169	49	37	2011	2011	NUM
chd-169	49	38	)	)	PUNCT
chd-169	49	39	.	.	PUNCT
chd-169	50	1	co	co	NOUN
chd-169	50	2	-	-	NOUN
chd-169	50	3	morbidities	morbidity	NOUN
chd-169	50	4	affecting	affect	VERB
chd-169	50	5	delivery	delivery	NOUN
chd-169	50	6	of	of	ADP
chd-169	50	7	optimal	optimal	ADJ
chd-169	50	8	treatment	treatment	NOUN
chd-169	50	9	,	,	PUNCT
chd-169	50	10	including	include	VERB
chd-169	50	11	obesity	obesity	NOUN
chd-169	50	12	,	,	PUNCT
chd-169	50	13	diabetes	diabetes	NOUN
chd-169	50	14	,	,	PUNCT
chd-169	50	15	and	and	CCONJ
chd-169	50	16	hypertension	hypertension	NOUN
chd-169	50	17	,	,	PUNCT
chd-169	50	18	are	be	AUX
chd-169	50	19	higher	high	ADJ
chd-169	50	20	in	in	ADP
chd-169	50	21	aas	aas	NOUN
chd-169	50	22	and	and	CCONJ
chd-169	50	23	may	may	AUX
chd-169	50	24	exacerbate	exacerbate	VERB
chd-169	50	25	pca	pca	NOUN
chd-169	50	26	mortality	mortality	NOUN
chd-169	50	27	(	(	PUNCT
chd-169	50	28	braithwaite	braithwaite	PROPN
chd-169	50	29	et	et	PROPN
chd-169	50	30	al	al	PROPN
chd-169	50	31	.	.	PROPN
chd-169	50	32	,	,	PUNCT
chd-169	50	33	2009	2009	NUM
chd-169	50	34	;	;	PUNCT
chd-169	50	35	tammemagi	tammemagi	NOUN
chd-169	50	36	et	et	PROPN
chd-169	50	37	al	al	PROPN
chd-169	50	38	.	.	PROPN
chd-169	50	39	,	,	PUNCT
chd-169	50	40	2005	2005	NUM
chd-169	50	41	;	;	PUNCT
chd-169	50	42	yancik	yancik	PROPN
chd-169	50	43	et	et	PROPN
chd-169	50	44	al	al	PROPN
chd-169	50	45	.	.	PROPN
chd-169	50	46	,	,	PUNCT
chd-169	50	47	1998	1998	NUM
chd-169	50	48	)	)	PUNCT
chd-169	50	49	.	.	PUNCT
chd-169	51	1	the	the	DET
chd-169	51	2	current	current	ADJ
chd-169	51	3	covid-19	covid-19	PROPN
chd-169	51	4	pandemic	pandemic	NOUN
chd-169	51	5	has	have	AUX
chd-169	51	6	clearly	clearly	ADV
chd-169	51	7	exposed	expose	VERB
chd-169	51	8	how	how	SCONJ
chd-169	51	9	these	these	DET
chd-169	51	10	co	co	NOUN
chd-169	51	11	-	-	NOUN
chd-169	51	12	morbidities	morbidity	NOUN
chd-169	51	13	,	,	PUNCT
chd-169	51	14	combined	combine	VERB
chd-169	51	15	with	with	ADP
chd-169	51	16	an	an	DET
chd-169	51	17	adverse	adverse	ADJ
chd-169	51	18	and	and	CCONJ
chd-169	51	19	stressful	stressful	ADJ
chd-169	51	20	host	host	NOUN
chd-169	51	21	-	-	PUNCT
chd-169	51	22	environment	environment	NOUN
chd-169	51	23	,	,	PUNCT
chd-169	51	24	have	have	AUX
chd-169	51	25	rendered	render	VERB
chd-169	51	26	aa	aa	NOUN
chd-169	51	27	populations	population	NOUN
chd-169	51	28	more	more	ADV
chd-169	51	29	vulnerable	vulnerable	ADJ
chd-169	51	30	during	during	ADP
chd-169	51	31	the	the	DET
chd-169	51	32	pandemic	pandemic	ADJ
chd-169	51	33	(	(	PUNCT
chd-169	51	34	holmes	holmes	PROPN
chd-169	51	35	et	et	PROPN
chd-169	51	36	al	al	PROPN
chd-169	51	37	.	.	PROPN
chd-169	51	38	,	,	PUNCT
chd-169	51	39	2020	2020	NUM
chd-169	51	40	)	)	PUNCT
chd-169	51	41	.	.	PUNCT
chd-169	52	1	molecular	molecular	ADJ
chd-169	52	2	determinants	determinant	NOUN
chd-169	52	3	of	of	ADP
chd-169	52	4	prostate	prostate	NOUN
chd-169	52	5	cancer	cancer	NOUN
chd-169	52	6	disparities	disparity	NOUN
chd-169	52	7	.	.	PUNCT
chd-169	53	1	although	although	SCONJ
chd-169	53	2	studies	study	NOUN
chd-169	53	3	from	from	ADP
chd-169	53	4	the	the	DET
chd-169	53	5	u.s	u.s	PROPN
chd-169	53	6	.	.	PROPN
chd-169	53	7	veteran	veteran	PROPN
chd-169	53	8	administration	administration	PROPN
chd-169	53	9	health	health	PROPN
chd-169	53	10	care	care	NOUN
chd-169	53	11	system	system	NOUN
chd-169	53	12	suggest	suggest	VERB
chd-169	53	13	that	that	SCONJ
chd-169	53	14	pca	pca	PROPN
chd-169	53	15	health	health	NOUN
chd-169	53	16	disparities	disparity	NOUN
chd-169	53	17	can	can	AUX
chd-169	53	18	be	be	AUX
chd-169	53	19	attenuated	attenuate	VERB
chd-169	53	20	with	with	ADP
chd-169	53	21	better	well	ADJ
chd-169	53	22	access	access	NOUN
chd-169	53	23	to	to	ADP
chd-169	53	24	health	health	NOUN
chd-169	53	25	care	care	NOUN
chd-169	53	26	(	(	PUNCT
chd-169	53	27	daskivich	daskivich	PROPN
chd-169	53	28	et	et	PROPN
chd-169	53	29	al	al	PROPN
chd-169	53	30	.	.	PROPN
chd-169	53	31	,	,	PUNCT
chd-169	53	32	2015	2015	NUM
chd-169	53	33	;	;	PUNCT
chd-169	53	34	riviere	riviere	PROPN
chd-169	53	35	et	et	PROPN
chd-169	53	36	al	al	PROPN
chd-169	53	37	.	.	PROPN
chd-169	53	38	,	,	PUNCT
chd-169	53	39	2020	2020	NUM
chd-169	53	40	)	)	PUNCT
chd-169	53	41	,	,	PUNCT
chd-169	53	42	other	other	ADJ
chd-169	53	43	studies	study	NOUN
chd-169	53	44	indicate	indicate	VERB
chd-169	53	45	that	that	SCONJ
chd-169	53	46	these	these	DET
chd-169	53	47	disparities	disparity	NOUN
chd-169	53	48	persist	persist	VERB
chd-169	53	49	even	even	ADV
chd-169	53	50	after	after	ADP
chd-169	53	51	controlling	control	VERB
chd-169	53	52	for	for	ADP
chd-169	53	53	ses	se	NOUN
chd-169	53	54	,	,	PUNCT
chd-169	53	55	clinical	clinical	ADJ
chd-169	53	56	setting	setting	NOUN
chd-169	53	57	,	,	PUNCT
chd-169	53	58	and	and	CCONJ
chd-169	53	59	access	access	NOUN
chd-169	53	60	to	to	ADP
chd-169	53	61	care	care	NOUN
chd-169	53	62	(	(	PUNCT
chd-169	53	63	du	du	PROPN
chd-169	53	64	et	et	PROPN
chd-169	53	65	al	al	PROPN
chd-169	53	66	.	.	PROPN
chd-169	53	67	,	,	PUNCT
chd-169	53	68	2011	2011	NUM
chd-169	53	69	;	;	PUNCT
chd-169	53	70	kish	kish	PROPN
chd-169	53	71	et	et	PROPN
chd-169	53	72	al	al	PROPN
chd-169	53	73	.	.	PROPN
chd-169	53	74	,	,	PUNCT
chd-169	53	75	2014	2014	NUM
chd-169	53	76	;	;	PUNCT
chd-169	53	77	nettey	nettey	PROPN
chd-169	53	78	et	et	PROPN
chd-169	53	79	al	al	PROPN
chd-169	53	80	.	.	PROPN
chd-169	53	81	,	,	PUNCT
chd-169	53	82	2018	2018	NUM
chd-169	53	83	)	)	PUNCT
chd-169	53	84	.	.	PUNCT
chd-169	54	1	this	this	PRON
chd-169	54	2	suggests	suggest	VERB
chd-169	54	3	that	that	SCONJ
chd-169	54	4	molecular	molecular	ADJ
chd-169	54	5	or	or	CCONJ
chd-169	54	6	biological	biological	ADJ
chd-169	54	7	determinants	determinant	NOUN
chd-169	54	8	may	may	AUX
chd-169	54	9	also	also	ADV
chd-169	54	10	contribute	contribute	VERB
chd-169	54	11	to	to	ADP
chd-169	54	12	these	these	DET
chd-169	54	13	disparities	disparity	NOUN
chd-169	54	14	(	(	PUNCT
chd-169	54	15	bhardwaj	bhardwaj	PROPN
chd-169	54	16	et	et	PROPN
chd-169	54	17	al	al	PROPN
chd-169	54	18	.	.	PROPN
chd-169	54	19	,	,	PUNCT
chd-169	54	20	2017	2017	NUM
chd-169	54	21	;	;	PUNCT
chd-169	54	22	singh	singh	PROPN
chd-169	54	23	et	et	PROPN
chd-169	54	24	al	al	PROPN
chd-169	54	25	.	.	PROPN
chd-169	54	26	,	,	PUNCT
chd-169	54	27	2017	2017	NUM
chd-169	54	28	)	)	PUNCT
chd-169	54	29	.	.	PUNCT
chd-169	55	1	genomic	genomic	ADJ
chd-169	55	2	differences	difference	NOUN
chd-169	55	3	between	between	ADP
chd-169	55	4	aa	aa	NOUN
chd-169	55	5	and	and	CCONJ
chd-169	55	6	ea	ea	NOUN
chd-169	55	7	men	man	NOUN
chd-169	55	8	with	with	ADP
chd-169	55	9	pca	pca	PROPN
chd-169	55	10	hint	hint	NOUN
chd-169	55	11	that	that	SCONJ
chd-169	55	12	genetic	genetic	ADJ
chd-169	55	13	mediators	mediator	NOUN
chd-169	55	14	may	may	AUX
chd-169	55	15	drive	drive	VERB
chd-169	55	16	pca	pca	PROPN
chd-169	55	17	health	health	NOUN
chd-169	55	18	disparities	disparity	NOUN
chd-169	55	19	(	(	PUNCT
chd-169	55	20	batai	batai	NOUN
chd-169	55	21	et	et	PROPN
chd-169	55	22	al	al	PROPN
chd-169	55	23	.	.	PROPN
chd-169	55	24	,	,	PUNCT
chd-169	55	25	2016	2016	NUM
chd-169	55	26	;	;	PUNCT
chd-169	55	27	gusev	gusev	NOUN
chd-169	55	28	et	et	PROPN
chd-169	55	29	al	al	PROPN
chd-169	55	30	.	.	PROPN
chd-169	55	31	,	,	PUNCT
chd-169	55	32	2016	2016	NUM
chd-169	55	33	;	;	PUNCT
chd-169	55	34	han	han	PROPN
chd-169	55	35	et	et	PROPN
chd-169	55	36	al	al	PROPN
chd-169	55	37	.	.	PROPN
chd-169	55	38	,	,	PUNCT
chd-169	55	39	2015	2015	NUM
chd-169	55	40	;	;	PUNCT
chd-169	55	41	hoffman	hoffman	PROPN
chd-169	55	42	et	et	PROPN
chd-169	55	43	al	al	PROPN
chd-169	55	44	.	.	PROPN
chd-169	55	45	,	,	PUNCT
chd-169	55	46	2001	2001	NUM
chd-169	55	47	;	;	PUNCT
chd-169	55	48	powell	powell	PROPN
chd-169	55	49	et	et	PROPN
chd-169	55	50	al	al	PROPN
chd-169	55	51	.	.	PROPN
chd-169	55	52	,	,	PUNCT
chd-169	55	53	2013	2013	NUM
chd-169	55	54	;	;	PUNCT
chd-169	55	55	rand	rand	NOUN
chd-169	55	56	et	et	PROPN
chd-169	55	57	al	al	PROPN
chd-169	55	58	.	.	PROPN
chd-169	55	59	,	,	PUNCT
chd-169	55	60	2016	2016	NUM
chd-169	55	61	;	;	PUNCT
chd-169	55	62	reams	ream	NOUN
chd-169	55	63	et	et	PROPN
chd-169	55	64	al	al	PROPN
chd-169	55	65	.	.	PROPN
chd-169	55	66	,	,	PUNCT
chd-169	55	67	2009	2009	NUM
chd-169	55	68	;	;	PUNCT
chd-169	55	69	wallace	wallace	PROPN
chd-169	55	70	et	et	PROPN
chd-169	55	71	al	al	PROPN
chd-169	55	72	.	.	PROPN
chd-169	55	73	,	,	PUNCT
chd-169	55	74	2008	2008	NUM
chd-169	55	75	;	;	PUNCT
chd-169	55	76	wang	wang	PROPN
chd-169	55	77	et	et	PROPN
chd-169	55	78	al	al	PROPN
chd-169	55	79	.	.	PROPN
chd-169	55	80	,	,	PUNCT
chd-169	55	81	2017	2017	NUM
chd-169	55	82	)	)	PUNCT
chd-169	55	83	.	.	PUNCT
chd-169	56	1	this	this	PRON
chd-169	56	2	is	be	AUX
chd-169	56	3	supported	support	VERB
chd-169	56	4	by	by	ADP
chd-169	56	5	the	the	DET
chd-169	56	6	identification	identification	NOUN
chd-169	56	7	of	of	ADP
chd-169	56	8	pca	pca	PROPN
chd-169	56	9	susceptibility	susceptibility	NOUN
chd-169	56	10	loci	locus	NOUN
chd-169	56	11	for	for	ADP
chd-169	56	12	aa	aa	NOUN
chd-169	56	13	men	man	NOUN
chd-169	56	14	in	in	ADP
chd-169	56	15	both	both	DET
chd-169	56	16	linkage	linkage	NOUN
chd-169	56	17	studies	study	NOUN
chd-169	56	18	and	and	CCONJ
chd-169	56	19	genome	genome	NOUN
chd-169	56	20	-	-	PUNCT
chd-169	56	21	wide	wide	ADJ
chd-169	56	22	association	association	NOUN
chd-169	56	23	studies	study	NOUN
chd-169	56	24	(	(	PUNCT
chd-169	56	25	gwas	gwas	PROPN
chd-169	56	26	)	)	PUNCT
chd-169	56	27	(	(	PUNCT
chd-169	56	28	gudmundsson	gudmundsson	NOUN
chd-169	56	29	et	et	PROPN
chd-169	56	30	al	al	PROPN
chd-169	56	31	.	.	PROPN
chd-169	56	32	,	,	PUNCT
chd-169	56	33	2007	2007	NUM
chd-169	56	34	;	;	PUNCT
chd-169	56	35	kote	kote	VERB
chd-169	56	36	-	-	PUNCT
chd-169	56	37	jarai	jarai	VERB
chd-169	56	38	et	et	PROPN
chd-169	56	39	al	al	PROPN
chd-169	56	40	.	.	PROPN
chd-169	56	41	,	,	PUNCT
chd-169	56	42	2011	2011	NUM
chd-169	56	43	;	;	PUNCT
chd-169	56	44	yeager	yeager	PROPN
chd-169	56	45	et	et	PROPN
chd-169	56	46	al	al	PROPN
chd-169	56	47	.	.	PROPN
chd-169	56	48	,	,	PUNCT
chd-169	56	49	2007	2007	NUM
chd-169	56	50	)	)	PUNCT
chd-169	56	51	.	.	PUNCT
chd-169	57	1	interestingly	interestingly	ADV
chd-169	57	2	,	,	PUNCT
chd-169	57	3	genetic	genetic	ADJ
chd-169	57	4	variation	variation	NOUN
chd-169	57	5	on	on	ADP
chd-169	57	6	the	the	DET
chd-169	57	7	chromosome	chromosome	NOUN
chd-169	57	8	8q24	8q24	NOUN
chd-169	57	9	region	region	NOUN
chd-169	57	10	,	,	PUNCT
chd-169	57	11	where	where	SCONJ
chd-169	57	12	the	the	DET
chd-169	57	13	c	c	NOUN
chd-169	57	14	-	-	PUNCT
chd-169	57	15	myc	myc	NOUN
chd-169	57	16	gene	gene	NOUN
chd-169	57	17	is	be	AUX
chd-169	57	18	located	locate	VERB
chd-169	57	19	,	,	PUNCT
chd-169	57	20	has	have	AUX
chd-169	57	21	been	be	AUX
chd-169	57	22	consistently	consistently	ADV
chd-169	57	23	associated	associate	VERB
chd-169	57	24	with	with	ADP
chd-169	57	25	pca	pca	PROPN
chd-169	57	26	risk	risk	NOUN
chd-169	57	27	,	,	PUNCT
chd-169	57	28	and	and	CCONJ
chd-169	57	29	ethnic	ethnic	ADJ
chd-169	57	30	specific	specific	ADJ
chd-169	57	31	mutations	mutation	NOUN
chd-169	57	32	and	and	CCONJ
chd-169	57	33	haplotypes	haplotype	NOUN
chd-169	57	34	have	have	AUX
chd-169	57	35	been	be	AUX
chd-169	57	36	reported	report	VERB
chd-169	57	37	in	in	ADP
chd-169	57	38	african	african	ADJ
chd-169	57	39	populations	population	NOUN
chd-169	57	40	(	(	PUNCT
chd-169	57	41	chung	chung	PROPN
chd-169	57	42	et	et	PROPN
chd-169	57	43	al	al	PROPN
chd-169	57	44	.	.	PROPN
chd-169	57	45	,	,	PUNCT
chd-169	57	46	2014	2014	NUM
chd-169	57	47	;	;	PUNCT
chd-169	58	1	darst	darst	ADV
chd-169	58	2	et	et	PROPN
chd-169	58	3	al	al	PROPN
chd-169	58	4	.	.	PROPN
chd-169	58	5	,	,	PUNCT
chd-169	58	6	2020	2020	NUM
chd-169	58	7	)	)	PUNCT
chd-169	58	8	.	.	PUNCT
chd-169	59	1	in	in	ADP
chd-169	59	2	addition	addition	NOUN
chd-169	59	3	to	to	ADP
chd-169	59	4	inherited	inherit	VERB
chd-169	59	5	genomic	genomic	NOUN
chd-169	59	6	factors	factor	NOUN
chd-169	59	7	linked	link	VERB
chd-169	59	8	to	to	ADP
chd-169	59	9	pca	pca	PROPN
chd-169	59	10	,	,	PUNCT
chd-169	59	11	there	there	PRON
chd-169	59	12	are	be	VERB
chd-169	59	13	also	also	ADV
chd-169	59	14	genetic	genetic	ADJ
chd-169	59	15	alterations	alteration	NOUN
chd-169	59	16	that	that	PRON
chd-169	59	17	are	be	AUX
chd-169	59	18	associated	associate	VERB
chd-169	59	19	with	with	ADP
chd-169	59	20	pca	pca	PROPN
chd-169	59	21	risk	risk	NOUN
chd-169	59	22	(	(	PUNCT
chd-169	59	23	rebbeck	rebbeck	NOUN
chd-169	59	24	,	,	PUNCT
chd-169	59	25	2017	2017	NUM
chd-169	59	26	)	)	PUNCT
chd-169	59	27	.	.	PUNCT
chd-169	60	1	recent	recent	ADJ
chd-169	60	2	genomic	genomic	ADJ
chd-169	60	3	studies	study	NOUN
chd-169	60	4	on	on	ADP
chd-169	60	5	human	human	ADJ
chd-169	60	6	prostate	prostate	NOUN
chd-169	60	7	tumors	tumor	NOUN
chd-169	60	8	have	have	AUX
chd-169	60	9	identified	identify	VERB
chd-169	60	10	multiple	multiple	ADJ
chd-169	60	11	oncogenic	oncogenic	ADJ
chd-169	60	12	drivers	driver	NOUN
chd-169	60	13	of	of	ADP
chd-169	60	14	pca	pca	PROPN
chd-169	60	15	development	development	NOUN
chd-169	60	16	.	.	PUNCT
chd-169	61	1	these	these	PRON
chd-169	61	2	include	include	VERB
chd-169	61	3	chromosomal	chromosomal	ADJ
chd-169	61	4	translocations	translocation	NOUN
chd-169	61	5	resulting	result	VERB
chd-169	61	6	in	in	ADP
chd-169	61	7	the	the	DET
chd-169	61	8	generation	generation	NOUN
chd-169	61	9	of	of	ADP
chd-169	61	10	a	a	DET
chd-169	61	11	fusion	fusion	NOUN
chd-169	61	12	between	between	ADP
chd-169	61	13	the	the	DET
chd-169	61	14	tmprss2	tmprss2	NOUN
chd-169	61	15	(	(	PUNCT
chd-169	61	16	a	a	DET
chd-169	61	17	transmembrane	transmembrane	ADJ
chd-169	61	18	serine	serine	NOUN
chd-169	61	19	protease	protease	NOUN
chd-169	61	20	)	)	PUNCT
chd-169	61	21	and	and	CCONJ
chd-169	61	22	erg	erg	PROPN
chd-169	61	23	(	(	PUNCT
chd-169	61	24	a	a	DET
chd-169	61	25	member	member	NOUN
chd-169	61	26	of	of	ADP
chd-169	61	27	the	the	DET
chd-169	61	28	ets	et	NOUN
chd-169	61	29	transcription	transcription	NOUN
chd-169	61	30	factor	factor	NOUN
chd-169	61	31	family	family	NOUN
chd-169	61	32	)	)	PUNCT
chd-169	61	33	genes	gene	NOUN
chd-169	61	34	,	,	PUNCT
chd-169	61	35	as	as	ADV
chd-169	61	36	well	well	ADV
chd-169	61	37	as	as	ADP
chd-169	61	38	mutations	mutation	NOUN
chd-169	61	39	or	or	CCONJ
chd-169	61	40	alterations	alteration	NOUN
chd-169	61	41	in	in	ADP
chd-169	61	42	genes	gene	NOUN
chd-169	61	43	associated	associate	VERB
chd-169	61	44	with	with	ADP
chd-169	61	45	phosphoinositide	phosphoinositide	NOUN
chd-169	61	46	3	3	NUM
chd-169	61	47	-	-	PUNCT
chd-169	61	48	kinase(pi3k)-akt	kinase(pi3k)-akt	NOUN
chd-169	61	49	signaling	signaling	NOUN
chd-169	61	50	,	,	PUNCT
chd-169	61	51	wnt	wnt	PROPN
chd-169	61	52	/	/	SYM
chd-169	61	53	β	β	NOUN
chd-169	61	54	-	-	ADJ
chd-169	61	55	catenin	catenin	ADJ
chd-169	61	56	pathway	pathway	NOUN
chd-169	61	57	,	,	PUNCT
chd-169	61	58	transcription	transcription	NOUN
chd-169	61	59	and	and	CCONJ
chd-169	61	60	epigenetic	epigenetic	ADJ
chd-169	61	61	regulation	regulation	NOUN
chd-169	61	62	(	(	PUNCT
chd-169	61	63	e.g.	e.g.	ADV
chd-169	61	64	ets	et	NOUN
chd-169	61	65	,	,	PUNCT
chd-169	61	66	foxa1	foxa1	NOUN
chd-169	61	67	,	,	PUNCT
chd-169	61	68	kmt2c	kmt2c	PROPN
chd-169	61	69	/	/	SYM
chd-169	61	70	d	d	PROPN
chd-169	61	71	,	,	PUNCT
chd-169	61	72	swi	swi	PROPN
chd-169	61	73	/	/	SYM
chd-169	61	74	snf	snf	PROPN
chd-169	61	75	complex	complex	ADJ
chd-169	61	76	members	member	NOUN
chd-169	61	77	)	)	PUNCT
chd-169	61	78	,	,	PUNCT
chd-169	61	79	ubiquitination	ubiquitination	NOUN
chd-169	61	80	(	(	PUNCT
chd-169	61	81	e.g.	e.g.	ADV
chd-169	61	82	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PUNCT
chd-169	61	83	e5	e5	PROPN
chd-169	61	84	cancer	cancer	NOUN
chd-169	61	85	health	health	NOUN
chd-169	61	86	disparities	disparity	NOUN
chd-169	61	87	research	research	NOUN
chd-169	61	88	spop	spop	NOUN
chd-169	61	89	and	and	CCONJ
chd-169	61	90	cul3	cul3	PROPN
chd-169	61	91	)	)	PUNCT
chd-169	61	92	,	,	PUNCT
chd-169	61	93	dna	dna	PROPN
chd-169	61	94	repair	repair	NOUN
chd-169	61	95	(	(	PUNCT
chd-169	61	96	e.g.	e.g.	ADV
chd-169	61	97	brca2	brca2	PROPN
chd-169	61	98	,	,	PUNCT
chd-169	61	99	atm	atm	PROPN
chd-169	61	100	,	,	PUNCT
chd-169	61	101	cdk12	cdk12	ADJ
chd-169	61	102	)	)	PUNCT
chd-169	61	103	,	,	PUNCT
chd-169	61	104	tumor	tumor	NOUN
chd-169	61	105	suppression	suppression	NOUN
chd-169	61	106	(	(	PUNCT
chd-169	61	107	e.g.	e.g.	ADV
chd-169	61	108	tp53	tp53	PROPN
chd-169	61	109	,	,	PUNCT
chd-169	61	110	pten	pten	NOUN
chd-169	61	111	)	)	PUNCT
chd-169	61	112	,	,	PUNCT
chd-169	61	113	rasmapk	rasmapk	NOUN
chd-169	61	114	signaling	signaling	NOUN
chd-169	61	115	,	,	PUNCT
chd-169	61	116	and	and	CCONJ
chd-169	61	117	ar	ar	NOUN
chd-169	61	118	signaling	signal	VERB
chd-169	61	119	(	(	PUNCT
chd-169	61	120	armenia	armenia	PROPN
chd-169	61	121	et	et	PROPN
chd-169	61	122	al	al	PROPN
chd-169	61	123	.	.	PROPN
chd-169	61	124	,	,	PUNCT
chd-169	61	125	2018	2018	NUM
chd-169	61	126	;	;	PUNCT
chd-169	61	127	banerjee	banerjee	PROPN
chd-169	61	128	et	et	PROPN
chd-169	61	129	al	al	PROPN
chd-169	61	130	.	.	PROPN
chd-169	61	131	,	,	PUNCT
chd-169	61	132	2018	2018	NUM
chd-169	61	133	;	;	PUNCT
chd-169	61	134	frank	frank	PROPN
chd-169	61	135	et	et	PROPN
chd-169	61	136	al	al	PROPN
chd-169	61	137	.	.	PROPN
chd-169	61	138	,	,	PUNCT
chd-169	61	139	2018	2018	NUM
chd-169	61	140	;	;	PUNCT
chd-169	61	141	warner	warner	PROPN
chd-169	61	142	et	et	PROPN
chd-169	61	143	al	al	PROPN
chd-169	61	144	.	.	PROPN
chd-169	61	145	,	,	PUNCT
chd-169	61	146	2019	2019	NUM
chd-169	61	147	)	)	PUNCT
chd-169	61	148	.	.	PUNCT
chd-169	62	1	the	the	DET
chd-169	62	2	frequencies	frequency	NOUN
chd-169	62	3	of	of	ADP
chd-169	62	4	mutations	mutation	NOUN
chd-169	62	5	and	and	CCONJ
chd-169	62	6	alterations	alteration	NOUN
chd-169	62	7	in	in	ADP
chd-169	62	8	these	these	DET
chd-169	62	9	genetic	genetic	ADJ
chd-169	62	10	drivers	driver	NOUN
chd-169	62	11	vary	vary	VERB
chd-169	62	12	according	accord	VERB
chd-169	62	13	to	to	ADP
chd-169	62	14	disease	disease	NOUN
chd-169	62	15	stage	stage	NOUN
chd-169	62	16	.	.	PUNCT
chd-169	63	1	the	the	DET
chd-169	63	2	tmprss2	tmprss2	NOUN
chd-169	63	3	:	:	PUNCT
chd-169	63	4	erg	erg	NOUN
chd-169	63	5	fusion	fusion	NOUN
chd-169	63	6	has	have	AUX
chd-169	63	7	been	be	AUX
chd-169	63	8	found	find	VERB
chd-169	63	9	at	at	ADP
chd-169	63	10	lower	low	ADJ
chd-169	63	11	frequencies	frequency	NOUN
chd-169	63	12	in	in	ADP
chd-169	63	13	aa	aa	PROPN
chd-169	63	14	men	man	NOUN
chd-169	63	15	(	(	PUNCT
chd-169	63	16	∼28	∼28	NOUN
chd-169	63	17	%	%	NOUN
chd-169	63	18	)	)	PUNCT
chd-169	63	19	and	and	CCONJ
chd-169	63	20	black	black	ADJ
chd-169	63	21	men	man	NOUN
chd-169	63	22	from	from	ADP
chd-169	63	23	africa	africa	PROPN
chd-169	63	24	(	(	PUNCT
chd-169	63	25	∼13	∼13	ADJ
chd-169	63	26	%	%	NOUN
chd-169	63	27	)	)	PUNCT
chd-169	63	28	,	,	PUNCT
chd-169	63	29	compared	compare	VERB
chd-169	63	30	to	to	ADP
chd-169	63	31	ea	ea	NOUN
chd-169	63	32	men	man	NOUN
chd-169	63	33	(	(	PUNCT
chd-169	63	34	49	49	NUM
chd-169	63	35	%	%	NOUN
chd-169	63	36	)	)	PUNCT
chd-169	63	37	(	(	PUNCT
chd-169	63	38	blackburn	blackburn	NOUN
chd-169	63	39	et	et	PROPN
chd-169	63	40	al	al	PROPN
chd-169	63	41	.	.	PROPN
chd-169	63	42	,	,	PUNCT
chd-169	63	43	2019	2019	NUM
chd-169	63	44	)	)	PUNCT
chd-169	63	45	.	.	PUNCT
chd-169	64	1	aa	aa	NOUN
chd-169	64	2	and	and	CCONJ
chd-169	64	3	ea	ea	NOUN
chd-169	64	4	men	man	NOUN
chd-169	64	5	also	also	ADV
chd-169	64	6	have	have	VERB
chd-169	64	7	significant	significant	ADJ
chd-169	64	8	differences	difference	NOUN
chd-169	64	9	in	in	ADP
chd-169	64	10	erg	erg	NOUN
chd-169	64	11	expression	expression	NOUN
chd-169	64	12	(	(	PUNCT
chd-169	64	13	yamoah	yamoah	NOUN
chd-169	64	14	et	et	PROPN
chd-169	64	15	al	al	PROPN
chd-169	64	16	.	.	PROPN
chd-169	64	17	,	,	PUNCT
chd-169	64	18	2015	2015	NUM
chd-169	64	19	)	)	PUNCT
chd-169	64	20	.	.	PUNCT
chd-169	65	1	the	the	DET
chd-169	65	2	prognostic	prognostic	ADJ
chd-169	65	3	values	value	NOUN
chd-169	65	4	of	of	ADP
chd-169	65	5	tmprss2	tmprss2	ADP
chd-169	65	6	:	:	PUNCT
chd-169	65	7	erg	erg	NOUN
chd-169	65	8	fusion	fusion	NOUN
chd-169	65	9	and	and	CCONJ
chd-169	65	10	erg	erg	PROPN
chd-169	65	11	expression	expression	NOUN
chd-169	65	12	are	be	AUX
chd-169	65	13	not	not	PART
chd-169	65	14	clear	clear	ADJ
chd-169	65	15	,	,	PUNCT
chd-169	65	16	but	but	CCONJ
chd-169	65	17	the	the	DET
chd-169	65	18	relationship	relationship	NOUN
chd-169	65	19	with	with	ADP
chd-169	65	20	pca	pca	PROPN
chd-169	65	21	risk	risk	NOUN
chd-169	65	22	factors	factor	NOUN
chd-169	65	23	differs	differ	VERB
chd-169	65	24	by	by	ADP
chd-169	65	25	tmprss2	tmprss2	NOUN
chd-169	65	26	:	:	PUNCT
chd-169	65	27	erg	erg	NOUN
chd-169	65	28	translocation	translocation	NOUN
chd-169	65	29	status	status	NOUN
chd-169	65	30	(	(	PUNCT
chd-169	65	31	ahearn	ahearn	PROPN
chd-169	65	32	et	et	PROPN
chd-169	65	33	al	al	PROPN
chd-169	65	34	.	.	PROPN
chd-169	65	35	,	,	PUNCT
chd-169	65	36	2016	2016	NUM
chd-169	65	37	;	;	PUNCT
chd-169	65	38	netto	netto	PROPN
chd-169	65	39	,	,	PUNCT
chd-169	65	40	2013	2013	NUM
chd-169	65	41	)	)	PUNCT
chd-169	65	42	.	.	PUNCT
chd-169	66	1	in	in	ADP
chd-169	66	2	addition	addition	NOUN
chd-169	66	3	,	,	PUNCT
chd-169	66	4	the	the	DET
chd-169	66	5	association	association	NOUN
chd-169	66	6	between	between	ADP
chd-169	66	7	obesity	obesity	NOUN
chd-169	66	8	and	and	CCONJ
chd-169	66	9	worse	bad	ADJ
chd-169	66	10	pca	pca	NOUN
chd-169	66	11	outcome	outcome	NOUN
chd-169	66	12	has	have	AUX
chd-169	66	13	been	be	AUX
chd-169	66	14	found	find	VERB
chd-169	66	15	in	in	ADP
chd-169	66	16	men	man	NOUN
chd-169	66	17	harboring	harbor	VERB
chd-169	66	18	the	the	DET
chd-169	66	19	tmprss2	tmprss2	NOUN
chd-169	66	20	:	:	PUNCT
chd-169	66	21	erg	erg	PROPN
chd-169	66	22	(	(	PUNCT
chd-169	66	23	pettersson	pettersson	VERB
chd-169	66	24	et	et	PROPN
chd-169	66	25	al	al	PROPN
chd-169	66	26	.	.	PROPN
chd-169	66	27	,	,	PUNCT
chd-169	66	28	2013	2013	NUM
chd-169	66	29	)	)	PUNCT
chd-169	66	30	.	.	PUNCT
chd-169	67	1	by	by	ADP
chd-169	67	2	default	default	NOUN
chd-169	67	3	,	,	PUNCT
chd-169	67	4	aa	aa	NOUN
chd-169	67	5	men	man	NOUN
chd-169	67	6	,	,	PUNCT
chd-169	67	7	who	who	PRON
chd-169	67	8	have	have	VERB
chd-169	67	9	greater	great	ADJ
chd-169	67	10	rates	rate	NOUN
chd-169	67	11	of	of	ADP
chd-169	67	12	obesity	obesity	NOUN
chd-169	67	13	than	than	ADP
chd-169	67	14	ea	ea	NUM
chd-169	67	15	men	man	NOUN
chd-169	67	16	(	(	PUNCT
chd-169	67	17	rebbeck	rebbeck	NOUN
chd-169	67	18	,	,	PUNCT
chd-169	67	19	2017	2017	NUM
chd-169	67	20	)	)	PUNCT
chd-169	67	21	,	,	PUNCT
chd-169	67	22	harboring	harbor	VERB
chd-169	67	23	the	the	DET
chd-169	67	24	tmprss2	tmprss2	NOUN
chd-169	67	25	:	:	PUNCT
chd-169	67	26	erg	erg	NUM
chd-169	67	27	translocation	translocation	NOUN
chd-169	67	28	may	may	AUX
chd-169	67	29	have	have	VERB
chd-169	67	30	a	a	DET
chd-169	67	31	poorer	poor	ADJ
chd-169	67	32	pca	pca	NOUN
chd-169	67	33	prognosis	prognosis	NOUN
chd-169	67	34	than	than	ADP
chd-169	67	35	ea	ea	NUM
chd-169	67	36	men	man	NOUN
chd-169	67	37	.	.	PUNCT
chd-169	68	1	interestingly	interestingly	ADV
chd-169	68	2	,	,	PUNCT
chd-169	68	3	exome	exome	NOUN
chd-169	68	4	and	and	CCONJ
chd-169	68	5	whole	whole	ADJ
chd-169	68	6	-	-	PUNCT
chd-169	68	7	genome	genome	NOUN
chd-169	68	8	sequencing	sequencing	NOUN
chd-169	68	9	of	of	ADP
chd-169	68	10	aa	aa	NOUN
chd-169	68	11	prostate	prostate	NOUN
chd-169	68	12	tumors	tumor	NOUN
chd-169	68	13	revealed	reveal	VERB
chd-169	68	14	loss	loss	NOUN
chd-169	68	15	of	of	ADP
chd-169	68	16	function	function	NOUN
chd-169	68	17	mutations	mutation	NOUN
chd-169	68	18	in	in	ADP
chd-169	68	19	erf	erf	NOUN
chd-169	68	20	,	,	PUNCT
chd-169	68	21	an	an	DET
chd-169	68	22	ets	et	NOUN
chd-169	68	23	transcriptional	transcriptional	NOUN
chd-169	68	24	repressor	repressor	NOUN
chd-169	68	25	,	,	PUNCT
chd-169	68	26	lower	low	ADJ
chd-169	68	27	frequency	frequency	NOUN
chd-169	68	28	of	of	ADP
chd-169	68	29	erg	erg	PROPN
chd-169	68	30	fusions	fusion	NOUN
chd-169	68	31	,	,	PUNCT
chd-169	68	32	pik3ca	pik3ca	VERB
chd-169	68	33	mutations	mutation	NOUN
chd-169	68	34	and	and	CCONJ
chd-169	68	35	pten	pten	VERB
chd-169	68	36	deletions	deletion	NOUN
chd-169	68	37	,	,	PUNCT
chd-169	68	38	as	as	ADV
chd-169	68	39	well	well	ADV
chd-169	68	40	as	as	ADP
chd-169	68	41	increased	increase	VERB
chd-169	68	42	frequency	frequency	NOUN
chd-169	68	43	of	of	ADP
chd-169	68	44	spop	spop	NOUN
chd-169	68	45	mutations	mutation	NOUN
chd-169	68	46	and	and	CCONJ
chd-169	68	47	expression	expression	NOUN
chd-169	68	48	of	of	ADP
chd-169	68	49	long	long	ADJ
chd-169	68	50	non	non	ADJ
chd-169	68	51	-	-	ADJ
chd-169	68	52	coding	coding	ADJ
chd-169	68	53	rnas	rna	NOUN
chd-169	68	54	(	(	PUNCT
chd-169	68	55	lncrnas	lncrnas	PROPN
chd-169	68	56	)	)	PUNCT
chd-169	68	57	,	,	PUNCT
chd-169	68	58	compared	compare	VERB
chd-169	68	59	to	to	ADP
chd-169	68	60	ea	ea	PROPN
chd-169	68	61	pca	pca	PROPN
chd-169	68	62	(	(	PUNCT
chd-169	68	63	huang	huang	PROPN
chd-169	68	64	et	et	PROPN
chd-169	68	65	al	al	PROPN
chd-169	68	66	.	.	PROPN
chd-169	68	67	,	,	PUNCT
chd-169	68	68	2017	2017	NUM
chd-169	68	69	;	;	PUNCT
chd-169	68	70	jaratlerdsiri	jaratlerdsiri	NOUN
chd-169	68	71	et	et	PROPN
chd-169	68	72	al	al	PROPN
chd-169	68	73	.	.	PROPN
chd-169	68	74	,	,	PUNCT
chd-169	68	75	2018	2018	NUM
chd-169	68	76	;	;	PUNCT
chd-169	68	77	yuan	yuan	NOUN
chd-169	68	78	et	et	PROPN
chd-169	68	79	al	al	PROPN
chd-169	68	80	.	.	PROPN
chd-169	68	81	,	,	PUNCT
chd-169	68	82	2020	2020	NUM
chd-169	68	83	)	)	PUNCT
chd-169	68	84	.	.	PUNCT
chd-169	69	1	another	another	DET
chd-169	69	2	recent	recent	ADJ
chd-169	69	3	study	study	NOUN
chd-169	69	4	showed	show	VERB
chd-169	69	5	that	that	SCONJ
chd-169	69	6	tp53	tp53	PROPN
chd-169	69	7	mutations	mutation	NOUN
chd-169	69	8	,	,	PUNCT
chd-169	69	9	mutations	mutation	NOUN
chd-169	69	10	in	in	ADP
chd-169	69	11	the	the	DET
chd-169	69	12	dna	dna	PROPN
chd-169	69	13	repair	repair	NOUN
chd-169	69	14	gene	gene	NOUN
chd-169	69	15	brca2	brca2	NOUN
chd-169	69	16	,	,	PUNCT
chd-169	69	17	and	and	CCONJ
chd-169	69	18	deletions	deletion	NOUN
chd-169	69	19	in	in	ADP
chd-169	69	20	cdkn1b	cdkn1b	PROPN
chd-169	69	21	(	(	PUNCT
chd-169	69	22	cyclin	cyclin	NOUN
chd-169	69	23	-	-	PUNCT
chd-169	69	24	dependent	dependent	ADJ
chd-169	69	25	kinase	kinase	PROPN
chd-169	69	26	inhibitor	inhibitor	PROPN
chd-169	69	27	b1	b1	PROPN
chd-169	69	28	)	)	PUNCT
chd-169	69	29	are	be	AUX
chd-169	69	30	associated	associate	VERB
chd-169	69	31	with	with	ADP
chd-169	69	32	increased	increase	VERB
chd-169	69	33	risk	risk	NOUN
chd-169	69	34	of	of	ADP
chd-169	69	35	metastasis	metastasis	NOUN
chd-169	69	36	among	among	ADP
chd-169	69	37	aa	aa	PROPN
chd-169	69	38	men	man	NOUN
chd-169	69	39	with	with	ADP
chd-169	69	40	pca	pca	PROPN
chd-169	69	41	(	(	PUNCT
chd-169	69	42	petrovics	petrovic	NOUN
chd-169	69	43	et	et	NOUN
chd-169	69	44	al	al	PROPN
chd-169	69	45	.	.	PROPN
chd-169	69	46	,	,	PUNCT
chd-169	69	47	2019	2019	NUM
chd-169	69	48	)	)	PUNCT
chd-169	69	49	.	.	PUNCT
chd-169	70	1	however	however	ADV
chd-169	70	2	,	,	PUNCT
chd-169	70	3	another	another	DET
chd-169	70	4	study	study	NOUN
chd-169	70	5	showed	show	VERB
chd-169	70	6	that	that	SCONJ
chd-169	70	7	alterations	alteration	NOUN
chd-169	70	8	in	in	ADP
chd-169	70	9	dna	dna	PROPN
chd-169	70	10	repair	repair	NOUN
chd-169	70	11	genes	gene	NOUN
chd-169	70	12	,	,	PUNCT
chd-169	70	13	including	include	VERB
chd-169	70	14	brca1/2	brca1/2	PROPN
chd-169	70	15	and	and	CCONJ
chd-169	70	16	atm	atm	ADJ
chd-169	70	17	,	,	PUNCT
chd-169	70	18	are	be	AUX
chd-169	70	19	less	less	ADV
chd-169	70	20	likely	likely	ADJ
chd-169	70	21	to	to	PART
chd-169	70	22	be	be	AUX
chd-169	70	23	detected	detect	VERB
chd-169	70	24	in	in	ADP
chd-169	70	25	aa	aa	PROPN
chd-169	70	26	patients	patient	NOUN
chd-169	70	27	with	with	ADP
chd-169	70	28	pca	pca	PROPN
chd-169	70	29	compared	compare	VERB
chd-169	70	30	to	to	ADP
chd-169	70	31	ea	ea	NOUN
chd-169	70	32	patients	patient	NOUN
chd-169	70	33	(	(	PUNCT
chd-169	70	34	sartor	sartor	NOUN
chd-169	70	35	et	et	PROPN
chd-169	70	36	al	al	PROPN
chd-169	70	37	.	.	PROPN
chd-169	70	38	,	,	PUNCT
chd-169	70	39	2020	2020	NUM
chd-169	70	40	)	)	PUNCT
chd-169	70	41	.	.	PUNCT
chd-169	71	1	gene	gene	NOUN
chd-169	71	2	expression	expression	NOUN
chd-169	71	3	profiling	profiling	NOUN
chd-169	71	4	of	of	ADP
chd-169	71	5	pca	pca	PROPN
chd-169	71	6	tumors	tumor	NOUN
chd-169	71	7	have	have	AUX
chd-169	71	8	also	also	ADV
chd-169	71	9	revealed	reveal	VERB
chd-169	71	10	differences	difference	NOUN
chd-169	71	11	in	in	ADP
chd-169	71	12	tumor	tumor	NOUN
chd-169	71	13	immunobiology	immunobiology	NOUN
chd-169	71	14	between	between	ADP
chd-169	71	15	aa	aa	PROPN
chd-169	71	16	and	and	CCONJ
chd-169	71	17	ea	ea	NOUN
chd-169	71	18	men	man	NOUN
chd-169	71	19	(	(	PUNCT
chd-169	71	20	wallace	wallace	PROPN
chd-169	71	21	et	et	PROPN
chd-169	71	22	al	al	PROPN
chd-169	71	23	.	.	PROPN
chd-169	71	24	,	,	PUNCT
chd-169	71	25	2008	2008	NUM
chd-169	71	26	)	)	PUNCT
chd-169	71	27	.	.	PUNCT
chd-169	72	1	for	for	ADP
chd-169	72	2	instance	instance	NOUN
chd-169	72	3	,	,	PUNCT
chd-169	72	4	genes	gene	NOUN
chd-169	72	5	associated	associate	VERB
chd-169	72	6	with	with	ADP
chd-169	72	7	autoimmunity	autoimmunity	NOUN
chd-169	72	8	and	and	CCONJ
chd-169	72	9	inflammation	inflammation	NOUN
chd-169	72	10	,	,	PUNCT
chd-169	72	11	particularly	particularly	ADV
chd-169	72	12	those	those	PRON
chd-169	72	13	clustering	cluster	VERB
chd-169	72	14	in	in	ADP
chd-169	72	15	immune	immune	ADJ
chd-169	72	16	response	response	NOUN
chd-169	72	17	,	,	PUNCT
chd-169	72	18	stress	stress	NOUN
chd-169	72	19	response	response	NOUN
chd-169	72	20	,	,	PUNCT
chd-169	72	21	cytokine	cytokine	ADJ
chd-169	72	22	signaling	signal	VERB
chd-169	72	23	,	,	PUNCT
chd-169	72	24	and	and	CCONJ
chd-169	72	25	chemotaxis	chemotaxis	ADJ
chd-169	72	26	pathways	pathway	NOUN
chd-169	72	27	are	be	AUX
chd-169	72	28	differentially	differentially	ADV
chd-169	72	29	upregulated	upregulate	VERB
chd-169	72	30	in	in	ADP
chd-169	72	31	aa	aa	NOUN
chd-169	72	32	prostate	prostate	NOUN
chd-169	72	33	tumors	tumor	NOUN
chd-169	72	34	(	(	PUNCT
chd-169	72	35	wallace	wallace	PROPN
chd-169	72	36	et	et	PROPN
chd-169	72	37	al	al	PROPN
chd-169	72	38	.	.	PROPN
chd-169	72	39	,	,	PUNCT
chd-169	72	40	2008	2008	NUM
chd-169	72	41	)	)	PUNCT
chd-169	72	42	.	.	PUNCT
chd-169	73	1	a	a	DET
chd-169	73	2	recent	recent	ADJ
chd-169	73	3	study	study	NOUN
chd-169	73	4	that	that	PRON
chd-169	73	5	integrated	integrate	VERB
chd-169	73	6	the	the	DET
chd-169	73	7	genomic	genomic	NOUN
chd-169	73	8	and	and	CCONJ
chd-169	73	9	transcriptomic	transcriptomic	ADJ
chd-169	73	10	landscape	landscape	NOUN
chd-169	73	11	between	between	ADP
chd-169	73	12	aa	aa	PROPN
chd-169	73	13	pca	pca	PROPN
chd-169	73	14	and	and	CCONJ
chd-169	73	15	ea	ea	PROPN
chd-169	73	16	pca	pca	PROPN
chd-169	73	17	revealed	reveal	VERB
chd-169	73	18	an	an	DET
chd-169	73	19	enrichment	enrichment	NOUN
chd-169	73	20	of	of	ADP
chd-169	73	21	highly	highly	ADV
chd-169	73	22	expressed	express	VERB
chd-169	73	23	differentially	differentially	ADV
chd-169	73	24	expressed	express	VERB
chd-169	73	25	genes	gene	NOUN
chd-169	73	26	(	(	PUNCT
chd-169	73	27	degs	deg	NOUN
chd-169	73	28	)	)	PUNCT
chd-169	73	29	for	for	ADP
chd-169	73	30	immune	immune	NOUN
chd-169	73	31	-	-	PUNCT
chd-169	73	32	related	relate	VERB
chd-169	73	33	pathways	pathway	NOUN
chd-169	73	34	in	in	ADP
chd-169	73	35	aa	aa	PROPN
chd-169	73	36	men	man	NOUN
chd-169	73	37	,	,	PUNCT
chd-169	73	38	compared	compare	VERB
chd-169	73	39	to	to	ADP
chd-169	73	40	increased	increase	VERB
chd-169	73	41	enrichment	enrichment	NOUN
chd-169	73	42	for	for	ADP
chd-169	73	43	pten	pten	NOUN
chd-169	73	44	/	/	SYM
chd-169	73	45	pi3k	pi3k	NOUN
chd-169	73	46	signaling	signal	VERB
chd-169	73	47	in	in	ADP
chd-169	73	48	ea	ea	NOUN
chd-169	73	49	men	man	NOUN
chd-169	73	50	(	(	PUNCT
chd-169	73	51	yuan	yuan	NOUN
chd-169	73	52	et	et	NOUN
chd-169	73	53	al	al	PROPN
chd-169	73	54	.	.	PROPN
chd-169	73	55	,	,	PUNCT
chd-169	73	56	2020	2020	NUM
chd-169	73	57	)	)	PUNCT
chd-169	73	58	.	.	PUNCT
chd-169	74	1	metastasis	metastasis	NOUN
chd-169	74	2	-	-	PUNCT
chd-169	74	3	promoting	promote	VERB
chd-169	74	4	genes	gene	NOUN
chd-169	74	5	are	be	AUX
chd-169	74	6	also	also	ADV
chd-169	74	7	more	more	ADV
chd-169	74	8	highly	highly	ADV
chd-169	74	9	expressed	express	VERB
chd-169	74	10	in	in	ADP
chd-169	74	11	aa	aa	NOUN
chd-169	74	12	prostate	prostate	NOUN
chd-169	74	13	tumors	tumor	NOUN
chd-169	74	14	,	,	PUNCT
chd-169	74	15	including	include	VERB
chd-169	74	16	autocrine	autocrine	NOUN
chd-169	74	17	mobility	mobility	NOUN
chd-169	74	18	factor	factor	NOUN
chd-169	74	19	receptor	receptor	NOUN
chd-169	74	20	,	,	PUNCT
chd-169	74	21	chemokine	chemokine	ADJ
chd-169	74	22	receptor	receptor	NOUN
chd-169	74	23	4	4	NUM
chd-169	74	24	,	,	PUNCT
chd-169	74	25	and	and	CCONJ
chd-169	74	26	matrix	matrix	NOUN
chd-169	74	27	metalloproteinase	metalloproteinase	NOUN
chd-169	74	28	9	9	NUM
chd-169	74	29	(	(	PUNCT
chd-169	74	30	wallace	wallace	PROPN
chd-169	74	31	et	et	PROPN
chd-169	74	32	al	al	PROPN
chd-169	74	33	.	.	PROPN
chd-169	74	34	,	,	PUNCT
chd-169	74	35	2008	2008	NUM
chd-169	74	36	)	)	PUNCT
chd-169	74	37	.	.	PUNCT
chd-169	75	1	inflammation	inflammation	NOUN
chd-169	75	2	associated	associate	VERB
chd-169	75	3	genes	gene	NOUN
chd-169	75	4	such	such	ADJ
chd-169	75	5	as	as	ADP
chd-169	75	6	il6	il6	NOUN
chd-169	75	7	,	,	PUNCT
chd-169	75	8	il8	il8	PROPN
chd-169	75	9	,	,	PUNCT
chd-169	75	10	il1b	il1b	PROPN
chd-169	75	11	,	,	PUNCT
chd-169	75	12	cxcr4	cxcr4	NOUN
chd-169	75	13	,	,	PUNCT
chd-169	75	14	and	and	CCONJ
chd-169	75	15	fasn	fasn	NOUN
chd-169	75	16	were	be	AUX
chd-169	75	17	also	also	ADV
chd-169	75	18	found	find	VERB
chd-169	75	19	to	to	PART
chd-169	75	20	be	be	AUX
chd-169	75	21	significantly	significantly	ADV
chd-169	75	22	expressed	express	VERB
chd-169	75	23	at	at	ADP
chd-169	75	24	higher	high	ADJ
chd-169	75	25	levels	level	NOUN
chd-169	75	26	in	in	ADP
chd-169	75	27	prostate	prostate	NOUN
chd-169	75	28	tumors	tumor	NOUN
chd-169	75	29	from	from	ADP
chd-169	75	30	aa	aa	NOUN
chd-169	75	31	compared	compare	VERB
chd-169	75	32	to	to	ADP
chd-169	75	33	ea	ea	NOUN
chd-169	75	34	men	man	NOUN
chd-169	75	35	(	(	PUNCT
chd-169	75	36	powell	powell	PROPN
chd-169	75	37	et	et	PROPN
chd-169	75	38	al	al	PROPN
chd-169	75	39	.	.	PROPN
chd-169	75	40	,	,	PUNCT
chd-169	75	41	2013	2013	NUM
chd-169	75	42	)	)	PUNCT
chd-169	75	43	.	.	PUNCT
chd-169	76	1	the	the	DET
chd-169	76	2	expression	expression	NOUN
chd-169	76	3	of	of	ADP
chd-169	76	4	many	many	ADJ
chd-169	76	5	of	of	ADP
chd-169	76	6	these	these	DET
chd-169	76	7	genes	gene	NOUN
chd-169	76	8	have	have	AUX
chd-169	76	9	been	be	AUX
chd-169	76	10	associated	associate	VERB
chd-169	76	11	with	with	ADP
chd-169	76	12	diet	diet	NOUN
chd-169	76	13	and	and	CCONJ
chd-169	76	14	lifestyle	lifestyle	NOUN
chd-169	76	15	,	,	PUNCT
chd-169	76	16	higher	high	ADJ
chd-169	76	17	gleason	gleason	PROPN
chd-169	76	18	scores	score	NOUN
chd-169	76	19	,	,	PUNCT
chd-169	76	20	androgen	androgen	NOUN
chd-169	76	21	receptor	receptor	NOUN
chd-169	76	22	(	(	PUNCT
chd-169	76	23	ar	ar	NOUN
chd-169	76	24	)	)	PUNCT
chd-169	76	25	signaling	signal	VERB
chd-169	76	26	,	,	PUNCT
chd-169	76	27	aggressive	aggressive	ADJ
chd-169	76	28	pca	pca	NOUN
chd-169	76	29	tumors	tumor	NOUN
chd-169	76	30	,	,	PUNCT
chd-169	76	31	and	and	CCONJ
chd-169	76	32	metastasis	metastasis	NOUN
chd-169	76	33	(	(	PUNCT
chd-169	76	34	dubrovska	dubrovska	NOUN
chd-169	76	35	et	et	NOUN
chd-169	76	36	al	al	PROPN
chd-169	76	37	.	.	PROPN
chd-169	76	38	,	,	PUNCT
chd-169	76	39	2012	2012	NUM
chd-169	76	40	;	;	PUNCT
chd-169	76	41	finley	finley	PROPN
chd-169	76	42	et	et	PROPN
chd-169	76	43	al	al	PROPN
chd-169	76	44	.	.	PROPN
chd-169	76	45	,	,	PUNCT
chd-169	76	46	2009	2009	NUM
chd-169	76	47	;	;	PUNCT
chd-169	76	48	jia	jia	PROPN
chd-169	76	49	et	et	PROPN
chd-169	76	50	al	al	PROPN
chd-169	76	51	.	.	PROPN
chd-169	76	52	,	,	PUNCT
chd-169	76	53	2004	2004	NUM
chd-169	76	54	;	;	PUNCT
chd-169	76	55	nguyen	nguyen	NOUN
chd-169	76	56	et	et	PROPN
chd-169	76	57	al	al	PROPN
chd-169	76	58	.	.	PROPN
chd-169	76	59	,	,	PUNCT
chd-169	76	60	2010	2010	NUM
chd-169	76	61	;	;	PUNCT
chd-169	76	62	powell	powell	PROPN
chd-169	76	63	et	et	PROPN
chd-169	76	64	al	al	PROPN
chd-169	76	65	.	.	PROPN
chd-169	76	66	,	,	PUNCT
chd-169	76	67	2013	2013	NUM
chd-169	76	68	;	;	PUNCT
chd-169	76	69	yang	yang	PROPN
chd-169	76	70	et	et	PROPN
chd-169	76	71	al	al	PROPN
chd-169	76	72	.	.	PROPN
chd-169	76	73	,	,	PUNCT
chd-169	76	74	2004	2004	NUM
chd-169	76	75	)	)	PUNCT
chd-169	76	76	.	.	PUNCT
chd-169	77	1	consistent	consistent	ADJ
chd-169	77	2	with	with	ADP
chd-169	77	3	the	the	DET
chd-169	77	4	notion	notion	NOUN
chd-169	77	5	of	of	ADP
chd-169	77	6	differential	differential	ADJ
chd-169	77	7	expression	expression	NOUN
chd-169	77	8	of	of	ADP
chd-169	77	9	immune	immune	ADJ
chd-169	77	10	function	function	NOUN
chd-169	77	11	-	-	PUNCT
chd-169	77	12	related	relate	VERB
chd-169	77	13	genes	gene	NOUN
chd-169	77	14	between	between	ADP
chd-169	77	15	aa	aa	NOUN
chd-169	77	16	and	and	CCONJ
chd-169	77	17	ea	ea	NOUN
chd-169	77	18	men	man	NOUN
chd-169	77	19	with	with	ADP
chd-169	77	20	pca	pca	PROPN
chd-169	77	21	,	,	PUNCT
chd-169	77	22	our	our	PRON
chd-169	77	23	group	group	NOUN
chd-169	77	24	reported	report	VERB
chd-169	77	25	race	race	NOUN
chd-169	77	26	-	-	PUNCT
chd-169	77	27	related	relate	VERB
chd-169	77	28	differences	difference	NOUN
chd-169	77	29	in	in	ADP
chd-169	77	30	serum	serum	NOUN
chd-169	77	31	autoantibody	autoantibody	NOUN
chd-169	77	32	responses	response	NOUN
chd-169	77	33	to	to	ADP
chd-169	77	34	specific	specific	ADJ
chd-169	77	35	tumor	tumor	NOUN
chd-169	77	36	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-169	77	37	e6	e6	NOUN
chd-169	77	38	cancer	cancer	NOUN
chd-169	77	39	health	health	NOUN
chd-169	77	40	disparities	disparity	NOUN
chd-169	77	41	research	research	VERB
chd-169	77	42	associated	associate	VERB
chd-169	77	43	antigens	antigen	NOUN
chd-169	77	44	in	in	ADP
chd-169	77	45	pca	pca	NOUN
chd-169	77	46	patients	patient	NOUN
chd-169	77	47	(	(	PUNCT
chd-169	77	48	sanchez	sanchez	PROPN
chd-169	77	49	et	et	PROPN
chd-169	77	50	al	al	PROPN
chd-169	77	51	.	.	PROPN
chd-169	77	52	,	,	PUNCT
chd-169	77	53	2016	2016	NUM
chd-169	77	54	)	)	PUNCT
chd-169	77	55	.	.	PUNCT
chd-169	78	1	the	the	DET
chd-169	78	2	rna	rna	NOUN
chd-169	78	3	splicing	splicing	NOUN
chd-169	78	4	landscape	landscape	NOUN
chd-169	78	5	has	have	AUX
chd-169	78	6	also	also	ADV
chd-169	78	7	been	be	AUX
chd-169	78	8	explored	explore	VERB
chd-169	78	9	as	as	ADP
chd-169	78	10	a	a	DET
chd-169	78	11	potential	potential	ADJ
chd-169	78	12	biological	biological	ADJ
chd-169	78	13	determinant	determinant	NOUN
chd-169	78	14	of	of	ADP
chd-169	78	15	pca	pca	PROPN
chd-169	78	16	health	health	NOUN
chd-169	78	17	disparities	disparity	NOUN
chd-169	78	18	(	(	PUNCT
chd-169	78	19	olender	olender	NOUN
chd-169	78	20	and	and	CCONJ
chd-169	78	21	lee	lee	PROPN
chd-169	78	22	,	,	PUNCT
chd-169	78	23	2019	2019	NUM
chd-169	78	24	;	;	PUNCT
chd-169	78	25	wang	wang	PROPN
chd-169	78	26	et	et	PROPN
chd-169	78	27	al	al	PROPN
chd-169	78	28	.	.	PROPN
chd-169	78	29	,	,	PUNCT
chd-169	78	30	2017	2017	NUM
chd-169	78	31	)	)	PUNCT
chd-169	78	32	.	.	PUNCT
chd-169	79	1	a	a	DET
chd-169	79	2	genome	genome	NOUN
chd-169	79	3	-	-	PUNCT
chd-169	79	4	wide	wide	ADJ
chd-169	79	5	analysis	analysis	NOUN
chd-169	79	6	of	of	ADP
chd-169	79	7	differential	differential	ADJ
chd-169	79	8	splicing	splicing	NOUN
chd-169	79	9	(	(	PUNCT
chd-169	79	10	ds	ds	ADJ
chd-169	79	11	)	)	PUNCT
chd-169	79	12	events	event	NOUN
chd-169	79	13	in	in	ADP
chd-169	79	14	racially	racially	ADV
chd-169	79	15	diverse	diverse	ADJ
chd-169	79	16	prostate	prostate	NOUN
chd-169	79	17	tumors	tumor	NOUN
chd-169	79	18	revealed	reveal	VERB
chd-169	79	19	hundreds	hundred	NOUN
chd-169	79	20	of	of	ADP
chd-169	79	21	ds	ds	ADJ
chd-169	79	22	events	event	NOUN
chd-169	79	23	that	that	PRON
chd-169	79	24	were	be	AUX
chd-169	79	25	unique	unique	ADJ
chd-169	79	26	to	to	ADP
chd-169	79	27	aa	aa	PROPN
chd-169	79	28	pca	pca	PROPN
chd-169	79	29	and	and	CCONJ
chd-169	79	30	affected	affect	VERB
chd-169	79	31	specific	specific	ADJ
chd-169	79	32	splice	splice	NOUN
chd-169	79	33	variants	variant	NOUN
chd-169	79	34	of	of	ADP
chd-169	79	35	several	several	ADJ
chd-169	79	36	oncogenes	oncogene	NOUN
chd-169	79	37	such	such	ADJ
chd-169	79	38	as	as	ADP
chd-169	79	39	pik3cd	pik3cd	PROPN
chd-169	79	40	,	,	PUNCT
chd-169	79	41	fgfr3	fgfr3	PROPN
chd-169	79	42	,	,	PUNCT
chd-169	79	43	tsc2	tsc2	NOUN
chd-169	79	44	,	,	PUNCT
chd-169	79	45	and	and	CCONJ
chd-169	79	46	rasgrp2	rasgrp2	PROPN
chd-169	79	47	(	(	PUNCT
chd-169	79	48	olender	olender	NOUN
chd-169	79	49	and	and	CCONJ
chd-169	79	50	lee	lee	PROPN
chd-169	79	51	,	,	PUNCT
chd-169	79	52	2019	2019	NUM
chd-169	79	53	)	)	PUNCT
chd-169	79	54	.	.	PUNCT
chd-169	80	1	validation	validation	NOUN
chd-169	80	2	studies	study	NOUN
chd-169	80	3	showed	show	VERB
chd-169	80	4	that	that	SCONJ
chd-169	80	5	ectopic	ectopic	ADJ
chd-169	80	6	overexpression	overexpression	NOUN
chd-169	80	7	of	of	ADP
chd-169	80	8	a	a	DET
chd-169	80	9	short	short	ADJ
chd-169	80	10	splice	splice	NOUN
chd-169	80	11	variant	variant	NOUN
chd-169	80	12	of	of	ADP
chd-169	80	13	pik3cd	pik3cd	PROPN
chd-169	80	14	,	,	PUNCT
chd-169	80	15	enriched	enrich	VERB
chd-169	80	16	in	in	ADP
chd-169	80	17	aa	aa	ADJ
chd-169	80	18	tumors	tumor	NOUN
chd-169	80	19	,	,	PUNCT
chd-169	80	20	enhanced	enhance	VERB
chd-169	80	21	the	the	DET
chd-169	80	22	aggressive	aggressive	ADJ
chd-169	80	23	properties	property	NOUN
chd-169	80	24	of	of	ADP
chd-169	80	25	pca	pca	NOUN
chd-169	80	26	cells	cell	NOUN
chd-169	80	27	compared	compare	VERB
chd-169	80	28	to	to	ADP
chd-169	80	29	the	the	DET
chd-169	80	30	corresponding	corresponding	ADJ
chd-169	80	31	variant	variant	NOUN
chd-169	80	32	enriched	enrich	VERB
chd-169	80	33	in	in	ADP
chd-169	80	34	ea	ea	NOUN
chd-169	80	35	tumors	tumor	NOUN
chd-169	80	36	.	.	PUNCT
chd-169	81	1	these	these	DET
chd-169	81	2	results	result	NOUN
chd-169	81	3	suggested	suggest	VERB
chd-169	81	4	that	that	SCONJ
chd-169	81	5	differential	differential	ADJ
chd-169	81	6	rna	rna	NOUN
chd-169	81	7	splicing	splicing	NOUN
chd-169	81	8	may	may	AUX
chd-169	81	9	contribute	contribute	VERB
chd-169	81	10	to	to	ADP
chd-169	81	11	increased	increase	VERB
chd-169	81	12	tumor	tumor	NOUN
chd-169	81	13	aggressiveness	aggressiveness	NOUN
chd-169	81	14	in	in	ADP
chd-169	81	15	aa	aa	PROPN
chd-169	81	16	pca	pca	PROPN
chd-169	81	17	and	and	CCONJ
chd-169	81	18	could	could	AUX
chd-169	81	19	be	be	AUX
chd-169	81	20	exploited	exploit	VERB
chd-169	81	21	for	for	ADP
chd-169	81	22	developmental	developmental	ADJ
chd-169	81	23	therapeutics	therapeutic	NOUN
chd-169	81	24	in	in	ADP
chd-169	81	25	aggressive	aggressive	ADJ
chd-169	81	26	pca	pca	NOUN
chd-169	81	27	.	.	PUNCT
chd-169	82	1	given	give	VERB
chd-169	82	2	that	that	DET
chd-169	82	3	androgens	androgens	NOUN
chd-169	82	4	drive	drive	NOUN
chd-169	82	5	pca	pca	PROPN
chd-169	82	6	etiology	etiology	NOUN
chd-169	82	7	and	and	CCONJ
chd-169	82	8	disease	disease	NOUN
chd-169	82	9	progression	progression	NOUN
chd-169	82	10	prior	prior	ADV
chd-169	82	11	to	to	ADP
chd-169	82	12	metastatic	metastatic	ADJ
chd-169	82	13	crpc	crpc	ADJ
chd-169	82	14	(	(	PUNCT
chd-169	82	15	mcrpc	mcrpc	PROPN
chd-169	82	16	)	)	PUNCT
chd-169	82	17	,	,	PUNCT
chd-169	82	18	several	several	ADJ
chd-169	82	19	studies	study	NOUN
chd-169	82	20	have	have	AUX
chd-169	82	21	also	also	ADV
chd-169	82	22	explored	explore	VERB
chd-169	82	23	racial	racial	ADJ
chd-169	82	24	differences	difference	NOUN
chd-169	82	25	in	in	ADP
chd-169	82	26	androgen	androgen	NOUN
chd-169	82	27	production	production	NOUN
chd-169	82	28	and	and	CCONJ
chd-169	82	29	ar	ar	NOUN
chd-169	82	30	signaling	signal	VERB
chd-169	82	31	(	(	PUNCT
chd-169	82	32	bosland	bosland	NOUN
chd-169	82	33	and	and	CCONJ
chd-169	82	34	mahmoud	mahmoud	PROPN
chd-169	82	35	,	,	PUNCT
chd-169	82	36	2011	2011	NUM
chd-169	82	37	;	;	PUNCT
chd-169	82	38	karakas	karakas	X
chd-169	82	39	et	et	PROPN
chd-169	82	40	al	al	PROPN
chd-169	82	41	.	.	PROPN
chd-169	82	42	,	,	PUNCT
chd-169	82	43	2017	2017	NUM
chd-169	82	44	;	;	PUNCT
chd-169	82	45	massengill	massengill	VERB
chd-169	82	46	et	et	PROPN
chd-169	82	47	al	al	PROPN
chd-169	82	48	.	.	PROPN
chd-169	82	49	,	,	PUNCT
chd-169	82	50	2003	2003	NUM
chd-169	82	51	;	;	PUNCT
chd-169	82	52	schatzl	schatzl	PROPN
chd-169	82	53	et	et	PROPN
chd-169	82	54	al	al	PROPN
chd-169	82	55	.	.	PROPN
chd-169	82	56	,	,	PUNCT
chd-169	82	57	2003	2003	NUM
chd-169	82	58	)	)	PUNCT
chd-169	82	59	.	.	PUNCT
chd-169	83	1	these	these	DET
chd-169	83	2	studies	study	NOUN
chd-169	83	3	have	have	AUX
chd-169	83	4	shown	show	VERB
chd-169	83	5	that	that	SCONJ
chd-169	83	6	aa	aa	PROPN
chd-169	83	7	men	man	NOUN
chd-169	83	8	have	have	VERB
chd-169	83	9	higher	high	ADJ
chd-169	83	10	testosterone	testosterone	NOUN
chd-169	83	11	and	and	CCONJ
chd-169	83	12	active	active	ADJ
chd-169	83	13	5	5	NUM
chd-169	83	14	-	-	PUNCT
chd-169	83	15	alpha	alpha	NOUN
chd-169	83	16	reductase	reductase	NOUN
chd-169	83	17	levels	level	NOUN
chd-169	83	18	than	than	ADP
chd-169	83	19	ea	ea	NUM
chd-169	83	20	men	man	NOUN
chd-169	83	21	,	,	PUNCT
chd-169	83	22	resulting	result	VERB
chd-169	83	23	in	in	ADP
chd-169	83	24	enhanced	enhanced	ADJ
chd-169	83	25	conversion	conversion	NOUN
chd-169	83	26	of	of	ADP
chd-169	83	27	testosterone	testosterone	NOUN
chd-169	83	28	to	to	ADP
chd-169	83	29	the	the	DET
chd-169	83	30	more	more	ADV
chd-169	83	31	potent	potent	ADJ
chd-169	83	32	dht	dht	NOUN
chd-169	83	33	(	(	PUNCT
chd-169	83	34	kheirandish	kheirandish	PROPN
chd-169	83	35	and	and	CCONJ
chd-169	83	36	chinegwundoh	chinegwundoh	PROPN
chd-169	83	37	,	,	PUNCT
chd-169	83	38	2011	2011	NUM
chd-169	83	39	;	;	PUNCT
chd-169	83	40	ross	ross	PROPN
chd-169	83	41	et	et	PROPN
chd-169	83	42	al	al	PROPN
chd-169	83	43	.	.	PROPN
chd-169	83	44	,	,	PUNCT
chd-169	83	45	1992	1992	NUM
chd-169	83	46	)	)	PUNCT
chd-169	83	47	.	.	PUNCT
chd-169	84	1	the	the	DET
chd-169	84	2	differential	differential	ADJ
chd-169	84	3	expression	expression	NOUN
chd-169	84	4	of	of	ADP
chd-169	84	5	epithelial	epithelial	ADJ
chd-169	84	6	and	and	CCONJ
chd-169	84	7	stromal	stromal	ADJ
chd-169	84	8	ar	ar	PROPN
chd-169	84	9	in	in	ADP
chd-169	84	10	pca	pca	NOUN
chd-169	84	11	tissue	tissue	NOUN
chd-169	84	12	is	be	AUX
chd-169	84	13	also	also	ADV
chd-169	84	14	emerging	emerge	VERB
chd-169	84	15	as	as	ADP
chd-169	84	16	a	a	DET
chd-169	84	17	possible	possible	ADJ
chd-169	84	18	driver	driver	NOUN
chd-169	84	19	of	of	ADP
chd-169	84	20	castration	castration	NOUN
chd-169	84	21	resistance	resistance	NOUN
chd-169	84	22	in	in	ADP
chd-169	84	23	patients	patient	NOUN
chd-169	84	24	receiving	receive	VERB
chd-169	84	25	adt	adt	NOUN
chd-169	84	26	(	(	PUNCT
chd-169	84	27	karakas	karakas	X
chd-169	84	28	et	et	PROPN
chd-169	84	29	al	al	PROPN
chd-169	84	30	.	.	PROPN
chd-169	84	31	,	,	PUNCT
chd-169	84	32	2017	2017	NUM
chd-169	84	33	)	)	PUNCT
chd-169	84	34	,	,	PUNCT
chd-169	84	35	and	and	CCONJ
chd-169	84	36	there	there	PRON
chd-169	84	37	is	be	VERB
chd-169	84	38	evidence	evidence	NOUN
chd-169	84	39	that	that	SCONJ
chd-169	84	40	while	while	SCONJ
chd-169	84	41	nuclear	nuclear	ADJ
chd-169	84	42	ar	ar	NOUN
chd-169	84	43	levels	level	NOUN
chd-169	84	44	are	be	AUX
chd-169	84	45	increased	increase	VERB
chd-169	84	46	in	in	ADP
chd-169	84	47	aa	aa	PROPN
chd-169	84	48	pca	pca	PROPN
chd-169	84	49	patients	patient	NOUN
chd-169	84	50	compared	compare	VERB
chd-169	84	51	to	to	ADP
chd-169	84	52	ea	ea	NOUN
chd-169	84	53	patients	patient	NOUN
chd-169	84	54	,	,	PUNCT
chd-169	84	55	stromal	stromal	ADJ
chd-169	84	56	levels	level	NOUN
chd-169	84	57	are	be	AUX
chd-169	84	58	decreased	decrease	VERB
chd-169	84	59	(	(	PUNCT
chd-169	84	60	li	li	PROPN
chd-169	84	61	et	et	PROPN
chd-169	84	62	al	al	PROPN
chd-169	84	63	.	.	PROPN
chd-169	84	64	,	,	PUNCT
chd-169	84	65	2008	2008	NUM
chd-169	84	66	;	;	PUNCT
chd-169	85	1	singh	singh	PROPN
chd-169	85	2	et	et	PROPN
chd-169	85	3	al	al	PROPN
chd-169	85	4	.	.	PROPN
chd-169	85	5	,	,	PUNCT
chd-169	85	6	2014	2014	NUM
chd-169	85	7	)	)	PUNCT
chd-169	85	8	.	.	PUNCT
chd-169	86	1	in	in	ADP
chd-169	86	2	addition	addition	NOUN
chd-169	86	3	,	,	PUNCT
chd-169	86	4	aa	aa	PROPN
chd-169	86	5	pca	pca	PROPN
chd-169	86	6	patients	patient	NOUN
chd-169	86	7	have	have	VERB
chd-169	86	8	higher	high	ADJ
chd-169	86	9	frequency	frequency	NOUN
chd-169	86	10	of	of	ADP
chd-169	86	11	germline	germline	NOUN
chd-169	86	12	and	and	CCONJ
chd-169	86	13	somatic	somatic	ADJ
chd-169	86	14	ar	ar	NOUN
chd-169	86	15	mutations	mutation	NOUN
chd-169	86	16	and	and	CCONJ
chd-169	86	17	their	their	PRON
chd-169	86	18	tumors	tumor	NOUN
chd-169	86	19	show	show	VERB
chd-169	86	20	increased	increase	VERB
chd-169	86	21	expression	expression	NOUN
chd-169	86	22	of	of	ADP
chd-169	86	23	specific	specific	ADJ
chd-169	86	24	ar	ar	NOUN
chd-169	86	25	target	target	NOUN
chd-169	86	26	genes	gene	NOUN
chd-169	86	27	associated	associate	VERB
chd-169	86	28	with	with	ADP
chd-169	86	29	tumor	tumor	NOUN
chd-169	86	30	aggressive	aggressive	ADJ
chd-169	86	31	properties	property	NOUN
chd-169	86	32	compared	compare	VERB
chd-169	86	33	to	to	ADP
chd-169	86	34	those	those	PRON
chd-169	86	35	of	of	ADP
chd-169	86	36	ea	ea	X
chd-169	86	37	pca	pca	NOUN
chd-169	86	38	men	man	NOUN
chd-169	86	39	(	(	PUNCT
chd-169	86	40	gaston	gaston	PROPN
chd-169	86	41	et	et	PROPN
chd-169	86	42	al	al	PROPN
chd-169	86	43	.	.	PROPN
chd-169	86	44	,	,	PUNCT
chd-169	86	45	2003	2003	NUM
chd-169	86	46	;	;	PUNCT
chd-169	86	47	jemal	jemal	PROPN
chd-169	86	48	et	et	PROPN
chd-169	86	49	al	al	PROPN
chd-169	86	50	.	.	PROPN
chd-169	86	51	,	,	PUNCT
chd-169	86	52	2006	2006	NUM
chd-169	86	53	;	;	PUNCT
chd-169	86	54	karakas	karakas	PROPN
chd-169	86	55	et	et	PROPN
chd-169	86	56	al	al	PROPN
chd-169	86	57	.	.	PROPN
chd-169	86	58	,	,	PUNCT
chd-169	86	59	2017	2017	NUM
chd-169	86	60	)	)	PUNCT
chd-169	86	61	.	.	PUNCT
chd-169	87	1	african	african	ADJ
chd-169	87	2	americans	americans	PROPN
chd-169	87	3	and	and	CCONJ
chd-169	87	4	psychosocial	psychosocial	ADJ
chd-169	87	5	stress	stress	NOUN
chd-169	87	6	aas	aas	PROPN
chd-169	87	7	are	be	AUX
chd-169	87	8	exposed	expose	VERB
chd-169	87	9	to	to	ADP
chd-169	87	10	more	more	ADV
chd-169	87	11	cumulative	cumulative	ADJ
chd-169	87	12	lifetime	lifetime	NOUN
chd-169	87	13	stressors	stressor	NOUN
chd-169	87	14	than	than	ADP
chd-169	87	15	other	other	ADJ
chd-169	87	16	racial	racial	ADJ
chd-169	87	17	/	/	SYM
chd-169	87	18	ethnic	ethnic	ADJ
chd-169	87	19	groups	group	NOUN
chd-169	87	20	,	,	PUNCT
chd-169	87	21	which	which	PRON
chd-169	87	22	detrimentally	detrimentally	ADV
chd-169	87	23	alters	alter	VERB
chd-169	87	24	psychological	psychological	ADJ
chd-169	87	25	and	and	CCONJ
chd-169	87	26	physical	physical	ADJ
chd-169	87	27	health	health	NOUN
chd-169	87	28	(	(	PUNCT
chd-169	87	29	cohen	cohen	PROPN
chd-169	87	30	et	et	PROPN
chd-169	87	31	al	al	PROPN
chd-169	87	32	.	.	PROPN
chd-169	87	33	,	,	PUNCT
chd-169	87	34	2006	2006	NUM
chd-169	87	35	;	;	PUNCT
chd-169	87	36	young	young	PROPN
chd-169	87	37	et	et	PROPN
chd-169	87	38	al	al	PROPN
chd-169	87	39	.	.	PROPN
chd-169	87	40	,	,	PUNCT
chd-169	87	41	1991	1991	NUM
chd-169	87	42	;	;	PUNCT
chd-169	87	43	zannas	zannas	PROPN
chd-169	87	44	et	et	PROPN
chd-169	87	45	al	al	PROPN
chd-169	87	46	.	.	PROPN
chd-169	87	47	,	,	PUNCT
chd-169	87	48	2015	2015	NUM
chd-169	87	49	)	)	PUNCT
chd-169	87	50	.	.	PUNCT
chd-169	88	1	the	the	DET
chd-169	88	2	elevated	elevated	ADJ
chd-169	88	3	levels	level	NOUN
chd-169	88	4	of	of	ADP
chd-169	88	5	stress	stress	NOUN
chd-169	88	6	among	among	ADP
chd-169	88	7	aas	aas	NOUN
chd-169	88	8	can	can	AUX
chd-169	88	9	be	be	AUX
chd-169	88	10	due	due	ADJ
chd-169	88	11	,	,	PUNCT
chd-169	88	12	among	among	ADP
chd-169	88	13	other	other	ADJ
chd-169	88	14	factors	factor	NOUN
chd-169	88	15	,	,	PUNCT
chd-169	88	16	to	to	ADP
chd-169	88	17	social	social	ADJ
chd-169	88	18	isolation	isolation	NOUN
chd-169	88	19	,	,	PUNCT
chd-169	88	20	racial	racial	ADJ
chd-169	88	21	discrimination	discrimination	NOUN
chd-169	88	22	,	,	PUNCT
chd-169	88	23	perceived	perceive	VERB
chd-169	88	24	discrimination	discrimination	NOUN
chd-169	88	25	,	,	PUNCT
chd-169	88	26	and	and	CCONJ
chd-169	88	27	segregation	segregation	NOUN
chd-169	88	28	(	(	PUNCT
chd-169	88	29	cacioppo	cacioppo	NOUN
chd-169	88	30	and	and	CCONJ
chd-169	88	31	hawkley	hawkley	NOUN
chd-169	88	32	,	,	PUNCT
chd-169	88	33	2003	2003	NUM
chd-169	88	34	;	;	PUNCT
chd-169	88	35	cuevas	cuevas	PROPN
chd-169	88	36	et	et	PROPN
chd-169	88	37	al	al	PROPN
chd-169	88	38	.	.	PROPN
chd-169	88	39	,	,	PUNCT
chd-169	88	40	2019	2019	NUM
chd-169	88	41	;	;	PUNCT
chd-169	88	42	williams	williams	PROPN
chd-169	88	43	and	and	CCONJ
chd-169	88	44	collins	collins	PROPN
chd-169	88	45	,	,	PUNCT
chd-169	88	46	2001	2001	NUM
chd-169	88	47	)	)	PUNCT
chd-169	88	48	.	.	PUNCT
chd-169	89	1	chronic	chronic	ADJ
chd-169	89	2	stress	stress	NOUN
chd-169	89	3	leading	lead	VERB
chd-169	89	4	to	to	ADP
chd-169	89	5	dysregulation	dysregulation	NOUN
chd-169	89	6	of	of	ADP
chd-169	89	7	endogenous	endogenous	ADJ
chd-169	89	8	cortisol	cortisol	ADJ
chd-169	89	9	production	production	NOUN
chd-169	89	10	via	via	ADP
chd-169	89	11	the	the	DET
chd-169	89	12	hypothalamic	hypothalamic	ADJ
chd-169	89	13	-	-	PUNCT
chd-169	89	14	pituitary	pituitary	ADJ
chd-169	89	15	-	-	PUNCT
chd-169	89	16	adrenocortical	adrenocortical	ADJ
chd-169	89	17	(	(	PUNCT
chd-169	89	18	hpa	hpa	NOUN
chd-169	89	19	)	)	PUNCT
chd-169	89	20	axis	axis	NOUN
chd-169	89	21	can	can	AUX
chd-169	89	22	enhance	enhance	VERB
chd-169	89	23	risk	risk	NOUN
chd-169	89	24	for	for	ADP
chd-169	89	25	metabolic	metabolic	NOUN
chd-169	89	26	disorders	disorder	NOUN
chd-169	89	27	and	and	CCONJ
chd-169	89	28	cancer	cancer	NOUN
chd-169	89	29	(	(	PUNCT
chd-169	89	30	cohen	cohen	PROPN
chd-169	89	31	et	et	PROPN
chd-169	89	32	al	al	PROPN
chd-169	89	33	.	.	PROPN
chd-169	89	34	,	,	PUNCT
chd-169	89	35	2006	2006	NUM
chd-169	89	36	;	;	PUNCT
chd-169	89	37	steptoe	steptoe	PROPN
chd-169	89	38	et	et	PROPN
chd-169	89	39	al	al	PROPN
chd-169	89	40	.	.	PROPN
chd-169	89	41	,	,	PUNCT
chd-169	89	42	2000	2000	NUM
chd-169	89	43	;	;	PUNCT
chd-169	89	44	vedhara	vedhara	X
chd-169	89	45	et	et	PROPN
chd-169	89	46	al	al	PROPN
chd-169	89	47	.	.	PROPN
chd-169	89	48	,	,	PUNCT
chd-169	89	49	1999	1999	NUM
chd-169	89	50	;	;	PUNCT
chd-169	89	51	zannas	zannas	PROPN
chd-169	89	52	et	et	PROPN
chd-169	89	53	al	al	PROPN
chd-169	89	54	.	.	PROPN
chd-169	89	55	,	,	PUNCT
chd-169	89	56	2015	2015	NUM
chd-169	89	57	)	)	PUNCT
chd-169	89	58	.	.	PUNCT
chd-169	90	1	as	as	SCONJ
chd-169	90	2	illustrated	illustrate	VERB
chd-169	90	3	in	in	ADP
chd-169	90	4	fig	fig	NOUN
chd-169	90	5	.	.	PUNCT
chd-169	91	1	2	2	NUM
chd-169	91	2	,	,	PUNCT
chd-169	91	3	when	when	SCONJ
chd-169	91	4	the	the	DET
chd-169	91	5	hpa	hpa	NOUN
chd-169	91	6	axis	axis	NOUN
chd-169	91	7	is	be	AUX
chd-169	91	8	activated	activate	VERB
chd-169	91	9	,	,	PUNCT
chd-169	91	10	neurons	neuron	NOUN
chd-169	91	11	in	in	ADP
chd-169	91	12	the	the	DET
chd-169	91	13	paraventricular	paraventricular	ADJ
chd-169	91	14	nucleus	nucleus	NOUN
chd-169	91	15	of	of	ADP
chd-169	91	16	the	the	DET
chd-169	91	17	hypothalamus	hypothalamus	NOUN
chd-169	91	18	are	be	AUX
chd-169	91	19	triggered	trigger	VERB
chd-169	91	20	to	to	PART
chd-169	91	21	release	release	VERB
chd-169	91	22	corticotropin	corticotropin	NOUN
chd-169	91	23	-	-	PUNCT
chd-169	91	24	releasing	release	VERB
chd-169	91	25	hormone	hormone	NOUN
chd-169	91	26	(	(	PUNCT
chd-169	91	27	crh	crh	PROPN
chd-169	91	28	)	)	PUNCT
chd-169	91	29	and	and	CCONJ
chd-169	91	30	arginine	arginine	NOUN
chd-169	91	31	vasopressin	vasopressin	NOUN
chd-169	91	32	,	,	PUNCT
chd-169	91	33	which	which	PRON
chd-169	91	34	stimulate	stimulate	VERB
chd-169	91	35	the	the	DET
chd-169	91	36	production	production	NOUN
chd-169	91	37	and	and	CCONJ
chd-169	91	38	secretion	secretion	NOUN
chd-169	91	39	of	of	ADP
chd-169	91	40	adrenocorticotropic	adrenocorticotropic	ADJ
chd-169	91	41	hormone	hormone	NOUN
chd-169	91	42	(	(	PUNCT
chd-169	91	43	acth	acth	NOUN
chd-169	91	44	)	)	PUNCT
chd-169	91	45	from	from	ADP
chd-169	91	46	the	the	DET
chd-169	91	47	anterior	anterior	ADJ
chd-169	91	48	pituitary	pituitary	ADJ
chd-169	91	49	gland	gland	NOUN
chd-169	91	50	,	,	PUNCT
chd-169	91	51	resulting	result	VERB
chd-169	91	52	in	in	ADP
chd-169	91	53	the	the	DET
chd-169	91	54	synthesis	synthesis	NOUN
chd-169	91	55	and	and	CCONJ
chd-169	91	56	secretion	secretion	NOUN
chd-169	91	57	of	of	ADP
chd-169	91	58	the	the	DET
chd-169	91	59	steroid	steroid	NOUN
chd-169	91	60	hormone	hormone	NOUN
chd-169	91	61	cortisol	cortisol	NOUN
chd-169	91	62	,	,	PUNCT
chd-169	91	63	an	an	DET
chd-169	91	64	endogenous	endogenous	ADJ
chd-169	91	65	glucocorticoid	glucocorticoid	NOUN
chd-169	91	66	,	,	PUNCT
chd-169	91	67	from	from	ADP
chd-169	91	68	the	the	DET
chd-169	91	69	adrenal	adrenal	ADJ
chd-169	91	70	cortex	cortex	NOUN
chd-169	91	71	(	(	PUNCT
chd-169	91	72	joseph	joseph	PROPN
chd-169	91	73	and	and	CCONJ
chd-169	91	74	whirledge	whirledge	VERB
chd-169	91	75	,	,	PUNCT
chd-169	91	76	2017	2017	NUM
chd-169	91	77	;	;	PUNCT
chd-169	91	78	stephens	stephen	NOUN
chd-169	91	79	and	and	CCONJ
chd-169	91	80	wand	wand	NOUN
chd-169	91	81	,	,	PUNCT
chd-169	91	82	2012	2012	NUM
chd-169	91	83	)	)	PUNCT
chd-169	91	84	.	.	PUNCT
chd-169	92	1	a	a	DET
chd-169	92	2	classical	classical	ADJ
chd-169	92	3	endocrine	endocrine	NOUN
chd-169	92	4	negative	negative	ADJ
chd-169	92	5	feedback	feedback	NOUN
chd-169	92	6	loop	loop	NOUN
chd-169	92	7	inhibits	inhibit	VERB
chd-169	92	8	further	further	ADJ
chd-169	92	9	release	release	NOUN
chd-169	92	10	of	of	ADP
chd-169	92	11	crh	crh	PROPN
chd-169	92	12	and	and	CCONJ
chd-169	92	13	acth	acth	NOUN
chd-169	92	14	in	in	ADP
chd-169	92	15	response	response	NOUN
chd-169	92	16	to	to	ADP
chd-169	92	17	rising	rise	VERB
chd-169	92	18	levels	level	NOUN
chd-169	92	19	of	of	ADP
chd-169	92	20	cortisol	cortisol	NOUN
chd-169	92	21	,	,	PUNCT
chd-169	92	22	thus	thus	ADV
chd-169	92	23	maintaining	maintain	VERB
chd-169	92	24	a	a	DET
chd-169	92	25	physiological	physiological	ADJ
chd-169	92	26	homeostasis	homeostasis	NOUN
chd-169	92	27	under	under	ADP
chd-169	92	28	normal	normal	ADJ
chd-169	92	29	conditions	condition	NOUN
chd-169	92	30	(	(	PUNCT
chd-169	92	31	joseph	joseph	PROPN
chd-169	92	32	and	and	CCONJ
chd-169	92	33	whirledge	whirledge	VERB
chd-169	92	34	,	,	PUNCT
chd-169	92	35	2017	2017	NUM
chd-169	92	36	)	)	PUNCT
chd-169	92	37	.	.	PUNCT
chd-169	93	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-169	93	2	e7	e7	PROPN
chd-169	93	3	cancer	cancer	NOUN
chd-169	93	4	health	health	NOUN
chd-169	93	5	disparities	disparity	NOUN
chd-169	93	6	research	research	VERB
chd-169	93	7	in	in	ADP
chd-169	93	8	addition	addition	NOUN
chd-169	93	9	,	,	PUNCT
chd-169	93	10	the	the	DET
chd-169	93	11	hpa	hpa	NOUN
chd-169	93	12	axis	axis	NOUN
chd-169	93	13	tightly	tightly	ADV
chd-169	93	14	regulates	regulate	VERB
chd-169	93	15	glucose	glucose	NOUN
chd-169	93	16	metabolism	metabolism	NOUN
chd-169	93	17	,	,	PUNCT
chd-169	93	18	cardiovascular	cardiovascular	ADJ
chd-169	93	19	function	function	NOUN
chd-169	93	20	,	,	PUNCT
chd-169	93	21	cell	cell	NOUN
chd-169	93	22	proliferation	proliferation	NOUN
chd-169	93	23	and	and	CCONJ
chd-169	93	24	survival	survival	NOUN
chd-169	93	25	,	,	PUNCT
chd-169	93	26	growth	growth	NOUN
chd-169	93	27	,	,	PUNCT
chd-169	93	28	cognition	cognition	NOUN
chd-169	93	29	and	and	CCONJ
chd-169	93	30	behavior	behavior	NOUN
chd-169	93	31	,	,	PUNCT
chd-169	93	32	immune	immune	ADJ
chd-169	93	33	function	function	NOUN
chd-169	93	34	,	,	PUNCT
chd-169	93	35	and	and	CCONJ
chd-169	93	36	reproduction	reproduction	NOUN
chd-169	93	37	directly	directly	ADV
chd-169	93	38	through	through	ADP
chd-169	93	39	cortisol	cortisol	ADJ
chd-169	93	40	production	production	NOUN
chd-169	93	41	(	(	PUNCT
chd-169	93	42	joseph	joseph	PROPN
chd-169	93	43	and	and	CCONJ
chd-169	93	44	whirledge	whirledge	VERB
chd-169	93	45	,	,	PUNCT
chd-169	93	46	2017	2017	NUM
chd-169	93	47	)	)	PUNCT
chd-169	93	48	.	.	PUNCT
chd-169	94	1	cortisol	cortisol	NOUN
chd-169	94	2	is	be	AUX
chd-169	94	3	secreted	secrete	VERB
chd-169	94	4	diurnally	diurnally	ADV
chd-169	94	5	,	,	PUNCT
chd-169	94	6	peaking	peak	VERB
chd-169	94	7	early	early	ADV
chd-169	94	8	in	in	ADP
chd-169	94	9	the	the	DET
chd-169	94	10	morning	morning	NOUN
chd-169	94	11	when	when	SCONJ
chd-169	94	12	blood	blood	NOUN
chd-169	94	13	glucose	glucose	NOUN
chd-169	94	14	levels	level	NOUN
chd-169	94	15	are	be	AUX
chd-169	94	16	at	at	ADP
chd-169	94	17	the	the	DET
chd-169	94	18	lowest	low	ADJ
chd-169	94	19	and	and	CCONJ
chd-169	94	20	tapering	taper	VERB
chd-169	94	21	throughout	throughout	ADP
chd-169	94	22	the	the	DET
chd-169	94	23	day	day	NOUN
chd-169	94	24	(	(	PUNCT
chd-169	94	25	cohen	cohen	PROPN
chd-169	94	26	et	et	PROPN
chd-169	94	27	al	al	PROPN
chd-169	94	28	.	.	PROPN
chd-169	94	29	,	,	PUNCT
chd-169	94	30	2006	2006	NUM
chd-169	94	31	)	)	PUNCT
chd-169	94	32	.	.	PUNCT
chd-169	95	1	this	this	DET
chd-169	95	2	diurnal	diurnal	ADJ
chd-169	95	3	rhythm	rhythm	NOUN
chd-169	95	4	is	be	AUX
chd-169	95	5	altered	alter	VERB
chd-169	95	6	in	in	ADP
chd-169	95	7	response	response	NOUN
chd-169	95	8	to	to	ADP
chd-169	95	9	chronically	chronically	ADV
chd-169	95	10	stressful	stressful	ADJ
chd-169	95	11	situations	situation	NOUN
chd-169	95	12	(	(	PUNCT
chd-169	95	13	adam	adam	PROPN
chd-169	95	14	and	and	CCONJ
chd-169	95	15	gunnar	gunnar	PROPN
chd-169	95	16	,	,	PUNCT
chd-169	95	17	2001	2001	NUM
chd-169	95	18	;	;	PUNCT
chd-169	95	19	cohen	cohen	PROPN
chd-169	95	20	et	et	PROPN
chd-169	95	21	al	al	PROPN
chd-169	95	22	.	.	PROPN
chd-169	95	23	,	,	PUNCT
chd-169	95	24	2006	2006	NUM
chd-169	95	25	)	)	PUNCT
chd-169	95	26	.	.	PUNCT
chd-169	96	1	fig	fig	NOUN
chd-169	96	2	.	.	PUNCT
chd-169	97	1	2	2	X
chd-169	97	2	.	.	X
chd-169	97	3	physiological	physiological	ADJ
chd-169	97	4	response	response	NOUN
chd-169	97	5	to	to	ADP
chd-169	97	6	stress	stress	NOUN
chd-169	97	7	.	.	PUNCT
chd-169	98	1	cortisol	cortisol	NOUN
chd-169	98	2	is	be	AUX
chd-169	98	3	secreted	secrete	VERB
chd-169	98	4	from	from	ADP
chd-169	98	5	the	the	DET
chd-169	98	6	adrenal	adrenal	ADJ
chd-169	98	7	cortex	cortex	NOUN
chd-169	98	8	in	in	ADP
chd-169	98	9	response	response	NOUN
chd-169	98	10	to	to	ADP
chd-169	98	11	acute	acute	ADJ
chd-169	98	12	stress	stress	NOUN
chd-169	98	13	.	.	PUNCT
chd-169	99	1	a	a	DET
chd-169	99	2	classical	classical	ADJ
chd-169	99	3	endocrine	endocrine	NOUN
chd-169	99	4	negative	negative	ADJ
chd-169	99	5	feedback	feedback	NOUN
chd-169	99	6	loop	loop	NOUN
chd-169	99	7	inhibits	inhibit	VERB
chd-169	99	8	further	further	ADJ
chd-169	99	9	release	release	NOUN
chd-169	99	10	of	of	ADP
chd-169	99	11	crh	crh	PROPN
chd-169	99	12	and	and	CCONJ
chd-169	99	13	acth	acth	NOUN
chd-169	99	14	in	in	ADP
chd-169	99	15	response	response	NOUN
chd-169	99	16	to	to	ADP
chd-169	99	17	rising	rise	VERB
chd-169	99	18	levels	level	NOUN
chd-169	99	19	of	of	ADP
chd-169	99	20	cortisol	cortisol	NOUN
chd-169	99	21	to	to	PART
chd-169	99	22	maintain	maintain	VERB
chd-169	99	23	a	a	DET
chd-169	99	24	physiological	physiological	ADJ
chd-169	99	25	homeostasis	homeostasis	NOUN
chd-169	99	26	under	under	ADP
chd-169	99	27	normal	normal	ADJ
chd-169	99	28	conditions	condition	NOUN
chd-169	99	29	.	.	PUNCT
chd-169	100	1	chronic	chronic	ADJ
chd-169	100	2	stress	stress	NOUN
chd-169	100	3	leading	lead	VERB
chd-169	100	4	to	to	ADP
chd-169	100	5	dysregulation	dysregulation	NOUN
chd-169	100	6	of	of	ADP
chd-169	100	7	endogenous	endogenous	ADJ
chd-169	100	8	cortisol	cortisol	ADJ
chd-169	100	9	production	production	NOUN
chd-169	100	10	via	via	ADP
chd-169	100	11	the	the	DET
chd-169	100	12	hpa	hpa	NOUN
chd-169	100	13	axis	axis	NOUN
chd-169	100	14	can	can	AUX
chd-169	100	15	enhance	enhance	VERB
chd-169	100	16	risk	risk	NOUN
chd-169	100	17	for	for	ADP
chd-169	100	18	metabolic	metabolic	NOUN
chd-169	100	19	disorders	disorder	NOUN
chd-169	100	20	and	and	CCONJ
chd-169	100	21	cancer	cancer	NOUN
chd-169	100	22	.	.	PUNCT
chd-169	101	1	acth	acth	NOUN
chd-169	101	2	,	,	PUNCT
chd-169	101	3	adrenocorticotropic	adrenocorticotropic	NOUN
chd-169	101	4	hormone	hormone	NOUN
chd-169	101	5	;	;	PUNCT
chd-169	101	6	crh	crh	PROPN
chd-169	101	7	,	,	PUNCT
chd-169	101	8	corticotropin	corticotropin	NOUN
chd-169	101	9	-	-	PUNCT
chd-169	101	10	releasing	release	VERB
chd-169	101	11	hormone	hormone	NOUN
chd-169	101	12	;	;	PUNCT
chd-169	101	13	gr	gr	NUM
chd-169	101	14	,	,	PUNCT
chd-169	101	15	glucocorticoid	glucocorticoid	ADJ
chd-169	101	16	receptor	receptor	NOUN
chd-169	101	17	;	;	PUNCT
chd-169	101	18	hpa	hpa	NOUN
chd-169	101	19	,	,	PUNCT
chd-169	101	20	hypothalamic	hypothalamic	ADJ
chd-169	101	21	-	-	PUNCT
chd-169	101	22	pituitary	pituitary	ADJ
chd-169	101	23	-	-	PUNCT
chd-169	101	24	adrenocortical	adrenocortical	NOUN
chd-169	101	25	.	.	PUNCT
chd-169	102	1	chronic	chronic	ADJ
chd-169	102	2	exposure	exposure	NOUN
chd-169	102	3	to	to	ADP
chd-169	102	4	stressors	stressor	NOUN
chd-169	102	5	is	be	AUX
chd-169	102	6	increased	increase	VERB
chd-169	102	7	in	in	ADP
chd-169	102	8	individuals	individual	NOUN
chd-169	102	9	of	of	ADP
chd-169	102	10	low	low	ADJ
chd-169	102	11	ses	se	NOUN
chd-169	102	12	,	,	PUNCT
chd-169	102	13	and	and	CCONJ
chd-169	102	14	there	there	PRON
chd-169	102	15	is	be	VERB
chd-169	102	16	a	a	DET
chd-169	102	17	positive	positive	ADJ
chd-169	102	18	association	association	NOUN
chd-169	102	19	between	between	ADP
chd-169	102	20	low	low	ADJ
chd-169	102	21	ses	se	NOUN
chd-169	102	22	and	and	CCONJ
chd-169	102	23	stress	stress	NOUN
chd-169	102	24	in	in	ADP
chd-169	102	25	aa	aa	PROPN
chd-169	102	26	men	man	NOUN
chd-169	102	27	(	(	PUNCT
chd-169	102	28	cohen	cohen	PROPN
chd-169	102	29	et	et	PROPN
chd-169	102	30	al	al	PROPN
chd-169	102	31	.	.	PROPN
chd-169	102	32	,	,	PUNCT
chd-169	102	33	2006	2006	NUM
chd-169	102	34	;	;	PUNCT
chd-169	102	35	williams	williams	PROPN
chd-169	102	36	,	,	PUNCT
chd-169	102	37	2003	2003	NUM
chd-169	102	38	)	)	PUNCT
chd-169	102	39	.	.	PUNCT
chd-169	103	1	low	low	ADJ
chd-169	103	2	ses	se	NOUN
chd-169	103	3	is	be	AUX
chd-169	103	4	defined	define	VERB
chd-169	103	5	by	by	ADP
chd-169	103	6	lower	low	ADJ
chd-169	103	7	income	income	NOUN
chd-169	103	8	,	,	PUNCT
chd-169	103	9	education	education	NOUN
chd-169	103	10	,	,	PUNCT
chd-169	103	11	or	or	CCONJ
chd-169	103	12	occupational	occupational	ADJ
chd-169	103	13	status	status	NOUN
chd-169	103	14	,	,	PUNCT
chd-169	103	15	and	and	CCONJ
chd-169	103	16	often	often	ADV
chd-169	103	17	results	result	VERB
chd-169	103	18	in	in	ADP
chd-169	103	19	increased	increase	VERB
chd-169	103	20	exposure	exposure	NOUN
chd-169	103	21	to	to	ADP
chd-169	103	22	environmental	environmental	ADJ
chd-169	103	23	stressors	stressor	NOUN
chd-169	103	24	leading	lead	VERB
chd-169	103	25	to	to	ADP
chd-169	103	26	stress	stress	NOUN
chd-169	103	27	-	-	PUNCT
chd-169	103	28	related	relate	VERB
chd-169	103	29	dysregulation	dysregulation	NOUN
chd-169	103	30	of	of	ADP
chd-169	103	31	physiological	physiological	ADJ
chd-169	103	32	systems	system	NOUN
chd-169	103	33	and	and	CCONJ
chd-169	103	34	increased	increase	VERB
chd-169	103	35	risk	risk	NOUN
chd-169	103	36	for	for	ADP
chd-169	103	37	disease	disease	NOUN
chd-169	103	38	(	(	PUNCT
chd-169	103	39	adler	adler	PROPN
chd-169	103	40	et	et	PROPN
chd-169	103	41	al	al	PROPN
chd-169	103	42	.	.	PROPN
chd-169	103	43	,	,	PUNCT
chd-169	103	44	1994	1994	NUM
chd-169	103	45	;	;	PUNCT
chd-169	104	1	cohen	cohen	PROPN
chd-169	104	2	et	et	PROPN
chd-169	104	3	al	al	PROPN
chd-169	104	4	.	.	PROPN
chd-169	104	5	,	,	PUNCT
chd-169	104	6	2006	2006	NUM
chd-169	104	7	;	;	PUNCT
chd-169	104	8	mcewen	mcewen	PROPN
chd-169	104	9	,	,	PUNCT
chd-169	104	10	1998	1998	NUM
chd-169	104	11	)	)	PUNCT
chd-169	104	12	.	.	PUNCT
chd-169	105	1	however	however	ADV
chd-169	105	2	,	,	PUNCT
chd-169	105	3	even	even	ADV
chd-169	105	4	in	in	ADP
chd-169	105	5	aas	aas	NOUN
chd-169	105	6	who	who	PRON
chd-169	105	7	have	have	VERB
chd-169	105	8	high	high	ADJ
chd-169	105	9	ses	se	NOUN
chd-169	105	10	,	,	PUNCT
chd-169	105	11	racial	racial	ADJ
chd-169	105	12	disparities	disparity	NOUN
chd-169	105	13	in	in	ADP
chd-169	105	14	health	health	NOUN
chd-169	105	15	persist	persist	NOUN
chd-169	105	16	,	,	PUNCT
chd-169	105	17	suggesting	suggest	VERB
chd-169	105	18	that	that	SCONJ
chd-169	105	19	there	there	PRON
chd-169	105	20	are	be	VERB
chd-169	105	21	alternative	alternative	ADJ
chd-169	105	22	sources	source	NOUN
chd-169	105	23	of	of	ADP
chd-169	105	24	stress	stress	NOUN
chd-169	105	25	other	other	ADJ
chd-169	105	26	than	than	ADP
chd-169	105	27	ses	se	NOUN
chd-169	105	28	(	(	PUNCT
chd-169	105	29	farmer	farmer	NOUN
chd-169	105	30	and	and	CCONJ
chd-169	105	31	ferraro	ferraro	NOUN
chd-169	105	32	,	,	PUNCT
chd-169	105	33	2005	2005	NUM
chd-169	105	34	)	)	PUNCT
chd-169	105	35	.	.	PUNCT
chd-169	106	1	for	for	ADP
chd-169	106	2	example	example	NOUN
chd-169	106	3	,	,	PUNCT
chd-169	106	4	a	a	DET
chd-169	106	5	poor	poor	ADJ
chd-169	106	6	lipid	lipid	NOUN
chd-169	106	7	profile	profile	NOUN
chd-169	106	8	characterized	characterize	VERB
chd-169	106	9	by	by	ADP
chd-169	106	10	high	high	ADJ
chd-169	106	11	triglycerides	triglyceride	NOUN
chd-169	106	12	,	,	PUNCT
chd-169	106	13	ldl	ldl	NOUN
chd-169	106	14	cholesterol	cholesterol	NOUN
chd-169	106	15	,	,	PUNCT
chd-169	106	16	and	and	CCONJ
chd-169	106	17	total	total	ADJ
chd-169	106	18	cholesterol	cholesterol	NOUN
chd-169	106	19	,	,	PUNCT
chd-169	106	20	as	as	ADV
chd-169	106	21	well	well	ADV
chd-169	106	22	as	as	ADP
chd-169	106	23	lower	low	ADJ
chd-169	106	24	hdl	hdl	PROPN
chd-169	106	25	cholesterol	cholesterol	PROPN
chd-169	106	26	,	,	PUNCT
chd-169	106	27	actually	actually	ADV
chd-169	106	28	increases	increase	VERB
chd-169	106	29	in	in	ADP
chd-169	106	30	aas	aas	NOUN
chd-169	106	31	as	as	ADP
chd-169	106	32	education	education	NOUN
chd-169	106	33	increases	increase	NOUN
chd-169	106	34	(	(	PUNCT
chd-169	106	35	knox	knox	PROPN
chd-169	106	36	et	et	PROPN
chd-169	106	37	al	al	PROPN
chd-169	106	38	.	.	PROPN
chd-169	106	39	,	,	PUNCT
chd-169	106	40	1996	1996	NUM
chd-169	106	41	)	)	PUNCT
chd-169	106	42	.	.	PUNCT
chd-169	107	1	national	national	ADJ
chd-169	107	2	data	data	PROPN
chd-169	107	3	reveals	reveal	VERB
chd-169	107	4	that	that	SCONJ
chd-169	107	5	strikingly	strikingly	ADV
chd-169	107	6	high	high	ADJ
chd-169	107	7	levels	level	NOUN
chd-169	107	8	of	of	ADP
chd-169	107	9	racial	racial	ADJ
chd-169	107	10	inequality	inequality	NOUN
chd-169	107	11	in	in	ADP
chd-169	107	12	ses	se	NOUN
chd-169	107	13	exist	exist	VERB
chd-169	107	14	in	in	ADP
chd-169	107	15	the	the	DET
chd-169	107	16	u.s	u.s	PROPN
chd-169	107	17	.	.	PROPN
chd-169	107	18	,	,	PUNCT
chd-169	107	19	having	having	AUX
chd-169	107	20	changed	change	VERB
chd-169	107	21	little	little	ADJ
chd-169	107	22	over	over	ADP
chd-169	107	23	time	time	NOUN
chd-169	107	24	,	,	PUNCT
chd-169	107	25	and	and	CCONJ
chd-169	107	26	that	that	DET
chd-169	107	27	aas	aas	NOUN
chd-169	107	28	continue	continue	VERB
chd-169	107	29	to	to	PART
chd-169	107	30	suffer	suffer	VERB
chd-169	107	31	from	from	ADP
chd-169	107	32	disproportionately	disproportionately	ADV
chd-169	107	33	lower	low	ADJ
chd-169	107	34	ses	se	NOUN
chd-169	107	35	(	(	PUNCT
chd-169	107	36	williams	williams	PROPN
chd-169	107	37	et	et	PROPN
chd-169	107	38	al	al	PROPN
chd-169	107	39	.	.	PROPN
chd-169	107	40	,	,	PUNCT
chd-169	107	41	2010	2010	NUM
chd-169	107	42	)	)	PUNCT
chd-169	107	43	,	,	PUNCT
chd-169	107	44	which	which	PRON
chd-169	107	45	has	have	AUX
chd-169	107	46	been	be	AUX
chd-169	107	47	shown	show	VERB
chd-169	107	48	to	to	PART
chd-169	107	49	influence	influence	VERB
chd-169	107	50	emotions	emotion	NOUN
chd-169	107	51	and	and	CCONJ
chd-169	107	52	behaviors	behavior	NOUN
chd-169	107	53	that	that	PRON
chd-169	107	54	alter	alter	VERB
chd-169	107	55	cortisol	cortisol	NOUN
chd-169	107	56	levels	level	NOUN
chd-169	107	57	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-169	107	58	e8	e8	PROPN
chd-169	107	59	cancer	cancer	NOUN
chd-169	107	60	health	health	NOUN
chd-169	107	61	disparities	disparity	NOUN
chd-169	107	62	research	research	NOUN
chd-169	107	63	(	(	PUNCT
chd-169	107	64	adler	adler	PROPN
chd-169	107	65	et	et	PROPN
chd-169	107	66	al	al	PROPN
chd-169	107	67	.	.	PROPN
chd-169	107	68	,	,	PUNCT
chd-169	107	69	1994	1994	NUM
chd-169	107	70	)	)	PUNCT
chd-169	107	71	.	.	PUNCT
chd-169	108	1	lower	low	ADJ
chd-169	108	2	ses	se	NOUN
chd-169	108	3	is	be	AUX
chd-169	108	4	also	also	ADV
chd-169	108	5	associated	associate	VERB
chd-169	108	6	with	with	ADP
chd-169	108	7	greater	great	ADJ
chd-169	108	8	perceived	perceive	VERB
chd-169	108	9	stress	stress	NOUN
chd-169	108	10	,	,	PUNCT
chd-169	108	11	depressive	depressive	ADJ
chd-169	108	12	symptoms	symptom	NOUN
chd-169	108	13	,	,	PUNCT
chd-169	108	14	negative	negative	ADJ
chd-169	108	15	affect	affect	NOUN
chd-169	108	16	,	,	PUNCT
chd-169	108	17	weak	weak	ADJ
chd-169	108	18	social	social	ADJ
chd-169	108	19	networks	network	NOUN
chd-169	108	20	and	and	CCONJ
chd-169	108	21	support	support	NOUN
chd-169	108	22	,	,	PUNCT
chd-169	108	23	and	and	CCONJ
chd-169	108	24	sleep	sleep	VERB
chd-169	108	25	deprivation	deprivation	NOUN
chd-169	108	26	(	(	PUNCT
chd-169	108	27	cohen	cohen	NOUN
chd-169	108	28	et	et	PROPN
chd-169	108	29	al	al	PROPN
chd-169	108	30	.	.	PROPN
chd-169	108	31	,	,	PUNCT
chd-169	108	32	2006	2006	NUM
chd-169	108	33	)	)	PUNCT
chd-169	108	34	,	,	PUNCT
chd-169	108	35	factors	factor	NOUN
chd-169	108	36	linked	link	VERB
chd-169	108	37	to	to	ADP
chd-169	108	38	greater	great	ADJ
chd-169	108	39	cortisol	cortisol	ADJ
chd-169	108	40	responses	response	NOUN
chd-169	108	41	(	(	PUNCT
chd-169	108	42	leproult	leproult	PROPN
chd-169	108	43	et	et	PROPN
chd-169	108	44	al	al	PROPN
chd-169	108	45	.	.	PROPN
chd-169	108	46	,	,	PUNCT
chd-169	108	47	1997	1997	NUM
chd-169	108	48	;	;	PUNCT
chd-169	108	49	polk	polk	PROPN
chd-169	108	50	et	et	PROPN
chd-169	108	51	al	al	PROPN
chd-169	108	52	.	.	PROPN
chd-169	108	53	,	,	PUNCT
chd-169	108	54	2005	2005	NUM
chd-169	108	55	;	;	PUNCT
chd-169	108	56	pruessner	pruessner	NOUN
chd-169	108	57	et	et	PROPN
chd-169	108	58	al	al	PROPN
chd-169	108	59	.	.	PROPN
chd-169	108	60	,	,	PUNCT
chd-169	108	61	2003	2003	NUM
chd-169	108	62	;	;	PUNCT
chd-169	108	63	seeman	seeman	PROPN
chd-169	108	64	et	et	PROPN
chd-169	108	65	al	al	PROPN
chd-169	108	66	.	.	PROPN
chd-169	108	67	,	,	PUNCT
chd-169	108	68	2001	2001	NUM
chd-169	108	69	)	)	PUNCT
chd-169	108	70	.	.	PUNCT
chd-169	109	1	however	however	ADV
chd-169	109	2	,	,	PUNCT
chd-169	109	3	whether	whether	SCONJ
chd-169	109	4	lower	low	ADJ
chd-169	109	5	ses	se	NOUN
chd-169	109	6	by	by	ADP
chd-169	109	7	itself	itself	PRON
chd-169	109	8	is	be	AUX
chd-169	109	9	associated	associate	VERB
chd-169	109	10	with	with	ADP
chd-169	109	11	increased	increase	VERB
chd-169	109	12	cortisol	cortisol	ADJ
chd-169	109	13	responses	response	NOUN
chd-169	109	14	among	among	ADP
chd-169	109	15	aas	aas	PROPN
chd-169	109	16	remains	remain	VERB
chd-169	109	17	to	to	PART
chd-169	109	18	be	be	AUX
chd-169	109	19	unambiguously	unambiguously	ADV
chd-169	109	20	established	establish	VERB
chd-169	109	21	.	.	PUNCT
chd-169	110	1	a	a	DET
chd-169	110	2	major	major	ADJ
chd-169	110	3	study	study	NOUN
chd-169	110	4	by	by	ADP
chd-169	110	5	cohen	cohen	PROPN
chd-169	110	6	and	and	CCONJ
chd-169	110	7	colleagues	colleague	NOUN
chd-169	110	8	explored	explore	VERB
chd-169	110	9	whether	whether	SCONJ
chd-169	110	10	sesassociated	sesassociate	VERB
chd-169	110	11	dysregulation	dysregulation	NOUN
chd-169	110	12	of	of	ADP
chd-169	110	13	cortisol	cortisol	ADJ
chd-169	110	14	diurnal	diurnal	ADJ
chd-169	110	15	rhythm	rhythm	NOUN
chd-169	110	16	is	be	AUX
chd-169	110	17	independent	independent	ADJ
chd-169	110	18	of	of	ADP
chd-169	110	19	race	race	NOUN
chd-169	110	20	and	and	CCONJ
chd-169	110	21	occurs	occur	VERB
chd-169	110	22	equally	equally	ADV
chd-169	110	23	in	in	ADP
chd-169	110	24	aas	aas	NOUN
chd-169	110	25	and	and	CCONJ
chd-169	110	26	eas	eas	PROPN
chd-169	110	27	(	(	PUNCT
chd-169	110	28	cohen	cohen	PROPN
chd-169	110	29	et	et	PROPN
chd-169	110	30	al	al	PROPN
chd-169	110	31	.	.	PROPN
chd-169	110	32	,	,	PUNCT
chd-169	110	33	2006	2006	NUM
chd-169	110	34	)	)	PUNCT
chd-169	110	35	.	.	PUNCT
chd-169	111	1	this	this	DET
chd-169	111	2	study	study	NOUN
chd-169	111	3	reported	report	VERB
chd-169	111	4	that	that	SCONJ
chd-169	111	5	both	both	PRON
chd-169	111	6	lower	low	ADJ
chd-169	111	7	ses	se	NOUN
chd-169	111	8	(	(	PUNCT
chd-169	111	9	education	education	NOUN
chd-169	111	10	and	and	CCONJ
chd-169	111	11	income	income	NOUN
chd-169	111	12	)	)	PUNCT
chd-169	111	13	and	and	CCONJ
chd-169	111	14	being	be	AUX
chd-169	111	15	black	black	ADJ
chd-169	111	16	were	be	AUX
chd-169	111	17	associated	associate	VERB
chd-169	111	18	with	with	ADP
chd-169	111	19	higher	high	ADJ
chd-169	111	20	evening	evening	NOUN
chd-169	111	21	levels	level	NOUN
chd-169	111	22	of	of	ADP
chd-169	111	23	cortisol	cortisol	NOUN
chd-169	111	24	(	(	PUNCT
chd-169	111	25	cohen	cohen	PROPN
chd-169	111	26	et	et	PROPN
chd-169	111	27	al	al	PROPN
chd-169	111	28	.	.	PROPN
chd-169	111	29	,	,	PUNCT
chd-169	111	30	2006	2006	NUM
chd-169	111	31	)	)	PUNCT
chd-169	111	32	.	.	PUNCT
chd-169	112	1	these	these	DET
chd-169	112	2	higher	high	ADJ
chd-169	112	3	cortisol	cortisol	ADJ
chd-169	112	4	levels	level	NOUN
chd-169	112	5	in	in	ADP
chd-169	112	6	aas	aas	PROPN
chd-169	112	7	were	be	AUX
chd-169	112	8	associated	associate	VERB
chd-169	112	9	with	with	ADP
chd-169	112	10	poorer	poor	ADJ
chd-169	112	11	health	health	NOUN
chd-169	112	12	practices	practice	NOUN
chd-169	112	13	(	(	PUNCT
chd-169	112	14	e.g.	e.g.	ADV
chd-169	112	15	smoking	smoking	NOUN
chd-169	112	16	)	)	PUNCT
chd-169	112	17	,	,	PUNCT
chd-169	112	18	higher	high	ADJ
chd-169	112	19	levels	level	NOUN
chd-169	112	20	of	of	ADP
chd-169	112	21	depressive	depressive	ADJ
chd-169	112	22	symptoms	symptom	NOUN
chd-169	112	23	,	,	PUNCT
chd-169	112	24	poorer	poor	ADJ
chd-169	112	25	social	social	ADJ
chd-169	112	26	networks	network	NOUN
chd-169	112	27	and	and	CCONJ
chd-169	112	28	supports	support	NOUN
chd-169	112	29	,	,	PUNCT
chd-169	112	30	and	and	CCONJ
chd-169	112	31	feelings	feeling	NOUN
chd-169	112	32	of	of	ADP
chd-169	112	33	helplessness	helplessness	NOUN
chd-169	112	34	(	(	PUNCT
chd-169	112	35	cohen	cohen	PROPN
chd-169	112	36	et	et	PROPN
chd-169	112	37	al	al	PROPN
chd-169	112	38	.	.	PROPN
chd-169	112	39	,	,	PUNCT
chd-169	112	40	2006	2006	NUM
chd-169	112	41	)	)	PUNCT
chd-169	112	42	.	.	PUNCT
chd-169	113	1	this	this	DET
chd-169	113	2	dysregulation	dysregulation	NOUN
chd-169	113	3	has	have	VERB
chd-169	113	4	negative	negative	ADJ
chd-169	113	5	longterm	longterm	ADJ
chd-169	113	6	repercussions	repercussion	NOUN
chd-169	113	7	for	for	ADP
chd-169	113	8	the	the	DET
chd-169	113	9	health	health	NOUN
chd-169	113	10	of	of	ADP
chd-169	113	11	aas	aas	PROPN
chd-169	113	12	(	(	PUNCT
chd-169	113	13	williams	williams	PROPN
chd-169	113	14	et	et	PROPN
chd-169	113	15	al	al	PROPN
chd-169	113	16	.	.	PROPN
chd-169	113	17	,	,	PUNCT
chd-169	113	18	2010	2010	NUM
chd-169	113	19	;	;	PUNCT
chd-169	113	20	williams	williams	PROPN
chd-169	113	21	and	and	CCONJ
chd-169	113	22	sternthal	sternthal	ADJ
chd-169	113	23	,	,	PUNCT
chd-169	113	24	2010	2010	NUM
chd-169	113	25	;	;	PUNCT
chd-169	113	26	zannas	zannas	PROPN
chd-169	113	27	et	et	PROPN
chd-169	113	28	al	al	PROPN
chd-169	113	29	.	.	PROPN
chd-169	113	30	,	,	PUNCT
chd-169	113	31	2015	2015	NUM
chd-169	113	32	)	)	PUNCT
chd-169	113	33	.	.	PUNCT
chd-169	114	1	employed	employ	VERB
chd-169	114	2	aas	aas	PROPN
chd-169	114	3	are	be	AUX
chd-169	114	4	also	also	ADV
chd-169	114	5	more	more	ADV
chd-169	114	6	likely	likely	ADJ
chd-169	114	7	to	to	PART
chd-169	114	8	be	be	AUX
chd-169	114	9	exposed	expose	VERB
chd-169	114	10	to	to	ADP
chd-169	114	11	carcinogens	carcinogen	NOUN
chd-169	114	12	and	and	CCONJ
chd-169	114	13	occupational	occupational	ADJ
chd-169	114	14	hazards	hazard	NOUN
chd-169	114	15	compared	compare	VERB
chd-169	114	16	to	to	ADP
chd-169	114	17	other	other	ADJ
chd-169	114	18	racial	racial	ADJ
chd-169	114	19	groups	group	NOUN
chd-169	114	20	with	with	ADP
chd-169	114	21	matched	match	VERB
chd-169	114	22	education	education	NOUN
chd-169	114	23	and	and	CCONJ
chd-169	114	24	job	job	NOUN
chd-169	114	25	experience	experience	NOUN
chd-169	114	26	(	(	PUNCT
chd-169	114	27	kaufman	kaufman	PROPN
chd-169	114	28	et	et	PROPN
chd-169	114	29	al	al	PROPN
chd-169	114	30	.	.	PROPN
chd-169	114	31	,	,	PUNCT
chd-169	114	32	1997	1997	NUM
chd-169	114	33	;	;	PUNCT
chd-169	114	34	williams	williams	PROPN
chd-169	114	35	and	and	CCONJ
chd-169	114	36	sternthal	sternthal	ADJ
chd-169	114	37	,	,	PUNCT
chd-169	114	38	2010	2010	NUM
chd-169	114	39	)	)	PUNCT
chd-169	114	40	.	.	PUNCT
chd-169	115	1	compounding	compound	VERB
chd-169	115	2	these	these	DET
chd-169	115	3	realities	reality	NOUN
chd-169	115	4	,	,	PUNCT
chd-169	115	5	aas	aas	PROPN
chd-169	115	6	have	have	VERB
chd-169	115	7	less	less	ADJ
chd-169	115	8	purchasing	purchasing	NOUN
chd-169	115	9	power	power	NOUN
chd-169	115	10	,	,	PUNCT
chd-169	115	11	as	as	SCONJ
chd-169	115	12	the	the	DET
chd-169	115	13	costs	cost	NOUN
chd-169	115	14	of	of	ADP
chd-169	115	15	goods	good	NOUN
chd-169	115	16	and	and	CCONJ
chd-169	115	17	services	service	NOUN
chd-169	115	18	are	be	AUX
chd-169	115	19	highest	high	ADJ
chd-169	115	20	in	in	ADP
chd-169	115	21	predominantly	predominantly	ADV
chd-169	116	1	aa	aa	ADJ
chd-169	117	1	communities	community	NOUN
chd-169	118	1	(	(	PUNCT
chd-169	118	2	kaufman	kaufman	PROPN
chd-169	118	3	et	et	PROPN
chd-169	118	4	al	al	PROPN
chd-169	118	5	.	.	PROPN
chd-169	118	6	,	,	PUNCT
chd-169	118	7	1997	1997	NUM
chd-169	118	8	;	;	PUNCT
chd-169	118	9	williams	williams	PROPN
chd-169	118	10	and	and	CCONJ
chd-169	118	11	sternthal	sternthal	ADJ
chd-169	118	12	,	,	PUNCT
chd-169	118	13	2010	2010	NUM
chd-169	118	14	)	)	PUNCT
chd-169	118	15	.	.	PUNCT
chd-169	119	1	outside	outside	ADP
chd-169	119	2	the	the	DET
chd-169	119	3	workplace	workplace	NOUN
chd-169	119	4	,	,	PUNCT
chd-169	119	5	aas	aas	PROPN
chd-169	119	6	are	be	AUX
chd-169	119	7	exposed	expose	VERB
chd-169	119	8	to	to	ADP
chd-169	119	9	daily	daily	ADJ
chd-169	119	10	stressors	stressor	NOUN
chd-169	119	11	within	within	ADP
chd-169	119	12	neighborhoods	neighborhood	NOUN
chd-169	119	13	that	that	PRON
chd-169	119	14	are	be	AUX
chd-169	119	15	highly	highly	ADV
chd-169	119	16	segregated	segregated	ADJ
chd-169	119	17	(	(	PUNCT
chd-169	119	18	williams	williams	PROPN
chd-169	119	19	et	et	PROPN
chd-169	119	20	al	al	PROPN
chd-169	119	21	.	.	PROPN
chd-169	119	22	,	,	PUNCT
chd-169	119	23	2010	2010	NUM
chd-169	119	24	)	)	PUNCT
chd-169	119	25	,	,	PUNCT
chd-169	119	26	the	the	DET
chd-169	119	27	effects	effect	NOUN
chd-169	119	28	of	of	ADP
chd-169	119	29	which	which	PRON
chd-169	119	30	negatively	negatively	ADV
chd-169	119	31	impact	impact	VERB
chd-169	119	32	the	the	DET
chd-169	119	33	ses	se	NOUN
chd-169	119	34	and	and	CCONJ
chd-169	119	35	health	health	NOUN
chd-169	119	36	of	of	ADP
chd-169	119	37	aa	aa	PROPN
chd-169	119	38	residents	resident	NOUN
chd-169	119	39	(	(	PUNCT
chd-169	119	40	schulz	schulz	PROPN
chd-169	119	41	et	et	PROPN
chd-169	119	42	al	al	PROPN
chd-169	119	43	.	.	PROPN
chd-169	119	44	,	,	PUNCT
chd-169	119	45	2002	2002	NUM
chd-169	119	46	;	;	PUNCT
chd-169	119	47	williams	williams	PROPN
chd-169	119	48	and	and	CCONJ
chd-169	119	49	collins	collins	PROPN
chd-169	119	50	,	,	PUNCT
chd-169	119	51	2001	2001	NUM
chd-169	119	52	)	)	PUNCT
chd-169	119	53	.	.	PUNCT
chd-169	120	1	for	for	ADP
chd-169	120	2	instance	instance	NOUN
chd-169	120	3	,	,	PUNCT
chd-169	120	4	optimal	optimal	ADJ
chd-169	120	5	health	health	NOUN
chd-169	120	6	is	be	AUX
chd-169	120	7	jeopardized	jeopardize	VERB
chd-169	120	8	in	in	ADP
chd-169	120	9	economically	economically	ADV
chd-169	120	10	-	-	PUNCT
chd-169	120	11	disadvantaged	disadvantaged	ADJ
chd-169	120	12	,	,	PUNCT
chd-169	120	13	segregated	segregate	VERB
chd-169	120	14	neighborhoods	neighborhood	NOUN
chd-169	120	15	as	as	SCONJ
chd-169	120	16	nutrition	nutrition	NOUN
chd-169	120	17	suffers	suffer	VERB
chd-169	120	18	in	in	ADP
chd-169	120	19	the	the	DET
chd-169	120	20	presence	presence	NOUN
chd-169	120	21	of	of	ADP
chd-169	120	22	higher	high	ADJ
chd-169	120	23	cost	cost	NOUN
chd-169	120	24	,	,	PUNCT
chd-169	120	25	lower	low	ADJ
chd-169	120	26	quality	quality	NOUN
chd-169	120	27	,	,	PUNCT
chd-169	120	28	and	and	CCONJ
chd-169	120	29	decreased	decrease	VERB
chd-169	120	30	availability	availability	NOUN
chd-169	120	31	of	of	ADP
chd-169	120	32	healthy	healthy	ADJ
chd-169	120	33	foods	food	NOUN
chd-169	120	34	(	(	PUNCT
chd-169	120	35	schulz	schulz	PROPN
chd-169	120	36	et	et	PROPN
chd-169	120	37	al	al	PROPN
chd-169	120	38	.	.	PROPN
chd-169	120	39	,	,	PUNCT
chd-169	120	40	2002	2002	NUM
chd-169	120	41	;	;	PUNCT
chd-169	120	42	williams	williams	PROPN
chd-169	120	43	and	and	CCONJ
chd-169	120	44	collins	collins	PROPN
chd-169	120	45	,	,	PUNCT
chd-169	120	46	2001	2001	NUM
chd-169	120	47	)	)	PUNCT
chd-169	120	48	.	.	PUNCT
chd-169	121	1	similarly	similarly	ADV
chd-169	121	2	,	,	PUNCT
chd-169	121	3	physical	physical	ADJ
chd-169	121	4	activity	activity	NOUN
chd-169	121	5	is	be	AUX
chd-169	121	6	reduced	reduce	VERB
chd-169	121	7	in	in	ADP
chd-169	121	8	the	the	DET
chd-169	121	9	absence	absence	NOUN
chd-169	121	10	of	of	ADP
chd-169	121	11	suitable	suitable	ADJ
chd-169	121	12	recreational	recreational	ADJ
chd-169	121	13	facilities	facility	NOUN
chd-169	121	14	amid	amid	ADP
chd-169	121	15	safety	safety	NOUN
chd-169	121	16	concerns	concern	NOUN
chd-169	121	17	(	(	PUNCT
chd-169	121	18	schulz	schulz	PROPN
chd-169	121	19	et	et	PROPN
chd-169	121	20	al	al	PROPN
chd-169	121	21	.	.	PROPN
chd-169	121	22	,	,	PUNCT
chd-169	121	23	2002	2002	NUM
chd-169	121	24	;	;	PUNCT
chd-169	121	25	williams	williams	PROPN
chd-169	121	26	and	and	CCONJ
chd-169	121	27	collins	collins	PROPN
chd-169	121	28	,	,	PUNCT
chd-169	121	29	2001	2001	NUM
chd-169	121	30	)	)	PUNCT
chd-169	121	31	.	.	PUNCT
chd-169	122	1	exposure	exposure	NOUN
chd-169	122	2	to	to	ADP
chd-169	122	3	environmental	environmental	ADJ
chd-169	122	4	toxins	toxin	NOUN
chd-169	122	5	and	and	CCONJ
chd-169	122	6	poor	poor	ADJ
chd-169	122	7	-	-	PUNCT
chd-169	122	8	quality	quality	NOUN
chd-169	122	9	living	living	NOUN
chd-169	122	10	conditions	condition	NOUN
chd-169	122	11	also	also	ADV
chd-169	122	12	exist	exist	VERB
chd-169	122	13	in	in	ADP
chd-169	122	14	neighborhoods	neighborhood	NOUN
chd-169	122	15	accustomed	accustom	VERB
chd-169	122	16	to	to	ADP
chd-169	122	17	institutional	institutional	ADJ
chd-169	122	18	neglect	neglect	NOUN
chd-169	122	19	and	and	CCONJ
chd-169	122	20	disinvestment	disinvestment	NOUN
chd-169	122	21	(	(	PUNCT
chd-169	122	22	schulz	schulz	PROPN
chd-169	122	23	et	et	PROPN
chd-169	122	24	al	al	PROPN
chd-169	122	25	.	.	PROPN
chd-169	122	26	,	,	PUNCT
chd-169	122	27	2002	2002	NUM
chd-169	122	28	;	;	PUNCT
chd-169	122	29	williams	williams	PROPN
chd-169	122	30	and	and	CCONJ
chd-169	122	31	collins	collins	PROPN
chd-169	122	32	,	,	PUNCT
chd-169	122	33	2001	2001	NUM
chd-169	122	34	)	)	PUNCT
chd-169	122	35	.	.	PUNCT
chd-169	123	1	adding	add	VERB
chd-169	123	2	to	to	ADP
chd-169	123	3	these	these	DET
chd-169	123	4	cumulative	cumulative	ADJ
chd-169	123	5	stressful	stressful	ADJ
chd-169	123	6	events	event	NOUN
chd-169	123	7	are	be	AUX
chd-169	123	8	frequent	frequent	ADJ
chd-169	123	9	experiences	experience	NOUN
chd-169	123	10	of	of	ADP
chd-169	123	11	discrimination	discrimination	NOUN
chd-169	123	12	and	and	CCONJ
chd-169	123	13	incarceration	incarceration	NOUN
chd-169	123	14	among	among	ADP
chd-169	123	15	aas	aas	PROPN
chd-169	123	16	,	,	PUNCT
chd-169	123	17	which	which	PRON
chd-169	123	18	are	be	AUX
chd-169	123	19	associated	associate	VERB
chd-169	123	20	with	with	ADP
chd-169	123	21	psychological	psychological	ADJ
chd-169	123	22	distress	distress	NOUN
chd-169	123	23	and	and	CCONJ
chd-169	123	24	adverse	adverse	ADJ
chd-169	123	25	physical	physical	ADJ
chd-169	123	26	health	health	NOUN
chd-169	123	27	effects	effect	NOUN
chd-169	123	28	,	,	PUNCT
chd-169	123	29	including	include	VERB
chd-169	123	30	high	high	ADJ
chd-169	123	31	incidence	incidence	NOUN
chd-169	123	32	of	of	ADP
chd-169	123	33	chronic	chronic	ADJ
chd-169	123	34	conditions	condition	NOUN
chd-169	123	35	such	such	ADJ
chd-169	123	36	as	as	ADP
chd-169	123	37	hypertension	hypertension	NOUN
chd-169	123	38	,	,	PUNCT
chd-169	123	39	obesity	obesity	NOUN
chd-169	123	40	,	,	PUNCT
chd-169	123	41	diabetes	diabetes	NOUN
chd-169	123	42	,	,	PUNCT
chd-169	123	43	substance	substance	NOUN
chd-169	123	44	abuse	abuse	NOUN
chd-169	123	45	,	,	PUNCT
chd-169	123	46	and	and	CCONJ
chd-169	123	47	cancer	cancer	NOUN
chd-169	123	48	(	(	PUNCT
chd-169	123	49	byrd	byrd	PROPN
chd-169	123	50	,	,	PUNCT
chd-169	123	51	2012	2012	NUM
chd-169	123	52	;	;	PUNCT
chd-169	123	53	krieger	krieger	PROPN
chd-169	123	54	et	et	PROPN
chd-169	123	55	al	al	PROPN
chd-169	123	56	.	.	PROPN
chd-169	123	57	,	,	PUNCT
chd-169	123	58	2011	2011	NUM
chd-169	123	59	)	)	PUNCT
chd-169	123	60	.	.	PUNCT
chd-169	124	1	combined	combine	VERB
chd-169	124	2	,	,	PUNCT
chd-169	124	3	these	these	DET
chd-169	124	4	stressors	stressor	NOUN
chd-169	124	5	are	be	AUX
chd-169	124	6	directly	directly	ADV
chd-169	124	7	linked	link	VERB
chd-169	124	8	to	to	ADP
chd-169	124	9	elevated	elevated	ADJ
chd-169	124	10	risk	risk	NOUN
chd-169	124	11	of	of	ADP
chd-169	124	12	illness	illness	NOUN
chd-169	124	13	and	and	CCONJ
chd-169	124	14	death	death	NOUN
chd-169	124	15	among	among	ADP
chd-169	124	16	aas	aas	PROPN
chd-169	124	17	,	,	PUNCT
chd-169	124	18	and	and	CCONJ
chd-169	124	19	greatly	greatly	ADV
chd-169	124	20	contribute	contribute	VERB
chd-169	124	21	to	to	ADP
chd-169	124	22	existing	exist	VERB
chd-169	124	23	racial	racial	ADJ
chd-169	124	24	disparities	disparity	NOUN
chd-169	124	25	in	in	ADP
chd-169	124	26	health	health	NOUN
chd-169	124	27	(	(	PUNCT
chd-169	124	28	acevedo	acevedo	PROPN
chd-169	124	29	-	-	PUNCT
chd-169	124	30	garcia	garcia	PROPN
chd-169	124	31	et	et	PROPN
chd-169	124	32	al	al	PROPN
chd-169	124	33	.	.	PROPN
chd-169	124	34	,	,	PUNCT
chd-169	124	35	2003	2003	NUM
chd-169	124	36	;	;	PUNCT
chd-169	124	37	williams	williams	PROPN
chd-169	124	38	and	and	CCONJ
chd-169	124	39	collins	collins	PROPN
chd-169	124	40	,	,	PUNCT
chd-169	124	41	2001	2001	NUM
chd-169	124	42	)	)	PUNCT
chd-169	124	43	.	.	PUNCT
chd-169	125	1	for	for	ADP
chd-169	125	2	example	example	NOUN
chd-169	125	3	,	,	PUNCT
chd-169	125	4	aa	aa	PROPN
chd-169	125	5	men	man	NOUN
chd-169	125	6	ages	age	VERB
chd-169	125	7	57	57	NUM
chd-169	125	8	-	-	SYM
chd-169	125	9	85	85	NUM
chd-169	125	10	may	may	AUX
chd-169	125	11	have	have	VERB
chd-169	125	12	worse	bad	ADJ
chd-169	125	13	metabolic	metabolic	NOUN
chd-169	125	14	outcomes	outcome	NOUN
chd-169	125	15	than	than	ADP
chd-169	125	16	their	their	PRON
chd-169	125	17	ea	ea	NOUN
chd-169	125	18	counterparts	counterpart	NOUN
chd-169	125	19	due	due	ADJ
chd-169	125	20	to	to	ADP
chd-169	125	21	chronic	chronic	ADJ
chd-169	125	22	inflammation	inflammation	NOUN
chd-169	125	23	arising	arise	VERB
chd-169	125	24	from	from	ADP
chd-169	125	25	cumulative	cumulative	ADJ
chd-169	125	26	,	,	PUNCT
chd-169	125	27	multi	multi	ADJ
chd-169	125	28	-	-	ADJ
chd-169	125	29	dimensional	dimensional	ADJ
chd-169	125	30	stress	stress	NOUN
chd-169	125	31	experienced	experience	VERB
chd-169	125	32	over	over	ADP
chd-169	125	33	their	their	PRON
chd-169	125	34	lives	life	NOUN
chd-169	125	35	(	(	PUNCT
chd-169	125	36	das	das	PROPN
chd-169	125	37	,	,	PUNCT
chd-169	125	38	2013	2013	NUM
chd-169	125	39	)	)	PUNCT
chd-169	125	40	.	.	PUNCT
chd-169	126	1	interestingly	interestingly	ADV
chd-169	126	2	,	,	PUNCT
chd-169	126	3	a	a	DET
chd-169	126	4	study	study	NOUN
chd-169	126	5	based	base	VERB
chd-169	126	6	in	in	ADP
chd-169	126	7	argentina	argentina	PROPN
chd-169	126	8	of	of	ADP
chd-169	126	9	men	man	NOUN
chd-169	126	10	ages	age	NOUN
chd-169	126	11	45	45	NUM
chd-169	126	12	-	-	SYM
chd-169	126	13	70	70	NUM
chd-169	126	14	reported	report	VERB
chd-169	126	15	that	that	SCONJ
chd-169	126	16	uncontrollable	uncontrollable	ADJ
chd-169	126	17	stressful	stressful	ADJ
chd-169	126	18	life	life	NOUN
chd-169	126	19	events	event	NOUN
chd-169	126	20	were	be	AUX
chd-169	126	21	inversely	inversely	ADV
chd-169	126	22	correlated	correlate	VERB
chd-169	126	23	with	with	ADP
chd-169	126	24	psa	psa	NOUN
chd-169	126	25	among	among	ADP
chd-169	126	26	men	man	NOUN
chd-169	126	27	with	with	ADP
chd-169	126	28	low	low	ADJ
chd-169	126	29	cortisol	cortisol	NOUN
chd-169	126	30	,	,	PUNCT
chd-169	126	31	but	but	CCONJ
chd-169	126	32	positively	positively	ADV
chd-169	126	33	correlated	correlate	VERB
chd-169	126	34	with	with	ADP
chd-169	126	35	psa	psa	NOUN
chd-169	126	36	among	among	ADP
chd-169	126	37	men	man	NOUN
chd-169	126	38	with	with	ADP
chd-169	126	39	high	high	ADJ
chd-169	126	40	cortisol	cortisol	NOUN
chd-169	126	41	,	,	PUNCT
chd-169	126	42	suggesting	suggest	VERB
chd-169	126	43	that	that	SCONJ
chd-169	126	44	such	such	ADJ
chd-169	126	45	events	event	NOUN
chd-169	126	46	may	may	AUX
chd-169	126	47	be	be	AUX
chd-169	126	48	related	relate	VERB
chd-169	126	49	to	to	ADP
chd-169	126	50	prostatic	prostatic	ADJ
chd-169	126	51	tumorigenic	tumorigenic	ADJ
chd-169	126	52	processes	process	NOUN
chd-169	126	53	in	in	ADP
chd-169	126	54	men	man	NOUN
chd-169	126	55	with	with	ADP
chd-169	126	56	high	high	ADJ
chd-169	126	57	cortisol	cortisol	NOUN
chd-169	126	58	(	(	PUNCT
chd-169	126	59	gidron	gidron	VERB
chd-169	126	60	et	et	PROPN
chd-169	126	61	al	al	PROPN
chd-169	126	62	.	.	PROPN
chd-169	126	63	,	,	PUNCT
chd-169	126	64	2011	2011	NUM
chd-169	126	65	)	)	PUNCT
chd-169	126	66	.	.	PUNCT
chd-169	127	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-169	127	2	e9	e9	PROPN
chd-169	127	3	cancer	cancer	NOUN
chd-169	127	4	health	health	NOUN
chd-169	127	5	disparities	disparity	NOUN
chd-169	127	6	research	research	VERB
chd-169	127	7	glucocorticoid	glucocorticoid	ADJ
chd-169	127	8	receptor	receptor	NOUN
chd-169	127	9	signaling	signal	VERB
chd-169	127	10	gr	gr	NOUN
chd-169	127	11	biology	biology	NOUN
chd-169	127	12	.	.	PUNCT
chd-169	128	1	the	the	DET
chd-169	128	2	cellular	cellular	ADJ
chd-169	128	3	and	and	CCONJ
chd-169	128	4	pharmacological	pharmacological	ADJ
chd-169	128	5	actions	action	NOUN
chd-169	128	6	of	of	ADP
chd-169	128	7	cortisol	cortisol	NOUN
chd-169	128	8	and	and	CCONJ
chd-169	128	9	other	other	ADJ
chd-169	128	10	glucocorticoids	glucocorticoid	NOUN
chd-169	128	11	are	be	AUX
chd-169	128	12	mediated	mediate	VERB
chd-169	128	13	by	by	ADP
chd-169	128	14	gr	gr	ADP
chd-169	128	15	,	,	PUNCT
chd-169	128	16	although	although	SCONJ
chd-169	128	17	low	low	ADJ
chd-169	128	18	levels	level	NOUN
chd-169	128	19	of	of	ADP
chd-169	128	20	glucocorticoids	glucocorticoid	NOUN
chd-169	128	21	can	can	AUX
chd-169	128	22	also	also	ADV
chd-169	128	23	stimulate	stimulate	VERB
chd-169	128	24	the	the	DET
chd-169	128	25	mineralocorticoid	mineralocorticoid	NOUN
chd-169	128	26	receptor	receptor	NOUN
chd-169	128	27	(	(	PUNCT
chd-169	128	28	mr	mr	PROPN
chd-169	128	29	)	)	PUNCT
chd-169	128	30	(	(	PUNCT
chd-169	128	31	gomez	gomez	PROPN
chd-169	128	32	-	-	PUNCT
chd-169	128	33	sanchez	sanchez	PROPN
chd-169	128	34	and	and	CCONJ
chd-169	128	35	gomez	gomez	PROPN
chd-169	128	36	-	-	PUNCT
chd-169	128	37	sanchez	sanchez	PROPN
chd-169	128	38	,	,	PUNCT
chd-169	128	39	2014	2014	NUM
chd-169	128	40	;	;	PUNCT
chd-169	128	41	joseph	joseph	PROPN
chd-169	128	42	and	and	CCONJ
chd-169	128	43	whirledge	whirledge	VERB
chd-169	128	44	,	,	PUNCT
chd-169	128	45	2017	2017	NUM
chd-169	128	46	)	)	PUNCT
chd-169	128	47	.	.	PUNCT
chd-169	129	1	gr	gr	PROPN
chd-169	129	2	is	be	AUX
chd-169	129	3	ubiquitously	ubiquitously	ADV
chd-169	129	4	expressed	express	VERB
chd-169	129	5	throughout	throughout	ADP
chd-169	129	6	the	the	DET
chd-169	129	7	human	human	ADJ
chd-169	129	8	body	body	NOUN
chd-169	129	9	,	,	PUNCT
chd-169	129	10	and	and	CCONJ
chd-169	129	11	signaling	signal	VERB
chd-169	129	12	through	through	ADP
chd-169	129	13	this	this	DET
chd-169	129	14	receptor	receptor	NOUN
chd-169	129	15	regulates	regulate	VERB
chd-169	129	16	metabolism	metabolism	NOUN
chd-169	129	17	,	,	PUNCT
chd-169	129	18	growth	growth	NOUN
chd-169	129	19	,	,	PUNCT
chd-169	129	20	development	development	NOUN
chd-169	129	21	,	,	PUNCT
chd-169	129	22	cardiovascular	cardiovascular	ADJ
chd-169	129	23	homeostasis	homeostasis	NOUN
chd-169	129	24	,	,	PUNCT
chd-169	129	25	and	and	CCONJ
chd-169	129	26	cognition	cognition	NOUN
chd-169	129	27	(	(	PUNCT
chd-169	129	28	biddie	biddie	NOUN
chd-169	129	29	et	et	PROPN
chd-169	129	30	al	al	PROPN
chd-169	129	31	.	.	PROPN
chd-169	129	32	,	,	PUNCT
chd-169	129	33	2012	2012	NUM
chd-169	129	34	;	;	PUNCT
chd-169	129	35	oakley	oakley	NOUN
chd-169	129	36	and	and	CCONJ
chd-169	129	37	cidlowski	cidlowski	VERB
chd-169	129	38	,	,	PUNCT
chd-169	129	39	2013	2013	NUM
chd-169	129	40	)	)	PUNCT
chd-169	129	41	.	.	PUNCT
chd-169	130	1	synthetic	synthetic	ADJ
chd-169	130	2	glucocorticoids	glucocorticoid	NOUN
chd-169	130	3	such	such	ADJ
chd-169	130	4	as	as	ADP
chd-169	130	5	prednisone	prednisone	NOUN
chd-169	130	6	and	and	CCONJ
chd-169	130	7	dexamethasone	dexamethasone	NOUN
chd-169	130	8	have	have	AUX
chd-169	130	9	long	long	ADV
chd-169	130	10	been	be	AUX
chd-169	130	11	integral	integral	ADJ
chd-169	130	12	components	component	NOUN
chd-169	130	13	of	of	ADP
chd-169	130	14	treatment	treatment	NOUN
chd-169	130	15	regimens	regimen	NOUN
chd-169	130	16	for	for	ADP
chd-169	130	17	inflammatory	inflammatory	ADJ
chd-169	130	18	and	and	CCONJ
chd-169	130	19	autoimmune	autoimmune	ADJ
chd-169	130	20	diseases	disease	NOUN
chd-169	130	21	as	as	ADV
chd-169	130	22	well	well	ADV
chd-169	130	23	as	as	ADP
chd-169	130	24	certain	certain	ADJ
chd-169	130	25	cancers	cancer	NOUN
chd-169	130	26	(	(	PUNCT
chd-169	130	27	vandewalle	vandewalle	PROPN
chd-169	130	28	et	et	PROPN
chd-169	130	29	al	al	PROPN
chd-169	130	30	.	.	PROPN
chd-169	130	31	,	,	PUNCT
chd-169	130	32	2018	2018	NUM
chd-169	130	33	)	)	PUNCT
chd-169	130	34	.	.	PUNCT
chd-169	131	1	as	as	ADP
chd-169	131	2	a	a	DET
chd-169	131	3	member	member	NOUN
chd-169	131	4	of	of	ADP
chd-169	131	5	the	the	DET
chd-169	131	6	nuclear	nuclear	ADJ
chd-169	131	7	receptor	receptor	NOUN
chd-169	131	8	family	family	NOUN
chd-169	131	9	(	(	PUNCT
chd-169	131	10	which	which	PRON
chd-169	131	11	also	also	ADV
chd-169	131	12	includes	include	VERB
chd-169	131	13	receptors	receptor	NOUN
chd-169	131	14	for	for	ADP
chd-169	131	15	estrogen	estrogen	NOUN
chd-169	131	16	,	,	PUNCT
chd-169	131	17	progesterone	progesterone	NOUN
chd-169	131	18	,	,	PUNCT
chd-169	131	19	and	and	CCONJ
chd-169	131	20	androgen	androgen	NOUN
chd-169	131	21	)	)	PUNCT
chd-169	131	22	,	,	PUNCT
chd-169	131	23	gr	gr	PROPN
chd-169	131	24	has	have	VERB
chd-169	131	25	both	both	CCONJ
chd-169	131	26	genomic	genomic	NOUN
chd-169	131	27	(	(	PUNCT
chd-169	131	28	regulating	regulate	VERB
chd-169	131	29	gene	gene	NOUN
chd-169	131	30	transcription	transcription	NOUN
chd-169	131	31	by	by	ADP
chd-169	131	32	binding	bind	VERB
chd-169	131	33	to	to	ADP
chd-169	131	34	glucocorticoid	glucocorticoid	ADJ
chd-169	131	35	response	response	NOUN
chd-169	131	36	elements	element	NOUN
chd-169	131	37	,	,	PUNCT
chd-169	131	38	gres	gre	NOUN
chd-169	131	39	,	,	PUNCT
chd-169	131	40	in	in	ADP
chd-169	131	41	promoter	promoter	NOUN
chd-169	131	42	regions	region	NOUN
chd-169	131	43	)	)	PUNCT
chd-169	131	44	and	and	CCONJ
chd-169	131	45	non	non	ADJ
chd-169	131	46	-	-	ADJ
chd-169	131	47	genomic	genomic	ADJ
chd-169	131	48	(	(	PUNCT
chd-169	131	49	modulating	modulate	VERB
chd-169	131	50	the	the	DET
chd-169	131	51	function	function	NOUN
chd-169	131	52	of	of	ADP
chd-169	131	53	intracellular	intracellular	ADJ
chd-169	131	54	kinases	kinase	NOUN
chd-169	131	55	,	,	PUNCT
chd-169	131	56	including	include	VERB
chd-169	131	57	c	c	NOUN
chd-169	131	58	-	-	PUNCT
chd-169	131	59	src	src	NOUN
chd-169	131	60	)	)	PUNCT
chd-169	131	61	effects	effect	NOUN
chd-169	131	62	(	(	PUNCT
chd-169	131	63	oakley	oakley	NOUN
chd-169	131	64	and	and	CCONJ
chd-169	131	65	cidlowski	cidlowski	VERB
chd-169	131	66	,	,	PUNCT
chd-169	131	67	2013	2013	NUM
chd-169	131	68	)	)	PUNCT
chd-169	131	69	.	.	PUNCT
chd-169	132	1	in	in	ADP
chd-169	132	2	the	the	DET
chd-169	132	3	absence	absence	NOUN
chd-169	132	4	of	of	ADP
chd-169	132	5	ligand	ligand	ADJ
chd-169	132	6	binding	bind	VERB
chd-169	132	7	,	,	PUNCT
chd-169	132	8	gr	gr	PROPN
chd-169	132	9	resides	reside	VERB
chd-169	132	10	in	in	ADP
chd-169	132	11	the	the	DET
chd-169	132	12	cytoplasm	cytoplasm	NOUN
chd-169	132	13	as	as	ADP
chd-169	132	14	part	part	NOUN
chd-169	132	15	of	of	ADP
chd-169	132	16	a	a	DET
chd-169	132	17	large	large	ADJ
chd-169	132	18	multi	multi	ADJ
chd-169	132	19	-	-	ADJ
chd-169	132	20	protein	protein	ADJ
chd-169	132	21	complex	complex	NOUN
chd-169	132	22	including	include	VERB
chd-169	132	23	chaperone	chaperone	NOUN
chd-169	132	24	heat	heat	NOUN
chd-169	132	25	shock	shock	NOUN
chd-169	132	26	proteins	protein	NOUN
chd-169	132	27	hsp90	hsp90	VERB
chd-169	132	28	,	,	PUNCT
chd-169	132	29	hsp70	hsp70	NOUN
chd-169	132	30	,	,	PUNCT
chd-169	132	31	and	and	CCONJ
chd-169	132	32	p23	p23	NOUN
chd-169	132	33	as	as	ADV
chd-169	132	34	well	well	ADV
chd-169	132	35	as	as	ADP
chd-169	132	36	immunophilins	immunophilin	NOUN
chd-169	132	37	of	of	ADP
chd-169	132	38	the	the	DET
chd-169	132	39	fk506	fk506	PROPN
chd-169	132	40	family	family	NOUN
chd-169	132	41	including	include	VERB
chd-169	132	42	fk506	fk506	NOUN
chd-169	132	43	-	-	PUNCT
chd-169	132	44	binding	bind	VERB
chd-169	132	45	protein	protein	NOUN
chd-169	132	46	(	(	PUNCT
chd-169	132	47	fkbp	fkbp	NOUN
chd-169	132	48	)	)	PUNCT
chd-169	132	49	51	51	NUM
chd-169	132	50	and	and	CCONJ
chd-169	132	51	fkbp52	fkbp52	NOUN
chd-169	132	52	(	(	PUNCT
chd-169	132	53	grad	grad	NOUN
chd-169	132	54	and	and	CCONJ
chd-169	132	55	picard	picard	NOUN
chd-169	132	56	,	,	PUNCT
chd-169	132	57	2007	2007	NUM
chd-169	132	58	;	;	PUNCT
chd-169	132	59	joseph	joseph	PROPN
chd-169	132	60	and	and	CCONJ
chd-169	132	61	whirledge	whirledge	VERB
chd-169	132	62	,	,	PUNCT
chd-169	132	63	2017	2017	NUM
chd-169	132	64	;	;	PUNCT
chd-169	132	65	pratt	pratt	PROPN
chd-169	132	66	and	and	CCONJ
chd-169	132	67	toft	toft	NOUN
chd-169	132	68	,	,	PUNCT
chd-169	132	69	1997	1997	NUM
chd-169	132	70	)	)	PUNCT
chd-169	132	71	.	.	PUNCT
chd-169	133	1	upon	upon	SCONJ
chd-169	133	2	ligand	ligand	NOUN
chd-169	133	3	binding	binding	NOUN
chd-169	133	4	,	,	PUNCT
chd-169	133	5	a	a	DET
chd-169	133	6	conformational	conformational	ADJ
chd-169	133	7	change	change	NOUN
chd-169	133	8	occurs	occur	VERB
chd-169	133	9	releasing	release	VERB
chd-169	133	10	gr	gr	NUM
chd-169	133	11	from	from	ADP
chd-169	133	12	the	the	DET
chd-169	133	13	chaperone	chaperone	NOUN
chd-169	133	14	proteins	protein	NOUN
chd-169	133	15	and	and	CCONJ
chd-169	133	16	promoting	promote	VERB
chd-169	133	17	its	its	PRON
chd-169	133	18	translocation	translocation	NOUN
chd-169	133	19	into	into	ADP
chd-169	133	20	the	the	DET
chd-169	133	21	nucleus	nucleus	NOUN
chd-169	133	22	where	where	SCONJ
chd-169	133	23	it	it	PRON
chd-169	133	24	exerts	exert	VERB
chd-169	133	25	transcriptional	transcriptional	ADJ
chd-169	133	26	regulation	regulation	NOUN
chd-169	133	27	functions	function	NOUN
chd-169	133	28	(	(	PUNCT
chd-169	133	29	joseph	joseph	PROPN
chd-169	133	30	and	and	CCONJ
chd-169	133	31	whirledge	whirledge	VERB
chd-169	133	32	,	,	PUNCT
chd-169	133	33	2017	2017	NUM
chd-169	133	34	)	)	PUNCT
chd-169	133	35	.	.	PUNCT
chd-169	134	1	this	this	DET
chd-169	134	2	nuclear	nuclear	ADJ
chd-169	134	3	translocation	translocation	NOUN
chd-169	134	4	is	be	AUX
chd-169	134	5	promoted	promote	VERB
chd-169	134	6	by	by	ADP
chd-169	134	7	signaling	signal	VERB
chd-169	134	8	through	through	ADP
chd-169	134	9	the	the	DET
chd-169	134	10	semaphorins	semaphorin	NOUN
chd-169	134	11	sema4d	sema4d	PROPN
chd-169	134	12	/	/	SYM
chd-169	134	13	sema3c	sema3c	VERB
chd-169	134	14	upon	upon	SCONJ
chd-169	134	15	binding	bind	VERB
chd-169	134	16	to	to	ADP
chd-169	134	17	their	their	PRON
chd-169	134	18	receptor	receptor	NOUN
chd-169	134	19	plexinb1	plexinb1	NOUN
chd-169	134	20	(	(	PUNCT
chd-169	134	21	williamson	williamson	PROPN
chd-169	134	22	et	et	PROPN
chd-169	134	23	al	al	PROPN
chd-169	134	24	.	.	PROPN
chd-169	134	25	,	,	PUNCT
chd-169	134	26	2019	2019	NUM
chd-169	134	27	)	)	PUNCT
chd-169	134	28	.	.	PUNCT
chd-169	135	1	gr	gr	VERB
chd-169	135	2	-	-	PUNCT
chd-169	135	3	mediated	mediate	VERB
chd-169	135	4	transcriptional	transcriptional	NOUN
chd-169	135	5	control	control	NOUN
chd-169	135	6	also	also	ADV
chd-169	135	7	extends	extend	VERB
chd-169	135	8	to	to	ADP
chd-169	135	9	sequestration	sequestration	NOUN
chd-169	135	10	of	of	ADP
chd-169	135	11	other	other	ADJ
chd-169	135	12	transcription	transcription	NOUN
chd-169	135	13	factors	factor	NOUN
chd-169	135	14	(	(	PUNCT
chd-169	135	15	including	include	VERB
chd-169	135	16	nfkb	nfkb	PROPN
chd-169	135	17	and	and	CCONJ
chd-169	135	18	ap-1	ap-1	ADV
chd-169	135	19	)	)	PUNCT
chd-169	135	20	to	to	PART
chd-169	135	21	inhibit	inhibit	VERB
chd-169	135	22	proinflammatory	proinflammatory	ADJ
chd-169	135	23	gene	gene	NOUN
chd-169	135	24	expression	expression	NOUN
chd-169	135	25	as	as	ADV
chd-169	135	26	well	well	ADV
chd-169	135	27	as	as	ADP
chd-169	135	28	tethering	tether	VERB
chd-169	135	29	transcription	transcription	NOUN
chd-169	135	30	factors	factor	NOUN
chd-169	135	31	to	to	PART
chd-169	135	32	facilitate	facilitate	VERB
chd-169	135	33	gene	gene	NOUN
chd-169	135	34	transcription	transcription	NOUN
chd-169	135	35	(	(	PUNCT
chd-169	135	36	oakley	oakley	NOUN
chd-169	135	37	and	and	CCONJ
chd-169	135	38	cidlowski	cidlowski	VERB
chd-169	135	39	,	,	PUNCT
chd-169	135	40	2011	2011	NUM
chd-169	135	41	;	;	PUNCT
chd-169	135	42	vandevyver	vandevyver	PROPN
chd-169	135	43	et	et	PROPN
chd-169	135	44	al	al	PROPN
chd-169	135	45	.	.	PROPN
chd-169	135	46	,	,	PUNCT
chd-169	135	47	2014	2014	NUM
chd-169	135	48	)	)	PUNCT
chd-169	135	49	.	.	PUNCT
chd-169	136	1	while	while	SCONJ
chd-169	136	2	most	most	ADJ
chd-169	136	3	cells	cell	NOUN
chd-169	136	4	express	express	VERB
chd-169	136	5	gr	gr	ADP
chd-169	136	6	,	,	PUNCT
chd-169	136	7	its	its	PRON
chd-169	136	8	genetic	genetic	ADJ
chd-169	136	9	structure	structure	NOUN
chd-169	136	10	is	be	AUX
chd-169	136	11	highly	highly	ADV
chd-169	136	12	complex	complex	ADJ
chd-169	136	13	,	,	PUNCT
chd-169	136	14	and	and	CCONJ
chd-169	136	15	tissue	tissue	NOUN
chd-169	136	16	-	-	PUNCT
chd-169	136	17	specific	specific	ADJ
chd-169	136	18	control	control	NOUN
chd-169	136	19	of	of	ADP
chd-169	136	20	gr	gr	PRON
chd-169	136	21	signaling	signal	VERB
chd-169	136	22	is	be	AUX
chd-169	136	23	conferred	confer	VERB
chd-169	136	24	,	,	PUNCT
chd-169	136	25	to	to	ADP
chd-169	136	26	a	a	DET
chd-169	136	27	large	large	ADJ
chd-169	136	28	extent	extent	NOUN
chd-169	136	29	,	,	PUNCT
chd-169	136	30	by	by	ADP
chd-169	136	31	the	the	DET
chd-169	136	32	type	type	NOUN
chd-169	136	33	and	and	CCONJ
chd-169	136	34	level	level	NOUN
chd-169	136	35	of	of	ADP
chd-169	136	36	gr	gr	NUM
chd-169	136	37	expressed	express	VERB
chd-169	136	38	(	(	PUNCT
chd-169	136	39	ito	ito	PROPN
chd-169	136	40	et	et	PROPN
chd-169	136	41	al	al	PROPN
chd-169	136	42	.	.	PROPN
chd-169	136	43	,	,	PUNCT
chd-169	136	44	2006	2006	NUM
chd-169	136	45	)	)	PUNCT
chd-169	136	46	.	.	PUNCT
chd-169	137	1	the	the	DET
chd-169	137	2	gene	gene	NOUN
chd-169	137	3	encoding	encode	VERB
chd-169	137	4	gr	gr	ADP
chd-169	137	5	,	,	PUNCT
chd-169	137	6	nr3c1	nr3c1	PROPN
chd-169	137	7	(	(	PUNCT
chd-169	137	8	nuclear	nuclear	ADJ
chd-169	137	9	receptor	receptor	NOUN
chd-169	137	10	subfamily	subfamily	ADV
chd-169	137	11	3	3	NUM
chd-169	137	12	group	group	NOUN
chd-169	137	13	c	c	PROPN
chd-169	137	14	member	member	NOUN
chd-169	137	15	1	1	NUM
chd-169	137	16	)	)	PUNCT
chd-169	137	17	,	,	PUNCT
chd-169	137	18	is	be	AUX
chd-169	137	19	composed	compose	VERB
chd-169	137	20	of	of	ADP
chd-169	137	21	9	9	NUM
chd-169	137	22	exons	exon	NOUN
chd-169	137	23	;	;	PUNCT
chd-169	137	24	however	however	ADV
chd-169	137	25	,	,	PUNCT
chd-169	137	26	the	the	DET
chd-169	137	27	major	major	ADJ
chd-169	137	28	transcriptional	transcriptional	NOUN
chd-169	137	29	start	start	NOUN
chd-169	137	30	site	site	NOUN
chd-169	137	31	is	be	AUX
chd-169	137	32	within	within	ADP
chd-169	137	33	exon	exon	NOUN
chd-169	137	34	2	2	NUM
chd-169	137	35	and	and	CCONJ
chd-169	137	36	only	only	ADJ
chd-169	137	37	exons	exon	NOUN
chd-169	137	38	2	2	NUM
chd-169	137	39	through	through	ADP
chd-169	137	40	9	9	NUM
chd-169	137	41	encode	encode	ADJ
chd-169	137	42	protein	protein	NOUN
chd-169	137	43	(	(	PUNCT
chd-169	137	44	ito	ito	PROPN
chd-169	137	45	et	et	PROPN
chd-169	137	46	al	al	PROPN
chd-169	137	47	.	.	PROPN
chd-169	137	48	,	,	PUNCT
chd-169	137	49	2006	2006	NUM
chd-169	137	50	;	;	PUNCT
chd-169	137	51	vandevyver	vandevyver	PROPN
chd-169	137	52	et	et	PROPN
chd-169	137	53	al	al	PROPN
chd-169	137	54	.	.	PROPN
chd-169	137	55	,	,	PUNCT
chd-169	137	56	2014	2014	NUM
chd-169	137	57	)	)	PUNCT
chd-169	137	58	.	.	PUNCT
chd-169	138	1	exon	exon	NOUN
chd-169	138	2	2	2	NUM
chd-169	138	3	encodes	encode	NOUN
chd-169	138	4	the	the	DET
chd-169	138	5	amino	amino	NOUN
chd-169	138	6	(	(	PUNCT
chd-169	138	7	n)-terminal	n)-terminal	ADJ
chd-169	138	8	modulatory	modulatory	ADJ
chd-169	138	9	domain	domain	NOUN
chd-169	138	10	,	,	PUNCT
chd-169	138	11	exons	exon	NOUN
chd-169	138	12	3	3	NUM
chd-169	138	13	and	and	CCONJ
chd-169	138	14	4	4	NUM
chd-169	138	15	encode	encode	VERB
chd-169	138	16	the	the	DET
chd-169	138	17	dna	dna	NOUN
chd-169	138	18	-	-	PUNCT
chd-169	138	19	binding	bind	VERB
chd-169	138	20	domain	domain	NOUN
chd-169	138	21	,	,	PUNCT
chd-169	138	22	exon	exon	NOUN
chd-169	138	23	5	5	NUM
chd-169	138	24	codes	code	NOUN
chd-169	138	25	for	for	ADP
chd-169	138	26	a	a	DET
chd-169	138	27	hinge	hinge	NOUN
chd-169	138	28	region	region	NOUN
chd-169	138	29	,	,	PUNCT
chd-169	138	30	and	and	CCONJ
chd-169	138	31	exons	exon	NOUN
chd-169	138	32	6	6	NUM
chd-169	138	33	-	-	SYM
chd-169	138	34	9	9	NUM
chd-169	138	35	encode	encode	VERB
chd-169	138	36	the	the	DET
chd-169	138	37	carboxy	carboxy	ADJ
chd-169	138	38	(	(	PUNCT
chd-169	138	39	c)terminal	c)terminal	ADJ
chd-169	138	40	ligand	ligand	ADJ
chd-169	138	41	binding	bind	VERB
chd-169	138	42	domain	domain	NOUN
chd-169	138	43	(	(	PUNCT
chd-169	138	44	kadmiel	kadmiel	NOUN
chd-169	138	45	and	and	CCONJ
chd-169	138	46	cidlowski	cidlowski	VERB
chd-169	138	47	,	,	PUNCT
chd-169	138	48	2013	2013	NUM
chd-169	138	49	)	)	PUNCT
chd-169	138	50	.	.	PUNCT
chd-169	139	1	the	the	DET
chd-169	139	2	13	13	NUM
chd-169	139	3	currently	currently	ADV
chd-169	139	4	-	-	PUNCT
chd-169	139	5	identified	identify	VERB
chd-169	139	6	variants	variant	NOUN
chd-169	139	7	of	of	ADP
chd-169	139	8	exon	exon	NOUN
chd-169	139	9	1	1	NUM
chd-169	139	10	,	,	PUNCT
chd-169	139	11	with	with	ADP
chd-169	139	12	9	9	NUM
chd-169	139	13	possible	possible	ADJ
chd-169	139	14	promoter	promoter	NOUN
chd-169	139	15	regions	region	NOUN
chd-169	139	16	,	,	PUNCT
chd-169	139	17	form	form	VERB
chd-169	139	18	the	the	DET
chd-169	139	19	5’-untranslated	5’-untranslated	NUM
chd-169	139	20	region	region	NOUN
chd-169	139	21	(	(	PUNCT
chd-169	139	22	utr	utr	PROPN
chd-169	139	23	)	)	PUNCT
chd-169	139	24	and	and	CCONJ
chd-169	139	25	are	be	AUX
chd-169	139	26	thought	think	VERB
chd-169	139	27	to	to	PART
chd-169	139	28	confer	confer	VERB
chd-169	139	29	tissue	tissue	NOUN
chd-169	139	30	specificity	specificity	NOUN
chd-169	139	31	of	of	ADP
chd-169	139	32	gr	gr	NOUN
chd-169	139	33	expression	expression	NOUN
chd-169	139	34	(	(	PUNCT
chd-169	139	35	turner	turner	NOUN
chd-169	139	36	and	and	CCONJ
chd-169	139	37	muller	muller	NOUN
chd-169	139	38	,	,	PUNCT
chd-169	139	39	2005	2005	NUM
chd-169	139	40	)	)	PUNCT
chd-169	139	41	.	.	PUNCT
chd-169	140	1	alternative	alternative	ADJ
chd-169	140	2	splicing	splicing	NOUN
chd-169	140	3	of	of	ADP
chd-169	140	4	gr	gr	PROPN
chd-169	140	5	mrna	mrna	PROPN
chd-169	140	6	yields	yield	NOUN
chd-169	140	7	grα	grα	PROPN
chd-169	140	8	,	,	PUNCT
chd-169	140	9	grβ	grβ	NOUN
chd-169	140	10	,	,	PUNCT
chd-169	140	11	grγ	grγ	PROPN
chd-169	140	12	,	,	PUNCT
chd-169	140	13	gr	gr	PROPN
chd-169	140	14	-	-	PUNCT
chd-169	140	15	a	a	NOUN
chd-169	140	16	,	,	PUNCT
chd-169	140	17	and	and	CCONJ
chd-169	140	18	gr	gr	PROPN
chd-169	140	19	-	-	PUNCT
chd-169	140	20	p.	p.	NOUN
chd-169	140	21	grα	grα	NOUN
chd-169	140	22	is	be	AUX
chd-169	140	23	expressed	express	VERB
chd-169	140	24	at	at	ADP
chd-169	140	25	higher	high	ADJ
chd-169	140	26	levels	level	NOUN
chd-169	140	27	in	in	ADP
chd-169	140	28	most	most	ADJ
chd-169	140	29	cells	cell	NOUN
chd-169	140	30	,	,	PUNCT
chd-169	140	31	including	include	VERB
chd-169	140	32	cancer	cancer	NOUN
chd-169	140	33	cells	cell	NOUN
chd-169	140	34	,	,	PUNCT
chd-169	140	35	than	than	ADP
chd-169	140	36	the	the	DET
chd-169	140	37	other	other	ADJ
chd-169	140	38	gr	gr	NOUN
chd-169	140	39	forms	form	NOUN
chd-169	140	40	(	(	PUNCT
chd-169	140	41	biddie	biddie	NOUN
chd-169	140	42	et	et	PROPN
chd-169	140	43	al	al	PROPN
chd-169	140	44	.	.	PROPN
chd-169	140	45	,	,	PUNCT
chd-169	140	46	2012	2012	NUM
chd-169	140	47	;	;	PUNCT
chd-169	140	48	vandevyver	vandevyver	PROPN
chd-169	140	49	et	et	PROPN
chd-169	140	50	al	al	PROPN
chd-169	140	51	.	.	PROPN
chd-169	140	52	,	,	PUNCT
chd-169	140	53	2014	2014	NUM
chd-169	140	54	)	)	PUNCT
chd-169	140	55	.	.	PUNCT
chd-169	141	1	grβ	grβ	PROPN
chd-169	141	2	is	be	AUX
chd-169	141	3	a	a	DET
chd-169	141	4	closely	closely	ADV
chd-169	141	5	-	-	PUNCT
chd-169	141	6	related	relate	VERB
chd-169	141	7	variant	variant	NOUN
chd-169	141	8	to	to	ADP
chd-169	141	9	grα	grα	PROPN
chd-169	141	10	,	,	PUNCT
chd-169	141	11	differing	differ	VERB
chd-169	141	12	by	by	ADP
chd-169	141	13	~35	~35	ADJ
chd-169	141	14	amino	amino	ADJ
chd-169	141	15	acids	acid	NOUN
chd-169	141	16	within	within	ADP
chd-169	141	17	the	the	DET
chd-169	141	18	ligand	ligand	ADJ
chd-169	141	19	binding	bind	VERB
chd-169	141	20	domain	domain	NOUN
chd-169	141	21	(	(	PUNCT
chd-169	141	22	fig	fig	NOUN
chd-169	141	23	.	.	PUNCT
chd-169	142	1	3	3	NUM
chd-169	142	2	)	)	PUNCT
chd-169	142	3	.	.	PUNCT
chd-169	143	1	in	in	ADP
chd-169	143	2	contrast	contrast	NOUN
chd-169	143	3	to	to	ADP
chd-169	143	4	grα	grα	PROPN
chd-169	143	5	,	,	PUNCT
chd-169	143	6	grβ	grβ	PROPN
chd-169	143	7	does	do	AUX
chd-169	143	8	not	not	PART
chd-169	143	9	bind	bind	VERB
chd-169	143	10	glucocorticoids	glucocorticoid	NOUN
chd-169	143	11	and	and	CCONJ
chd-169	143	12	is	be	AUX
chd-169	143	13	constitutively	constitutively	ADV
chd-169	143	14	located	locate	VERB
chd-169	143	15	in	in	ADP
chd-169	143	16	the	the	DET
chd-169	143	17	nucleus	nucleus	NOUN
chd-169	143	18	(	(	PUNCT
chd-169	143	19	biddie	biddie	PROPN
chd-169	143	20	et	et	PROPN
chd-169	143	21	al	al	PROPN
chd-169	143	22	.	.	PROPN
chd-169	143	23	,	,	PUNCT
chd-169	143	24	2012	2012	NUM
chd-169	143	25	;	;	PUNCT
chd-169	144	1	kassel	kassel	PROPN
chd-169	144	2	and	and	CCONJ
chd-169	144	3	herrlich	herrlich	NOUN
chd-169	144	4	,	,	PUNCT
chd-169	144	5	2007	2007	NUM
chd-169	144	6	;	;	PUNCT
chd-169	144	7	mata	mata	PROPN
chd-169	144	8	-	-	PUNCT
chd-169	144	9	greenwood	greenwood	PROPN
chd-169	144	10	et	et	PROPN
chd-169	144	11	al	al	PROPN
chd-169	144	12	.	.	PROPN
chd-169	144	13	,	,	PUNCT
chd-169	144	14	2015	2015	NUM
chd-169	144	15	)	)	PUNCT
chd-169	144	16	.	.	PUNCT
chd-169	145	1	although	although	SCONJ
chd-169	145	2	it	it	PRON
chd-169	145	3	does	do	AUX
chd-169	145	4	not	not	PART
chd-169	145	5	directly	directly	ADV
chd-169	145	6	mediate	mediate	VERB
chd-169	145	7	transcription	transcription	NOUN
chd-169	145	8	,	,	PUNCT
chd-169	145	9	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	X
chd-169	145	10	e10	e10	NUM
chd-169	145	11	cancer	cancer	NOUN
chd-169	145	12	health	health	NOUN
chd-169	145	13	disparities	disparity	NOUN
chd-169	145	14	research	research	NOUN
chd-169	145	15	grβ	grβ	NOUN
chd-169	145	16	has	have	AUX
chd-169	145	17	been	be	AUX
chd-169	145	18	shown	show	VERB
chd-169	145	19	to	to	PART
chd-169	145	20	regulate	regulate	VERB
chd-169	145	21	gene	gene	NOUN
chd-169	145	22	expression	expression	NOUN
chd-169	145	23	through	through	ADP
chd-169	145	24	dominant	dominant	ADJ
chd-169	145	25	-	-	PUNCT
chd-169	145	26	negative	negative	ADJ
chd-169	145	27	effects	effect	NOUN
chd-169	145	28	on	on	ADP
chd-169	145	29	grα	grα	NOUN
chd-169	145	30	via	via	ADP
chd-169	145	31	heterodimer	heterodimer	NOUN
chd-169	145	32	formation	formation	NOUN
chd-169	145	33	and	and	CCONJ
chd-169	145	34	also	also	ADV
chd-169	145	35	by	by	ADP
chd-169	145	36	epigenetically	epigenetically	ADV
chd-169	145	37	modifying	modify	VERB
chd-169	145	38	chromatin	chromatin	NOUN
chd-169	145	39	structure	structure	NOUN
chd-169	145	40	through	through	ADP
chd-169	145	41	interactions	interaction	NOUN
chd-169	145	42	with	with	ADP
chd-169	145	43	histone	histone	NOUN
chd-169	145	44	deacetylases	deacetylase	NOUN
chd-169	145	45	(	(	PUNCT
chd-169	145	46	nicolaides	nicolaide	NOUN
chd-169	145	47	et	et	PROPN
chd-169	145	48	al	al	PROPN
chd-169	145	49	.	.	PROPN
chd-169	145	50	,	,	PUNCT
chd-169	145	51	2010	2010	NUM
chd-169	145	52	;	;	PUNCT
chd-169	145	53	oakley	oakley	NOUN
chd-169	145	54	and	and	CCONJ
chd-169	145	55	cidlowski	cidlowski	VERB
chd-169	145	56	,	,	PUNCT
chd-169	145	57	2013	2013	NUM
chd-169	145	58	)	)	PUNCT
chd-169	145	59	.	.	PUNCT
chd-169	146	1	grγ	grγ	PROPN
chd-169	146	2	,	,	PUNCT
chd-169	146	3	which	which	PRON
chd-169	146	4	makes	make	VERB
chd-169	146	5	up	up	ADP
chd-169	146	6	about	about	ADV
chd-169	146	7	10	10	NUM
chd-169	146	8	%	%	NOUN
chd-169	146	9	of	of	ADP
chd-169	146	10	total	total	ADJ
chd-169	146	11	gr	gr	NOUN
chd-169	146	12	expression	expression	NOUN
chd-169	146	13	in	in	ADP
chd-169	146	14	most	most	ADJ
chd-169	146	15	cells	cell	NOUN
chd-169	146	16	,	,	PUNCT
chd-169	146	17	is	be	AUX
chd-169	146	18	formed	form	VERB
chd-169	146	19	through	through	ADP
chd-169	146	20	alternative	alternative	ADJ
chd-169	146	21	splicing	splicing	NOUN
chd-169	146	22	between	between	ADP
chd-169	146	23	exons	exon	NOUN
chd-169	146	24	3	3	NUM
chd-169	146	25	and	and	CCONJ
chd-169	146	26	4	4	NUM
chd-169	146	27	,	,	PUNCT
chd-169	146	28	with	with	ADP
chd-169	146	29	the	the	DET
chd-169	146	30	incorporation	incorporation	NOUN
chd-169	146	31	of	of	ADP
chd-169	146	32	a	a	DET
chd-169	146	33	single	single	ADJ
chd-169	146	34	additional	additional	ADJ
chd-169	146	35	arginine	arginine	NOUN
chd-169	146	36	nucleotide	nucleotide	NOUN
chd-169	146	37	into	into	ADP
chd-169	146	38	the	the	DET
chd-169	146	39	dna	dna	NOUN
chd-169	146	40	binding	bind	VERB
chd-169	146	41	domain	domain	NOUN
chd-169	146	42	(	(	PUNCT
chd-169	146	43	morgan	morgan	PROPN
chd-169	146	44	et	et	PROPN
chd-169	146	45	al	al	PROPN
chd-169	146	46	.	.	PROPN
chd-169	146	47	,	,	PUNCT
chd-169	146	48	2016	2016	NUM
chd-169	146	49	)	)	PUNCT
chd-169	146	50	.	.	PUNCT
chd-169	147	1	this	this	DET
chd-169	147	2	minor	minor	ADJ
chd-169	147	3	structural	structural	ADJ
chd-169	147	4	difference	difference	NOUN
chd-169	147	5	,	,	PUNCT
chd-169	147	6	while	while	SCONJ
chd-169	147	7	not	not	PART
chd-169	147	8	affecting	affect	VERB
chd-169	147	9	dna	dna	NOUN
chd-169	147	10	binding	bind	VERB
chd-169	147	11	affinity	affinity	NOUN
chd-169	147	12	or	or	CCONJ
chd-169	147	13	total	total	ADJ
chd-169	147	14	gr	gr	NOUN
chd-169	147	15	occupancy	occupancy	NOUN
chd-169	147	16	of	of	ADP
chd-169	147	17	target	target	NOUN
chd-169	147	18	genes	gene	NOUN
chd-169	147	19	,	,	PUNCT
chd-169	147	20	still	still	ADV
chd-169	147	21	confers	confer	VERB
chd-169	147	22	different	different	ADJ
chd-169	147	23	sequence	sequence	NOUN
chd-169	147	24	specificity	specificity	NOUN
chd-169	147	25	and	and	CCONJ
chd-169	147	26	target	target	NOUN
chd-169	147	27	gene	gene	NOUN
chd-169	147	28	control	control	NOUN
chd-169	147	29	(	(	PUNCT
chd-169	147	30	through	through	ADP
chd-169	147	31	variable	variable	ADJ
chd-169	147	32	allosteric	allosteric	ADJ
chd-169	147	33	signal	signal	NOUN
chd-169	147	34	interpretation	interpretation	NOUN
chd-169	147	35	)	)	PUNCT
chd-169	147	36	compared	compare	VERB
chd-169	147	37	to	to	ADP
chd-169	147	38	grα	grα	PROPN
chd-169	147	39	(	(	PUNCT
chd-169	147	40	morgan	morgan	PROPN
chd-169	147	41	et	et	PROPN
chd-169	147	42	al	al	PROPN
chd-169	147	43	.	.	PROPN
chd-169	147	44	,	,	PUNCT
chd-169	147	45	2016	2016	NUM
chd-169	147	46	)	)	PUNCT
chd-169	147	47	.	.	PUNCT
chd-169	148	1	other	other	ADJ
chd-169	148	2	notable	notable	ADJ
chd-169	148	3	aspects	aspect	NOUN
chd-169	148	4	of	of	ADP
chd-169	148	5	grγ	grγ	PROPN
chd-169	148	6	are	be	AUX
chd-169	148	7	a	a	DET
chd-169	148	8	delayed	delay	VERB
chd-169	148	9	ligand	ligand	NOUN
chd-169	148	10	-	-	PUNCT
chd-169	148	11	induced	induce	VERB
chd-169	148	12	nuclear	nuclear	ADJ
chd-169	148	13	import	import	NOUN
chd-169	148	14	(	(	PUNCT
chd-169	148	15	unlike	unlike	ADP
chd-169	148	16	beta	beta	NOUN
chd-169	148	17	,	,	PUNCT
chd-169	148	18	resides	reside	VERB
chd-169	148	19	in	in	ADP
chd-169	148	20	the	the	DET
chd-169	148	21	cytoplasmic	cytoplasmic	ADJ
chd-169	148	22	region	region	NOUN
chd-169	148	23	)	)	PUNCT
chd-169	148	24	as	as	ADV
chd-169	148	25	well	well	ADV
chd-169	148	26	as	as	ADP
chd-169	148	27	a	a	DET
chd-169	148	28	pro	pro	ADJ
chd-169	148	29	-	-	ADJ
chd-169	148	30	cellular	cellular	ADJ
chd-169	148	31	respiration	respiration	NOUN
chd-169	148	32	function	function	NOUN
chd-169	148	33	within	within	ADP
chd-169	148	34	mitochondria	mitochondria	PROPN
chd-169	148	35	(	(	PUNCT
chd-169	148	36	morgan	morgan	PROPN
chd-169	148	37	et	et	PROPN
chd-169	148	38	al	al	PROPN
chd-169	148	39	.	.	PROPN
chd-169	148	40	,	,	PUNCT
chd-169	148	41	2016	2016	NUM
chd-169	148	42	)	)	PUNCT
chd-169	148	43	.	.	PUNCT
chd-169	149	1	the	the	DET
chd-169	149	2	gr	gr	NOUN
chd-169	149	3	-	-	PUNCT
chd-169	149	4	a	a	NOUN
chd-169	149	5	and	and	CCONJ
chd-169	149	6	gr	gr	PROPN
chd-169	149	7	-	-	PUNCT
chd-169	149	8	p	p	NOUN
chd-169	149	9	isoforms	isoform	NOUN
chd-169	149	10	are	be	AUX
chd-169	149	11	formed	form	VERB
chd-169	149	12	through	through	ADP
chd-169	149	13	removal	removal	NOUN
chd-169	149	14	of	of	ADP
chd-169	149	15	large	large	ADJ
chd-169	149	16	portions	portion	NOUN
chd-169	149	17	of	of	ADP
chd-169	149	18	the	the	DET
chd-169	149	19	ligand	ligand	ADJ
chd-169	149	20	binding	bind	VERB
chd-169	149	21	domain	domain	NOUN
chd-169	149	22	(	(	PUNCT
chd-169	149	23	exons	exon	NOUN
chd-169	149	24	5	5	NUM
chd-169	149	25	-	-	SYM
chd-169	149	26	7	7	NUM
chd-169	149	27	and	and	CCONJ
chd-169	149	28	exons	exon	NOUN
chd-169	149	29	8	8	NUM
chd-169	149	30	-	-	SYM
chd-169	149	31	9	9	NUM
chd-169	149	32	,	,	PUNCT
chd-169	149	33	respectively	respectively	ADV
chd-169	149	34	)	)	PUNCT
chd-169	149	35	(	(	PUNCT
chd-169	149	36	oakley	oakley	NOUN
chd-169	149	37	and	and	CCONJ
chd-169	149	38	cidlowski	cidlowski	VERB
chd-169	149	39	,	,	PUNCT
chd-169	149	40	2013	2013	NUM
chd-169	149	41	)	)	PUNCT
chd-169	149	42	.	.	PUNCT
chd-169	150	1	comparatively	comparatively	ADV
chd-169	150	2	less	less	ADV
chd-169	150	3	is	be	AUX
chd-169	150	4	known	know	VERB
chd-169	150	5	concerning	concern	VERB
chd-169	150	6	these	these	DET
chd-169	150	7	isoforms	isoform	NOUN
chd-169	150	8	,	,	PUNCT
chd-169	150	9	but	but	CCONJ
chd-169	150	10	evidence	evidence	NOUN
chd-169	150	11	suggests	suggest	VERB
chd-169	150	12	a	a	DET
chd-169	150	13	ligandindependent	ligandindependent	NOUN
chd-169	150	14	ability	ability	NOUN
chd-169	150	15	to	to	PART
chd-169	150	16	modulate	modulate	VERB
chd-169	150	17	grα	grα	PROPN
chd-169	150	18	function	function	NOUN
chd-169	150	19	(	(	PUNCT
chd-169	150	20	oakley	oakley	NOUN
chd-169	150	21	and	and	CCONJ
chd-169	150	22	cidlowski	cidlowski	VERB
chd-169	150	23	,	,	PUNCT
chd-169	150	24	2013	2013	NUM
chd-169	150	25	;	;	PUNCT
chd-169	151	1	vandevyver	vandevyver	PROPN
chd-169	151	2	et	et	PROPN
chd-169	151	3	al	al	PROPN
chd-169	151	4	.	.	PROPN
chd-169	151	5	,	,	PUNCT
chd-169	151	6	2014	2014	NUM
chd-169	151	7	)	)	PUNCT
chd-169	151	8	.	.	PUNCT
chd-169	152	1	a	a	DET
chd-169	152	2	further	further	ADJ
chd-169	152	3	layer	layer	NOUN
chd-169	152	4	of	of	ADP
chd-169	152	5	complexity	complexity	NOUN
chd-169	152	6	in	in	ADP
chd-169	152	7	gr	gr	NOUN
chd-169	152	8	expression	expression	NOUN
chd-169	152	9	is	be	AUX
chd-169	152	10	introduced	introduce	VERB
chd-169	152	11	by	by	ADP
chd-169	152	12	8	8	NUM
chd-169	152	13	alternate	alternate	ADJ
chd-169	152	14	translation	translation	NOUN
chd-169	152	15	initiation	initiation	NOUN
chd-169	152	16	sites	site	NOUN
chd-169	152	17	within	within	ADP
chd-169	152	18	exon	exon	PROPN
chd-169	152	19	2	2	NUM
chd-169	152	20	,	,	PUNCT
chd-169	152	21	yielding	yield	VERB
chd-169	152	22	a	a	DET
chd-169	152	23	number	number	NOUN
chd-169	152	24	of	of	ADP
chd-169	152	25	additional	additional	ADJ
chd-169	152	26	isoforms	isoform	NOUN
chd-169	152	27	(	(	PUNCT
chd-169	152	28	oakley	oakley	NOUN
chd-169	152	29	and	and	CCONJ
chd-169	152	30	cidlowski	cidlowski	VERB
chd-169	152	31	,	,	PUNCT
chd-169	152	32	2013	2013	NUM
chd-169	152	33	;	;	PUNCT
chd-169	152	34	vandevyver	vandevyver	PROPN
chd-169	152	35	et	et	PROPN
chd-169	152	36	al	al	PROPN
chd-169	152	37	.	.	PROPN
chd-169	152	38	,	,	PUNCT
chd-169	152	39	2014	2014	NUM
chd-169	152	40	)	)	PUNCT
chd-169	152	41	.	.	PUNCT
chd-169	153	1	these	these	PRON
chd-169	153	2	have	have	AUX
chd-169	153	3	been	be	AUX
chd-169	153	4	identified	identify	VERB
chd-169	153	5	for	for	ADP
chd-169	153	6	grα	grα	NOUN
chd-169	153	7	and	and	CCONJ
chd-169	153	8	are	be	AUX
chd-169	153	9	predicted	predict	VERB
chd-169	153	10	to	to	PART
chd-169	153	11	exist	exist	VERB
chd-169	153	12	for	for	ADP
chd-169	153	13	each	each	PRON
chd-169	153	14	of	of	ADP
chd-169	153	15	the	the	DET
chd-169	153	16	other	other	ADJ
chd-169	153	17	splice	splice	NOUN
chd-169	153	18	variants	variant	NOUN
chd-169	153	19	grβ	grβ	NOUN
chd-169	153	20	,	,	PUNCT
chd-169	153	21	grγ	grγ	PROPN
chd-169	153	22	,	,	PUNCT
chd-169	153	23	gr	gr	PROPN
chd-169	153	24	-	-	PUNCT
chd-169	153	25	a	a	NOUN
chd-169	153	26	,	,	PUNCT
chd-169	153	27	and	and	CCONJ
chd-169	153	28	gr	gr	NOUN
chd-169	153	29	-	-	PUNCT
chd-169	153	30	p	p	X
chd-169	153	31	(	(	PUNCT
chd-169	153	32	oakley	oakley	NOUN
chd-169	153	33	and	and	CCONJ
chd-169	153	34	cidlowski	cidlowski	VERB
chd-169	153	35	,	,	PUNCT
chd-169	153	36	2013	2013	NUM
chd-169	153	37	;	;	PUNCT
chd-169	153	38	vandevyver	vandevyver	PROPN
chd-169	153	39	et	et	PROPN
chd-169	153	40	al	al	PROPN
chd-169	153	41	.	.	PROPN
chd-169	153	42	,	,	PUNCT
chd-169	153	43	2014	2014	NUM
chd-169	153	44	)	)	PUNCT
chd-169	153	45	.	.	PUNCT
chd-169	154	1	furthermore	furthermore	ADV
chd-169	154	2	,	,	PUNCT
chd-169	154	3	post	post	ADJ
chd-169	154	4	-	-	ADJ
chd-169	154	5	translational	translational	ADJ
chd-169	154	6	modifications	modification	NOUN
chd-169	154	7	of	of	ADP
chd-169	154	8	gr	gr	PRON
chd-169	154	9	also	also	ADV
chd-169	154	10	regulate	regulate	VERB
chd-169	154	11	the	the	DET
chd-169	154	12	receptor	receptor	NOUN
chd-169	154	13	’s	’s	PART
chd-169	154	14	function	function	NOUN
chd-169	154	15	in	in	ADP
chd-169	154	16	target	target	NOUN
chd-169	154	17	cells	cell	NOUN
chd-169	154	18	(	(	PUNCT
chd-169	154	19	vandevyver	vandevyver	NOUN
chd-169	154	20	et	et	PROPN
chd-169	154	21	al	al	PROPN
chd-169	154	22	.	.	PROPN
chd-169	154	23	,	,	PUNCT
chd-169	154	24	2014	2014	NUM
chd-169	154	25	)	)	PUNCT
chd-169	154	26	.	.	PUNCT
chd-169	155	1	kinase	kinase	PROPN
chd-169	155	2	activity	activity	NOUN
chd-169	155	3	(	(	PUNCT
chd-169	155	4	including	include	VERB
chd-169	155	5	mapk	mapk	PROPN
chd-169	155	6	,	,	PUNCT
chd-169	155	7	cdk	cdk	PROPN
chd-169	155	8	,	,	PUNCT
chd-169	155	9	ck2	ck2	PROPN
chd-169	155	10	,	,	PUNCT
chd-169	155	11	gsk-3β	gsk-3β	PROPN
chd-169	155	12	)	)	PUNCT
chd-169	155	13	at	at	ADP
chd-169	155	14	serine	serine	NOUN
chd-169	155	15	residues	residue	NOUN
chd-169	155	16	within	within	ADP
chd-169	155	17	the	the	DET
chd-169	155	18	n	n	CCONJ
chd-169	155	19	-	-	PUNCT
chd-169	155	20	terminal	terminal	ADJ
chd-169	155	21	domain	domain	NOUN
chd-169	155	22	occurs	occur	VERB
chd-169	155	23	following	follow	VERB
chd-169	155	24	glucocorticoid	glucocorticoid	ADJ
chd-169	155	25	exposure	exposure	NOUN
chd-169	155	26	(	(	PUNCT
chd-169	155	27	oakley	oakley	NOUN
chd-169	155	28	and	and	CCONJ
chd-169	155	29	cidlowski	cidlowski	VERB
chd-169	155	30	,	,	PUNCT
chd-169	155	31	2013	2013	NUM
chd-169	155	32	;	;	PUNCT
chd-169	155	33	vandevyver	vandevyver	PROPN
chd-169	155	34	et	et	PROPN
chd-169	155	35	al	al	PROPN
chd-169	155	36	.	.	PROPN
chd-169	155	37	,	,	PUNCT
chd-169	155	38	2014	2014	NUM
chd-169	155	39	)	)	PUNCT
chd-169	155	40	.	.	PUNCT
chd-169	156	1	these	these	DET
chd-169	156	2	phosphorylation	phosphorylation	NOUN
chd-169	156	3	events	event	NOUN
chd-169	156	4	may	may	AUX
chd-169	156	5	result	result	VERB
chd-169	156	6	in	in	ADP
chd-169	156	7	cytoplasmic	cytoplasmic	ADJ
chd-169	156	8	sequestration	sequestration	NOUN
chd-169	156	9	(	(	PUNCT
chd-169	156	10	ser-203	ser-203	X
chd-169	156	11	,	,	PUNCT
chd-169	156	12	-226	-226	PROPN
chd-169	156	13	,	,	PUNCT
chd-169	156	14	-404	-404	NOUN
chd-169	156	15	)	)	PUNCT
chd-169	156	16	,	,	PUNCT
chd-169	156	17	degradation	degradation	NOUN
chd-169	156	18	,	,	PUNCT
chd-169	156	19	or	or	CCONJ
chd-169	156	20	enhanced	enhanced	ADJ
chd-169	156	21	transcriptional	transcriptional	ADJ
chd-169	156	22	activity	activity	NOUN
chd-169	156	23	(	(	PUNCT
chd-169	156	24	-211	-211	PROPN
chd-169	156	25	)	)	PUNCT
chd-169	156	26	(	(	PUNCT
chd-169	156	27	oakley	oakley	NOUN
chd-169	156	28	and	and	CCONJ
chd-169	156	29	cidlowski	cidlowski	VERB
chd-169	156	30	,	,	PUNCT
chd-169	156	31	2013	2013	NUM
chd-169	156	32	;	;	PUNCT
chd-169	156	33	vandevyver	vandevyver	PROPN
chd-169	156	34	et	et	PROPN
chd-169	156	35	al	al	PROPN
chd-169	156	36	.	.	PROPN
chd-169	156	37	,	,	PUNCT
chd-169	156	38	2014	2014	NUM
chd-169	156	39	)	)	PUNCT
chd-169	156	40	.	.	PUNCT
chd-169	157	1	other	other	ADJ
chd-169	157	2	gr	gr	PROPN
chd-169	157	3	modifications	modification	NOUN
chd-169	157	4	include	include	VERB
chd-169	157	5	the	the	DET
chd-169	157	6	addition	addition	NOUN
chd-169	157	7	of	of	ADP
chd-169	157	8	a	a	DET
chd-169	157	9	ubiquitin	ubiquitin	ADJ
chd-169	157	10	moiety	moiety	NOUN
chd-169	157	11	at	at	ADP
chd-169	157	12	lysine	lysine	NOUN
chd-169	157	13	419	419	NUM
chd-169	157	14	,	,	PUNCT
chd-169	157	15	which	which	PRON
chd-169	157	16	targets	target	VERB
chd-169	157	17	gr	gr	NOUN
chd-169	157	18	for	for	ADP
chd-169	157	19	proteasomal	proteasomal	ADJ
chd-169	157	20	degradation	degradation	NOUN
chd-169	157	21	;	;	PUNCT
chd-169	157	22	sumoylation	sumoylation	NOUN
chd-169	157	23	of	of	ADP
chd-169	157	24	lysines	lysine	NOUN
chd-169	157	25	277	277	NUM
chd-169	157	26	,	,	PUNCT
chd-169	157	27	293	293	NUM
chd-169	157	28	,	,	PUNCT
chd-169	157	29	and	and	CCONJ
chd-169	157	30	703	703	NUM
chd-169	157	31	,	,	PUNCT
chd-169	157	32	which	which	PRON
chd-169	157	33	modulate	modulate	VERB
chd-169	157	34	gr	gr	NOUN
chd-169	157	35	interactions	interaction	NOUN
chd-169	157	36	with	with	ADP
chd-169	157	37	transcriptional	transcriptional	ADJ
chd-169	157	38	co	co	NOUN
chd-169	157	39	-	-	NOUN
chd-169	157	40	regulators	regulator	NOUN
chd-169	157	41	;	;	PUNCT
chd-169	157	42	and	and	CCONJ
chd-169	157	43	acetylation	acetylation	NOUN
chd-169	157	44	of	of	ADP
chd-169	157	45	lysines	lysine	NOUN
chd-169	157	46	494	494	NUM
chd-169	157	47	and	and	CCONJ
chd-169	157	48	495	495	NUM
chd-169	157	49	,	,	PUNCT
chd-169	157	50	which	which	PRON
chd-169	157	51	inhibit	inhibit	VERB
chd-169	157	52	gr	gr	NOUN
chd-169	157	53	binding	bind	VERB
chd-169	157	54	(	(	PUNCT
chd-169	157	55	and	and	CCONJ
chd-169	157	56	suppression	suppression	NOUN
chd-169	157	57	)	)	PUNCT
chd-169	157	58	to	to	PART
chd-169	157	59	nfkb	nfkb	VERB
chd-169	157	60	,	,	PUNCT
chd-169	157	61	thus	thus	ADV
chd-169	157	62	regulating	regulate	VERB
chd-169	157	63	gr	gr	PROPN
chd-169	157	64	’s	’s	PART
chd-169	157	65	anti	anti	ADJ
chd-169	157	66	-	-	ADJ
chd-169	157	67	inflammatory	inflammatory	ADJ
chd-169	157	68	function	function	NOUN
chd-169	157	69	(	(	PUNCT
chd-169	157	70	oakley	oakley	NOUN
chd-169	157	71	and	and	CCONJ
chd-169	157	72	cidlowski	cidlowski	VERB
chd-169	157	73	,	,	PUNCT
chd-169	157	74	2013	2013	NUM
chd-169	157	75	;	;	PUNCT
chd-169	157	76	vandevyver	vandevyver	PROPN
chd-169	157	77	et	et	PROPN
chd-169	157	78	al	al	PROPN
chd-169	157	79	.	.	PROPN
chd-169	157	80	,	,	PUNCT
chd-169	157	81	2014	2014	NUM
chd-169	157	82	)	)	PUNCT
chd-169	157	83	.	.	PUNCT
chd-169	158	1	in	in	ADP
chd-169	158	2	addition	addition	NOUN
chd-169	158	3	to	to	ADP
chd-169	158	4	modulating	modulate	VERB
chd-169	158	5	the	the	DET
chd-169	158	6	level	level	NOUN
chd-169	158	7	and	and	CCONJ
chd-169	158	8	form	form	NOUN
chd-169	158	9	of	of	ADP
chd-169	158	10	gr	gr	NOUN
chd-169	158	11	expression	expression	NOUN
chd-169	158	12	,	,	PUNCT
chd-169	158	13	cells	cell	NOUN
chd-169	158	14	and	and	CCONJ
chd-169	158	15	tissues	tissue	NOUN
chd-169	158	16	may	may	AUX
chd-169	158	17	also	also	ADV
chd-169	158	18	regulate	regulate	VERB
chd-169	158	19	immediate	immediate	ADJ
chd-169	158	20	ligand	ligand	NOUN
chd-169	158	21	availability	availability	NOUN
chd-169	158	22	(	(	PUNCT
chd-169	158	23	oakley	oakley	NOUN
chd-169	158	24	and	and	CCONJ
chd-169	158	25	cidlowski	cidlowski	VERB
chd-169	158	26	,	,	PUNCT
chd-169	158	27	2013	2013	NUM
chd-169	158	28	)	)	PUNCT
chd-169	158	29	.	.	PUNCT
chd-169	159	1	at	at	ADP
chd-169	159	2	the	the	DET
chd-169	159	3	cellular	cellular	ADJ
chd-169	159	4	level	level	NOUN
chd-169	159	5	,	,	PUNCT
chd-169	159	6	the	the	DET
chd-169	159	7	enzyme	enzyme	NOUN
chd-169	159	8	11β	11β	NOUN
chd-169	159	9	-	-	PUNCT
chd-169	159	10	hydroxysteroid	hydroxysteroid	ADJ
chd-169	159	11	dehydrogenase	dehydrogenase	NOUN
chd-169	159	12	type	type	NOUN
chd-169	159	13	2	2	NUM
chd-169	159	14	(	(	PUNCT
chd-169	159	15	11βhsd2	11βhsd2	NUM
chd-169	159	16	)	)	PUNCT
chd-169	159	17	catalyzes	catalyze	VERB
chd-169	159	18	the	the	DET
chd-169	159	19	inactivation	inactivation	NOUN
chd-169	159	20	of	of	ADP
chd-169	159	21	cortisol	cortisol	NOUN
chd-169	159	22	to	to	ADP
chd-169	159	23	cortisone	cortisone	PROPN
chd-169	159	24	,	,	PUNCT
chd-169	159	25	while	while	SCONJ
chd-169	159	26	the	the	DET
chd-169	159	27	opposing	opposing	ADJ
chd-169	159	28	type	type	NOUN
chd-169	159	29	1	1	NUM
chd-169	159	30	enzyme	enzyme	NOUN
chd-169	159	31	(	(	PUNCT
chd-169	159	32	11βhsd1	11βhsd1	NUM
chd-169	159	33	)	)	PUNCT
chd-169	159	34	reverses	reverse	VERB
chd-169	159	35	the	the	DET
chd-169	159	36	reaction	reaction	NOUN
chd-169	159	37	,	,	PUNCT
chd-169	159	38	promoting	promote	VERB
chd-169	159	39	cortisol	cortisol	ADJ
chd-169	159	40	production	production	NOUN
chd-169	159	41	(	(	PUNCT
chd-169	159	42	oakley	oakley	NOUN
chd-169	159	43	and	and	CCONJ
chd-169	159	44	cidlowski	cidlowski	VERB
chd-169	159	45	,	,	PUNCT
chd-169	159	46	2013	2013	NUM
chd-169	159	47	)	)	PUNCT
chd-169	159	48	.	.	PUNCT
chd-169	160	1	thus	thus	ADV
chd-169	160	2	,	,	PUNCT
chd-169	160	3	the	the	DET
chd-169	160	4	relative	relative	ADJ
chd-169	160	5	activities	activity	NOUN
chd-169	160	6	of	of	ADP
chd-169	160	7	these	these	DET
chd-169	160	8	enzymes	enzyme	NOUN
chd-169	160	9	within	within	ADP
chd-169	160	10	a	a	DET
chd-169	160	11	cell	cell	NOUN
chd-169	160	12	confer	confer	NOUN
chd-169	160	13	control	control	NOUN
chd-169	160	14	over	over	ADP
chd-169	160	15	the	the	DET
chd-169	160	16	local	local	ADJ
chd-169	160	17	availability	availability	NOUN
chd-169	160	18	of	of	ADP
chd-169	160	19	cortisol	cortisol	NOUN
chd-169	160	20	.	.	PUNCT
chd-169	161	1	of	of	ADP
chd-169	161	2	note	note	NOUN
chd-169	161	3	,	,	PUNCT
chd-169	161	4	most	most	ADV
chd-169	161	5	synthetic	synthetic	ADJ
chd-169	161	6	glucocorticoids	glucocorticoid	NOUN
chd-169	161	7	are	be	AUX
chd-169	161	8	not	not	PART
chd-169	161	9	inactivated	inactivate	VERB
chd-169	161	10	by	by	ADP
chd-169	161	11	11β	11β	NOUN
chd-169	161	12	-	-	PUNCT
chd-169	161	13	hsd2	hsd2	PROPN
chd-169	161	14	and	and	CCONJ
chd-169	161	15	their	their	PRON
chd-169	161	16	activities	activity	NOUN
chd-169	161	17	are	be	AUX
chd-169	161	18	preserved	preserve	VERB
chd-169	161	19	despite	despite	SCONJ
chd-169	161	20	cellular	cellular	ADJ
chd-169	161	21	upregulation	upregulation	NOUN
chd-169	161	22	of	of	ADP
chd-169	161	23	11βhsd2	11βhsd2	NUM
chd-169	161	24	(	(	PUNCT
chd-169	161	25	oakley	oakley	NOUN
chd-169	161	26	and	and	CCONJ
chd-169	161	27	cidlowski	cidlowski	VERB
chd-169	161	28	,	,	PUNCT
chd-169	161	29	2013	2013	NUM
chd-169	161	30	)	)	PUNCT
chd-169	161	31	.	.	PUNCT
chd-169	162	1	as	as	SCONJ
chd-169	162	2	grα	grα	PROPN
chd-169	162	3	is	be	AUX
chd-169	162	4	the	the	DET
chd-169	162	5	biologically	biologically	ADV
chd-169	162	6	relevant	relevant	ADJ
chd-169	162	7	isoform	isoform	NOUN
chd-169	162	8	,	,	PUNCT
chd-169	162	9	all	all	DET
chd-169	162	10	references	reference	NOUN
chd-169	162	11	henceforth	henceforth	ADV
chd-169	162	12	to	to	ADP
chd-169	162	13	gr	gr	PROPN
chd-169	162	14	will	will	AUX
chd-169	162	15	imply	imply	VERB
chd-169	162	16	grα	grα	PROPN
chd-169	162	17	(	(	PUNCT
chd-169	162	18	matagreenwood	matagreenwood	NOUN
chd-169	162	19	et	et	PROPN
chd-169	162	20	al	al	PROPN
chd-169	162	21	.	.	PROPN
chd-169	162	22	,	,	PUNCT
chd-169	162	23	2015	2015	NUM
chd-169	162	24	)	)	PUNCT
chd-169	162	25	.	.	PUNCT
chd-169	163	1	gr	gr	PROPN
chd-169	163	2	encompasses	encompass	VERB
chd-169	163	3	three	three	NUM
chd-169	163	4	functional	functional	ADJ
chd-169	163	5	domains	domain	NOUN
chd-169	163	6	including	include	VERB
chd-169	163	7	an	an	DET
chd-169	163	8	amino	amino	NOUN
chd-169	163	9	-	-	PUNCT
chd-169	163	10	terminal	terminal	ADJ
chd-169	163	11	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-169	163	12	e11	e11	ADJ
chd-169	163	13	cancer	cancer	NOUN
chd-169	163	14	health	health	NOUN
chd-169	163	15	disparities	disparity	NOUN
chd-169	163	16	research	research	NOUN
chd-169	163	17	transactivation	transactivation	NOUN
chd-169	163	18	domain	domain	NOUN
chd-169	163	19	,	,	PUNCT
chd-169	163	20	a	a	DET
chd-169	163	21	central	central	ADJ
chd-169	163	22	dna	dna	NOUN
chd-169	163	23	-	-	PUNCT
chd-169	163	24	binding	bind	VERB
chd-169	163	25	domain	domain	NOUN
chd-169	163	26	,	,	PUNCT
chd-169	163	27	and	and	CCONJ
chd-169	163	28	a	a	DET
chd-169	163	29	carboxy	carboxy	ADJ
chd-169	163	30	-	-	PUNCT
chd-169	163	31	terminal	terminal	ADJ
chd-169	163	32	ligand	ligand	NOUN
chd-169	163	33	-	-	PUNCT
chd-169	163	34	binding	bind	VERB
chd-169	163	35	domain	domain	NOUN
chd-169	163	36	(	(	PUNCT
chd-169	163	37	joseph	joseph	PROPN
chd-169	163	38	and	and	CCONJ
chd-169	163	39	whirledge	whirledge	VERB
chd-169	163	40	,	,	PUNCT
chd-169	163	41	2017	2017	NUM
chd-169	163	42	)	)	PUNCT
chd-169	163	43	.	.	PUNCT
chd-169	164	1	there	there	PRON
chd-169	164	2	is	be	VERB
chd-169	164	3	a	a	DET
chd-169	164	4	flexible	flexible	ADJ
chd-169	164	5	hinge	hinge	NOUN
chd-169	164	6	region	region	NOUN
chd-169	164	7	that	that	PRON
chd-169	164	8	contains	contain	VERB
chd-169	164	9	a	a	DET
chd-169	164	10	nuclear	nuclear	ADJ
chd-169	164	11	localization	localization	NOUN
chd-169	164	12	signal	signal	NOUN
chd-169	164	13	between	between	ADP
chd-169	164	14	the	the	DET
chd-169	164	15	dna	dna	NOUN
chd-169	164	16	-	-	PUNCT
chd-169	164	17	binding	bind	VERB
chd-169	164	18	domain	domain	NOUN
chd-169	164	19	and	and	CCONJ
chd-169	164	20	the	the	DET
chd-169	164	21	ligand	ligand	NOUN
chd-169	164	22	-	-	PUNCT
chd-169	164	23	binding	bind	VERB
chd-169	164	24	domain	domain	NOUN
chd-169	164	25	(	(	PUNCT
chd-169	164	26	fig	fig	NOUN
chd-169	164	27	.	.	PUNCT
chd-169	164	28	3	3	NUM
chd-169	164	29	)	)	PUNCT
chd-169	164	30	.	.	PUNCT
chd-169	165	1	it	it	PRON
chd-169	165	2	is	be	AUX
chd-169	165	3	within	within	ADP
chd-169	165	4	this	this	DET
chd-169	165	5	flexible	flexible	ADJ
chd-169	165	6	hinge	hinge	NOUN
chd-169	165	7	region	region	NOUN
chd-169	165	8	that	that	SCONJ
chd-169	165	9	genomic	genomic	ADJ
chd-169	165	10	interactions	interaction	NOUN
chd-169	165	11	occur	occur	VERB
chd-169	165	12	(	(	PUNCT
chd-169	165	13	joseph	joseph	PROPN
chd-169	165	14	and	and	CCONJ
chd-169	165	15	whirledge	whirledge	VERB
chd-169	165	16	,	,	PUNCT
chd-169	165	17	2017	2017	NUM
chd-169	165	18	)	)	PUNCT
chd-169	165	19	.	.	PUNCT
chd-169	166	1	in	in	ADP
chd-169	166	2	the	the	DET
chd-169	166	3	nucleus	nucleus	NOUN
chd-169	166	4	,	,	PUNCT
chd-169	166	5	gr	gr	PROPN
chd-169	166	6	homodimers	homodimer	NOUN
chd-169	166	7	bind	bind	VERB
chd-169	166	8	to	to	ADP
chd-169	166	9	gr	gr	NUM
chd-169	166	10	response	response	NOUN
chd-169	166	11	elements	element	NOUN
chd-169	166	12	(	(	PUNCT
chd-169	166	13	gre	gre	PROPN
chd-169	166	14	)	)	PUNCT
chd-169	166	15	within	within	ADP
chd-169	166	16	promoter	promoter	NOUN
chd-169	166	17	regions	region	NOUN
chd-169	166	18	of	of	ADP
chd-169	166	19	target	target	NOUN
chd-169	166	20	genes	gene	NOUN
chd-169	166	21	(	(	PUNCT
chd-169	166	22	luisi	luisi	VERB
chd-169	166	23	et	et	PROPN
chd-169	166	24	al	al	PROPN
chd-169	166	25	.	.	PROPN
chd-169	166	26	,	,	PUNCT
chd-169	166	27	1991	1991	NUM
chd-169	166	28	)	)	PUNCT
chd-169	166	29	.	.	PUNCT
chd-169	167	1	the	the	DET
chd-169	167	2	consensus	consensus	NOUN
chd-169	167	3	gre	gre	PROPN
chd-169	167	4	sequences	sequence	NOUN
chd-169	167	5	are	be	AUX
chd-169	167	6	comprised	comprise	VERB
chd-169	167	7	of	of	ADP
chd-169	167	8	two	two	NUM
chd-169	167	9	hexameric	hexameric	NOUN
chd-169	167	10	halfsites	halfsite	NOUN
chd-169	167	11	separated	separate	VERB
chd-169	167	12	by	by	ADP
chd-169	167	13	a	a	DET
chd-169	167	14	spacer	spacer	NOUN
chd-169	167	15	of	of	ADP
chd-169	167	16	three	three	NUM
chd-169	167	17	nucleotides	nucleotide	NOUN
chd-169	167	18	(	(	PUNCT
chd-169	167	19	e.g.	e.g.	ADV
chd-169	167	20	,	,	PUNCT
chd-169	167	21	agaacannntgttct	agaacannntgttct	NOUN
chd-169	167	22	)	)	PUNCT
chd-169	167	23	(	(	PUNCT
chd-169	167	24	strahle	strahle	NOUN
chd-169	167	25	et	et	PROPN
chd-169	167	26	al	al	PROPN
chd-169	167	27	.	.	PROPN
chd-169	167	28	,	,	PUNCT
chd-169	167	29	1987	1987	NUM
chd-169	167	30	)	)	PUNCT
chd-169	167	31	.	.	PUNCT
chd-169	168	1	once	once	SCONJ
chd-169	168	2	gr	gr	X
chd-169	168	3	homodimers	homodimer	NOUN
chd-169	168	4	bind	bind	VERB
chd-169	168	5	to	to	ADP
chd-169	168	6	gres	gre	NOUN
chd-169	168	7	,	,	PUNCT
chd-169	168	8	chromatin	chromatin	NOUN
chd-169	168	9	is	be	AUX
chd-169	168	10	remodeled	remodel	VERB
chd-169	168	11	,	,	PUNCT
chd-169	168	12	co	co	NOUN
chd-169	168	13	-	-	NOUN
chd-169	168	14	regulators	regulator	NOUN
chd-169	168	15	are	be	AUX
chd-169	168	16	recruited	recruit	VERB
chd-169	168	17	,	,	PUNCT
chd-169	168	18	and	and	CCONJ
chd-169	168	19	grinduced	grinduce	VERB
chd-169	168	20	transcription	transcription	NOUN
chd-169	168	21	is	be	AUX
chd-169	168	22	initiated	initiate	VERB
chd-169	168	23	(	(	PUNCT
chd-169	168	24	joseph	joseph	NOUN
chd-169	168	25	and	and	CCONJ
chd-169	168	26	whirledge	whirledge	VERB
chd-169	168	27	,	,	PUNCT
chd-169	168	28	2017	2017	NUM
chd-169	168	29	)	)	PUNCT
chd-169	168	30	.	.	PUNCT
chd-169	169	1	in	in	ADP
chd-169	169	2	addition	addition	NOUN
chd-169	169	3	to	to	ADP
chd-169	169	4	activation	activation	NOUN
chd-169	169	5	of	of	ADP
chd-169	169	6	grtarget	grtarget	NOUN
chd-169	169	7	genes	gene	NOUN
chd-169	169	8	,	,	PUNCT
chd-169	169	9	gr	gr	PROPN
chd-169	169	10	may	may	AUX
chd-169	169	11	also	also	ADV
chd-169	169	12	negatively	negatively	ADV
chd-169	169	13	repress	repress	VERB
chd-169	169	14	genes	gene	NOUN
chd-169	169	15	(	(	PUNCT
chd-169	169	16	surjit	surjit	NOUN
chd-169	169	17	et	et	PROPN
chd-169	169	18	al	al	PROPN
chd-169	169	19	.	.	PROPN
chd-169	169	20	,	,	PUNCT
chd-169	169	21	2011	2011	NUM
chd-169	169	22	)	)	PUNCT
chd-169	169	23	.	.	PUNCT
chd-169	170	1	this	this	PRON
chd-169	170	2	occurs	occur	VERB
chd-169	170	3	when	when	SCONJ
chd-169	170	4	gr	gr	NOUN
chd-169	170	5	binds	bind	VERB
chd-169	170	6	to	to	ADP
chd-169	170	7	gres	gre	NOUN
chd-169	170	8	with	with	ADP
chd-169	170	9	consensus	consensus	NOUN
chd-169	170	10	sequence	sequence	NOUN
chd-169	170	11	ctcc(n)02ggaga	ctcc(n)02ggaga	NOUN
chd-169	170	12	and	and	CCONJ
chd-169	170	13	co	co	NOUN
chd-169	170	14	-	-	NOUN
chd-169	170	15	repressors	repressor	NOUN
chd-169	170	16	are	be	AUX
chd-169	170	17	recruited	recruit	VERB
chd-169	170	18	(	(	PUNCT
chd-169	170	19	surjit	surjit	PROPN
chd-169	170	20	et	et	PROPN
chd-169	170	21	al	al	PROPN
chd-169	170	22	.	.	PROPN
chd-169	170	23	,	,	PUNCT
chd-169	170	24	2011	2011	NUM
chd-169	170	25	)	)	PUNCT
chd-169	170	26	.	.	PUNCT
chd-169	171	1	gr	gr	NOUN
chd-169	171	2	also	also	ADV
chd-169	171	3	mediates	mediate	VERB
chd-169	171	4	gene	gene	NOUN
chd-169	171	5	transcription	transcription	NOUN
chd-169	171	6	via	via	ADP
chd-169	171	7	interactions	interaction	NOUN
chd-169	171	8	with	with	ADP
chd-169	171	9	other	other	ADJ
chd-169	171	10	transcription	transcription	NOUN
chd-169	171	11	factors	factor	NOUN
chd-169	171	12	(	(	PUNCT
chd-169	171	13	joseph	joseph	PROPN
chd-169	171	14	and	and	CCONJ
chd-169	171	15	whirledge	whirledge	VERB
chd-169	171	16	,	,	PUNCT
chd-169	171	17	2017	2017	NUM
chd-169	171	18	)	)	PUNCT
chd-169	171	19	.	.	PUNCT
chd-169	172	1	fig	fig	NOUN
chd-169	172	2	.	.	PUNCT
chd-169	173	1	3	3	NUM
chd-169	173	2	nr3c1	nr3c1	X
chd-169	173	3	(	(	PUNCT
chd-169	173	4	gr	gr	NOUN
chd-169	173	5	)	)	PUNCT
chd-169	173	6	domain	domain	NOUN
chd-169	173	7	structure	structure	NOUN
chd-169	173	8	.	.	PUNCT
chd-169	174	1	the	the	DET
chd-169	174	2	domain	domain	NOUN
chd-169	174	3	structure	structure	NOUN
chd-169	174	4	of	of	ADP
chd-169	174	5	grα	grα	PROPN
chd-169	174	6	is	be	AUX
chd-169	174	7	composed	compose	VERB
chd-169	174	8	of	of	ADP
chd-169	174	9	an	an	DET
chd-169	174	10	n	n	CCONJ
chd-169	174	11	-	-	PUNCT
chd-169	174	12	terminal	terminal	ADJ
chd-169	174	13	modulatory	modulatory	NOUN
chd-169	174	14	domain	domain	NOUN
chd-169	174	15	,	,	PUNCT
chd-169	174	16	a	a	DET
chd-169	174	17	dna	dna	NOUN
chd-169	174	18	-	-	PUNCT
chd-169	174	19	binding	bind	VERB
chd-169	174	20	domain	domain	NOUN
chd-169	174	21	,	,	PUNCT
chd-169	174	22	a	a	DET
chd-169	174	23	hinge	hinge	NOUN
chd-169	174	24	region	region	NOUN
chd-169	174	25	,	,	PUNCT
chd-169	174	26	a	a	DET
chd-169	174	27	ligand	ligand	NOUN
chd-169	174	28	-	-	PUNCT
chd-169	174	29	binding	bind	VERB
chd-169	174	30	domain	domain	NOUN
chd-169	174	31	,	,	PUNCT
chd-169	174	32	and	and	CCONJ
chd-169	174	33	a	a	DET
chd-169	174	34	c	c	NOUN
chd-169	174	35	-	-	PUNCT
chd-169	174	36	terminal	terminal	ADJ
chd-169	174	37	ligand	ligand	ADJ
chd-169	174	38	binding	bind	VERB
chd-169	174	39	domain	domain	NOUN
chd-169	174	40	.	.	PUNCT
chd-169	175	1	regions	region	NOUN
chd-169	175	2	involved	involve	VERB
chd-169	175	3	in	in	ADP
chd-169	175	4	transcriptional	transcriptional	ADJ
chd-169	175	5	activation	activation	NOUN
chd-169	175	6	,	,	PUNCT
chd-169	175	7	dimerization	dimerization	NOUN
chd-169	175	8	,	,	PUNCT
chd-169	175	9	glucocorticoid	glucocorticoid	ADJ
chd-169	175	10	binding	binding	NOUN
chd-169	175	11	,	,	PUNCT
chd-169	175	12	and	and	CCONJ
chd-169	175	13	dna	dna	PROPN
chd-169	175	14	binding	binding	NOUN
chd-169	175	15	are	be	AUX
chd-169	175	16	indicated	indicate	VERB
chd-169	175	17	.	.	PUNCT
chd-169	176	1	the	the	DET
chd-169	176	2	nuclear	nuclear	ADJ
chd-169	176	3	localization	localization	NOUN
chd-169	176	4	signal	signal	NOUN
chd-169	176	5	is	be	AUX
chd-169	176	6	located	locate	VERB
chd-169	176	7	within	within	ADP
chd-169	176	8	the	the	DET
chd-169	176	9	flexible	flexible	ADJ
chd-169	176	10	hinge	hinge	NOUN
chd-169	176	11	region	region	NOUN
chd-169	176	12	.	.	PUNCT
chd-169	177	1	for	for	ADP
chd-169	177	2	comparison	comparison	NOUN
chd-169	177	3	,	,	PUNCT
chd-169	177	4	the	the	DET
chd-169	177	5	domain	domain	NOUN
chd-169	177	6	structures	structure	NOUN
chd-169	177	7	of	of	ADP
chd-169	177	8	grβ	grβ	NOUN
chd-169	177	9	and	and	CCONJ
chd-169	177	10	ar	ar	PROPN
chd-169	177	11	and	and	CCONJ
chd-169	177	12	its	its	PRON
chd-169	177	13	splice	splice	NOUN
chd-169	177	14	variant	variant	NOUN
chd-169	177	15	ar	ar	NOUN
chd-169	177	16	-	-	PUNCT
chd-169	177	17	v7	v7	NOUN
chd-169	177	18	are	be	AUX
chd-169	177	19	included	include	VERB
chd-169	177	20	.	.	PUNCT
chd-169	178	1	note	note	VERB
chd-169	178	2	the	the	DET
chd-169	178	3	structural	structural	ADJ
chd-169	178	4	similarities	similarity	NOUN
chd-169	178	5	between	between	ADP
chd-169	178	6	these	these	DET
chd-169	178	7	transcription	transcription	NOUN
chd-169	178	8	factors	factor	NOUN
chd-169	178	9	.	.	PUNCT
chd-169	179	1	ar	ar	NOUN
chd-169	179	2	,	,	PUNCT
chd-169	179	3	androgen	androgen	NOUN
chd-169	179	4	receptor	receptor	NOUN
chd-169	179	5	,	,	PUNCT
chd-169	179	6	are	be	AUX
chd-169	179	7	,	,	PUNCT
chd-169	179	8	androgen	androgen	NOUN
chd-169	179	9	response	response	NOUN
chd-169	179	10	element	element	NOUN
chd-169	179	11	;	;	PUNCT
chd-169	179	12	ce3	ce3	PROPN
chd-169	179	13	,	,	PUNCT
chd-169	179	14	cryptic	cryptic	ADJ
chd-169	179	15	exon	exon	NOUN
chd-169	179	16	3	3	NUM
chd-169	179	17	;	;	PUNCT
chd-169	179	18	dbd	dbd	PROPN
chd-169	179	19	,	,	PUNCT
chd-169	179	20	dna	dna	NOUN
chd-169	179	21	-	-	PUNCT
chd-169	179	22	binding	bind	VERB
chd-169	179	23	domain	domain	NOUN
chd-169	179	24	;	;	PUNCT
chd-169	179	25	dna	dna	PROPN
chd-169	179	26	,	,	PUNCT
chd-169	179	27	deoxyribonucleic	deoxyribonucleic	ADJ
chd-169	179	28	acid	acid	NOUN
chd-169	179	29	;	;	PUNCT
chd-169	179	30	gr	gr	NUM
chd-169	179	31	,	,	PUNCT
chd-169	179	32	glucocorticoid	glucocorticoid	ADJ
chd-169	179	33	receptor	receptor	NOUN
chd-169	179	34	;	;	PUNCT
chd-169	179	35	gre	gre	NOUN
chd-169	179	36	,	,	PUNCT
chd-169	179	37	glucocorticoid	glucocorticoid	ADJ
chd-169	179	38	response	response	NOUN
chd-169	179	39	element	element	NOUN
chd-169	179	40	;	;	PUNCT
chd-169	179	41	lbd	lbd	PROPN
chd-169	179	42	,	,	PUNCT
chd-169	179	43	ligand	ligand	NOUN
chd-169	179	44	-	-	PUNCT
chd-169	179	45	binding	bind	VERB
chd-169	179	46	domain	domain	NOUN
chd-169	179	47	;	;	PUNCT
chd-169	179	48	ntd	ntd	PROPN
chd-169	179	49	,	,	PUNCT
chd-169	179	50	n	n	CCONJ
chd-169	179	51	-	-	PUNCT
chd-169	179	52	terminal	terminal	ADJ
chd-169	179	53	domain	domain	NOUN
chd-169	179	54	.	.	PUNCT
chd-169	180	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	180	2	e12	e12	NOUN
chd-169	180	3	cancer	cancer	NOUN
chd-169	180	4	health	health	NOUN
chd-169	180	5	disparities	disparity	NOUN
chd-169	180	6	research	research	VERB
chd-169	180	7	gr	gr	NOUN
chd-169	180	8	signaling	signal	VERB
chd-169	180	9	in	in	ADP
chd-169	180	10	aas	aas	PROPN
chd-169	180	11	.	.	PUNCT
chd-169	181	1	gr	gr	NOUN
chd-169	181	2	signaling	signal	VERB
chd-169	181	3	is	be	AUX
chd-169	181	4	triggered	trigger	VERB
chd-169	181	5	by	by	ADP
chd-169	181	6	a	a	DET
chd-169	181	7	variety	variety	NOUN
chd-169	181	8	of	of	ADP
chd-169	181	9	physiological	physiological	ADJ
chd-169	181	10	and	and	CCONJ
chd-169	181	11	environmental	environmental	ADJ
chd-169	181	12	factors	factor	NOUN
chd-169	181	13	(	(	PUNCT
chd-169	181	14	joseph	joseph	PROPN
chd-169	181	15	and	and	CCONJ
chd-169	181	16	whirledge	whirledge	VERB
chd-169	181	17	,	,	PUNCT
chd-169	181	18	2017	2017	NUM
chd-169	181	19	)	)	PUNCT
chd-169	181	20	.	.	PUNCT
chd-169	182	1	chronic	chronic	ADJ
chd-169	182	2	stress	stress	NOUN
chd-169	182	3	resulting	result	VERB
chd-169	182	4	in	in	ADP
chd-169	182	5	sustained	sustained	ADJ
chd-169	182	6	elevated	elevated	ADJ
chd-169	182	7	glucocorticoid	glucocorticoid	ADJ
chd-169	182	8	exposure	exposure	NOUN
chd-169	182	9	throughout	throughout	ADP
chd-169	182	10	a	a	DET
chd-169	182	11	lifetime	lifetime	NOUN
chd-169	182	12	has	have	VERB
chd-169	182	13	negative	negative	ADJ
chd-169	182	14	physiological	physiological	ADJ
chd-169	182	15	consequences	consequence	NOUN
chd-169	182	16	(	(	PUNCT
chd-169	182	17	cohen	cohen	NOUN
chd-169	182	18	et	et	PROPN
chd-169	182	19	al	al	PROPN
chd-169	182	20	.	.	PROPN
chd-169	182	21	,	,	PUNCT
chd-169	182	22	2006	2006	NUM
chd-169	182	23	;	;	PUNCT
chd-169	182	24	joseph	joseph	PROPN
chd-169	182	25	and	and	CCONJ
chd-169	182	26	whirledge	whirledge	VERB
chd-169	182	27	,	,	PUNCT
chd-169	182	28	2017	2017	NUM
chd-169	182	29	;	;	PUNCT
chd-169	182	30	williams	williams	PROPN
chd-169	182	31	et	et	PROPN
chd-169	182	32	al	al	PROPN
chd-169	182	33	.	.	PROPN
chd-169	182	34	,	,	PUNCT
chd-169	182	35	2010	2010	NUM
chd-169	182	36	;	;	PUNCT
chd-169	182	37	zannas	zannas	PROPN
chd-169	182	38	et	et	PROPN
chd-169	182	39	al	al	PROPN
chd-169	182	40	.	.	PROPN
chd-169	182	41	,	,	PUNCT
chd-169	182	42	2015	2015	NUM
chd-169	182	43	)	)	PUNCT
chd-169	182	44	.	.	PUNCT
chd-169	183	1	constant	constant	ADJ
chd-169	183	2	gre	gre	PROPN
chd-169	183	3	binding	bind	VERB
chd-169	183	4	induces	induce	VERB
chd-169	183	5	local	local	ADJ
chd-169	183	6	lasting	last	VERB
chd-169	183	7	changes	change	NOUN
chd-169	183	8	in	in	ADP
chd-169	183	9	dna	dna	PROPN
chd-169	183	10	methylation	methylation	NOUN
chd-169	183	11	,	,	PUNCT
chd-169	183	12	shaping	shape	VERB
chd-169	183	13	subsequent	subsequent	ADJ
chd-169	183	14	responses	response	NOUN
chd-169	183	15	to	to	ADP
chd-169	183	16	stressors	stressor	NOUN
chd-169	183	17	and	and	CCONJ
chd-169	183	18	glucocorticoids	glucocorticoid	NOUN
chd-169	183	19	(	(	PUNCT
chd-169	183	20	klengel	klengel	PROPN
chd-169	183	21	et	et	PROPN
chd-169	183	22	al	al	PROPN
chd-169	183	23	.	.	PROPN
chd-169	183	24	,	,	PUNCT
chd-169	183	25	2013	2013	NUM
chd-169	183	26	;	;	PUNCT
chd-169	183	27	thomassin	thomassin	NOUN
chd-169	183	28	et	et	PROPN
chd-169	183	29	al	al	PROPN
chd-169	183	30	.	.	PROPN
chd-169	183	31	,	,	PUNCT
chd-169	183	32	2001	2001	NUM
chd-169	183	33	;	;	PUNCT
chd-169	183	34	wiench	wiench	NOUN
chd-169	183	35	et	et	PROPN
chd-169	183	36	al	al	PROPN
chd-169	183	37	.	.	PROPN
chd-169	183	38	,	,	PUNCT
chd-169	183	39	2011a	2011a	NUM
chd-169	183	40	;	;	PUNCT
chd-169	183	41	wiench	wiench	NOUN
chd-169	183	42	et	et	PROPN
chd-169	183	43	al	al	PROPN
chd-169	183	44	.	.	PROPN
chd-169	183	45	,	,	PUNCT
chd-169	183	46	2011b	2011b	NUM
chd-169	183	47	;	;	PUNCT
chd-169	183	48	zannas	zanna	NOUN
chd-169	183	49	and	and	CCONJ
chd-169	183	50	west	west	NOUN
chd-169	183	51	,	,	PUNCT
chd-169	183	52	2014	2014	NUM
chd-169	183	53	)	)	PUNCT
chd-169	183	54	.	.	PUNCT
chd-169	184	1	it	it	PRON
chd-169	184	2	is	be	AUX
chd-169	184	3	therefore	therefore	ADV
chd-169	184	4	plausible	plausible	ADJ
chd-169	184	5	that	that	SCONJ
chd-169	184	6	chronic	chronic	ADJ
chd-169	184	7	stress	stress	NOUN
chd-169	184	8	confers	confer	NOUN
chd-169	184	9	cumulative	cumulative	ADJ
chd-169	184	10	effects	effect	NOUN
chd-169	184	11	on	on	ADP
chd-169	184	12	dna	dna	PROPN
chd-169	184	13	methylation	methylation	NOUN
chd-169	184	14	sites	site	NOUN
chd-169	184	15	with	with	ADP
chd-169	184	16	long	long	ADJ
chd-169	184	17	-	-	PUNCT
chd-169	184	18	term	term	NOUN
chd-169	184	19	epigenetic	epigenetic	ADJ
chd-169	184	20	ramifications	ramification	NOUN
chd-169	184	21	(	(	PUNCT
chd-169	184	22	zannas	zannas	PROPN
chd-169	184	23	et	et	PROPN
chd-169	184	24	al	al	PROPN
chd-169	184	25	.	.	PROPN
chd-169	184	26	,	,	PUNCT
chd-169	184	27	2015	2015	NUM
chd-169	184	28	)	)	PUNCT
chd-169	184	29	.	.	PUNCT
chd-169	185	1	profound	profound	ADJ
chd-169	185	2	changes	change	NOUN
chd-169	185	3	in	in	ADP
chd-169	185	4	dna	dna	PROPN
chd-169	185	5	methylation	methylation	NOUN
chd-169	185	6	are	be	AUX
chd-169	185	7	associated	associate	VERB
chd-169	185	8	with	with	ADP
chd-169	185	9	aging	age	VERB
chd-169	185	10	-	-	PUNCT
chd-169	185	11	related	relate	VERB
chd-169	185	12	diseases	disease	NOUN
chd-169	185	13	(	(	PUNCT
chd-169	185	14	bjornsson	bjornsson	NOUN
chd-169	185	15	et	et	PROPN
chd-169	185	16	al	al	PROPN
chd-169	185	17	.	.	PROPN
chd-169	185	18	,	,	PUNCT
chd-169	185	19	2008	2008	NUM
chd-169	185	20	;	;	PUNCT
chd-169	185	21	christensen	christensen	PROPN
chd-169	185	22	et	et	PROPN
chd-169	185	23	al	al	PROPN
chd-169	185	24	.	.	PROPN
chd-169	185	25	,	,	PUNCT
chd-169	185	26	2009	2009	NUM
chd-169	185	27	;	;	PUNCT
chd-169	185	28	hernandez	hernandez	PROPN
chd-169	185	29	et	et	PROPN
chd-169	185	30	al	al	PROPN
chd-169	185	31	.	.	PROPN
chd-169	185	32	,	,	PUNCT
chd-169	185	33	2011	2011	NUM
chd-169	185	34	;	;	PUNCT
chd-169	185	35	heyn	heyn	NOUN
chd-169	185	36	et	et	PROPN
chd-169	185	37	al	al	PROPN
chd-169	185	38	.	.	PROPN
chd-169	185	39	,	,	PUNCT
chd-169	185	40	2012	2012	NUM
chd-169	185	41	;	;	PUNCT
chd-169	185	42	horvath	horvath	PROPN
chd-169	185	43	,	,	PUNCT
chd-169	185	44	2013	2013	NUM
chd-169	185	45	;	;	PUNCT
chd-169	185	46	horvath	horvath	PROPN
chd-169	185	47	et	et	PROPN
chd-169	185	48	al	al	PROPN
chd-169	185	49	.	.	PROPN
chd-169	185	50	,	,	PUNCT
chd-169	185	51	2012	2012	NUM
chd-169	185	52	;	;	PUNCT
chd-169	185	53	rakyan	rakyan	PROPN
chd-169	185	54	et	et	PROPN
chd-169	185	55	al	al	PROPN
chd-169	185	56	.	.	PROPN
chd-169	185	57	,	,	PUNCT
chd-169	185	58	2010	2010	NUM
chd-169	185	59	)	)	PUNCT
chd-169	185	60	.	.	PUNCT
chd-169	186	1	because	because	SCONJ
chd-169	186	2	of	of	ADP
chd-169	186	3	this	this	PRON
chd-169	186	4	,	,	PUNCT
chd-169	186	5	several	several	ADJ
chd-169	186	6	dna	dna	PROPN
chd-169	186	7	methylation	methylation	NOUN
chd-169	186	8	-	-	PUNCT
chd-169	186	9	based	base	VERB
chd-169	186	10	predictors	predictor	NOUN
chd-169	186	11	of	of	ADP
chd-169	186	12	aging	aging	NOUN
chd-169	186	13	have	have	AUX
chd-169	186	14	been	be	AUX
chd-169	186	15	recently	recently	ADV
chd-169	186	16	developed	develop	VERB
chd-169	186	17	(	(	PUNCT
chd-169	186	18	bocklandt	bocklandt	PROPN
chd-169	186	19	et	et	PROPN
chd-169	186	20	al	al	PROPN
chd-169	186	21	.	.	PROPN
chd-169	186	22	,	,	PUNCT
chd-169	186	23	2011	2011	NUM
chd-169	186	24	;	;	PUNCT
chd-169	186	25	hannum	hannum	PROPN
chd-169	186	26	et	et	PROPN
chd-169	186	27	al	al	PROPN
chd-169	186	28	.	.	PROPN
chd-169	186	29	,	,	PUNCT
chd-169	186	30	2013	2013	NUM
chd-169	186	31	;	;	PUNCT
chd-169	186	32	horvath	horvath	PROPN
chd-169	186	33	,	,	PUNCT
chd-169	186	34	2013	2013	NUM
chd-169	186	35	;	;	PUNCT
chd-169	186	36	weidner	weidner	PROPN
chd-169	186	37	et	et	PROPN
chd-169	186	38	al	al	PROPN
chd-169	186	39	.	.	PROPN
chd-169	186	40	,	,	PUNCT
chd-169	186	41	2014	2014	NUM
chd-169	186	42	)	)	PUNCT
chd-169	186	43	.	.	PUNCT
chd-169	187	1	for	for	ADP
chd-169	187	2	example	example	NOUN
chd-169	187	3	,	,	PUNCT
chd-169	187	4	a	a	DET
chd-169	187	5	composite	composite	ADJ
chd-169	187	6	predictor	predictor	NOUN
chd-169	187	7	comprised	comprise	VERB
chd-169	187	8	of	of	ADP
chd-169	187	9	353	353	NUM
chd-169	187	10	cytosine	cytosine	NOUN
chd-169	187	11	-	-	PUNCT
chd-169	187	12	phosphate	phosphate	NOUN
chd-169	187	13	-	-	PUNCT
chd-169	187	14	guanosine	guanosine	NOUN
chd-169	187	15	sites	site	NOUN
chd-169	187	16	(	(	PUNCT
chd-169	187	17	cpgs	cpgs	NOUN
chd-169	187	18	)	)	PUNCT
chd-169	187	19	across	across	ADP
chd-169	187	20	the	the	DET
chd-169	187	21	genome	genome	NOUN
chd-169	187	22	was	be	AUX
chd-169	187	23	shown	show	VERB
chd-169	187	24	to	to	PART
chd-169	187	25	strongly	strongly	ADV
chd-169	187	26	correlate	correlate	VERB
chd-169	187	27	with	with	ADP
chd-169	187	28	chronological	chronological	ADJ
chd-169	187	29	age	age	NOUN
chd-169	187	30	across	across	ADP
chd-169	187	31	multiple	multiple	ADJ
chd-169	187	32	human	human	ADJ
chd-169	187	33	tissues	tissue	NOUN
chd-169	187	34	(	(	PUNCT
chd-169	187	35	horvath	horvath	PROPN
chd-169	187	36	,	,	PUNCT
chd-169	187	37	2013	2013	NUM
chd-169	187	38	)	)	PUNCT
chd-169	187	39	.	.	PUNCT
chd-169	188	1	several	several	ADJ
chd-169	188	2	studies	study	NOUN
chd-169	188	3	have	have	AUX
chd-169	188	4	used	use	VERB
chd-169	188	5	this	this	DET
chd-169	188	6	predictor	predictor	NOUN
chd-169	188	7	to	to	PART
chd-169	188	8	calculate	calculate	VERB
chd-169	188	9	accelerated	accelerate	VERB
chd-169	188	10	epigenetic	epigenetic	ADJ
chd-169	188	11	aging	aging	NOUN
chd-169	188	12	,	,	PUNCT
chd-169	188	13	defined	define	VERB
chd-169	188	14	as	as	ADP
chd-169	188	15	the	the	DET
chd-169	188	16	difference	difference	NOUN
chd-169	188	17	between	between	ADP
chd-169	188	18	dna	dna	NOUN
chd-169	188	19	-	-	PUNCT
chd-169	188	20	methylation	methylation	NOUN
chd-169	188	21	-	-	PUNCT
chd-169	188	22	predicted	predict	VERB
chd-169	188	23	age	age	NOUN
chd-169	188	24	and	and	CCONJ
chd-169	188	25	chronological	chronological	ADJ
chd-169	188	26	age	age	NOUN
chd-169	188	27	(	(	PUNCT
chd-169	188	28	boks	bok	NOUN
chd-169	188	29	et	et	PROPN
chd-169	188	30	al	al	PROPN
chd-169	188	31	.	.	PROPN
chd-169	188	32	,	,	PUNCT
chd-169	188	33	2015	2015	NUM
chd-169	188	34	;	;	PUNCT
chd-169	188	35	horvath	horvath	PROPN
chd-169	188	36	,	,	PUNCT
chd-169	188	37	2015	2015	NUM
chd-169	188	38	;	;	PUNCT
chd-169	188	39	marioni	marioni	NOUN
chd-169	188	40	et	et	PROPN
chd-169	188	41	al	al	PROPN
chd-169	188	42	.	.	PROPN
chd-169	188	43	,	,	PUNCT
chd-169	188	44	2015a	2015a	NUM
chd-169	188	45	;	;	PUNCT
chd-169	188	46	marioni	marioni	NOUN
chd-169	188	47	et	et	PROPN
chd-169	188	48	al	al	PROPN
chd-169	188	49	.	.	PROPN
chd-169	188	50	,	,	PUNCT
chd-169	188	51	2015b	2015b	NUM
chd-169	188	52	)	)	PUNCT
chd-169	188	53	.	.	PUNCT
chd-169	189	1	this	this	PRON
chd-169	189	2	accelerated	accelerate	VERB
chd-169	189	3	epigenetic	epigenetic	ADJ
chd-169	189	4	aging	aging	NOUN
chd-169	189	5	has	have	AUX
chd-169	189	6	been	be	AUX
chd-169	189	7	associated	associate	VERB
chd-169	189	8	with	with	ADP
chd-169	189	9	cancer	cancer	NOUN
chd-169	189	10	,	,	PUNCT
chd-169	189	11	obesity	obesity	NOUN
chd-169	189	12	,	,	PUNCT
chd-169	189	13	ptsd	ptsd	NOUN
chd-169	189	14	,	,	PUNCT
chd-169	189	15	physical	physical	ADJ
chd-169	189	16	and	and	CCONJ
chd-169	189	17	cognitive	cognitive	ADJ
chd-169	189	18	decline	decline	NOUN
chd-169	189	19	,	,	PUNCT
chd-169	189	20	all	all	DET
chd-169	189	21	-	-	PUNCT
chd-169	189	22	cause	cause	NOUN
chd-169	189	23	mortality	mortality	NOUN
chd-169	189	24	,	,	PUNCT
chd-169	189	25	lower	low	ADJ
chd-169	189	26	ses	se	NOUN
chd-169	189	27	,	,	PUNCT
chd-169	189	28	and	and	CCONJ
chd-169	189	29	cumulative	cumulative	ADJ
chd-169	189	30	lifetime	lifetime	NOUN
chd-169	189	31	stress	stress	NOUN
chd-169	189	32	(	(	PUNCT
chd-169	189	33	boks	bok	NOUN
chd-169	189	34	et	et	PROPN
chd-169	189	35	al	al	PROPN
chd-169	189	36	.	.	PROPN
chd-169	189	37	,	,	PUNCT
chd-169	189	38	2015	2015	NUM
chd-169	189	39	;	;	PUNCT
chd-169	189	40	horvath	horvath	PROPN
chd-169	189	41	,	,	PUNCT
chd-169	189	42	2013	2013	NUM
chd-169	189	43	;	;	PUNCT
chd-169	189	44	marioni	marioni	NOUN
chd-169	189	45	et	et	PROPN
chd-169	189	46	al	al	PROPN
chd-169	189	47	.	.	PROPN
chd-169	189	48	,	,	PUNCT
chd-169	189	49	2015a	2015a	NUM
chd-169	189	50	;	;	PUNCT
chd-169	189	51	zannas	zannas	PROPN
chd-169	189	52	et	et	PROPN
chd-169	189	53	al	al	PROPN
chd-169	189	54	.	.	PROPN
chd-169	189	55	,	,	PUNCT
chd-169	189	56	2015	2015	NUM
chd-169	189	57	)	)	PUNCT
chd-169	189	58	.	.	PUNCT
chd-169	190	1	cumulative	cumulative	ADJ
chd-169	190	2	lifetime	lifetime	NOUN
chd-169	190	3	stress	stress	NOUN
chd-169	190	4	has	have	AUX
chd-169	190	5	been	be	AUX
chd-169	190	6	associated	associate	VERB
chd-169	190	7	with	with	ADP
chd-169	190	8	accelerated	accelerate	VERB
chd-169	190	9	epigenetic	epigenetic	ADJ
chd-169	190	10	aging	aging	NOUN
chd-169	190	11	in	in	ADP
chd-169	190	12	aas	aas	PROPN
chd-169	190	13	(	(	PUNCT
chd-169	190	14	zannas	zannas	PROPN
chd-169	190	15	et	et	PROPN
chd-169	190	16	al	al	PROPN
chd-169	190	17	.	.	PROPN
chd-169	190	18	,	,	PUNCT
chd-169	190	19	2015	2015	NUM
chd-169	190	20	)	)	PUNCT
chd-169	190	21	.	.	PUNCT
chd-169	191	1	this	this	PRON
chd-169	191	2	is	be	AUX
chd-169	191	3	attributed	attribute	VERB
chd-169	191	4	to	to	PART
chd-169	191	5	altered	alter	VERB
chd-169	191	6	gr	gr	NOUN
chd-169	191	7	signaling	signal	VERB
chd-169	191	8	marked	mark	VERB
chd-169	191	9	by	by	ADP
chd-169	191	10	an	an	DET
chd-169	191	11	increased	increase	VERB
chd-169	191	12	number	number	NOUN
chd-169	191	13	of	of	ADP
chd-169	191	14	epigenetic	epigenetic	ADJ
chd-169	191	15	clock	clock	NOUN
chd-169	191	16	cpgs	cpgs	NOUN
chd-169	191	17	located	locate	VERB
chd-169	191	18	within	within	ADP
chd-169	191	19	functional	functional	ADJ
chd-169	191	20	gres	gre	NOUN
chd-169	191	21	,	,	PUNCT
chd-169	191	22	dynamic	dynamic	ADJ
chd-169	191	23	methylation	methylation	NOUN
chd-169	191	24	changes	change	NOUN
chd-169	191	25	following	follow	VERB
chd-169	191	26	exposure	exposure	NOUN
chd-169	191	27	to	to	ADP
chd-169	191	28	dexamethasone	dexamethasone	NOUN
chd-169	191	29	,	,	PUNCT
chd-169	191	30	and	and	CCONJ
chd-169	191	31	dynamic	dynamic	ADJ
chd-169	191	32	regulation	regulation	NOUN
chd-169	191	33	by	by	ADP
chd-169	191	34	genes	gene	NOUN
chd-169	191	35	with	with	ADP
chd-169	191	36	enriched	enriched	ADJ
chd-169	191	37	association	association	NOUN
chd-169	191	38	for	for	ADP
chd-169	191	39	aging	age	VERB
chd-169	191	40	-	-	PUNCT
chd-169	191	41	related	relate	VERB
chd-169	191	42	diseases	disease	NOUN
chd-169	191	43	which	which	PRON
chd-169	191	44	neighbored	neighbor	VERB
chd-169	191	45	these	these	DET
chd-169	191	46	cpgs	cpgs	NOUN
chd-169	191	47	(	(	PUNCT
chd-169	191	48	zannas	zannas	PROPN
chd-169	191	49	et	et	PROPN
chd-169	191	50	al	al	PROPN
chd-169	191	51	.	.	PROPN
chd-169	191	52	,	,	PUNCT
chd-169	191	53	2015	2015	NUM
chd-169	191	54	)	)	PUNCT
chd-169	191	55	.	.	PUNCT
chd-169	192	1	these	these	DET
chd-169	192	2	results	result	NOUN
chd-169	192	3	support	support	VERB
chd-169	192	4	a	a	DET
chd-169	192	5	model	model	NOUN
chd-169	192	6	of	of	ADP
chd-169	192	7	stressinduced	stressinduce	VERB
chd-169	192	8	accelerated	accelerate	VERB
chd-169	192	9	epigenetic	epigenetic	ADJ
chd-169	192	10	aging	aging	NOUN
chd-169	192	11	mediated	mediate	VERB
chd-169	192	12	by	by	ADP
chd-169	192	13	the	the	DET
chd-169	192	14	lasting	last	VERB
chd-169	192	15	effects	effect	NOUN
chd-169	192	16	of	of	ADP
chd-169	192	17	chronic	chronic	ADJ
chd-169	192	18	stressor	stressor	NOUN
chd-169	192	19	exposure	exposure	NOUN
chd-169	192	20	and	and	CCONJ
chd-169	192	21	aberrant	aberrant	ADJ
chd-169	192	22	glucocorticoid	glucocorticoid	NOUN
chd-169	192	23	signaling	signal	VERB
chd-169	192	24	on	on	ADP
chd-169	192	25	the	the	DET
chd-169	192	26	epigenome	epigenome	NOUN
chd-169	192	27	(	(	PUNCT
chd-169	192	28	zannas	zannas	PROPN
chd-169	192	29	et	et	PROPN
chd-169	192	30	al	al	PROPN
chd-169	192	31	.	.	PROPN
chd-169	192	32	,	,	PUNCT
chd-169	192	33	2015	2015	NUM
chd-169	192	34	)	)	PUNCT
chd-169	192	35	.	.	PUNCT
chd-169	193	1	aas	aas	PROPN
chd-169	193	2	also	also	ADV
chd-169	193	3	appear	appear	VERB
chd-169	193	4	to	to	PART
chd-169	193	5	have	have	AUX
chd-169	193	6	amplified	amplify	VERB
chd-169	193	7	gr	gr	NOUN
chd-169	193	8	signaling	signal	VERB
chd-169	193	9	and	and	CCONJ
chd-169	193	10	increased	increase	VERB
chd-169	193	11	glucocorticoid	glucocorticoid	ADJ
chd-169	193	12	resistance	resistance	NOUN
chd-169	193	13	(	(	PUNCT
chd-169	193	14	frazier	frazier	PROPN
chd-169	193	15	et	et	PROPN
chd-169	193	16	al	al	PROPN
chd-169	193	17	.	.	PROPN
chd-169	193	18	,	,	PUNCT
chd-169	193	19	2010	2010	NUM
chd-169	193	20	)	)	PUNCT
chd-169	193	21	.	.	PUNCT
chd-169	194	1	this	this	PRON
chd-169	194	2	was	be	AUX
chd-169	194	3	reported	report	VERB
chd-169	194	4	in	in	ADP
chd-169	194	5	a	a	DET
chd-169	194	6	study	study	NOUN
chd-169	194	7	that	that	PRON
chd-169	194	8	explored	explore	VERB
chd-169	194	9	the	the	DET
chd-169	194	10	role	role	NOUN
chd-169	194	11	of	of	ADP
chd-169	194	12	body	body	NOUN
chd-169	194	13	weight	weight	NOUN
chd-169	194	14	and	and	CCONJ
chd-169	194	15	body	body	NOUN
chd-169	194	16	composition	composition	NOUN
chd-169	194	17	in	in	ADP
chd-169	194	18	insulin	insulin	NOUN
chd-169	194	19	resistance	resistance	NOUN
chd-169	194	20	among	among	ADP
chd-169	194	21	participants	participant	NOUN
chd-169	194	22	who	who	PRON
chd-169	194	23	were	be	AUX
chd-169	194	24	treated	treat	VERB
chd-169	194	25	with	with	ADP
chd-169	194	26	placebo	placebo	NOUN
chd-169	194	27	or	or	CCONJ
chd-169	194	28	4	4	NUM
chd-169	194	29	mg	mg	NOUN
chd-169	194	30	dexamethasone	dexamethasone	NOUN
chd-169	194	31	(	(	PUNCT
chd-169	194	32	frazier	frazier	PROPN
chd-169	194	33	et	et	PROPN
chd-169	194	34	al	al	PROPN
chd-169	194	35	.	.	PROPN
chd-169	194	36	,	,	PUNCT
chd-169	194	37	2010	2010	NUM
chd-169	194	38	)	)	PUNCT
chd-169	194	39	.	.	PUNCT
chd-169	195	1	results	result	NOUN
chd-169	195	2	revealed	reveal	VERB
chd-169	195	3	that	that	SCONJ
chd-169	195	4	aas	aas	PROPN
chd-169	195	5	were	be	AUX
chd-169	195	6	significantly	significantly	ADV
chd-169	195	7	more	more	ADV
chd-169	195	8	hyperinsulinemic	hyperinsulinemic	ADJ
chd-169	195	9	after	after	ADP
chd-169	195	10	dexamethasone	dexamethasone	NOUN
chd-169	195	11	treatment	treatment	NOUN
chd-169	195	12	than	than	ADP
chd-169	195	13	eas	ea	NOUN
chd-169	195	14	,	,	PUNCT
chd-169	195	15	indicated	indicate	VERB
chd-169	195	16	by	by	ADP
chd-169	195	17	higher	high	ADJ
chd-169	195	18	peak	peak	NOUN
chd-169	195	19	insulin	insulin	NOUN
chd-169	195	20	and	and	CCONJ
chd-169	195	21	postprandial	postprandial	ADJ
chd-169	195	22	insulin	insulin	NOUN
chd-169	195	23	(	(	PUNCT
chd-169	195	24	frazier	frazier	PROPN
chd-169	195	25	et	et	PROPN
chd-169	195	26	al	al	PROPN
chd-169	195	27	.	.	PROPN
chd-169	195	28	,	,	PUNCT
chd-169	195	29	2010	2010	NUM
chd-169	195	30	)	)	PUNCT
chd-169	195	31	.	.	PUNCT
chd-169	196	1	aas	aas	PROPN
chd-169	196	2	were	be	AUX
chd-169	196	3	also	also	ADV
chd-169	196	4	found	find	VERB
chd-169	196	5	to	to	PART
chd-169	196	6	be	be	AUX
chd-169	196	7	more	more	ADV
chd-169	196	8	insulin	insulin	NOUN
chd-169	196	9	resistant	resistant	ADJ
chd-169	196	10	as	as	SCONJ
chd-169	196	11	determined	determine	VERB
chd-169	196	12	by	by	ADP
chd-169	196	13	fasting	fast	VERB
chd-169	196	14	insulin	insulin	NOUN
chd-169	196	15	and	and	CCONJ
chd-169	196	16	homeostatic	homeostatic	ADJ
chd-169	196	17	model	model	NOUN
chd-169	196	18	assessment	assessment	NOUN
chd-169	196	19	(	(	PUNCT
chd-169	196	20	frazier	frazier	PROPN
chd-169	196	21	et	et	PROPN
chd-169	196	22	al	al	PROPN
chd-169	196	23	.	.	PROPN
chd-169	196	24	,	,	PUNCT
chd-169	196	25	2010	2010	NUM
chd-169	196	26	)	)	PUNCT
chd-169	196	27	.	.	PUNCT
chd-169	197	1	this	this	DET
chd-169	197	2	hyperinsulinemia	hyperinsulinemia	NOUN
chd-169	197	3	and	and	CCONJ
chd-169	197	4	increased	increase	VERB
chd-169	197	5	insulin	insulin	NOUN
chd-169	197	6	resistance	resistance	NOUN
chd-169	197	7	in	in	ADP
chd-169	197	8	aas	aas	PROPN
chd-169	197	9	was	be	AUX
chd-169	197	10	independent	independent	ADJ
chd-169	197	11	of	of	ADP
chd-169	197	12	body	body	NOUN
chd-169	197	13	weight	weight	NOUN
chd-169	197	14	or	or	CCONJ
chd-169	197	15	composition	composition	NOUN
chd-169	197	16	(	(	PUNCT
chd-169	197	17	body	body	NOUN
chd-169	197	18	mass	mass	PROPN
chd-169	197	19	index	index	NOUN
chd-169	197	20	,	,	PUNCT
chd-169	197	21	percent	percent	NOUN
chd-169	197	22	body	body	NOUN
chd-169	197	23	fat	fat	NOUN
chd-169	197	24	,	,	PUNCT
chd-169	197	25	waist	waist	NOUN
chd-169	197	26	circumference	circumference	NOUN
chd-169	197	27	)	)	PUNCT
chd-169	197	28	,	,	PUNCT
chd-169	197	29	suggesting	suggest	VERB
chd-169	197	30	that	that	SCONJ
chd-169	197	31	amplified	amplify	VERB
chd-169	197	32	gr	gr	NOUN
chd-169	197	33	signaling	signal	VERB
chd-169	197	34	was	be	AUX
chd-169	197	35	more	more	ADV
chd-169	197	36	prevalent	prevalent	ADJ
chd-169	197	37	in	in	ADP
chd-169	197	38	the	the	DET
chd-169	197	39	aa	aa	PROPN
chd-169	197	40	study	study	NOUN
chd-169	197	41	participants	participant	NOUN
chd-169	197	42	(	(	PUNCT
chd-169	197	43	frazier	frazier	PROPN
chd-169	197	44	et	et	PROPN
chd-169	197	45	al	al	PROPN
chd-169	197	46	.	.	PROPN
chd-169	197	47	,	,	PUNCT
chd-169	197	48	2010	2010	NUM
chd-169	197	49	)	)	PUNCT
chd-169	197	50	.	.	PUNCT
chd-169	198	1	in	in	ADP
chd-169	198	2	another	another	DET
chd-169	198	3	study	study	NOUN
chd-169	198	4	,	,	PUNCT
chd-169	198	5	aas	aas	PROPN
chd-169	198	6	showed	show	VERB
chd-169	198	7	increased	increase	VERB
chd-169	198	8	activity	activity	NOUN
chd-169	198	9	in	in	ADP
chd-169	198	10	pro	pro	ADJ
chd-169	198	11	-	-	ADJ
chd-169	198	12	inflammatory	inflammatory	ADJ
chd-169	198	13	pathways	pathway	NOUN
chd-169	198	14	and	and	CCONJ
chd-169	198	15	gr	gr	NOUN
chd-169	198	16	signaling	signal	VERB
chd-169	198	17	,	,	PUNCT
chd-169	198	18	compared	compare	VERB
chd-169	198	19	to	to	ADP
chd-169	198	20	eas	ea	NOUN
chd-169	198	21	,	,	PUNCT
chd-169	198	22	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-169	198	23	e13	e13	NOUN
chd-169	198	24	cancer	cancer	NOUN
chd-169	198	25	health	health	NOUN
chd-169	198	26	disparities	disparity	NOUN
chd-169	198	27	research	research	NOUN
chd-169	198	28	which	which	PRON
chd-169	198	29	was	be	AUX
chd-169	198	30	linked	link	VERB
chd-169	198	31	to	to	ADP
chd-169	198	32	exposure	exposure	NOUN
chd-169	198	33	to	to	ADP
chd-169	198	34	discrimination	discrimination	NOUN
chd-169	198	35	(	(	PUNCT
chd-169	198	36	thames	thame	NOUN
chd-169	198	37	et	et	NOUN
chd-169	198	38	al	al	PROPN
chd-169	198	39	.	.	PROPN
chd-169	198	40	,	,	PUNCT
chd-169	198	41	2019	2019	NUM
chd-169	198	42	)	)	PUNCT
chd-169	198	43	.	.	PUNCT
chd-169	199	1	taken	take	VERB
chd-169	199	2	together	together	ADV
chd-169	199	3	,	,	PUNCT
chd-169	199	4	the	the	DET
chd-169	199	5	studies	study	NOUN
chd-169	199	6	discussed	discuss	VERB
chd-169	199	7	above	above	ADP
chd-169	199	8	provide	provide	VERB
chd-169	199	9	support	support	NOUN
chd-169	199	10	for	for	ADP
chd-169	199	11	our	our	PRON
chd-169	199	12	model	model	NOUN
chd-169	199	13	(	(	PUNCT
chd-169	199	14	fig	fig	NOUN
chd-169	199	15	.	.	NOUN
chd-169	200	1	1	1	NUM
chd-169	200	2	)	)	PUNCT
chd-169	201	1	which	which	PRON
chd-169	201	2	links	link	VERB
chd-169	201	3	chronic	chronic	ADJ
chd-169	201	4	exposure	exposure	NOUN
chd-169	201	5	to	to	ADP
chd-169	201	6	stressors	stressor	NOUN
chd-169	201	7	(	(	PUNCT
chd-169	201	8	low	low	ADJ
chd-169	201	9	ses	se	NOUN
chd-169	201	10	,	,	PUNCT
chd-169	201	11	discrimination	discrimination	NOUN
chd-169	201	12	,	,	PUNCT
chd-169	201	13	neighborhood	neighborhood	NOUN
chd-169	201	14	effects	effect	NOUN
chd-169	201	15	,	,	PUNCT
chd-169	201	16	lesser	less	ADJ
chd-169	201	17	education	education	NOUN
chd-169	201	18	status	status	NOUN
chd-169	201	19	)	)	PUNCT
chd-169	201	20	to	to	ADP
chd-169	201	21	elevated	elevate	VERB
chd-169	201	22	cortisol	cortisol	NOUN
chd-169	201	23	and	and	CCONJ
chd-169	201	24	amplified	amplify	VERB
chd-169	201	25	gr	gr	NOUN
chd-169	201	26	signaling	signal	VERB
chd-169	202	1	.	.	PUNCT
chd-169	203	1	this	this	PRON
chd-169	203	2	amplified	amplify	VERB
chd-169	203	3	gr	gr	NOUN
chd-169	203	4	signaling	signal	VERB
chd-169	203	5	could	could	AUX
chd-169	203	6	be	be	AUX
chd-169	203	7	exacerbated	exacerbate	VERB
chd-169	203	8	during	during	ADP
chd-169	203	9	the	the	DET
chd-169	203	10	current	current	ADJ
chd-169	203	11	covid-19	covid-19	PROPN
chd-169	203	12	pandemic	pandemic	NOUN
chd-169	203	13	,	,	PUNCT
chd-169	203	14	given	give	VERB
chd-169	203	15	the	the	DET
chd-169	203	16	chronic	chronic	ADJ
chd-169	203	17	psychosocial	psychosocial	ADJ
chd-169	203	18	stress	stress	NOUN
chd-169	203	19	disproportionately	disproportionately	ADV
chd-169	203	20	affecting	affect	VERB
chd-169	203	21	minority	minority	NOUN
chd-169	203	22	populations	population	NOUN
chd-169	203	23	,	,	PUNCT
chd-169	203	24	particularly	particularly	ADV
chd-169	203	25	aas	aas	PROPN
chd-169	203	26	,	,	PUNCT
chd-169	203	27	during	during	ADP
chd-169	203	28	this	this	DET
chd-169	203	29	pandemic	pandemic	ADJ
chd-169	203	30	(	(	PUNCT
chd-169	203	31	holmes	holmes	PROPN
chd-169	203	32	et	et	PROPN
chd-169	203	33	al	al	PROPN
chd-169	203	34	.	.	PROPN
chd-169	203	35	,	,	PUNCT
chd-169	203	36	2020	2020	NUM
chd-169	203	37	)	)	PUNCT
chd-169	203	38	.	.	PUNCT
chd-169	204	1	the	the	DET
chd-169	204	2	implications	implication	NOUN
chd-169	204	3	of	of	ADP
chd-169	204	4	this	this	PRON
chd-169	204	5	increased	increase	VERB
chd-169	204	6	gr	gr	NOUN
chd-169	204	7	signaling	signal	VERB
chd-169	204	8	for	for	ADP
chd-169	204	9	pca	pca	NOUN
chd-169	204	10	progression	progression	NOUN
chd-169	204	11	and	and	CCONJ
chd-169	204	12	resistance	resistance	NOUN
chd-169	204	13	to	to	ADP
chd-169	204	14	therapy	therapy	NOUN
chd-169	204	15	is	be	AUX
chd-169	204	16	discussed	discuss	VERB
chd-169	204	17	below	below	ADV
chd-169	204	18	.	.	PUNCT
chd-169	205	1	gr	gr	NOUN
chd-169	205	2	signaling	signal	VERB
chd-169	205	3	in	in	ADP
chd-169	205	4	pca	pca	PROPN
chd-169	205	5	.	.	PUNCT
chd-169	206	1	gr	gr	PROPN
chd-169	206	2	has	have	AUX
chd-169	206	3	recently	recently	ADV
chd-169	206	4	emerged	emerge	VERB
chd-169	206	5	as	as	ADP
chd-169	206	6	a	a	DET
chd-169	206	7	major	major	ADJ
chd-169	206	8	driver	driver	NOUN
chd-169	206	9	of	of	ADP
chd-169	206	10	pca	pca	PROPN
chd-169	206	11	progression	progression	NOUN
chd-169	206	12	and	and	CCONJ
chd-169	206	13	resistance	resistance	NOUN
chd-169	206	14	to	to	ADP
chd-169	206	15	ar	ar	NOUN
chd-169	206	16	-	-	ADJ
chd-169	206	17	signaling	signal	VERB
chd-169	206	18	inhibitor	inhibitor	NOUN
chd-169	206	19	(	(	PUNCT
chd-169	206	20	arsi	arsi	ADJ
chd-169	206	21	)	)	PUNCT
chd-169	206	22	therapy	therapy	NOUN
chd-169	206	23	,	,	PUNCT
chd-169	206	24	chemotherapy	chemotherapy	NOUN
chd-169	206	25	,	,	PUNCT
chd-169	206	26	and	and	CCONJ
chd-169	206	27	radiotherapy	radiotherapy	NOUN
chd-169	206	28	(	(	PUNCT
chd-169	206	29	arora	arora	PROPN
chd-169	206	30	et	et	PROPN
chd-169	206	31	al	al	PROPN
chd-169	206	32	.	.	PROPN
chd-169	206	33	,	,	PUNCT
chd-169	206	34	2013	2013	NUM
chd-169	206	35	;	;	PUNCT
chd-169	206	36	beer	beer	NOUN
chd-169	206	37	et	et	PROPN
chd-169	206	38	al	al	PROPN
chd-169	206	39	.	.	PROPN
chd-169	206	40	,	,	PUNCT
chd-169	206	41	2017	2017	NUM
chd-169	206	42	;	;	PUNCT
chd-169	206	43	chen	chen	PROPN
chd-169	206	44	et	et	PROPN
chd-169	206	45	al	al	PROPN
chd-169	206	46	.	.	PROPN
chd-169	206	47	,	,	PUNCT
chd-169	206	48	2019	2019	NUM
chd-169	206	49	;	;	PUNCT
chd-169	206	50	claessens	claessen	VERB
chd-169	206	51	et	et	PROPN
chd-169	206	52	al	al	PROPN
chd-169	206	53	.	.	PROPN
chd-169	206	54	,	,	PUNCT
chd-169	206	55	2017	2017	NUM
chd-169	206	56	;	;	PUNCT
chd-169	206	57	kroon	kroon	PROPN
chd-169	206	58	et	et	PROPN
chd-169	206	59	al	al	PROPN
chd-169	206	60	.	.	PROPN
chd-169	206	61	,	,	PUNCT
chd-169	206	62	2016	2016	NUM
chd-169	206	63	;	;	PUNCT
chd-169	206	64	li	li	PROPN
chd-169	206	65	et	et	PROPN
chd-169	206	66	al	al	PROPN
chd-169	206	67	.	.	PROPN
chd-169	206	68	,	,	PUNCT
chd-169	206	69	2017	2017	NUM
chd-169	206	70	;	;	PUNCT
chd-169	206	71	montgomery	montgomery	PROPN
chd-169	206	72	et	et	PROPN
chd-169	206	73	al	al	PROPN
chd-169	206	74	.	.	PROPN
chd-169	206	75	,	,	PUNCT
chd-169	206	76	2014	2014	NUM
chd-169	206	77	;	;	PUNCT
chd-169	206	78	narayanan	narayanan	PROPN
chd-169	206	79	et	et	PROPN
chd-169	206	80	al	al	PROPN
chd-169	206	81	.	.	PROPN
chd-169	206	82	,	,	PUNCT
chd-169	206	83	2016	2016	NUM
chd-169	206	84	;	;	PUNCT
chd-169	206	85	puhr	puhr	NOUN
chd-169	206	86	et	et	PROPN
chd-169	206	87	al	al	PROPN
chd-169	206	88	.	.	PROPN
chd-169	206	89	,	,	PUNCT
chd-169	206	90	2018	2018	NUM
chd-169	206	91	;	;	PUNCT
chd-169	206	92	sartor	sartor	NOUN
chd-169	206	93	et	et	PROPN
chd-169	206	94	al	al	PROPN
chd-169	206	95	.	.	PROPN
chd-169	206	96	,	,	PUNCT
chd-169	206	97	2014	2014	NUM
chd-169	206	98	)	)	PUNCT
chd-169	206	99	.	.	PUNCT
chd-169	207	1	a	a	DET
chd-169	207	2	seminal	seminal	ADJ
chd-169	207	3	study	study	NOUN
chd-169	207	4	by	by	ADP
chd-169	207	5	sawyers	sawyer	NOUN
chd-169	207	6	and	and	CCONJ
chd-169	207	7	colleagues	colleague	NOUN
chd-169	207	8	identified	identify	VERB
chd-169	207	9	gr	gr	NUM
chd-169	207	10	overexpression	overexpression	NOUN
chd-169	207	11	as	as	ADP
chd-169	207	12	a	a	DET
chd-169	207	13	common	common	ADJ
chd-169	207	14	feature	feature	NOUN
chd-169	207	15	of	of	ADP
chd-169	207	16	arsiresistant	arsiresistant	ADJ
chd-169	207	17	pca	pca	NOUN
chd-169	207	18	tumors	tumor	NOUN
chd-169	207	19	using	use	VERB
chd-169	207	20	pre	pre	ADJ
chd-169	207	21	-	-	ADJ
chd-169	207	22	clinical	clinical	ADJ
chd-169	207	23	models	model	NOUN
chd-169	207	24	and	and	CCONJ
chd-169	207	25	confirmed	confirm	VERB
chd-169	207	26	in	in	ADP
chd-169	207	27	patient	patient	ADJ
chd-169	207	28	samples	sample	NOUN
chd-169	207	29	(	(	PUNCT
chd-169	207	30	arora	arora	X
chd-169	207	31	et	et	PROPN
chd-169	207	32	al	al	PROPN
chd-169	207	33	.	.	PROPN
chd-169	207	34	,	,	PUNCT
chd-169	207	35	2013	2013	NUM
chd-169	207	36	)	)	PUNCT
chd-169	207	37	.	.	PUNCT
chd-169	208	1	gr	gr	NOUN
chd-169	208	2	overexpression	overexpression	NOUN
chd-169	208	3	in	in	ADP
chd-169	208	4	arsi	arsi	ADJ
chd-169	208	5	-	-	PUNCT
chd-169	208	6	resistant	resistant	ADJ
chd-169	208	7	pca	pca	NOUN
chd-169	208	8	cells	cell	NOUN
chd-169	208	9	and	and	CCONJ
chd-169	208	10	tissues	tissue	NOUN
chd-169	208	11	have	have	AUX
chd-169	208	12	since	since	ADV
chd-169	208	13	been	be	AUX
chd-169	208	14	validated	validate	VERB
chd-169	208	15	in	in	ADP
chd-169	208	16	cellular	cellular	ADJ
chd-169	208	17	models	model	NOUN
chd-169	208	18	of	of	ADP
chd-169	208	19	resistance	resistance	NOUN
chd-169	208	20	and	and	CCONJ
chd-169	208	21	patient	patient	ADJ
chd-169	208	22	biospecimens	biospecimen	NOUN
chd-169	208	23	(	(	PUNCT
chd-169	208	24	isikbay	isikbay	PROPN
chd-169	208	25	et	et	PROPN
chd-169	208	26	al	al	PROPN
chd-169	208	27	.	.	PROPN
chd-169	208	28	,	,	PUNCT
chd-169	208	29	2014	2014	NUM
chd-169	208	30	;	;	PUNCT
chd-169	208	31	li	li	PROPN
chd-169	208	32	et	et	PROPN
chd-169	208	33	al	al	PROPN
chd-169	208	34	.	.	PROPN
chd-169	208	35	,	,	PUNCT
chd-169	208	36	2017	2017	NUM
chd-169	208	37	;	;	PUNCT
chd-169	208	38	puhr	puhr	NOUN
chd-169	208	39	et	et	PROPN
chd-169	208	40	al	al	PROPN
chd-169	208	41	.	.	PROPN
chd-169	208	42	,	,	PUNCT
chd-169	208	43	2018	2018	NUM
chd-169	208	44	)	)	PUNCT
chd-169	208	45	.	.	PUNCT
chd-169	209	1	growth	growth	NOUN
chd-169	209	2	factors	factor	NOUN
chd-169	209	3	produced	produce	VERB
chd-169	209	4	in	in	ADP
chd-169	209	5	prostate	prostate	NOUN
chd-169	209	6	stroma	stroma	NOUN
chd-169	209	7	regulate	regulate	VERB
chd-169	209	8	glandular	glandular	ADJ
chd-169	209	9	epithelial	epithelial	ADJ
chd-169	209	10	proliferation	proliferation	NOUN
chd-169	209	11	and	and	CCONJ
chd-169	209	12	differentiation	differentiation	NOUN
chd-169	209	13	,	,	PUNCT
chd-169	209	14	and	and	CCONJ
chd-169	209	15	steroid	steroid	NOUN
chd-169	209	16	hormones	hormone	NOUN
chd-169	209	17	including	include	VERB
chd-169	209	18	glucocorticoids	glucocorticoid	NOUN
chd-169	209	19	are	be	AUX
chd-169	209	20	important	important	ADJ
chd-169	209	21	modulators	modulator	NOUN
chd-169	209	22	of	of	ADP
chd-169	209	23	stromal	stromal	ADJ
chd-169	209	24	-	-	ADJ
chd-169	209	25	epithelial	epithelial	ADJ
chd-169	209	26	cell	cell	NOUN
chd-169	209	27	signaling	signal	VERB
chd-169	209	28	interactions	interaction	NOUN
chd-169	209	29	in	in	ADP
chd-169	209	30	the	the	DET
chd-169	209	31	prostate	prostate	NOUN
chd-169	209	32	(	(	PUNCT
chd-169	209	33	hidalgo	hidalgo	PROPN
chd-169	209	34	et	et	PROPN
chd-169	209	35	al	al	PROPN
chd-169	209	36	.	.	PROPN
chd-169	209	37	,	,	PUNCT
chd-169	209	38	2011	2011	NUM
chd-169	209	39	;	;	PUNCT
chd-169	209	40	taylor	taylor	PROPN
chd-169	209	41	and	and	CCONJ
chd-169	209	42	risbridger	risbridger	NOUN
chd-169	209	43	,	,	PUNCT
chd-169	209	44	2008	2008	NUM
chd-169	209	45	)	)	PUNCT
chd-169	209	46	.	.	PUNCT
chd-169	210	1	gr	gr	VERB
chd-169	210	2	-	-	PUNCT
chd-169	210	3	mediated	mediate	VERB
chd-169	210	4	transcriptional	transcriptional	ADJ
chd-169	210	5	activity	activity	NOUN
chd-169	210	6	has	have	AUX
chd-169	210	7	been	be	AUX
chd-169	210	8	found	find	VERB
chd-169	210	9	to	to	PART
chd-169	210	10	be	be	AUX
chd-169	210	11	altered	alter	VERB
chd-169	210	12	in	in	ADP
chd-169	210	13	carcinoma	carcinoma	NOUN
chd-169	210	14	-	-	PUNCT
chd-169	210	15	associated	associate	VERB
chd-169	210	16	stroma	stroma	NOUN
chd-169	210	17	and	and	CCONJ
chd-169	210	18	confers	confer	NOUN
chd-169	210	19	cellspecific	cellspecific	NOUN
chd-169	210	20	effects	effect	NOUN
chd-169	210	21	with	with	ADP
chd-169	210	22	the	the	DET
chd-169	210	23	potential	potential	NOUN
chd-169	210	24	to	to	PART
chd-169	210	25	induce	induce	VERB
chd-169	210	26	antiandrogen	antiandrogen	NOUN
chd-169	210	27	therapy	therapy	NOUN
chd-169	210	28	resistance	resistance	NOUN
chd-169	210	29	(	(	PUNCT
chd-169	210	30	hidalgo	hidalgo	PROPN
chd-169	210	31	et	et	PROPN
chd-169	210	32	al	al	PROPN
chd-169	210	33	.	.	PROPN
chd-169	210	34	,	,	PUNCT
chd-169	210	35	2011	2011	NUM
chd-169	210	36	;	;	PUNCT
chd-169	210	37	zhao	zhao	PROPN
chd-169	210	38	et	et	PROPN
chd-169	210	39	al	al	PROPN
chd-169	210	40	.	.	PROPN
chd-169	210	41	,	,	PUNCT
chd-169	210	42	2014	2014	NUM
chd-169	210	43	)	)	PUNCT
chd-169	210	44	.	.	PUNCT
chd-169	211	1	significant	significant	ADJ
chd-169	211	2	structural	structural	ADJ
chd-169	211	3	similarities	similarity	NOUN
chd-169	211	4	(	(	PUNCT
chd-169	211	5	fig	fig	NOUN
chd-169	211	6	.	.	PUNCT
chd-169	212	1	3	3	NUM
chd-169	212	2	)	)	PUNCT
chd-169	212	3	and	and	CCONJ
chd-169	212	4	transcriptomic	transcriptomic	ADJ
chd-169	212	5	overlap	overlap	NOUN
chd-169	212	6	between	between	ADP
chd-169	212	7	ar	ar	NOUN
chd-169	212	8	and	and	CCONJ
chd-169	212	9	gr	gr	NOUN
chd-169	212	10	accounts	account	NOUN
chd-169	212	11	for	for	ADP
chd-169	212	12	gr	gr	ADV
chd-169	212	13	-	-	PUNCT
chd-169	212	14	mediated	mediate	VERB
chd-169	212	15	bypass	bypass	NOUN
chd-169	212	16	of	of	ADP
chd-169	212	17	ar	ar	NOUN
chd-169	212	18	blockade	blockade	NOUN
chd-169	212	19	(	(	PUNCT
chd-169	212	20	sahu	sahu	PROPN
chd-169	212	21	et	et	PROPN
chd-169	212	22	al	al	PROPN
chd-169	212	23	.	.	PROPN
chd-169	212	24	,	,	PUNCT
chd-169	212	25	2013	2013	NUM
chd-169	212	26	)	)	PUNCT
chd-169	212	27	.	.	PUNCT
chd-169	213	1	in	in	ADP
chd-169	213	2	addition	addition	NOUN
chd-169	213	3	,	,	PUNCT
chd-169	213	4	there	there	PRON
chd-169	213	5	is	be	VERB
chd-169	213	6	overlap	overlap	NOUN
chd-169	213	7	in	in	ADP
chd-169	213	8	the	the	DET
chd-169	213	9	transcription	transcription	NOUN
chd-169	213	10	protein	protein	NOUN
chd-169	213	11	interactome	interactome	NOUN
chd-169	213	12	of	of	ADP
chd-169	213	13	both	both	DET
chd-169	213	14	nuclear	nuclear	ADJ
chd-169	213	15	receptors	receptor	NOUN
chd-169	213	16	(	(	PUNCT
chd-169	213	17	lempiainen	lempiainen	PROPN
chd-169	213	18	et	et	PROPN
chd-169	213	19	al	al	PROPN
chd-169	213	20	.	.	PROPN
chd-169	213	21	,	,	PUNCT
chd-169	213	22	2017	2017	NUM
chd-169	213	23	)	)	PUNCT
chd-169	213	24	.	.	PUNCT
chd-169	214	1	induction	induction	NOUN
chd-169	214	2	of	of	ADP
chd-169	214	3	gr	gr	NOUN
chd-169	214	4	expression	expression	NOUN
chd-169	214	5	is	be	AUX
chd-169	214	6	also	also	ADV
chd-169	214	7	accompanied	accompany	VERB
chd-169	214	8	in	in	ADP
chd-169	214	9	arsi	arsi	ADJ
chd-169	214	10	-	-	PUNCT
chd-169	214	11	resistant	resistant	ADJ
chd-169	214	12	tissues	tissue	NOUN
chd-169	214	13	by	by	ADP
chd-169	214	14	the	the	DET
chd-169	214	15	loss	loss	NOUN
chd-169	214	16	of	of	ADP
chd-169	214	17	11b	11b	NOUN
chd-169	214	18	-	-	PUNCT
chd-169	214	19	hsd2	hsd2	PROPN
chd-169	214	20	,	,	PUNCT
chd-169	214	21	resulting	result	VERB
chd-169	214	22	in	in	ADP
chd-169	214	23	increased	increase	VERB
chd-169	214	24	stability	stability	NOUN
chd-169	214	25	of	of	ADP
chd-169	214	26	intratumoral	intratumoral	ADJ
chd-169	214	27	cortisol	cortisol	NOUN
chd-169	214	28	(	(	PUNCT
chd-169	214	29	li	li	PROPN
chd-169	214	30	et	et	PROPN
chd-169	214	31	al	al	PROPN
chd-169	214	32	.	.	PROPN
chd-169	214	33	,	,	PUNCT
chd-169	214	34	2017	2017	NUM
chd-169	214	35	)	)	PUNCT
chd-169	214	36	.	.	PUNCT
chd-169	215	1	the	the	DET
chd-169	215	2	implications	implication	NOUN
chd-169	215	3	of	of	ADP
chd-169	215	4	these	these	DET
chd-169	215	5	initial	initial	ADJ
chd-169	215	6	findings	finding	NOUN
chd-169	215	7	have	have	AUX
chd-169	215	8	sparked	spark	VERB
chd-169	215	9	great	great	ADJ
chd-169	215	10	interest	interest	NOUN
chd-169	215	11	,	,	PUNCT
chd-169	215	12	as	as	SCONJ
chd-169	215	13	pca	pca	NOUN
chd-169	215	14	patients	patient	NOUN
chd-169	215	15	are	be	AUX
chd-169	215	16	routinely	routinely	ADV
chd-169	215	17	administered	administer	VERB
chd-169	215	18	synthetic	synthetic	ADJ
chd-169	215	19	glucocorticoids	glucocorticoid	NOUN
chd-169	215	20	(	(	PUNCT
chd-169	215	21	e.g.	e.g.	ADV
chd-169	215	22	prednisone	prednisone	NOUN
chd-169	215	23	and	and	CCONJ
chd-169	215	24	dexamethasone	dexamethasone	NOUN
chd-169	215	25	)	)	PUNCT
chd-169	215	26	alongside	alongside	ADP
chd-169	215	27	arsi	arsi	ADV
chd-169	215	28	and	and	CCONJ
chd-169	215	29	taxane	taxane	NOUN
chd-169	215	30	chemotherapy	chemotherapy	NOUN
chd-169	215	31	for	for	ADP
chd-169	215	32	palliative	palliative	ADJ
chd-169	215	33	purposes	purpose	NOUN
chd-169	215	34	(	(	PUNCT
chd-169	215	35	chi	chi	NOUN
chd-169	215	36	et	et	PROPN
chd-169	215	37	al	al	PROPN
chd-169	215	38	.	.	PROPN
chd-169	215	39	,	,	PUNCT
chd-169	215	40	2017	2017	NUM
chd-169	215	41	;	;	PUNCT
chd-169	215	42	collins	collins	PROPN
chd-169	215	43	et	et	PROPN
chd-169	215	44	al	al	PROPN
chd-169	215	45	.	.	PROPN
chd-169	215	46	,	,	PUNCT
chd-169	215	47	2007	2007	NUM
chd-169	215	48	;	;	PUNCT
chd-169	215	49	narayanan	narayanan	PROPN
chd-169	215	50	et	et	PROPN
chd-169	215	51	al	al	PROPN
chd-169	215	52	.	.	PROPN
chd-169	215	53	,	,	PUNCT
chd-169	215	54	2016	2016	NUM
chd-169	215	55	;	;	PUNCT
chd-169	215	56	tannock	tannock	PROPN
chd-169	215	57	et	et	PROPN
chd-169	215	58	al	al	PROPN
chd-169	215	59	.	.	PROPN
chd-169	215	60	,	,	PUNCT
chd-169	215	61	1989	1989	NUM
chd-169	215	62	)	)	PUNCT
chd-169	215	63	.	.	PUNCT
chd-169	216	1	furthermore	furthermore	ADV
chd-169	216	2	,	,	PUNCT
chd-169	216	3	the	the	DET
chd-169	216	4	mechanisms	mechanism	NOUN
chd-169	216	5	underlying	underlie	VERB
chd-169	216	6	arsi	arsi	ADJ
chd-169	216	7	-	-	PUNCT
chd-169	216	8	resistance	resistance	NOUN
chd-169	216	9	in	in	ADP
chd-169	216	10	pca	pca	PROPN
chd-169	216	11	and	and	CCONJ
chd-169	216	12	their	their	PRON
chd-169	216	13	contribution	contribution	NOUN
chd-169	216	14	to	to	ADP
chd-169	216	15	disease	disease	NOUN
chd-169	216	16	progression	progression	NOUN
chd-169	216	17	had	have	AUX
chd-169	216	18	not	not	PART
chd-169	216	19	been	be	AUX
chd-169	216	20	fully	fully	ADV
chd-169	216	21	previously	previously	ADV
chd-169	216	22	elucidated	elucidate	VERB
chd-169	216	23	,	,	PUNCT
chd-169	216	24	and	and	CCONJ
chd-169	216	25	these	these	DET
chd-169	216	26	findings	finding	NOUN
chd-169	216	27	paved	pave	VERB
chd-169	216	28	the	the	DET
chd-169	216	29	way	way	NOUN
chd-169	216	30	for	for	ADP
chd-169	216	31	research	research	NOUN
chd-169	216	32	on	on	ADP
chd-169	216	33	the	the	DET
chd-169	216	34	role	role	NOUN
chd-169	216	35	of	of	ADP
chd-169	216	36	gr	gr	NOUN
chd-169	216	37	in	in	ADP
chd-169	216	38	these	these	DET
chd-169	216	39	processes	process	NOUN
chd-169	216	40	(	(	PUNCT
chd-169	216	41	narayanan	narayanan	X
chd-169	216	42	et	et	PROPN
chd-169	216	43	al	al	PROPN
chd-169	216	44	.	.	PROPN
chd-169	216	45	,	,	PUNCT
chd-169	216	46	2016	2016	NUM
chd-169	216	47	)	)	PUNCT
chd-169	216	48	.	.	PUNCT
chd-169	217	1	while	while	SCONJ
chd-169	217	2	anti	anti	ADJ
chd-169	217	3	-	-	ADJ
chd-169	217	4	androgen	androgen	ADJ
chd-169	217	5	therapy	therapy	NOUN
chd-169	217	6	is	be	AUX
chd-169	217	7	highly	highly	ADV
chd-169	217	8	effective	effective	ADJ
chd-169	217	9	in	in	ADP
chd-169	217	10	producing	produce	VERB
chd-169	217	11	an	an	DET
chd-169	217	12	initial	initial	ADJ
chd-169	217	13	period	period	NOUN
chd-169	217	14	of	of	ADP
chd-169	217	15	pca	pca	PROPN
chd-169	217	16	regression	regression	NOUN
chd-169	217	17	,	,	PUNCT
chd-169	217	18	mcrpc	mcrpc	PROPN
chd-169	217	19	eventually	eventually	ADV
chd-169	217	20	develops	develop	VERB
chd-169	217	21	for	for	ADP
chd-169	217	22	many	many	ADJ
chd-169	217	23	patients	patient	NOUN
chd-169	217	24	,	,	PUNCT
chd-169	217	25	characterized	characterize	VERB
chd-169	217	26	by	by	ADP
chd-169	217	27	rapidly	rapidly	ADV
chd-169	217	28	rising	rise	VERB
chd-169	217	29	psa	psa	NOUN
chd-169	217	30	levels	level	NOUN
chd-169	217	31	,	,	PUNCT
chd-169	217	32	even	even	ADV
chd-169	217	33	though	though	SCONJ
chd-169	217	34	circulating	circulate	VERB
chd-169	217	35	testosterone	testosterone	NOUN
chd-169	217	36	levels	level	NOUN
chd-169	217	37	are	be	AUX
chd-169	217	38	in	in	ADP
chd-169	217	39	the	the	DET
chd-169	217	40	typical	typical	ADJ
chd-169	217	41	castration	castration	NOUN
chd-169	217	42	range	range	NOUN
chd-169	217	43	(	(	PUNCT
chd-169	217	44	<	<	X
chd-169	217	45	50	50	NUM
chd-169	217	46	ng	ng	PROPN
chd-169	217	47	/	/	SYM
chd-169	217	48	dl	dl	PROPN
chd-169	217	49	)	)	PUNCT
chd-169	217	50	(	(	PUNCT
chd-169	217	51	chen	chen	PROPN
chd-169	217	52	et	et	PROPN
chd-169	217	53	al	al	PROPN
chd-169	217	54	.	.	PROPN
chd-169	217	55	,	,	PUNCT
chd-169	217	56	2004	2004	NUM
chd-169	217	57	;	;	PUNCT
chd-169	217	58	feldman	feldman	PROPN
chd-169	217	59	and	and	CCONJ
chd-169	217	60	feldman	feldman	PROPN
chd-169	217	61	,	,	PUNCT
chd-169	217	62	2001	2001	NUM
chd-169	217	63	;	;	PUNCT
chd-169	217	64	lamont	lamont	PROPN
chd-169	217	65	and	and	CCONJ
chd-169	217	66	tindall	tindall	PROPN
chd-169	217	67	,	,	PUNCT
chd-169	217	68	2011	2011	NUM
chd-169	217	69	;	;	PUNCT
chd-169	217	70	schrecengost	schrecengost	ADJ
chd-169	217	71	and	and	CCONJ
chd-169	217	72	knudsen	knudsen	PROPN
chd-169	217	73	,	,	PUNCT
chd-169	217	74	2013	2013	NUM
chd-169	217	75	;	;	PUNCT
chd-169	217	76	sharifi	sharifi	NOUN
chd-169	217	77	,	,	PUNCT
chd-169	217	78	2013	2013	NUM
chd-169	217	79	)	)	PUNCT
chd-169	217	80	.	.	PUNCT
chd-169	218	1	this	this	PRON
chd-169	218	2	means	mean	VERB
chd-169	218	3	that	that	SCONJ
chd-169	218	4	ar	ar	NOUN
chd-169	218	5	-	-	PUNCT
chd-169	218	6	target	target	NOUN
chd-169	218	7	genes	gene	NOUN
chd-169	218	8	are	be	AUX
chd-169	218	9	operating	operate	VERB
chd-169	218	10	in	in	ADP
chd-169	218	11	the	the	DET
chd-169	218	12	absence	absence	NOUN
chd-169	218	13	of	of	ADP
chd-169	218	14	androgen	androgen	NOUN
chd-169	218	15	to	to	PART
chd-169	218	16	stimulate	stimulate	VERB
chd-169	218	17	pca	pca	NOUN
chd-169	218	18	cell	cell	NOUN
chd-169	218	19	survival	survival	NOUN
chd-169	218	20	,	,	PUNCT
chd-169	218	21	growth	growth	NOUN
chd-169	218	22	,	,	PUNCT
chd-169	218	23	and	and	CCONJ
chd-169	218	24	psa	psa	VERB
chd-169	218	25	secretion	secretion	NOUN
chd-169	218	26	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PART
chd-169	218	27	e14	e14	NOUN
chd-169	218	28	cancer	cancer	NOUN
chd-169	218	29	health	health	NOUN
chd-169	218	30	disparities	disparity	NOUN
chd-169	218	31	research	research	NOUN
chd-169	218	32	(	(	PUNCT
chd-169	218	33	narayanan	narayanan	PROPN
chd-169	218	34	et	et	PROPN
chd-169	218	35	al	al	PROPN
chd-169	218	36	.	.	PROPN
chd-169	218	37	,	,	PUNCT
chd-169	218	38	2016	2016	NUM
chd-169	218	39	)	)	PUNCT
chd-169	218	40	.	.	PUNCT
chd-169	219	1	to	to	PART
chd-169	219	2	understand	understand	VERB
chd-169	219	3	the	the	DET
chd-169	219	4	prospect	prospect	NOUN
chd-169	219	5	of	of	ADP
chd-169	219	6	gr	gr	NUM
chd-169	219	7	bypassing	bypass	VERB
chd-169	219	8	the	the	DET
chd-169	219	9	ar	ar	NOUN
chd-169	219	10	signaling	signal	VERB
chd-169	219	11	pathway	pathway	NOUN
chd-169	219	12	and	and	CCONJ
chd-169	219	13	directly	directly	ADV
chd-169	219	14	activating	activate	VERB
chd-169	219	15	ar	ar	NOUN
chd-169	219	16	-	-	NOUN
chd-169	219	17	target	target	NOUN
chd-169	219	18	genes	gene	NOUN
chd-169	219	19	(	(	PUNCT
chd-169	219	20	fig	fig	NOUN
chd-169	219	21	.	.	PUNCT
chd-169	220	1	4	4	NUM
chd-169	220	2	)	)	PUNCT
chd-169	220	3	,	,	PUNCT
chd-169	220	4	the	the	DET
chd-169	220	5	similarities	similarity	NOUN
chd-169	220	6	between	between	ADP
chd-169	220	7	ar	ar	NOUN
chd-169	220	8	and	and	CCONJ
chd-169	220	9	gr	gr	PROPN
chd-169	220	10	must	must	AUX
chd-169	220	11	be	be	AUX
chd-169	220	12	considered	consider	VERB
chd-169	220	13	.	.	PUNCT
chd-169	221	1	ar	ar	PROPN
chd-169	221	2	and	and	CCONJ
chd-169	221	3	gr	gr	PROPN
chd-169	221	4	belong	belong	VERB
chd-169	221	5	to	to	ADP
chd-169	221	6	the	the	DET
chd-169	221	7	same	same	ADJ
chd-169	221	8	intracellular	intracellular	ADJ
chd-169	221	9	receptor	receptor	NOUN
chd-169	221	10	family	family	NOUN
chd-169	221	11	of	of	ADP
chd-169	221	12	transcriptional	transcriptional	ADJ
chd-169	221	13	regulators	regulator	NOUN
chd-169	221	14	,	,	PUNCT
chd-169	221	15	and	and	CCONJ
chd-169	221	16	the	the	DET
chd-169	221	17	dna	dna	NOUN
chd-169	221	18	binding	bind	VERB
chd-169	221	19	domains	domain	NOUN
chd-169	221	20	of	of	ADP
chd-169	221	21	ar	ar	PROPN
chd-169	221	22	and	and	CCONJ
chd-169	221	23	gr	gr	PROPN
chd-169	221	24	are	be	AUX
chd-169	221	25	highly	highly	ADV
chd-169	221	26	conserved	conserved	ADJ
chd-169	221	27	with	with	ADP
chd-169	221	28	an	an	DET
chd-169	221	29	80	80	NUM
chd-169	221	30	%	%	NOUN
chd-169	221	31	match	match	NOUN
chd-169	221	32	in	in	ADP
chd-169	221	33	amino	amino	NOUN
chd-169	221	34	acid	acid	NOUN
chd-169	221	35	sequence	sequence	NOUN
chd-169	221	36	(	(	PUNCT
chd-169	221	37	mangelsdorf	mangelsdorf	X
chd-169	221	38	et	et	PROPN
chd-169	221	39	al	al	PROPN
chd-169	221	40	.	.	PROPN
chd-169	221	41	,	,	PUNCT
chd-169	221	42	1995	1995	NUM
chd-169	221	43	;	;	PUNCT
chd-169	221	44	narayanan	narayanan	PROPN
chd-169	221	45	et	et	PROPN
chd-169	221	46	al	al	PROPN
chd-169	221	47	.	.	PROPN
chd-169	221	48	,	,	PUNCT
chd-169	221	49	2016	2016	NUM
chd-169	221	50	;	;	PUNCT
chd-169	221	51	rundlett	rundlett	PROPN
chd-169	221	52	and	and	CCONJ
chd-169	221	53	miesfeld	miesfeld	NOUN
chd-169	221	54	,	,	PUNCT
chd-169	221	55	1995	1995	NUM
chd-169	221	56	)	)	PUNCT
chd-169	221	57	.	.	PUNCT
chd-169	222	1	as	as	SCONJ
chd-169	222	2	shown	show	VERB
chd-169	222	3	in	in	ADP
chd-169	222	4	fig	fig	NOUN
chd-169	222	5	.	.	PUNCT
chd-169	223	1	3	3	NUM
chd-169	223	2	the	the	DET
chd-169	223	3	domain	domain	NOUN
chd-169	223	4	structures	structure	NOUN
chd-169	223	5	of	of	ADP
chd-169	223	6	gr	gr	NOUN
chd-169	223	7	and	and	CCONJ
chd-169	223	8	ar	ar	NOUN
chd-169	223	9	are	be	AUX
chd-169	223	10	very	very	ADV
chd-169	223	11	similar	similar	ADJ
chd-169	223	12	.	.	PUNCT
chd-169	224	1	like	like	ADP
chd-169	224	2	gres	gre	NOUN
chd-169	224	3	,	,	PUNCT
chd-169	224	4	ar	ar	NOUN
chd-169	224	5	response	response	NOUN
chd-169	224	6	elements	element	NOUN
chd-169	224	7	(	(	PUNCT
chd-169	224	8	ares	are	NOUN
chd-169	224	9	)	)	PUNCT
chd-169	224	10	in	in	ADP
chd-169	224	11	the	the	DET
chd-169	224	12	promoter	promoter	NOUN
chd-169	224	13	regions	region	NOUN
chd-169	224	14	of	of	ADP
chd-169	224	15	ar	ar	NOUN
chd-169	224	16	-	-	NOUN
chd-169	224	17	target	target	NOUN
chd-169	224	18	genes	gene	NOUN
chd-169	224	19	are	be	AUX
chd-169	224	20	composed	compose	VERB
chd-169	224	21	of	of	ADP
chd-169	224	22	a	a	DET
chd-169	224	23	15	15	NUM
chd-169	224	24	base	base	NOUN
chd-169	224	25	pair	pair	NOUN
chd-169	224	26	binding	bind	VERB
chd-169	224	27	sequence	sequence	NOUN
chd-169	224	28	comprised	comprise	VERB
chd-169	224	29	of	of	ADP
chd-169	224	30	two	two	NUM
chd-169	224	31	hexamer	hexamer	ADJ
chd-169	224	32	half	half	ADJ
chd-169	224	33	-	-	PUNCT
chd-169	224	34	sites	site	NOUN
chd-169	224	35	and	and	CCONJ
chd-169	224	36	separated	separate	VERB
chd-169	224	37	by	by	ADP
chd-169	224	38	a	a	DET
chd-169	224	39	3	3	NUM
chd-169	224	40	base	base	NOUN
chd-169	224	41	pair	pair	NOUN
chd-169	224	42	spacer	spacer	NOUN
chd-169	224	43	(	(	PUNCT
chd-169	224	44	bolton	bolton	PROPN
chd-169	224	45	et	et	PROPN
chd-169	224	46	al	al	PROPN
chd-169	224	47	.	.	PROPN
chd-169	224	48	,	,	PUNCT
chd-169	224	49	2007	2007	NUM
chd-169	224	50	)	)	PUNCT
chd-169	224	51	.	.	PUNCT
chd-169	225	1	this	this	DET
chd-169	225	2	similarity	similarity	NOUN
chd-169	225	3	allows	allow	VERB
chd-169	225	4	gr	gr	NOUN
chd-169	225	5	to	to	PART
chd-169	225	6	interact	interact	VERB
chd-169	225	7	with	with	ADP
chd-169	225	8	ares	are	NOUN
chd-169	225	9	and	and	CCONJ
chd-169	225	10	alter	alter	VERB
chd-169	225	11	the	the	DET
chd-169	225	12	expression	expression	NOUN
chd-169	225	13	of	of	ADP
chd-169	225	14	artarget	artarget	NOUN
chd-169	225	15	genes	gene	NOUN
chd-169	225	16	in	in	ADP
chd-169	225	17	the	the	DET
chd-169	225	18	absence	absence	NOUN
chd-169	225	19	of	of	ADP
chd-169	225	20	androgens	androgen	NOUN
chd-169	225	21	(	(	PUNCT
chd-169	225	22	arora	arora	PROPN
chd-169	225	23	et	et	PROPN
chd-169	225	24	al	al	PROPN
chd-169	225	25	.	.	PROPN
chd-169	225	26	,	,	PUNCT
chd-169	225	27	2013	2013	NUM
chd-169	225	28	)	)	PUNCT
chd-169	225	29	.	.	PUNCT
chd-169	226	1	while	while	SCONJ
chd-169	226	2	that	that	DET
chd-169	226	3	study	study	NOUN
chd-169	226	4	identified	identify	VERB
chd-169	226	5	52	52	NUM
chd-169	226	6	common	common	ADJ
chd-169	226	7	overlapping	overlapping	NOUN
chd-169	226	8	genes	gene	NOUN
chd-169	226	9	out	out	ADP
chd-169	226	10	of	of	ADP
chd-169	226	11	105	105	NUM
chd-169	226	12	ar	ar	NOUN
chd-169	226	13	signature	signature	NOUN
chd-169	226	14	genes	gene	NOUN
chd-169	226	15	and	and	CCONJ
chd-169	226	16	121	121	NUM
chd-169	226	17	gr	gr	NOUN
chd-169	226	18	signature	signature	NOUN
chd-169	226	19	genes	gene	NOUN
chd-169	226	20	,	,	PUNCT
chd-169	226	21	several	several	ADJ
chd-169	226	22	canonical	canonical	ADJ
chd-169	226	23	ar	ar	NOUN
chd-169	226	24	-	-	PUNCT
chd-169	226	25	target	target	NOUN
chd-169	226	26	genes	gene	NOUN
chd-169	226	27	were	be	AUX
chd-169	226	28	found	find	VERB
chd-169	226	29	to	to	PART
chd-169	226	30	be	be	AUX
chd-169	226	31	regulated	regulate	VERB
chd-169	226	32	by	by	ADP
chd-169	226	33	gr	gr	PROPN
chd-169	226	34	,	,	PUNCT
chd-169	226	35	including	include	VERB
chd-169	226	36	pca	pca	NOUN
chd-169	226	37	key	key	ADJ
chd-169	226	38	genes	gene	NOUN
chd-169	226	39	klk3	klk3	VERB
chd-169	226	40	(	(	PUNCT
chd-169	226	41	encoding	encode	VERB
chd-169	226	42	psa	psa	NOUN
chd-169	226	43	)	)	PUNCT
chd-169	226	44	and	and	CCONJ
chd-169	226	45	tmprss2	tmprss2	ADP
chd-169	226	46	(	(	PUNCT
chd-169	226	47	involved	involve	VERB
chd-169	226	48	in	in	ADP
chd-169	226	49	fusions	fusion	NOUN
chd-169	226	50	with	with	ADP
chd-169	226	51	erg	erg	PROPN
chd-169	226	52	in	in	ADP
chd-169	226	53	a	a	DET
chd-169	226	54	race	race	NOUN
chd-169	226	55	-	-	PUNCT
chd-169	226	56	related	relate	VERB
chd-169	226	57	manner	manner	NOUN
chd-169	226	58	)	)	PUNCT
chd-169	226	59	(	(	PUNCT
chd-169	226	60	arora	arora	PROPN
chd-169	226	61	et	et	PROPN
chd-169	226	62	al	al	PROPN
chd-169	226	63	.	.	PROPN
chd-169	226	64	,	,	PUNCT
chd-169	226	65	2013	2013	NUM
chd-169	226	66	)	)	PUNCT
chd-169	226	67	.	.	PUNCT
chd-169	227	1	also	also	ADV
chd-169	227	2	,	,	PUNCT
chd-169	227	3	gr	gr	PRON
chd-169	227	4	expression	expression	NOUN
chd-169	227	5	is	be	AUX
chd-169	227	6	normally	normally	ADV
chd-169	227	7	repressed	repress	VERB
chd-169	227	8	in	in	ADP
chd-169	227	9	pca	pca	NOUN
chd-169	227	10	cells	cell	NOUN
chd-169	227	11	in	in	ADP
chd-169	227	12	the	the	DET
chd-169	227	13	presence	presence	NOUN
chd-169	227	14	of	of	ADP
chd-169	227	15	ar	ar	PROPN
chd-169	227	16	,	,	PUNCT
chd-169	227	17	however	however	ADV
chd-169	227	18	this	this	DET
chd-169	227	19	study	study	NOUN
chd-169	227	20	demonstrated	demonstrate	VERB
chd-169	227	21	that	that	SCONJ
chd-169	227	22	ar	ar	NOUN
chd-169	227	23	blockade	blockade	NOUN
chd-169	227	24	removes	remove	VERB
chd-169	227	25	this	this	DET
chd-169	227	26	gr	gr	NOUN
chd-169	227	27	inhibition	inhibition	NOUN
chd-169	227	28	and	and	CCONJ
chd-169	227	29	stimulates	stimulate	VERB
chd-169	227	30	gr	gr	NOUN
chd-169	227	31	amplification	amplification	NOUN
chd-169	227	32	(	(	PUNCT
chd-169	227	33	arora	arora	PROPN
chd-169	227	34	et	et	PROPN
chd-169	227	35	al	al	PROPN
chd-169	227	36	.	.	PROPN
chd-169	227	37	,	,	PUNCT
chd-169	227	38	2013	2013	NUM
chd-169	227	39	)	)	PUNCT
chd-169	227	40	.	.	PUNCT
chd-169	228	1	intriguingly	intriguingly	ADV
chd-169	228	2	,	,	PUNCT
chd-169	228	3	the	the	DET
chd-169	228	4	tmprss2	tmprss2	ADJ
chd-169	228	5	protein	protein	NOUN
chd-169	228	6	is	be	AUX
chd-169	228	7	a	a	DET
chd-169	228	8	key	key	ADJ
chd-169	228	9	receptor	receptor	NOUN
chd-169	228	10	used	use	VERB
chd-169	228	11	by	by	ADP
chd-169	228	12	sars	sar	NOUN
chd-169	228	13	-	-	PUNCT
chd-169	228	14	cov-2	cov-2	PART
chd-169	228	15	virus	virus	NOUN
chd-169	228	16	to	to	PART
chd-169	228	17	infect	infect	VERB
chd-169	228	18	host	host	NOUN
chd-169	228	19	cells	cell	NOUN
chd-169	228	20	,	,	PUNCT
chd-169	228	21	which	which	PRON
chd-169	228	22	has	have	AUX
chd-169	228	23	prompted	prompt	VERB
chd-169	228	24	recent	recent	ADJ
chd-169	228	25	speculation	speculation	NOUN
chd-169	228	26	that	that	SCONJ
chd-169	228	27	race	race	NOUN
chd-169	228	28	-	-	PUNCT
chd-169	228	29	related	relate	VERB
chd-169	228	30	and	and	CCONJ
chd-169	228	31	gender	gender	NOUN
chd-169	228	32	-	-	PUNCT
chd-169	228	33	related	relate	VERB
chd-169	228	34	differences	difference	NOUN
chd-169	228	35	in	in	ADP
chd-169	228	36	ar	ar	NOUN
chd-169	228	37	signaling	signal	VERB
chd-169	228	38	may	may	AUX
chd-169	228	39	explain	explain	VERB
chd-169	228	40	in	in	ADP
chd-169	228	41	part	part	NOUN
chd-169	228	42	the	the	DET
chd-169	228	43	racial	racial	ADJ
chd-169	228	44	and	and	CCONJ
chd-169	228	45	gender	gender	NOUN
chd-169	228	46	variations	variation	NOUN
chd-169	228	47	in	in	ADP
chd-169	228	48	covid-19	covid-19	PROPN
chd-169	228	49	deaths	death	NOUN
chd-169	228	50	and	and	CCONJ
chd-169	228	51	that	that	SCONJ
chd-169	228	52	anti	anti	ADJ
chd-169	228	53	-	-	ADJ
chd-169	228	54	androgen	androgen	ADJ
chd-169	228	55	agents	agent	NOUN
chd-169	228	56	combined	combine	VERB
chd-169	228	57	with	with	ADP
chd-169	228	58	tmprss2	tmprss2	PRON
chd-169	228	59	inhibitors	inhibitor	NOUN
chd-169	228	60	could	could	AUX
chd-169	228	61	potentially	potentially	ADV
chd-169	228	62	decrease	decrease	VERB
chd-169	228	63	disease	disease	NOUN
chd-169	228	64	severity	severity	NOUN
chd-169	228	65	(	(	PUNCT
chd-169	228	66	mccoy	mccoy	PROPN
chd-169	228	67	et	et	PROPN
chd-169	228	68	al	al	PROPN
chd-169	228	69	.	.	PROPN
chd-169	228	70	,	,	PUNCT
chd-169	228	71	2020	2020	NUM
chd-169	228	72	)	)	PUNCT
chd-169	228	73	.	.	PUNCT
chd-169	229	1	fig	fig	NOUN
chd-169	229	2	.	.	PUNCT
chd-169	230	1	4	4	NUM
chd-169	230	2	the	the	DET
chd-169	230	3	interplay	interplay	NOUN
chd-169	230	4	between	between	ADP
chd-169	230	5	gr	gr	NOUN
chd-169	230	6	and	and	CCONJ
chd-169	230	7	ar	ar	NOUN
chd-169	230	8	in	in	ADP
chd-169	230	9	the	the	DET
chd-169	230	10	context	context	NOUN
chd-169	230	11	of	of	ADP
chd-169	230	12	pca	pca	PROPN
chd-169	230	13	.	.	PROPN
chd-169	230	14	ar	ar	PROPN
chd-169	230	15	and	and	CCONJ
chd-169	230	16	gr	gr	PROPN
chd-169	230	17	belong	belong	VERB
chd-169	230	18	to	to	ADP
chd-169	230	19	the	the	DET
chd-169	230	20	same	same	ADJ
chd-169	230	21	intracellular	intracellular	ADJ
chd-169	230	22	receptor	receptor	NOUN
chd-169	230	23	family	family	NOUN
chd-169	230	24	of	of	ADP
chd-169	230	25	transcriptional	transcriptional	ADJ
chd-169	230	26	regulators	regulator	NOUN
chd-169	230	27	and	and	CCONJ
chd-169	230	28	their	their	PRON
chd-169	230	29	dna	dna	NOUN
chd-169	230	30	binding	bind	VERB
chd-169	230	31	domains	domain	NOUN
chd-169	230	32	are	be	AUX
chd-169	230	33	highly	highly	ADV
chd-169	230	34	conserved	conserve	VERB
chd-169	230	35	.	.	PUNCT
chd-169	231	1	gres	gre	NOUN
chd-169	231	2	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	231	3	e15	e15	PROPN
chd-169	231	4	cancer	cancer	NOUN
chd-169	231	5	health	health	NOUN
chd-169	231	6	disparities	disparity	NOUN
chd-169	231	7	research	research	NOUN
chd-169	231	8	and	and	CCONJ
chd-169	231	9	ares	are	NOUN
chd-169	231	10	in	in	ADP
chd-169	231	11	the	the	DET
chd-169	231	12	promoter	promoter	NOUN
chd-169	231	13	regions	region	NOUN
chd-169	231	14	of	of	ADP
chd-169	231	15	gr	gr	NOUN
chd-169	231	16	-	-	PUNCT
chd-169	231	17	and	and	CCONJ
chd-169	231	18	ar	ar	NOUN
chd-169	231	19	-	-	NOUN
chd-169	231	20	target	target	NOUN
chd-169	231	21	genes	gene	NOUN
chd-169	231	22	are	be	AUX
chd-169	231	23	also	also	ADV
chd-169	231	24	similar	similar	ADJ
chd-169	231	25	and	and	CCONJ
chd-169	231	26	are	be	AUX
chd-169	231	27	composed	compose	VERB
chd-169	231	28	of	of	ADP
chd-169	231	29	a	a	DET
chd-169	231	30	15	15	NUM
chd-169	231	31	base	base	NOUN
chd-169	231	32	pair	pair	NOUN
chd-169	231	33	binding	bind	VERB
chd-169	231	34	sequence	sequence	NOUN
chd-169	231	35	with	with	ADP
chd-169	231	36	2	2	NUM
chd-169	231	37	hexamer	hexamer	ADJ
chd-169	231	38	half	half	ADJ
chd-169	231	39	-	-	PUNCT
chd-169	231	40	sites	site	NOUN
chd-169	231	41	separated	separate	VERB
chd-169	231	42	by	by	ADP
chd-169	231	43	a	a	DET
chd-169	231	44	3	3	NUM
chd-169	231	45	base	base	NOUN
chd-169	231	46	pair	pair	NOUN
chd-169	231	47	spacer	spacer	NOUN
chd-169	231	48	.	.	PUNCT
chd-169	232	1	gr	gr	NOUN
chd-169	232	2	expression	expression	NOUN
chd-169	232	3	is	be	AUX
chd-169	232	4	normally	normally	ADV
chd-169	232	5	repressed	repress	VERB
chd-169	232	6	in	in	ADP
chd-169	232	7	pca	pca	NOUN
chd-169	232	8	cells	cell	NOUN
chd-169	232	9	in	in	ADP
chd-169	232	10	the	the	DET
chd-169	232	11	presence	presence	NOUN
chd-169	232	12	of	of	ADP
chd-169	232	13	ar	ar	PROPN
chd-169	232	14	.	.	PROPN
chd-169	233	1	however	however	ADV
chd-169	233	2	,	,	PUNCT
chd-169	233	3	an	an	DET
chd-169	233	4	ar	ar	NOUN
chd-169	233	5	blockade	blockade	NOUN
chd-169	233	6	removes	remove	VERB
chd-169	233	7	gr	gr	NOUN
chd-169	233	8	inhibition	inhibition	NOUN
chd-169	233	9	and	and	CCONJ
chd-169	233	10	stimulates	stimulate	VERB
chd-169	233	11	gr	gr	PRON
chd-169	233	12	amplification	amplification	NOUN
chd-169	233	13	allowing	allow	VERB
chd-169	233	14	gr	gr	NOUN
chd-169	233	15	to	to	PART
chd-169	233	16	interact	interact	VERB
chd-169	233	17	with	with	ADP
chd-169	233	18	ares	are	NOUN
chd-169	233	19	and	and	CCONJ
chd-169	233	20	alter	alter	VERB
chd-169	233	21	the	the	DET
chd-169	233	22	expression	expression	NOUN
chd-169	233	23	of	of	ADP
chd-169	233	24	ar	ar	NOUN
chd-169	233	25	-	-	NOUN
chd-169	233	26	target	target	NOUN
chd-169	233	27	genes	gene	NOUN
chd-169	233	28	.	.	PUNCT
chd-169	234	1	this	this	DET
chd-169	234	2	complex	complex	ADJ
chd-169	234	3	ar	ar	PROPN
chd-169	234	4	-	-	ADJ
chd-169	234	5	gr	gr	NOUN
chd-169	234	6	interplay	interplay	NOUN
chd-169	234	7	creates	create	VERB
chd-169	234	8	a	a	DET
chd-169	234	9	major	major	ADJ
chd-169	234	10	clinical	clinical	ADJ
chd-169	234	11	dilemma	dilemma	NOUN
chd-169	234	12	as	as	SCONJ
chd-169	234	13	the	the	DET
chd-169	234	14	effects	effect	NOUN
chd-169	234	15	of	of	ADP
chd-169	234	16	glucocorticoids	glucocorticoid	NOUN
chd-169	234	17	can	can	AUX
chd-169	234	18	be	be	AUX
chd-169	234	19	beneficial	beneficial	ADJ
chd-169	234	20	and/or	and/or	CCONJ
chd-169	234	21	harmful	harmful	ADJ
chd-169	234	22	to	to	ADP
chd-169	234	23	patients	patient	NOUN
chd-169	234	24	.	.	PUNCT
chd-169	235	1	treatment	treatment	NOUN
chd-169	235	2	options	option	NOUN
chd-169	235	3	for	for	ADP
chd-169	235	4	prostate	prostate	NOUN
chd-169	235	5	cancer	cancer	NOUN
chd-169	235	6	patients	patient	NOUN
chd-169	235	7	the	the	DET
chd-169	235	8	interplay	interplay	NOUN
chd-169	235	9	between	between	ADP
chd-169	235	10	gr	gr	NOUN
chd-169	235	11	and	and	CCONJ
chd-169	235	12	ar	ar	NOUN
chd-169	235	13	in	in	ADP
chd-169	235	14	the	the	DET
chd-169	235	15	context	context	NOUN
chd-169	235	16	of	of	ADP
chd-169	235	17	pca	pca	PROPN
chd-169	235	18	treatment	treatment	NOUN
chd-169	235	19	presents	present	VERB
chd-169	235	20	a	a	DET
chd-169	235	21	major	major	ADJ
chd-169	235	22	clinical	clinical	ADJ
chd-169	235	23	dilemma	dilemma	NOUN
chd-169	235	24	because	because	SCONJ
chd-169	235	25	the	the	DET
chd-169	235	26	effects	effect	NOUN
chd-169	235	27	of	of	ADP
chd-169	235	28	glucocorticoids	glucocorticoid	NOUN
chd-169	235	29	are	be	AUX
chd-169	235	30	both	both	PRON
chd-169	235	31	beneficial	beneficial	ADJ
chd-169	235	32	and	and	CCONJ
chd-169	235	33	harmful	harmful	ADJ
chd-169	235	34	to	to	ADP
chd-169	235	35	patients	patient	NOUN
chd-169	235	36	(	(	PUNCT
chd-169	235	37	arora	arora	PROPN
chd-169	235	38	et	et	PROPN
chd-169	235	39	al	al	PROPN
chd-169	235	40	.	.	PROPN
chd-169	235	41	,	,	PUNCT
chd-169	235	42	2013	2013	NUM
chd-169	235	43	;	;	PUNCT
chd-169	235	44	claessens	claessen	VERB
chd-169	235	45	et	et	PROPN
chd-169	235	46	al	al	PROPN
chd-169	235	47	.	.	PROPN
chd-169	235	48	,	,	PUNCT
chd-169	235	49	2017	2017	NUM
chd-169	235	50	;	;	PUNCT
chd-169	235	51	montgomery	montgomery	PROPN
chd-169	235	52	et	et	PROPN
chd-169	235	53	al	al	PROPN
chd-169	235	54	.	.	PROPN
chd-169	235	55	,	,	PUNCT
chd-169	235	56	2014	2014	NUM
chd-169	235	57	;	;	PUNCT
chd-169	235	58	narayanan	narayanan	PROPN
chd-169	235	59	et	et	PROPN
chd-169	235	60	al	al	PROPN
chd-169	235	61	.	.	PROPN
chd-169	235	62	,	,	PUNCT
chd-169	235	63	2016	2016	NUM
chd-169	235	64	;	;	PUNCT
chd-169	235	65	puhr	puhr	NOUN
chd-169	235	66	et	et	PROPN
chd-169	235	67	al	al	PROPN
chd-169	235	68	.	.	PROPN
chd-169	235	69	,	,	PUNCT
chd-169	235	70	2018	2018	NUM
chd-169	235	71	;	;	PUNCT
chd-169	235	72	sartor	sartor	NOUN
chd-169	235	73	et	et	PROPN
chd-169	235	74	al	al	PROPN
chd-169	235	75	.	.	PROPN
chd-169	235	76	,	,	PUNCT
chd-169	235	77	2014	2014	NUM
chd-169	235	78	)	)	PUNCT
chd-169	235	79	.	.	PUNCT
chd-169	236	1	ar	ar	PROPN
chd-169	236	2	signaling	signal	VERB
chd-169	236	3	has	have	AUX
chd-169	236	4	been	be	AUX
chd-169	236	5	traditionally	traditionally	ADV
chd-169	236	6	considered	consider	VERB
chd-169	236	7	as	as	ADP
chd-169	236	8	the	the	DET
chd-169	236	9	key	key	ADJ
chd-169	236	10	actionable	actionable	ADJ
chd-169	236	11	driver	driver	NOUN
chd-169	236	12	of	of	ADP
chd-169	236	13	pca	pca	PROPN
chd-169	236	14	recurrence	recurrence	NOUN
chd-169	236	15	and	and	CCONJ
chd-169	236	16	progression	progression	NOUN
chd-169	236	17	(	(	PUNCT
chd-169	236	18	banerjee	banerjee	PROPN
chd-169	236	19	et	et	PROPN
chd-169	236	20	al	al	PROPN
chd-169	236	21	.	.	PROPN
chd-169	236	22	,	,	PUNCT
chd-169	236	23	2018	2018	NUM
chd-169	236	24	)	)	PUNCT
chd-169	236	25	.	.	PUNCT
chd-169	237	1	because	because	SCONJ
chd-169	237	2	of	of	ADP
chd-169	237	3	this	this	PRON
chd-169	237	4	,	,	PUNCT
chd-169	237	5	targeting	target	VERB
chd-169	237	6	androgen	androgen	NOUN
chd-169	237	7	biosynthesis	biosynthesis	NOUN
chd-169	237	8	and	and	CCONJ
chd-169	237	9	ar	ar	NOUN
chd-169	237	10	has	have	AUX
chd-169	237	11	been	be	AUX
chd-169	237	12	a	a	DET
chd-169	237	13	standard	standard	NOUN
chd-169	237	14	of	of	ADP
chd-169	237	15	care	care	NOUN
chd-169	237	16	for	for	ADP
chd-169	237	17	pca	pca	NOUN
chd-169	237	18	treatment	treatment	NOUN
chd-169	237	19	for	for	ADP
chd-169	237	20	over	over	ADP
chd-169	237	21	seven	seven	NUM
chd-169	237	22	decades	decade	NOUN
chd-169	237	23	(	(	PUNCT
chd-169	237	24	huggins	huggins	PROPN
chd-169	237	25	and	and	CCONJ
chd-169	237	26	hodges	hodge	NOUN
chd-169	237	27	,	,	PUNCT
chd-169	237	28	1972	1972	NUM
chd-169	237	29	)	)	PUNCT
chd-169	237	30	.	.	PUNCT
chd-169	238	1	huggins	huggins	PROPN
chd-169	238	2	and	and	CCONJ
chd-169	238	3	colleagues	colleague	NOUN
chd-169	238	4	made	make	VERB
chd-169	238	5	the	the	DET
chd-169	238	6	seminal	seminal	ADJ
chd-169	238	7	observation	observation	NOUN
chd-169	238	8	that	that	SCONJ
chd-169	238	9	both	both	CCONJ
chd-169	238	10	surgical	surgical	ADJ
chd-169	238	11	castration	castration	NOUN
chd-169	238	12	and	and	CCONJ
chd-169	238	13	estrogen	estrogen	PROPN
chd-169	238	14	administration	administration	NOUN
chd-169	238	15	resulted	result	VERB
chd-169	238	16	in	in	ADP
chd-169	238	17	regression	regression	NOUN
chd-169	238	18	of	of	ADP
chd-169	238	19	pca	pca	NOUN
chd-169	238	20	metastasis	metastasis	NOUN
chd-169	238	21	(	(	PUNCT
chd-169	238	22	huggins	huggins	PROPN
chd-169	238	23	and	and	CCONJ
chd-169	238	24	hodges	hodge	NOUN
chd-169	238	25	,	,	PUNCT
chd-169	238	26	1972	1972	NUM
chd-169	238	27	)	)	PUNCT
chd-169	238	28	,	,	PUNCT
chd-169	238	29	which	which	PRON
chd-169	238	30	led	lead	VERB
chd-169	238	31	to	to	ADP
chd-169	238	32	the	the	DET
chd-169	238	33	development	development	NOUN
chd-169	238	34	of	of	ADP
chd-169	238	35	androgen	androgen	NOUN
chd-169	238	36	deprivation	deprivation	NOUN
chd-169	238	37	therapy	therapy	NOUN
chd-169	238	38	(	(	PUNCT
chd-169	238	39	adt	adt	NOUN
chd-169	238	40	)	)	PUNCT
chd-169	238	41	.	.	PUNCT
chd-169	239	1	both	both	DET
chd-169	239	2	agonists	agonist	NOUN
chd-169	239	3	and	and	CCONJ
chd-169	239	4	antagonists	antagonist	NOUN
chd-169	239	5	of	of	ADP
chd-169	239	6	luteinizing	luteinize	VERB
chd-169	239	7	hormone	hormone	NOUN
chd-169	239	8	-	-	PUNCT
chd-169	239	9	releasing	release	VERB
chd-169	239	10	hormone	hormone	NOUN
chd-169	239	11	(	(	PUNCT
chd-169	239	12	lhrh	lhrh	PROPN
chd-169	239	13	)	)	PUNCT
chd-169	239	14	are	be	AUX
chd-169	239	15	typically	typically	ADV
chd-169	239	16	used	use	VERB
chd-169	239	17	as	as	ADP
chd-169	239	18	first	first	ADJ
chd-169	239	19	-	-	PUNCT
chd-169	239	20	line	line	NOUN
chd-169	239	21	adt	adt	NOUN
chd-169	239	22	in	in	ADP
chd-169	239	23	patients	patient	NOUN
chd-169	239	24	with	with	ADP
chd-169	239	25	hormone	hormone	NOUN
chd-169	239	26	-	-	PUNCT
chd-169	239	27	sensitive	sensitive	ADJ
chd-169	239	28	pca	pca	PROPN
chd-169	239	29	to	to	PART
chd-169	239	30	decrease	decrease	VERB
chd-169	239	31	endogenous	endogenous	ADJ
chd-169	239	32	testosterone	testosterone	NOUN
chd-169	239	33	production	production	NOUN
chd-169	239	34	through	through	ADP
chd-169	239	35	the	the	DET
chd-169	239	36	hypothalamic	hypothalamic	ADJ
chd-169	239	37	-	-	PUNCT
chd-169	239	38	pituitary	pituitary	ADJ
chd-169	239	39	-	-	PUNCT
chd-169	239	40	testicular	testicular	NOUN
chd-169	239	41	(	(	PUNCT
chd-169	239	42	hpt	hpt	NOUN
chd-169	239	43	)	)	PUNCT
chd-169	239	44	axis	axis	NOUN
chd-169	239	45	.	.	PUNCT
chd-169	240	1	there	there	PRON
chd-169	240	2	are	be	VERB
chd-169	240	3	also	also	ADV
chd-169	240	4	first	first	ADJ
chd-169	240	5	-	-	PUNCT
chd-169	240	6	line	line	NOUN
chd-169	240	7	anti	anti	ADJ
chd-169	240	8	-	-	NOUN
chd-169	240	9	androgens	androgens	ADJ
chd-169	240	10	that	that	PRON
chd-169	240	11	bind	bind	VERB
chd-169	240	12	to	to	PART
chd-169	240	13	ar	ar	VERB
chd-169	240	14	and	and	CCONJ
chd-169	240	15	inhibit	inhibit	VERB
chd-169	240	16	its	its	PRON
chd-169	240	17	activity	activity	NOUN
chd-169	240	18	including	include	VERB
chd-169	240	19	flutamide	flutamide	NOUN
chd-169	240	20	,	,	PUNCT
chd-169	240	21	bicalutamide	bicalutamide	VERB
chd-169	240	22	,	,	PUNCT
chd-169	240	23	and	and	CCONJ
chd-169	240	24	nilutamide	nilutamide	ADV
chd-169	240	25	(	(	PUNCT
chd-169	240	26	boccon	boccon	NOUN
chd-169	240	27	-	-	PUNCT
chd-169	240	28	gibod	gibod	NOUN
chd-169	240	29	et	et	PROPN
chd-169	240	30	al	al	PROPN
chd-169	240	31	.	.	PROPN
chd-169	240	32	,	,	PUNCT
chd-169	240	33	1997	1997	NUM
chd-169	240	34	;	;	PUNCT
chd-169	240	35	kolvenbag	kolvenbag	PROPN
chd-169	240	36	and	and	CCONJ
chd-169	240	37	nash	nash	PROPN
chd-169	240	38	,	,	PUNCT
chd-169	240	39	1999	1999	NUM
chd-169	240	40	;	;	PUNCT
chd-169	240	41	todd	todd	PROPN
chd-169	240	42	et	et	PROPN
chd-169	240	43	al	al	PROPN
chd-169	240	44	.	.	PROPN
chd-169	240	45	,	,	PUNCT
chd-169	240	46	2005	2005	NUM
chd-169	240	47	)	)	PUNCT
chd-169	240	48	.	.	PUNCT
chd-169	241	1	while	while	SCONJ
chd-169	241	2	adt	adt	NOUN
chd-169	241	3	with	with	ADP
chd-169	241	4	first	first	ADJ
chd-169	241	5	-	-	PUNCT
chd-169	241	6	line	line	NOUN
chd-169	241	7	anti	anti	ADJ
chd-169	241	8	-	-	ADJ
chd-169	241	9	androgens	androgens	ADJ
chd-169	241	10	is	be	AUX
chd-169	241	11	initially	initially	ADV
chd-169	241	12	successful	successful	ADJ
chd-169	241	13	in	in	ADP
chd-169	241	14	most	most	ADJ
chd-169	241	15	pca	pca	NOUN
chd-169	241	16	patients	patient	NOUN
chd-169	241	17	who	who	PRON
chd-169	241	18	choose	choose	VERB
chd-169	241	19	this	this	DET
chd-169	241	20	option	option	NOUN
chd-169	241	21	after	after	ADP
chd-169	241	22	biochemical	biochemical	ADJ
chd-169	241	23	recurrence	recurrence	NOUN
chd-169	241	24	,	,	PUNCT
chd-169	241	25	resistance	resistance	NOUN
chd-169	241	26	to	to	ADP
chd-169	241	27	this	this	DET
chd-169	241	28	therapy	therapy	NOUN
chd-169	241	29	is	be	AUX
chd-169	241	30	inevitable	inevitable	ADJ
chd-169	241	31	,	,	PUNCT
chd-169	241	32	occurring	occur	VERB
chd-169	241	33	within	within	ADP
chd-169	241	34	18	18	NUM
chd-169	241	35	-	-	SYM
chd-169	241	36	24	24	NUM
chd-169	241	37	months	month	NOUN
chd-169	241	38	(	(	PUNCT
chd-169	241	39	asmane	asmane	NOUN
chd-169	241	40	et	et	PROPN
chd-169	241	41	al	al	PROPN
chd-169	241	42	.	.	PROPN
chd-169	241	43	,	,	PUNCT
chd-169	241	44	2011	2011	NUM
chd-169	241	45	)	)	PUNCT
chd-169	241	46	.	.	PUNCT
chd-169	242	1	prostatic	prostatic	ADJ
chd-169	242	2	epithelial	epithelial	ADJ
chd-169	242	3	cells	cell	NOUN
chd-169	242	4	demonstrate	demonstrate	VERB
chd-169	242	5	great	great	ADJ
chd-169	242	6	plasticity	plasticity	NOUN
chd-169	242	7	in	in	ADP
chd-169	242	8	response	response	NOUN
chd-169	242	9	to	to	ADP
chd-169	242	10	adt	adt	NOUN
chd-169	242	11	,	,	PUNCT
chd-169	242	12	giving	give	VERB
chd-169	242	13	rise	rise	NOUN
chd-169	242	14	to	to	ADP
chd-169	242	15	a	a	DET
chd-169	242	16	highly	highly	ADV
chd-169	242	17	heterogeneous	heterogeneous	ADJ
chd-169	242	18	coexistence	coexistence	NOUN
chd-169	242	19	of	of	ADP
chd-169	242	20	ar	ar	NOUN
chd-169	242	21	-	-	ADJ
chd-169	242	22	positive	positive	ADJ
chd-169	242	23	and	and	CCONJ
chd-169	242	24	ar	ar	ADJ
chd-169	242	25	-	-	ADJ
chd-169	242	26	negative	negative	ADJ
chd-169	242	27	cells	cell	NOUN
chd-169	242	28	(	(	PUNCT
chd-169	242	29	banerjee	banerjee	PROPN
chd-169	242	30	et	et	PROPN
chd-169	242	31	al	al	PROPN
chd-169	242	32	.	.	PROPN
chd-169	242	33	,	,	PUNCT
chd-169	242	34	2018	2018	NUM
chd-169	242	35	)	)	PUNCT
chd-169	242	36	.	.	PUNCT
chd-169	243	1	a	a	DET
chd-169	243	2	relatively	relatively	ADV
chd-169	243	3	short	short	ADJ
chd-169	243	4	time	time	NOUN
chd-169	243	5	after	after	ADP
chd-169	243	6	development	development	NOUN
chd-169	243	7	of	of	ADP
chd-169	243	8	adt	adt	NOUN
chd-169	243	9	-	-	PUNCT
chd-169	243	10	resistance	resistance	NOUN
chd-169	243	11	,	,	PUNCT
chd-169	243	12	the	the	DET
chd-169	243	13	patient	patient	NOUN
chd-169	243	14	enters	enter	VERB
chd-169	243	15	a	a	DET
chd-169	243	16	disease	disease	NOUN
chd-169	243	17	stage	stage	NOUN
chd-169	243	18	referred	refer	VERB
chd-169	243	19	to	to	ADP
chd-169	243	20	as	as	ADP
chd-169	243	21	mcrpc	mcrpc	NOUN
chd-169	243	22	,	,	PUNCT
chd-169	243	23	which	which	PRON
chd-169	243	24	typically	typically	ADV
chd-169	243	25	has	have	VERB
chd-169	243	26	a	a	DET
chd-169	243	27	5	5	NUM
chd-169	243	28	-	-	PUNCT
chd-169	243	29	year	year	NOUN
chd-169	243	30	survival	survival	NOUN
chd-169	243	31	rate	rate	NOUN
chd-169	243	32	of	of	ADP
chd-169	243	33	30	30	NUM
chd-169	243	34	%	%	NOUN
chd-169	243	35	(	(	PUNCT
chd-169	243	36	scher	scher	PROPN
chd-169	243	37	et	et	PROPN
chd-169	243	38	al	al	PROPN
chd-169	243	39	.	.	PROPN
chd-169	243	40	,	,	PUNCT
chd-169	243	41	2004	2004	NUM
chd-169	243	42	;	;	PUNCT
chd-169	243	43	thoreson	thoreson	PROPN
chd-169	243	44	et	et	PROPN
chd-169	243	45	al	al	PROPN
chd-169	243	46	.	.	PROPN
chd-169	243	47	,	,	PUNCT
chd-169	243	48	2014	2014	NUM
chd-169	243	49	)	)	PUNCT
chd-169	243	50	.	.	PUNCT
chd-169	244	1	therapeutic	therapeutic	ADJ
chd-169	244	2	options	option	NOUN
chd-169	244	3	for	for	ADP
chd-169	244	4	patients	patient	NOUN
chd-169	244	5	with	with	ADP
chd-169	244	6	mcrpc	mcrpc	NOUN
chd-169	244	7	include	include	VERB
chd-169	244	8	arsi	arsi	ADJ
chd-169	244	9	,	,	PUNCT
chd-169	244	10	immunotherapy	immunotherapy	NOUN
chd-169	244	11	,	,	PUNCT
chd-169	244	12	radiation	radiation	NOUN
chd-169	244	13	therapy	therapy	NOUN
chd-169	244	14	with	with	ADP
chd-169	244	15	radium223	radium223	PROPN
chd-169	244	16	,	,	PUNCT
chd-169	244	17	and	and	CCONJ
chd-169	244	18	taxane	taxane	NOUN
chd-169	244	19	-	-	PUNCT
chd-169	244	20	based	base	VERB
chd-169	244	21	chemotherapy	chemotherapy	NOUN
chd-169	244	22	with	with	ADP
chd-169	244	23	docetaxel	docetaxel	PROPN
chd-169	244	24	(	(	PUNCT
chd-169	244	25	dtx	dtx	PROPN
chd-169	244	26	)	)	PUNCT
chd-169	244	27	or	or	CCONJ
chd-169	244	28	cabazitaxel	cabazitaxel	PROPN
chd-169	244	29	(	(	PUNCT
chd-169	244	30	cbz	cbz	NOUN
chd-169	244	31	)	)	PUNCT
chd-169	244	32	plus	plus	CCONJ
chd-169	244	33	the	the	DET
chd-169	244	34	glucocorticoids	glucocorticoid	NOUN
chd-169	244	35	dexamethasone	dexamethasone	NOUN
chd-169	244	36	or	or	CCONJ
chd-169	244	37	prednisone	prednisone	PROPN
chd-169	244	38	(	(	PUNCT
chd-169	244	39	arlen	arlen	PROPN
chd-169	244	40	and	and	CCONJ
chd-169	244	41	gulley	gulley	NOUN
chd-169	244	42	,	,	PUNCT
chd-169	244	43	2005	2005	NUM
chd-169	244	44	;	;	PUNCT
chd-169	244	45	corn	corn	NOUN
chd-169	244	46	et	et	PROPN
chd-169	244	47	al	al	PROPN
chd-169	244	48	.	.	PROPN
chd-169	244	49	,	,	PUNCT
chd-169	244	50	2017	2017	NUM
chd-169	244	51	;	;	PUNCT
chd-169	244	52	gilbert	gilbert	PROPN
chd-169	244	53	and	and	CCONJ
chd-169	244	54	parker	parker	PROPN
chd-169	244	55	,	,	PUNCT
chd-169	244	56	2005	2005	NUM
chd-169	244	57	)	)	PUNCT
chd-169	244	58	.	.	PUNCT
chd-169	245	1	second	second	ADJ
chd-169	245	2	-	-	PUNCT
chd-169	245	3	line	line	NOUN
chd-169	245	4	,	,	PUNCT
chd-169	245	5	next	next	ADJ
chd-169	245	6	-	-	PUNCT
chd-169	245	7	generation	generation	NOUN
chd-169	245	8	arsis	arsis	NOUN
chd-169	245	9	such	such	ADJ
chd-169	245	10	as	as	ADP
chd-169	245	11	enzalutamide	enzalutamide	ADV
chd-169	245	12	and	and	CCONJ
chd-169	245	13	apalutamide	apalutamide	ADV
chd-169	245	14	have	have	AUX
chd-169	245	15	been	be	AUX
chd-169	245	16	developed	develop	VERB
chd-169	245	17	during	during	ADP
chd-169	245	18	the	the	DET
chd-169	245	19	past	past	ADJ
chd-169	245	20	decade	decade	NOUN
chd-169	245	21	for	for	ADP
chd-169	245	22	pca	pca	NOUN
chd-169	245	23	patients	patient	NOUN
chd-169	245	24	who	who	PRON
chd-169	245	25	have	have	AUX
chd-169	245	26	failed	fail	VERB
chd-169	245	27	lhrh	lhrh	NOUN
chd-169	245	28	agonists	agonist	NOUN
chd-169	245	29	/	/	SYM
chd-169	245	30	antagonists	antagonist	NOUN
chd-169	245	31	or	or	CCONJ
chd-169	245	32	other	other	ADJ
chd-169	245	33	first	first	ADJ
chd-169	245	34	-	-	PUNCT
chd-169	245	35	line	line	NOUN
chd-169	245	36	antiandrogens	antiandrogen	NOUN
chd-169	245	37	(	(	PUNCT
chd-169	245	38	banerjee	banerjee	PROPN
chd-169	245	39	et	et	PROPN
chd-169	245	40	al	al	PROPN
chd-169	245	41	.	.	PROPN
chd-169	245	42	,	,	PUNCT
chd-169	245	43	2018	2018	NUM
chd-169	245	44	)	)	PUNCT
chd-169	245	45	.	.	PUNCT
chd-169	246	1	another	another	DET
chd-169	246	2	clinically	clinically	ADV
chd-169	246	3	relevant	relevant	ADJ
chd-169	246	4	arsi	arsi	ADJ
chd-169	246	5	,	,	PUNCT
chd-169	246	6	abiraterone	abiraterone	NOUN
chd-169	246	7	,	,	PUNCT
chd-169	246	8	is	be	AUX
chd-169	246	9	an	an	DET
chd-169	246	10	inhibitor	inhibitor	NOUN
chd-169	246	11	of	of	ADP
chd-169	246	12	androgen	androgen	NOUN
chd-169	246	13	biosynthesis	biosynthesis	NOUN
chd-169	246	14	that	that	PRON
chd-169	246	15	acts	act	VERB
chd-169	246	16	by	by	ADP
chd-169	246	17	blocking	block	VERB
chd-169	246	18	the	the	DET
chd-169	246	19	activity	activity	NOUN
chd-169	246	20	of	of	ADP
chd-169	246	21	cytochrome	cytochrome	NOUN
chd-169	246	22	p450	p450	NUM
chd-169	246	23	17	17	NUM
chd-169	246	24	alpha	alpha	NOUN
chd-169	246	25	-	-	PUNCT
chd-169	246	26	hydroxylase	hydroxylase	NOUN
chd-169	246	27	(	(	PUNCT
chd-169	246	28	cyp17	cyp17	PROPN
chd-169	246	29	)	)	PUNCT
chd-169	246	30	,	,	PUNCT
chd-169	246	31	a	a	DET
chd-169	246	32	key	key	ADJ
chd-169	246	33	enzyme	enzyme	NOUN
chd-169	246	34	that	that	PRON
chd-169	246	35	is	be	AUX
chd-169	246	36	essential	essential	ADJ
chd-169	246	37	for	for	ADP
chd-169	246	38	the	the	DET
chd-169	246	39	generation	generation	NOUN
chd-169	246	40	of	of	ADP
chd-169	246	41	the	the	DET
chd-169	246	42	androgen	androgen	NOUN
chd-169	246	43	precursor	precursor	NOUN
chd-169	246	44	dehydroepiandrosterone	dehydroepiandrosterone	PROPN
chd-169	246	45	(	(	PUNCT
chd-169	246	46	dhea	dhea	PROPN
chd-169	246	47	)	)	PUNCT
chd-169	246	48	(	(	PUNCT
chd-169	246	49	rehman	rehman	NOUN
chd-169	246	50	and	and	CCONJ
chd-169	246	51	rosenberg	rosenberg	PROPN
chd-169	246	52	,	,	PUNCT
chd-169	246	53	2012	2012	NUM
chd-169	246	54	)	)	PUNCT
chd-169	246	55	.	.	PUNCT
chd-169	247	1	dtx	dtx	PROPN
chd-169	247	2	and/or	and/or	CCONJ
chd-169	247	3	cbz	cbz	NOUN
chd-169	247	4	can	can	AUX
chd-169	247	5	extend	extend	VERB
chd-169	247	6	patient	patient	ADJ
chd-169	247	7	survival	survival	NOUN
chd-169	247	8	by	by	ADP
chd-169	247	9	a	a	DET
chd-169	247	10	few	few	ADJ
chd-169	247	11	months	month	NOUN
chd-169	247	12	,	,	PUNCT
chd-169	247	13	but	but	CCONJ
chd-169	247	14	chemoresistance	chemoresistance	NOUN
chd-169	247	15	develops	develop	VERB
chd-169	247	16	,	,	PUNCT
chd-169	247	17	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-169	247	18	e16	e16	PROPN
chd-169	247	19	cancer	cancer	NOUN
chd-169	247	20	health	health	NOUN
chd-169	247	21	disparities	disparity	NOUN
chd-169	247	22	research	research	NOUN
chd-169	247	23	curtailing	curtail	VERB
chd-169	247	24	the	the	DET
chd-169	247	25	beneficial	beneficial	ADJ
chd-169	247	26	effects	effect	NOUN
chd-169	247	27	of	of	ADP
chd-169	247	28	these	these	DET
chd-169	247	29	taxane	taxane	NOUN
chd-169	247	30	drugs	drug	NOUN
chd-169	247	31	(	(	PUNCT
chd-169	247	32	arlen	arlen	NOUN
chd-169	247	33	and	and	CCONJ
chd-169	247	34	gulley	gulley	NOUN
chd-169	247	35	,	,	PUNCT
chd-169	247	36	2005	2005	NUM
chd-169	247	37	;	;	PUNCT
chd-169	247	38	corn	corn	NOUN
chd-169	247	39	et	et	PROPN
chd-169	247	40	al	al	PROPN
chd-169	247	41	.	.	PROPN
chd-169	247	42	,	,	PUNCT
chd-169	247	43	2017	2017	NUM
chd-169	247	44	;	;	PUNCT
chd-169	247	45	gilbert	gilbert	PROPN
chd-169	247	46	and	and	CCONJ
chd-169	247	47	parker	parker	PROPN
chd-169	247	48	,	,	PUNCT
chd-169	247	49	2005	2005	NUM
chd-169	247	50	)	)	PUNCT
chd-169	247	51	.	.	PUNCT
chd-169	248	1	although	although	SCONJ
chd-169	248	2	not	not	PART
chd-169	248	3	all	all	DET
chd-169	248	4	pca	pca	NOUN
chd-169	248	5	patients	patient	NOUN
chd-169	248	6	that	that	PRON
chd-169	248	7	fail	fail	VERB
chd-169	248	8	anti	anti	ADJ
chd-169	248	9	-	-	ADJ
chd-169	248	10	androgen	androgen	ADJ
chd-169	248	11	therapy	therapy	NOUN
chd-169	248	12	undergo	undergo	VERB
chd-169	248	13	chemotherapy	chemotherapy	NOUN
chd-169	248	14	,	,	PUNCT
chd-169	248	15	results	result	VERB
chd-169	248	16	from	from	ADP
chd-169	248	17	the	the	DET
chd-169	248	18	recent	recent	ADJ
chd-169	248	19	clinical	clinical	ADJ
chd-169	248	20	trials	trial	NOUN
chd-169	248	21	chaarted	chaarte	VERB
chd-169	248	22	and	and	CCONJ
chd-169	248	23	stampede	stampede	NOUN
chd-169	248	24	showed	show	VERB
chd-169	248	25	that	that	SCONJ
chd-169	248	26	administering	administer	VERB
chd-169	248	27	dtx	dtx	NOUN
chd-169	248	28	together	together	ADV
chd-169	248	29	with	with	ADP
chd-169	248	30	anti	anti	ADJ
chd-169	248	31	-	-	ADJ
chd-169	248	32	androgen	androgen	ADJ
chd-169	248	33	therapy	therapy	NOUN
chd-169	248	34	in	in	ADP
chd-169	248	35	newly	newly	ADV
chd-169	248	36	diagnosed	diagnose	VERB
chd-169	248	37	mcrpc	mcrpc	NOUN
chd-169	248	38	patients	patient	NOUN
chd-169	248	39	provides	provide	VERB
chd-169	248	40	a	a	DET
chd-169	248	41	dramatic	dramatic	ADJ
chd-169	248	42	increase	increase	NOUN
chd-169	248	43	in	in	ADP
chd-169	248	44	overall	overall	ADJ
chd-169	248	45	survival	survival	NOUN
chd-169	248	46	advantage	advantage	NOUN
chd-169	248	47	compared	compare	VERB
chd-169	248	48	to	to	ADP
chd-169	248	49	adt	adt	NOUN
chd-169	248	50	alone	alone	ADV
chd-169	248	51	(	(	PUNCT
chd-169	248	52	james	james	PROPN
chd-169	248	53	et	et	PROPN
chd-169	248	54	al	al	PROPN
chd-169	248	55	.	.	PROPN
chd-169	248	56	,	,	PUNCT
chd-169	248	57	2016	2016	NUM
chd-169	248	58	;	;	PUNCT
chd-169	248	59	kyriakopoulos	kyriakopoulos	PROPN
chd-169	248	60	et	et	PROPN
chd-169	248	61	al	al	PROPN
chd-169	248	62	.	.	PROPN
chd-169	248	63	,	,	PUNCT
chd-169	248	64	2018	2018	NUM
chd-169	248	65	)	)	PUNCT
chd-169	248	66	.	.	PUNCT
chd-169	249	1	other	other	ADJ
chd-169	249	2	recent	recent	ADJ
chd-169	249	3	trials	trial	NOUN
chd-169	249	4	combining	combine	VERB
chd-169	249	5	emerging	emerge	VERB
chd-169	249	6	therapies	therapy	NOUN
chd-169	249	7	or	or	CCONJ
chd-169	249	8	modifying	modify	VERB
chd-169	249	9	the	the	DET
chd-169	249	10	sequence	sequence	NOUN
chd-169	249	11	of	of	ADP
chd-169	249	12	available	available	ADJ
chd-169	249	13	therapies	therapy	NOUN
chd-169	249	14	have	have	AUX
chd-169	249	15	yielded	yield	VERB
chd-169	249	16	promising	promising	ADJ
chd-169	249	17	results	result	NOUN
chd-169	249	18	for	for	ADP
chd-169	249	19	the	the	DET
chd-169	249	20	treatment	treatment	NOUN
chd-169	249	21	of	of	ADP
chd-169	249	22	mcrpc	mcrpc	NOUN
chd-169	249	23	(	(	PUNCT
chd-169	249	24	ku	ku	PROPN
chd-169	249	25	et	et	PROPN
chd-169	249	26	al	al	PROPN
chd-169	249	27	.	.	PROPN
chd-169	249	28	,	,	PUNCT
chd-169	249	29	2019	2019	NUM
chd-169	249	30	;	;	PUNCT
chd-169	249	31	schmid	schmid	PROPN
chd-169	249	32	and	and	CCONJ
chd-169	249	33	omlin	omlin	PROPN
chd-169	249	34	,	,	PUNCT
chd-169	249	35	2020	2020	NUM
chd-169	249	36	)	)	PUNCT
chd-169	249	37	.	.	PUNCT
chd-169	250	1	because	because	SCONJ
chd-169	250	2	of	of	ADP
chd-169	250	3	the	the	DET
chd-169	250	4	tumor	tumor	NOUN
chd-169	250	5	heterogeneity	heterogeneity	NOUN
chd-169	250	6	observed	observe	VERB
chd-169	250	7	within	within	ADP
chd-169	250	8	and	and	CCONJ
chd-169	250	9	among	among	ADP
chd-169	250	10	pca	pca	NOUN
chd-169	250	11	patients	patient	NOUN
chd-169	250	12	,	,	PUNCT
chd-169	250	13	developing	develop	VERB
chd-169	250	14	effective	effective	ADJ
chd-169	250	15	therapies	therapy	NOUN
chd-169	250	16	for	for	ADP
chd-169	250	17	this	this	DET
chd-169	250	18	malignancy	malignancy	NOUN
chd-169	250	19	remains	remain	VERB
chd-169	250	20	challenging	challenge	VERB
chd-169	250	21	(	(	PUNCT
chd-169	250	22	ku	ku	PROPN
chd-169	250	23	et	et	PROPN
chd-169	250	24	al	al	PROPN
chd-169	250	25	.	.	PROPN
chd-169	250	26	,	,	PUNCT
chd-169	250	27	2019	2019	NUM
chd-169	250	28	;	;	PUNCT
chd-169	250	29	maitland	maitland	PROPN
chd-169	250	30	et	et	PROPN
chd-169	250	31	al	al	PROPN
chd-169	250	32	.	.	PROPN
chd-169	250	33	,	,	PUNCT
chd-169	250	34	2019	2019	NUM
chd-169	250	35	)	)	PUNCT
chd-169	250	36	.	.	PUNCT
chd-169	251	1	despite	despite	SCONJ
chd-169	251	2	the	the	DET
chd-169	251	3	spectrum	spectrum	NOUN
chd-169	251	4	of	of	ADP
chd-169	251	5	therapeutic	therapeutic	ADJ
chd-169	251	6	options	option	NOUN
chd-169	251	7	for	for	ADP
chd-169	251	8	mcrpc	mcrpc	NOUN
chd-169	251	9	which	which	PRON
chd-169	251	10	provide	provide	VERB
chd-169	251	11	increased	increase	VERB
chd-169	251	12	overall	overall	ADJ
chd-169	251	13	survival	survival	NOUN
chd-169	251	14	benefits	benefit	NOUN
chd-169	251	15	with	with	ADP
chd-169	251	16	improved	improved	ADJ
chd-169	251	17	quality	quality	NOUN
chd-169	251	18	of	of	ADP
chd-169	251	19	life	life	NOUN
chd-169	251	20	,	,	PUNCT
chd-169	251	21	this	this	DET
chd-169	251	22	advanced	advanced	ADJ
chd-169	251	23	stage	stage	NOUN
chd-169	251	24	of	of	ADP
chd-169	251	25	the	the	DET
chd-169	251	26	disease	disease	NOUN
chd-169	251	27	still	still	ADV
chd-169	251	28	remains	remain	VERB
chd-169	251	29	incurable	incurable	ADJ
chd-169	251	30	due	due	ADP
chd-169	251	31	to	to	ADP
chd-169	251	32	the	the	DET
chd-169	251	33	development	development	NOUN
chd-169	251	34	of	of	ADP
chd-169	251	35	therapy	therapy	NOUN
chd-169	251	36	resistance	resistance	NOUN
chd-169	251	37	.	.	PUNCT
chd-169	252	1	a	a	DET
chd-169	252	2	promising	promising	ADJ
chd-169	252	3	emerging	emerge	VERB
chd-169	252	4	therapy	therapy	NOUN
chd-169	252	5	for	for	ADP
chd-169	252	6	mcrpc	mcrpc	NOUN
chd-169	252	7	based	base	VERB
chd-169	252	8	on	on	ADP
chd-169	252	9	prostate	prostate	NOUN
chd-169	252	10	specific	specific	ADJ
chd-169	252	11	membrane	membrane	NOUN
chd-169	252	12	antigen	antigen	NOUN
chd-169	252	13	(	(	PUNCT
chd-169	252	14	psma	psma	NOUN
chd-169	252	15	)	)	PUNCT
chd-169	252	16	theranostics	theranostic	NOUN
chd-169	252	17	,	,	PUNCT
chd-169	252	18	which	which	PRON
chd-169	252	19	combines	combine	VERB
chd-169	252	20	positron	positron	NOUN
chd-169	252	21	emission	emission	NOUN
chd-169	252	22	tomography	tomography	NOUN
chd-169	252	23	(	(	PUNCT
chd-169	252	24	pet	pet	NOUN
chd-169	252	25	)	)	PUNCT
chd-169	252	26	imaging	imaging	NOUN
chd-169	252	27	with	with	ADP
chd-169	252	28	tumor	tumor	NOUN
chd-169	252	29	targeting	target	VERB
chd-169	252	30	,	,	PUNCT
chd-169	252	31	is	be	AUX
chd-169	252	32	bringing	bring	VERB
chd-169	252	33	hope	hope	NOUN
chd-169	252	34	to	to	ADP
chd-169	252	35	the	the	DET
chd-169	252	36	diagnosis	diagnosis	NOUN
chd-169	252	37	and	and	CCONJ
chd-169	252	38	treatment	treatment	NOUN
chd-169	252	39	of	of	ADP
chd-169	252	40	men	man	NOUN
chd-169	252	41	with	with	ADP
chd-169	252	42	advanced	advanced	ADJ
chd-169	252	43	pca	pca	NOUN
chd-169	252	44	(	(	PUNCT
chd-169	252	45	kratochwil	kratochwil	NOUN
chd-169	252	46	et	et	PROPN
chd-169	252	47	al	al	PROPN
chd-169	252	48	.	.	PROPN
chd-169	252	49	,	,	PUNCT
chd-169	252	50	2019	2019	NUM
chd-169	252	51	)	)	PUNCT
chd-169	252	52	.	.	PUNCT
chd-169	253	1	psma	psma	PROPN
chd-169	253	2	is	be	AUX
chd-169	253	3	a	a	DET
chd-169	253	4	transmembrane	transmembrane	ADJ
chd-169	253	5	glycoprotein	glycoprotein	NOUN
chd-169	253	6	that	that	PRON
chd-169	253	7	is	be	AUX
chd-169	253	8	highly	highly	ADV
chd-169	253	9	expressed	express	VERB
chd-169	253	10	in	in	ADP
chd-169	253	11	pca	pca	PROPN
chd-169	253	12	,	,	PUNCT
chd-169	253	13	particularly	particularly	ADV
chd-169	253	14	in	in	ADP
chd-169	253	15	high	high	ADJ
chd-169	253	16	grade	grade	NOUN
chd-169	253	17	tumors	tumor	NOUN
chd-169	253	18	or	or	CCONJ
chd-169	253	19	mcrpc	mcrpc	NOUN
chd-169	253	20	,	,	PUNCT
chd-169	253	21	with	with	ADP
chd-169	253	22	minimal	minimal	ADJ
chd-169	253	23	or	or	CCONJ
chd-169	253	24	no	no	PRON
chd-169	253	25	expression	expression	NOUN
chd-169	253	26	in	in	ADP
chd-169	253	27	normal	normal	ADJ
chd-169	253	28	tissues	tissue	NOUN
chd-169	253	29	(	(	PUNCT
chd-169	253	30	silver	silver	NOUN
chd-169	253	31	et	et	PROPN
chd-169	253	32	al	al	PROPN
chd-169	253	33	.	.	PROPN
chd-169	253	34	,	,	PUNCT
chd-169	253	35	1997	1997	NUM
chd-169	253	36	)	)	PUNCT
chd-169	253	37	.	.	PUNCT
chd-169	254	1	currently	currently	ADV
chd-169	254	2	,	,	PUNCT
chd-169	254	3	a	a	DET
chd-169	254	4	psma	psma	NOUN
chd-169	254	5	specific	specific	ADJ
chd-169	254	6	ligand	ligand	NOUN
chd-169	254	7	labeled	label	VERB
chd-169	254	8	with	with	ADP
chd-169	254	9	a	a	DET
chd-169	254	10	positron	positron	NOUN
chd-169	254	11	emitter	emitter	NOUN
chd-169	254	12	is	be	AUX
chd-169	254	13	a	a	DET
chd-169	254	14	desirable	desirable	ADJ
chd-169	254	15	diagnostic	diagnostic	ADJ
chd-169	254	16	tool	tool	NOUN
chd-169	254	17	for	for	ADP
chd-169	254	18	detecting	detect	VERB
chd-169	254	19	metastatic	metastatic	ADJ
chd-169	254	20	disease	disease	NOUN
chd-169	254	21	at	at	ADP
chd-169	254	22	much	much	ADV
chd-169	254	23	lower	low	ADJ
chd-169	254	24	psa	psa	NOUN
chd-169	254	25	levels	level	NOUN
chd-169	254	26	than	than	ADP
chd-169	254	27	conventional	conventional	ADJ
chd-169	254	28	imaging	imaging	NOUN
chd-169	254	29	.	.	PUNCT
chd-169	255	1	patients	patient	NOUN
chd-169	255	2	with	with	ADP
chd-169	255	3	high	high	ADJ
chd-169	255	4	psma	psma	NOUN
chd-169	255	5	tumor	tumor	NOUN
chd-169	255	6	expression	expression	NOUN
chd-169	255	7	can	can	AUX
chd-169	255	8	then	then	ADV
chd-169	255	9	undergo	undergo	VERB
chd-169	255	10	targeted	target	VERB
chd-169	255	11	radioligand	radioligand	NOUN
chd-169	255	12	therapy	therapy	NOUN
chd-169	255	13	using	use	VERB
chd-169	255	14	the	the	DET
chd-169	255	15	same	same	ADJ
chd-169	255	16	psma	psma	NOUN
chd-169	255	17	ligand	ligand	NOUN
chd-169	255	18	labeled	label	VERB
chd-169	255	19	with	with	ADP
chd-169	255	20	a	a	DET
chd-169	255	21	beta	beta	NOUN
chd-169	255	22	emitter	emitter	NOUN
chd-169	255	23	(	(	PUNCT
chd-169	255	24	e.g.	e.g.	ADV
chd-169	255	25	177lutetium	177lutetium	NUM
chd-169	255	26	)	)	PUNCT
chd-169	255	27	or	or	CCONJ
chd-169	255	28	an	an	DET
chd-169	255	29	alpha	alpha	NOUN
chd-169	255	30	emitter	emitter	NOUN
chd-169	255	31	(	(	PUNCT
chd-169	255	32	e.g.	e.g.	ADV
chd-169	255	33	225actinium	225actinium	PROPN
chd-169	255	34	)	)	PUNCT
chd-169	255	35	to	to	PART
chd-169	255	36	selectively	selectively	ADV
chd-169	255	37	destroy	destroy	VERB
chd-169	255	38	the	the	DET
chd-169	255	39	cancer	cancer	NOUN
chd-169	255	40	cells	cell	NOUN
chd-169	255	41	without	without	ADP
chd-169	255	42	damaging	damage	VERB
chd-169	255	43	normal	normal	ADJ
chd-169	255	44	tissues	tissue	NOUN
chd-169	255	45	(	(	PUNCT
chd-169	255	46	baum	baum	PROPN
chd-169	255	47	and	and	CCONJ
chd-169	255	48	kulkarni	kulkarni	PROPN
chd-169	255	49	,	,	PUNCT
chd-169	255	50	2012	2012	NUM
chd-169	255	51	)	)	PUNCT
chd-169	255	52	.	.	PUNCT
chd-169	256	1	the	the	DET
chd-169	256	2	implementation	implementation	NOUN
chd-169	256	3	of	of	ADP
chd-169	256	4	psma	psma	NOUN
chd-169	256	5	theranostics	theranostic	NOUN
chd-169	256	6	in	in	ADP
chd-169	256	7	clinical	clinical	ADJ
chd-169	256	8	practice	practice	NOUN
chd-169	256	9	has	have	VERB
chd-169	256	10	the	the	DET
chd-169	256	11	potential	potential	NOUN
chd-169	256	12	to	to	PART
chd-169	256	13	revolutionize	revolutionize	VERB
chd-169	256	14	mcrpc	mcrpc	PROPN
chd-169	256	15	treatment	treatment	NOUN
chd-169	256	16	and	and	CCONJ
chd-169	256	17	improve	improve	VERB
chd-169	256	18	patient	patient	ADJ
chd-169	256	19	outcomes	outcome	NOUN
chd-169	256	20	.	.	PUNCT
chd-169	257	1	prospective	prospective	ADJ
chd-169	257	2	randomized	randomized	ADJ
chd-169	257	3	clinical	clinical	ADJ
chd-169	257	4	trials	trial	NOUN
chd-169	257	5	are	be	AUX
chd-169	257	6	currently	currently	ADV
chd-169	257	7	underway	underway	ADJ
chd-169	257	8	worldwide	worldwide	ADV
chd-169	257	9	to	to	PART
chd-169	257	10	validate	validate	VERB
chd-169	257	11	psma	psma	NOUN
chd-169	257	12	theranostics	theranostic	NOUN
chd-169	257	13	compared	compare	VERB
chd-169	257	14	to	to	ADP
chd-169	257	15	available	available	ADJ
chd-169	257	16	standard	standard	NOUN
chd-169	257	17	of	of	ADP
chd-169	257	18	care	care	NOUN
chd-169	257	19	therapies	therapy	NOUN
chd-169	257	20	for	for	ADP
chd-169	257	21	mcrpc	mcrpc	NOUN
chd-169	257	22	.	.	PUNCT
chd-169	258	1	the	the	DET
chd-169	258	2	optimal	optimal	ADJ
chd-169	258	3	timing	timing	NOUN
chd-169	258	4	for	for	ADP
chd-169	258	5	administering	administer	VERB
chd-169	258	6	this	this	DET
chd-169	258	7	therapy	therapy	NOUN
chd-169	258	8	relative	relative	ADJ
chd-169	258	9	to	to	ADP
chd-169	258	10	the	the	DET
chd-169	258	11	sequence	sequence	NOUN
chd-169	258	12	of	of	ADP
chd-169	258	13	other	other	ADJ
chd-169	258	14	therapies	therapy	NOUN
chd-169	258	15	has	have	VERB
chd-169	258	16	yet	yet	ADV
chd-169	258	17	to	to	PART
chd-169	258	18	be	be	AUX
chd-169	258	19	defined	define	VERB
chd-169	258	20	.	.	PUNCT
chd-169	259	1	glucocorticoids	glucocorticoid	NOUN
chd-169	259	2	in	in	ADP
chd-169	259	3	pca	pca	NOUN
chd-169	259	4	treatment	treatment	NOUN
chd-169	259	5	the	the	DET
chd-169	259	6	synthetic	synthetic	ADJ
chd-169	259	7	glucocorticoids	glucocorticoid	NOUN
chd-169	259	8	prednisone	prednisone	NOUN
chd-169	259	9	and	and	CCONJ
chd-169	259	10	dexamethasone	dexamethasone	NOUN
chd-169	259	11	are	be	AUX
chd-169	259	12	routinely	routinely	ADV
chd-169	259	13	used	use	VERB
chd-169	259	14	therapeutically	therapeutically	ADV
chd-169	259	15	and	and	CCONJ
chd-169	259	16	have	have	VERB
chd-169	259	17	much	much	ADV
chd-169	259	18	higher	high	ADJ
chd-169	259	19	potency	potency	NOUN
chd-169	259	20	than	than	ADP
chd-169	259	21	cortisol	cortisol	NOUN
chd-169	259	22	in	in	ADP
chd-169	259	23	activating	activate	VERB
chd-169	259	24	gr	gr	PRON
chd-169	259	25	.	.	PUNCT
chd-169	260	1	for	for	ADP
chd-169	260	2	example	example	NOUN
chd-169	260	3	,	,	PUNCT
chd-169	260	4	4	4	NUM
chd-169	260	5	mg	mg	NOUN
chd-169	260	6	of	of	ADP
chd-169	260	7	prednisone	prednisone	PROPN
chd-169	260	8	and	and	CCONJ
chd-169	260	9	0.75	0.75	NUM
chd-169	260	10	mg	mg	NOUN
chd-169	260	11	of	of	ADP
chd-169	260	12	dexamethasone	dexamethasone	NOUN
chd-169	260	13	provide	provide	VERB
chd-169	260	14	the	the	DET
chd-169	260	15	physiological	physiological	ADJ
chd-169	260	16	equivalent	equivalent	NOUN
chd-169	260	17	of	of	ADP
chd-169	260	18	20	20	NUM
chd-169	260	19	mg	mg	NOUN
chd-169	260	20	of	of	ADP
chd-169	260	21	cortisol.(narayanan	cortisol.(narayanan	PROPN
chd-169	260	22	et	et	PROPN
chd-169	260	23	al	al	PROPN
chd-169	260	24	.	.	PROPN
chd-169	260	25	,	,	PUNCT
chd-169	260	26	2016	2016	NUM
chd-169	260	27	)	)	PUNCT
chd-169	260	28	prednisone	prednisone	NOUN
chd-169	260	29	is	be	AUX
chd-169	260	30	clinically	clinically	ADV
chd-169	260	31	used	use	VERB
chd-169	260	32	in	in	ADP
chd-169	260	33	doses	dose	NOUN
chd-169	260	34	of	of	ADP
chd-169	260	35	5	5	NUM
chd-169	260	36	-	-	SYM
chd-169	260	37	10	10	NUM
chd-169	260	38	mg	mg	NOUN
chd-169	260	39	once	once	ADV
chd-169	260	40	or	or	CCONJ
chd-169	260	41	twice	twice	ADV
chd-169	260	42	per	per	ADP
chd-169	260	43	day	day	NOUN
chd-169	260	44	and	and	CCONJ
chd-169	260	45	dexamethasone	dexamethasone	NOUN
chd-169	260	46	is	be	AUX
chd-169	260	47	used	use	VERB
chd-169	260	48	in	in	ADP
chd-169	260	49	doses	dose	NOUN
chd-169	260	50	at	at	ADP
chd-169	260	51	0.75	0.75	NUM
chd-169	260	52	-	-	SYM
chd-169	260	53	1	1	NUM
chd-169	260	54	mg	mg	NOUN
chd-169	260	55	once	once	ADV
chd-169	260	56	or	or	CCONJ
chd-169	260	57	twice	twice	ADV
chd-169	260	58	per	per	ADP
chd-169	260	59	day	day	NOUN
chd-169	260	60	(	(	PUNCT
chd-169	260	61	narayanan	narayanan	PROPN
chd-169	260	62	et	et	PROPN
chd-169	260	63	al	al	PROPN
chd-169	260	64	.	.	PROPN
chd-169	260	65	,	,	PUNCT
chd-169	260	66	2016	2016	NUM
chd-169	260	67	)	)	PUNCT
chd-169	260	68	.	.	PUNCT
chd-169	261	1	when	when	SCONJ
chd-169	261	2	co	co	VERB
chd-169	261	3	-	-	VERB
chd-169	261	4	administered	administer	VERB
chd-169	261	5	with	with	ADP
chd-169	261	6	taxane	taxane	NOUN
chd-169	261	7	chemotherapy	chemotherapy	NOUN
chd-169	261	8	for	for	ADP
chd-169	261	9	pca	pca	PROPN
chd-169	261	10	,	,	PUNCT
chd-169	261	11	their	their	PRON
chd-169	261	12	potent	potent	ADJ
chd-169	261	13	antiinflammatory	antiinflammatory	NOUN
chd-169	261	14	properties	property	NOUN
chd-169	261	15	counteract	counteract	VERB
chd-169	261	16	pain	pain	NOUN
chd-169	261	17	,	,	PUNCT
chd-169	261	18	nausea	nausea	NOUN
chd-169	261	19	,	,	PUNCT
chd-169	261	20	lack	lack	NOUN
chd-169	261	21	of	of	ADP
chd-169	261	22	appetite	appetite	NOUN
chd-169	261	23	,	,	PUNCT
chd-169	261	24	fatigue	fatigue	NOUN
chd-169	261	25	,	,	PUNCT
chd-169	261	26	hypersensitivity	hypersensitivity	NOUN
chd-169	261	27	,	,	PUNCT
chd-169	261	28	and	and	CCONJ
chd-169	261	29	fluid	fluid	ADJ
chd-169	261	30	retention	retention	NOUN
chd-169	261	31	(	(	PUNCT
chd-169	261	32	de	de	X
chd-169	261	33	bono	bono	X
chd-169	261	34	et	et	PROPN
chd-169	261	35	al	al	PROPN
chd-169	261	36	.	.	PROPN
chd-169	261	37	,	,	PUNCT
chd-169	261	38	2010	2010	NUM
chd-169	261	39	;	;	PUNCT
chd-169	261	40	dorff	dorff	PROPN
chd-169	261	41	and	and	CCONJ
chd-169	261	42	crawford	crawford	PROPN
chd-169	261	43	,	,	PUNCT
chd-169	261	44	2013	2013	NUM
chd-169	261	45	;	;	PUNCT
chd-169	261	46	lafeuille	lafeuille	VERB
chd-169	261	47	et	et	PROPN
chd-169	261	48	al	al	PROPN
chd-169	261	49	.	.	PROPN
chd-169	261	50	,	,	PUNCT
chd-169	261	51	2013	2013	NUM
chd-169	261	52	;	;	PUNCT
chd-169	261	53	schwartz	schwartz	PROPN
chd-169	261	54	,	,	PUNCT
chd-169	261	55	2012	2012	NUM
chd-169	261	56	;	;	PUNCT
chd-169	261	57	tannock	tannock	NOUN
chd-169	261	58	et	et	PROPN
chd-169	261	59	al	al	PROPN
chd-169	261	60	.	.	PROPN
chd-169	261	61	,	,	PUNCT
chd-169	261	62	2004	2004	NUM
chd-169	261	63	)	)	PUNCT
chd-169	261	64	.	.	PUNCT
chd-169	262	1	while	while	SCONJ
chd-169	262	2	the	the	DET
chd-169	262	3	benefits	benefit	NOUN
chd-169	262	4	of	of	ADP
chd-169	262	5	glucocorticoid	glucocorticoid	ADJ
chd-169	262	6	coadministration	coadministration	NOUN
chd-169	262	7	to	to	ADP
chd-169	262	8	pca	pca	NOUN
chd-169	262	9	patients	patient	NOUN
chd-169	262	10	have	have	AUX
chd-169	262	11	been	be	AUX
chd-169	262	12	established	establish	VERB
chd-169	262	13	,	,	PUNCT
chd-169	262	14	there	there	PRON
chd-169	262	15	is	be	VERB
chd-169	262	16	evidence	evidence	NOUN
chd-169	262	17	that	that	PRON
chd-169	262	18	increased	increase	VERB
chd-169	262	19	gr	gr	NOUN
chd-169	262	20	signaling	signal	VERB
chd-169	262	21	could	could	AUX
chd-169	262	22	also	also	ADV
chd-169	262	23	be	be	AUX
chd-169	262	24	detrimental	detrimental	ADJ
chd-169	262	25	to	to	ADP
chd-169	262	26	these	these	DET
chd-169	262	27	patients	patient	NOUN
chd-169	262	28	(	(	PUNCT
chd-169	262	29	arora	arora	PROPN
chd-169	262	30	et	et	PROPN
chd-169	262	31	al	al	PROPN
chd-169	262	32	.	.	PROPN
chd-169	262	33	,	,	PUNCT
chd-169	262	34	2013	2013	NUM
chd-169	262	35	;	;	PUNCT
chd-169	262	36	claessens	claessen	VERB
chd-169	262	37	et	et	PROPN
chd-169	262	38	al	al	PROPN
chd-169	262	39	.	.	PROPN
chd-169	262	40	,	,	PUNCT
chd-169	262	41	2017	2017	NUM
chd-169	262	42	;	;	PUNCT
chd-169	262	43	isikbay	isikbay	PROPN
chd-169	262	44	et	et	PROPN
chd-169	262	45	al	al	PROPN
chd-169	262	46	.	.	PROPN
chd-169	262	47	,	,	PUNCT
chd-169	262	48	2014	2014	NUM
chd-169	262	49	;	;	PUNCT
chd-169	262	50	kroon	kroon	PROPN
chd-169	262	51	et	et	PROPN
chd-169	262	52	al	al	PROPN
chd-169	262	53	.	.	PROPN
chd-169	262	54	,	,	PUNCT
chd-169	262	55	2016	2016	NUM
chd-169	262	56	;	;	PUNCT
chd-169	262	57	li	li	PROPN
chd-169	262	58	et	et	PROPN
chd-169	262	59	al	al	PROPN
chd-169	262	60	.	.	PROPN
chd-169	262	61	,	,	PUNCT
chd-169	262	62	2017	2017	NUM
chd-169	262	63	;	;	PUNCT
chd-169	262	64	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	X
chd-169	262	65	e17	e17	NOUN
chd-169	262	66	cancer	cancer	NOUN
chd-169	262	67	health	health	NOUN
chd-169	262	68	disparities	disparity	NOUN
chd-169	262	69	research	research	VERB
chd-169	262	70	montgomery	montgomery	PROPN
chd-169	262	71	et	et	PROPN
chd-169	262	72	al	al	PROPN
chd-169	262	73	.	.	PROPN
chd-169	262	74	,	,	PUNCT
chd-169	262	75	2014	2014	NUM
chd-169	262	76	;	;	PUNCT
chd-169	262	77	narayanan	narayanan	PROPN
chd-169	262	78	et	et	PROPN
chd-169	262	79	al	al	PROPN
chd-169	262	80	.	.	PROPN
chd-169	262	81	,	,	PUNCT
chd-169	262	82	2016	2016	NUM
chd-169	262	83	;	;	PUNCT
chd-169	262	84	puhr	puhr	NOUN
chd-169	262	85	et	et	PROPN
chd-169	262	86	al	al	PROPN
chd-169	262	87	.	.	PROPN
chd-169	262	88	,	,	PUNCT
chd-169	262	89	2018	2018	NUM
chd-169	262	90	;	;	PUNCT
chd-169	262	91	sartor	sartor	NOUN
chd-169	262	92	et	et	PROPN
chd-169	262	93	al	al	PROPN
chd-169	262	94	.	.	PROPN
chd-169	262	95	,	,	PUNCT
chd-169	262	96	2014	2014	NUM
chd-169	262	97	)	)	PUNCT
chd-169	262	98	.	.	PUNCT
chd-169	263	1	one	one	NUM
chd-169	263	2	study	study	NOUN
chd-169	263	3	by	by	ADP
chd-169	263	4	puhr	puhr	PROPN
chd-169	263	5	et	et	PROPN
chd-169	263	6	al	al	PROPN
chd-169	263	7	.	.	PROPN
chd-169	263	8	found	find	VERB
chd-169	263	9	that	that	SCONJ
chd-169	263	10	gr	gr	NUM
chd-169	263	11	expression	expression	NOUN
chd-169	263	12	is	be	AUX
chd-169	263	13	initially	initially	ADV
chd-169	263	14	reduced	reduce	VERB
chd-169	263	15	in	in	ADP
chd-169	263	16	primary	primary	ADJ
chd-169	263	17	pca	pca	NOUN
chd-169	263	18	tissue	tissue	NOUN
chd-169	263	19	,	,	PUNCT
chd-169	263	20	but	but	CCONJ
chd-169	263	21	is	be	AUX
chd-169	263	22	restored	restore	VERB
chd-169	263	23	in	in	ADP
chd-169	263	24	metastatic	metastatic	ADJ
chd-169	263	25	lesions	lesion	NOUN
chd-169	263	26	(	(	PUNCT
chd-169	263	27	puhr	puhr	NOUN
chd-169	263	28	et	et	PROPN
chd-169	263	29	al	al	PROPN
chd-169	263	30	.	.	PROPN
chd-169	263	31	,	,	PUNCT
chd-169	263	32	2018	2018	NUM
chd-169	263	33	)	)	PUNCT
chd-169	263	34	.	.	PUNCT
chd-169	264	1	this	this	DET
chd-169	264	2	group	group	NOUN
chd-169	264	3	also	also	ADV
chd-169	264	4	found	find	VERB
chd-169	264	5	that	that	SCONJ
chd-169	264	6	genetic	genetic	ADJ
chd-169	264	7	or	or	CCONJ
chd-169	264	8	pharmacological	pharmacological	ADJ
chd-169	264	9	inhibition	inhibition	NOUN
chd-169	264	10	of	of	ADP
chd-169	264	11	gr	gr	NUM
chd-169	264	12	impaired	impair	VERB
chd-169	264	13	the	the	DET
chd-169	264	14	proliferation	proliferation	NOUN
chd-169	264	15	and	and	CCONJ
chd-169	264	16	3d	3d	NUM
chd-169	264	17	spheroid	spheroid	NOUN
chd-169	264	18	-	-	PUNCT
chd-169	264	19	forming	form	VERB
chd-169	264	20	capabilities	capability	NOUN
chd-169	264	21	of	of	ADP
chd-169	264	22	pca	pca	NOUN
chd-169	264	23	cell	cell	NOUN
chd-169	264	24	lines	line	NOUN
chd-169	264	25	(	(	PUNCT
chd-169	264	26	puhr	puhr	NOUN
chd-169	264	27	et	et	PROPN
chd-169	264	28	al	al	PROPN
chd-169	264	29	.	.	PROPN
chd-169	264	30	,	,	PUNCT
chd-169	264	31	2018	2018	NUM
chd-169	264	32	)	)	PUNCT
chd-169	264	33	.	.	PUNCT
chd-169	265	1	additionally	additionally	ADV
chd-169	265	2	,	,	PUNCT
chd-169	265	3	these	these	DET
chd-169	265	4	investigators	investigator	NOUN
chd-169	265	5	also	also	ADV
chd-169	265	6	reported	report	VERB
chd-169	265	7	that	that	SCONJ
chd-169	265	8	gr	gr	PROPN
chd-169	265	9	levels	level	NOUN
chd-169	265	10	increase	increase	VERB
chd-169	265	11	in	in	ADP
chd-169	265	12	dtxresistant	dtxresistant	ADJ
chd-169	265	13	pca	pca	NOUN
chd-169	265	14	cell	cell	NOUN
chd-169	265	15	lines	line	NOUN
chd-169	265	16	and	and	CCONJ
chd-169	265	17	in	in	ADP
chd-169	265	18	tissues	tissue	NOUN
chd-169	265	19	from	from	ADP
chd-169	265	20	patients	patient	NOUN
chd-169	265	21	who	who	PRON
chd-169	265	22	have	have	AUX
chd-169	265	23	been	be	AUX
chd-169	265	24	treated	treat	VERB
chd-169	265	25	with	with	ADP
chd-169	265	26	dtx	dtx	PROPN
chd-169	265	27	,	,	PUNCT
chd-169	265	28	and	and	CCONJ
chd-169	265	29	that	that	SCONJ
chd-169	265	30	patients	patient	NOUN
chd-169	265	31	who	who	PRON
chd-169	265	32	relapse	relapse	VERB
chd-169	265	33	with	with	ADP
chd-169	265	34	biochemical	biochemical	ADJ
chd-169	265	35	recurrence	recurrence	NOUN
chd-169	265	36	and	and	CCONJ
chd-169	265	37	have	have	VERB
chd-169	265	38	high	high	ADJ
chd-169	265	39	gr	gr	NOUN
chd-169	265	40	levels	level	NOUN
chd-169	265	41	experience	experience	NOUN
chd-169	265	42	shortened	shorten	VERB
chd-169	265	43	progressionfree	progressionfree	ADJ
chd-169	265	44	survival	survival	NOUN
chd-169	265	45	(	(	PUNCT
chd-169	265	46	puhr	puhr	NOUN
chd-169	265	47	et	et	PROPN
chd-169	265	48	al	al	PROPN
chd-169	265	49	.	.	PROPN
chd-169	265	50	,	,	PUNCT
chd-169	265	51	2018	2018	NUM
chd-169	265	52	)	)	PUNCT
chd-169	265	53	.	.	PUNCT
chd-169	266	1	there	there	PRON
chd-169	266	2	are	be	VERB
chd-169	266	3	also	also	ADV
chd-169	266	4	reports	report	NOUN
chd-169	266	5	that	that	SCONJ
chd-169	266	6	pca	pca	NOUN
chd-169	266	7	patients	patient	NOUN
chd-169	266	8	enrolled	enrol	VERB
chd-169	266	9	in	in	ADP
chd-169	266	10	clinical	clinical	ADJ
chd-169	266	11	trials	trial	NOUN
chd-169	266	12	have	have	VERB
chd-169	266	13	worse	bad	ADJ
chd-169	266	14	overall	overall	ADJ
chd-169	266	15	survival	survival	NOUN
chd-169	266	16	outcomes	outcome	NOUN
chd-169	266	17	when	when	SCONJ
chd-169	266	18	receiving	receive	VERB
chd-169	266	19	glucocorticoids	glucocorticoid	NOUN
chd-169	266	20	compared	compare	VERB
chd-169	266	21	to	to	ADP
chd-169	266	22	patients	patient	NOUN
chd-169	266	23	not	not	PART
chd-169	266	24	receiving	receive	VERB
chd-169	266	25	glucocorticoids	glucocorticoid	NOUN
chd-169	266	26	(	(	PUNCT
chd-169	266	27	montgomery	montgomery	PROPN
chd-169	266	28	et	et	PROPN
chd-169	266	29	al	al	PROPN
chd-169	266	30	.	.	PROPN
chd-169	266	31	,	,	PUNCT
chd-169	266	32	2014	2014	NUM
chd-169	266	33	;	;	PUNCT
chd-169	266	34	montgomery	montgomery	PROPN
chd-169	266	35	et	et	PROPN
chd-169	266	36	al	al	PROPN
chd-169	266	37	.	.	PROPN
chd-169	266	38	,	,	PUNCT
chd-169	266	39	2015	2015	NUM
chd-169	266	40	;	;	PUNCT
chd-169	266	41	narayanan	narayanan	PROPN
chd-169	266	42	et	et	PROPN
chd-169	266	43	al	al	PROPN
chd-169	266	44	.	.	PROPN
chd-169	266	45	,	,	PUNCT
chd-169	266	46	2016	2016	NUM
chd-169	266	47	)	)	PUNCT
chd-169	266	48	.	.	PUNCT
chd-169	267	1	this	this	DET
chd-169	267	2	trend	trend	NOUN
chd-169	267	3	was	be	AUX
chd-169	267	4	observed	observe	VERB
chd-169	267	5	in	in	ADP
chd-169	267	6	the	the	DET
chd-169	267	7	affirm	affirm	ADJ
chd-169	267	8	phase	phase	NOUN
chd-169	267	9	3	3	NUM
chd-169	267	10	clinical	clinical	ADJ
chd-169	267	11	trial	trial	NOUN
chd-169	267	12	evaluating	evaluate	VERB
chd-169	267	13	the	the	DET
chd-169	267	14	use	use	NOUN
chd-169	267	15	of	of	ADP
chd-169	267	16	enzalutamide	enzalutamide	NOUN
chd-169	267	17	as	as	ADV
chd-169	267	18	well	well	ADV
chd-169	267	19	as	as	ADP
chd-169	267	20	in	in	ADP
chd-169	267	21	the	the	DET
chd-169	267	22	cou	cou	NOUN
chd-169	267	23	-	-	PUNCT
chd-169	267	24	aa-301	aa-301	NOUN
chd-169	267	25	phase	phase	NOUN
chd-169	267	26	3	3	NUM
chd-169	267	27	clinical	clinical	ADJ
chd-169	267	28	trial	trial	NOUN
chd-169	267	29	in	in	ADP
chd-169	267	30	which	which	PRON
chd-169	267	31	patients	patient	NOUN
chd-169	267	32	were	be	AUX
chd-169	267	33	randomized	randomize	VERB
chd-169	267	34	to	to	ADP
chd-169	267	35	prednisone	prednisone	NOUN
chd-169	267	36	plus	plus	CCONJ
chd-169	267	37	abiraterone	abiraterone	NOUN
chd-169	267	38	after	after	ADP
chd-169	267	39	failing	fail	VERB
chd-169	267	40	taxane	taxane	NOUN
chd-169	267	41	chemotherapy	chemotherapy	NOUN
chd-169	267	42	(	(	PUNCT
chd-169	267	43	de	de	X
chd-169	267	44	bono	bono	X
chd-169	267	45	et	et	PROPN
chd-169	267	46	al	al	PROPN
chd-169	267	47	.	.	PROPN
chd-169	267	48	,	,	PUNCT
chd-169	267	49	2011	2011	NUM
chd-169	267	50	;	;	PUNCT
chd-169	267	51	narayanan	narayanan	PROPN
chd-169	267	52	et	et	PROPN
chd-169	267	53	al	al	PROPN
chd-169	267	54	.	.	PROPN
chd-169	267	55	,	,	PUNCT
chd-169	267	56	2016	2016	NUM
chd-169	267	57	)	)	PUNCT
chd-169	267	58	.	.	PUNCT
chd-169	268	1	on	on	ADP
chd-169	268	2	the	the	DET
chd-169	268	3	other	other	ADJ
chd-169	268	4	hand	hand	NOUN
chd-169	268	5	,	,	PUNCT
chd-169	268	6	recent	recent	ADJ
chd-169	268	7	results	result	NOUN
chd-169	268	8	from	from	ADP
chd-169	268	9	the	the	DET
chd-169	268	10	switch	switch	NOUN
chd-169	268	11	trial	trial	NOUN
chd-169	268	12	showed	show	VERB
chd-169	268	13	that	that	SCONJ
chd-169	268	14	in	in	ADP
chd-169	268	15	selected	select	VERB
chd-169	268	16	clinically	clinically	ADV
chd-169	268	17	stable	stable	ADJ
chd-169	268	18	mcrpc	mcrpc	NOUN
chd-169	268	19	patients	patient	NOUN
chd-169	268	20	with	with	ADP
chd-169	268	21	limited	limited	ADJ
chd-169	268	22	disease	disease	NOUN
chd-169	268	23	progression	progression	NOUN
chd-169	268	24	,	,	PUNCT
chd-169	268	25	the	the	DET
chd-169	268	26	combination	combination	NOUN
chd-169	268	27	of	of	ADP
chd-169	268	28	abiraterone	abiraterone	NOUN
chd-169	268	29	with	with	ADP
chd-169	268	30	dexamethasone	dexamethasone	NOUN
chd-169	268	31	provided	provide	VERB
chd-169	268	32	a	a	DET
chd-169	268	33	benefit	benefit	NOUN
chd-169	268	34	,	,	PUNCT
chd-169	268	35	measurable	measurable	ADJ
chd-169	268	36	by	by	ADP
chd-169	268	37	psa	psa	NOUN
chd-169	268	38	decline	decline	NOUN
chd-169	268	39	and	and	CCONJ
chd-169	268	40	disease	disease	NOUN
chd-169	268	41	stabilization	stabilization	NOUN
chd-169	268	42	,	,	PUNCT
chd-169	268	43	to	to	ADP
chd-169	268	44	patients	patient	NOUN
chd-169	268	45	with	with	ADP
chd-169	268	46	normal	normal	ADJ
chd-169	268	47	ar	ar	NOUN
chd-169	268	48	status	status	NOUN
chd-169	268	49	but	but	CCONJ
chd-169	268	50	not	not	PART
chd-169	268	51	patients	patient	NOUN
chd-169	268	52	with	with	ADP
chd-169	268	53	ar	ar	NOUN
chd-169	268	54	aberrations	aberration	NOUN
chd-169	268	55	(	(	PUNCT
chd-169	268	56	romero	romero	PROPN
chd-169	268	57	-	-	PUNCT
chd-169	268	58	laorden	laorden	PROPN
chd-169	268	59	et	et	PROPN
chd-169	268	60	al	al	PROPN
chd-169	268	61	.	.	PROPN
chd-169	268	62	,	,	PUNCT
chd-169	268	63	2018	2018	NUM
chd-169	268	64	)	)	PUNCT
chd-169	268	65	.	.	PUNCT
chd-169	269	1	one	one	NUM
chd-169	269	2	limitation	limitation	NOUN
chd-169	269	3	of	of	ADP
chd-169	269	4	this	this	DET
chd-169	269	5	study	study	NOUN
chd-169	269	6	,	,	PUNCT
chd-169	269	7	however	however	ADV
chd-169	269	8	,	,	PUNCT
chd-169	269	9	was	be	AUX
chd-169	269	10	the	the	DET
chd-169	269	11	lack	lack	NOUN
chd-169	269	12	of	of	ADP
chd-169	269	13	a	a	DET
chd-169	269	14	molecular	molecular	ADJ
chd-169	269	15	analysis	analysis	NOUN
chd-169	269	16	that	that	PRON
chd-169	269	17	included	include	VERB
chd-169	269	18	predictive	predictive	ADJ
chd-169	269	19	biomarkers	biomarker	NOUN
chd-169	269	20	such	such	ADJ
chd-169	269	21	as	as	ADP
chd-169	269	22	the	the	DET
chd-169	269	23	ar	ar	NOUN
chd-169	269	24	-	-	PUNCT
chd-169	269	25	v7	v7	VERB
chd-169	269	26	splicing	splicing	NOUN
chd-169	269	27	variant	variant	NOUN
chd-169	269	28	(	(	PUNCT
chd-169	269	29	fig	fig	NOUN
chd-169	269	30	.	.	PUNCT
chd-169	270	1	3	3	NUM
chd-169	270	2	)	)	PUNCT
chd-169	270	3	,	,	PUNCT
chd-169	270	4	also	also	ADV
chd-169	270	5	implicated	implicate	VERB
chd-169	270	6	in	in	ADP
chd-169	270	7	both	both	CCONJ
chd-169	270	8	arsi	arsi	ADJ
chd-169	270	9	and	and	CCONJ
chd-169	270	10	taxane	taxane	NOUN
chd-169	270	11	resistance	resistance	NOUN
chd-169	270	12	,	,	PUNCT
chd-169	270	13	and	and	CCONJ
chd-169	270	14	gr	gr	NOUN
chd-169	270	15	expression	expression	NOUN
chd-169	270	16	or	or	CCONJ
chd-169	270	17	signaling	signal	VERB
chd-169	270	18	(	(	PUNCT
chd-169	270	19	romero	romero	PROPN
chd-169	270	20	-	-	PUNCT
chd-169	270	21	laorden	laorden	PROPN
chd-169	270	22	et	et	PROPN
chd-169	270	23	al	al	PROPN
chd-169	270	24	.	.	PROPN
chd-169	270	25	,	,	PUNCT
chd-169	270	26	2018	2018	NUM
chd-169	270	27	)	)	PUNCT
chd-169	270	28	.	.	PUNCT
chd-169	271	1	our	our	PRON
chd-169	271	2	group	group	NOUN
chd-169	271	3	recently	recently	ADV
chd-169	271	4	demonstrated	demonstrate	VERB
chd-169	271	5	the	the	DET
chd-169	271	6	ability	ability	NOUN
chd-169	271	7	of	of	ADP
chd-169	271	8	liganded	ligande	VERB
chd-169	271	9	gr	gr	PROPN
chd-169	271	10	to	to	PART
chd-169	271	11	upregulate	upregulate	VERB
chd-169	271	12	the	the	DET
chd-169	271	13	expression	expression	NOUN
chd-169	271	14	of	of	ADP
chd-169	271	15	clusterin	clusterin	NOUN
chd-169	271	16	(	(	PUNCT
chd-169	271	17	clu	clu	PROPN
chd-169	271	18	)	)	PUNCT
chd-169	271	19	and	and	CCONJ
chd-169	271	20	lens	len	VERB
chd-169	271	21	epithelium	epithelium	NOUN
chd-169	271	22	-	-	PUNCT
chd-169	271	23	derived	derive	VERB
chd-169	271	24	growth	growth	NOUN
chd-169	271	25	factor	factor	NOUN
chd-169	271	26	of	of	ADP
chd-169	271	27	75	75	NUM
chd-169	271	28	kd	kd	NOUN
chd-169	271	29	(	(	PUNCT
chd-169	271	30	ledgf	ledgf	NOUN
chd-169	271	31	/	/	SYM
chd-169	271	32	p75	p75	NOUN
chd-169	271	33	)	)	PUNCT
chd-169	271	34	,	,	PUNCT
chd-169	271	35	two	two	NUM
chd-169	271	36	stress	stress	NOUN
chd-169	271	37	oncoproteins	oncoprotein	NOUN
chd-169	271	38	previously	previously	ADV
chd-169	271	39	established	establish	VERB
chd-169	271	40	as	as	ADP
chd-169	271	41	key	key	ADJ
chd-169	271	42	contributors	contributor	NOUN
chd-169	271	43	to	to	PART
chd-169	271	44	therapy	therapy	NOUN
chd-169	271	45	resistance	resistance	NOUN
chd-169	271	46	in	in	ADP
chd-169	271	47	various	various	ADJ
chd-169	271	48	cancer	cancer	NOUN
chd-169	271	49	types	type	NOUN
chd-169	271	50	,	,	PUNCT
chd-169	271	51	in	in	ADP
chd-169	271	52	racially	racially	ADV
chd-169	271	53	diverse	diverse	ADJ
chd-169	271	54	preclinical	preclinical	ADJ
chd-169	271	55	pca	pca	NOUN
chd-169	271	56	cellular	cellular	ADJ
chd-169	271	57	models	model	NOUN
chd-169	271	58	(	(	PUNCT
chd-169	271	59	chun	chun	PROPN
chd-169	271	60	,	,	PUNCT
chd-169	271	61	2014	2014	NUM
chd-169	271	62	;	;	PUNCT
chd-169	271	63	djeu	djeu	NOUN
chd-169	271	64	and	and	CCONJ
chd-169	271	65	wei	wei	PROPN
chd-169	271	66	,	,	PUNCT
chd-169	271	67	2009	2009	NUM
chd-169	271	68	;	;	PUNCT
chd-169	271	69	huang	huang	PROPN
chd-169	271	70	et	et	PROPN
chd-169	271	71	al	al	PROPN
chd-169	271	72	.	.	PROPN
chd-169	271	73	,	,	PUNCT
chd-169	271	74	2007	2007	NUM
chd-169	271	75	;	;	PUNCT
chd-169	271	76	july	july	PROPN
chd-169	271	77	et	et	PROPN
chd-169	271	78	al	al	PROPN
chd-169	271	79	.	.	PROPN
chd-169	271	80	,	,	PUNCT
chd-169	271	81	2002	2002	NUM
chd-169	271	82	;	;	PUNCT
chd-169	271	83	koltai	koltai	PROPN
chd-169	271	84	,	,	PUNCT
chd-169	271	85	2014	2014	NUM
chd-169	271	86	;	;	PUNCT
chd-169	271	87	matsumoto	matsumoto	PROPN
chd-169	271	88	et	et	PROPN
chd-169	271	89	al	al	PROPN
chd-169	271	90	.	.	PROPN
chd-169	271	91	,	,	PUNCT
chd-169	271	92	2013	2013	NUM
chd-169	271	93	;	;	PUNCT
chd-169	271	94	mediavilla	mediavilla	PROPN
chd-169	271	95	-	-	PUNCT
chd-169	271	96	varela	varela	PROPN
chd-169	271	97	et	et	PROPN
chd-169	271	98	al	al	PROPN
chd-169	271	99	.	.	PROPN
chd-169	271	100	,	,	PUNCT
chd-169	271	101	2009	2009	NUM
chd-169	271	102	;	;	PUNCT
chd-169	271	103	rios	rio	NOUN
chd-169	271	104	-	-	PUNCT
chd-169	271	105	colon	colon	NOUN
chd-169	271	106	et	et	NOUN
chd-169	271	107	al	al	PROPN
chd-169	271	108	.	.	PROPN
chd-169	271	109	,	,	PUNCT
chd-169	271	110	2017	2017	NUM
chd-169	271	111	;	;	PUNCT
chd-169	271	112	woods	wood	NOUN
chd-169	271	113	-	-	PUNCT
chd-169	271	114	burnham	burnham	PROPN
chd-169	271	115	et	et	NOUN
chd-169	271	116	al	al	PROPN
chd-169	271	117	.	.	PROPN
chd-169	271	118	,	,	PUNCT
chd-169	271	119	2018a	2018a	NUM
chd-169	271	120	)	)	PUNCT
chd-169	271	121	.	.	PUNCT
chd-169	272	1	this	this	DET
chd-169	272	2	upregulation	upregulation	NOUN
chd-169	272	3	could	could	AUX
chd-169	272	4	be	be	AUX
chd-169	272	5	reversed	reverse	VERB
chd-169	272	6	by	by	ADP
chd-169	272	7	blocking	block	VERB
chd-169	272	8	gr	gr	NOUN
chd-169	272	9	signaling	signal	VERB
chd-169	272	10	with	with	ADP
chd-169	272	11	the	the	DET
chd-169	272	12	steroidal	steroidal	NOUN
chd-169	272	13	antagonist	antagonist	NOUN
chd-169	272	14	mifepristone	mifepristone	NOUN
chd-169	272	15	(	(	PUNCT
chd-169	272	16	ru-486	ru-486	ADJ
chd-169	272	17	)	)	PUNCT
chd-169	272	18	or	or	CCONJ
chd-169	272	19	gr	gr	NOUN
chd-169	272	20	knockdown	knockdown	NOUN
chd-169	272	21	(	(	PUNCT
chd-169	272	22	woodsburnham	woodsburnham	NOUN
chd-169	272	23	et	et	PROPN
chd-169	272	24	al	al	PROPN
chd-169	272	25	.	.	PROPN
chd-169	272	26	,	,	PUNCT
chd-169	272	27	2018a	2018a	NUM
chd-169	272	28	)	)	PUNCT
chd-169	272	29	.	.	PUNCT
chd-169	273	1	the	the	DET
chd-169	273	2	particular	particular	ADJ
chd-169	273	3	observation	observation	NOUN
chd-169	273	4	of	of	ADP
chd-169	273	5	high	high	ADJ
chd-169	273	6	endogenous	endogenous	ADJ
chd-169	273	7	clu	clu	NOUN
chd-169	273	8	expression	expression	NOUN
chd-169	273	9	in	in	ADP
chd-169	273	10	the	the	DET
chd-169	273	11	aa	aa	PROPN
chd-169	273	12	pca	pca	PROPN
chd-169	273	13	cell	cell	NOUN
chd-169	273	14	line	line	NOUN
chd-169	273	15	mda	mda	PROPN
chd-169	273	16	-	-	PUNCT
chd-169	273	17	pca-2b	pca-2b	NOUN
chd-169	273	18	suggests	suggest	VERB
chd-169	273	19	that	that	SCONJ
chd-169	273	20	downstream	downstream	ADJ
chd-169	273	21	effects	effect	NOUN
chd-169	273	22	of	of	ADP
chd-169	273	23	gr	gr	NOUN
chd-169	273	24	signaling	signal	VERB
chd-169	273	25	such	such	ADJ
chd-169	273	26	as	as	ADP
chd-169	273	27	the	the	DET
chd-169	273	28	upregulation	upregulation	NOUN
chd-169	273	29	of	of	ADP
chd-169	273	30	genes	gene	NOUN
chd-169	273	31	associated	associate	VERB
chd-169	273	32	with	with	ADP
chd-169	273	33	therapy	therapy	NOUN
chd-169	273	34	-	-	PUNCT
chd-169	273	35	resistance	resistance	NOUN
chd-169	273	36	may	may	AUX
chd-169	273	37	be	be	AUX
chd-169	273	38	exaggerated	exaggerated	ADJ
chd-169	273	39	in	in	ADP
chd-169	273	40	aa	aa	PROPN
chd-169	273	41	pca	pca	PROPN
chd-169	273	42	patients	patient	NOUN
chd-169	273	43	,	,	PUNCT
chd-169	273	44	and	and	CCONJ
chd-169	273	45	is	be	AUX
chd-169	273	46	consistent	consistent	ADJ
chd-169	273	47	with	with	ADP
chd-169	273	48	the	the	DET
chd-169	273	49	emerging	emerge	VERB
chd-169	273	50	notion	notion	NOUN
chd-169	273	51	that	that	SCONJ
chd-169	273	52	gr	gr	NOUN
chd-169	273	53	signaling	signal	VERB
chd-169	273	54	is	be	AUX
chd-169	273	55	enhanced	enhance	VERB
chd-169	273	56	in	in	ADP
chd-169	273	57	the	the	DET
chd-169	273	58	aa	aa	PROPN
chd-169	273	59	population	population	NOUN
chd-169	273	60	(	(	PUNCT
chd-169	273	61	frazier	frazier	PROPN
chd-169	273	62	et	et	PROPN
chd-169	273	63	al	al	PROPN
chd-169	273	64	.	.	PROPN
chd-169	273	65	,	,	PUNCT
chd-169	273	66	2010	2010	NUM
chd-169	273	67	;	;	PUNCT
chd-169	273	68	woods	wood	NOUN
chd-169	273	69	-	-	PUNCT
chd-169	273	70	burnham	burnham	PROPN
chd-169	273	71	et	et	NOUN
chd-169	273	72	al	al	PROPN
chd-169	273	73	.	.	PROPN
chd-169	273	74	,	,	PUNCT
chd-169	273	75	2018a	2018a	NUM
chd-169	273	76	;	;	PUNCT
chd-169	273	77	zannas	zannas	PROPN
chd-169	273	78	et	et	PROPN
chd-169	273	79	al	al	PROPN
chd-169	273	80	.	.	PROPN
chd-169	273	81	,	,	PUNCT
chd-169	273	82	2015	2015	NUM
chd-169	273	83	)	)	PUNCT
chd-169	273	84	.	.	PUNCT
chd-169	274	1	our	our	PRON
chd-169	274	2	recent	recent	ADJ
chd-169	274	3	study	study	NOUN
chd-169	274	4	also	also	ADV
chd-169	274	5	revealed	reveal	VERB
chd-169	274	6	higher	high	ADJ
chd-169	274	7	median	median	ADJ
chd-169	274	8	values	value	NOUN
chd-169	274	9	of	of	ADP
chd-169	274	10	gr	gr	NOUN
chd-169	274	11	in	in	ADP
chd-169	274	12	aa	aa	NOUN
chd-169	274	13	prostate	prostate	NOUN
chd-169	274	14	tissues	tissue	NOUN
chd-169	274	15	compared	compare	VERB
chd-169	274	16	to	to	ADP
chd-169	274	17	ea	ea	NOUN
chd-169	274	18	prostate	prostate	NOUN
chd-169	274	19	tissues	tissue	NOUN
chd-169	274	20	using	use	VERB
chd-169	274	21	the	the	DET
chd-169	274	22	taylor	taylor	PROPN
chd-169	274	23	and	and	CCONJ
chd-169	274	24	wallace	wallace	PROPN
chd-169	274	25	datasets	dataset	NOUN
chd-169	274	26	within	within	ADP
chd-169	274	27	the	the	DET
chd-169	274	28	oncomine	oncomine	NOUN
chd-169	274	29	database	database	NOUN
chd-169	274	30	,	,	PUNCT
chd-169	274	31	supporting	support	VERB
chd-169	274	32	the	the	DET
chd-169	274	33	premise	premise	NOUN
chd-169	274	34	that	that	SCONJ
chd-169	274	35	aa	aa	PROPN
chd-169	274	36	men	man	NOUN
chd-169	274	37	with	with	ADP
chd-169	274	38	pca	pca	PROPN
chd-169	274	39	may	may	AUX
chd-169	274	40	have	have	AUX
chd-169	274	41	enhanced	enhance	VERB
chd-169	274	42	intratumoral	intratumoral	ADJ
chd-169	274	43	gr	gr	NOUN
chd-169	274	44	signaling	signal	VERB
chd-169	274	45	(	(	PUNCT
chd-169	274	46	woods	wood	NOUN
chd-169	274	47	-	-	PUNCT
chd-169	274	48	burnham	burnham	NOUN
chd-169	274	49	et	et	NOUN
chd-169	274	50	al	al	PROPN
chd-169	274	51	.	.	PROPN
chd-169	274	52	,	,	PUNCT
chd-169	274	53	2018a	2018a	NUM
chd-169	274	54	)	)	PUNCT
chd-169	274	55	.	.	PUNCT
chd-169	275	1	regardless	regardless	ADV
chd-169	275	2	of	of	ADP
chd-169	275	3	whether	whether	SCONJ
chd-169	275	4	gr	gr	NOUN
chd-169	275	5	drives	drive	VERB
chd-169	275	6	resistance	resistance	NOUN
chd-169	275	7	to	to	PART
chd-169	275	8	arsi	arsi	ADJ
chd-169	275	9	by	by	ADP
chd-169	275	10	activating	activate	VERB
chd-169	275	11	ar	ar	NOUN
chd-169	275	12	-	-	NOUN
chd-169	275	13	target	target	NOUN
chd-169	275	14	genes	gene	NOUN
chd-169	275	15	only	only	ADV
chd-169	275	16	or	or	CCONJ
chd-169	275	17	also	also	ADV
chd-169	275	18	by	by	ADP
chd-169	275	19	activating	activate	VERB
chd-169	275	20	an	an	DET
chd-169	275	21	independent	independent	ADJ
chd-169	275	22	transcriptome	transcriptome	NOUN
chd-169	275	23	that	that	PRON
chd-169	275	24	drives	drive	VERB
chd-169	275	25	therapy	therapy	NOUN
chd-169	275	26	resistance	resistance	NOUN
chd-169	275	27	,	,	PUNCT
chd-169	275	28	it	it	PRON
chd-169	275	29	is	be	AUX
chd-169	275	30	becoming	become	VERB
chd-169	275	31	very	very	ADV
chd-169	275	32	clear	clear	ADJ
chd-169	275	33	that	that	SCONJ
chd-169	275	34	gr	gr	NOUN
chd-169	275	35	plays	play	VERB
chd-169	275	36	a	a	DET
chd-169	275	37	major	major	ADJ
chd-169	275	38	role	role	NOUN
chd-169	275	39	in	in	ADP
chd-169	275	40	the	the	DET
chd-169	275	41	progression	progression	NOUN
chd-169	275	42	of	of	ADP
chd-169	275	43	mcrpc	mcrpc	NOUN
chd-169	275	44	.	.	PUNCT
chd-169	276	1	there	there	PRON
chd-169	276	2	remains	remain	VERB
chd-169	276	3	an	an	DET
chd-169	276	4	urgent	urgent	ADJ
chd-169	276	5	need	need	NOUN
chd-169	276	6	,	,	PUNCT
chd-169	276	7	however	however	ADV
chd-169	276	8	,	,	PUNCT
chd-169	276	9	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	276	10	e18	e18	PROPN
chd-169	276	11	cancer	cancer	NOUN
chd-169	276	12	health	health	NOUN
chd-169	276	13	disparities	disparity	NOUN
chd-169	276	14	research	research	VERB
chd-169	276	15	to	to	PART
chd-169	276	16	further	far	ADV
chd-169	276	17	elucidate	elucidate	VERB
chd-169	276	18	genes	gene	NOUN
chd-169	276	19	driven	drive	VERB
chd-169	276	20	by	by	ADP
chd-169	276	21	gr	gr	NOUN
chd-169	276	22	signaling	signal	VERB
chd-169	276	23	that	that	PRON
chd-169	276	24	are	be	AUX
chd-169	276	25	specifically	specifically	ADV
chd-169	276	26	associated	associate	VERB
chd-169	276	27	with	with	ADP
chd-169	276	28	arsi	arsi	ADJ
chd-169	276	29	-	-	PUNCT
chd-169	276	30	resistance	resistance	NOUN
chd-169	276	31	while	while	SCONJ
chd-169	276	32	also	also	ADV
chd-169	276	33	identifying	identify	VERB
chd-169	276	34	precise	precise	ADJ
chd-169	276	35	genes	gene	NOUN
chd-169	276	36	that	that	PRON
chd-169	276	37	have	have	AUX
chd-169	276	38	been	be	AUX
chd-169	276	39	linked	link	VERB
chd-169	276	40	to	to	ADP
chd-169	276	41	taxane	taxane	NOUN
chd-169	276	42	chemotherapy	chemotherapy	NOUN
chd-169	276	43	.	.	PUNCT
chd-169	277	1	this	this	PRON
chd-169	277	2	is	be	AUX
chd-169	277	3	critical	critical	ADJ
chd-169	277	4	to	to	ADP
chd-169	277	5	our	our	PRON
chd-169	277	6	understanding	understanding	NOUN
chd-169	277	7	of	of	ADP
chd-169	277	8	mechanisms	mechanism	NOUN
chd-169	277	9	by	by	ADP
chd-169	277	10	which	which	PRON
chd-169	277	11	gr	gr	NOUN
chd-169	277	12	may	may	AUX
chd-169	277	13	contribute	contribute	VERB
chd-169	277	14	to	to	ADP
chd-169	277	15	therapy	therapy	NOUN
chd-169	277	16	resistance	resistance	NOUN
chd-169	277	17	,	,	PUNCT
chd-169	277	18	supporting	support	VERB
chd-169	277	19	the	the	DET
chd-169	277	20	development	development	NOUN
chd-169	277	21	of	of	ADP
chd-169	277	22	novel	novel	ADJ
chd-169	277	23	therapeutic	therapeutic	ADJ
chd-169	277	24	strategies	strategy	NOUN
chd-169	277	25	.	.	PUNCT
chd-169	278	1	furthermore	furthermore	ADV
chd-169	278	2	,	,	PUNCT
chd-169	278	3	given	give	VERB
chd-169	278	4	that	that	SCONJ
chd-169	278	5	aa	aa	PROPN
chd-169	278	6	men	man	NOUN
chd-169	278	7	suffer	suffer	VERB
chd-169	278	8	from	from	ADP
chd-169	278	9	disproportionate	disproportionate	ADJ
chd-169	278	10	pca	pca	NOUN
chd-169	278	11	incidence	incidence	NOUN
chd-169	278	12	and	and	CCONJ
chd-169	278	13	mortality	mortality	NOUN
chd-169	278	14	as	as	ADV
chd-169	278	15	well	well	ADV
chd-169	278	16	as	as	ADP
chd-169	278	17	an	an	DET
chd-169	278	18	enhanced	enhanced	ADJ
chd-169	278	19	physiological	physiological	ADJ
chd-169	278	20	response	response	NOUN
chd-169	278	21	to	to	ADP
chd-169	278	22	glucocorticoids	glucocorticoid	NOUN
chd-169	278	23	,	,	PUNCT
chd-169	278	24	additional	additional	ADJ
chd-169	278	25	studies	study	NOUN
chd-169	278	26	are	be	AUX
chd-169	278	27	warranted	warrant	VERB
chd-169	278	28	to	to	PART
chd-169	278	29	fully	fully	ADV
chd-169	278	30	elucidate	elucidate	VERB
chd-169	278	31	the	the	DET
chd-169	278	32	interplay	interplay	NOUN
chd-169	278	33	between	between	ADP
chd-169	278	34	gr	gr	ADP
chd-169	278	35	signaling	signal	VERB
chd-169	278	36	and	and	CCONJ
chd-169	278	37	pca	pca	NOUN
chd-169	278	38	tumor	tumor	NOUN
chd-169	278	39	aggressiveness	aggressiveness	NOUN
chd-169	278	40	specifically	specifically	ADV
chd-169	278	41	in	in	ADP
chd-169	278	42	this	this	DET
chd-169	278	43	racial	racial	ADJ
chd-169	278	44	/	/	SYM
chd-169	278	45	ethnic	ethnic	ADJ
chd-169	278	46	group	group	NOUN
chd-169	278	47	.	.	PUNCT
chd-169	279	1	given	give	VERB
chd-169	279	2	the	the	DET
chd-169	279	3	emerging	emerge	VERB
chd-169	279	4	role	role	NOUN
chd-169	279	5	of	of	ADP
chd-169	279	6	gr	gr	NOUN
chd-169	279	7	signaling	signal	VERB
chd-169	279	8	in	in	ADP
chd-169	279	9	pca	pca	NOUN
chd-169	279	10	progression	progression	NOUN
chd-169	279	11	,	,	PUNCT
chd-169	279	12	we	we	PRON
chd-169	279	13	propose	propose	VERB
chd-169	279	14	that	that	SCONJ
chd-169	279	15	cumulative	cumulative	ADJ
chd-169	279	16	psychosocial	psychosocial	ADJ
chd-169	279	17	stress	stress	NOUN
chd-169	279	18	leading	lead	VERB
chd-169	279	19	to	to	ADP
chd-169	279	20	chronically	chronically	ADV
chd-169	279	21	elevated	elevated	ADJ
chd-169	279	22	cortisol	cortisol	ADJ
chd-169	279	23	levels	level	NOUN
chd-169	279	24	,	,	PUNCT
chd-169	279	25	increased	increase	VERB
chd-169	279	26	gr	gr	NOUN
chd-169	279	27	expression	expression	NOUN
chd-169	279	28	,	,	PUNCT
chd-169	279	29	and	and	CCONJ
chd-169	279	30	sustained	sustain	VERB
chd-169	279	31	gr	gr	NOUN
chd-169	279	32	signaling	signal	VERB
chd-169	279	33	in	in	ADP
chd-169	279	34	aa	aa	PROPN
chd-169	279	35	men	man	NOUN
chd-169	279	36	over	over	ADP
chd-169	279	37	time	time	NOUN
chd-169	279	38	could	could	AUX
chd-169	279	39	predispose	predispose	VERB
chd-169	279	40	them	they	PRON
chd-169	279	41	to	to	PART
chd-169	279	42	develop	develop	VERB
chd-169	279	43	aggressive	aggressive	ADJ
chd-169	279	44	pca	pca	NOUN
chd-169	279	45	tumors	tumor	NOUN
chd-169	279	46	as	as	ADV
chd-169	279	47	well	well	ADV
chd-169	279	48	as	as	ADP
chd-169	279	49	prime	prime	ADJ
chd-169	279	50	them	they	PRON
chd-169	279	51	towards	towards	ADP
chd-169	279	52	poor	poor	ADJ
chd-169	279	53	response	response	NOUN
chd-169	279	54	to	to	ADP
chd-169	279	55	conventional	conventional	ADJ
chd-169	279	56	treatments	treatment	NOUN
chd-169	279	57	(	(	PUNCT
chd-169	279	58	fig	fig	NOUN
chd-169	279	59	.	.	PUNCT
chd-169	280	1	1	1	NUM
chd-169	280	2	)	)	PUNCT
chd-169	280	3	.	.	PUNCT
chd-169	281	1	therapeutic	therapeutic	ADJ
chd-169	281	2	gr	gr	NOUN
chd-169	281	3	modulators	modulator	NOUN
chd-169	281	4	.	.	PUNCT
chd-169	282	1	the	the	DET
chd-169	282	2	emerging	emerge	VERB
chd-169	282	3	contribution	contribution	NOUN
chd-169	282	4	of	of	ADP
chd-169	282	5	gr	gr	NOUN
chd-169	282	6	signaling	signal	VERB
chd-169	282	7	to	to	ADP
chd-169	282	8	pca	pca	NOUN
chd-169	282	9	therapy	therapy	NOUN
chd-169	282	10	resistance	resistance	NOUN
chd-169	282	11	has	have	AUX
chd-169	282	12	led	lead	VERB
chd-169	282	13	to	to	ADP
chd-169	282	14	increasing	increase	VERB
chd-169	282	15	efforts	effort	NOUN
chd-169	282	16	to	to	PART
chd-169	282	17	therapeutically	therapeutically	ADV
chd-169	282	18	target	target	VERB
chd-169	282	19	this	this	DET
chd-169	282	20	signaling	signal	VERB
chd-169	282	21	as	as	ADP
chd-169	282	22	a	a	DET
chd-169	282	23	potential	potential	ADJ
chd-169	282	24	treatment	treatment	NOUN
chd-169	282	25	for	for	ADP
chd-169	282	26	mcrpc	mcrpc	NOUN
chd-169	282	27	.	.	PUNCT
chd-169	283	1	a	a	DET
chd-169	283	2	phase	phase	NOUN
chd-169	283	3	i	i	PRON
chd-169	283	4	/	/	SYM
chd-169	283	5	ii	ii	PROPN
chd-169	283	6	clinical	clinical	ADJ
chd-169	283	7	trial	trial	NOUN
chd-169	283	8	(	(	PUNCT
chd-169	283	9	nct02012296	nct02012296	NOUN
chd-169	283	10	)	)	PUNCT
chd-169	283	11	is	be	AUX
chd-169	283	12	currently	currently	ADV
chd-169	283	13	ongoing	ongoing	ADJ
chd-169	283	14	to	to	PART
chd-169	283	15	determine	determine	VERB
chd-169	283	16	if	if	SCONJ
chd-169	283	17	combination	combination	NOUN
chd-169	283	18	therapy	therapy	NOUN
chd-169	283	19	with	with	ADP
chd-169	283	20	enzalutamide	enzalutamide	NOUN
chd-169	283	21	and	and	CCONJ
chd-169	283	22	mifepristone	mifepristone	NOUN
chd-169	283	23	,	,	PUNCT
chd-169	283	24	a	a	DET
chd-169	283	25	gr	gr	NOUN
chd-169	283	26	antagonist	antagonist	NOUN
chd-169	283	27	that	that	PRON
chd-169	283	28	delayed	delay	VERB
chd-169	283	29	mcrpc	mcrpc	NOUN
chd-169	283	30	in	in	ADP
chd-169	283	31	pre	pre	ADJ
chd-169	283	32	-	-	ADJ
chd-169	283	33	clinical	clinical	ADJ
chd-169	283	34	models	model	NOUN
chd-169	283	35	,	,	PUNCT
chd-169	283	36	extends	extend	VERB
chd-169	283	37	the	the	DET
chd-169	283	38	time	time	NOUN
chd-169	283	39	to	to	PART
chd-169	283	40	psa	psa	VERB
chd-169	283	41	progression	progression	NOUN
chd-169	283	42	.	.	PUNCT
chd-169	284	1	because	because	SCONJ
chd-169	284	2	complete	complete	ADJ
chd-169	284	3	antagonism	antagonism	NOUN
chd-169	284	4	of	of	ADP
chd-169	284	5	gr	gr	PRON
chd-169	284	6	may	may	AUX
chd-169	284	7	introduce	introduce	VERB
chd-169	284	8	adverse	adverse	ADJ
chd-169	284	9	systemic	systemic	ADJ
chd-169	284	10	consequences	consequence	NOUN
chd-169	284	11	,	,	PUNCT
chd-169	284	12	highly	highly	ADV
chd-169	284	13	selective	selective	ADJ
chd-169	284	14	gr	gr	NOUN
chd-169	284	15	modulators	modulator	NOUN
chd-169	284	16	(	(	PUNCT
chd-169	284	17	sgrms	sgrm	NOUN
chd-169	284	18	)	)	PUNCT
chd-169	284	19	that	that	PRON
chd-169	284	20	target	target	VERB
chd-169	284	21	this	this	DET
chd-169	284	22	receptor	receptor	NOUN
chd-169	284	23	in	in	ADP
chd-169	284	24	specific	specific	ADJ
chd-169	284	25	tissues	tissue	NOUN
chd-169	284	26	are	be	AUX
chd-169	284	27	currently	currently	ADV
chd-169	284	28	under	under	ADP
chd-169	284	29	development	development	NOUN
chd-169	284	30	and	and	CCONJ
chd-169	284	31	are	be	AUX
chd-169	284	32	being	be	AUX
chd-169	284	33	evaluated	evaluate	VERB
chd-169	284	34	in	in	ADP
chd-169	284	35	preclinical	preclinical	ADJ
chd-169	284	36	models	model	NOUN
chd-169	284	37	of	of	ADP
chd-169	284	38	mcrpc	mcrpc	NOUN
chd-169	284	39	(	(	PUNCT
chd-169	284	40	hunt	hunt	NOUN
chd-169	284	41	et	et	NOUN
chd-169	284	42	al	al	PROPN
chd-169	284	43	.	.	PROPN
chd-169	284	44	,	,	PUNCT
chd-169	284	45	2018	2018	NUM
chd-169	284	46	;	;	PUNCT
chd-169	284	47	kach	kach	PROPN
chd-169	284	48	et	et	PROPN
chd-169	284	49	al	al	PROPN
chd-169	284	50	.	.	PROPN
chd-169	284	51	,	,	PUNCT
chd-169	284	52	2017	2017	NUM
chd-169	284	53	;	;	PUNCT
chd-169	284	54	nguyen	nguyen	NOUN
chd-169	284	55	et	et	PROPN
chd-169	284	56	al	al	PROPN
chd-169	284	57	.	.	PROPN
chd-169	284	58	,	,	PUNCT
chd-169	284	59	2017	2017	NUM
chd-169	284	60	)	)	PUNCT
chd-169	284	61	.	.	PUNCT
chd-169	285	1	the	the	DET
chd-169	285	2	specificity	specificity	NOUN
chd-169	285	3	of	of	ADP
chd-169	285	4	these	these	DET
chd-169	285	5	new	new	ADJ
chd-169	285	6	generation	generation	NOUN
chd-169	285	7	modulators	modulator	NOUN
chd-169	285	8	are	be	AUX
chd-169	285	9	often	often	ADV
chd-169	285	10	dependent	dependent	ADJ
chd-169	285	11	upon	upon	SCONJ
chd-169	285	12	their	their	PRON
chd-169	285	13	superior	superior	ADJ
chd-169	285	14	selectivity	selectivity	NOUN
chd-169	285	15	for	for	ADP
chd-169	285	16	gr	gr	NOUN
chd-169	285	17	over	over	ADP
chd-169	285	18	other	other	ADJ
chd-169	285	19	steroid	steroid	NOUN
chd-169	285	20	receptors	receptor	NOUN
chd-169	285	21	,	,	PUNCT
chd-169	285	22	which	which	PRON
chd-169	285	23	is	be	AUX
chd-169	285	24	a	a	DET
chd-169	285	25	characteristic	characteristic	NOUN
chd-169	285	26	of	of	ADP
chd-169	285	27	mifepristone	mifepristone	NOUN
chd-169	285	28	(	(	PUNCT
chd-169	285	29	baulieu	baulieu	VERB
chd-169	285	30	,	,	PUNCT
chd-169	285	31	1991	1991	NUM
chd-169	285	32	;	;	PUNCT
chd-169	285	33	hunt	hunt	NOUN
chd-169	285	34	et	et	NOUN
chd-169	285	35	al	al	PROPN
chd-169	285	36	.	.	PROPN
chd-169	285	37	,	,	PUNCT
chd-169	285	38	2018	2018	NUM
chd-169	285	39	;	;	PUNCT
chd-169	285	40	kach	kach	PROPN
chd-169	285	41	et	et	PROPN
chd-169	285	42	al	al	PROPN
chd-169	285	43	.	.	PROPN
chd-169	285	44	,	,	PUNCT
chd-169	285	45	2017	2017	NUM
chd-169	285	46	;	;	PUNCT
chd-169	285	47	meijer	meijer	NOUN
chd-169	285	48	et	et	PROPN
chd-169	285	49	al	al	PROPN
chd-169	285	50	.	.	PROPN
chd-169	285	51	,	,	PUNCT
chd-169	285	52	2018	2018	NUM
chd-169	285	53	;	;	PUNCT
chd-169	285	54	nguyen	nguyen	NOUN
chd-169	285	55	et	et	PROPN
chd-169	285	56	al	al	PROPN
chd-169	285	57	.	.	PROPN
chd-169	285	58	,	,	PUNCT
chd-169	285	59	2017	2017	NUM
chd-169	285	60	)	)	PUNCT
chd-169	285	61	.	.	PUNCT
chd-169	286	1	for	for	ADP
chd-169	286	2	example	example	NOUN
chd-169	286	3	,	,	PUNCT
chd-169	286	4	the	the	DET
chd-169	286	5	sgrm	sgrm	NOUN
chd-169	286	6	cort118335	cort118335	PROPN
chd-169	286	7	has	have	VERB
chd-169	286	8	a	a	DET
chd-169	286	9	high	high	ADJ
chd-169	286	10	gr	gr	NOUN
chd-169	286	11	affinity	affinity	NOUN
chd-169	286	12	with	with	ADP
chd-169	286	13	only	only	ADV
chd-169	286	14	modest	modest	ADJ
chd-169	286	15	mr	mr	PROPN
chd-169	286	16	affinity	affinity	NOUN
chd-169	286	17	(	(	PUNCT
chd-169	286	18	atucha	atucha	NOUN
chd-169	286	19	et	et	PROPN
chd-169	286	20	al	al	PROPN
chd-169	286	21	.	.	PROPN
chd-169	286	22	,	,	PUNCT
chd-169	286	23	2015	2015	NUM
chd-169	286	24	;	;	PUNCT
chd-169	286	25	hunt	hunt	NOUN
chd-169	286	26	et	et	NOUN
chd-169	286	27	al	al	PROPN
chd-169	286	28	.	.	PROPN
chd-169	286	29	,	,	PUNCT
chd-169	286	30	2012	2012	NUM
chd-169	286	31	;	;	PUNCT
chd-169	286	32	nguyen	nguyen	NOUN
chd-169	286	33	et	et	PROPN
chd-169	286	34	al	al	PROPN
chd-169	286	35	.	.	PROPN
chd-169	286	36	,	,	PUNCT
chd-169	286	37	2017	2017	NUM
chd-169	286	38	)	)	PUNCT
chd-169	286	39	.	.	PUNCT
chd-169	287	1	this	this	PRON
chd-169	287	2	and	and	CCONJ
chd-169	287	3	another	another	DET
chd-169	287	4	sgrm	sgrm	NOUN
chd-169	287	5	,	,	PUNCT
chd-169	287	6	cort108297	cort108297	PROPN
chd-169	287	7	,	,	PUNCT
chd-169	287	8	showed	show	VERB
chd-169	287	9	ability	ability	NOUN
chd-169	287	10	to	to	PART
chd-169	287	11	block	block	VERB
chd-169	287	12	gr	gr	DET
chd-169	287	13	transcriptional	transcriptional	ADJ
chd-169	287	14	activity	activity	NOUN
chd-169	287	15	and	and	CCONJ
chd-169	287	16	slow	slow	ADJ
chd-169	287	17	crpc	crpc	ADJ
chd-169	287	18	progression	progression	NOUN
chd-169	287	19	in	in	ADP
chd-169	287	20	pre	pre	ADJ
chd-169	287	21	-	-	ADJ
chd-169	287	22	clinical	clinical	ADJ
chd-169	287	23	models	model	NOUN
chd-169	287	24	,	,	PUNCT
chd-169	287	25	and	and	CCONJ
chd-169	287	26	unlike	unlike	ADP
chd-169	287	27	mifepristone	mifepristone	NOUN
chd-169	287	28	did	do	AUX
chd-169	287	29	not	not	PART
chd-169	287	30	affect	affect	VERB
chd-169	287	31	ar	ar	NOUN
chd-169	287	32	signaling	signal	VERB
chd-169	287	33	(	(	PUNCT
chd-169	287	34	kach	kach	PROPN
chd-169	287	35	et	et	PROPN
chd-169	287	36	al	al	PROPN
chd-169	287	37	.	.	PROPN
chd-169	287	38	,	,	PUNCT
chd-169	287	39	2017	2017	NUM
chd-169	287	40	)	)	PUNCT
chd-169	287	41	.	.	PUNCT
chd-169	288	1	another	another	DET
chd-169	288	2	sgrm	sgrm	NOUN
chd-169	288	3	,	,	PUNCT
chd-169	288	4	cort125134	cort125134	PROPN
chd-169	288	5	,	,	PUNCT
chd-169	288	6	was	be	AUX
chd-169	288	7	shown	show	VERB
chd-169	288	8	to	to	PART
chd-169	288	9	reverse	reverse	VERB
chd-169	288	10	the	the	DET
chd-169	288	11	effects	effect	NOUN
chd-169	288	12	of	of	ADP
chd-169	288	13	prednisone	prednisone	NOUN
chd-169	288	14	without	without	ADP
chd-169	288	15	binding	bind	VERB
chd-169	288	16	to	to	ADP
chd-169	288	17	progesterone	progesterone	NOUN
chd-169	288	18	receptor	receptor	NOUN
chd-169	288	19	(	(	PUNCT
chd-169	288	20	pr	pr	NOUN
chd-169	288	21	)	)	PUNCT
chd-169	288	22	and	and	CCONJ
chd-169	288	23	is	be	AUX
chd-169	288	24	well	well	ADV
chd-169	288	25	tolerated	tolerate	VERB
chd-169	288	26	in	in	ADP
chd-169	288	27	humans	human	NOUN
chd-169	288	28	.	.	PUNCT
chd-169	289	1	however	however	ADV
chd-169	289	2	,	,	PUNCT
chd-169	289	3	it	it	PRON
chd-169	289	4	should	should	AUX
chd-169	289	5	be	be	AUX
chd-169	289	6	noted	note	VERB
chd-169	289	7	that	that	SCONJ
chd-169	289	8	the	the	DET
chd-169	289	9	overwhelming	overwhelming	ADJ
chd-169	289	10	majority	majority	NOUN
chd-169	289	11	of	of	ADP
chd-169	289	12	study	study	NOUN
chd-169	289	13	participants	participant	NOUN
chd-169	289	14	were	be	AUX
chd-169	289	15	ea	ea	NOUN
chd-169	289	16	males	male	NOUN
chd-169	289	17	and	and	CCONJ
chd-169	289	18	the	the	DET
chd-169	289	19	study	study	NOUN
chd-169	289	20	did	do	AUX
chd-169	289	21	not	not	PART
chd-169	289	22	take	take	VERB
chd-169	289	23	into	into	ADP
chd-169	289	24	account	account	NOUN
chd-169	289	25	potential	potential	ADJ
chd-169	289	26	racial	racial	ADJ
chd-169	289	27	or	or	CCONJ
chd-169	289	28	ethnic	ethnic	ADJ
chd-169	289	29	differences	difference	NOUN
chd-169	289	30	in	in	ADP
chd-169	289	31	gr	gr	PRON
chd-169	289	32	signaling	signal	VERB
chd-169	289	33	(	(	PUNCT
chd-169	289	34	hunt	hunt	NOUN
chd-169	289	35	et	et	NOUN
chd-169	289	36	al	al	PROPN
chd-169	289	37	.	.	PROPN
chd-169	289	38	,	,	PUNCT
chd-169	289	39	2018	2018	NUM
chd-169	289	40	)	)	PUNCT
chd-169	289	41	.	.	PUNCT
chd-169	290	1	an	an	DET
chd-169	290	2	additional	additional	ADJ
chd-169	290	3	determinant	determinant	NOUN
chd-169	290	4	of	of	ADP
chd-169	290	5	the	the	DET
chd-169	290	6	ability	ability	NOUN
chd-169	290	7	of	of	ADP
chd-169	290	8	gr	gr	DET
chd-169	290	9	modulators	modulator	NOUN
chd-169	290	10	to	to	PART
chd-169	290	11	bind	bind	VERB
chd-169	290	12	to	to	ADP
chd-169	290	13	specific	specific	ADJ
chd-169	290	14	tissues	tissue	NOUN
chd-169	290	15	is	be	AUX
chd-169	290	16	the	the	DET
chd-169	290	17	presence	presence	NOUN
chd-169	290	18	or	or	CCONJ
chd-169	290	19	lack	lack	NOUN
chd-169	290	20	of	of	ADP
chd-169	290	21	gr	gr	DET
chd-169	290	22	co	co	NOUN
chd-169	290	23	-	-	NOUN
chd-169	290	24	regulators	regulator	NOUN
chd-169	290	25	that	that	PRON
chd-169	290	26	may	may	AUX
chd-169	290	27	either	either	CCONJ
chd-169	290	28	serve	serve	VERB
chd-169	290	29	as	as	ADP
chd-169	290	30	coactivators	coactivator	NOUN
chd-169	290	31	or	or	CCONJ
chd-169	290	32	corepressors	corepressor	NOUN
chd-169	290	33	(	(	PUNCT
chd-169	290	34	hunt	hunt	NOUN
chd-169	290	35	et	et	NOUN
chd-169	290	36	al	al	PROPN
chd-169	290	37	.	.	PROPN
chd-169	290	38	,	,	PUNCT
chd-169	290	39	2018	2018	NUM
chd-169	290	40	;	;	PUNCT
chd-169	290	41	lonard	lonard	NOUN
chd-169	290	42	and	and	CCONJ
chd-169	290	43	o'malley	o'malley	PROPN
chd-169	290	44	,	,	PUNCT
chd-169	290	45	2012	2012	NUM
chd-169	290	46	;	;	PUNCT
chd-169	290	47	meijer	meijer	NOUN
chd-169	290	48	et	et	PROPN
chd-169	290	49	al	al	PROPN
chd-169	290	50	.	.	PROPN
chd-169	290	51	,	,	PUNCT
chd-169	290	52	2018	2018	NUM
chd-169	290	53	;	;	PUNCT
chd-169	290	54	nguyen	nguyen	NOUN
chd-169	290	55	et	et	PROPN
chd-169	290	56	al	al	PROPN
chd-169	290	57	.	.	PROPN
chd-169	290	58	,	,	PUNCT
chd-169	290	59	2017	2017	NUM
chd-169	290	60	)	)	PUNCT
chd-169	290	61	.	.	PUNCT
chd-169	291	1	gres	gre	NOUN
chd-169	291	2	in	in	ADP
chd-169	291	3	different	different	ADJ
chd-169	291	4	genes	gene	NOUN
chd-169	291	5	depend	depend	VERB
chd-169	291	6	on	on	ADP
chd-169	291	7	particular	particular	ADJ
chd-169	291	8	sets	set	NOUN
chd-169	291	9	of	of	ADP
chd-169	291	10	coactivators	coactivator	NOUN
chd-169	291	11	(	(	PUNCT
chd-169	291	12	lachize	lachize	VERB
chd-169	291	13	et	et	PROPN
chd-169	291	14	al	al	PROPN
chd-169	291	15	.	.	PROPN
chd-169	291	16	,	,	PUNCT
chd-169	291	17	2009	2009	NUM
chd-169	291	18	;	;	PUNCT
chd-169	291	19	meijer	meijer	NOUN
chd-169	291	20	et	et	PROPN
chd-169	291	21	al	al	PROPN
chd-169	291	22	.	.	PROPN
chd-169	291	23	,	,	PUNCT
chd-169	291	24	2018	2018	NUM
chd-169	291	25	;	;	PUNCT
chd-169	291	26	zalachoras	zalachoras	PROPN
chd-169	291	27	et	et	PROPN
chd-169	291	28	al	al	PROPN
chd-169	291	29	.	.	PROPN
chd-169	291	30	,	,	PUNCT
chd-169	291	31	2016	2016	NUM
chd-169	291	32	)	)	PUNCT
chd-169	291	33	.	.	PUNCT
chd-169	292	1	selective	selective	ADJ
chd-169	292	2	gr	gr	NOUN
chd-169	292	3	modulators	modulator	NOUN
chd-169	292	4	that	that	PRON
chd-169	292	5	act	act	VERB
chd-169	292	6	via	via	ADP
chd-169	292	7	gres	gre	NOUN
chd-169	292	8	may	may	AUX
chd-169	292	9	differ	differ	VERB
chd-169	292	10	in	in	ADP
chd-169	292	11	their	their	PRON
chd-169	292	12	ability	ability	NOUN
chd-169	292	13	to	to	PART
chd-169	292	14	induce	induce	VERB
chd-169	292	15	interactions	interaction	NOUN
chd-169	292	16	with	with	ADP
chd-169	292	17	other	other	ADJ
chd-169	292	18	transcription	transcription	NOUN
chd-169	292	19	factors	factor	NOUN
chd-169	292	20	that	that	PRON
chd-169	292	21	bind	bind	VERB
chd-169	292	22	dna	dna	NOUN
chd-169	292	23	in	in	ADP
chd-169	292	24	the	the	DET
chd-169	292	25	vicinity	vicinity	NOUN
chd-169	292	26	of	of	ADP
chd-169	292	27	the	the	DET
chd-169	292	28	gres	gre	NOUN
chd-169	292	29	(	(	PUNCT
chd-169	292	30	meijer	meijer	NOUN
chd-169	292	31	et	et	PROPN
chd-169	292	32	al	al	PROPN
chd-169	292	33	.	.	PROPN
chd-169	292	34	,	,	PUNCT
chd-169	292	35	2018	2018	NUM
chd-169	292	36	)	)	PUNCT
chd-169	292	37	.	.	PUNCT
chd-169	293	1	the	the	DET
chd-169	293	2	ability	ability	NOUN
chd-169	293	3	to	to	PART
chd-169	293	4	treat	treat	VERB
chd-169	293	5	a	a	DET
chd-169	293	6	specific	specific	ADJ
chd-169	293	7	disease	disease	NOUN
chd-169	293	8	independently	independently	ADV
chd-169	293	9	from	from	ADP
chd-169	293	10	all	all	DET
chd-169	293	11	the	the	DET
chd-169	293	12	other	other	ADJ
chd-169	293	13	gr	gr	ADJ
chd-169	293	14	-	-	PUNCT
chd-169	293	15	dependent	dependent	ADJ
chd-169	293	16	effects	effect	NOUN
chd-169	293	17	would	would	AUX
chd-169	293	18	be	be	AUX
chd-169	293	19	considered	consider	VERB
chd-169	293	20	a	a	DET
chd-169	293	21	“	"	PUNCT
chd-169	293	22	game	game	NOUN
chd-169	293	23	changer	changer	NOUN
chd-169	293	24	”	"	PUNCT
chd-169	293	25	in	in	ADP
chd-169	293	26	medicine	medicine	NOUN
chd-169	293	27	(	(	PUNCT
chd-169	293	28	de	de	X
chd-169	293	29	bosscher	bosscher	PROPN
chd-169	293	30	et	et	PROPN
chd-169	293	31	al	al	PROPN
chd-169	293	32	.	.	PROPN
chd-169	293	33	,	,	PUNCT
chd-169	293	34	2016	2016	NUM
chd-169	293	35	;	;	PUNCT
chd-169	293	36	meijer	meijer	NOUN
chd-169	293	37	et	et	PROPN
chd-169	293	38	al	al	PROPN
chd-169	293	39	.	.	PROPN
chd-169	293	40	,	,	PUNCT
chd-169	293	41	2018	2018	NUM
chd-169	293	42	)	)	PUNCT
chd-169	293	43	.	.	PUNCT
chd-169	294	1	to	to	ADP
chd-169	294	2	that	that	DET
chd-169	294	3	end	end	NOUN
chd-169	294	4	,	,	PUNCT
chd-169	294	5	sgrms	sgrm	NOUN
chd-169	294	6	are	be	AUX
chd-169	294	7	being	be	AUX
chd-169	294	8	introduced	introduce	VERB
chd-169	294	9	in	in	ADP
chd-169	294	10	clinical	clinical	ADJ
chd-169	294	11	trials	trial	NOUN
chd-169	294	12	for	for	ADP
chd-169	294	13	pca	pca	NOUN
chd-169	294	14	patients	patient	NOUN
chd-169	294	15	.	.	PUNCT
chd-169	295	1	a	a	DET
chd-169	295	2	current	current	ADJ
chd-169	295	3	trial	trial	NOUN
chd-169	295	4	seeks	seek	VERB
chd-169	295	5	to	to	PART
chd-169	295	6	establish	establish	VERB
chd-169	295	7	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	ADJ
chd-169	295	8	e19	e19	ADJ
chd-169	295	9	cancer	cancer	NOUN
chd-169	295	10	health	health	NOUN
chd-169	295	11	disparities	disparity	NOUN
chd-169	295	12	research	research	VERB
chd-169	295	13	the	the	DET
chd-169	295	14	recommended	recommend	VERB
chd-169	295	15	dose	dose	NOUN
chd-169	295	16	,	,	PUNCT
chd-169	295	17	safety	safety	NOUN
chd-169	295	18	,	,	PUNCT
chd-169	295	19	pharmacokinetics	pharmacokinetic	NOUN
chd-169	295	20	,	,	PUNCT
chd-169	295	21	pharmacodynamics	pharmacodynamic	NOUN
chd-169	295	22	,	,	PUNCT
chd-169	295	23	and	and	CCONJ
chd-169	295	24	preliminary	preliminary	ADJ
chd-169	295	25	antitumor	antitumor	NOUN
chd-169	295	26	activity	activity	NOUN
chd-169	295	27	of	of	ADP
chd-169	295	28	the	the	DET
chd-169	295	29	specific	specific	ADJ
chd-169	295	30	gr	gr	NOUN
chd-169	295	31	antagonist	antagonist	NOUN
chd-169	295	32	oric-101	oric-101	NOUN
chd-169	295	33	in	in	ADP
chd-169	295	34	combination	combination	NOUN
chd-169	295	35	with	with	ADP
chd-169	295	36	enzalutamide	enzalutamide	NOUN
chd-169	295	37	in	in	ADP
chd-169	295	38	mcrpc	mcrpc	NOUN
chd-169	295	39	patients	patient	NOUN
chd-169	295	40	(	(	PUNCT
chd-169	295	41	nct04033328	nct04033328	NUM
chd-169	295	42	)	)	PUNCT
chd-169	295	43	(	(	PUNCT
chd-169	295	44	multani	multani	NOUN
chd-169	295	45	,	,	PUNCT
chd-169	295	46	2019	2019	NUM
chd-169	295	47	)	)	PUNCT
chd-169	295	48	.	.	PUNCT
chd-169	296	1	a	a	DET
chd-169	296	2	similar	similar	ADJ
chd-169	296	3	trial	trial	NOUN
chd-169	296	4	is	be	AUX
chd-169	296	5	underway	underway	ADJ
chd-169	296	6	to	to	PART
chd-169	296	7	examine	examine	VERB
chd-169	296	8	the	the	DET
chd-169	296	9	same	same	ADJ
chd-169	296	10	primary	primary	ADJ
chd-169	296	11	outcomes	outcome	NOUN
chd-169	296	12	using	use	VERB
chd-169	296	13	a	a	DET
chd-169	296	14	different	different	ADJ
chd-169	296	15	gr	gr	NOUN
chd-169	296	16	antagonist	antagonist	NOUN
chd-169	296	17	,	,	PUNCT
chd-169	296	18	cort125281	cort125281	PROPN
chd-169	296	19	(	(	PUNCT
chd-169	296	20	nct03437941	nct03437941	ADJ
chd-169	296	21	)	)	PUNCT
chd-169	296	22	(	(	PUNCT
chd-169	296	23	shepherd	shepherd	NOUN
chd-169	296	24	,	,	PUNCT
chd-169	296	25	2018	2018	NUM
chd-169	296	26	)	)	PUNCT
chd-169	296	27	.	.	PUNCT
chd-169	297	1	given	give	VERB
chd-169	297	2	the	the	DET
chd-169	297	3	potential	potential	ADJ
chd-169	297	4	role	role	NOUN
chd-169	297	5	of	of	ADP
chd-169	297	6	gr	gr	NOUN
chd-169	297	7	in	in	ADP
chd-169	297	8	promoting	promote	VERB
chd-169	297	9	dtx	dtx	PROPN
chd-169	297	10	resistance	resistance	NOUN
chd-169	297	11	,	,	PUNCT
chd-169	297	12	future	future	ADJ
chd-169	297	13	pre	pre	ADJ
chd-169	297	14	-	-	ADJ
chd-169	297	15	clinical	clinical	ADJ
chd-169	297	16	studies	study	NOUN
chd-169	297	17	and	and	CCONJ
chd-169	297	18	clinical	clinical	ADJ
chd-169	297	19	trials	trial	NOUN
chd-169	297	20	evaluating	evaluate	VERB
chd-169	297	21	selective	selective	ADJ
chd-169	297	22	gr	gr	NOUN
chd-169	297	23	modulation	modulation	NOUN
chd-169	297	24	in	in	ADP
chd-169	297	25	combination	combination	NOUN
chd-169	297	26	with	with	ADP
chd-169	297	27	taxane	taxane	NOUN
chd-169	297	28	drugs	drug	NOUN
chd-169	297	29	for	for	ADP
chd-169	297	30	patients	patient	NOUN
chd-169	297	31	with	with	ADP
chd-169	297	32	mcrpc	mcrpc	PROPN
chd-169	297	33	are	be	AUX
chd-169	297	34	warranted	warrant	VERB
chd-169	297	35	.	.	PUNCT
chd-169	298	1	conclusions	conclusion	NOUN
chd-169	298	2	and	and	CCONJ
chd-169	298	3	future	future	ADJ
chd-169	298	4	perspectives	perspective	NOUN
chd-169	298	5	emerging	emerge	VERB
chd-169	298	6	data	datum	NOUN
chd-169	298	7	support	support	VERB
chd-169	298	8	the	the	DET
chd-169	298	9	notion	notion	NOUN
chd-169	298	10	that	that	SCONJ
chd-169	298	11	pca	pca	PROPN
chd-169	298	12	health	health	NOUN
chd-169	298	13	disparities	disparity	NOUN
chd-169	298	14	are	be	AUX
chd-169	298	15	influenced	influence	VERB
chd-169	298	16	by	by	ADP
chd-169	298	17	the	the	DET
chd-169	298	18	interplay	interplay	NOUN
chd-169	298	19	between	between	ADP
chd-169	298	20	socioeconomic	socioeconomic	ADJ
chd-169	298	21	,	,	PUNCT
chd-169	298	22	psychosocial	psychosocial	ADJ
chd-169	298	23	,	,	PUNCT
chd-169	298	24	health	health	NOUN
chd-169	298	25	care	care	NOUN
chd-169	298	26	,	,	PUNCT
chd-169	298	27	and	and	CCONJ
chd-169	298	28	biological	biological	ADJ
chd-169	298	29	/	/	SYM
chd-169	298	30	genetic	genetic	ADJ
chd-169	298	31	factors	factor	NOUN
chd-169	298	32	.	.	PUNCT
chd-169	299	1	chronic	chronic	ADJ
chd-169	299	2	and	and	CCONJ
chd-169	299	3	amplified	amplify	VERB
chd-169	299	4	gr	gr	NOUN
chd-169	299	5	signaling	signal	VERB
chd-169	299	6	triggered	trigger	VERB
chd-169	299	7	by	by	ADP
chd-169	299	8	cumulative	cumulative	ADJ
chd-169	299	9	psychosocial	psychosocial	ADJ
chd-169	299	10	stress	stress	NOUN
chd-169	299	11	may	may	AUX
chd-169	299	12	negatively	negatively	ADV
chd-169	299	13	influence	influence	VERB
chd-169	299	14	health	health	NOUN
chd-169	299	15	outcomes	outcome	NOUN
chd-169	299	16	in	in	ADP
chd-169	299	17	aa	aa	PROPN
chd-169	299	18	men	man	NOUN
chd-169	299	19	by	by	ADP
chd-169	299	20	promoting	promote	VERB
chd-169	299	21	the	the	DET
chd-169	299	22	activation	activation	NOUN
chd-169	299	23	of	of	ADP
chd-169	299	24	molecular	molecular	ADJ
chd-169	299	25	pathways	pathway	NOUN
chd-169	299	26	that	that	PRON
chd-169	299	27	contribute	contribute	VERB
chd-169	299	28	to	to	ADP
chd-169	299	29	pca	pca	NOUN
chd-169	299	30	progression	progression	NOUN
chd-169	299	31	(	(	PUNCT
chd-169	299	32	fig	fig	NOUN
chd-169	299	33	.	.	PUNCT
chd-169	299	34	1	1	NUM
chd-169	299	35	)	)	PUNCT
chd-169	299	36	.	.	PUNCT
chd-169	300	1	this	this	PRON
chd-169	300	2	enhanced	enhance	VERB
chd-169	300	3	gr	gr	NOUN
chd-169	300	4	signaling	signal	VERB
chd-169	300	5	,	,	PUNCT
chd-169	300	6	combined	combine	VERB
chd-169	300	7	with	with	ADP
chd-169	300	8	diminished	diminished	ADJ
chd-169	300	9	access	access	NOUN
chd-169	300	10	to	to	ADP
chd-169	300	11	health	health	NOUN
chd-169	300	12	care	care	NOUN
chd-169	300	13	and	and	CCONJ
chd-169	300	14	genetic	genetic	ADJ
chd-169	300	15	drivers	driver	NOUN
chd-169	300	16	of	of	ADP
chd-169	300	17	pca	pca	PROPN
chd-169	300	18	that	that	PRON
chd-169	300	19	increase	increase	VERB
chd-169	300	20	risk	risk	NOUN
chd-169	300	21	of	of	ADP
chd-169	300	22	aggressive	aggressive	ADJ
chd-169	300	23	disease	disease	NOUN
chd-169	300	24	in	in	ADP
chd-169	300	25	aa	aa	PROPN
chd-169	300	26	men	man	NOUN
chd-169	300	27	may	may	AUX
chd-169	300	28	promote	promote	VERB
chd-169	300	29	a	a	DET
chd-169	300	30	more	more	ADV
chd-169	300	31	aggressive	aggressive	ADJ
chd-169	300	32	tumor	tumor	NOUN
chd-169	300	33	phenotype	phenotype	NOUN
chd-169	300	34	,	,	PUNCT
chd-169	300	35	including	include	VERB
chd-169	300	36	the	the	DET
chd-169	300	37	possibility	possibility	NOUN
chd-169	300	38	of	of	ADP
chd-169	300	39	increased	increase	VERB
chd-169	300	40	resistance	resistance	NOUN
chd-169	300	41	to	to	ADP
chd-169	300	42	standard	standard	ADJ
chd-169	300	43	therapies	therapy	NOUN
chd-169	300	44	(	(	PUNCT
chd-169	300	45	fig	fig	NOUN
chd-169	300	46	.	.	PUNCT
chd-169	300	47	1	1	NUM
chd-169	300	48	)	)	PUNCT
chd-169	300	49	.	.	PUNCT
chd-169	301	1	however	however	ADV
chd-169	301	2	,	,	PUNCT
chd-169	301	3	it	it	PRON
chd-169	301	4	remains	remain	VERB
chd-169	301	5	to	to	PART
chd-169	301	6	be	be	AUX
chd-169	301	7	determined	determine	VERB
chd-169	301	8	if	if	SCONJ
chd-169	301	9	mcrpc	mcrpc	NOUN
chd-169	301	10	therapies	therapy	NOUN
chd-169	301	11	involving	involve	VERB
chd-169	301	12	glucocorticoids	glucocorticoid	NOUN
chd-169	301	13	such	such	ADJ
chd-169	301	14	as	as	ADP
chd-169	301	15	dexamethasone	dexamethasone	NOUN
chd-169	301	16	or	or	CCONJ
chd-169	301	17	prednisone	prednisone	NOUN
chd-169	301	18	produce	produce	VERB
chd-169	301	19	lower	low	ADJ
chd-169	301	20	benefits	benefit	NOUN
chd-169	301	21	in	in	ADP
chd-169	301	22	aa	aa	PROPN
chd-169	301	23	patients	patient	NOUN
chd-169	301	24	compared	compare	VERB
chd-169	301	25	to	to	ADP
chd-169	301	26	ea	ea	NOUN
chd-169	301	27	patients	patient	NOUN
chd-169	301	28	.	.	PUNCT
chd-169	302	1	likewise	likewise	ADV
chd-169	302	2	,	,	PUNCT
chd-169	302	3	it	it	PRON
chd-169	302	4	remains	remain	VERB
chd-169	302	5	to	to	PART
chd-169	302	6	be	be	AUX
chd-169	302	7	determined	determine	VERB
chd-169	302	8	if	if	SCONJ
chd-169	302	9	aa	aa	ADJ
chd-169	302	10	men	man	NOUN
chd-169	302	11	with	with	ADP
chd-169	302	12	mcrpc	mcrpc	NOUN
chd-169	302	13	may	may	AUX
chd-169	302	14	benefit	benefit	VERB
chd-169	302	15	more	more	ADV
chd-169	302	16	from	from	ADP
chd-169	302	17	combinatorial	combinatorial	ADJ
chd-169	302	18	therapies	therapy	NOUN
chd-169	302	19	involving	involve	VERB
chd-169	302	20	gr	gr	NOUN
chd-169	302	21	antagonists	antagonist	NOUN
chd-169	302	22	such	such	ADJ
chd-169	302	23	as	as	ADP
chd-169	302	24	mifepristone	mifepristone	NOUN
chd-169	302	25	and	and	CCONJ
chd-169	302	26	sgrms	sgrm	NOUN
chd-169	302	27	compared	compare	VERB
chd-169	302	28	to	to	ADP
chd-169	302	29	ea	ea	NOUN
chd-169	302	30	patients	patient	NOUN
chd-169	302	31	.	.	PUNCT
chd-169	303	1	critical	critical	ADJ
chd-169	303	2	for	for	ADP
chd-169	303	3	addressing	address	VERB
chd-169	303	4	these	these	DET
chd-169	303	5	issues	issue	NOUN
chd-169	303	6	is	be	AUX
chd-169	303	7	the	the	DET
chd-169	303	8	recruitment	recruitment	NOUN
chd-169	303	9	and	and	CCONJ
chd-169	303	10	retention	retention	NOUN
chd-169	303	11	of	of	ADP
chd-169	303	12	large	large	ADJ
chd-169	303	13	numbers	number	NOUN
chd-169	303	14	of	of	ADP
chd-169	303	15	aa	aa	PROPN
chd-169	303	16	pca	pca	PROPN
chd-169	303	17	patients	patient	NOUN
chd-169	303	18	to	to	PART
chd-169	303	19	current	current	ADJ
chd-169	303	20	and	and	CCONJ
chd-169	303	21	future	future	ADJ
chd-169	303	22	clinical	clinical	ADJ
chd-169	303	23	trials	trial	NOUN
chd-169	303	24	examining	examine	VERB
chd-169	303	25	the	the	DET
chd-169	303	26	contribution	contribution	NOUN
chd-169	303	27	of	of	ADP
chd-169	303	28	glucocorticoids	glucocorticoid	NOUN
chd-169	303	29	or	or	CCONJ
chd-169	303	30	gr	gr	NOUN
chd-169	303	31	antagonists	antagonist	NOUN
chd-169	303	32	to	to	ADP
chd-169	303	33	overall	overall	ADJ
chd-169	303	34	patient	patient	ADJ
chd-169	303	35	survival	survival	NOUN
chd-169	303	36	.	.	PUNCT
chd-169	304	1	it	it	PRON
chd-169	304	2	would	would	AUX
chd-169	304	3	therefore	therefore	ADV
chd-169	304	4	be	be	AUX
chd-169	304	5	of	of	ADP
chd-169	304	6	great	great	ADJ
chd-169	304	7	interest	interest	NOUN
chd-169	304	8	to	to	PART
chd-169	304	9	determine	determine	VERB
chd-169	304	10	if	if	SCONJ
chd-169	304	11	there	there	PRON
chd-169	304	12	are	be	VERB
chd-169	304	13	racial	racial	ADJ
chd-169	304	14	differences	difference	NOUN
chd-169	304	15	in	in	ADP
chd-169	304	16	the	the	DET
chd-169	304	17	outcomes	outcome	NOUN
chd-169	304	18	of	of	ADP
chd-169	304	19	the	the	DET
chd-169	304	20	switch	switch	NOUN
chd-169	304	21	trial	trial	NOUN
chd-169	304	22	(	(	PUNCT
chd-169	304	23	abiraterone	abiraterone	NOUN
chd-169	304	24	plus	plus	CCONJ
chd-169	304	25	dexamethasone	dexamethasone	NOUN
chd-169	304	26	)	)	PUNCT
chd-169	304	27	,	,	PUNCT
chd-169	304	28	the	the	DET
chd-169	304	29	nct02012296	nct02012296	NOUN
chd-169	304	30	trial	trial	NOUN
chd-169	304	31	(	(	PUNCT
chd-169	304	32	enzalutamide	enzalutamide	ADV
chd-169	304	33	plus	plus	CCONJ
chd-169	304	34	mifepristone	mifepristone	NOUN
chd-169	304	35	)	)	PUNCT
chd-169	304	36	,	,	PUNCT
chd-169	304	37	the	the	DET
chd-169	304	38	nct03437941	nct03437941	ADJ
chd-169	304	39	trial	trial	NOUN
chd-169	304	40	(	(	PUNCT
chd-169	304	41	enzalutamide	enzalutamide	ADP
chd-169	304	42	plus	plus	CCONJ
chd-169	304	43	the	the	DET
chd-169	304	44	gr	gr	NOUN
chd-169	304	45	antagonist	antagonist	NOUN
chd-169	304	46	cort125281	cort125281	PROPN
chd-169	304	47	)	)	PUNCT
chd-169	304	48	,	,	PUNCT
chd-169	304	49	and	and	CCONJ
chd-169	304	50	the	the	DET
chd-169	304	51	nct0403328	nct0403328	NOUN
chd-169	304	52	trial	trial	NOUN
chd-169	304	53	(	(	PUNCT
chd-169	304	54	enzalutamide	enzalutamide	ADP
chd-169	304	55	plus	plus	CCONJ
chd-169	304	56	the	the	DET
chd-169	304	57	gr	gr	NOUN
chd-169	304	58	antagonist	antagonist	NOUN
chd-169	304	59	oric101	oric101	PROPN
chd-169	304	60	)	)	PUNCT
chd-169	304	61	.	.	PUNCT
chd-169	305	1	as	as	SCONJ
chd-169	305	2	our	our	PRON
chd-169	305	3	understanding	understanding	NOUN
chd-169	305	4	of	of	ADP
chd-169	305	5	the	the	DET
chd-169	305	6	contribution	contribution	NOUN
chd-169	305	7	of	of	ADP
chd-169	305	8	gr	gr	NOUN
chd-169	305	9	signaling	signal	VERB
chd-169	305	10	to	to	ADP
chd-169	305	11	pca	pca	NOUN
chd-169	305	12	progression	progression	NOUN
chd-169	305	13	and	and	CCONJ
chd-169	305	14	therapy	therapy	NOUN
chd-169	305	15	resistance	resistance	NOUN
chd-169	305	16	increases	increase	NOUN
chd-169	305	17	,	,	PUNCT
chd-169	305	18	clinicians	clinician	NOUN
chd-169	305	19	and	and	CCONJ
chd-169	305	20	researchers	researcher	NOUN
chd-169	305	21	must	must	AUX
chd-169	305	22	consider	consider	VERB
chd-169	305	23	carefully	carefully	ADV
chd-169	305	24	the	the	DET
chd-169	305	25	clinical	clinical	ADJ
chd-169	305	26	implications	implication	NOUN
chd-169	305	27	of	of	ADP
chd-169	305	28	standard	standard	ADJ
chd-169	305	29	and	and	CCONJ
chd-169	305	30	upcoming	upcoming	ADJ
chd-169	305	31	treatments	treatment	NOUN
chd-169	305	32	for	for	ADP
chd-169	305	33	pca	pca	PROPN
chd-169	305	34	that	that	PRON
chd-169	305	35	modulate	modulate	VERB
chd-169	305	36	gr	gr	NOUN
chd-169	305	37	function	function	NOUN
chd-169	305	38	in	in	ADP
chd-169	305	39	aa	aa	NOUN
chd-169	305	40	men	man	NOUN
chd-169	305	41	.	.	PUNCT
chd-169	306	1	it	it	PRON
chd-169	306	2	is	be	AUX
chd-169	306	3	probable	probable	ADJ
chd-169	306	4	that	that	SCONJ
chd-169	306	5	ongoing	ongoing	ADJ
chd-169	306	6	clinical	clinical	ADJ
chd-169	306	7	trials	trial	NOUN
chd-169	306	8	may	may	AUX
chd-169	306	9	reveal	reveal	VERB
chd-169	306	10	race	race	NOUN
chd-169	306	11	-	-	PUNCT
chd-169	306	12	related	relate	VERB
chd-169	306	13	differential	differential	ADJ
chd-169	306	14	benefits	benefit	NOUN
chd-169	306	15	,	,	PUNCT
chd-169	306	16	or	or	CCONJ
chd-169	306	17	harms	harm	NOUN
chd-169	306	18	,	,	PUNCT
chd-169	306	19	of	of	ADP
chd-169	306	20	modulating	modulate	VERB
chd-169	306	21	gr	gr	NOUN
chd-169	306	22	function	function	NOUN
chd-169	306	23	for	for	ADP
chd-169	306	24	mcrpc	mcrpc	PROPN
chd-169	306	25	treatment	treatment	NOUN
chd-169	306	26	.	.	PUNCT
chd-169	307	1	this	this	PRON
chd-169	307	2	would	would	AUX
chd-169	307	3	necessitate	necessitate	VERB
chd-169	307	4	clinical	clinical	ADJ
chd-169	307	5	and	and	CCONJ
chd-169	307	6	socio	socio	NOUN
chd-169	307	7	-	-	PUNCT
chd-169	307	8	behavioral	behavioral	ADJ
chd-169	307	9	scientists	scientist	NOUN
chd-169	307	10	working	work	VERB
chd-169	307	11	together	together	ADV
chd-169	307	12	to	to	PART
chd-169	307	13	measure	measure	VERB
chd-169	307	14	psychosocial	psychosocial	ADJ
chd-169	307	15	indicators	indicator	NOUN
chd-169	307	16	linked	link	VERB
chd-169	307	17	to	to	ADP
chd-169	307	18	increased	increase	VERB
chd-169	307	19	gr	gr	NOUN
chd-169	307	20	signaling	signal	VERB
chd-169	307	21	in	in	ADP
chd-169	307	22	aa	aa	PROPN
chd-169	307	23	pca	pca	PROPN
chd-169	307	24	patients	patient	NOUN
chd-169	307	25	.	.	PUNCT
chd-169	308	1	socio	socio	NOUN
chd-169	308	2	-	-	PUNCT
chd-169	308	3	behavioral	behavioral	ADJ
chd-169	308	4	scientists	scientist	NOUN
chd-169	308	5	and	and	CCONJ
chd-169	308	6	clinicians	clinician	NOUN
chd-169	308	7	could	could	AUX
chd-169	308	8	also	also	ADV
chd-169	308	9	implement	implement	VERB
chd-169	308	10	novel	novel	ADJ
chd-169	308	11	community	community	NOUN
chd-169	308	12	and	and	CCONJ
chd-169	308	13	clinic	clinic	NOUN
chd-169	308	14	-	-	PUNCT
chd-169	308	15	based	base	VERB
chd-169	308	16	interventions	intervention	NOUN
chd-169	308	17	to	to	PART
chd-169	308	18	reduce	reduce	VERB
chd-169	308	19	chronic	chronic	ADJ
chd-169	308	20	stress	stress	NOUN
chd-169	308	21	,	,	PUNCT
chd-169	308	22	which	which	PRON
chd-169	308	23	may	may	AUX
chd-169	308	24	result	result	VERB
chd-169	308	25	in	in	ADP
chd-169	308	26	attenuated	attenuate	VERB
chd-169	308	27	gr	gr	NOUN
chd-169	308	28	signaling	signal	VERB
chd-169	308	29	and	and	CCONJ
chd-169	308	30	,	,	PUNCT
chd-169	308	31	potentially	potentially	ADV
chd-169	308	32	,	,	PUNCT
chd-169	308	33	better	well	ADJ
chd-169	308	34	outcomes	outcome	NOUN
chd-169	308	35	for	for	ADP
chd-169	308	36	aa	aa	PROPN
chd-169	308	37	men	man	NOUN
chd-169	308	38	,	,	PUNCT
chd-169	308	39	who	who	PRON
chd-169	308	40	are	be	AUX
chd-169	308	41	most	most	ADV
chd-169	308	42	at	at	ADP
chd-169	308	43	risk	risk	NOUN
chd-169	308	44	of	of	ADP
chd-169	308	45	developing	develop	VERB
chd-169	308	46	aggressive	aggressive	ADJ
chd-169	308	47	pca	pca	NOUN
chd-169	308	48	.	.	PUNCT
chd-169	309	1	finally	finally	ADV
chd-169	309	2	,	,	PUNCT
chd-169	309	3	preventive	preventive	ADJ
chd-169	309	4	policy	policy	NOUN
chd-169	309	5	interventions	intervention	NOUN
chd-169	309	6	targeting	target	VERB
chd-169	309	7	upstream	upstream	ADJ
chd-169	309	8	determinants	determinant	NOUN
chd-169	309	9	of	of	ADP
chd-169	309	10	ses	se	NOUN
chd-169	309	11	including	include	VERB
chd-169	309	12	education	education	NOUN
chd-169	309	13	,	,	PUNCT
chd-169	309	14	housing	housing	NOUN
chd-169	309	15	,	,	PUNCT
chd-169	309	16	urban	urban	ADJ
chd-169	309	17	planning	planning	NOUN
chd-169	309	18	,	,	PUNCT
chd-169	309	19	community	community	NOUN
chd-169	309	20	development	development	NOUN
chd-169	309	21	,	,	PUNCT
chd-169	309	22	employment	employment	NOUN
chd-169	309	23	,	,	PUNCT
chd-169	309	24	and	and	CCONJ
chd-169	309	25	income	income	NOUN
chd-169	309	26	enhancements	enhancement	NOUN
chd-169	309	27	should	should	AUX
chd-169	309	28	be	be	AUX
chd-169	309	29	considered	consider	VERB
chd-169	309	30	to	to	PART
chd-169	309	31	ameliorate	ameliorate	VERB
chd-169	309	32	the	the	DET
chd-169	309	33	discriminatory	discriminatory	ADJ
chd-169	309	34	contributors	contributor	NOUN
chd-169	309	35	to	to	PART
chd-169	309	36	chronic	chronic	ADJ
chd-169	309	37	psychosocial	psychosocial	ADJ
chd-169	309	38	stress	stress	NOUN
chd-169	309	39	experienced	experience	VERB
chd-169	309	40	by	by	ADP
chd-169	309	41	african	african	ADJ
chd-169	309	42	american	american	ADJ
chd-169	309	43	men	man	NOUN
chd-169	309	44	.	.	PUNCT
chd-169	310	1	funding	funding	NOUN
chd-169	310	2	sources	source	NOUN
chd-169	310	3	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-169	310	4	e20	e20	NOUN
chd-169	310	5	cancer	cancer	NOUN
chd-169	310	6	health	health	NOUN
chd-169	310	7	disparities	disparity	NOUN
chd-169	310	8	research	research	VERB
chd-169	310	9	the	the	DET
chd-169	310	10	authors	author	NOUN
chd-169	310	11	acknowledge	acknowledge	VERB
chd-169	310	12	research	research	NOUN
chd-169	310	13	support	support	NOUN
chd-169	310	14	from	from	ADP
chd-169	310	15	the	the	DET
chd-169	310	16	national	national	PROPN
chd-169	310	17	institutes	institutes	PROPN
chd-169	310	18	of	of	ADP
chd-169	310	19	health	health	PROPN
chd-169	310	20	(	(	PUNCT
chd-169	310	21	nih	nih	NOUN
chd-169	310	22	)	)	PUNCT
chd-169	310	23	grants	grant	VERB
chd-169	310	24	r21ca226654	r21ca226654	PROPN
chd-169	310	25	-	-	PUNCT
chd-169	310	26	01a1	01a1	PROPN
chd-169	310	27	(	(	PUNCT
chd-169	310	28	c.a.c	c.a.c	ADJ
chd-169	310	29	)	)	PUNCT
chd-169	310	30	and	and	CCONJ
chd-169	310	31	p20md006988project	p20md006988project	PROPN
chd-169	310	32	2	2	NUM
chd-169	310	33	(	(	PUNCT
chd-169	310	34	c.a.c	c.a.c	ADJ
chd-169	310	35	.	.	PUNCT
chd-169	310	36	)	)	PUNCT
chd-169	310	37	,	,	PUNCT
chd-169	310	38	the	the	DET
chd-169	310	39	loma	loma	PROPN
chd-169	310	40	linda	linda	PROPN
chd-169	310	41	university	university	PROPN
chd-169	310	42	health	health	PROPN
chd-169	310	43	(	(	PUNCT
chd-169	310	44	lluh	lluh	NOUN
chd-169	310	45	)	)	PUNCT
chd-169	310	46	center	center	NOUN
chd-169	310	47	for	for	ADP
chd-169	310	48	health	health	NOUN
chd-169	310	49	disparities	disparity	NOUN
chd-169	310	50	and	and	CCONJ
chd-169	310	51	molecular	molecular	ADJ
chd-169	310	52	medicine	medicine	NOUN
chd-169	310	53	(	(	PUNCT
chd-169	310	54	c.a.c	c.a.c	ADJ
chd-169	310	55	.	.	PUNCT
chd-169	310	56	and	and	CCONJ
chd-169	310	57	s.m	s.m	PROPN
chd-169	310	58	)	)	PUNCT
chd-169	310	59	and	and	CCONJ
chd-169	310	60	the	the	DET
chd-169	310	61	lluh	lluh	NOUN
chd-169	310	62	schools	school	NOUN
chd-169	310	63	of	of	ADP
chd-169	310	64	medicine	medicine	NOUN
chd-169	310	65	(	(	PUNCT
chd-169	310	66	c.a.c	c.a.c	ADJ
chd-169	310	67	,	,	PUNCT
chd-169	310	68	h.c.r	h.c.r	PROPN
chd-169	310	69	.	.	PUNCT
chd-169	310	70	,	,	PUNCT
chd-169	310	71	f.g.a	f.g.a	ADJ
chd-169	310	72	)	)	PUNCT
chd-169	310	73	,	,	PUNCT
chd-169	310	74	behavioral	behavioral	ADJ
chd-169	310	75	health	health	NOUN
chd-169	310	76	(	(	PUNCT
chd-169	310	77	s.m	s.m	PROPN
chd-169	310	78	.	.	PROPN
chd-169	310	79	)	)	PUNCT
chd-169	310	80	,	,	PUNCT
chd-169	310	81	and	and	CCONJ
chd-169	310	82	nursing	nursing	NOUN
chd-169	310	83	(	(	PUNCT
chd-169	310	84	l.r.r	l.r.r	ADJ
chd-169	310	85	)	)	PUNCT
chd-169	310	86	.	.	PUNCT
chd-169	311	1	l.w.b	l.w.b	PROPN
chd-169	311	2	.	.	PROPN
chd-169	311	3	,	,	PUNCT
chd-169	311	4	s.r.m	s.r.m	PROPN
chd-169	311	5	.	.	PUNCT
chd-169	311	6	,	,	PUNCT
chd-169	311	7	and	and	CCONJ
chd-169	311	8	e.s.s.h	e.s.s.h	PROPN
chd-169	311	9	.	.	PROPN
chd-169	311	10	were	be	AUX
chd-169	311	11	supported	support	VERB
chd-169	311	12	by	by	ADP
chd-169	311	13	nih	nih	PROPN
chd-169	311	14	grant	grant	PROPN
chd-169	311	15	r25gm060507	r25gm060507	NOUN
chd-169	311	16	and	and	CCONJ
chd-169	311	17	the	the	DET
chd-169	311	18	llu	llu	PROPN
chd-169	311	19	-	-	PUNCT
chd-169	311	20	nih	nih	PROPN
chd-169	311	21	initiative	initiative	NOUN
chd-169	311	22	for	for	ADP
chd-169	311	23	maximizing	maximize	VERB
chd-169	311	24	student	student	NOUN
chd-169	311	25	development	development	NOUN
chd-169	311	26	(	(	PUNCT
chd-169	311	27	imsd	imsd	NOUN
chd-169	311	28	)	)	PUNCT
chd-169	311	29	graduate	graduate	NOUN
chd-169	311	30	training	training	NOUN
chd-169	311	31	program	program	NOUN
chd-169	311	32	.	.	PUNCT
chd-169	312	1	e.s.s.h	e.s.s.h	NOUN
chd-169	312	2	.	.	PROPN
chd-169	312	3	is	be	AUX
chd-169	312	4	currently	currently	ADV
chd-169	312	5	supported	support	VERB
chd-169	312	6	by	by	ADP
chd-169	312	7	nih	nih	PROPN
chd-169	312	8	grant	grant	PROPN
chd-169	312	9	r21ca226654	r21ca226654	PROPN
chd-169	312	10	-	-	PUNCT
chd-169	312	11	01a1s1	01a1s1	NOUN
chd-169	312	12	.	.	PUNCT
chd-169	313	1	l.w.b	l.w.b	PROPN
chd-169	313	2	.	.	PROPN
chd-169	313	3	is	be	AUX
chd-169	313	4	currently	currently	ADV
chd-169	313	5	supported	support	VERB
chd-169	313	6	by	by	ADP
chd-169	313	7	nih	nih	PROPN
chd-169	313	8	grant	grant	PROPN
chd-169	313	9	t32	t32	NOUN
chd-169	313	10	ca186895	ca186895	PROPN
chd-169	313	11	.	.	PUNCT
chd-169	314	1	acknowledgements	acknowledgement	NOUN
chd-169	314	2	the	the	DET
chd-169	314	3	authors	author	NOUN
chd-169	314	4	thank	thank	VERB
chd-169	314	5	dr	dr	PROPN
chd-169	314	6	.	.	PROPN
chd-169	314	7	marino	marino	PROPN
chd-169	314	8	de	de	PROPN
chd-169	314	9	leon	leon	PROPN
chd-169	314	10	,	,	PUNCT
chd-169	314	11	director	director	NOUN
chd-169	314	12	of	of	ADP
chd-169	314	13	the	the	DET
chd-169	314	14	lluh	lluh	NOUN
chd-169	314	15	center	center	NOUN
chd-169	314	16	for	for	ADP
chd-169	314	17	health	health	NOUN
chd-169	314	18	disparities	disparity	NOUN
chd-169	314	19	and	and	CCONJ
chd-169	314	20	molecular	molecular	ADJ
chd-169	314	21	medicine	medicine	NOUN
chd-169	314	22	,	,	PUNCT
chd-169	314	23	for	for	ADP
chd-169	314	24	his	his	PRON
chd-169	314	25	support	support	NOUN
chd-169	314	26	of	of	ADP
chd-169	314	27	this	this	DET
chd-169	314	28	work	work	NOUN
chd-169	314	29	.	.	PUNCT
chd-169	315	1	we	we	PRON
chd-169	315	2	also	also	ADV
chd-169	315	3	thank	thank	VERB
chd-169	315	4	the	the	DET
chd-169	315	5	members	member	NOUN
chd-169	315	6	of	of	ADP
chd-169	315	7	this	this	DET
chd-169	315	8	center	center	NOUN
chd-169	315	9	and	and	CCONJ
chd-169	315	10	many	many	ADJ
chd-169	315	11	other	other	ADJ
chd-169	315	12	colleagues	colleague	NOUN
chd-169	315	13	for	for	ADP
chd-169	315	14	stimulating	stimulate	VERB
chd-169	315	15	discussions	discussion	NOUN
chd-169	315	16	leading	lead	VERB
chd-169	315	17	to	to	ADP
chd-169	315	18	the	the	DET
chd-169	315	19	writing	writing	NOUN
chd-169	315	20	of	of	ADP
chd-169	315	21	this	this	DET
chd-169	315	22	comprehensive	comprehensive	ADJ
chd-169	315	23	review	review	NOUN
chd-169	315	24	paper	paper	NOUN
chd-169	315	25	.	.	PUNCT
chd-169	316	1	conflict	conflict	NOUN
chd-169	316	2	of	of	ADP
chd-169	316	3	interest	interest	NOUN
chd-169	316	4	the	the	DET
chd-169	316	5	authors	author	NOUN
chd-169	316	6	declare	declare	VERB
chd-169	316	7	that	that	SCONJ
chd-169	316	8	no	no	DET
chd-169	316	9	competing	compete	VERB
chd-169	316	10	or	or	CCONJ
chd-169	316	11	conflict	conflict	NOUN
chd-169	316	12	of	of	ADP
chd-169	316	13	interests	interest	NOUN
chd-169	316	14	exist	exist	VERB
chd-169	316	15	.	.	PUNCT
chd-169	317	1	the	the	DET
chd-169	317	2	funders	funder	NOUN
chd-169	317	3	had	have	VERB
chd-169	317	4	no	no	DET
chd-169	317	5	role	role	NOUN
chd-169	317	6	in	in	ADP
chd-169	317	7	study	study	NOUN
chd-169	317	8	design	design	NOUN
chd-169	317	9	,	,	PUNCT
chd-169	317	10	writing	writing	NOUN
chd-169	317	11	of	of	ADP
chd-169	317	12	the	the	DET
chd-169	317	13	manuscript	manuscript	NOUN
chd-169	317	14	,	,	PUNCT
chd-169	317	15	or	or	CCONJ
chd-169	317	16	decision	decision	NOUN
chd-169	317	17	to	to	PART
chd-169	317	18	publish	publish	VERB
chd-169	317	19	.	.	PUNCT
chd-169	318	1	authors	author	NOUN
chd-169	318	2	’	’	PART
chd-169	318	3	contributions	contribution	NOUN
chd-169	318	4	l.w.b	l.w.b	PROPN
chd-169	318	5	.	.	PROPN
chd-169	318	6	,	,	PUNCT
chd-169	319	1	l.s	l.s	PROPN
chd-169	319	2	.	.	PROPN
chd-169	319	3	,	,	PUNCT
chd-169	319	4	s.m	s.m	PROPN
chd-169	319	5	.	.	PROPN
chd-169	319	6	,	,	PUNCT
chd-169	319	7	and	and	CCONJ
chd-169	319	8	c.a.c	c.a.c	PROPN
chd-169	319	9	.	.	PUNCT
chd-169	319	10	contributed	contribute	VERB
chd-169	319	11	to	to	ADP
chd-169	319	12	the	the	DET
chd-169	319	13	conceptual	conceptual	ADJ
chd-169	319	14	design	design	NOUN
chd-169	319	15	of	of	ADP
chd-169	319	16	the	the	DET
chd-169	319	17	original	original	ADJ
chd-169	319	18	research	research	NOUN
chd-169	319	19	topic	topic	NOUN
chd-169	319	20	.	.	PUNCT
chd-169	320	1	l.w.b	l.w.b	PROPN
chd-169	320	2	.	.	PROPN
chd-169	320	3	wrote	write	VERB
chd-169	320	4	the	the	DET
chd-169	320	5	initial	initial	ADJ
chd-169	320	6	version	version	NOUN
chd-169	320	7	of	of	ADP
chd-169	320	8	the	the	DET
chd-169	320	9	manuscript	manuscript	NOUN
chd-169	320	10	and	and	CCONJ
chd-169	320	11	prepared	prepare	VERB
chd-169	320	12	fig	fig	NOUN
chd-169	320	13	.	.	PUNCT
chd-169	321	1	1	1	X
chd-169	321	2	.	.	X
chd-169	321	3	s.r.m	s.r.m	PROPN
chd-169	321	4	.	.	PUNCT
chd-169	322	1	wrote	write	VERB
chd-169	322	2	the	the	DET
chd-169	322	3	sections	section	NOUN
chd-169	322	4	on	on	ADP
chd-169	322	5	gr	gr	NOUN
chd-169	322	6	biology	biology	NOUN
chd-169	322	7	.	.	PUNCT
chd-169	323	1	h.r.c	h.r.c	NOUN
chd-169	323	2	.	.	PUNCT
chd-169	323	3	contributed	contribute	VERB
chd-169	323	4	to	to	ADP
chd-169	323	5	the	the	DET
chd-169	323	6	section	section	NOUN
chd-169	323	7	on	on	ADP
chd-169	323	8	prostate	prostate	NOUN
chd-169	323	9	cancer	cancer	NOUN
chd-169	323	10	treatment	treatment	NOUN
chd-169	323	11	options	option	NOUN
chd-169	323	12	.	.	PUNCT
chd-169	324	1	f.g.a	f.g.a	AUX
chd-169	324	2	.	.	PROPN
chd-169	324	3	wrote	write	VERB
chd-169	324	4	the	the	DET
chd-169	324	5	section	section	NOUN
chd-169	324	6	on	on	ADP
chd-169	324	7	psma	psma	NOUN
chd-169	324	8	theranostics	theranostic	NOUN
chd-169	324	9	.	.	PUNCT
chd-169	325	1	e.s.s.h	e.s.s.h	NOUN
chd-169	325	2	.	.	PROPN
chd-169	325	3	prepared	prepare	VERB
chd-169	325	4	figs	fig	NOUN
chd-169	325	5	.	.	PUNCT
chd-169	326	1	2	2	NUM
chd-169	326	2	,	,	PUNCT
chd-169	326	3	3	3	NUM
chd-169	326	4	,	,	PUNCT
chd-169	326	5	and	and	CCONJ
chd-169	326	6	4	4	NUM
chd-169	326	7	,	,	PUNCT
chd-169	326	8	and	and	CCONJ
chd-169	326	9	cross	cros	VERB
chd-169	326	10	-	-	VERB
chd-169	326	11	checked	check	VERB
chd-169	326	12	for	for	ADP
chd-169	326	13	accuracy	accuracy	NOUN
chd-169	326	14	the	the	DET
chd-169	326	15	literature	literature	NOUN
chd-169	326	16	citations	citation	VERB
chd-169	326	17	throughout	throughout	ADP
chd-169	326	18	the	the	DET
chd-169	326	19	manuscript	manuscript	NOUN
chd-169	326	20	.	.	PUNCT
chd-169	327	1	m.c.s	m.c.s	PROPN
chd-169	327	2	.	.	PUNCT
chd-169	327	3	,	,	PUNCT
chd-169	327	4	l.r.r	l.r.r	PROPN
chd-169	327	5	.	.	PUNCT
chd-169	327	6	,	,	PUNCT
chd-169	327	7	and	and	CCONJ
chd-169	327	8	d.r.w	d.r.w	PROPN
chd-169	327	9	.	.	PUNCT
chd-169	328	1	provided	provide	VERB
chd-169	328	2	unique	unique	ADJ
chd-169	328	3	perspectives	perspective	NOUN
chd-169	328	4	that	that	PRON
chd-169	328	5	guided	guide	VERB
chd-169	328	6	the	the	DET
chd-169	328	7	writing	writing	NOUN
chd-169	328	8	of	of	ADP
chd-169	328	9	sections	section	NOUN
chd-169	328	10	related	relate	VERB
chd-169	328	11	to	to	ADP
chd-169	328	12	socioeconomic	socioeconomic	ADJ
chd-169	328	13	and	and	CCONJ
chd-169	328	14	psychosocial	psychosocial	ADJ
chd-169	328	15	aspects	aspect	NOUN
chd-169	328	16	of	of	ADP
chd-169	328	17	pca	pca	PROPN
chd-169	328	18	.	.	PUNCT
chd-169	329	1	l.w.b	l.w.b	PROPN
chd-169	329	2	.	.	PROPN
chd-169	329	3	,	,	PUNCT
chd-169	329	4	l.s	l.s	PROPN
chd-169	329	5	.	.	NOUN
chd-169	329	6	,	,	PUNCT
chd-169	329	7	and	and	CCONJ
chd-169	329	8	c.a.c	c.a.c	ADJ
chd-169	329	9	.	.	PUNCT
chd-169	329	10	edited	edit	VERB
chd-169	329	11	the	the	DET
chd-169	329	12	various	various	ADJ
chd-169	329	13	drafts	draft	NOUN
chd-169	329	14	of	of	ADP
chd-169	329	15	the	the	DET
chd-169	329	16	manuscript	manuscript	NOUN
chd-169	329	17	.	.	PUNCT
chd-169	330	1	all	all	DET
chd-169	330	2	authors	author	NOUN
chd-169	330	3	reviewed	review	VERB
chd-169	330	4	and	and	CCONJ
chd-169	330	5	approved	approve	VERB
chd-169	330	6	the	the	DET
chd-169	330	7	manuscript	manuscript	NOUN
chd-169	330	8	prior	prior	ADV
chd-169	330	9	to	to	ADP
chd-169	330	10	submission	submission	NOUN
chd-169	330	11	.	.	PUNCT
chd-169	331	1	references	reference	NOUN
chd-169	331	2	abdalla	abdalla	PROPN
chd-169	331	3	,	,	PUNCT
chd-169	331	4	i.	i.	PROPN
chd-169	331	5	,	,	PUNCT
chd-169	331	6	ray	ray	PROPN
chd-169	331	7	,	,	PUNCT
chd-169	331	8	p.	p.	PROPN
chd-169	331	9	,	,	PUNCT
chd-169	331	10	vaida	vaida	PROPN
chd-169	331	11	,	,	PUNCT
chd-169	331	12	f.	f.	PROPN
chd-169	331	13	,	,	PUNCT
chd-169	331	14	and	and	CCONJ
chd-169	331	15	vijayakumar	vijayakumar	PROPN
chd-169	331	16	,	,	PUNCT
chd-169	331	17	s.	s.	PROPN
chd-169	331	18	(	(	PUNCT
chd-169	331	19	1999	1999	NUM
chd-169	331	20	)	)	PUNCT
chd-169	331	21	.	.	PUNCT
chd-169	332	1	racial	racial	ADJ
chd-169	332	2	differences	difference	NOUN
chd-169	332	3	in	in	ADP
chd-169	332	4	prostate	prostate	NOUN
chd-169	332	5	-	-	PUNCT
chd-169	332	6	specific	specific	ADJ
chd-169	332	7	antigen	antigen	ADJ
chd-169	332	8	levels	level	NOUN
chd-169	332	9	and	and	CCONJ
chd-169	332	10	prostate	prostate	NOUN
chd-169	332	11	-	-	PUNCT
chd-169	332	12	specific	specific	ADJ
chd-169	332	13	antigen	antigen	ADJ
chd-169	332	14	densities	density	NOUN
chd-169	332	15	in	in	ADP
chd-169	332	16	patients	patient	NOUN
chd-169	332	17	with	with	ADP
chd-169	332	18	prostate	prostate	NOUN
chd-169	332	19	cancer	cancer	NOUN
chd-169	332	20	.	.	PUNCT
chd-169	333	1	am	be	AUX
chd-169	333	2	j	j	PROPN
chd-169	333	3	clin	clin	PROPN
chd-169	333	4	oncol	oncol	PROPN
chd-169	333	5	22	22	NUM
chd-169	333	6	,	,	PUNCT
chd-169	333	7	537	537	NUM
chd-169	333	8	-	-	SYM
chd-169	333	9	541	541	NUM
chd-169	333	10	.	.	PUNCT
chd-169	334	1	acevedo	acevedo	PROPN
chd-169	334	2	-	-	PUNCT
chd-169	334	3	garcia	garcia	PROPN
chd-169	334	4	,	,	PUNCT
chd-169	334	5	d.	d.	PROPN
chd-169	334	6	,	,	PUNCT
chd-169	334	7	lochner	lochner	PROPN
chd-169	334	8	,	,	PUNCT
chd-169	334	9	k.a	k.a	PROPN
chd-169	334	10	.	.	PROPN
chd-169	334	11	,	,	PUNCT
chd-169	334	12	osypuk	osypuk	PROPN
chd-169	334	13	,	,	PUNCT
chd-169	334	14	t.l	t.l	PROPN
chd-169	334	15	.	.	PROPN
chd-169	334	16	,	,	PUNCT
chd-169	334	17	and	and	CCONJ
chd-169	334	18	subramanian	subramanian	ADJ
chd-169	334	19	,	,	PUNCT
chd-169	334	20	s.v	s.v	PROPN
chd-169	334	21	.	.	PROPN
chd-169	334	22	(	(	PUNCT
chd-169	334	23	2003	2003	NUM
chd-169	334	24	)	)	PUNCT
chd-169	334	25	.	.	PUNCT
chd-169	335	1	future	future	ADJ
chd-169	335	2	directions	direction	NOUN
chd-169	335	3	in	in	ADP
chd-169	335	4	residential	residential	ADJ
chd-169	335	5	segregation	segregation	NOUN
chd-169	335	6	and	and	CCONJ
chd-169	335	7	health	health	NOUN
chd-169	335	8	research	research	NOUN
chd-169	335	9	:	:	PUNCT
chd-169	335	10	a	a	DET
chd-169	335	11	multilevel	multilevel	ADJ
chd-169	335	12	approach	approach	NOUN
chd-169	335	13	.	.	PUNCT
chd-169	336	1	am	be	AUX
chd-169	336	2	j	j	PROPN
chd-169	336	3	public	public	ADJ
chd-169	336	4	health	health	NOUN
chd-169	336	5	93	93	NUM
chd-169	336	6	,	,	PUNCT
chd-169	336	7	215	215	NUM
chd-169	336	8	-	-	SYM
chd-169	336	9	221	221	NUM
chd-169	336	10	.	.	PUNCT
chd-169	337	1	adam	adam	PROPN
chd-169	337	2	,	,	PUNCT
chd-169	337	3	e.k	e.k	PROPN
chd-169	337	4	.	.	PROPN
chd-169	337	5	,	,	PUNCT
chd-169	337	6	and	and	CCONJ
chd-169	337	7	gunnar	gunnar	PROPN
chd-169	337	8	,	,	PUNCT
chd-169	337	9	m.r	m.r	PROPN
chd-169	337	10	.	.	PROPN
chd-169	337	11	(	(	PUNCT
chd-169	337	12	2001	2001	NUM
chd-169	337	13	)	)	PUNCT
chd-169	337	14	.	.	PUNCT
chd-169	338	1	relationship	relationship	NOUN
chd-169	338	2	functioning	functioning	NOUN
chd-169	338	3	and	and	CCONJ
chd-169	338	4	home	home	NOUN
chd-169	338	5	and	and	CCONJ
chd-169	338	6	work	work	NOUN
chd-169	338	7	demands	demand	NOUN
chd-169	338	8	predict	predict	VERB
chd-169	338	9	individual	individual	ADJ
chd-169	338	10	differences	difference	NOUN
chd-169	338	11	in	in	ADP
chd-169	338	12	diurnal	diurnal	ADJ
chd-169	338	13	cortisol	cortisol	ADJ
chd-169	338	14	patterns	pattern	NOUN
chd-169	338	15	in	in	ADP
chd-169	338	16	women	woman	NOUN
chd-169	338	17	.	.	PUNCT
chd-169	339	1	psychoneuroendocrinology	psychoneuroendocrinology	NOUN
chd-169	339	2	26	26	NUM
chd-169	339	3	,	,	PUNCT
chd-169	339	4	189	189	NUM
chd-169	339	5	-	-	SYM
chd-169	339	6	208	208	NUM
chd-169	339	7	.	.	PUNCT
chd-169	340	1	adler	adler	PROPN
chd-169	340	2	,	,	PUNCT
chd-169	340	3	n.e	n.e	PROPN
chd-169	340	4	.	.	PROPN
chd-169	340	5	,	,	PUNCT
chd-169	340	6	boyce	boyce	PROPN
chd-169	340	7	,	,	PUNCT
chd-169	340	8	t.	t.	PROPN
chd-169	340	9	,	,	PUNCT
chd-169	340	10	chesney	chesney	PROPN
chd-169	340	11	,	,	PUNCT
chd-169	340	12	m.a	m.a	PROPN
chd-169	340	13	.	.	PROPN
chd-169	340	14	,	,	PUNCT
chd-169	340	15	cohen	cohen	PROPN
chd-169	340	16	,	,	PUNCT
chd-169	340	17	s.	s.	PROPN
chd-169	340	18	,	,	PUNCT
chd-169	340	19	folkman	folkman	PROPN
chd-169	340	20	,	,	PUNCT
chd-169	340	21	s.	s.	PROPN
chd-169	340	22	,	,	PUNCT
chd-169	340	23	kahn	kahn	PROPN
chd-169	340	24	,	,	PUNCT
chd-169	340	25	r.l	r.l	PROPN
chd-169	340	26	.	.	PROPN
chd-169	340	27	,	,	PUNCT
chd-169	340	28	and	and	CCONJ
chd-169	340	29	syme	syme	PROPN
chd-169	340	30	,	,	PUNCT
chd-169	340	31	s.l	s.l	PROPN
chd-169	340	32	.	.	PROPN
chd-169	340	33	(	(	PUNCT
chd-169	340	34	1994	1994	NUM
chd-169	340	35	)	)	PUNCT
chd-169	340	36	.	.	PUNCT
chd-169	341	1	socioeconomic	socioeconomic	ADJ
chd-169	341	2	status	status	NOUN
chd-169	341	3	and	and	CCONJ
chd-169	341	4	health	health	NOUN
chd-169	341	5	.	.	PUNCT
chd-169	342	1	the	the	DET
chd-169	342	2	challenge	challenge	NOUN
chd-169	342	3	of	of	ADP
chd-169	342	4	the	the	DET
chd-169	342	5	gradient	gradient	NOUN
chd-169	342	6	.	.	PUNCT
chd-169	343	1	am	be	AUX
chd-169	343	2	psychol	psychol	NOUN
chd-169	343	3	49	49	NUM
chd-169	343	4	,	,	PUNCT
chd-169	343	5	15	15	NUM
chd-169	343	6	-	-	SYM
chd-169	343	7	24	24	NUM
chd-169	343	8	.	.	PUNCT
chd-169	344	1	ahearn	ahearn	PROPN
chd-169	344	2	,	,	PUNCT
chd-169	344	3	t.u	t.u	PROPN
chd-169	344	4	.	.	PROPN
chd-169	344	5	,	,	PUNCT
chd-169	344	6	pettersson	pettersson	PROPN
chd-169	344	7	,	,	PUNCT
chd-169	344	8	a.	a.	NOUN
chd-169	344	9	,	,	PUNCT
chd-169	344	10	ebot	ebot	PROPN
chd-169	344	11	,	,	PUNCT
chd-169	344	12	e.m	e.m	PROPN
chd-169	344	13	.	.	PROPN
chd-169	344	14	,	,	PUNCT
chd-169	344	15	gerke	gerke	NOUN
chd-169	344	16	,	,	PUNCT
chd-169	344	17	t.	t.	PROPN
chd-169	344	18	,	,	PUNCT
chd-169	344	19	graff	graff	PROPN
chd-169	344	20	,	,	PUNCT
chd-169	344	21	r.e	r.e	PROPN
chd-169	344	22	.	.	PROPN
chd-169	344	23	,	,	PUNCT
chd-169	344	24	morais	morais	PROPN
chd-169	344	25	,	,	PUNCT
chd-169	344	26	c.l	c.l	PROPN
chd-169	344	27	.	.	PROPN
chd-169	344	28	,	,	PUNCT
chd-169	344	29	hicks	hicks	PROPN
chd-169	344	30	,	,	PUNCT
chd-169	344	31	j.l	j.l	PROPN
chd-169	344	32	.	.	PROPN
chd-169	344	33	,	,	PUNCT
chd-169	344	34	wilson	wilson	PROPN
chd-169	344	35	,	,	PUNCT
chd-169	344	36	k.m	k.m	PROPN
chd-169	344	37	.	.	PROPN
chd-169	344	38	,	,	PUNCT
chd-169	344	39	rider	rider	NOUN
chd-169	344	40	,	,	PUNCT
chd-169	344	41	j.r	j.r	PROPN
chd-169	344	42	.	.	PROPN
chd-169	344	43	,	,	PUNCT
chd-169	344	44	sesso	sesso	PROPN
chd-169	344	45	,	,	PUNCT
chd-169	344	46	h.d	h.d	PROPN
chd-169	344	47	.	.	PROPN
chd-169	344	48	,	,	PUNCT
chd-169	344	49	et	et	PROPN
chd-169	344	50	al	al	PROPN
chd-169	344	51	.	.	PUNCT
chd-169	345	1	(	(	PUNCT
chd-169	345	2	2016	2016	NUM
chd-169	345	3	)	)	PUNCT
chd-169	345	4	.	.	PUNCT
chd-169	346	1	a	a	DET
chd-169	346	2	prospective	prospective	ADJ
chd-169	346	3	investigation	investigation	NOUN
chd-169	346	4	of	of	ADP
chd-169	346	5	pten	pten	ADJ
chd-169	346	6	loss	loss	NOUN
chd-169	346	7	and	and	CCONJ
chd-169	346	8	erg	erg	NOUN
chd-169	346	9	expression	expression	NOUN
chd-169	346	10	in	in	ADP
chd-169	346	11	lethal	lethal	ADJ
chd-169	346	12	prostate	prostate	NOUN
chd-169	346	13	cancer	cancer	NOUN
chd-169	346	14	.	.	PUNCT
chd-169	347	1	journal	journal	NOUN
chd-169	347	2	of	of	ADP
chd-169	347	3	the	the	DET
chd-169	347	4	national	national	PROPN
chd-169	347	5	cancer	cancer	PROPN
chd-169	347	6	institute	institute	PROPN
chd-169	347	7	108	108	NUM
chd-169	347	8	.	.	PUNCT
chd-169	348	1	arace	arace	NOUN
chd-169	348	2	,	,	PUNCT
chd-169	348	3	j.	j.	PROPN
chd-169	348	4	,	,	PUNCT
chd-169	348	5	flores	flores	PROPN
chd-169	348	6	,	,	PUNCT
chd-169	348	7	v.	v.	PROPN
chd-169	348	8	,	,	PUNCT
chd-169	348	9	monaghan	monaghan	PROPN
chd-169	348	10	,	,	PUNCT
chd-169	348	11	t.	t.	PROPN
chd-169	348	12	,	,	PUNCT
chd-169	348	13	robins	robin	NOUN
chd-169	348	14	,	,	PUNCT
chd-169	348	15	d.	d.	PROPN
chd-169	348	16	,	,	PUNCT
chd-169	348	17	karanikolas	karanikola	NOUN
chd-169	348	18	,	,	PUNCT
chd-169	348	19	n.	n.	NOUN
chd-169	348	20	,	,	PUNCT
chd-169	348	21	winer	winer	NOUN
chd-169	348	22	,	,	PUNCT
chd-169	348	23	a.	a.	NOUN
chd-169	348	24	,	,	PUNCT
chd-169	348	25	and	and	CCONJ
chd-169	348	26	weiss	weiss	PROPN
chd-169	348	27	,	,	PUNCT
chd-169	348	28	j.	j.	PROPN
chd-169	348	29	(	(	PUNCT
chd-169	348	30	2020	2020	NUM
chd-169	348	31	)	)	PUNCT
chd-169	348	32	.	.	PUNCT
chd-169	349	1	rates	rate	NOUN
chd-169	349	2	of	of	ADP
chd-169	349	3	clinically	clinically	ADV
chd-169	349	4	significant	significant	ADJ
chd-169	349	5	prostate	prostate	NOUN
chd-169	349	6	cancer	cancer	NOUN
chd-169	349	7	in	in	ADP
chd-169	349	8	african	african	ADJ
chd-169	349	9	americans	americans	PROPN
chd-169	349	10	increased	increase	VERB
chd-169	349	11	significantly	significantly	ADV
chd-169	349	12	following	follow	VERB
chd-169	349	13	the	the	DET
chd-169	349	14	2012	2012	NUM
chd-169	349	15	us	us	PROPN
chd-169	349	16	preventative	preventative	ADJ
chd-169	349	17	services	service	NOUN
chd-169	349	18	task	task	PROPN
chd-169	349	19	force	force	NOUN
chd-169	349	20	recommendation	recommendation	NOUN
chd-169	349	21	against	against	ADP
chd-169	349	22	prostate	prostate	NOUN
chd-169	349	23	specific	specific	ADJ
chd-169	349	24	antigen	antigen	NOUN
chd-169	349	25	screening	screening	NOUN
chd-169	349	26	:	:	PUNCT
chd-169	349	27	a	a	DET
chd-169	349	28	single	single	ADJ
chd-169	349	29	institution	institution	NOUN
chd-169	349	30	retrospective	retrospective	ADJ
chd-169	349	31	study	study	NOUN
chd-169	349	32	.	.	PUNCT
chd-169	350	1	int	int	PROPN
chd-169	351	1	j	j	PROPN
chd-169	351	2	clin	clin	PROPN
chd-169	351	3	pract	pract	PROPN
chd-169	351	4	74	74	NUM
chd-169	351	5	,	,	PUNCT
chd-169	351	6	e13447	e13447	PROPN
chd-169	351	7	.	.	PUNCT
chd-169	352	1	arlen	arlen	PROPN
chd-169	352	2	,	,	PUNCT
chd-169	352	3	p.m.	p.m.	NOUN
chd-169	352	4	,	,	PUNCT
chd-169	352	5	and	and	CCONJ
chd-169	352	6	gulley	gulley	NOUN
chd-169	352	7	,	,	PUNCT
chd-169	352	8	j.l	j.l	PROPN
chd-169	352	9	.	.	PROPN
chd-169	352	10	(	(	PUNCT
chd-169	352	11	2005	2005	NUM
chd-169	352	12	)	)	PUNCT
chd-169	352	13	.	.	PUNCT
chd-169	353	1	docetaxel	docetaxel	NOUN
chd-169	353	2	-	-	PUNCT
chd-169	353	3	based	base	VERB
chd-169	353	4	regimens	regimen	NOUN
chd-169	353	5	,	,	PUNCT
chd-169	353	6	the	the	DET
chd-169	353	7	standard	standard	NOUN
chd-169	353	8	of	of	ADP
chd-169	353	9	care	care	NOUN
chd-169	353	10	for	for	ADP
chd-169	353	11	metastatic	metastatic	ADJ
chd-169	353	12	androgen	androgen	NOUN
chd-169	353	13	-	-	PUNCT
chd-169	353	14	insensitive	insensitive	ADJ
chd-169	353	15	prostate	prostate	NOUN
chd-169	353	16	cancer	cancer	NOUN
chd-169	353	17	.	.	PUNCT
chd-169	354	1	future	future	ADJ
chd-169	354	2	oncol	oncol	ADJ
chd-169	354	3	1	1	NUM
chd-169	354	4	,	,	PUNCT
chd-169	354	5	19	19	NUM
chd-169	354	6	-	-	SYM
chd-169	354	7	22	22	NUM
chd-169	354	8	.	.	PUNCT
chd-169	355	1	armenia	armenia	PROPN
chd-169	355	2	,	,	PUNCT
chd-169	355	3	j.	j.	PROPN
chd-169	355	4	,	,	PUNCT
chd-169	355	5	wankowicz	wankowicz	INTJ
chd-169	355	6	,	,	PUNCT
chd-169	355	7	s.a.m	s.a.m	ADJ
chd-169	355	8	.	.	PROPN
chd-169	355	9	,	,	PUNCT
chd-169	355	10	liu	liu	PROPN
chd-169	355	11	,	,	PUNCT
chd-169	355	12	d.	d.	PROPN
chd-169	355	13	,	,	PUNCT
chd-169	355	14	gao	gao	PROPN
chd-169	355	15	,	,	PUNCT
chd-169	355	16	j.	j.	PROPN
chd-169	355	17	,	,	PUNCT
chd-169	355	18	kundra	kundra	PROPN
chd-169	355	19	,	,	PUNCT
chd-169	355	20	r.	r.	PROPN
chd-169	355	21	,	,	PUNCT
chd-169	355	22	reznik	reznik	X
chd-169	355	23	,	,	PUNCT
chd-169	355	24	e.	e.	PROPN
chd-169	355	25	,	,	PUNCT
chd-169	355	26	chatila	chatila	PROPN
chd-169	355	27	,	,	PUNCT
chd-169	355	28	w.k	w.k	PROPN
chd-169	355	29	.	.	PROPN
chd-169	355	30	,	,	PUNCT
chd-169	355	31	chakravarty	chakravarty	PROPN
chd-169	355	32	,	,	PUNCT
chd-169	355	33	d.	d.	PROPN
chd-169	355	34	,	,	PUNCT
chd-169	355	35	han	han	PROPN
chd-169	355	36	,	,	PUNCT
chd-169	355	37	g.c	g.c	PROPN
chd-169	355	38	.	.	PROPN
chd-169	355	39	,	,	PUNCT
chd-169	355	40	coleman	coleman	PROPN
chd-169	355	41	,	,	PUNCT
chd-169	355	42	i.	i.	PROPN
chd-169	355	43	,	,	PUNCT
chd-169	355	44	et	et	PROPN
chd-169	355	45	al	al	PROPN
chd-169	355	46	.	.	PUNCT
chd-169	355	47	(	(	PUNCT
chd-169	355	48	2018	2018	NUM
chd-169	355	49	)	)	PUNCT
chd-169	355	50	.	.	PUNCT
chd-169	356	1	the	the	DET
chd-169	356	2	long	long	ADJ
chd-169	356	3	tail	tail	NOUN
chd-169	356	4	of	of	ADP
chd-169	356	5	oncogenic	oncogenic	ADJ
chd-169	356	6	drivers	driver	NOUN
chd-169	356	7	in	in	ADP
chd-169	356	8	prostate	prostate	NOUN
chd-169	356	9	cancer	cancer	NOUN
chd-169	356	10	.	.	PUNCT
chd-169	357	1	nat	nat	PROPN
chd-169	357	2	genet	genet	PROPN
chd-169	357	3	50	50	NUM
chd-169	357	4	,	,	PUNCT
chd-169	357	5	645	645	NUM
chd-169	357	6	-	-	SYM
chd-169	357	7	651	651	NUM
chd-169	357	8	.	.	PUNCT
chd-169	358	1	arora	arora	PROPN
chd-169	358	2	,	,	PUNCT
chd-169	358	3	v.k	v.k	PROPN
chd-169	358	4	.	.	PROPN
chd-169	358	5	,	,	PUNCT
chd-169	358	6	schenkein	schenkein	PROPN
chd-169	358	7	,	,	PUNCT
chd-169	358	8	e.	e.	PROPN
chd-169	358	9	,	,	PUNCT
chd-169	358	10	murali	murali	PROPN
chd-169	358	11	,	,	PUNCT
chd-169	358	12	r.	r.	PROPN
chd-169	358	13	,	,	PUNCT
chd-169	358	14	subudhi	subudhi	PROPN
chd-169	358	15	,	,	PUNCT
chd-169	358	16	s.k	s.k	PROPN
chd-169	358	17	.	.	PROPN
chd-169	358	18	,	,	PUNCT
chd-169	358	19	wongvipat	wongvipat	PROPN
chd-169	358	20	,	,	PUNCT
chd-169	358	21	j.	j.	PROPN
chd-169	358	22	,	,	PUNCT
chd-169	358	23	balbas	balbas	PROPN
chd-169	358	24	,	,	PUNCT
chd-169	358	25	m.d	m.d	PROPN
chd-169	358	26	.	.	PROPN
chd-169	358	27	,	,	PUNCT
chd-169	358	28	shah	shah	PROPN
chd-169	358	29	,	,	PUNCT
chd-169	358	30	n.	n.	PROPN
chd-169	358	31	,	,	PUNCT
chd-169	358	32	cai	cai	PROPN
chd-169	358	33	,	,	PUNCT
chd-169	358	34	l.	l.	PROPN
chd-169	358	35	,	,	PUNCT
chd-169	358	36	efstathiou	efstathiou	PROPN
chd-169	358	37	,	,	PUNCT
chd-169	358	38	e.	e.	PROPN
chd-169	358	39	,	,	PUNCT
chd-169	358	40	logothetis	logothetis	PROPN
chd-169	358	41	,	,	PUNCT
chd-169	358	42	c.	c.	PROPN
chd-169	358	43	,	,	PUNCT
chd-169	358	44	et	et	PROPN
chd-169	358	45	al	al	PROPN
chd-169	358	46	.	.	PROPN
chd-169	359	1	(	(	PUNCT
chd-169	359	2	2013	2013	NUM
chd-169	359	3	)	)	PUNCT
chd-169	359	4	.	.	PUNCT
chd-169	360	1	glucocorticoid	glucocorticoid	ADJ
chd-169	360	2	receptor	receptor	NOUN
chd-169	360	3	confers	confer	NOUN
chd-169	360	4	resistance	resistance	NOUN
chd-169	360	5	to	to	ADP
chd-169	360	6	antiandrogens	antiandrogen	NOUN
chd-169	360	7	by	by	ADP
chd-169	360	8	bypassing	bypass	VERB
chd-169	360	9	androgen	androgen	NOUN
chd-169	360	10	receptor	receptor	NOUN
chd-169	360	11	blockade	blockade	NOUN
chd-169	360	12	.	.	PUNCT
chd-169	361	1	cell	cell	NOUN
chd-169	361	2	155	155	NUM
chd-169	361	3	,	,	PUNCT
chd-169	361	4	1309	1309	NUM
chd-169	361	5	-	-	SYM
chd-169	361	6	1322	1322	NUM
chd-169	361	7	.	.	PUNCT
chd-169	362	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	362	2	e21	e21	ADJ
chd-169	362	3	cancer	cancer	NOUN
chd-169	362	4	health	health	NOUN
chd-169	362	5	disparities	disparity	NOUN
chd-169	362	6	research	research	PROPN
chd-169	362	7	asmane	asmane	PROPN
chd-169	362	8	,	,	PUNCT
chd-169	362	9	i.	i.	PROPN
chd-169	362	10	,	,	PUNCT
chd-169	362	11	ceraline	ceraline	PROPN
chd-169	362	12	,	,	PUNCT
chd-169	362	13	j.	j.	PROPN
chd-169	362	14	,	,	PUNCT
chd-169	362	15	duclos	duclos	PROPN
chd-169	362	16	,	,	PUNCT
chd-169	362	17	b.	b.	PROPN
chd-169	362	18	,	,	PUNCT
chd-169	362	19	rob	rob	PROPN
chd-169	362	20	,	,	PUNCT
chd-169	362	21	l.	l.	PROPN
chd-169	362	22	,	,	PUNCT
chd-169	362	23	litique	litique	NOUN
chd-169	362	24	,	,	PUNCT
chd-169	362	25	v.	v.	PROPN
chd-169	362	26	,	,	PUNCT
chd-169	362	27	barthelemy	barthelemy	PROPN
chd-169	362	28	,	,	PUNCT
chd-169	362	29	p.	p.	PROPN
chd-169	362	30	,	,	PUNCT
chd-169	362	31	bergerat	bergerat	PROPN
chd-169	362	32	,	,	PUNCT
chd-169	362	33	j.p	j.p	PROPN
chd-169	362	34	.	.	PROPN
chd-169	362	35	,	,	PUNCT
chd-169	362	36	dufour	dufour	PROPN
chd-169	362	37	,	,	PUNCT
chd-169	362	38	p.	p.	PROPN
chd-169	362	39	,	,	PUNCT
chd-169	362	40	and	and	CCONJ
chd-169	362	41	kurtz	kurtz	PROPN
chd-169	362	42	,	,	PUNCT
chd-169	362	43	j.e	j.e	PROPN
chd-169	362	44	.	.	PROPN
chd-169	362	45	(	(	PUNCT
chd-169	362	46	2011	2011	NUM
chd-169	362	47	)	)	PUNCT
chd-169	362	48	.	.	PUNCT
chd-169	363	1	new	new	ADJ
chd-169	363	2	strategies	strategy	NOUN
chd-169	363	3	for	for	ADP
chd-169	363	4	medical	medical	ADJ
chd-169	363	5	management	management	NOUN
chd-169	363	6	of	of	ADP
chd-169	363	7	castration	castration	NOUN
chd-169	363	8	-	-	PUNCT
chd-169	363	9	resistant	resistant	ADJ
chd-169	363	10	prostate	prostate	NOUN
chd-169	363	11	cancer	cancer	NOUN
chd-169	363	12	.	.	PUNCT
chd-169	364	1	oncology	oncology	NOUN
chd-169	364	2	80	80	NUM
chd-169	364	3	,	,	PUNCT
chd-169	364	4	1	1	NUM
chd-169	364	5	-	-	SYM
chd-169	364	6	11	11	NUM
chd-169	364	7	.	.	PUNCT
chd-169	365	1	atucha	atucha	PROPN
chd-169	365	2	,	,	PUNCT
chd-169	365	3	e.	e.	PROPN
chd-169	365	4	,	,	PUNCT
chd-169	365	5	zalachoras	zalachoras	PROPN
chd-169	365	6	,	,	PUNCT
chd-169	365	7	i.	i.	PROPN
chd-169	365	8	,	,	PUNCT
chd-169	365	9	van	van	PROPN
chd-169	365	10	den	den	PROPN
chd-169	365	11	heuvel	heuvel	PROPN
chd-169	365	12	,	,	PUNCT
chd-169	365	13	j.k	j.k	PROPN
chd-169	365	14	.	.	PROPN
chd-169	365	15	,	,	PUNCT
chd-169	365	16	van	van	PROPN
chd-169	365	17	weert	weert	PROPN
chd-169	365	18	,	,	PUNCT
chd-169	365	19	l.t	l.t	PROPN
chd-169	365	20	.	.	PROPN
chd-169	365	21	,	,	PUNCT
chd-169	365	22	melchers	melchers	PROPN
chd-169	365	23	,	,	PUNCT
chd-169	365	24	d.	d.	PROPN
chd-169	365	25	,	,	PUNCT
chd-169	365	26	mol	mol	PROPN
chd-169	365	27	,	,	PUNCT
chd-169	365	28	i.m	i.m	PROPN
chd-169	365	29	.	.	PROPN
chd-169	365	30	,	,	PUNCT
chd-169	365	31	belanoff	belanoff	PROPN
chd-169	365	32	,	,	PUNCT
chd-169	365	33	j.k	j.k	PROPN
chd-169	365	34	.	.	PROPN
chd-169	365	35	,	,	PUNCT
chd-169	365	36	houtman	houtman	NOUN
chd-169	365	37	,	,	PUNCT
chd-169	365	38	r.	r.	PROPN
chd-169	365	39	,	,	PUNCT
chd-169	365	40	hunt	hunt	PROPN
chd-169	365	41	,	,	PUNCT
chd-169	365	42	h.	h.	PROPN
chd-169	365	43	,	,	PUNCT
chd-169	365	44	roozendaal	roozendaal	PROPN
chd-169	365	45	,	,	PUNCT
chd-169	365	46	b.	b.	PROPN
chd-169	365	47	,	,	PUNCT
chd-169	365	48	et	et	PROPN
chd-169	365	49	al	al	PROPN
chd-169	365	50	.	.	PUNCT
chd-169	366	1	(	(	PUNCT
chd-169	366	2	2015	2015	NUM
chd-169	366	3	)	)	PUNCT
chd-169	366	4	.	.	PUNCT
chd-169	367	1	a	a	DET
chd-169	367	2	mixed	mixed	ADJ
chd-169	367	3	glucocorticoid	glucocorticoid	NOUN
chd-169	367	4	/	/	SYM
chd-169	367	5	mineralocorticoid	mineralocorticoid	NOUN
chd-169	367	6	selective	selective	ADJ
chd-169	367	7	modulator	modulator	NOUN
chd-169	367	8	with	with	ADP
chd-169	367	9	dominant	dominant	ADJ
chd-169	367	10	antagonism	antagonism	NOUN
chd-169	367	11	in	in	ADP
chd-169	367	12	the	the	DET
chd-169	367	13	male	male	ADJ
chd-169	367	14	rat	rat	NOUN
chd-169	367	15	brain	brain	NOUN
chd-169	367	16	.	.	PUNCT
chd-169	368	1	endocrinology	endocrinology	NOUN
chd-169	368	2	156	156	NUM
chd-169	368	3	,	,	PUNCT
chd-169	368	4	4105	4105	NUM
chd-169	368	5	-	-	SYM
chd-169	368	6	4114	4114	NUM
chd-169	368	7	.	.	PUNCT
chd-169	369	1	bach	bach	PROPN
chd-169	369	2	,	,	PUNCT
chd-169	369	3	p.b	p.b	PROPN
chd-169	369	4	.	.	PROPN
chd-169	369	5	,	,	PUNCT
chd-169	369	6	schrag	schrag	PROPN
chd-169	369	7	,	,	PUNCT
chd-169	369	8	d.	d.	PROPN
chd-169	369	9	,	,	PUNCT
chd-169	369	10	brawley	brawley	PROPN
chd-169	369	11	,	,	PUNCT
chd-169	369	12	o.w	o.w	PROPN
chd-169	369	13	.	.	PROPN
chd-169	369	14	,	,	PUNCT
chd-169	369	15	galaznik	galaznik	PROPN
chd-169	369	16	,	,	PUNCT
chd-169	369	17	a.	a.	NOUN
chd-169	369	18	,	,	PUNCT
chd-169	369	19	yakren	yakren	PROPN
chd-169	369	20	,	,	PUNCT
chd-169	369	21	s.	s.	PROPN
chd-169	369	22	,	,	PUNCT
chd-169	369	23	and	and	CCONJ
chd-169	369	24	begg	begg	PROPN
chd-169	369	25	,	,	PUNCT
chd-169	369	26	c.b	c.b	PROPN
chd-169	369	27	.	.	PROPN
chd-169	369	28	(	(	PUNCT
chd-169	369	29	2002	2002	NUM
chd-169	369	30	)	)	PUNCT
chd-169	369	31	.	.	PUNCT
chd-169	370	1	survival	survival	NOUN
chd-169	370	2	of	of	ADP
chd-169	370	3	blacks	black	NOUN
chd-169	370	4	and	and	CCONJ
chd-169	370	5	whites	white	NOUN
chd-169	370	6	after	after	ADP
chd-169	370	7	a	a	DET
chd-169	370	8	cancer	cancer	NOUN
chd-169	370	9	diagnosis	diagnosis	NOUN
chd-169	370	10	.	.	PUNCT
chd-169	371	1	jama	jama	PROPN
chd-169	371	2	287	287	NUM
chd-169	371	3	,	,	PUNCT
chd-169	371	4	2106	2106	NUM
chd-169	371	5	-	-	SYM
chd-169	371	6	2113	2113	NUM
chd-169	371	7	.	.	PUNCT
chd-169	372	1	banerjee	banerjee	PROPN
chd-169	372	2	,	,	PUNCT
chd-169	372	3	p.p	p.p	PROPN
chd-169	372	4	.	.	PROPN
chd-169	372	5	,	,	PUNCT
chd-169	372	6	banerjee	banerjee	PROPN
chd-169	372	7	,	,	PUNCT
chd-169	372	8	s.	s.	PROPN
chd-169	372	9	,	,	PUNCT
chd-169	372	10	brown	brown	PROPN
chd-169	372	11	,	,	PUNCT
chd-169	372	12	t.r	t.r	PROPN
chd-169	372	13	.	.	PROPN
chd-169	372	14	,	,	PUNCT
chd-169	372	15	and	and	CCONJ
chd-169	372	16	zirkin	zirkin	PROPN
chd-169	372	17	,	,	PUNCT
chd-169	372	18	b.r	b.r	PROPN
chd-169	372	19	.	.	PROPN
chd-169	372	20	(	(	PUNCT
chd-169	372	21	2018	2018	NUM
chd-169	372	22	)	)	PUNCT
chd-169	372	23	.	.	PUNCT
chd-169	373	1	androgen	androgen	NOUN
chd-169	373	2	action	action	NOUN
chd-169	373	3	in	in	ADP
chd-169	373	4	prostate	prostate	NOUN
chd-169	373	5	function	function	NOUN
chd-169	373	6	and	and	CCONJ
chd-169	373	7	disease	disease	NOUN
chd-169	373	8	.	.	PUNCT
chd-169	374	1	am	be	AUX
chd-169	374	2	j	j	PROPN
chd-169	374	3	clin	clin	PROPN
chd-169	374	4	exp	exp	PROPN
chd-169	374	5	urol	urol	PROPN
chd-169	374	6	6	6	NUM
chd-169	374	7	,	,	PUNCT
chd-169	374	8	62	62	NUM
chd-169	374	9	-	-	SYM
chd-169	374	10	77	77	NUM
chd-169	374	11	.	.	PUNCT
chd-169	375	1	batai	batai	PROPN
chd-169	375	2	,	,	PUNCT
chd-169	375	3	k.	k.	PROPN
chd-169	375	4	,	,	PUNCT
chd-169	375	5	murphy	murphy	PROPN
chd-169	375	6	,	,	PUNCT
chd-169	375	7	a.b	a.b	PROPN
chd-169	375	8	.	.	PROPN
chd-169	375	9	,	,	PUNCT
chd-169	375	10	nonn	nonn	PROPN
chd-169	375	11	,	,	PUNCT
chd-169	375	12	l.	l.	PROPN
chd-169	375	13	,	,	PUNCT
chd-169	375	14	and	and	CCONJ
chd-169	375	15	kittles	kittles	PROPN
chd-169	375	16	,	,	PUNCT
chd-169	375	17	r.a	r.a	PROPN
chd-169	375	18	.	.	PROPN
chd-169	375	19	(	(	PUNCT
chd-169	375	20	2016	2016	NUM
chd-169	375	21	)	)	PUNCT
chd-169	375	22	.	.	PUNCT
chd-169	376	1	vitamin	vitamin	NOUN
chd-169	376	2	d	d	NOUN
chd-169	376	3	and	and	CCONJ
chd-169	376	4	immune	immune	ADJ
chd-169	376	5	response	response	NOUN
chd-169	376	6	:	:	PUNCT
chd-169	376	7	implications	implication	NOUN
chd-169	376	8	for	for	ADP
chd-169	376	9	prostate	prostate	NOUN
chd-169	376	10	cancer	cancer	NOUN
chd-169	376	11	in	in	ADP
chd-169	376	12	african	african	ADJ
chd-169	376	13	americans	americans	PROPN
chd-169	376	14	.	.	PUNCT
chd-169	377	1	front	front	ADJ
chd-169	377	2	immunol	immunol	NOUN
chd-169	377	3	7	7	NUM
chd-169	377	4	,	,	PUNCT
chd-169	377	5	53	53	NUM
chd-169	377	6	.	.	PUNCT
chd-169	378	1	baulieu	baulieu	PROPN
chd-169	378	2	,	,	PUNCT
chd-169	378	3	e.e	e.e	PROPN
chd-169	378	4	.	.	PROPN
chd-169	378	5	(	(	PUNCT
chd-169	378	6	1991	1991	NUM
chd-169	378	7	)	)	PUNCT
chd-169	378	8	.	.	PUNCT
chd-169	379	1	the	the	DET
chd-169	379	2	antisteroid	antisteroid	PROPN
chd-169	379	3	ru486	ru486	PROPN
chd-169	379	4	:	:	PUNCT
chd-169	379	5	its	its	PRON
chd-169	379	6	cellular	cellular	ADJ
chd-169	379	7	and	and	CCONJ
chd-169	379	8	molecular	molecular	ADJ
chd-169	379	9	mode	mode	NOUN
chd-169	379	10	of	of	ADP
chd-169	379	11	action	action	NOUN
chd-169	379	12	.	.	PUNCT
chd-169	380	1	trends	trend	NOUN
chd-169	380	2	endocrinol	endocrinol	VERB
chd-169	380	3	metab	metab	ADJ
chd-169	380	4	2	2	NUM
chd-169	380	5	,	,	PUNCT
chd-169	380	6	233	233	NUM
chd-169	380	7	-	-	SYM
chd-169	380	8	239	239	NUM
chd-169	380	9	.	.	PUNCT
chd-169	381	1	baum	baum	PROPN
chd-169	381	2	,	,	PUNCT
chd-169	381	3	r.p	r.p	PROPN
chd-169	381	4	.	.	PROPN
chd-169	381	5	,	,	PUNCT
chd-169	381	6	and	and	CCONJ
chd-169	381	7	kulkarni	kulkarni	PROPN
chd-169	381	8	,	,	PUNCT
chd-169	381	9	h.r	h.r	PROPN
chd-169	381	10	.	.	PROPN
chd-169	381	11	(	(	PUNCT
chd-169	381	12	2012	2012	NUM
chd-169	381	13	)	)	PUNCT
chd-169	381	14	.	.	PUNCT
chd-169	382	1	theranostics	theranostic	NOUN
chd-169	382	2	:	:	PUNCT
chd-169	382	3	from	from	ADP
chd-169	382	4	molecular	molecular	ADJ
chd-169	382	5	imaging	imaging	NOUN
chd-169	382	6	using	use	VERB
chd-169	382	7	ga-68	ga-68	PRON
chd-169	382	8	labeled	label	VERB
chd-169	382	9	tracers	tracer	NOUN
chd-169	382	10	and	and	CCONJ
chd-169	382	11	pet	pet	NOUN
chd-169	382	12	/	/	SYM
chd-169	382	13	ct	ct	NOUN
chd-169	382	14	to	to	ADP
chd-169	382	15	personalized	personalized	ADJ
chd-169	382	16	radionuclide	radionuclide	NOUN
chd-169	382	17	therapy	therapy	NOUN
chd-169	382	18	the	the	DET
chd-169	382	19	bad	bad	ADJ
chd-169	382	20	berka	berka	PROPN
chd-169	382	21	experience	experience	NOUN
chd-169	382	22	.	.	PUNCT
chd-169	383	1	theranostics	theranostic	NOUN
chd-169	383	2	2	2	NUM
chd-169	383	3	,	,	PUNCT
chd-169	383	4	437	437	NUM
chd-169	383	5	-	-	SYM
chd-169	383	6	447	447	NUM
chd-169	383	7	.	.	PUNCT
chd-169	384	1	beer	beer	NOUN
chd-169	384	2	,	,	PUNCT
chd-169	384	3	t.m	t.m	PROPN
chd-169	384	4	.	.	PROPN
chd-169	384	5	,	,	PUNCT
chd-169	384	6	hotte	hotte	PROPN
chd-169	384	7	,	,	PUNCT
chd-169	384	8	s.j	s.j	PROPN
chd-169	384	9	.	.	PROPN
chd-169	384	10	,	,	PUNCT
chd-169	384	11	saad	saad	PROPN
chd-169	384	12	,	,	PUNCT
chd-169	384	13	f.	f.	PROPN
chd-169	384	14	,	,	PUNCT
chd-169	384	15	alekseev	alekseev	PROPN
chd-169	384	16	,	,	PUNCT
chd-169	384	17	b.	b.	PROPN
chd-169	384	18	,	,	PUNCT
chd-169	384	19	matveev	matveev	PROPN
chd-169	384	20	,	,	PUNCT
chd-169	384	21	v.	v.	ADV
chd-169	384	22	,	,	PUNCT
chd-169	384	23	flechon	flechon	ADJ
chd-169	384	24	,	,	PUNCT
chd-169	384	25	a.	a.	NOUN
chd-169	384	26	,	,	PUNCT
chd-169	384	27	gravis	gravis	PROPN
chd-169	384	28	,	,	PUNCT
chd-169	384	29	g.	g.	PROPN
chd-169	384	30	,	,	PUNCT
chd-169	384	31	joly	joly	PROPN
chd-169	384	32	,	,	PUNCT
chd-169	384	33	f.	f.	PROPN
chd-169	384	34	,	,	PUNCT
chd-169	384	35	chi	chi	PROPN
chd-169	384	36	,	,	PUNCT
chd-169	384	37	k.n	k.n	PROPN
chd-169	384	38	.	.	PROPN
chd-169	384	39	,	,	PUNCT
chd-169	384	40	malik	malik	PROPN
chd-169	384	41	,	,	PUNCT
chd-169	384	42	z.	z.	PROPN
chd-169	384	43	,	,	PUNCT
chd-169	384	44	et	et	PROPN
chd-169	384	45	al	al	PROPN
chd-169	384	46	.	.	PUNCT
chd-169	384	47	(	(	PUNCT
chd-169	384	48	2017	2017	NUM
chd-169	384	49	)	)	PUNCT
chd-169	384	50	.	.	PUNCT
chd-169	385	1	custirsen	custirsen	NOUN
chd-169	385	2	(	(	PUNCT
chd-169	385	3	ogx-011	ogx-011	NOUN
chd-169	385	4	)	)	PUNCT
chd-169	385	5	combined	combine	VERB
chd-169	385	6	with	with	ADP
chd-169	385	7	cabazitaxel	cabazitaxel	PROPN
chd-169	385	8	and	and	CCONJ
chd-169	385	9	prednisone	prednisone	PROPN
chd-169	385	10	versus	versus	ADP
chd-169	385	11	cabazitaxel	cabazitaxel	PROPN
chd-169	385	12	and	and	CCONJ
chd-169	385	13	prednisone	prednisone	PROPN
chd-169	385	14	alone	alone	ADV
chd-169	385	15	in	in	ADP
chd-169	385	16	patients	patient	NOUN
chd-169	385	17	with	with	ADP
chd-169	385	18	metastatic	metastatic	ADJ
chd-169	385	19	castration	castration	NOUN
chd-169	385	20	-	-	PUNCT
chd-169	385	21	resistant	resistant	ADJ
chd-169	385	22	prostate	prostate	NOUN
chd-169	385	23	cancer	cancer	NOUN
chd-169	385	24	previously	previously	ADV
chd-169	385	25	treated	treat	VERB
chd-169	385	26	with	with	ADP
chd-169	385	27	docetaxel	docetaxel	PROPN
chd-169	385	28	(	(	PUNCT
chd-169	385	29	affinity	affinity	NOUN
chd-169	385	30	):	):	PUNCT
chd-169	385	31	a	a	DET
chd-169	385	32	randomised	randomised	ADJ
chd-169	385	33	,	,	PUNCT
chd-169	385	34	open	open	ADJ
chd-169	385	35	-	-	PUNCT
chd-169	385	36	label	label	NOUN
chd-169	385	37	,	,	PUNCT
chd-169	385	38	international	international	ADJ
chd-169	385	39	,	,	PUNCT
chd-169	385	40	phase	phase	NOUN
chd-169	385	41	3	3	NUM
chd-169	385	42	trial	trial	NOUN
chd-169	385	43	.	.	PUNCT
chd-169	386	1	the	the	DET
chd-169	386	2	lancet	lancet	PROPN
chd-169	386	3	oncology	oncology	NOUN
chd-169	386	4	18	18	NUM
chd-169	386	5	,	,	PUNCT
chd-169	386	6	1532	1532	NUM
chd-169	386	7	-	-	SYM
chd-169	386	8	1542	1542	NUM
chd-169	386	9	.	.	PUNCT
chd-169	387	1	benjamins	benjamin	NOUN
chd-169	387	2	,	,	PUNCT
chd-169	387	3	m.r	m.r	PROPN
chd-169	387	4	.	.	PROPN
chd-169	387	5	,	,	PUNCT
chd-169	387	6	hunt	hunt	PROPN
chd-169	387	7	,	,	PUNCT
chd-169	387	8	b.r	b.r	PROPN
chd-169	387	9	.	.	PROPN
chd-169	387	10	,	,	PUNCT
chd-169	387	11	raleigh	raleigh	PROPN
chd-169	387	12	,	,	PUNCT
chd-169	387	13	s.m	s.m	PROPN
chd-169	387	14	.	.	PROPN
chd-169	387	15	,	,	PUNCT
chd-169	387	16	hirschtick	hirschtick	PROPN
chd-169	387	17	,	,	PUNCT
chd-169	387	18	j.l	j.l	PROPN
chd-169	387	19	.	.	PROPN
chd-169	387	20	,	,	PUNCT
chd-169	387	21	and	and	CCONJ
chd-169	387	22	hughes	hughes	PROPN
chd-169	387	23	,	,	PUNCT
chd-169	387	24	m.m	m.m	PROPN
chd-169	387	25	.	.	PROPN
chd-169	387	26	(	(	PUNCT
chd-169	387	27	2016	2016	NUM
chd-169	387	28	)	)	PUNCT
chd-169	387	29	.	.	PUNCT
chd-169	388	1	racial	racial	ADJ
chd-169	388	2	disparities	disparity	NOUN
chd-169	388	3	in	in	ADP
chd-169	388	4	prostate	prostate	NOUN
chd-169	388	5	cancer	cancer	NOUN
chd-169	388	6	mortality	mortality	NOUN
chd-169	388	7	in	in	ADP
chd-169	388	8	the	the	DET
chd-169	388	9	50	50	NUM
chd-169	388	10	largest	large	ADJ
chd-169	388	11	us	us	PROPN
chd-169	388	12	cities	city	NOUN
chd-169	388	13	.	.	PUNCT
chd-169	389	1	cancer	cancer	NOUN
chd-169	389	2	epidemiol	epidemiol	PROPN
chd-169	389	3	44	44	NUM
chd-169	389	4	,	,	PUNCT
chd-169	389	5	125	125	NUM
chd-169	389	6	-	-	SYM
chd-169	389	7	131	131	NUM
chd-169	389	8	.	.	PUNCT
chd-169	390	1	bhardwaj	bhardwaj	PROPN
chd-169	390	2	,	,	PUNCT
chd-169	390	3	a.	a.	PROPN
chd-169	390	4	,	,	PUNCT
chd-169	390	5	srivastava	srivastava	PROPN
chd-169	390	6	,	,	PUNCT
chd-169	390	7	s.k	s.k	PROPN
chd-169	390	8	.	.	PROPN
chd-169	390	9	,	,	PUNCT
chd-169	390	10	khan	khan	PROPN
chd-169	390	11	,	,	PUNCT
chd-169	390	12	m.a	m.a	PROPN
chd-169	390	13	.	.	PROPN
chd-169	390	14	,	,	PUNCT
chd-169	390	15	prajapati	prajapati	PROPN
chd-169	390	16	,	,	PUNCT
chd-169	390	17	v.k	v.k	PROPN
chd-169	390	18	.	.	PROPN
chd-169	390	19	,	,	PUNCT
chd-169	390	20	singh	singh	PROPN
chd-169	390	21	,	,	PUNCT
chd-169	390	22	s.	s.	PROPN
chd-169	390	23	,	,	PUNCT
chd-169	390	24	carter	carter	PROPN
chd-169	390	25	,	,	PUNCT
chd-169	390	26	j.e	j.e	PROPN
chd-169	390	27	.	.	PROPN
chd-169	390	28	,	,	PUNCT
chd-169	390	29	and	and	CCONJ
chd-169	390	30	singh	singh	PROPN
chd-169	390	31	,	,	PUNCT
chd-169	390	32	a.p	a.p	PROPN
chd-169	390	33	.	.	PROPN
chd-169	390	34	(	(	PUNCT
chd-169	390	35	2017	2017	NUM
chd-169	390	36	)	)	PUNCT
chd-169	390	37	.	.	PUNCT
chd-169	391	1	racial	racial	ADJ
chd-169	391	2	disparities	disparity	NOUN
chd-169	391	3	in	in	ADP
chd-169	391	4	prostate	prostate	NOUN
chd-169	391	5	cancer	cancer	NOUN
chd-169	391	6	:	:	PUNCT
chd-169	391	7	a	a	DET
chd-169	391	8	molecular	molecular	ADJ
chd-169	391	9	perspective	perspective	NOUN
chd-169	391	10	.	.	PUNCT
chd-169	392	1	front	front	ADJ
chd-169	392	2	biosci	biosci	PROPN
chd-169	392	3	(	(	PUNCT
chd-169	392	4	landmark	landmark	PROPN
chd-169	392	5	ed	ed	NOUN
chd-169	392	6	)	)	PUNCT
chd-169	392	7	22	22	NUM
chd-169	392	8	,	,	PUNCT
chd-169	392	9	772	772	NUM
chd-169	392	10	-	-	SYM
chd-169	392	11	782	782	NUM
chd-169	392	12	.	.	PUNCT
chd-169	392	13	biddie	biddie	NOUN
chd-169	392	14	,	,	PUNCT
chd-169	392	15	s.c	s.c	PROPN
chd-169	392	16	.	.	PROPN
chd-169	392	17	,	,	PUNCT
chd-169	392	18	conway	conway	PROPN
chd-169	392	19	-	-	PUNCT
chd-169	392	20	campbell	campbell	PROPN
chd-169	392	21	,	,	PUNCT
chd-169	392	22	b.l	b.l	PROPN
chd-169	392	23	.	.	PROPN
chd-169	392	24	,	,	PUNCT
chd-169	392	25	and	and	CCONJ
chd-169	392	26	lightman	lightman	PROPN
chd-169	392	27	,	,	PUNCT
chd-169	392	28	s.l	s.l	PROPN
chd-169	392	29	.	.	PROPN
chd-169	392	30	(	(	PUNCT
chd-169	392	31	2012	2012	NUM
chd-169	392	32	)	)	PUNCT
chd-169	392	33	.	.	PUNCT
chd-169	393	1	dynamic	dynamic	ADJ
chd-169	393	2	regulation	regulation	NOUN
chd-169	393	3	of	of	ADP
chd-169	393	4	glucocorticoid	glucocorticoid	NOUN
chd-169	393	5	signalling	signal	VERB
chd-169	393	6	in	in	ADP
chd-169	393	7	health	health	NOUN
chd-169	393	8	and	and	CCONJ
chd-169	393	9	disease	disease	NOUN
chd-169	393	10	.	.	PUNCT
chd-169	394	1	rheumatology	rheumatology	NOUN
chd-169	394	2	(	(	PUNCT
chd-169	394	3	oxford	oxford	PROPN
chd-169	394	4	,	,	PUNCT
chd-169	394	5	england	england	PROPN
chd-169	394	6	)	)	PUNCT
chd-169	394	7	51	51	NUM
chd-169	394	8	,	,	PUNCT
chd-169	394	9	403412	403412	NUM
chd-169	394	10	.	.	PUNCT
chd-169	395	1	bjornsson	bjornsson	PROPN
chd-169	395	2	,	,	PUNCT
chd-169	395	3	h.t	h.t	PROPN
chd-169	395	4	.	.	PROPN
chd-169	395	5	,	,	PUNCT
chd-169	395	6	sigurdsson	sigurdsson	PROPN
chd-169	395	7	,	,	PUNCT
chd-169	395	8	m.i	m.i	PROPN
chd-169	395	9	.	.	PROPN
chd-169	395	10	,	,	PUNCT
chd-169	395	11	fallin	fallin	PROPN
chd-169	395	12	,	,	PUNCT
chd-169	395	13	m.d	m.d	PROPN
chd-169	395	14	.	.	PROPN
chd-169	395	15	,	,	PUNCT
chd-169	395	16	irizarry	irizarry	NOUN
chd-169	395	17	,	,	PUNCT
chd-169	395	18	r.a	r.a	PROPN
chd-169	395	19	.	.	PROPN
chd-169	395	20	,	,	PUNCT
chd-169	395	21	aspelund	aspelund	NOUN
chd-169	395	22	,	,	PUNCT
chd-169	395	23	t.	t.	PROPN
chd-169	395	24	,	,	PUNCT
chd-169	395	25	cui	cui	PROPN
chd-169	395	26	,	,	PUNCT
chd-169	395	27	h.	h.	PROPN
chd-169	395	28	,	,	PUNCT
chd-169	395	29	yu	yu	PROPN
chd-169	395	30	,	,	PUNCT
chd-169	395	31	w.	w.	PROPN
chd-169	395	32	,	,	PUNCT
chd-169	395	33	rongione	rongione	PROPN
chd-169	395	34	,	,	PUNCT
chd-169	395	35	m.a	m.a	PROPN
chd-169	395	36	.	.	PROPN
chd-169	395	37	,	,	PUNCT
chd-169	395	38	ekstrom	ekstrom	PROPN
chd-169	395	39	,	,	PUNCT
chd-169	395	40	t.j	t.j	PROPN
chd-169	395	41	.	.	PROPN
chd-169	395	42	,	,	PUNCT
chd-169	395	43	harris	harris	PROPN
chd-169	395	44	,	,	PUNCT
chd-169	395	45	t.b	t.b	PROPN
chd-169	395	46	.	.	PROPN
chd-169	395	47	,	,	PUNCT
chd-169	395	48	et	et	PROPN
chd-169	395	49	al	al	PROPN
chd-169	395	50	.	.	PUNCT
chd-169	395	51	(	(	PUNCT
chd-169	395	52	2008	2008	NUM
chd-169	395	53	)	)	PUNCT
chd-169	395	54	.	.	PUNCT
chd-169	396	1	intra	intra	ADJ
chd-169	396	2	-	-	ADJ
chd-169	396	3	individual	individual	ADJ
chd-169	396	4	change	change	NOUN
chd-169	396	5	over	over	ADP
chd-169	396	6	time	time	NOUN
chd-169	396	7	in	in	ADP
chd-169	396	8	dna	dna	PROPN
chd-169	396	9	methylation	methylation	NOUN
chd-169	396	10	with	with	ADP
chd-169	396	11	familial	familial	ADJ
chd-169	396	12	clustering	clustering	NOUN
chd-169	396	13	.	.	PUNCT
chd-169	397	1	jama	jama	PROPN
chd-169	397	2	299	299	NUM
chd-169	397	3	,	,	PUNCT
chd-169	397	4	2877	2877	NUM
chd-169	397	5	-	-	SYM
chd-169	397	6	2883	2883	NUM
chd-169	397	7	.	.	PUNCT
chd-169	398	1	blackburn	blackburn	PROPN
chd-169	398	2	,	,	PUNCT
chd-169	398	3	j.	j.	PROPN
chd-169	398	4	,	,	PUNCT
chd-169	398	5	vecchiarelli	vecchiarelli	PROPN
chd-169	398	6	,	,	PUNCT
chd-169	398	7	s.	s.	PROPN
chd-169	398	8	,	,	PUNCT
chd-169	398	9	heyer	heyer	PROPN
chd-169	398	10	,	,	PUNCT
chd-169	398	11	e.e	e.e	PROPN
chd-169	398	12	.	.	PROPN
chd-169	398	13	,	,	PUNCT
chd-169	398	14	patrick	patrick	PROPN
chd-169	398	15	,	,	PUNCT
chd-169	398	16	s.m	s.m	PROPN
chd-169	398	17	.	.	PROPN
chd-169	398	18	,	,	PUNCT
chd-169	398	19	lyons	lyons	PROPN
chd-169	398	20	,	,	PUNCT
chd-169	398	21	r.j	r.j	PROPN
chd-169	398	22	.	.	PROPN
chd-169	398	23	,	,	PUNCT
chd-169	398	24	jaratlerdsiri	jaratlerdsiri	PROPN
chd-169	398	25	,	,	PUNCT
chd-169	398	26	w.	w.	PROPN
chd-169	398	27	,	,	PUNCT
chd-169	398	28	van	van	PROPN
chd-169	398	29	zyl	zyl	PROPN
chd-169	398	30	,	,	PUNCT
chd-169	398	31	s.	s.	PROPN
chd-169	398	32	,	,	PUNCT
chd-169	398	33	bornman	bornman	NOUN
chd-169	398	34	,	,	PUNCT
chd-169	398	35	m.s.r	m.s.r	PROPN
chd-169	398	36	.	.	PROPN
chd-169	398	37	,	,	PUNCT
chd-169	398	38	mercer	mercer	PROPN
chd-169	398	39	,	,	PUNCT
chd-169	398	40	t.r	t.r	PROPN
chd-169	398	41	.	.	PROPN
chd-169	398	42	,	,	PUNCT
chd-169	398	43	and	and	CCONJ
chd-169	398	44	hayes	hayes	PROPN
chd-169	398	45	,	,	PUNCT
chd-169	398	46	v.m	v.m	PROPN
chd-169	398	47	.	.	PUNCT
chd-169	398	48	(	(	PUNCT
chd-169	398	49	2019	2019	NUM
chd-169	398	50	)	)	PUNCT
chd-169	398	51	.	.	PUNCT
chd-169	399	1	tmprss2	tmprss2	PROPN
chd-169	399	2	-	-	PUNCT
chd-169	399	3	erg	erg	PROPN
chd-169	399	4	fusions	fusion	NOUN
chd-169	399	5	linked	link	VERB
chd-169	399	6	to	to	ADP
chd-169	399	7	prostate	prostate	NOUN
chd-169	399	8	cancer	cancer	NOUN
chd-169	399	9	racial	racial	ADJ
chd-169	399	10	health	health	NOUN
chd-169	399	11	disparities	disparity	NOUN
chd-169	399	12	:	:	PUNCT
chd-169	399	13	a	a	DET
chd-169	399	14	focus	focus	NOUN
chd-169	399	15	on	on	ADP
chd-169	399	16	africa	africa	PROPN
chd-169	399	17	.	.	PUNCT
chd-169	400	1	prostate	prostate	PROPN
chd-169	400	2	79	79	NUM
chd-169	400	3	,	,	PUNCT
chd-169	400	4	1191	1191	NUM
chd-169	400	5	-	-	SYM
chd-169	400	6	1196	1196	NUM
chd-169	400	7	.	.	PUNCT
chd-169	401	1	boccon	boccon	NOUN
chd-169	401	2	-	-	PUNCT
chd-169	401	3	gibod	gibod	PROPN
chd-169	401	4	,	,	PUNCT
chd-169	401	5	l.	l.	PROPN
chd-169	401	6	,	,	PUNCT
chd-169	401	7	fournier	fournier	PROPN
chd-169	401	8	,	,	PUNCT
chd-169	401	9	g.	g.	PROPN
chd-169	401	10	,	,	PUNCT
chd-169	401	11	bottet	bottet	NOUN
chd-169	401	12	,	,	PUNCT
chd-169	401	13	p.	p.	PROPN
chd-169	401	14	,	,	PUNCT
chd-169	401	15	marechal	marechal	PROPN
chd-169	401	16	,	,	PUNCT
chd-169	401	17	j.m	j.m	PROPN
chd-169	401	18	.	.	PROPN
chd-169	401	19	,	,	PUNCT
chd-169	401	20	guiter	guiter	PROPN
chd-169	401	21	,	,	PUNCT
chd-169	401	22	j.	j.	PROPN
chd-169	401	23	,	,	PUNCT
chd-169	401	24	rischman	rischman	NOUN
chd-169	401	25	,	,	PUNCT
chd-169	401	26	p.	p.	PROPN
chd-169	401	27	,	,	PUNCT
chd-169	401	28	hubert	hubert	PROPN
chd-169	401	29	,	,	PUNCT
chd-169	401	30	j.	j.	PROPN
chd-169	401	31	,	,	PUNCT
chd-169	401	32	soret	soret	PROPN
chd-169	401	33	,	,	PUNCT
chd-169	401	34	j.y	j.y	PROPN
chd-169	401	35	.	.	PROPN
chd-169	401	36	,	,	PUNCT
chd-169	401	37	mangin	mangin	NOUN
chd-169	401	38	,	,	PUNCT
chd-169	401	39	p.	p.	PROPN
chd-169	401	40	,	,	PUNCT
chd-169	401	41	mallo	mallo	PROPN
chd-169	401	42	,	,	PUNCT
chd-169	401	43	c.	c.	PROPN
chd-169	401	44	,	,	PUNCT
chd-169	401	45	et	et	PROPN
chd-169	401	46	al	al	PROPN
chd-169	401	47	.	.	PROPN
chd-169	402	1	(	(	PUNCT
chd-169	402	2	1997	1997	NUM
chd-169	402	3	)	)	PUNCT
chd-169	402	4	.	.	PUNCT
chd-169	403	1	flutamide	flutamide	NOUN
chd-169	403	2	versus	versus	ADP
chd-169	403	3	orchidectomy	orchidectomy	NOUN
chd-169	403	4	in	in	ADP
chd-169	403	5	the	the	DET
chd-169	403	6	treatment	treatment	NOUN
chd-169	403	7	of	of	ADP
chd-169	403	8	metastatic	metastatic	ADJ
chd-169	403	9	prostate	prostate	NOUN
chd-169	403	10	carcinoma	carcinoma	NOUN
chd-169	403	11	.	.	PUNCT
chd-169	404	1	eur	eur	PROPN
chd-169	404	2	urol	urol	ADJ
chd-169	404	3	32	32	NUM
chd-169	404	4	,	,	PUNCT
chd-169	404	5	391	391	NUM
chd-169	404	6	-	-	SYM
chd-169	404	7	395	395	NUM
chd-169	404	8	;	;	PUNCT
chd-169	404	9	discussion	discussion	NOUN
chd-169	404	10	395	395	NUM
chd-169	404	11	-	-	SYM
chd-169	404	12	396	396	NUM
chd-169	404	13	.	.	PUNCT
chd-169	405	1	bocklandt	bocklandt	PROPN
chd-169	405	2	,	,	PUNCT
chd-169	405	3	s.	s.	PROPN
chd-169	405	4	,	,	PUNCT
chd-169	405	5	lin	lin	PROPN
chd-169	405	6	,	,	PUNCT
chd-169	405	7	w.	w.	PROPN
chd-169	405	8	,	,	PUNCT
chd-169	405	9	sehl	sehl	PROPN
chd-169	405	10	,	,	PUNCT
chd-169	405	11	m.e	m.e	PROPN
chd-169	405	12	.	.	PROPN
chd-169	405	13	,	,	PUNCT
chd-169	405	14	sanchez	sanchez	PROPN
chd-169	405	15	,	,	PUNCT
chd-169	405	16	f.j	f.j	PROPN
chd-169	405	17	.	.	PROPN
chd-169	405	18	,	,	PUNCT
chd-169	405	19	sinsheimer	sinsheimer	PROPN
chd-169	405	20	,	,	PUNCT
chd-169	405	21	j.s	j.s	PROPN
chd-169	405	22	.	.	PROPN
chd-169	405	23	,	,	PUNCT
chd-169	405	24	horvath	horvath	PROPN
chd-169	405	25	,	,	PUNCT
chd-169	405	26	s.	s.	PROPN
chd-169	405	27	,	,	PUNCT
chd-169	405	28	and	and	CCONJ
chd-169	405	29	vilain	vilain	NOUN
chd-169	405	30	,	,	PUNCT
chd-169	405	31	e.	e.	PROPN
chd-169	405	32	(	(	PUNCT
chd-169	405	33	2011	2011	NUM
chd-169	405	34	)	)	PUNCT
chd-169	405	35	.	.	PUNCT
chd-169	406	1	epigenetic	epigenetic	ADJ
chd-169	406	2	predictor	predictor	NOUN
chd-169	406	3	of	of	ADP
chd-169	406	4	age	age	NOUN
chd-169	406	5	.	.	PUNCT
chd-169	407	1	plos	plos	PROPN
chd-169	407	2	one	one	NUM
chd-169	407	3	6	6	NUM
chd-169	407	4	,	,	PUNCT
chd-169	407	5	e14821	e14821	PROPN
chd-169	407	6	.	.	PROPN
chd-169	407	7	boks	boks	PROPN
chd-169	407	8	,	,	PUNCT
chd-169	407	9	m.p	m.p	PROPN
chd-169	407	10	.	.	PROPN
chd-169	407	11	,	,	PUNCT
chd-169	407	12	van	van	PROPN
chd-169	407	13	mierlo	mierlo	PROPN
chd-169	407	14	,	,	PUNCT
chd-169	407	15	h.c	h.c	PROPN
chd-169	407	16	.	.	PROPN
chd-169	407	17	,	,	PUNCT
chd-169	407	18	rutten	rutten	PROPN
chd-169	407	19	,	,	PUNCT
chd-169	407	20	b.p	b.p	PROPN
chd-169	407	21	.	.	PROPN
chd-169	407	22	,	,	PUNCT
chd-169	407	23	radstake	radstake	NOUN
chd-169	407	24	,	,	PUNCT
chd-169	407	25	t.r	t.r	PROPN
chd-169	407	26	.	.	PROPN
chd-169	407	27	,	,	PUNCT
chd-169	407	28	de	de	PROPN
chd-169	407	29	witte	witte	PROPN
chd-169	407	30	,	,	PUNCT
chd-169	407	31	l.	l.	PROPN
chd-169	407	32	,	,	PUNCT
chd-169	407	33	geuze	geuze	PROPN
chd-169	407	34	,	,	PUNCT
chd-169	407	35	e.	e.	PROPN
chd-169	407	36	,	,	PUNCT
chd-169	407	37	horvath	horvath	PROPN
chd-169	407	38	,	,	PUNCT
chd-169	407	39	s.	s.	PROPN
chd-169	407	40	,	,	PUNCT
chd-169	407	41	schalkwyk	schalkwyk	NOUN
chd-169	407	42	,	,	PUNCT
chd-169	407	43	l.c	l.c	PROPN
chd-169	407	44	.	.	PROPN
chd-169	407	45	,	,	PUNCT
chd-169	407	46	vinkers	vinker	NOUN
chd-169	407	47	,	,	PUNCT
chd-169	407	48	c.h	c.h	PROPN
chd-169	407	49	.	.	PROPN
chd-169	407	50	,	,	PUNCT
chd-169	407	51	broen	broen	PROPN
chd-169	407	52	,	,	PUNCT
chd-169	407	53	j.c	j.c	PROPN
chd-169	407	54	.	.	PROPN
chd-169	407	55	,	,	PUNCT
chd-169	407	56	et	et	PROPN
chd-169	407	57	al	al	PROPN
chd-169	407	58	.	.	PUNCT
chd-169	408	1	(	(	PUNCT
chd-169	408	2	2015	2015	NUM
chd-169	408	3	)	)	PUNCT
chd-169	408	4	.	.	PUNCT
chd-169	409	1	longitudinal	longitudinal	ADJ
chd-169	409	2	changes	change	NOUN
chd-169	409	3	of	of	ADP
chd-169	409	4	telomere	telomere	NOUN
chd-169	409	5	length	length	NOUN
chd-169	409	6	and	and	CCONJ
chd-169	409	7	epigenetic	epigenetic	ADJ
chd-169	409	8	age	age	NOUN
chd-169	409	9	related	relate	VERB
chd-169	409	10	to	to	ADP
chd-169	409	11	traumatic	traumatic	ADJ
chd-169	409	12	stress	stress	NOUN
chd-169	409	13	and	and	CCONJ
chd-169	409	14	post	post	ADJ
chd-169	409	15	-	-	ADJ
chd-169	409	16	traumatic	traumatic	ADJ
chd-169	409	17	stress	stress	NOUN
chd-169	409	18	disorder	disorder	NOUN
chd-169	409	19	.	.	PUNCT
chd-169	410	1	psychoneuroendocrinology	psychoneuroendocrinology	NOUN
chd-169	410	2	51	51	NUM
chd-169	410	3	,	,	PUNCT
chd-169	410	4	506	506	NUM
chd-169	410	5	-	-	SYM
chd-169	410	6	512	512	NUM
chd-169	410	7	.	.	PUNCT
chd-169	411	1	bolton	bolton	PROPN
chd-169	411	2	,	,	PUNCT
chd-169	411	3	e.c	e.c	PROPN
chd-169	411	4	.	.	PROPN
chd-169	411	5	,	,	PUNCT
chd-169	411	6	so	so	ADV
chd-169	411	7	,	,	PUNCT
chd-169	411	8	a.y	a.y	PROPN
chd-169	411	9	.	.	PROPN
chd-169	411	10	,	,	PUNCT
chd-169	411	11	chaivorapol	chaivorapol	PROPN
chd-169	411	12	,	,	PUNCT
chd-169	411	13	c.	c.	PROPN
chd-169	411	14	,	,	PUNCT
chd-169	411	15	haqq	haqq	INTJ
chd-169	411	16	,	,	PUNCT
chd-169	411	17	c.m	c.m	PROPN
chd-169	411	18	.	.	PROPN
chd-169	411	19	,	,	PUNCT
chd-169	411	20	li	li	PROPN
chd-169	411	21	,	,	PUNCT
chd-169	411	22	h.	h.	PROPN
chd-169	411	23	,	,	PUNCT
chd-169	411	24	and	and	CCONJ
chd-169	411	25	yamamoto	yamamoto	PROPN
chd-169	411	26	,	,	PUNCT
chd-169	411	27	k.r	k.r	PROPN
chd-169	411	28	.	.	PROPN
chd-169	411	29	(	(	PUNCT
chd-169	411	30	2007	2007	NUM
chd-169	411	31	)	)	PUNCT
chd-169	411	32	.	.	PUNCT
chd-169	412	1	celland	celland	NOUN
chd-169	412	2	gene	gene	NOUN
chd-169	412	3	-	-	PUNCT
chd-169	412	4	specific	specific	ADJ
chd-169	412	5	regulation	regulation	NOUN
chd-169	412	6	of	of	ADP
chd-169	412	7	primary	primary	ADJ
chd-169	412	8	target	target	NOUN
chd-169	412	9	genes	gene	NOUN
chd-169	412	10	by	by	ADP
chd-169	412	11	the	the	DET
chd-169	412	12	androgen	androgen	NOUN
chd-169	412	13	receptor	receptor	NOUN
chd-169	412	14	.	.	PUNCT
chd-169	413	1	genes	gene	NOUN
chd-169	413	2	&	&	CCONJ
chd-169	413	3	development	development	NOUN
chd-169	413	4	21	21	NUM
chd-169	413	5	,	,	PUNCT
chd-169	413	6	2005	2005	NUM
chd-169	413	7	-	-	SYM
chd-169	413	8	2017	2017	NUM
chd-169	413	9	.	.	PUNCT
chd-169	414	1	bosland	bosland	PROPN
chd-169	414	2	,	,	PUNCT
chd-169	414	3	m.c	m.c	PROPN
chd-169	414	4	.	.	PROPN
chd-169	414	5	,	,	PUNCT
chd-169	414	6	and	and	CCONJ
chd-169	414	7	mahmoud	mahmoud	PROPN
chd-169	414	8	,	,	PUNCT
chd-169	414	9	a.m.	a.m.	PROPN
chd-169	414	10	(	(	PUNCT
chd-169	414	11	2011	2011	NUM
chd-169	414	12	)	)	PUNCT
chd-169	414	13	.	.	PUNCT
chd-169	415	1	hormones	hormone	NOUN
chd-169	415	2	and	and	CCONJ
chd-169	415	3	prostate	prostate	NOUN
chd-169	415	4	carcinogenesis	carcinogenesis	NOUN
chd-169	415	5	:	:	PUNCT
chd-169	415	6	androgens	androgen	NOUN
chd-169	415	7	and	and	CCONJ
chd-169	415	8	estrogens	estrogen	NOUN
chd-169	415	9	.	.	PUNCT
chd-169	415	10	journal	journal	NOUN
chd-169	415	11	of	of	ADP
chd-169	415	12	carcinogenesis	carcinogenesis	NOUN
chd-169	415	13	10	10	NUM
chd-169	415	14	,	,	PUNCT
chd-169	415	15	33	33	NUM
chd-169	415	16	.	.	PUNCT
chd-169	416	1	braithwaite	braithwaite	PROPN
chd-169	416	2	,	,	PUNCT
chd-169	416	3	d.	d.	PROPN
chd-169	416	4	,	,	PUNCT
chd-169	416	5	tammemagi	tammemagi	PROPN
chd-169	416	6	,	,	PUNCT
chd-169	416	7	c.m	c.m	PROPN
chd-169	416	8	.	.	PROPN
chd-169	416	9	,	,	PUNCT
chd-169	416	10	moore	moore	PROPN
chd-169	416	11	,	,	PUNCT
chd-169	416	12	d.h	d.h	PROPN
chd-169	416	13	.	.	PROPN
chd-169	416	14	,	,	PUNCT
chd-169	416	15	ozanne	ozanne	PROPN
chd-169	416	16	,	,	PUNCT
chd-169	416	17	e.m	e.m	PROPN
chd-169	416	18	.	.	PROPN
chd-169	416	19	,	,	PUNCT
chd-169	416	20	hiatt	hiatt	PROPN
chd-169	416	21	,	,	PUNCT
chd-169	416	22	r.a	r.a	PROPN
chd-169	416	23	.	.	PROPN
chd-169	416	24	,	,	PUNCT
chd-169	416	25	belkora	belkora	PROPN
chd-169	416	26	,	,	PUNCT
chd-169	416	27	j.	j.	PROPN
chd-169	416	28	,	,	PUNCT
chd-169	416	29	west	west	PROPN
chd-169	416	30	,	,	PUNCT
chd-169	416	31	d.w	d.w	PROPN
chd-169	416	32	.	.	PROPN
chd-169	416	33	,	,	PUNCT
chd-169	416	34	satariano	satariano	PROPN
chd-169	416	35	,	,	PUNCT
chd-169	416	36	w.a	w.a	PROPN
chd-169	416	37	.	.	PROPN
chd-169	416	38	,	,	PUNCT
chd-169	416	39	liebman	liebman	PROPN
chd-169	416	40	,	,	PUNCT
chd-169	416	41	m.	m.	NOUN
chd-169	416	42	,	,	PUNCT
chd-169	416	43	and	and	CCONJ
chd-169	416	44	esserman	esserman	NOUN
chd-169	416	45	,	,	PUNCT
chd-169	416	46	l.	l.	PROPN
chd-169	416	47	(	(	PUNCT
chd-169	416	48	2009	2009	NUM
chd-169	416	49	)	)	PUNCT
chd-169	416	50	.	.	PUNCT
chd-169	417	1	hypertension	hypertension	NOUN
chd-169	417	2	is	be	AUX
chd-169	417	3	an	an	DET
chd-169	417	4	independent	independent	ADJ
chd-169	417	5	predictor	predictor	NOUN
chd-169	417	6	of	of	ADP
chd-169	417	7	survival	survival	NOUN
chd-169	417	8	disparity	disparity	NOUN
chd-169	417	9	between	between	ADP
chd-169	417	10	african	african	ADJ
chd-169	417	11	-	-	PUNCT
chd-169	417	12	american	american	ADJ
chd-169	417	13	and	and	CCONJ
chd-169	417	14	white	white	ADJ
chd-169	417	15	breast	breast	NOUN
chd-169	417	16	cancer	cancer	NOUN
chd-169	417	17	patients	patient	NOUN
chd-169	417	18	.	.	PUNCT
chd-169	418	1	int	int	NOUN
chd-169	418	2	j	j	PROPN
chd-169	418	3	cancer	cancer	NOUN
chd-169	418	4	124	124	NUM
chd-169	418	5	,	,	PUNCT
chd-169	418	6	1213	1213	NUM
chd-169	418	7	-	-	SYM
chd-169	418	8	1219	1219	NUM
chd-169	418	9	.	.	PUNCT
chd-169	419	1	byrd	byrd	PROPN
chd-169	419	2	,	,	PUNCT
chd-169	419	3	d.r	d.r	PROPN
chd-169	419	4	.	.	PROPN
chd-169	419	5	(	(	PUNCT
chd-169	419	6	2012	2012	NUM
chd-169	419	7	)	)	PUNCT
chd-169	419	8	.	.	PUNCT
chd-169	420	1	race	race	NOUN
chd-169	420	2	/	/	SYM
chd-169	420	3	ethnicity	ethnicity	NOUN
chd-169	420	4	and	and	CCONJ
chd-169	420	5	self	self	NOUN
chd-169	420	6	-	-	PUNCT
chd-169	420	7	reported	report	VERB
chd-169	420	8	levels	level	NOUN
chd-169	420	9	of	of	ADP
chd-169	420	10	discrimination	discrimination	NOUN
chd-169	420	11	and	and	CCONJ
chd-169	420	12	psychological	psychological	ADJ
chd-169	420	13	distress	distress	NOUN
chd-169	420	14	,	,	PUNCT
chd-169	420	15	california	california	PROPN
chd-169	420	16	,	,	PUNCT
chd-169	420	17	2005	2005	NUM
chd-169	420	18	.	.	PUNCT
chd-169	421	1	preventing	prevent	VERB
chd-169	421	2	chronic	chronic	ADJ
chd-169	421	3	disease	disease	NOUN
chd-169	421	4	9	9	NUM
chd-169	421	5	,	,	PUNCT
chd-169	421	6	e156	e156	PROPN
chd-169	421	7	-	-	PUNCT
chd-169	421	8	e156	e156	PROPN
chd-169	421	9	.	.	PUNCT
chd-169	421	10	cacioppo	cacioppo	PROPN
chd-169	421	11	,	,	PUNCT
chd-169	421	12	j.t	j.t	PROPN
chd-169	421	13	.	.	PROPN
chd-169	421	14	,	,	PUNCT
chd-169	421	15	and	and	CCONJ
chd-169	421	16	hawkley	hawkley	NOUN
chd-169	421	17	,	,	PUNCT
chd-169	421	18	l.c	l.c	PROPN
chd-169	421	19	.	.	PROPN
chd-169	421	20	(	(	PUNCT
chd-169	421	21	2003	2003	NUM
chd-169	421	22	)	)	PUNCT
chd-169	421	23	.	.	PUNCT
chd-169	422	1	social	social	ADJ
chd-169	422	2	isolation	isolation	NOUN
chd-169	422	3	and	and	CCONJ
chd-169	422	4	health	health	NOUN
chd-169	422	5	,	,	PUNCT
chd-169	422	6	with	with	ADP
chd-169	422	7	an	an	DET
chd-169	422	8	emphasis	emphasis	NOUN
chd-169	422	9	on	on	ADP
chd-169	422	10	underlying	underlie	VERB
chd-169	422	11	mechanisms	mechanism	NOUN
chd-169	422	12	.	.	PUNCT
chd-169	423	1	perspect	perspect	VERB
chd-169	423	2	biol	biol	PROPN
chd-169	423	3	med	me	VERB
chd-169	423	4	46	46	NUM
chd-169	423	5	,	,	PUNCT
chd-169	423	6	s39	s39	NOUN
chd-169	423	7	-	-	SYM
chd-169	423	8	52	52	NUM
chd-169	423	9	.	.	PUNCT
chd-169	424	1	chen	chen	PROPN
chd-169	424	2	,	,	PUNCT
chd-169	424	3	c.d	c.d	PROPN
chd-169	424	4	.	.	PROPN
chd-169	424	5	,	,	PUNCT
chd-169	424	6	welsbie	welsbie	PROPN
chd-169	424	7	,	,	PUNCT
chd-169	424	8	d.s	d.s	PROPN
chd-169	424	9	.	.	PROPN
chd-169	424	10	,	,	PUNCT
chd-169	424	11	tran	tran	PROPN
chd-169	424	12	,	,	PUNCT
chd-169	424	13	c.	c.	PROPN
chd-169	424	14	,	,	PUNCT
chd-169	424	15	baek	baek	PROPN
chd-169	424	16	,	,	PUNCT
chd-169	424	17	s.h	s.h	PROPN
chd-169	424	18	.	.	PROPN
chd-169	424	19	,	,	PUNCT
chd-169	424	20	chen	chen	PROPN
chd-169	424	21	,	,	PUNCT
chd-169	424	22	r.	r.	PROPN
chd-169	424	23	,	,	PUNCT
chd-169	424	24	vessella	vessella	NOUN
chd-169	424	25	,	,	PUNCT
chd-169	424	26	r.	r.	PROPN
chd-169	424	27	,	,	PUNCT
chd-169	424	28	rosenfeld	rosenfeld	PROPN
chd-169	424	29	,	,	PUNCT
chd-169	424	30	m.g	m.g	PROPN
chd-169	424	31	.	.	PROPN
chd-169	424	32	,	,	PUNCT
chd-169	424	33	and	and	CCONJ
chd-169	424	34	sawyers	sawyer	NOUN
chd-169	424	35	,	,	PUNCT
chd-169	424	36	c.l	c.l	PROPN
chd-169	424	37	.	.	PROPN
chd-169	424	38	(	(	PUNCT
chd-169	424	39	2004	2004	NUM
chd-169	424	40	)	)	PUNCT
chd-169	424	41	.	.	PUNCT
chd-169	425	1	molecular	molecular	ADJ
chd-169	425	2	determinants	determinant	NOUN
chd-169	425	3	of	of	ADP
chd-169	425	4	resistance	resistance	NOUN
chd-169	425	5	to	to	ADP
chd-169	425	6	antiandrogen	antiandrogen	NOUN
chd-169	425	7	therapy	therapy	NOUN
chd-169	425	8	.	.	PUNCT
chd-169	426	1	nat	nat	PROPN
chd-169	426	2	med	me	VERB
chd-169	426	3	10	10	NUM
chd-169	426	4	,	,	PUNCT
chd-169	426	5	33	33	NUM
chd-169	426	6	-	-	SYM
chd-169	426	7	39	39	NUM
chd-169	426	8	.	.	PUNCT
chd-169	427	1	chen	chen	PROPN
chd-169	427	2	,	,	PUNCT
chd-169	427	3	x.	x.	PROPN
chd-169	427	4	,	,	PUNCT
chd-169	427	5	chen	chen	PROPN
chd-169	427	6	,	,	PUNCT
chd-169	427	7	f.	f.	PROPN
chd-169	427	8	,	,	PUNCT
chd-169	427	9	ren	ren	PROPN
chd-169	427	10	,	,	PUNCT
chd-169	427	11	y.	y.	PROPN
chd-169	427	12	,	,	PUNCT
chd-169	427	13	weng	weng	PROPN
chd-169	427	14	,	,	PUNCT
chd-169	427	15	g.	g.	PROPN
chd-169	427	16	,	,	PUNCT
chd-169	427	17	keng	keng	PROPN
chd-169	427	18	,	,	PUNCT
chd-169	427	19	p.c	p.c	PROPN
chd-169	427	20	.	.	PROPN
chd-169	427	21	,	,	PUNCT
chd-169	427	22	chen	chen	PROPN
chd-169	427	23	,	,	PUNCT
chd-169	427	24	y.	y.	PROPN
chd-169	427	25	,	,	PUNCT
chd-169	427	26	and	and	CCONJ
chd-169	427	27	lee	lee	PROPN
chd-169	427	28	,	,	PUNCT
chd-169	427	29	s.o	s.o	PROPN
chd-169	427	30	.	.	PROPN
chd-169	427	31	(	(	PUNCT
chd-169	427	32	2019	2019	NUM
chd-169	427	33	)	)	PUNCT
chd-169	427	34	.	.	PUNCT
chd-169	428	1	glucocorticoid	glucocorticoid	ADJ
chd-169	428	2	receptor	receptor	NOUN
chd-169	428	3	upregulation	upregulation	NOUN
chd-169	428	4	increases	increase	VERB
chd-169	428	5	radioresistance	radioresistance	NOUN
chd-169	428	6	and	and	CCONJ
chd-169	428	7	triggers	trigger	VERB
chd-169	428	8	androgen	androgen	NOUN
chd-169	428	9	independence	independence	NOUN
chd-169	428	10	of	of	ADP
chd-169	428	11	prostate	prostate	NOUN
chd-169	428	12	cancer	cancer	NOUN
chd-169	428	13	.	.	PUNCT
chd-169	429	1	prostate	prostate	NOUN
chd-169	429	2	79	79	NUM
chd-169	429	3	,	,	PUNCT
chd-169	429	4	1386	1386	NUM
chd-169	429	5	-	-	SYM
chd-169	429	6	1398	1398	NUM
chd-169	429	7	.	.	PUNCT
chd-169	430	1	chi	chi	PROPN
chd-169	430	2	,	,	PUNCT
chd-169	430	3	k.n	k.n	PROPN
chd-169	430	4	.	.	PROPN
chd-169	430	5	,	,	PUNCT
chd-169	430	6	higano	higano	PROPN
chd-169	430	7	,	,	PUNCT
chd-169	430	8	c.s	c.s	PROPN
chd-169	430	9	.	.	PROPN
chd-169	430	10	,	,	PUNCT
chd-169	430	11	blumenstein	blumenstein	PROPN
chd-169	430	12	,	,	PUNCT
chd-169	430	13	b.	b.	PROPN
chd-169	430	14	,	,	PUNCT
chd-169	430	15	ferrero	ferrero	PROPN
chd-169	430	16	,	,	PUNCT
chd-169	430	17	j.m	j.m	PROPN
chd-169	430	18	.	.	PROPN
chd-169	430	19	,	,	PUNCT
chd-169	430	20	reeves	reeves	PROPN
chd-169	430	21	,	,	PUNCT
chd-169	430	22	j.	j.	PROPN
chd-169	430	23	,	,	PUNCT
chd-169	430	24	feyerabend	feyerabend	PROPN
chd-169	430	25	,	,	PUNCT
chd-169	430	26	s.	s.	PROPN
chd-169	430	27	,	,	PUNCT
chd-169	430	28	gravis	gravis	PROPN
chd-169	430	29	,	,	PUNCT
chd-169	430	30	g.	g.	PROPN
chd-169	430	31	,	,	PUNCT
chd-169	430	32	merseburger	merseburger	NOUN
chd-169	430	33	,	,	PUNCT
chd-169	430	34	a.s	a.s	PROPN
chd-169	430	35	.	.	PROPN
chd-169	430	36	,	,	PUNCT
chd-169	430	37	stenzl	stenzl	PROPN
chd-169	430	38	,	,	PUNCT
chd-169	430	39	a.	a.	NOUN
chd-169	430	40	,	,	PUNCT
chd-169	430	41	bergman	bergman	PROPN
chd-169	430	42	,	,	PUNCT
chd-169	430	43	a.m.	a.m.	ADV
chd-169	430	44	,	,	PUNCT
chd-169	430	45	et	et	PROPN
chd-169	430	46	al	al	PROPN
chd-169	430	47	.	.	PUNCT
chd-169	430	48	(	(	PUNCT
chd-169	430	49	2017	2017	NUM
chd-169	430	50	)	)	PUNCT
chd-169	430	51	.	.	PUNCT
chd-169	431	1	custirsen	custirsen	NOUN
chd-169	431	2	in	in	ADP
chd-169	431	3	combination	combination	NOUN
chd-169	431	4	with	with	ADP
chd-169	431	5	docetaxel	docetaxel	NOUN
chd-169	431	6	and	and	CCONJ
chd-169	431	7	prednisone	prednisone	NOUN
chd-169	431	8	for	for	ADP
chd-169	431	9	patients	patient	NOUN
chd-169	431	10	with	with	ADP
chd-169	431	11	metastatic	metastatic	ADJ
chd-169	431	12	castration	castration	NOUN
chd-169	431	13	-	-	PUNCT
chd-169	431	14	resistant	resistant	ADJ
chd-169	431	15	prostate	prostate	NOUN
chd-169	431	16	cancer	cancer	NOUN
chd-169	431	17	(	(	PUNCT
chd-169	431	18	synergy	synergy	NOUN
chd-169	431	19	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-169	431	20	e22	e22	PROPN
chd-169	431	21	cancer	cancer	NOUN
chd-169	431	22	health	health	NOUN
chd-169	431	23	disparities	disparity	NOUN
chd-169	431	24	research	research	NOUN
chd-169	431	25	trial	trial	NOUN
chd-169	431	26	):	):	PUNCT
chd-169	431	27	a	a	DET
chd-169	431	28	phase	phase	NOUN
chd-169	431	29	3	3	NUM
chd-169	431	30	,	,	PUNCT
chd-169	431	31	multicentre	multicentre	NOUN
chd-169	431	32	,	,	PUNCT
chd-169	431	33	open	open	ADJ
chd-169	431	34	-	-	PUNCT
chd-169	431	35	label	label	NOUN
chd-169	431	36	,	,	PUNCT
chd-169	431	37	randomised	randomise	VERB
chd-169	431	38	trial	trial	NOUN
chd-169	431	39	.	.	PUNCT
chd-169	432	1	lancet	lancet	PROPN
chd-169	432	2	oncol	oncol	ADJ
chd-169	432	3	18	18	NUM
chd-169	432	4	,	,	PUNCT
chd-169	432	5	473	473	NUM
chd-169	432	6	-	-	NUM
chd-169	432	7	485	485	NUM
chd-169	432	8	.	.	PUNCT
chd-169	433	1	chornokur	chornokur	PROPN
chd-169	433	2	,	,	PUNCT
chd-169	433	3	g.	g.	PROPN
chd-169	433	4	,	,	PUNCT
chd-169	433	5	dalton	dalton	PROPN
chd-169	433	6	,	,	PUNCT
chd-169	433	7	k.	k.	PROPN
chd-169	433	8	,	,	PUNCT
chd-169	433	9	borysova	borysova	PROPN
chd-169	433	10	,	,	PUNCT
chd-169	433	11	m.e	m.e	PROPN
chd-169	433	12	.	.	PROPN
chd-169	433	13	,	,	PUNCT
chd-169	433	14	and	and	CCONJ
chd-169	433	15	kumar	kumar	PROPN
chd-169	433	16	,	,	PUNCT
chd-169	433	17	n.b	n.b	PROPN
chd-169	433	18	.	.	PROPN
chd-169	433	19	(	(	PUNCT
chd-169	433	20	2011	2011	NUM
chd-169	433	21	)	)	PUNCT
chd-169	433	22	.	.	PUNCT
chd-169	434	1	disparities	disparity	NOUN
chd-169	434	2	at	at	ADP
chd-169	434	3	presentation	presentation	NOUN
chd-169	434	4	,	,	PUNCT
chd-169	434	5	diagnosis	diagnosis	NOUN
chd-169	434	6	,	,	PUNCT
chd-169	434	7	treatment	treatment	NOUN
chd-169	434	8	,	,	PUNCT
chd-169	434	9	and	and	CCONJ
chd-169	434	10	survival	survival	NOUN
chd-169	434	11	in	in	ADP
chd-169	434	12	african	african	ADJ
chd-169	434	13	american	american	ADJ
chd-169	434	14	men	man	NOUN
chd-169	434	15	,	,	PUNCT
chd-169	434	16	affected	affect	VERB
chd-169	434	17	by	by	ADP
chd-169	434	18	prostate	prostate	NOUN
chd-169	434	19	cancer	cancer	NOUN
chd-169	434	20	.	.	PUNCT
chd-169	435	1	the	the	DET
chd-169	435	2	prostate	prostate	NOUN
chd-169	435	3	71	71	NUM
chd-169	435	4	,	,	PUNCT
chd-169	435	5	985	985	NUM
chd-169	435	6	-	-	SYM
chd-169	435	7	997	997	NUM
chd-169	435	8	.	.	PUNCT
chd-169	436	1	christensen	christensen	PROPN
chd-169	436	2	,	,	PUNCT
chd-169	436	3	b.c	b.c	PROPN
chd-169	436	4	.	.	PROPN
chd-169	436	5	,	,	PUNCT
chd-169	436	6	houseman	houseman	NOUN
chd-169	436	7	,	,	PUNCT
chd-169	436	8	e.a	e.a	PROPN
chd-169	436	9	.	.	PROPN
chd-169	436	10	,	,	PUNCT
chd-169	436	11	marsit	marsit	PROPN
chd-169	436	12	,	,	PUNCT
chd-169	436	13	c.j	c.j	PROPN
chd-169	436	14	.	.	PROPN
chd-169	436	15	,	,	PUNCT
chd-169	436	16	zheng	zheng	PROPN
chd-169	436	17	,	,	PUNCT
chd-169	436	18	s.	s.	PROPN
chd-169	436	19	,	,	PUNCT
chd-169	436	20	wrensch	wrensch	PROPN
chd-169	436	21	,	,	PUNCT
chd-169	436	22	m.r	m.r	PROPN
chd-169	436	23	.	.	PROPN
chd-169	436	24	,	,	PUNCT
chd-169	436	25	wiemels	wiemel	NOUN
chd-169	436	26	,	,	PUNCT
chd-169	436	27	j.l	j.l	PROPN
chd-169	436	28	.	.	PROPN
chd-169	436	29	,	,	PUNCT
chd-169	436	30	nelson	nelson	PROPN
chd-169	436	31	,	,	PUNCT
chd-169	436	32	h.h	h.h	PROPN
chd-169	436	33	.	.	PROPN
chd-169	436	34	,	,	PUNCT
chd-169	436	35	karagas	karagas	NOUN
chd-169	436	36	,	,	PUNCT
chd-169	436	37	m.r	m.r	PROPN
chd-169	436	38	.	.	PROPN
chd-169	436	39	,	,	PUNCT
chd-169	436	40	padbury	padbury	NOUN
chd-169	436	41	,	,	PUNCT
chd-169	436	42	j.f	j.f	PROPN
chd-169	436	43	.	.	PROPN
chd-169	436	44	,	,	PUNCT
chd-169	436	45	bueno	bueno	PROPN
chd-169	436	46	,	,	PUNCT
chd-169	436	47	r.	r.	PROPN
chd-169	436	48	,	,	PUNCT
chd-169	436	49	et	et	PROPN
chd-169	436	50	al	al	PROPN
chd-169	436	51	.	.	PUNCT
chd-169	436	52	(	(	PUNCT
chd-169	436	53	2009	2009	NUM
chd-169	436	54	)	)	PUNCT
chd-169	436	55	.	.	PUNCT
chd-169	437	1	aging	age	VERB
chd-169	437	2	and	and	CCONJ
chd-169	437	3	environmental	environmental	ADJ
chd-169	437	4	exposures	exposure	NOUN
chd-169	437	5	alter	alter	VERB
chd-169	437	6	tissue	tissue	NOUN
chd-169	437	7	-	-	PUNCT
chd-169	437	8	specific	specific	ADJ
chd-169	437	9	dna	dna	NOUN
chd-169	437	10	methylation	methylation	NOUN
chd-169	437	11	dependent	dependent	ADJ
chd-169	437	12	upon	upon	SCONJ
chd-169	437	13	cpg	cpg	PROPN
chd-169	437	14	island	island	NOUN
chd-169	437	15	context	context	NOUN
chd-169	437	16	.	.	PUNCT
chd-169	438	1	plos	plos	PROPN
chd-169	438	2	genetics	genetics	PROPN
chd-169	438	3	5	5	NUM
chd-169	438	4	,	,	PUNCT
chd-169	438	5	e1000602	e1000602	VERB
chd-169	438	6	.	.	PUNCT
chd-169	439	1	chun	chun	PROPN
chd-169	439	2	,	,	PUNCT
chd-169	439	3	y.j	y.j	PROPN
chd-169	439	4	.	.	PUNCT
chd-169	439	5	(	(	PUNCT
chd-169	439	6	2014	2014	NUM
chd-169	439	7	)	)	PUNCT
chd-169	439	8	.	.	PUNCT
chd-169	440	1	knockdown	knockdown	NOUN
chd-169	440	2	of	of	ADP
chd-169	440	3	clusterin	clusterin	ADJ
chd-169	440	4	expression	expression	NOUN
chd-169	440	5	increases	increase	VERB
chd-169	440	6	the	the	DET
chd-169	440	7	in	in	X
chd-169	440	8	vitro	vitro	X
chd-169	440	9	sensitivity	sensitivity	NOUN
chd-169	440	10	of	of	ADP
chd-169	440	11	human	human	ADJ
chd-169	440	12	prostate	prostate	NOUN
chd-169	440	13	cancer	cancer	NOUN
chd-169	440	14	cells	cell	NOUN
chd-169	440	15	to	to	ADP
chd-169	440	16	paclitaxel	paclitaxel	PROPN
chd-169	440	17	.	.	PUNCT
chd-169	441	1	j	j	PROPN
chd-169	441	2	toxicol	toxicol	PROPN
chd-169	441	3	environ	environ	PROPN
chd-169	441	4	health	health	PROPN
chd-169	441	5	a	a	DET
chd-169	441	6	77	77	NUM
chd-169	441	7	,	,	PUNCT
chd-169	441	8	1443	1443	NUM
chd-169	441	9	-	-	SYM
chd-169	441	10	1450	1450	NUM
chd-169	441	11	.	.	PUNCT
chd-169	442	1	chung	chung	PROPN
chd-169	442	2	,	,	PUNCT
chd-169	442	3	c.c	c.c	PROPN
chd-169	442	4	.	.	PROPN
chd-169	442	5	,	,	PUNCT
chd-169	442	6	hsing	hsing	PROPN
chd-169	442	7	,	,	PUNCT
chd-169	442	8	a.w	a.w	PROPN
chd-169	442	9	.	.	PROPN
chd-169	442	10	,	,	PUNCT
chd-169	442	11	edward	edward	PROPN
chd-169	442	12	,	,	PUNCT
chd-169	442	13	y.	y.	PROPN
chd-169	442	14	,	,	PUNCT
chd-169	442	15	biritwum	biritwum	PROPN
chd-169	442	16	,	,	PUNCT
chd-169	442	17	r.	r.	PROPN
chd-169	442	18	,	,	PUNCT
chd-169	442	19	tettey	tettey	PROPN
chd-169	442	20	,	,	PUNCT
chd-169	442	21	y.	y.	PROPN
chd-169	442	22	,	,	PUNCT
chd-169	442	23	adjei	adjei	PROPN
chd-169	442	24	,	,	PUNCT
chd-169	442	25	a.	a.	PROPN
chd-169	442	26	,	,	PUNCT
chd-169	442	27	cook	cook	NOUN
chd-169	442	28	,	,	PUNCT
chd-169	442	29	m.b	m.b	PROPN
chd-169	442	30	.	.	PROPN
chd-169	442	31	,	,	PUNCT
chd-169	442	32	de	de	PROPN
chd-169	442	33	marzo	marzo	X
chd-169	442	34	,	,	PUNCT
chd-169	442	35	a.	a.	NOUN
chd-169	442	36	,	,	PUNCT
chd-169	442	37	netto	netto	PROPN
chd-169	442	38	,	,	PUNCT
chd-169	442	39	g.	g.	PROPN
chd-169	442	40	,	,	PUNCT
chd-169	442	41	tay	tay	PROPN
chd-169	442	42	,	,	PUNCT
chd-169	442	43	e.	e.	PROPN
chd-169	442	44	,	,	PUNCT
chd-169	442	45	et	et	PROPN
chd-169	442	46	al	al	PROPN
chd-169	442	47	.	.	PUNCT
chd-169	442	48	(	(	PUNCT
chd-169	442	49	2014	2014	NUM
chd-169	442	50	)	)	PUNCT
chd-169	442	51	.	.	PUNCT
chd-169	443	1	a	a	DET
chd-169	443	2	comprehensive	comprehensive	ADJ
chd-169	443	3	resequence	resequence	NOUN
chd-169	443	4	-	-	PUNCT
chd-169	443	5	analysis	analysis	NOUN
chd-169	443	6	of	of	ADP
chd-169	443	7	250	250	NUM
chd-169	443	8	kb	kb	PROPN
chd-169	443	9	region	region	NOUN
chd-169	443	10	of	of	ADP
chd-169	443	11	8q24.21	8q24.21	NUM
chd-169	443	12	in	in	ADP
chd-169	443	13	men	man	NOUN
chd-169	443	14	of	of	ADP
chd-169	443	15	african	african	ADJ
chd-169	443	16	ancestry	ancestry	NOUN
chd-169	443	17	.	.	PUNCT
chd-169	444	1	the	the	DET
chd-169	444	2	prostate	prostate	NOUN
chd-169	444	3	74	74	NUM
chd-169	444	4	,	,	PUNCT
chd-169	444	5	579	579	NUM
chd-169	444	6	-	-	SYM
chd-169	444	7	589	589	NUM
chd-169	444	8	.	.	PUNCT
chd-169	444	9	claessens	claessen	NOUN
chd-169	444	10	,	,	PUNCT
chd-169	444	11	f.	f.	PROPN
chd-169	444	12	,	,	PUNCT
chd-169	444	13	joniau	joniau	PROPN
chd-169	444	14	,	,	PUNCT
chd-169	444	15	s.	s.	PROPN
chd-169	444	16	,	,	PUNCT
chd-169	444	17	and	and	CCONJ
chd-169	444	18	helsen	helsen	PROPN
chd-169	444	19	,	,	PUNCT
chd-169	444	20	c.	c.	NOUN
chd-169	444	21	(	(	PUNCT
chd-169	444	22	2017	2017	NUM
chd-169	444	23	)	)	PUNCT
chd-169	444	24	.	.	PUNCT
chd-169	445	1	comparing	compare	VERB
chd-169	445	2	the	the	DET
chd-169	445	3	rules	rule	NOUN
chd-169	445	4	of	of	ADP
chd-169	445	5	engagement	engagement	NOUN
chd-169	445	6	of	of	ADP
chd-169	445	7	androgen	androgen	NOUN
chd-169	445	8	and	and	CCONJ
chd-169	445	9	glucocorticoid	glucocorticoid	ADJ
chd-169	445	10	receptors	receptor	NOUN
chd-169	445	11	.	.	PUNCT
chd-169	446	1	cell	cell	NOUN
chd-169	446	2	mol	mol	ADP
chd-169	446	3	life	life	NOUN
chd-169	446	4	sci	sci	PROPN
chd-169	446	5	74	74	NUM
chd-169	446	6	,	,	PUNCT
chd-169	446	7	2217	2217	NUM
chd-169	446	8	-	-	SYM
chd-169	446	9	2228	2228	NUM
chd-169	446	10	.	.	PUNCT
chd-169	447	1	cohen	cohen	PROPN
chd-169	447	2	,	,	PUNCT
chd-169	447	3	s.	s.	PROPN
chd-169	447	4	,	,	PUNCT
chd-169	447	5	schwartz	schwartz	PROPN
chd-169	447	6	,	,	PUNCT
chd-169	447	7	j.e	j.e	PROPN
chd-169	447	8	.	.	PROPN
chd-169	447	9	,	,	PUNCT
chd-169	447	10	epel	epel	PROPN
chd-169	447	11	,	,	PUNCT
chd-169	447	12	e.	e.	PROPN
chd-169	447	13	,	,	PUNCT
chd-169	447	14	kirschbaum	kirschbaum	PROPN
chd-169	447	15	,	,	PUNCT
chd-169	447	16	c.	c.	PROPN
chd-169	447	17	,	,	PUNCT
chd-169	447	18	sidney	sidney	PROPN
chd-169	447	19	,	,	PUNCT
chd-169	447	20	s.	s.	PROPN
chd-169	447	21	,	,	PUNCT
chd-169	447	22	and	and	CCONJ
chd-169	447	23	seeman	seeman	PROPN
chd-169	447	24	,	,	PUNCT
chd-169	447	25	t.	t.	PROPN
chd-169	447	26	(	(	PUNCT
chd-169	447	27	2006	2006	NUM
chd-169	447	28	)	)	PUNCT
chd-169	447	29	.	.	PUNCT
chd-169	448	1	socioeconomic	socioeconomic	ADJ
chd-169	448	2	status	status	NOUN
chd-169	448	3	,	,	PUNCT
chd-169	448	4	race	race	NOUN
chd-169	448	5	,	,	PUNCT
chd-169	448	6	and	and	CCONJ
chd-169	448	7	diurnal	diurnal	ADJ
chd-169	448	8	cortisol	cortisol	NOUN
chd-169	448	9	decline	decline	NOUN
chd-169	448	10	in	in	ADP
chd-169	448	11	the	the	DET
chd-169	448	12	coronary	coronary	ADJ
chd-169	448	13	artery	artery	NOUN
chd-169	448	14	risk	risk	NOUN
chd-169	448	15	development	development	NOUN
chd-169	448	16	in	in	ADP
chd-169	448	17	young	young	ADJ
chd-169	448	18	adults	adult	NOUN
chd-169	448	19	(	(	PUNCT
chd-169	448	20	cardia	cardia	NOUN
chd-169	448	21	)	)	PUNCT
chd-169	448	22	study	study	NOUN
chd-169	448	23	.	.	PUNCT
chd-169	449	1	psychosom	psychosom	PROPN
chd-169	449	2	med	med	PROPN
chd-169	449	3	68	68	NUM
chd-169	449	4	,	,	PUNCT
chd-169	449	5	41	41	NUM
chd-169	449	6	-	-	SYM
chd-169	449	7	50	50	NUM
chd-169	449	8	.	.	PUNCT
chd-169	450	1	collins	collins	PROPN
chd-169	450	2	,	,	PUNCT
chd-169	450	3	r.	r.	PROPN
chd-169	450	4	,	,	PUNCT
chd-169	450	5	fenwick	fenwick	PROPN
chd-169	450	6	,	,	PUNCT
chd-169	450	7	e.	e.	PROPN
chd-169	450	8	,	,	PUNCT
chd-169	450	9	trowman	trowman	NOUN
chd-169	450	10	,	,	PUNCT
chd-169	450	11	r.	r.	PROPN
chd-169	450	12	,	,	PUNCT
chd-169	450	13	perard	perard	PROPN
chd-169	450	14	,	,	PUNCT
chd-169	450	15	r.	r.	PROPN
chd-169	450	16	,	,	PUNCT
chd-169	450	17	norman	norman	PROPN
chd-169	450	18	,	,	PUNCT
chd-169	450	19	g.	g.	PROPN
chd-169	450	20	,	,	PUNCT
chd-169	450	21	light	light	NOUN
chd-169	450	22	,	,	PUNCT
chd-169	450	23	k.	k.	PROPN
chd-169	450	24	,	,	PUNCT
chd-169	450	25	birtle	birtle	PROPN
chd-169	450	26	,	,	PUNCT
chd-169	450	27	a.	a.	NOUN
chd-169	450	28	,	,	PUNCT
chd-169	450	29	palmer	palmer	PROPN
chd-169	450	30	,	,	PUNCT
chd-169	450	31	s.	s.	PROPN
chd-169	450	32	,	,	PUNCT
chd-169	450	33	and	and	CCONJ
chd-169	450	34	riemsma	riemsma	PROPN
chd-169	450	35	,	,	PUNCT
chd-169	450	36	r.	r.	PROPN
chd-169	450	37	(	(	PUNCT
chd-169	450	38	2007	2007	NUM
chd-169	450	39	)	)	PUNCT
chd-169	450	40	.	.	PUNCT
chd-169	451	1	a	a	DET
chd-169	451	2	systematic	systematic	ADJ
chd-169	451	3	review	review	NOUN
chd-169	451	4	and	and	CCONJ
chd-169	451	5	economic	economic	ADJ
chd-169	451	6	model	model	NOUN
chd-169	451	7	of	of	ADP
chd-169	451	8	the	the	DET
chd-169	451	9	clinical	clinical	ADJ
chd-169	451	10	effectiveness	effectiveness	NOUN
chd-169	451	11	and	and	CCONJ
chd-169	451	12	cost	cost	NOUN
chd-169	451	13	-	-	PUNCT
chd-169	451	14	effectiveness	effectiveness	NOUN
chd-169	451	15	of	of	ADP
chd-169	451	16	docetaxel	docetaxel	NOUN
chd-169	451	17	in	in	ADP
chd-169	451	18	combination	combination	NOUN
chd-169	451	19	with	with	ADP
chd-169	451	20	prednisone	prednisone	NOUN
chd-169	451	21	or	or	CCONJ
chd-169	451	22	prednisolone	prednisolone	PROPN
chd-169	451	23	for	for	ADP
chd-169	451	24	the	the	DET
chd-169	451	25	treatment	treatment	NOUN
chd-169	451	26	of	of	ADP
chd-169	451	27	hormone	hormone	NOUN
chd-169	451	28	-	-	PUNCT
chd-169	451	29	refractory	refractory	NOUN
chd-169	451	30	metastatic	metastatic	ADJ
chd-169	451	31	prostate	prostate	NOUN
chd-169	451	32	cancer	cancer	NOUN
chd-169	451	33	.	.	PUNCT
chd-169	452	1	health	health	NOUN
chd-169	452	2	technol	technol	PROPN
chd-169	452	3	assess	assess	NOUN
chd-169	452	4	11	11	NUM
chd-169	452	5	,	,	PUNCT
chd-169	452	6	iii	iii	X
chd-169	452	7	-	-	PUNCT
chd-169	452	8	iv	iv	NUM
chd-169	452	9	,	,	PUNCT
chd-169	452	10	xv	xv	PROPN
chd-169	452	11	-	-	PUNCT
chd-169	452	12	xviii	xviii	PROPN
chd-169	452	13	,	,	PUNCT
chd-169	452	14	1	1	NUM
chd-169	452	15	-	-	SYM
chd-169	452	16	179	179	NUM
chd-169	452	17	.	.	PUNCT
chd-169	453	1	corn	corn	PROPN
chd-169	453	2	,	,	PUNCT
chd-169	453	3	p.g	p.g	PROPN
chd-169	453	4	.	.	PROPN
chd-169	453	5	,	,	PUNCT
chd-169	453	6	agarwal	agarwal	PROPN
chd-169	453	7	,	,	PUNCT
chd-169	453	8	n.	n.	NOUN
chd-169	453	9	,	,	PUNCT
chd-169	453	10	araujo	araujo	PROPN
chd-169	453	11	,	,	PUNCT
chd-169	453	12	j.c	j.c	PROPN
chd-169	453	13	.	.	PROPN
chd-169	453	14	,	,	PUNCT
chd-169	453	15	and	and	CCONJ
chd-169	453	16	sonpavde	sonpavde	NOUN
chd-169	453	17	,	,	PUNCT
chd-169	453	18	g.	g.	PROPN
chd-169	453	19	(	(	PUNCT
chd-169	453	20	2017	2017	NUM
chd-169	453	21	)	)	PUNCT
chd-169	453	22	.	.	PUNCT
chd-169	454	1	taxane	taxane	NOUN
chd-169	454	2	-	-	PUNCT
chd-169	454	3	based	base	VERB
chd-169	454	4	combination	combination	NOUN
chd-169	454	5	therapies	therapy	NOUN
chd-169	454	6	for	for	ADP
chd-169	454	7	metastatic	metastatic	ADJ
chd-169	454	8	prostate	prostate	NOUN
chd-169	454	9	cancer	cancer	NOUN
chd-169	454	10	.	.	PUNCT
chd-169	455	1	european	european	ADJ
chd-169	455	2	urology	urology	NOUN
chd-169	455	3	focus	focus	NOUN
chd-169	455	4	.	.	PUNCT
chd-169	456	1	cuevas	cuevas	PROPN
chd-169	456	2	,	,	PUNCT
chd-169	456	3	a.g	a.g	PROPN
chd-169	456	4	.	.	PROPN
chd-169	456	5	,	,	PUNCT
chd-169	456	6	trudel	trudel	PROPN
chd-169	456	7	-	-	PUNCT
chd-169	456	8	fitzgerald	fitzgerald	PROPN
chd-169	456	9	,	,	PUNCT
chd-169	456	10	c.	c.	PROPN
chd-169	456	11	,	,	PUNCT
chd-169	456	12	cofie	cofie	PROPN
chd-169	456	13	,	,	PUNCT
chd-169	456	14	l.	l.	PROPN
chd-169	456	15	,	,	PUNCT
chd-169	456	16	zaitsu	zaitsu	NOUN
chd-169	456	17	,	,	PUNCT
chd-169	456	18	m.	m.	NOUN
chd-169	456	19	,	,	PUNCT
chd-169	456	20	allen	allen	PROPN
chd-169	456	21	,	,	PUNCT
chd-169	456	22	j.	j.	PROPN
chd-169	456	23	,	,	PUNCT
chd-169	456	24	and	and	CCONJ
chd-169	456	25	williams	williams	PROPN
chd-169	456	26	,	,	PUNCT
chd-169	456	27	d.r	d.r	PROPN
chd-169	456	28	.	.	PROPN
chd-169	456	29	(	(	PUNCT
chd-169	456	30	2019	2019	NUM
chd-169	456	31	)	)	PUNCT
chd-169	456	32	.	.	PUNCT
chd-169	457	1	placing	place	VERB
chd-169	457	2	prostate	prostate	NOUN
chd-169	457	3	cancer	cancer	NOUN
chd-169	457	4	disparities	disparity	NOUN
chd-169	457	5	within	within	ADP
chd-169	457	6	a	a	DET
chd-169	457	7	psychosocial	psychosocial	ADJ
chd-169	457	8	context	context	NOUN
chd-169	457	9	:	:	PUNCT
chd-169	457	10	challenges	challenge	NOUN
chd-169	457	11	and	and	CCONJ
chd-169	457	12	opportunities	opportunity	NOUN
chd-169	457	13	for	for	ADP
chd-169	457	14	future	future	ADJ
chd-169	457	15	research	research	NOUN
chd-169	457	16	.	.	PUNCT
chd-169	458	1	cancer	cancer	NOUN
chd-169	458	2	causes	cause	VERB
chd-169	458	3	control	control	NOUN
chd-169	458	4	30	30	NUM
chd-169	458	5	,	,	PUNCT
chd-169	458	6	443	443	NUM
chd-169	458	7	-	-	NUM
chd-169	458	8	456	456	NUM
chd-169	458	9	.	.	PUNCT
chd-169	459	1	darst	darst	PROPN
chd-169	459	2	,	,	PUNCT
chd-169	459	3	b.f	b.f	PROPN
chd-169	459	4	.	.	PROPN
chd-169	459	5	,	,	PUNCT
chd-169	459	6	wan	wan	PROPN
chd-169	459	7	,	,	PUNCT
chd-169	459	8	p.	p.	PROPN
chd-169	459	9	,	,	PUNCT
chd-169	459	10	sheng	sheng	PROPN
chd-169	459	11	,	,	PUNCT
chd-169	459	12	x.	x.	PROPN
chd-169	459	13	,	,	PUNCT
chd-169	459	14	bensen	bensen	PROPN
chd-169	459	15	,	,	PUNCT
chd-169	459	16	j.t	j.t	PROPN
chd-169	459	17	.	.	PROPN
chd-169	459	18	,	,	PUNCT
chd-169	459	19	ingles	ingles	PROPN
chd-169	459	20	,	,	PUNCT
chd-169	459	21	s.a	s.a	PROPN
chd-169	459	22	.	.	PROPN
chd-169	459	23	,	,	PUNCT
chd-169	459	24	rybicki	rybicki	PROPN
chd-169	459	25	,	,	PUNCT
chd-169	459	26	b.a	b.a	PROPN
chd-169	459	27	.	.	PROPN
chd-169	459	28	,	,	PUNCT
chd-169	459	29	nemesure	nemesure	PROPN
chd-169	459	30	,	,	PUNCT
chd-169	459	31	b.	b.	PROPN
chd-169	459	32	,	,	PUNCT
chd-169	459	33	john	john	PROPN
chd-169	459	34	,	,	PUNCT
chd-169	459	35	e.m	e.m	PROPN
chd-169	459	36	.	.	PROPN
chd-169	459	37	,	,	PUNCT
chd-169	459	38	fowke	fowke	NOUN
chd-169	459	39	,	,	PUNCT
chd-169	459	40	j.h	j.h	PROPN
chd-169	459	41	.	.	PROPN
chd-169	459	42	,	,	PUNCT
chd-169	459	43	stevens	stevens	PROPN
chd-169	459	44	,	,	PUNCT
chd-169	459	45	v.l	v.l	PROPN
chd-169	459	46	.	.	PROPN
chd-169	459	47	,	,	PUNCT
chd-169	459	48	et	et	PROPN
chd-169	459	49	al	al	PROPN
chd-169	459	50	.	.	PROPN
chd-169	459	51	(	(	PUNCT
chd-169	459	52	2020	2020	NUM
chd-169	459	53	)	)	PUNCT
chd-169	459	54	.	.	PUNCT
chd-169	460	1	a	a	DET
chd-169	460	2	germline	germline	NOUN
chd-169	460	3	variant	variant	NOUN
chd-169	460	4	at	at	ADP
chd-169	460	5	8q24	8q24	NOUN
chd-169	460	6	contributes	contribute	VERB
chd-169	460	7	to	to	ADP
chd-169	460	8	familial	familial	ADJ
chd-169	460	9	clustering	clustering	NOUN
chd-169	460	10	of	of	ADP
chd-169	460	11	prostate	prostate	NOUN
chd-169	460	12	cancer	cancer	NOUN
chd-169	460	13	in	in	ADP
chd-169	460	14	men	man	NOUN
chd-169	460	15	of	of	ADP
chd-169	460	16	african	african	ADJ
chd-169	460	17	ancestry	ancestry	NOUN
chd-169	460	18	.	.	PUNCT
chd-169	461	1	eur	eur	PROPN
chd-169	461	2	urol	urol	PROPN
chd-169	461	3	.	.	PUNCT
chd-169	462	1	das	das	PROPN
chd-169	462	2	,	,	PUNCT
chd-169	462	3	a.	a.	NOUN
chd-169	462	4	(	(	PUNCT
chd-169	462	5	2013	2013	NUM
chd-169	462	6	)	)	PUNCT
chd-169	462	7	.	.	PUNCT
chd-169	463	1	how	how	SCONJ
chd-169	463	2	does	do	AUX
chd-169	463	3	race	race	NOUN
chd-169	463	4	get	get	VERB
chd-169	463	5	“	"	PUNCT
chd-169	463	6	under	under	ADP
chd-169	463	7	the	the	DET
chd-169	463	8	skin	skin	NOUN
chd-169	463	9	”	"	PUNCT
chd-169	463	10	?	?	PUNCT
chd-169	463	11	:	:	PUNCT
chd-169	464	1	inflammation	inflammation	NOUN
chd-169	464	2	,	,	PUNCT
chd-169	464	3	weathering	weathering	NOUN
chd-169	464	4	,	,	PUNCT
chd-169	464	5	and	and	CCONJ
chd-169	464	6	metabolic	metabolic	NOUN
chd-169	464	7	problems	problem	NOUN
chd-169	464	8	in	in	ADP
chd-169	464	9	late	late	ADJ
chd-169	464	10	life	life	NOUN
chd-169	464	11	.	.	PUNCT
chd-169	465	1	social	social	ADJ
chd-169	465	2	science	science	PROPN
chd-169	465	3	&	&	CCONJ
chd-169	465	4	medicine	medicine	PROPN
chd-169	465	5	77	77	NUM
chd-169	465	6	,	,	PUNCT
chd-169	465	7	75	75	NUM
chd-169	465	8	-	-	SYM
chd-169	465	9	83	83	NUM
chd-169	465	10	.	.	PUNCT
chd-169	466	1	daskivich	daskivich	PROPN
chd-169	466	2	,	,	PUNCT
chd-169	466	3	t.j	t.j	PROPN
chd-169	466	4	.	.	PROPN
chd-169	466	5	,	,	PUNCT
chd-169	466	6	kwan	kwan	PROPN
chd-169	466	7	,	,	PUNCT
chd-169	466	8	l.	l.	PROPN
chd-169	466	9	,	,	PUNCT
chd-169	466	10	dash	dash	NOUN
chd-169	466	11	,	,	PUNCT
chd-169	466	12	a.	a.	NOUN
chd-169	466	13	,	,	PUNCT
chd-169	466	14	and	and	CCONJ
chd-169	466	15	litwin	litwin	PROPN
chd-169	466	16	,	,	PUNCT
chd-169	466	17	m.s	m.s	PROPN
chd-169	466	18	.	.	PROPN
chd-169	466	19	(	(	PUNCT
chd-169	466	20	2015	2015	NUM
chd-169	466	21	)	)	PUNCT
chd-169	466	22	.	.	PUNCT
chd-169	467	1	racial	racial	ADJ
chd-169	467	2	parity	parity	NOUN
chd-169	467	3	in	in	ADP
chd-169	467	4	tumor	tumor	NOUN
chd-169	467	5	burden	burden	NOUN
chd-169	467	6	,	,	PUNCT
chd-169	467	7	treatment	treatment	NOUN
chd-169	467	8	choice	choice	NOUN
chd-169	467	9	and	and	CCONJ
chd-169	467	10	survival	survival	NOUN
chd-169	467	11	outcomes	outcome	NOUN
chd-169	467	12	in	in	ADP
chd-169	467	13	men	man	NOUN
chd-169	467	14	with	with	ADP
chd-169	467	15	prostate	prostate	NOUN
chd-169	467	16	cancer	cancer	NOUN
chd-169	467	17	in	in	ADP
chd-169	467	18	the	the	DET
chd-169	467	19	va	va	PROPN
chd-169	467	20	healthcare	healthcare	PROPN
chd-169	467	21	system	system	NOUN
chd-169	467	22	.	.	PUNCT
chd-169	468	1	prostate	prostate	NOUN
chd-169	468	2	cancer	cancer	NOUN
chd-169	468	3	prostatic	prostatic	ADJ
chd-169	468	4	dis	dis	PROPN
chd-169	468	5	18	18	NUM
chd-169	468	6	,	,	PUNCT
chd-169	468	7	104109	104109	NUM
chd-169	468	8	.	.	PUNCT
chd-169	469	1	de	de	X
chd-169	469	2	bono	bono	X
chd-169	469	3	,	,	PUNCT
chd-169	469	4	j.s	j.s	PROPN
chd-169	469	5	.	.	PROPN
chd-169	469	6	,	,	PUNCT
chd-169	469	7	logothetis	logothetis	PROPN
chd-169	469	8	,	,	PUNCT
chd-169	469	9	c.j	c.j	PROPN
chd-169	469	10	.	.	PROPN
chd-169	469	11	,	,	PUNCT
chd-169	469	12	molina	molina	PROPN
chd-169	469	13	,	,	PUNCT
chd-169	469	14	a.	a.	NOUN
chd-169	469	15	,	,	PUNCT
chd-169	469	16	fizazi	fizazi	PROPN
chd-169	469	17	,	,	PUNCT
chd-169	469	18	k.	k.	PROPN
chd-169	469	19	,	,	PUNCT
chd-169	469	20	north	north	PROPN
chd-169	469	21	,	,	PUNCT
chd-169	469	22	s.	s.	PROPN
chd-169	469	23	,	,	PUNCT
chd-169	469	24	chu	chu	PROPN
chd-169	469	25	,	,	PUNCT
chd-169	469	26	l.	l.	PROPN
chd-169	469	27	,	,	PUNCT
chd-169	469	28	chi	chi	PROPN
chd-169	469	29	,	,	PUNCT
chd-169	469	30	k.n	k.n	PROPN
chd-169	469	31	.	.	PROPN
chd-169	469	32	,	,	PUNCT
chd-169	469	33	jones	jones	PROPN
chd-169	469	34	,	,	PUNCT
chd-169	469	35	r.j	r.j	PROPN
chd-169	469	36	.	.	PROPN
chd-169	469	37	,	,	PUNCT
chd-169	469	38	goodman	goodman	PROPN
chd-169	469	39	,	,	PUNCT
chd-169	469	40	o.b	o.b	PROPN
chd-169	469	41	.	.	PROPN
chd-169	469	42	,	,	PUNCT
chd-169	469	43	jr	jr	PROPN
chd-169	469	44	.	.	PROPN
chd-169	469	45	,	,	PUNCT
chd-169	469	46	saad	saad	PROPN
chd-169	469	47	,	,	PUNCT
chd-169	469	48	f.	f.	PROPN
chd-169	469	49	,	,	PUNCT
chd-169	469	50	et	et	PROPN
chd-169	469	51	al	al	PROPN
chd-169	469	52	.	.	PUNCT
chd-169	470	1	(	(	PUNCT
chd-169	470	2	2011	2011	NUM
chd-169	470	3	)	)	PUNCT
chd-169	470	4	.	.	PUNCT
chd-169	471	1	abiraterone	abiraterone	NOUN
chd-169	471	2	and	and	CCONJ
chd-169	471	3	increased	increase	VERB
chd-169	471	4	survival	survival	NOUN
chd-169	471	5	in	in	ADP
chd-169	471	6	metastatic	metastatic	ADJ
chd-169	471	7	prostate	prostate	NOUN
chd-169	471	8	cancer	cancer	NOUN
chd-169	471	9	.	.	PUNCT
chd-169	472	1	n	n	PROPN
chd-169	472	2	engl	engl	PROPN
chd-169	472	3	j	j	PROPN
chd-169	472	4	med	med	PROPN
chd-169	472	5	364	364	NUM
chd-169	472	6	,	,	PUNCT
chd-169	472	7	1995	1995	NUM
chd-169	472	8	-	-	SYM
chd-169	472	9	2005	2005	NUM
chd-169	472	10	.	.	PUNCT
chd-169	473	1	de	de	X
chd-169	473	2	bono	bono	X
chd-169	473	3	,	,	PUNCT
chd-169	473	4	j.s	j.s	PROPN
chd-169	473	5	.	.	PROPN
chd-169	473	6	,	,	PUNCT
chd-169	473	7	oudard	oudard	ADJ
chd-169	473	8	,	,	PUNCT
chd-169	473	9	s.	s.	PROPN
chd-169	473	10	,	,	PUNCT
chd-169	473	11	ozguroglu	ozguroglu	PROPN
chd-169	473	12	,	,	PUNCT
chd-169	473	13	m.	m.	NOUN
chd-169	473	14	,	,	PUNCT
chd-169	473	15	hansen	hansen	PROPN
chd-169	473	16	,	,	PUNCT
chd-169	473	17	s.	s.	PROPN
chd-169	473	18	,	,	PUNCT
chd-169	473	19	machiels	machiels	PROPN
chd-169	473	20	,	,	PUNCT
chd-169	473	21	j.p	j.p	PROPN
chd-169	473	22	.	.	PROPN
chd-169	473	23	,	,	PUNCT
chd-169	473	24	kocak	kocak	PROPN
chd-169	473	25	,	,	PUNCT
chd-169	473	26	i.	i.	NOUN
chd-169	473	27	,	,	PUNCT
chd-169	473	28	gravis	gravis	PROPN
chd-169	473	29	,	,	PUNCT
chd-169	473	30	g.	g.	PROPN
chd-169	473	31	,	,	PUNCT
chd-169	473	32	bodrogi	bodrogi	PROPN
chd-169	473	33	,	,	PUNCT
chd-169	473	34	i.	i.	PROPN
chd-169	473	35	,	,	PUNCT
chd-169	473	36	mackenzie	mackenzie	PROPN
chd-169	473	37	,	,	PUNCT
chd-169	473	38	m.j	m.j	PROPN
chd-169	473	39	.	.	PROPN
chd-169	473	40	,	,	PUNCT
chd-169	473	41	shen	shen	PROPN
chd-169	473	42	,	,	PUNCT
chd-169	473	43	l.	l.	PROPN
chd-169	473	44	,	,	PUNCT
chd-169	473	45	et	et	PROPN
chd-169	473	46	al	al	PROPN
chd-169	473	47	.	.	PUNCT
chd-169	474	1	(	(	PUNCT
chd-169	474	2	2010	2010	NUM
chd-169	474	3	)	)	PUNCT
chd-169	474	4	.	.	PUNCT
chd-169	475	1	prednisone	prednisone	PROPN
chd-169	475	2	plus	plus	CCONJ
chd-169	475	3	cabazitaxel	cabazitaxel	PROPN
chd-169	475	4	or	or	CCONJ
chd-169	475	5	mitoxantrone	mitoxantrone	NOUN
chd-169	475	6	for	for	ADP
chd-169	475	7	metastatic	metastatic	ADJ
chd-169	475	8	castration	castration	NOUN
chd-169	475	9	-	-	PUNCT
chd-169	475	10	resistant	resistant	ADJ
chd-169	475	11	prostate	prostate	NOUN
chd-169	475	12	cancer	cancer	NOUN
chd-169	475	13	progressing	progressing	NOUN
chd-169	475	14	after	after	ADP
chd-169	475	15	docetaxel	docetaxel	NOUN
chd-169	475	16	treatment	treatment	NOUN
chd-169	475	17	:	:	PUNCT
chd-169	475	18	a	a	DET
chd-169	475	19	randomised	randomise	VERB
chd-169	475	20	open	open	ADJ
chd-169	475	21	-	-	PUNCT
chd-169	475	22	label	label	NOUN
chd-169	475	23	trial	trial	NOUN
chd-169	475	24	.	.	PUNCT
chd-169	476	1	lancet	lancet	PROPN
chd-169	476	2	376	376	NUM
chd-169	476	3	,	,	PUNCT
chd-169	476	4	1147	1147	NUM
chd-169	476	5	-	-	SYM
chd-169	476	6	1154	1154	NUM
chd-169	476	7	.	.	PUNCT
chd-169	477	1	de	de	PROPN
chd-169	477	2	bosscher	bosscher	PROPN
chd-169	477	3	,	,	PUNCT
chd-169	477	4	k.	k.	PROPN
chd-169	477	5	,	,	PUNCT
chd-169	477	6	beck	beck	PROPN
chd-169	477	7	,	,	PUNCT
chd-169	477	8	i.m	i.m	PROPN
chd-169	477	9	.	.	PROPN
chd-169	477	10	,	,	PUNCT
chd-169	477	11	ratman	ratman	PROPN
chd-169	477	12	,	,	PUNCT
chd-169	477	13	d.	d.	PROPN
chd-169	477	14	,	,	PUNCT
chd-169	477	15	berghe	berghe	PROPN
chd-169	477	16	,	,	PUNCT
chd-169	477	17	w.v	w.v	PROPN
chd-169	477	18	.	.	PROPN
chd-169	477	19	,	,	PUNCT
chd-169	477	20	and	and	CCONJ
chd-169	477	21	libert	libert	NOUN
chd-169	477	22	,	,	PUNCT
chd-169	477	23	c.	c.	PROPN
chd-169	477	24	(	(	PUNCT
chd-169	477	25	2016	2016	NUM
chd-169	477	26	)	)	PUNCT
chd-169	477	27	.	.	PUNCT
chd-169	478	1	activation	activation	NOUN
chd-169	478	2	of	of	ADP
chd-169	478	3	the	the	DET
chd-169	478	4	glucocorticoid	glucocorticoid	ADJ
chd-169	478	5	receptor	receptor	NOUN
chd-169	478	6	in	in	ADP
chd-169	478	7	acute	acute	ADJ
chd-169	478	8	inflammation	inflammation	NOUN
chd-169	478	9	:	:	PUNCT
chd-169	478	10	the	the	DET
chd-169	478	11	sedigram	sedigram	NOUN
chd-169	478	12	concept	concept	NOUN
chd-169	478	13	.	.	PUNCT
chd-169	479	1	trends	trend	NOUN
chd-169	479	2	pharmacol	pharmacol	VERB
chd-169	479	3	sci	sci	PROPN
chd-169	479	4	37	37	NUM
chd-169	479	5	,	,	PUNCT
chd-169	479	6	4	4	NUM
chd-169	479	7	-	-	SYM
chd-169	479	8	16	16	NUM
chd-169	479	9	.	.	PUNCT
chd-169	480	1	derouen	derouen	PROPN
chd-169	480	2	,	,	PUNCT
chd-169	480	3	m.c	m.c	PROPN
chd-169	480	4	.	.	PROPN
chd-169	480	5	,	,	PUNCT
chd-169	480	6	schupp	schupp	PROPN
chd-169	480	7	,	,	PUNCT
chd-169	480	8	c.w	c.w	PROPN
chd-169	480	9	.	.	PROPN
chd-169	480	10	,	,	PUNCT
chd-169	480	11	koo	koo	PROPN
chd-169	480	12	,	,	PUNCT
chd-169	480	13	j.	j.	PROPN
chd-169	480	14	,	,	PUNCT
chd-169	480	15	yang	yang	PROPN
chd-169	480	16	,	,	PUNCT
chd-169	480	17	j.	j.	PROPN
chd-169	480	18	,	,	PUNCT
chd-169	480	19	hertz	hertz	NOUN
chd-169	480	20	,	,	PUNCT
chd-169	480	21	a.	a.	NOUN
chd-169	480	22	,	,	PUNCT
chd-169	480	23	shariff	shariff	PROPN
chd-169	480	24	-	-	PUNCT
chd-169	480	25	marco	marco	PROPN
chd-169	480	26	,	,	PUNCT
chd-169	480	27	s.	s.	PROPN
chd-169	480	28	,	,	PUNCT
chd-169	480	29	cockburn	cockburn	NOUN
chd-169	480	30	,	,	PUNCT
chd-169	480	31	m.	m.	NOUN
chd-169	480	32	,	,	PUNCT
chd-169	480	33	nelson	nelson	PROPN
chd-169	480	34	,	,	PUNCT
chd-169	480	35	d.o	d.o	PROPN
chd-169	480	36	.	.	PROPN
chd-169	480	37	,	,	PUNCT
chd-169	480	38	ingles	ingles	PROPN
chd-169	480	39	,	,	PUNCT
chd-169	480	40	s.a	s.a	PROPN
chd-169	480	41	.	.	PROPN
chd-169	480	42	,	,	PUNCT
chd-169	480	43	john	john	PROPN
chd-169	480	44	,	,	PUNCT
chd-169	480	45	e.m	e.m	PROPN
chd-169	480	46	.	.	PROPN
chd-169	480	47	,	,	PUNCT
chd-169	480	48	et	et	PROPN
chd-169	480	49	al	al	PROPN
chd-169	480	50	.	.	PUNCT
chd-169	480	51	(	(	PUNCT
chd-169	480	52	2018	2018	NUM
chd-169	480	53	)	)	PUNCT
chd-169	480	54	.	.	PUNCT
chd-169	481	1	impact	impact	NOUN
chd-169	481	2	of	of	ADP
chd-169	481	3	individual	individual	ADJ
chd-169	481	4	and	and	CCONJ
chd-169	481	5	neighborhood	neighborhood	NOUN
chd-169	481	6	factors	factor	NOUN
chd-169	481	7	on	on	ADP
chd-169	481	8	disparities	disparity	NOUN
chd-169	481	9	in	in	ADP
chd-169	481	10	prostate	prostate	NOUN
chd-169	481	11	cancer	cancer	NOUN
chd-169	481	12	survival	survival	NOUN
chd-169	481	13	.	.	PUNCT
chd-169	482	1	cancer	cancer	NOUN
chd-169	482	2	epidemiol	epidemiol	PROPN
chd-169	482	3	53	53	NUM
chd-169	482	4	,	,	PUNCT
chd-169	482	5	1	1	NUM
chd-169	482	6	-	-	SYM
chd-169	482	7	11	11	NUM
chd-169	482	8	.	.	PUNCT
chd-169	483	1	desantis	desantis	PROPN
chd-169	483	2	,	,	PUNCT
chd-169	483	3	c.e	c.e	PROPN
chd-169	483	4	.	.	PROPN
chd-169	483	5	,	,	PUNCT
chd-169	483	6	miller	miller	PROPN
chd-169	483	7	,	,	PUNCT
chd-169	483	8	k.d	k.d	PROPN
chd-169	483	9	.	.	PROPN
chd-169	483	10	,	,	PUNCT
chd-169	483	11	goding	gode	VERB
chd-169	483	12	sauer	sauer	NOUN
chd-169	483	13	,	,	PUNCT
chd-169	483	14	a.	a.	NOUN
chd-169	483	15	,	,	PUNCT
chd-169	483	16	jemal	jemal	ADJ
chd-169	483	17	,	,	PUNCT
chd-169	483	18	a.	a.	NOUN
chd-169	483	19	,	,	PUNCT
chd-169	483	20	and	and	CCONJ
chd-169	483	21	siegel	siegel	PROPN
chd-169	483	22	,	,	PUNCT
chd-169	483	23	r.l	r.l	PROPN
chd-169	483	24	.	.	PROPN
chd-169	483	25	(	(	PUNCT
chd-169	483	26	2019	2019	NUM
chd-169	483	27	)	)	PUNCT
chd-169	483	28	.	.	PUNCT
chd-169	484	1	cancer	cancer	NOUN
chd-169	484	2	statistics	statistic	NOUN
chd-169	484	3	for	for	ADP
chd-169	484	4	african	african	ADJ
chd-169	484	5	americans	americans	PROPN
chd-169	484	6	,	,	PUNCT
chd-169	484	7	2019	2019	NUM
chd-169	484	8	.	.	PUNCT
chd-169	485	1	ca	can	AUX
chd-169	485	2	cancer	cancer	PROPN
chd-169	485	3	j	j	PROPN
chd-169	485	4	clin	clin	PROPN
chd-169	485	5	69	69	NUM
chd-169	485	6	,	,	PUNCT
chd-169	485	7	211	211	NUM
chd-169	485	8	-	-	SYM
chd-169	485	9	233	233	NUM
chd-169	485	10	.	.	PUNCT
chd-169	486	1	desantis	desantis	PROPN
chd-169	486	2	,	,	PUNCT
chd-169	486	3	c.e	c.e	PROPN
chd-169	486	4	.	.	PROPN
chd-169	486	5	,	,	PUNCT
chd-169	486	6	siegel	siegel	PROPN
chd-169	486	7	,	,	PUNCT
chd-169	486	8	r.l	r.l	PROPN
chd-169	486	9	.	.	PROPN
chd-169	486	10	,	,	PUNCT
chd-169	486	11	sauer	sauer	PROPN
chd-169	486	12	,	,	PUNCT
chd-169	486	13	a.g	a.g	PROPN
chd-169	486	14	.	.	PROPN
chd-169	486	15	,	,	PUNCT
chd-169	486	16	miller	miller	PROPN
chd-169	486	17	,	,	PUNCT
chd-169	486	18	k.d	k.d	PROPN
chd-169	486	19	.	.	PROPN
chd-169	486	20	,	,	PUNCT
chd-169	486	21	fedewa	fedewa	PROPN
chd-169	486	22	,	,	PUNCT
chd-169	486	23	s.a	s.a	PROPN
chd-169	486	24	.	.	PROPN
chd-169	486	25	,	,	PUNCT
chd-169	486	26	alcaraz	alcaraz	NOUN
chd-169	486	27	,	,	PUNCT
chd-169	486	28	k.i	k.i	PROPN
chd-169	486	29	.	.	PROPN
chd-169	486	30	,	,	PUNCT
chd-169	486	31	and	and	CCONJ
chd-169	486	32	jemal	jemal	ADJ
chd-169	486	33	,	,	PUNCT
chd-169	486	34	a.	a.	NOUN
chd-169	486	35	(	(	PUNCT
chd-169	486	36	2016	2016	NUM
chd-169	486	37	)	)	PUNCT
chd-169	486	38	.	.	PUNCT
chd-169	487	1	cancer	cancer	NOUN
chd-169	487	2	statistics	statistic	NOUN
chd-169	487	3	for	for	ADP
chd-169	487	4	african	african	ADJ
chd-169	487	5	americans	americans	PROPN
chd-169	487	6	,	,	PUNCT
chd-169	487	7	2016	2016	NUM
chd-169	487	8	:	:	PUNCT
chd-169	487	9	progress	progress	NOUN
chd-169	487	10	and	and	CCONJ
chd-169	487	11	opportunities	opportunity	NOUN
chd-169	487	12	in	in	ADP
chd-169	487	13	reducing	reduce	VERB
chd-169	487	14	racial	racial	ADJ
chd-169	487	15	disparities	disparity	NOUN
chd-169	487	16	.	.	PUNCT
chd-169	488	1	ca	can	AUX
chd-169	488	2	cancer	cancer	PROPN
chd-169	488	3	j	j	PROPN
chd-169	488	4	clin	clin	PROPN
chd-169	488	5	66	66	NUM
chd-169	488	6	,	,	PUNCT
chd-169	488	7	290308	290308	NUM
chd-169	488	8	.	.	PUNCT
chd-169	489	1	deshmukh	deshmukh	PROPN
chd-169	489	2	,	,	PUNCT
chd-169	489	3	s.k	s.k	PROPN
chd-169	489	4	.	.	PROPN
chd-169	489	5	,	,	PUNCT
chd-169	489	6	azim	azim	PROPN
chd-169	489	7	,	,	PUNCT
chd-169	489	8	s.	s.	PROPN
chd-169	489	9	,	,	PUNCT
chd-169	489	10	ahmad	ahmad	PROPN
chd-169	489	11	,	,	PUNCT
chd-169	489	12	a.	a.	PROPN
chd-169	489	13	,	,	PUNCT
chd-169	489	14	zubair	zubair	PROPN
chd-169	489	15	,	,	PUNCT
chd-169	489	16	h.	h.	PROPN
chd-169	489	17	,	,	PUNCT
chd-169	489	18	tyagi	tyagi	PROPN
chd-169	489	19	,	,	PUNCT
chd-169	489	20	n.	n.	PROPN
chd-169	489	21	,	,	PUNCT
chd-169	489	22	srivastava	srivastava	PROPN
chd-169	489	23	,	,	PUNCT
chd-169	489	24	s.k	s.k	PROPN
chd-169	489	25	.	.	PROPN
chd-169	489	26	,	,	PUNCT
chd-169	489	27	bhardwaj	bhardwaj	PROPN
chd-169	489	28	,	,	PUNCT
chd-169	489	29	a.	a.	PROPN
chd-169	489	30	,	,	PUNCT
chd-169	489	31	singh	singh	PROPN
chd-169	489	32	,	,	PUNCT
chd-169	489	33	s.	s.	PROPN
chd-169	489	34	,	,	PUNCT
chd-169	489	35	rocconi	rocconi	PROPN
chd-169	489	36	,	,	PUNCT
chd-169	489	37	r.p	r.p	PROPN
chd-169	489	38	.	.	PROPN
chd-169	489	39	,	,	PUNCT
chd-169	489	40	and	and	CCONJ
chd-169	489	41	singh	singh	PROPN
chd-169	489	42	,	,	PUNCT
chd-169	489	43	a.p	a.p	PROPN
chd-169	489	44	.	.	PROPN
chd-169	489	45	(	(	PUNCT
chd-169	489	46	2017	2017	NUM
chd-169	489	47	)	)	PUNCT
chd-169	489	48	.	.	PUNCT
chd-169	490	1	biological	biological	ADJ
chd-169	490	2	basis	basis	NOUN
chd-169	490	3	of	of	ADP
chd-169	490	4	cancer	cancer	NOUN
chd-169	490	5	health	health	NOUN
chd-169	490	6	disparities	disparity	NOUN
chd-169	490	7	:	:	PUNCT
chd-169	490	8	resources	resource	NOUN
chd-169	490	9	and	and	CCONJ
chd-169	490	10	challenges	challenge	NOUN
chd-169	490	11	for	for	ADP
chd-169	490	12	research	research	NOUN
chd-169	490	13	.	.	PUNCT
chd-169	491	1	am	be	AUX
chd-169	491	2	j	j	PROPN
chd-169	491	3	cancer	cancer	NOUN
chd-169	491	4	res	re	NOUN
chd-169	491	5	7	7	NUM
chd-169	491	6	,	,	PUNCT
chd-169	491	7	1	1	NUM
chd-169	491	8	-	-	SYM
chd-169	491	9	12	12	NUM
chd-169	491	10	.	.	PUNCT
chd-169	492	1	djeu	djeu	NOUN
chd-169	492	2	,	,	PUNCT
chd-169	492	3	j.y	j.y	PROPN
chd-169	492	4	.	.	PROPN
chd-169	492	5	,	,	PUNCT
chd-169	492	6	and	and	CCONJ
chd-169	492	7	wei	wei	PROPN
chd-169	492	8	,	,	PUNCT
chd-169	492	9	s.	s.	PROPN
chd-169	492	10	(	(	PUNCT
chd-169	492	11	2009	2009	NUM
chd-169	492	12	)	)	PUNCT
chd-169	492	13	.	.	PUNCT
chd-169	493	1	clusterin	clusterin	NOUN
chd-169	493	2	and	and	CCONJ
chd-169	493	3	chemoresistance	chemoresistance	NOUN
chd-169	493	4	.	.	PUNCT
chd-169	494	1	adv	adv	PROPN
chd-169	494	2	cancer	cancer	NOUN
chd-169	494	3	res	re	NOUN
chd-169	494	4	105	105	NUM
chd-169	494	5	,	,	PUNCT
chd-169	494	6	77	77	NUM
chd-169	494	7	-	-	SYM
chd-169	494	8	92	92	NUM
chd-169	494	9	.	.	PUNCT
chd-169	495	1	dorff	dorff	PROPN
chd-169	495	2	,	,	PUNCT
chd-169	495	3	t.b	t.b	PROPN
chd-169	495	4	.	.	PROPN
chd-169	495	5	,	,	PUNCT
chd-169	495	6	and	and	CCONJ
chd-169	495	7	crawford	crawford	PROPN
chd-169	495	8	,	,	PUNCT
chd-169	495	9	e.d	e.d	PROPN
chd-169	495	10	.	.	PROPN
chd-169	495	11	(	(	PUNCT
chd-169	495	12	2013	2013	NUM
chd-169	495	13	)	)	PUNCT
chd-169	495	14	.	.	PUNCT
chd-169	496	1	management	management	NOUN
chd-169	496	2	and	and	CCONJ
chd-169	496	3	challenges	challenge	NOUN
chd-169	496	4	of	of	ADP
chd-169	496	5	corticosteroid	corticosteroid	ADJ
chd-169	496	6	therapy	therapy	NOUN
chd-169	496	7	in	in	ADP
chd-169	496	8	men	man	NOUN
chd-169	496	9	with	with	ADP
chd-169	496	10	metastatic	metastatic	ADJ
chd-169	496	11	castrate	castrate	NOUN
chd-169	496	12	-	-	PUNCT
chd-169	496	13	resistant	resistant	ADJ
chd-169	496	14	prostate	prostate	NOUN
chd-169	496	15	cancer	cancer	NOUN
chd-169	496	16	.	.	PUNCT
chd-169	497	1	ann	ann	PROPN
chd-169	497	2	oncol	oncol	PROPN
chd-169	497	3	24	24	NUM
chd-169	497	4	,	,	PUNCT
chd-169	497	5	31	31	NUM
chd-169	497	6	-	-	SYM
chd-169	497	7	38	38	NUM
chd-169	497	8	.	.	PUNCT
chd-169	498	1	du	du	PROPN
chd-169	498	2	,	,	PUNCT
chd-169	498	3	x.l	x.l	PROPN
chd-169	498	4	.	.	PROPN
chd-169	498	5	,	,	PUNCT
chd-169	498	6	lin	lin	PROPN
chd-169	498	7	,	,	PUNCT
chd-169	498	8	c.c	c.c	PROPN
chd-169	498	9	.	.	PROPN
chd-169	498	10	,	,	PUNCT
chd-169	498	11	johnson	johnson	PROPN
chd-169	498	12	,	,	PUNCT
chd-169	498	13	n.j	n.j	PROPN
chd-169	498	14	.	.	PROPN
chd-169	498	15	,	,	PUNCT
chd-169	498	16	and	and	CCONJ
chd-169	498	17	altekruse	altekruse	PROPN
chd-169	498	18	,	,	PUNCT
chd-169	498	19	s.	s.	PROPN
chd-169	498	20	(	(	PUNCT
chd-169	498	21	2011	2011	NUM
chd-169	498	22	)	)	PUNCT
chd-169	498	23	.	.	PUNCT
chd-169	499	1	effects	effect	NOUN
chd-169	499	2	of	of	ADP
chd-169	499	3	individual	individual	ADJ
chd-169	499	4	-	-	PUNCT
chd-169	499	5	level	level	NOUN
chd-169	499	6	socioeconomic	socioeconomic	ADJ
chd-169	499	7	factors	factor	NOUN
chd-169	499	8	on	on	ADP
chd-169	499	9	racial	racial	ADJ
chd-169	499	10	disparities	disparity	NOUN
chd-169	499	11	in	in	ADP
chd-169	499	12	cancer	cancer	NOUN
chd-169	499	13	treatment	treatment	NOUN
chd-169	499	14	and	and	CCONJ
chd-169	499	15	survival	survival	NOUN
chd-169	499	16	:	:	PUNCT
chd-169	499	17	findings	finding	NOUN
chd-169	499	18	from	from	ADP
chd-169	499	19	the	the	DET
chd-169	499	20	national	national	ADJ
chd-169	499	21	longitudinal	longitudinal	ADJ
chd-169	499	22	mortality	mortality	NOUN
chd-169	499	23	study	study	NOUN
chd-169	499	24	,	,	PUNCT
chd-169	499	25	1979	1979	NUM
chd-169	499	26	-	-	SYM
chd-169	499	27	2003	2003	NUM
chd-169	499	28	.	.	PUNCT
chd-169	500	1	cancer	cancer	NOUN
chd-169	500	2	117	117	NUM
chd-169	500	3	,	,	PUNCT
chd-169	500	4	3242	3242	NUM
chd-169	500	5	-	-	SYM
chd-169	500	6	3251	3251	NUM
chd-169	500	7	.	.	PUNCT
chd-169	501	1	dubrovska	dubrovska	NOUN
chd-169	501	2	,	,	PUNCT
chd-169	501	3	a.	a.	PROPN
chd-169	501	4	,	,	PUNCT
chd-169	501	5	elliott	elliott	PROPN
chd-169	501	6	,	,	PUNCT
chd-169	501	7	j.	j.	PROPN
chd-169	501	8	,	,	PUNCT
chd-169	501	9	salamone	salamone	NOUN
chd-169	501	10	,	,	PUNCT
chd-169	501	11	r.j	r.j	PROPN
chd-169	501	12	.	.	PROPN
chd-169	501	13	,	,	PUNCT
chd-169	501	14	telegeev	telegeev	PROPN
chd-169	501	15	,	,	PUNCT
chd-169	501	16	g.d	g.d	PROPN
chd-169	501	17	.	.	PROPN
chd-169	501	18	,	,	PUNCT
chd-169	501	19	stakhovsky	stakhovsky	PROPN
chd-169	501	20	,	,	PUNCT
chd-169	501	21	a.e	a.e	PROPN
chd-169	501	22	.	.	PROPN
chd-169	501	23	,	,	PUNCT
chd-169	501	24	schepotin	schepotin	PROPN
chd-169	501	25	,	,	PUNCT
chd-169	501	26	i.b	i.b	PROPN
chd-169	501	27	.	.	PROPN
chd-169	501	28	,	,	PUNCT
chd-169	501	29	yan	yan	PROPN
chd-169	501	30	,	,	PUNCT
chd-169	501	31	f.	f.	PROPN
chd-169	501	32	,	,	PUNCT
chd-169	501	33	wang	wang	PROPN
chd-169	501	34	,	,	PUNCT
chd-169	501	35	y.	y.	PROPN
chd-169	501	36	,	,	PUNCT
chd-169	501	37	bouchez	bouchez	PROPN
chd-169	501	38	,	,	PUNCT
chd-169	501	39	l.c	l.c	PROPN
chd-169	501	40	.	.	PROPN
chd-169	501	41	,	,	PUNCT
chd-169	501	42	kularatne	kularatne	PROPN
chd-169	501	43	,	,	PUNCT
chd-169	501	44	s.a	s.a	PROPN
chd-169	501	45	.	.	PROPN
chd-169	501	46	,	,	PUNCT
chd-169	501	47	et	et	PROPN
chd-169	501	48	al	al	PROPN
chd-169	501	49	.	.	PUNCT
chd-169	501	50	(	(	PUNCT
chd-169	501	51	2012	2012	NUM
chd-169	501	52	)	)	PUNCT
chd-169	501	53	.	.	PUNCT
chd-169	502	1	cxcr4	cxcr4	NOUN
chd-169	502	2	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-169	502	3	e23	e23	NOUN
chd-169	502	4	cancer	cancer	NOUN
chd-169	502	5	health	health	NOUN
chd-169	502	6	disparities	disparity	NOUN
chd-169	502	7	research	research	NOUN
chd-169	502	8	expression	expression	NOUN
chd-169	502	9	in	in	ADP
chd-169	502	10	prostate	prostate	NOUN
chd-169	502	11	cancer	cancer	NOUN
chd-169	502	12	progenitor	progenitor	NOUN
chd-169	502	13	cells	cell	NOUN
chd-169	502	14	.	.	PUNCT
chd-169	503	1	plos	plos	PROPN
chd-169	503	2	one	one	NUM
chd-169	503	3	7	7	NUM
chd-169	503	4	,	,	PUNCT
chd-169	503	5	e31226	e31226	PROPN
chd-169	503	6	.	.	PUNCT
chd-169	503	7	farmer	farmer	PROPN
chd-169	503	8	,	,	PUNCT
chd-169	503	9	m.m	m.m	PROPN
chd-169	503	10	.	.	PROPN
chd-169	503	11	,	,	PUNCT
chd-169	503	12	and	and	CCONJ
chd-169	503	13	ferraro	ferraro	PROPN
chd-169	503	14	,	,	PUNCT
chd-169	503	15	k.f	k.f	PROPN
chd-169	503	16	.	.	PROPN
chd-169	503	17	(	(	PUNCT
chd-169	503	18	2005	2005	NUM
chd-169	503	19	)	)	PUNCT
chd-169	503	20	.	.	PUNCT
chd-169	504	1	are	be	AUX
chd-169	504	2	racial	racial	ADJ
chd-169	504	3	disparities	disparity	NOUN
chd-169	504	4	in	in	ADP
chd-169	504	5	health	health	NOUN
chd-169	504	6	conditional	conditional	NOUN
chd-169	504	7	on	on	ADP
chd-169	504	8	socioeconomic	socioeconomic	ADJ
chd-169	504	9	status	status	NOUN
chd-169	504	10	?	?	PUNCT
chd-169	505	1	soc	soc	PROPN
chd-169	505	2	sci	sci	PROPN
chd-169	505	3	med	med	PROPN
chd-169	505	4	60	60	NUM
chd-169	505	5	,	,	PUNCT
chd-169	505	6	191	191	NUM
chd-169	505	7	-	-	SYM
chd-169	505	8	204	204	NUM
chd-169	505	9	.	.	PUNCT
chd-169	506	1	feldman	feldman	PROPN
chd-169	506	2	,	,	PUNCT
chd-169	506	3	b.j	b.j	PROPN
chd-169	506	4	.	.	PROPN
chd-169	506	5	,	,	PUNCT
chd-169	506	6	and	and	CCONJ
chd-169	506	7	feldman	feldman	PROPN
chd-169	506	8	,	,	PUNCT
chd-169	506	9	d.	d.	PROPN
chd-169	506	10	(	(	PUNCT
chd-169	506	11	2001	2001	NUM
chd-169	506	12	)	)	PUNCT
chd-169	506	13	.	.	PUNCT
chd-169	507	1	the	the	DET
chd-169	507	2	development	development	NOUN
chd-169	507	3	of	of	ADP
chd-169	507	4	androgen	androgen	NOUN
chd-169	507	5	-	-	PUNCT
chd-169	507	6	independent	independent	ADJ
chd-169	507	7	prostate	prostate	NOUN
chd-169	507	8	cancer	cancer	NOUN
chd-169	507	9	.	.	PUNCT
chd-169	508	1	nat	nat	PROPN
chd-169	508	2	rev	rev	VERB
chd-169	508	3	cancer	cancer	NOUN
chd-169	508	4	1	1	NUM
chd-169	508	5	,	,	PUNCT
chd-169	508	6	34	34	NUM
chd-169	508	7	-	-	SYM
chd-169	508	8	45	45	NUM
chd-169	508	9	.	.	PUNCT
chd-169	509	1	finley	finley	PROPN
chd-169	509	2	,	,	PUNCT
chd-169	509	3	d.s	d.s	PROPN
chd-169	509	4	.	.	PROPN
chd-169	509	5	,	,	PUNCT
chd-169	509	6	calvert	calvert	PROPN
chd-169	509	7	,	,	PUNCT
chd-169	509	8	v.s.	v.s.	ADJ
chd-169	509	9	,	,	PUNCT
chd-169	509	10	inokuchi	inokuchi	PROPN
chd-169	509	11	,	,	PUNCT
chd-169	509	12	j.	j.	PROPN
chd-169	509	13	,	,	PUNCT
chd-169	509	14	lau	lau	PROPN
chd-169	509	15	,	,	PUNCT
chd-169	509	16	a.	a.	PROPN
chd-169	509	17	,	,	PUNCT
chd-169	509	18	narula	narula	NOUN
chd-169	509	19	,	,	PUNCT
chd-169	509	20	n.	n.	NOUN
chd-169	509	21	,	,	PUNCT
chd-169	509	22	petricoin	petricoin	PROPN
chd-169	509	23	,	,	PUNCT
chd-169	509	24	e.f	e.f	PROPN
chd-169	509	25	.	.	PROPN
chd-169	509	26	,	,	PUNCT
chd-169	509	27	zaldivar	zaldivar	PROPN
chd-169	509	28	,	,	PUNCT
chd-169	509	29	f.	f.	PROPN
chd-169	509	30	,	,	PUNCT
chd-169	509	31	santos	santos	PROPN
chd-169	509	32	,	,	PUNCT
chd-169	509	33	r.	r.	PROPN
chd-169	509	34	,	,	PUNCT
chd-169	509	35	tyson	tyson	PROPN
chd-169	509	36	,	,	PUNCT
chd-169	509	37	d.r	d.r	PROPN
chd-169	509	38	.	.	PROPN
chd-169	509	39	,	,	PUNCT
chd-169	509	40	and	and	CCONJ
chd-169	509	41	ornstein	ornstein	PROPN
chd-169	509	42	,	,	PUNCT
chd-169	509	43	d.k	d.k	PROPN
chd-169	509	44	.	.	PROPN
chd-169	509	45	(	(	PUNCT
chd-169	509	46	2009	2009	NUM
chd-169	509	47	)	)	PUNCT
chd-169	509	48	.	.	PUNCT
chd-169	510	1	periprostatic	periprostatic	ADJ
chd-169	510	2	adipose	adipose	ADJ
chd-169	510	3	tissue	tissue	NOUN
chd-169	510	4	as	as	ADP
chd-169	510	5	a	a	DET
chd-169	510	6	modulator	modulator	NOUN
chd-169	510	7	of	of	ADP
chd-169	510	8	prostate	prostate	NOUN
chd-169	510	9	cancer	cancer	NOUN
chd-169	510	10	aggressiveness	aggressiveness	NOUN
chd-169	510	11	.	.	PUNCT
chd-169	511	1	j	j	PROPN
chd-169	511	2	urol	urol	PROPN
chd-169	511	3	182	182	NUM
chd-169	511	4	,	,	PUNCT
chd-169	511	5	1621	1621	NUM
chd-169	511	6	-	-	SYM
chd-169	511	7	1627	1627	NUM
chd-169	511	8	.	.	PUNCT
chd-169	512	1	frank	frank	PROPN
chd-169	512	2	,	,	PUNCT
chd-169	512	3	s.	s.	PROPN
chd-169	512	4	,	,	PUNCT
chd-169	512	5	nelson	nelson	PROPN
chd-169	512	6	,	,	PUNCT
chd-169	512	7	p.	p.	PROPN
chd-169	512	8	,	,	PUNCT
chd-169	512	9	and	and	CCONJ
chd-169	512	10	vasioukhin	vasioukhin	ADV
chd-169	512	11	,	,	PUNCT
chd-169	512	12	v.	v.	PROPN
chd-169	512	13	(	(	PUNCT
chd-169	512	14	2018	2018	NUM
chd-169	512	15	)	)	PUNCT
chd-169	512	16	.	.	PUNCT
chd-169	513	1	recent	recent	ADJ
chd-169	513	2	advances	advance	NOUN
chd-169	513	3	in	in	ADP
chd-169	513	4	prostate	prostate	NOUN
chd-169	513	5	cancer	cancer	NOUN
chd-169	513	6	research	research	NOUN
chd-169	513	7	:	:	PUNCT
chd-169	513	8	large	large	ADJ
chd-169	513	9	-	-	PUNCT
chd-169	513	10	scale	scale	NOUN
chd-169	513	11	genomic	genomic	NOUN
chd-169	513	12	analyses	analysis	NOUN
chd-169	513	13	reveal	reveal	VERB
chd-169	513	14	novel	novel	ADJ
chd-169	513	15	driver	driver	NOUN
chd-169	513	16	mutations	mutation	NOUN
chd-169	513	17	and	and	CCONJ
chd-169	513	18	dna	dna	PROPN
chd-169	513	19	repair	repair	NOUN
chd-169	513	20	defects	defect	NOUN
chd-169	513	21	.	.	PUNCT
chd-169	514	1	f1000res	f1000res	ADP
chd-169	514	2	7	7	NUM
chd-169	514	3	.	.	PUNCT
chd-169	514	4	frazier	frazier	PROPN
chd-169	514	5	,	,	PUNCT
chd-169	514	6	b.	b.	PROPN
chd-169	514	7	,	,	PUNCT
chd-169	514	8	hsiao	hsiao	PROPN
chd-169	514	9	,	,	PUNCT
chd-169	514	10	c.w	c.w	PROPN
chd-169	514	11	.	.	PROPN
chd-169	514	12	,	,	PUNCT
chd-169	514	13	deuster	deuster	PROPN
chd-169	514	14	,	,	PUNCT
chd-169	514	15	p.	p.	NOUN
chd-169	514	16	,	,	PUNCT
chd-169	514	17	and	and	CCONJ
chd-169	514	18	poth	poth	NOUN
chd-169	514	19	,	,	PUNCT
chd-169	514	20	m.	m.	NOUN
chd-169	514	21	(	(	PUNCT
chd-169	514	22	2010	2010	NUM
chd-169	514	23	)	)	PUNCT
chd-169	514	24	.	.	PUNCT
chd-169	515	1	african	african	ADJ
chd-169	515	2	americans	americans	PROPN
chd-169	515	3	and	and	CCONJ
chd-169	515	4	caucasian	caucasian	ADJ
chd-169	515	5	americans	americans	PROPN
chd-169	515	6	:	:	PUNCT
chd-169	515	7	differences	difference	NOUN
chd-169	515	8	in	in	ADP
chd-169	515	9	glucocorticoid	glucocorticoid	NOUN
chd-169	515	10	-	-	PUNCT
chd-169	515	11	induced	induce	VERB
chd-169	515	12	insulin	insulin	NOUN
chd-169	515	13	resistance	resistance	NOUN
chd-169	515	14	.	.	PUNCT
chd-169	516	1	horm	horm	PROPN
chd-169	516	2	metab	metab	PROPN
chd-169	516	3	res	re	NOUN
chd-169	516	4	42	42	NUM
chd-169	516	5	,	,	PUNCT
chd-169	516	6	887	887	NUM
chd-169	516	7	-	-	SYM
chd-169	516	8	891	891	NUM
chd-169	516	9	.	.	PUNCT
chd-169	517	1	gaston	gaston	PROPN
chd-169	517	2	,	,	PUNCT
chd-169	517	3	k.e	k.e	PROPN
chd-169	517	4	.	.	PROPN
chd-169	517	5	,	,	PUNCT
chd-169	517	6	kim	kim	PROPN
chd-169	517	7	,	,	PUNCT
chd-169	517	8	d.	d.	PROPN
chd-169	517	9	,	,	PUNCT
chd-169	517	10	singh	singh	PROPN
chd-169	517	11	,	,	PUNCT
chd-169	517	12	s.	s.	PROPN
chd-169	517	13	,	,	PUNCT
chd-169	517	14	ford	ford	PROPN
chd-169	517	15	,	,	PUNCT
chd-169	517	16	o.h	o.h	PROPN
chd-169	517	17	.	.	PROPN
chd-169	517	18	,	,	PUNCT
chd-169	517	19	3rd	3rd	NOUN
chd-169	517	20	,	,	PUNCT
chd-169	517	21	and	and	CCONJ
chd-169	517	22	mohler	mohler	NOUN
chd-169	517	23	,	,	PUNCT
chd-169	517	24	j.l	j.l	PROPN
chd-169	517	25	.	.	PROPN
chd-169	517	26	(	(	PUNCT
chd-169	517	27	2003	2003	NUM
chd-169	517	28	)	)	PUNCT
chd-169	517	29	.	.	PUNCT
chd-169	518	1	racial	racial	ADJ
chd-169	518	2	differences	difference	NOUN
chd-169	518	3	in	in	ADP
chd-169	518	4	androgen	androgen	NOUN
chd-169	518	5	receptor	receptor	NOUN
chd-169	518	6	protein	protein	NOUN
chd-169	518	7	expression	expression	NOUN
chd-169	518	8	in	in	ADP
chd-169	518	9	men	man	NOUN
chd-169	518	10	with	with	ADP
chd-169	518	11	clinically	clinically	ADV
chd-169	518	12	localized	localize	VERB
chd-169	518	13	prostate	prostate	NOUN
chd-169	518	14	cancer	cancer	NOUN
chd-169	518	15	.	.	PUNCT
chd-169	519	1	j	j	PROPN
chd-169	519	2	urol	urol	PROPN
chd-169	519	3	170	170	NUM
chd-169	519	4	,	,	PUNCT
chd-169	519	5	990	990	NUM
chd-169	519	6	-	-	SYM
chd-169	519	7	993	993	NUM
chd-169	519	8	.	.	PUNCT
chd-169	520	1	gidron	gidron	PROPN
chd-169	520	2	,	,	PUNCT
chd-169	520	3	y.	y.	PROPN
chd-169	520	4	,	,	PUNCT
chd-169	520	5	fabre	fabre	PROPN
chd-169	520	6	,	,	PUNCT
chd-169	520	7	b.	b.	PROPN
chd-169	520	8	,	,	PUNCT
chd-169	520	9	grosman	grosman	NOUN
chd-169	520	10	,	,	PUNCT
chd-169	520	11	h.	h.	PROPN
chd-169	520	12	,	,	PUNCT
chd-169	520	13	nolazco	nolazco	PROPN
chd-169	520	14	,	,	PUNCT
chd-169	520	15	c.	c.	PROPN
chd-169	520	16	,	,	PUNCT
chd-169	520	17	mesch	mesch	PROPN
chd-169	520	18	,	,	PUNCT
chd-169	520	19	v.	v.	PROPN
chd-169	520	20	,	,	PUNCT
chd-169	520	21	mazza	mazza	PROPN
chd-169	520	22	,	,	PUNCT
chd-169	520	23	o.	o.	PROPN
chd-169	520	24	,	,	PUNCT
chd-169	520	25	and	and	CCONJ
chd-169	520	26	berg	berg	PROPN
chd-169	520	27	,	,	PUNCT
chd-169	520	28	g.	g.	PROPN
chd-169	520	29	(	(	PUNCT
chd-169	520	30	2011	2011	NUM
chd-169	520	31	)	)	PUNCT
chd-169	520	32	.	.	PUNCT
chd-169	521	1	life	life	NOUN
chd-169	521	2	events	event	NOUN
chd-169	521	3	,	,	PUNCT
chd-169	521	4	cortisol	cortisol	NOUN
chd-169	521	5	and	and	CCONJ
chd-169	521	6	levels	level	NOUN
chd-169	521	7	of	of	ADP
chd-169	521	8	prostate	prostate	NOUN
chd-169	521	9	specific	specific	ADJ
chd-169	521	10	antigen	antigen	NOUN
chd-169	521	11	:	:	PUNCT
chd-169	521	12	a	a	DET
chd-169	521	13	story	story	NOUN
chd-169	521	14	of	of	ADP
chd-169	521	15	synergism	synergism	NOUN
chd-169	521	16	.	.	PUNCT
chd-169	522	1	psychoneuroendocrinology	psychoneuroendocrinology	NOUN
chd-169	522	2	36	36	NUM
chd-169	522	3	,	,	PUNCT
chd-169	522	4	874	874	NUM
chd-169	522	5	-	-	SYM
chd-169	522	6	880	880	NUM
chd-169	522	7	.	.	PUNCT
chd-169	523	1	gilbert	gilbert	PROPN
chd-169	523	2	,	,	PUNCT
chd-169	523	3	d.c	d.c	PROPN
chd-169	523	4	.	.	PROPN
chd-169	523	5	,	,	PUNCT
chd-169	523	6	and	and	CCONJ
chd-169	523	7	parker	parker	PROPN
chd-169	523	8	,	,	PUNCT
chd-169	523	9	c.	c.	PROPN
chd-169	523	10	(	(	PUNCT
chd-169	523	11	2005	2005	NUM
chd-169	523	12	)	)	PUNCT
chd-169	523	13	.	.	PUNCT
chd-169	524	1	docetaxel	docetaxel	PROPN
chd-169	524	2	for	for	ADP
chd-169	524	3	the	the	DET
chd-169	524	4	treatment	treatment	NOUN
chd-169	524	5	of	of	ADP
chd-169	524	6	prostate	prostate	NOUN
chd-169	524	7	cancer	cancer	NOUN
chd-169	524	8	.	.	PUNCT
chd-169	525	1	future	future	ADJ
chd-169	525	2	oncol	oncol	ADJ
chd-169	525	3	1	1	NUM
chd-169	525	4	,	,	PUNCT
chd-169	525	5	307	307	NUM
chd-169	525	6	-	-	SYM
chd-169	525	7	314	314	NUM
chd-169	525	8	.	.	PUNCT
chd-169	526	1	gomez	gomez	PROPN
chd-169	526	2	-	-	PUNCT
chd-169	526	3	sanchez	sanchez	PROPN
chd-169	526	4	,	,	PUNCT
chd-169	526	5	e.	e.	PROPN
chd-169	526	6	,	,	PUNCT
chd-169	526	7	and	and	CCONJ
chd-169	526	8	gomez	gomez	PROPN
chd-169	526	9	-	-	PUNCT
chd-169	526	10	sanchez	sanchez	PROPN
chd-169	526	11	,	,	PUNCT
chd-169	526	12	c.e	c.e	PROPN
chd-169	526	13	.	.	PROPN
chd-169	526	14	(	(	PUNCT
chd-169	526	15	2014	2014	NUM
chd-169	526	16	)	)	PUNCT
chd-169	526	17	.	.	PUNCT
chd-169	527	1	the	the	DET
chd-169	527	2	multifaceted	multifaceted	ADJ
chd-169	527	3	mineralocorticoid	mineralocorticoid	NOUN
chd-169	527	4	receptor	receptor	NOUN
chd-169	527	5	.	.	PUNCT
chd-169	528	1	compr	compr	PROPN
chd-169	528	2	physiol	physiol	PROPN
chd-169	528	3	4	4	NUM
chd-169	528	4	,	,	PUNCT
chd-169	528	5	965	965	NUM
chd-169	528	6	-	-	SYM
chd-169	528	7	994	994	NUM
chd-169	528	8	.	.	PUNCT
chd-169	529	1	grad	grad	PROPN
chd-169	529	2	,	,	PUNCT
chd-169	529	3	i.	i.	PROPN
chd-169	529	4	,	,	PUNCT
chd-169	529	5	and	and	CCONJ
chd-169	529	6	picard	picard	PROPN
chd-169	529	7	,	,	PUNCT
chd-169	529	8	d.	d.	PROPN
chd-169	529	9	(	(	PUNCT
chd-169	529	10	2007	2007	NUM
chd-169	529	11	)	)	PUNCT
chd-169	529	12	.	.	PUNCT
chd-169	530	1	the	the	DET
chd-169	530	2	glucocorticoid	glucocorticoid	ADJ
chd-169	530	3	responses	response	NOUN
chd-169	530	4	are	be	AUX
chd-169	530	5	shaped	shape	VERB
chd-169	530	6	by	by	ADP
chd-169	530	7	molecular	molecular	ADJ
chd-169	530	8	chaperones	chaperone	NOUN
chd-169	530	9	.	.	PUNCT
chd-169	531	1	mol	mol	ADP
chd-169	531	2	cell	cell	NOUN
chd-169	531	3	endocrinol	endocrinol	NOUN
chd-169	531	4	275	275	NUM
chd-169	531	5	,	,	PUNCT
chd-169	531	6	2	2	NUM
chd-169	531	7	-	-	SYM
chd-169	531	8	12	12	NUM
chd-169	531	9	.	.	PUNCT
chd-169	532	1	gudmundsson	gudmundsson	PROPN
chd-169	532	2	,	,	PUNCT
chd-169	532	3	j.	j.	PROPN
chd-169	532	4	,	,	PUNCT
chd-169	532	5	sulem	sulem	PROPN
chd-169	532	6	,	,	PUNCT
chd-169	532	7	p.	p.	PROPN
chd-169	532	8	,	,	PUNCT
chd-169	532	9	manolescu	manolescu	PROPN
chd-169	532	10	,	,	PUNCT
chd-169	532	11	a.	a.	NOUN
chd-169	532	12	,	,	PUNCT
chd-169	532	13	amundadottir	amundadottir	ADJ
chd-169	532	14	,	,	PUNCT
chd-169	532	15	l.t	l.t	PROPN
chd-169	532	16	.	.	PROPN
chd-169	532	17	,	,	PUNCT
chd-169	532	18	gudbjartsson	gudbjartsson	PROPN
chd-169	532	19	,	,	PUNCT
chd-169	532	20	d.	d.	PROPN
chd-169	532	21	,	,	PUNCT
chd-169	532	22	helgason	helgason	PROPN
chd-169	532	23	,	,	PUNCT
chd-169	532	24	a.	a.	NOUN
chd-169	532	25	,	,	PUNCT
chd-169	532	26	rafnar	rafnar	NOUN
chd-169	532	27	,	,	PUNCT
chd-169	532	28	t.	t.	PROPN
chd-169	532	29	,	,	PUNCT
chd-169	532	30	bergthorsson	bergthorsson	NOUN
chd-169	532	31	,	,	PUNCT
chd-169	532	32	j.t	j.t	PROPN
chd-169	532	33	.	.	PROPN
chd-169	532	34	,	,	PUNCT
chd-169	532	35	agnarsson	agnarsson	PROPN
chd-169	532	36	,	,	PUNCT
chd-169	532	37	b.a	b.a	PROPN
chd-169	532	38	.	.	PROPN
chd-169	532	39	,	,	PUNCT
chd-169	532	40	baker	baker	PROPN
chd-169	532	41	,	,	PUNCT
chd-169	532	42	a.	a.	PROPN
chd-169	532	43	,	,	PUNCT
chd-169	532	44	et	et	PROPN
chd-169	532	45	al	al	PROPN
chd-169	532	46	.	.	PUNCT
chd-169	533	1	(	(	PUNCT
chd-169	533	2	2007	2007	NUM
chd-169	533	3	)	)	PUNCT
chd-169	533	4	.	.	PUNCT
chd-169	534	1	genome	genome	NOUN
chd-169	534	2	-	-	PUNCT
chd-169	534	3	wide	wide	ADJ
chd-169	534	4	association	association	NOUN
chd-169	534	5	study	study	NOUN
chd-169	534	6	identifies	identify	VERB
chd-169	534	7	a	a	DET
chd-169	534	8	second	second	ADJ
chd-169	534	9	prostate	prostate	NOUN
chd-169	534	10	cancer	cancer	NOUN
chd-169	534	11	susceptibility	susceptibility	NOUN
chd-169	534	12	variant	variant	NOUN
chd-169	534	13	at	at	ADP
chd-169	534	14	8q24	8q24	NOUN
chd-169	534	15	.	.	PUNCT
chd-169	535	1	nat	nat	PROPN
chd-169	535	2	genet	genet	PROPN
chd-169	535	3	39	39	NUM
chd-169	535	4	,	,	PUNCT
chd-169	535	5	631	631	NUM
chd-169	535	6	-	-	SYM
chd-169	535	7	637	637	NUM
chd-169	535	8	.	.	PUNCT
chd-169	536	1	gusev	gusev	NOUN
chd-169	536	2	,	,	PUNCT
chd-169	536	3	a.	a.	PROPN
chd-169	536	4	,	,	PUNCT
chd-169	536	5	shi	shi	PROPN
chd-169	536	6	,	,	PUNCT
chd-169	536	7	h.	h.	PROPN
chd-169	536	8	,	,	PUNCT
chd-169	536	9	kichaev	kichaev	PROPN
chd-169	536	10	,	,	PUNCT
chd-169	536	11	g.	g.	PROPN
chd-169	536	12	,	,	PUNCT
chd-169	536	13	pomerantz	pomerantz	NOUN
chd-169	536	14	,	,	PUNCT
chd-169	536	15	m.	m.	NOUN
chd-169	536	16	,	,	PUNCT
chd-169	536	17	li	li	PROPN
chd-169	536	18	,	,	PUNCT
chd-169	536	19	f.	f.	PROPN
chd-169	536	20	,	,	PUNCT
chd-169	536	21	long	long	ADV
chd-169	536	22	,	,	PUNCT
chd-169	536	23	h.w	h.w	PROPN
chd-169	536	24	.	.	PROPN
chd-169	536	25	,	,	PUNCT
chd-169	536	26	ingles	ingles	PROPN
chd-169	536	27	,	,	PUNCT
chd-169	536	28	s.a	s.a	PROPN
chd-169	536	29	.	.	PROPN
chd-169	536	30	,	,	PUNCT
chd-169	536	31	kittles	kittles	PROPN
chd-169	536	32	,	,	PUNCT
chd-169	536	33	r.a	r.a	PROPN
chd-169	536	34	.	.	PROPN
chd-169	536	35	,	,	PUNCT
chd-169	536	36	strom	strom	PROPN
chd-169	536	37	,	,	PUNCT
chd-169	536	38	s.s	s.s	PROPN
chd-169	536	39	.	.	PROPN
chd-169	536	40	,	,	PUNCT
chd-169	536	41	rybicki	rybicki	PROPN
chd-169	536	42	,	,	PUNCT
chd-169	536	43	b.a	b.a	PROPN
chd-169	536	44	.	.	PROPN
chd-169	536	45	,	,	PUNCT
chd-169	536	46	et	et	PROPN
chd-169	536	47	al	al	PROPN
chd-169	536	48	.	.	PUNCT
chd-169	537	1	(	(	PUNCT
chd-169	537	2	2016	2016	NUM
chd-169	537	3	)	)	PUNCT
chd-169	537	4	.	.	PUNCT
chd-169	538	1	atlas	atlas	PROPN
chd-169	538	2	of	of	ADP
chd-169	538	3	prostate	prostate	NOUN
chd-169	538	4	cancer	cancer	NOUN
chd-169	538	5	heritability	heritability	NOUN
chd-169	538	6	in	in	ADP
chd-169	538	7	european	european	ADJ
chd-169	538	8	and	and	CCONJ
chd-169	538	9	african	african	ADJ
chd-169	538	10	-	-	PUNCT
chd-169	538	11	american	american	ADJ
chd-169	538	12	men	man	NOUN
chd-169	538	13	pinpoints	pinpoint	NOUN
chd-169	538	14	tissue	tissue	NOUN
chd-169	538	15	-	-	PUNCT
chd-169	538	16	specific	specific	ADJ
chd-169	538	17	regulation	regulation	NOUN
chd-169	538	18	.	.	PUNCT
chd-169	539	1	nat	nat	PROPN
chd-169	539	2	commun	commun	PROPN
chd-169	539	3	7	7	NUM
chd-169	539	4	,	,	PUNCT
chd-169	539	5	10979	10979	NUM
chd-169	539	6	.	.	PUNCT
chd-169	540	1	han	han	PROPN
chd-169	540	2	,	,	PUNCT
chd-169	540	3	y.	y.	PROPN
chd-169	540	4	,	,	PUNCT
chd-169	540	5	signorello	signorello	PROPN
chd-169	540	6	,	,	PUNCT
chd-169	540	7	l.b	l.b	PROPN
chd-169	540	8	.	.	PROPN
chd-169	540	9	,	,	PUNCT
chd-169	540	10	strom	strom	PROPN
chd-169	540	11	,	,	PUNCT
chd-169	540	12	s.s	s.s	PROPN
chd-169	540	13	.	.	PROPN
chd-169	540	14	,	,	PUNCT
chd-169	540	15	kittles	kittles	PROPN
chd-169	540	16	,	,	PUNCT
chd-169	540	17	r.a	r.a	PROPN
chd-169	540	18	.	.	PROPN
chd-169	540	19	,	,	PUNCT
chd-169	540	20	rybicki	rybicki	PROPN
chd-169	540	21	,	,	PUNCT
chd-169	540	22	b.a	b.a	PROPN
chd-169	540	23	.	.	PROPN
chd-169	540	24	,	,	PUNCT
chd-169	540	25	stanford	stanford	PROPN
chd-169	540	26	,	,	PUNCT
chd-169	540	27	j.l	j.l	PROPN
chd-169	540	28	.	.	PROPN
chd-169	540	29	,	,	PUNCT
chd-169	540	30	goodman	goodman	PROPN
chd-169	540	31	,	,	PUNCT
chd-169	540	32	p.j	p.j	PROPN
chd-169	540	33	.	.	PROPN
chd-169	540	34	,	,	PUNCT
chd-169	540	35	berndt	berndt	PROPN
chd-169	540	36	,	,	PUNCT
chd-169	540	37	s.i	s.i	PROPN
chd-169	540	38	.	.	PROPN
chd-169	540	39	,	,	PUNCT
chd-169	540	40	carpten	carpten	PROPN
chd-169	540	41	,	,	PUNCT
chd-169	540	42	j.	j.	PROPN
chd-169	540	43	,	,	PUNCT
chd-169	540	44	casey	casey	PROPN
chd-169	540	45	,	,	PUNCT
chd-169	540	46	g.	g.	PROPN
chd-169	540	47	,	,	PUNCT
chd-169	540	48	et	et	PROPN
chd-169	540	49	al	al	PROPN
chd-169	540	50	.	.	PUNCT
chd-169	540	51	(	(	PUNCT
chd-169	540	52	2015	2015	NUM
chd-169	540	53	)	)	PUNCT
chd-169	540	54	.	.	PUNCT
chd-169	541	1	generalizability	generalizability	NOUN
chd-169	541	2	of	of	ADP
chd-169	541	3	established	establish	VERB
chd-169	541	4	prostate	prostate	NOUN
chd-169	541	5	cancer	cancer	NOUN
chd-169	541	6	risk	risk	NOUN
chd-169	541	7	variants	variant	NOUN
chd-169	541	8	in	in	ADP
chd-169	541	9	men	man	NOUN
chd-169	541	10	of	of	ADP
chd-169	541	11	african	african	ADJ
chd-169	541	12	ancestry	ancestry	NOUN
chd-169	541	13	.	.	PUNCT
chd-169	542	1	int	int	NOUN
chd-169	542	2	j	j	PROPN
chd-169	542	3	cancer	cancer	NOUN
chd-169	542	4	136	136	NUM
chd-169	542	5	,	,	PUNCT
chd-169	542	6	1210	1210	NUM
chd-169	542	7	-	-	SYM
chd-169	542	8	1217	1217	NUM
chd-169	542	9	.	.	PUNCT
chd-169	543	1	hannum	hannum	PROPN
chd-169	543	2	,	,	PUNCT
chd-169	543	3	g.	g.	PROPN
chd-169	543	4	,	,	PUNCT
chd-169	543	5	guinney	guinney	PROPN
chd-169	543	6	,	,	PUNCT
chd-169	543	7	j.	j.	PROPN
chd-169	543	8	,	,	PUNCT
chd-169	543	9	zhao	zhao	PROPN
chd-169	543	10	,	,	PUNCT
chd-169	543	11	l.	l.	PROPN
chd-169	543	12	,	,	PUNCT
chd-169	543	13	zhang	zhang	PROPN
chd-169	543	14	,	,	PUNCT
chd-169	543	15	l.	l.	PROPN
chd-169	543	16	,	,	PUNCT
chd-169	543	17	hughes	hughes	PROPN
chd-169	543	18	,	,	PUNCT
chd-169	543	19	g.	g.	PROPN
chd-169	543	20	,	,	PUNCT
chd-169	543	21	sadda	sadda	NOUN
chd-169	543	22	,	,	PUNCT
chd-169	543	23	s.	s.	PROPN
chd-169	543	24	,	,	PUNCT
chd-169	543	25	klotzle	klotzle	PROPN
chd-169	543	26	,	,	PUNCT
chd-169	543	27	b.	b.	PROPN
chd-169	543	28	,	,	PUNCT
chd-169	543	29	bibikova	bibikova	PROPN
chd-169	543	30	,	,	PUNCT
chd-169	543	31	m.	m.	NOUN
chd-169	543	32	,	,	PUNCT
chd-169	543	33	fan	fan	PROPN
chd-169	543	34	,	,	PUNCT
chd-169	543	35	j.b	j.b	PROPN
chd-169	543	36	.	.	PROPN
chd-169	543	37	,	,	PUNCT
chd-169	543	38	gao	gao	PROPN
chd-169	543	39	,	,	PUNCT
chd-169	543	40	y.	y.	PROPN
chd-169	543	41	,	,	PUNCT
chd-169	543	42	et	et	PROPN
chd-169	543	43	al	al	PROPN
chd-169	543	44	.	.	PROPN
chd-169	544	1	(	(	PUNCT
chd-169	544	2	2013	2013	NUM
chd-169	544	3	)	)	PUNCT
chd-169	544	4	.	.	PUNCT
chd-169	545	1	genome	genome	NOUN
chd-169	545	2	-	-	PUNCT
chd-169	545	3	wide	wide	ADJ
chd-169	545	4	methylation	methylation	NOUN
chd-169	545	5	profiles	profile	NOUN
chd-169	545	6	reveal	reveal	VERB
chd-169	545	7	quantitative	quantitative	ADJ
chd-169	545	8	views	view	NOUN
chd-169	545	9	of	of	ADP
chd-169	545	10	human	human	ADJ
chd-169	545	11	aging	age	VERB
chd-169	545	12	rates	rate	NOUN
chd-169	545	13	.	.	PUNCT
chd-169	546	1	molecular	molecular	ADJ
chd-169	546	2	cell	cell	NOUN
chd-169	546	3	49	49	NUM
chd-169	546	4	,	,	PUNCT
chd-169	546	5	359	359	NUM
chd-169	546	6	-	-	SYM
chd-169	546	7	367	367	NUM
chd-169	546	8	.	.	PUNCT
chd-169	547	1	hernandez	hernandez	PROPN
chd-169	547	2	,	,	PUNCT
chd-169	547	3	d.g	d.g	PROPN
chd-169	547	4	.	.	PROPN
chd-169	547	5	,	,	PUNCT
chd-169	547	6	nalls	nalls	PROPN
chd-169	547	7	,	,	PUNCT
chd-169	547	8	m.a	m.a	PROPN
chd-169	547	9	.	.	PROPN
chd-169	547	10	,	,	PUNCT
chd-169	547	11	gibbs	gibbs	PROPN
chd-169	547	12	,	,	PUNCT
chd-169	547	13	j.r	j.r	PROPN
chd-169	547	14	.	.	PROPN
chd-169	547	15	,	,	PUNCT
chd-169	547	16	arepalli	arepalli	PROPN
chd-169	547	17	,	,	PUNCT
chd-169	547	18	s.	s.	PROPN
chd-169	547	19	,	,	PUNCT
chd-169	547	20	van	van	PROPN
chd-169	547	21	der	der	PROPN
chd-169	547	22	brug	brug	PROPN
chd-169	547	23	,	,	PUNCT
chd-169	547	24	m.	m.	NOUN
chd-169	547	25	,	,	PUNCT
chd-169	547	26	chong	chong	PROPN
chd-169	547	27	,	,	PUNCT
chd-169	547	28	s.	s.	PROPN
chd-169	547	29	,	,	PUNCT
chd-169	547	30	moore	moore	PROPN
chd-169	547	31	,	,	PUNCT
chd-169	547	32	m.	m.	NOUN
chd-169	547	33	,	,	PUNCT
chd-169	547	34	longo	longo	PROPN
chd-169	547	35	,	,	PUNCT
chd-169	547	36	d.l	d.l	PROPN
chd-169	547	37	.	.	PROPN
chd-169	547	38	,	,	PUNCT
chd-169	547	39	cookson	cookson	PROPN
chd-169	547	40	,	,	PUNCT
chd-169	547	41	m.r	m.r	PROPN
chd-169	547	42	.	.	PROPN
chd-169	547	43	,	,	PUNCT
chd-169	547	44	traynor	traynor	PROPN
chd-169	547	45	,	,	PUNCT
chd-169	547	46	b.j	b.j	PROPN
chd-169	547	47	.	.	PROPN
chd-169	547	48	,	,	PUNCT
chd-169	547	49	et	et	PROPN
chd-169	547	50	al	al	PROPN
chd-169	547	51	.	.	PUNCT
chd-169	547	52	(	(	PUNCT
chd-169	547	53	2011	2011	NUM
chd-169	547	54	)	)	PUNCT
chd-169	547	55	.	.	PUNCT
chd-169	548	1	distinct	distinct	ADJ
chd-169	548	2	dna	dna	PROPN
chd-169	548	3	methylation	methylation	NOUN
chd-169	548	4	changes	change	NOUN
chd-169	548	5	highly	highly	ADV
chd-169	548	6	correlated	correlate	VERB
chd-169	548	7	with	with	ADP
chd-169	548	8	chronological	chronological	ADJ
chd-169	548	9	age	age	NOUN
chd-169	548	10	in	in	ADP
chd-169	548	11	the	the	DET
chd-169	548	12	human	human	ADJ
chd-169	548	13	brain	brain	NOUN
chd-169	548	14	.	.	PUNCT
chd-169	549	1	hum	hum	PROPN
chd-169	549	2	mol	mol	ADP
chd-169	549	3	genet	genet	PROPN
chd-169	549	4	20	20	NUM
chd-169	549	5	,	,	PUNCT
chd-169	549	6	1164	1164	NUM
chd-169	549	7	-	-	SYM
chd-169	549	8	1172	1172	NUM
chd-169	549	9	.	.	PUNCT
chd-169	550	1	heyn	heyn	PROPN
chd-169	550	2	,	,	PUNCT
chd-169	550	3	h.	h.	PROPN
chd-169	550	4	,	,	PUNCT
chd-169	550	5	li	li	PROPN
chd-169	550	6	,	,	PUNCT
chd-169	550	7	n.	n.	PROPN
chd-169	550	8	,	,	PUNCT
chd-169	550	9	ferreira	ferreira	PROPN
chd-169	550	10	,	,	PUNCT
chd-169	550	11	h.j	h.j	PROPN
chd-169	550	12	.	.	PROPN
chd-169	550	13	,	,	PUNCT
chd-169	550	14	moran	moran	PROPN
chd-169	550	15	,	,	PUNCT
chd-169	550	16	s.	s.	PROPN
chd-169	550	17	,	,	PUNCT
chd-169	550	18	pisano	pisano	PROPN
chd-169	550	19	,	,	PUNCT
chd-169	550	20	d.g	d.g	PROPN
chd-169	550	21	.	.	PROPN
chd-169	550	22	,	,	PUNCT
chd-169	550	23	gomez	gomez	PROPN
chd-169	550	24	,	,	PUNCT
chd-169	550	25	a.	a.	PROPN
chd-169	550	26	,	,	PUNCT
chd-169	550	27	diez	diez	PROPN
chd-169	550	28	,	,	PUNCT
chd-169	550	29	j.	j.	PROPN
chd-169	550	30	,	,	PUNCT
chd-169	550	31	sanchez	sanchez	PROPN
chd-169	550	32	-	-	PUNCT
chd-169	550	33	mut	mut	PROPN
chd-169	550	34	,	,	PUNCT
chd-169	550	35	j.v	j.v	PROPN
chd-169	550	36	.	.	PROPN
chd-169	550	37	,	,	PUNCT
chd-169	550	38	setien	setien	PROPN
chd-169	550	39	,	,	PUNCT
chd-169	550	40	f.	f.	PROPN
chd-169	550	41	,	,	PUNCT
chd-169	550	42	carmona	carmona	PROPN
chd-169	550	43	,	,	PUNCT
chd-169	550	44	f.j	f.j	PROPN
chd-169	550	45	.	.	PROPN
chd-169	550	46	,	,	PUNCT
chd-169	550	47	et	et	PROPN
chd-169	550	48	al	al	PROPN
chd-169	550	49	.	.	PUNCT
chd-169	550	50	(	(	PUNCT
chd-169	550	51	2012	2012	NUM
chd-169	550	52	)	)	PUNCT
chd-169	550	53	.	.	PUNCT
chd-169	551	1	distinct	distinct	ADJ
chd-169	551	2	dna	dna	PROPN
chd-169	551	3	methylomes	methylome	NOUN
chd-169	551	4	of	of	ADP
chd-169	551	5	newborns	newborn	NOUN
chd-169	551	6	and	and	CCONJ
chd-169	551	7	centenarians	centenarian	NOUN
chd-169	551	8	.	.	PUNCT
chd-169	552	1	proceedings	proceeding	NOUN
chd-169	552	2	of	of	ADP
chd-169	552	3	the	the	DET
chd-169	552	4	national	national	PROPN
chd-169	552	5	academy	academy	PROPN
chd-169	552	6	of	of	ADP
chd-169	552	7	sciences	sciences	PROPN
chd-169	552	8	of	of	ADP
chd-169	552	9	the	the	DET
chd-169	552	10	united	united	PROPN
chd-169	552	11	states	states	PROPN
chd-169	552	12	of	of	ADP
chd-169	552	13	america	america	PROPN
chd-169	552	14	109	109	NUM
chd-169	552	15	,	,	PUNCT
chd-169	552	16	1052210527	1052210527	NUM
chd-169	552	17	.	.	PUNCT
chd-169	553	1	hidalgo	hidalgo	PROPN
chd-169	553	2	,	,	PUNCT
chd-169	553	3	a.a	a.a	PROPN
chd-169	553	4	.	.	PROPN
chd-169	553	5	,	,	PUNCT
chd-169	553	6	montecinos	montecinos	PROPN
chd-169	553	7	,	,	PUNCT
chd-169	553	8	v.p	v.p	PROPN
chd-169	553	9	.	.	PROPN
chd-169	553	10	,	,	PUNCT
chd-169	553	11	paredes	paredes	PROPN
chd-169	553	12	,	,	PUNCT
chd-169	553	13	r.	r.	PROPN
chd-169	553	14	,	,	PUNCT
chd-169	553	15	godoy	godoy	PROPN
chd-169	553	16	,	,	PUNCT
chd-169	553	17	a.s	a.s	PROPN
chd-169	553	18	.	.	PROPN
chd-169	553	19	,	,	PUNCT
chd-169	553	20	mcnerney	mcnerney	PROPN
chd-169	553	21	,	,	PUNCT
chd-169	553	22	e.m	e.m	PROPN
chd-169	553	23	.	.	PROPN
chd-169	553	24	,	,	PUNCT
chd-169	553	25	tovar	tovar	PROPN
chd-169	553	26	,	,	PUNCT
chd-169	553	27	h.	h.	PROPN
chd-169	553	28	,	,	PUNCT
chd-169	553	29	pantoja	pantoja	PROPN
chd-169	553	30	,	,	PUNCT
chd-169	553	31	d.	d.	PROPN
chd-169	553	32	,	,	PUNCT
chd-169	553	33	johnson	johnson	PROPN
chd-169	553	34	,	,	PUNCT
chd-169	553	35	c.	c.	PROPN
chd-169	553	36	,	,	PUNCT
chd-169	553	37	trump	trump	NOUN
chd-169	553	38	,	,	PUNCT
chd-169	553	39	d.	d.	PROPN
chd-169	553	40	,	,	PUNCT
chd-169	553	41	and	and	CCONJ
chd-169	553	42	onate	onate	PROPN
chd-169	553	43	,	,	PUNCT
chd-169	553	44	s.a	s.a	PROPN
chd-169	553	45	.	.	PROPN
chd-169	553	46	(	(	PUNCT
chd-169	553	47	2011	2011	NUM
chd-169	553	48	)	)	PUNCT
chd-169	553	49	.	.	PUNCT
chd-169	554	1	biochemical	biochemical	ADJ
chd-169	554	2	characterization	characterization	NOUN
chd-169	554	3	of	of	ADP
chd-169	554	4	nuclear	nuclear	ADJ
chd-169	554	5	receptors	receptor	NOUN
chd-169	554	6	for	for	ADP
chd-169	554	7	vitamin	vitamin	NOUN
chd-169	554	8	d3	d3	NOUN
chd-169	554	9	and	and	CCONJ
chd-169	554	10	glucocorticoids	glucocorticoid	NOUN
chd-169	554	11	in	in	ADP
chd-169	554	12	prostate	prostate	NOUN
chd-169	554	13	stroma	stroma	ADJ
chd-169	554	14	cell	cell	NOUN
chd-169	554	15	microenvironment	microenvironment	NOUN
chd-169	554	16	.	.	PUNCT
chd-169	555	1	biochem	biochem	PROPN
chd-169	555	2	biophys	biophys	PROPN
chd-169	555	3	res	res	PROPN
chd-169	555	4	commun	commun	PROPN
chd-169	555	5	412	412	NUM
chd-169	555	6	,	,	PUNCT
chd-169	555	7	13	13	NUM
chd-169	555	8	-	-	SYM
chd-169	555	9	19	19	NUM
chd-169	555	10	.	.	PUNCT
chd-169	555	11	hoffman	hoffman	PROPN
chd-169	555	12	,	,	PUNCT
chd-169	555	13	r.m	r.m	PROPN
chd-169	555	14	.	.	PROPN
chd-169	555	15	,	,	PUNCT
chd-169	555	16	gilliland	gilliland	PROPN
chd-169	555	17	,	,	PUNCT
chd-169	555	18	f.d	f.d	PROPN
chd-169	555	19	.	.	PROPN
chd-169	555	20	,	,	PUNCT
chd-169	555	21	eley	eley	PROPN
chd-169	555	22	,	,	PUNCT
chd-169	555	23	j.w	j.w	PROPN
chd-169	555	24	.	.	PROPN
chd-169	555	25	,	,	PUNCT
chd-169	555	26	harlan	harlan	PROPN
chd-169	555	27	,	,	PUNCT
chd-169	555	28	l.c	l.c	PROPN
chd-169	555	29	.	.	PROPN
chd-169	555	30	,	,	PUNCT
chd-169	555	31	stephenson	stephenson	PROPN
chd-169	555	32	,	,	PUNCT
chd-169	555	33	r.a	r.a	PROPN
chd-169	555	34	.	.	PROPN
chd-169	555	35	,	,	PUNCT
chd-169	555	36	stanford	stanford	PROPN
chd-169	555	37	,	,	PUNCT
chd-169	555	38	j.l	j.l	PROPN
chd-169	555	39	.	.	PROPN
chd-169	555	40	,	,	PUNCT
chd-169	555	41	albertson	albertson	PROPN
chd-169	555	42	,	,	PUNCT
chd-169	555	43	p.c	p.c	PROPN
chd-169	555	44	.	.	PROPN
chd-169	555	45	,	,	PUNCT
chd-169	555	46	hamilton	hamilton	PROPN
chd-169	555	47	,	,	PUNCT
chd-169	555	48	a.s	a.s	PROPN
chd-169	555	49	.	.	PROPN
chd-169	555	50	,	,	PUNCT
chd-169	555	51	hunt	hunt	PROPN
chd-169	555	52	,	,	PUNCT
chd-169	555	53	w.c	w.c	PROPN
chd-169	555	54	.	.	PROPN
chd-169	555	55	,	,	PUNCT
chd-169	555	56	and	and	CCONJ
chd-169	555	57	potosky	potosky	NOUN
chd-169	555	58	,	,	PUNCT
chd-169	555	59	a.l	a.l	PROPN
chd-169	555	60	.	.	PROPN
chd-169	556	1	(	(	PUNCT
chd-169	556	2	2001	2001	NUM
chd-169	556	3	)	)	PUNCT
chd-169	556	4	.	.	PUNCT
chd-169	557	1	racial	racial	ADJ
chd-169	557	2	and	and	CCONJ
chd-169	557	3	ethnic	ethnic	ADJ
chd-169	557	4	differences	difference	NOUN
chd-169	557	5	in	in	ADP
chd-169	557	6	advanced	advanced	ADJ
chd-169	557	7	-	-	PUNCT
chd-169	557	8	stage	stage	NOUN
chd-169	557	9	prostate	prostate	NOUN
chd-169	557	10	cancer	cancer	NOUN
chd-169	557	11	:	:	PUNCT
chd-169	557	12	the	the	DET
chd-169	557	13	prostate	prostate	NOUN
chd-169	557	14	cancer	cancer	NOUN
chd-169	557	15	outcomes	outcome	NOUN
chd-169	557	16	study	study	VERB
chd-169	557	17	.	.	PUNCT
chd-169	558	1	j	j	PROPN
chd-169	558	2	natl	natl	PROPN
chd-169	558	3	cancer	cancer	PROPN
chd-169	558	4	inst	inst	PROPN
chd-169	558	5	93	93	NUM
chd-169	558	6	,	,	PUNCT
chd-169	558	7	388	388	NUM
chd-169	558	8	-	-	SYM
chd-169	558	9	395	395	NUM
chd-169	558	10	.	.	PUNCT
chd-169	559	1	holmes	holmes	PROPN
chd-169	559	2	,	,	PUNCT
chd-169	559	3	l.	l.	PROPN
chd-169	559	4	,	,	PUNCT
chd-169	559	5	jr	jr	PROPN
chd-169	559	6	.	.	PROPN
chd-169	559	7	,	,	PUNCT
chd-169	559	8	enwere	enwere	NOUN
chd-169	559	9	,	,	PUNCT
chd-169	559	10	m.	m.	NOUN
chd-169	559	11	,	,	PUNCT
chd-169	559	12	williams	williams	PROPN
chd-169	559	13	,	,	PUNCT
chd-169	559	14	j.	j.	PROPN
chd-169	559	15	,	,	PUNCT
chd-169	559	16	ogundele	ogundele	PROPN
chd-169	559	17	,	,	PUNCT
chd-169	559	18	b.	b.	PROPN
chd-169	559	19	,	,	PUNCT
chd-169	559	20	chavan	chavan	PROPN
chd-169	559	21	,	,	PUNCT
chd-169	559	22	p.	p.	NOUN
chd-169	559	23	,	,	PUNCT
chd-169	559	24	piccoli	piccoli	ADJ
chd-169	559	25	,	,	PUNCT
chd-169	559	26	t.	t.	PROPN
chd-169	559	27	,	,	PUNCT
chd-169	559	28	chinacherem	chinacherem	PROPN
chd-169	559	29	,	,	PUNCT
chd-169	559	30	c.	c.	PROPN
chd-169	559	31	,	,	PUNCT
chd-169	559	32	comeaux	comeaux	PROPN
chd-169	559	33	,	,	PUNCT
chd-169	559	34	c.	c.	PROPN
chd-169	559	35	,	,	PUNCT
chd-169	559	36	pelaez	pelaez	PROPN
chd-169	559	37	,	,	PUNCT
chd-169	559	38	l.	l.	PROPN
chd-169	559	39	,	,	PUNCT
chd-169	559	40	okundaye	okundaye	NOUN
chd-169	559	41	,	,	PUNCT
chd-169	559	42	o.	o.	PROPN
chd-169	559	43	,	,	PUNCT
chd-169	559	44	et	et	PROPN
chd-169	559	45	al	al	PROPN
chd-169	559	46	.	.	PROPN
chd-169	559	47	(	(	PUNCT
chd-169	559	48	2020	2020	NUM
chd-169	559	49	)	)	PUNCT
chd-169	559	50	.	.	PUNCT
chd-169	560	1	black	black	ADJ
chd-169	560	2	-	-	PUNCT
chd-169	560	3	white	white	ADJ
chd-169	560	4	risk	risk	NOUN
chd-169	560	5	differentials	differential	NOUN
chd-169	560	6	in	in	ADP
chd-169	560	7	covid-19	covid-19	PROPN
chd-169	560	8	(	(	PUNCT
chd-169	560	9	sars	sars	PROPN
chd-169	560	10	-	-	PUNCT
chd-169	560	11	cov2	cov2	PROPN
chd-169	560	12	)	)	PUNCT
chd-169	560	13	transmission	transmission	NOUN
chd-169	560	14	,	,	PUNCT
chd-169	560	15	mortality	mortality	NOUN
chd-169	560	16	and	and	CCONJ
chd-169	560	17	case	case	NOUN
chd-169	560	18	fatality	fatality	NOUN
chd-169	560	19	in	in	ADP
chd-169	560	20	the	the	DET
chd-169	560	21	united	united	PROPN
chd-169	560	22	states	states	PROPN
chd-169	560	23	:	:	PUNCT
chd-169	560	24	translational	translational	ADJ
chd-169	560	25	epidemiologic	epidemiologic	ADJ
chd-169	560	26	perspective	perspective	NOUN
chd-169	560	27	and	and	CCONJ
chd-169	560	28	challenges	challenge	NOUN
chd-169	560	29	.	.	PUNCT
chd-169	561	1	int	int	NOUN
chd-169	561	2	j	j	PROPN
chd-169	561	3	environ	environ	PROPN
chd-169	561	4	res	res	PROPN
chd-169	561	5	public	public	ADJ
chd-169	561	6	health	health	PROPN
chd-169	561	7	17	17	NUM
chd-169	561	8	.	.	PUNCT
chd-169	562	1	horvath	horvath	PROPN
chd-169	562	2	,	,	PUNCT
chd-169	562	3	s.	s.	PROPN
chd-169	562	4	(	(	PUNCT
chd-169	562	5	2013	2013	NUM
chd-169	562	6	)	)	PUNCT
chd-169	562	7	.	.	PUNCT
chd-169	563	1	dna	dna	PROPN
chd-169	563	2	methylation	methylation	NOUN
chd-169	563	3	age	age	NOUN
chd-169	563	4	of	of	ADP
chd-169	563	5	human	human	ADJ
chd-169	563	6	tissues	tissue	NOUN
chd-169	563	7	and	and	CCONJ
chd-169	563	8	cell	cell	NOUN
chd-169	563	9	types	type	NOUN
chd-169	563	10	.	.	PUNCT
chd-169	564	1	genome	genome	NOUN
chd-169	564	2	biol	biol	NOUN
chd-169	564	3	14	14	NUM
chd-169	564	4	,	,	PUNCT
chd-169	564	5	r115	r115	PROPN
chd-169	564	6	.	.	PUNCT
chd-169	565	1	horvath	horvath	PROPN
chd-169	565	2	,	,	PUNCT
chd-169	565	3	s.	s.	PROPN
chd-169	565	4	(	(	PUNCT
chd-169	565	5	2015	2015	NUM
chd-169	565	6	)	)	PUNCT
chd-169	565	7	.	.	PUNCT
chd-169	566	1	erratum	erratum	PROPN
chd-169	566	2	to	to	PART
chd-169	566	3	:	:	PUNCT
chd-169	566	4	dna	dna	PROPN
chd-169	566	5	methylation	methylation	NOUN
chd-169	566	6	age	age	NOUN
chd-169	566	7	of	of	ADP
chd-169	566	8	human	human	ADJ
chd-169	566	9	tissues	tissue	NOUN
chd-169	566	10	and	and	CCONJ
chd-169	566	11	cell	cell	NOUN
chd-169	566	12	types	type	NOUN
chd-169	566	13	.	.	PUNCT
chd-169	567	1	genome	genome	NOUN
chd-169	567	2	biol	biol	NOUN
chd-169	567	3	16	16	NUM
chd-169	567	4	,	,	PUNCT
chd-169	567	5	96	96	NUM
chd-169	567	6	.	.	PUNCT
chd-169	568	1	horvath	horvath	PROPN
chd-169	568	2	,	,	PUNCT
chd-169	568	3	s.	s.	PROPN
chd-169	568	4	,	,	PUNCT
chd-169	568	5	zhang	zhang	PROPN
chd-169	568	6	,	,	PUNCT
chd-169	568	7	y.	y.	PROPN
chd-169	568	8	,	,	PUNCT
chd-169	568	9	langfelder	langfelder	NOUN
chd-169	568	10	,	,	PUNCT
chd-169	568	11	p.	p.	PROPN
chd-169	568	12	,	,	PUNCT
chd-169	568	13	kahn	kahn	PROPN
chd-169	568	14	,	,	PUNCT
chd-169	568	15	r.s	r.s	PROPN
chd-169	568	16	.	.	PROPN
chd-169	568	17	,	,	PUNCT
chd-169	568	18	boks	boks	PROPN
chd-169	568	19	,	,	PUNCT
chd-169	568	20	m.p	m.p	PROPN
chd-169	568	21	.	.	PROPN
chd-169	568	22	,	,	PUNCT
chd-169	568	23	van	van	PROPN
chd-169	568	24	eijk	eijk	PROPN
chd-169	568	25	,	,	PUNCT
chd-169	568	26	k.	k.	PROPN
chd-169	568	27	,	,	PUNCT
chd-169	568	28	van	van	PROPN
chd-169	568	29	den	den	PROPN
chd-169	568	30	berg	berg	PROPN
chd-169	568	31	,	,	PUNCT
chd-169	568	32	l.h	l.h	PROPN
chd-169	568	33	.	.	PROPN
chd-169	568	34	,	,	PUNCT
chd-169	568	35	and	and	CCONJ
chd-169	568	36	ophoff	ophoff	NOUN
chd-169	568	37	,	,	PUNCT
chd-169	568	38	r.a	r.a	PROPN
chd-169	568	39	.	.	PROPN
chd-169	568	40	(	(	PUNCT
chd-169	568	41	2012	2012	NUM
chd-169	568	42	)	)	PUNCT
chd-169	568	43	.	.	PUNCT
chd-169	569	1	aging	age	VERB
chd-169	569	2	effects	effect	NOUN
chd-169	569	3	on	on	ADP
chd-169	569	4	dna	dna	PROPN
chd-169	569	5	methylation	methylation	NOUN
chd-169	569	6	modules	module	NOUN
chd-169	569	7	in	in	ADP
chd-169	569	8	human	human	ADJ
chd-169	569	9	brain	brain	NOUN
chd-169	569	10	and	and	CCONJ
chd-169	569	11	blood	blood	NOUN
chd-169	569	12	tissue	tissue	NOUN
chd-169	569	13	.	.	PUNCT
chd-169	570	1	genome	genome	NOUN
chd-169	570	2	biol	biol	NOUN
chd-169	570	3	13	13	NUM
chd-169	570	4	,	,	PUNCT
chd-169	570	5	r97	r97	NOUN
chd-169	570	6	.	.	PUNCT
chd-169	571	1	huang	huang	PROPN
chd-169	571	2	,	,	PUNCT
chd-169	571	3	f.w	f.w	PROPN
chd-169	571	4	.	.	PROPN
chd-169	571	5	,	,	PUNCT
chd-169	571	6	mosquera	mosquera	NOUN
chd-169	571	7	,	,	PUNCT
chd-169	571	8	j.m	j.m	PROPN
chd-169	571	9	.	.	PROPN
chd-169	571	10	,	,	PUNCT
chd-169	571	11	garofalo	garofalo	PROPN
chd-169	571	12	,	,	PUNCT
chd-169	571	13	a.	a.	NOUN
chd-169	571	14	,	,	PUNCT
chd-169	571	15	oh	oh	INTJ
chd-169	571	16	,	,	PUNCT
chd-169	571	17	c.	c.	PROPN
chd-169	571	18	,	,	PUNCT
chd-169	571	19	baco	baco	PROPN
chd-169	571	20	,	,	PUNCT
chd-169	571	21	m.	m.	NOUN
chd-169	571	22	,	,	PUNCT
chd-169	571	23	amin	amin	PROPN
chd-169	571	24	-	-	PROPN
chd-169	571	25	mansour	mansour	PROPN
chd-169	571	26	,	,	PUNCT
chd-169	571	27	a.	a.	NOUN
chd-169	571	28	,	,	PUNCT
chd-169	571	29	rabasha	rabasha	PROPN
chd-169	571	30	,	,	PUNCT
chd-169	571	31	b.	b.	PROPN
chd-169	571	32	,	,	PUNCT
chd-169	571	33	bahl	bahl	PROPN
chd-169	571	34	,	,	PUNCT
chd-169	571	35	s.	s.	PROPN
chd-169	571	36	,	,	PUNCT
chd-169	571	37	mullane	mullane	PROPN
chd-169	571	38	,	,	PUNCT
chd-169	571	39	s.a	s.a	PROPN
chd-169	571	40	.	.	PROPN
chd-169	571	41	,	,	PUNCT
chd-169	571	42	robinson	robinson	PROPN
chd-169	571	43	,	,	PUNCT
chd-169	571	44	b.d	b.d	PROPN
chd-169	571	45	.	.	PROPN
chd-169	571	46	,	,	PUNCT
chd-169	571	47	et	et	PROPN
chd-169	571	48	al	al	PROPN
chd-169	571	49	.	.	PUNCT
chd-169	571	50	(	(	PUNCT
chd-169	571	51	2017	2017	NUM
chd-169	571	52	)	)	PUNCT
chd-169	571	53	.	.	PUNCT
chd-169	572	1	exome	exome	NOUN
chd-169	572	2	sequencing	sequencing	NOUN
chd-169	572	3	of	of	ADP
chd-169	572	4	african	african	ADJ
chd-169	572	5	-	-	PUNCT
chd-169	572	6	american	american	ADJ
chd-169	572	7	prostate	prostate	NOUN
chd-169	572	8	cancer	cancer	NOUN
chd-169	572	9	reveals	reveal	VERB
chd-169	572	10	loss	loss	NOUN
chd-169	572	11	-	-	PUNCT
chd-169	572	12	offunction	offunction	NOUN
chd-169	572	13	erf	erf	NOUN
chd-169	572	14	mutations	mutation	NOUN
chd-169	572	15	.	.	PUNCT
chd-169	573	1	cancer	cancer	NOUN
chd-169	573	2	discov	discov	PROPN
chd-169	573	3	7	7	NUM
chd-169	573	4	,	,	PUNCT
chd-169	573	5	973	973	NUM
chd-169	573	6	-	-	SYM
chd-169	573	7	983	983	NUM
chd-169	573	8	.	.	PUNCT
chd-169	574	1	huang	huang	PROPN
chd-169	574	2	,	,	PUNCT
chd-169	574	3	t.s	t.s	PROPN
chd-169	574	4	.	.	PROPN
chd-169	574	5	,	,	PUNCT
chd-169	574	6	myklebust	myklebust	PROPN
chd-169	574	7	,	,	PUNCT
chd-169	574	8	l.m	l.m	PROPN
chd-169	574	9	.	.	PROPN
chd-169	574	10	,	,	PUNCT
chd-169	574	11	kjarland	kjarland	PROPN
chd-169	574	12	,	,	PUNCT
chd-169	574	13	e.	e.	PROPN
chd-169	574	14	,	,	PUNCT
chd-169	574	15	gjertsen	gjertsen	ADV
chd-169	574	16	,	,	PUNCT
chd-169	574	17	b.t	b.t	PROPN
chd-169	574	18	.	.	PROPN
chd-169	574	19	,	,	PUNCT
chd-169	574	20	pendino	pendino	PROPN
chd-169	574	21	,	,	PUNCT
chd-169	574	22	f.	f.	PROPN
chd-169	574	23	,	,	PUNCT
chd-169	574	24	bruserud	bruserud	NOUN
chd-169	574	25	,	,	PUNCT
chd-169	574	26	o.	o.	PROPN
chd-169	574	27	,	,	PUNCT
chd-169	574	28	doskeland	doskeland	PROPN
chd-169	574	29	,	,	PUNCT
chd-169	574	30	s.o	s.o	PROPN
chd-169	574	31	.	.	PROPN
chd-169	574	32	,	,	PUNCT
chd-169	574	33	and	and	CCONJ
chd-169	574	34	lillehaug	lillehaug	PROPN
chd-169	574	35	,	,	PUNCT
chd-169	574	36	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-169	574	37	e24	e24	PROPN
chd-169	574	38	cancer	cancer	NOUN
chd-169	574	39	health	health	NOUN
chd-169	574	40	disparities	disparity	NOUN
chd-169	574	41	research	research	PROPN
chd-169	574	42	j.r	j.r	PROPN
chd-169	574	43	.	.	PROPN
chd-169	574	44	(	(	PUNCT
chd-169	574	45	2007	2007	NUM
chd-169	574	46	)	)	PUNCT
chd-169	574	47	.	.	PUNCT
chd-169	575	1	ledgf	ledgf	NOUN
chd-169	575	2	/	/	SYM
chd-169	575	3	p75	p75	PROPN
chd-169	575	4	has	have	AUX
chd-169	575	5	increased	increase	VERB
chd-169	575	6	expression	expression	NOUN
chd-169	575	7	in	in	ADP
chd-169	575	8	blasts	blast	NOUN
chd-169	575	9	from	from	ADP
chd-169	575	10	chemotherapy	chemotherapy	NOUN
chd-169	575	11	-	-	ADJ
chd-169	575	12	resistant	resistant	ADJ
chd-169	575	13	human	human	ADJ
chd-169	575	14	acute	acute	ADJ
chd-169	575	15	myelogenic	myelogenic	ADJ
chd-169	575	16	leukemia	leukemia	NOUN
chd-169	575	17	patients	patient	NOUN
chd-169	575	18	and	and	CCONJ
chd-169	575	19	protects	protect	VERB
chd-169	575	20	leukemia	leukemia	NOUN
chd-169	575	21	cells	cell	NOUN
chd-169	575	22	from	from	ADP
chd-169	575	23	apoptosis	apoptosis	NOUN
chd-169	575	24	in	in	ADP
chd-169	575	25	vitro	vitro	X
chd-169	575	26	.	.	PUNCT
chd-169	576	1	molecular	molecular	ADJ
chd-169	576	2	cancer	cancer	NOUN
chd-169	576	3	6	6	NUM
chd-169	576	4	,	,	PUNCT
chd-169	576	5	31	31	NUM
chd-169	576	6	.	.	PUNCT
chd-169	577	1	huggins	huggins	PROPN
chd-169	577	2	,	,	PUNCT
chd-169	577	3	c.	c.	PROPN
chd-169	577	4	,	,	PUNCT
chd-169	577	5	and	and	CCONJ
chd-169	577	6	hodges	hodge	NOUN
chd-169	577	7	,	,	PUNCT
chd-169	577	8	c.v	c.v	PROPN
chd-169	577	9	.	.	PROPN
chd-169	577	10	(	(	PUNCT
chd-169	577	11	1972	1972	NUM
chd-169	577	12	)	)	PUNCT
chd-169	577	13	.	.	PUNCT
chd-169	578	1	studies	study	NOUN
chd-169	578	2	on	on	ADP
chd-169	578	3	prostatic	prostatic	ADJ
chd-169	578	4	cancer	cancer	NOUN
chd-169	578	5	.	.	PUNCT
chd-169	579	1	i.	i.	PROPN
chd-169	579	2	the	the	DET
chd-169	579	3	effect	effect	NOUN
chd-169	579	4	of	of	ADP
chd-169	579	5	castration	castration	NOUN
chd-169	579	6	,	,	PUNCT
chd-169	579	7	of	of	ADP
chd-169	579	8	estrogen	estrogen	NOUN
chd-169	579	9	and	and	CCONJ
chd-169	579	10	androgen	androgen	NOUN
chd-169	579	11	injection	injection	NOUN
chd-169	579	12	on	on	ADP
chd-169	579	13	serum	serum	NOUN
chd-169	579	14	phosphatases	phosphatase	NOUN
chd-169	579	15	in	in	ADP
chd-169	579	16	metastatic	metastatic	ADJ
chd-169	579	17	carcinoma	carcinoma	NOUN
chd-169	579	18	of	of	ADP
chd-169	579	19	the	the	DET
chd-169	579	20	prostate	prostate	NOUN
chd-169	579	21	.	.	PUNCT
chd-169	580	1	ca	can	AUX
chd-169	580	2	cancer	cancer	PROPN
chd-169	580	3	j	j	PROPN
chd-169	580	4	clin	clin	PROPN
chd-169	580	5	22	22	NUM
chd-169	580	6	,	,	PUNCT
chd-169	580	7	232	232	NUM
chd-169	580	8	-	-	SYM
chd-169	580	9	240	240	NUM
chd-169	580	10	.	.	PUNCT
chd-169	581	1	hunt	hunt	PROPN
chd-169	581	2	,	,	PUNCT
chd-169	581	3	h.	h.	PROPN
chd-169	581	4	,	,	PUNCT
chd-169	581	5	donaldson	donaldson	PROPN
chd-169	581	6	,	,	PUNCT
chd-169	581	7	k.	k.	PROPN
chd-169	581	8	,	,	PUNCT
chd-169	581	9	strem	strem	PROPN
chd-169	581	10	,	,	PUNCT
chd-169	581	11	m.	m.	NOUN
chd-169	581	12	,	,	PUNCT
chd-169	581	13	zann	zann	PROPN
chd-169	581	14	,	,	PUNCT
chd-169	581	15	v.	v.	PROPN
chd-169	581	16	,	,	PUNCT
chd-169	581	17	leung	leung	PROPN
chd-169	581	18	,	,	PUNCT
chd-169	581	19	p.	p.	PROPN
chd-169	581	20	,	,	PUNCT
chd-169	581	21	sweet	sweet	ADJ
chd-169	581	22	,	,	PUNCT
chd-169	581	23	s.	s.	PROPN
chd-169	581	24	,	,	PUNCT
chd-169	581	25	connor	connor	PROPN
chd-169	581	26	,	,	PUNCT
chd-169	581	27	a.	a.	NOUN
chd-169	581	28	,	,	PUNCT
chd-169	581	29	combs	comb	NOUN
chd-169	581	30	,	,	PUNCT
chd-169	581	31	d.	d.	NOUN
chd-169	581	32	,	,	PUNCT
chd-169	581	33	and	and	CCONJ
chd-169	581	34	belanoff	belanoff	NOUN
chd-169	581	35	,	,	PUNCT
chd-169	581	36	j.	j.	PROPN
chd-169	581	37	(	(	PUNCT
chd-169	581	38	2018	2018	NUM
chd-169	581	39	)	)	PUNCT
chd-169	581	40	.	.	PUNCT
chd-169	582	1	assessment	assessment	NOUN
chd-169	582	2	of	of	ADP
chd-169	582	3	safety	safety	NOUN
chd-169	582	4	,	,	PUNCT
chd-169	582	5	tolerability	tolerability	NOUN
chd-169	582	6	,	,	PUNCT
chd-169	582	7	pharmacokinetics	pharmacokinetic	NOUN
chd-169	582	8	,	,	PUNCT
chd-169	582	9	and	and	CCONJ
chd-169	582	10	pharmacological	pharmacological	ADJ
chd-169	582	11	effect	effect	NOUN
chd-169	582	12	of	of	ADP
chd-169	582	13	orally	orally	ADV
chd-169	582	14	administered	administer	VERB
chd-169	582	15	cort125134	cort125134	PROPN
chd-169	582	16	:	:	PUNCT
chd-169	582	17	an	an	DET
chd-169	582	18	adaptive	adaptive	ADJ
chd-169	582	19	,	,	PUNCT
chd-169	582	20	double	double	ADJ
chd-169	582	21	-	-	PUNCT
chd-169	582	22	blind	blind	ADJ
chd-169	582	23	,	,	PUNCT
chd-169	582	24	randomized	randomize	VERB
chd-169	582	25	,	,	PUNCT
chd-169	582	26	placebo	placebo	NOUN
chd-169	582	27	-	-	PUNCT
chd-169	582	28	controlled	control	VERB
chd-169	582	29	phase	phase	NOUN
chd-169	582	30	1	1	NUM
chd-169	582	31	clinical	clinical	ADJ
chd-169	582	32	study	study	NOUN
chd-169	582	33	.	.	PUNCT
chd-169	583	1	clin	clin	PROPN
chd-169	583	2	pharmacol	pharmacol	PROPN
chd-169	583	3	drug	drug	PROPN
chd-169	583	4	dev	dev	PROPN
chd-169	583	5	7	7	NUM
chd-169	583	6	,	,	PUNCT
chd-169	583	7	408	408	NUM
chd-169	583	8	-	-	SYM
chd-169	583	9	421	421	NUM
chd-169	583	10	.	.	PUNCT
chd-169	584	1	hunt	hunt	PROPN
chd-169	584	2	,	,	PUNCT
chd-169	584	3	h.j	h.j	PROPN
chd-169	584	4	.	.	PROPN
chd-169	584	5	,	,	PUNCT
chd-169	584	6	ray	ray	PROPN
chd-169	584	7	,	,	PUNCT
chd-169	584	8	n.c	n.c	PROPN
chd-169	584	9	.	.	PROPN
chd-169	584	10	,	,	PUNCT
chd-169	584	11	hynd	hynd	PROPN
chd-169	584	12	,	,	PUNCT
chd-169	584	13	g.	g.	PROPN
chd-169	584	14	,	,	PUNCT
chd-169	584	15	sutton	sutton	PROPN
chd-169	584	16	,	,	PUNCT
chd-169	584	17	j.	j.	PROPN
chd-169	584	18	,	,	PUNCT
chd-169	584	19	sajad	sajad	PROPN
chd-169	584	20	,	,	PUNCT
chd-169	584	21	m.	m.	NOUN
chd-169	584	22	,	,	PUNCT
chd-169	584	23	o'connor	o'connor	PROPN
chd-169	584	24	,	,	PUNCT
chd-169	584	25	e.	e.	PROPN
chd-169	584	26	,	,	PUNCT
chd-169	584	27	ahmed	ahmed	PROPN
chd-169	584	28	,	,	PUNCT
chd-169	584	29	s.	s.	PROPN
chd-169	584	30	,	,	PUNCT
chd-169	584	31	lockey	lockey	NOUN
chd-169	584	32	,	,	PUNCT
chd-169	584	33	p.	p.	NOUN
chd-169	584	34	,	,	PUNCT
chd-169	584	35	daly	daly	PROPN
chd-169	584	36	,	,	PUNCT
chd-169	584	37	s.	s.	PROPN
chd-169	584	38	,	,	PUNCT
chd-169	584	39	buckley	buckley	PROPN
chd-169	584	40	,	,	PUNCT
chd-169	584	41	g.	g.	PROPN
chd-169	584	42	,	,	PUNCT
chd-169	584	43	et	et	PROPN
chd-169	584	44	al	al	PROPN
chd-169	584	45	.	.	PUNCT
chd-169	584	46	(	(	PUNCT
chd-169	584	47	2012	2012	NUM
chd-169	584	48	)	)	PUNCT
chd-169	584	49	.	.	PUNCT
chd-169	585	1	discovery	discovery	NOUN
chd-169	585	2	of	of	ADP
chd-169	585	3	a	a	DET
chd-169	585	4	novel	novel	ADJ
chd-169	585	5	non	non	ADJ
chd-169	585	6	-	-	ADJ
chd-169	585	7	steroidal	steroidal	ADJ
chd-169	585	8	gr	gr	NOUN
chd-169	585	9	antagonist	antagonist	NOUN
chd-169	585	10	with	with	ADP
chd-169	585	11	in	in	ADP
chd-169	585	12	vivo	vivo	ADJ
chd-169	585	13	efficacy	efficacy	NOUN
chd-169	585	14	in	in	ADP
chd-169	585	15	the	the	DET
chd-169	585	16	olanzapine	olanzapine	NOUN
chd-169	585	17	-	-	PUNCT
chd-169	585	18	induced	induce	VERB
chd-169	585	19	weight	weight	NOUN
chd-169	585	20	gain	gain	NOUN
chd-169	585	21	model	model	NOUN
chd-169	585	22	in	in	ADP
chd-169	585	23	the	the	DET
chd-169	585	24	rat	rat	PROPN
chd-169	585	25	.	.	PROPN
chd-169	585	26	bioorg	bioorg	PROPN
chd-169	585	27	med	med	PROPN
chd-169	585	28	chem	chem	NOUN
chd-169	585	29	lett	lett	NOUN
chd-169	585	30	22	22	NUM
chd-169	585	31	,	,	PUNCT
chd-169	585	32	73767380	73767380	NUM
chd-169	585	33	.	.	PUNCT
chd-169	586	1	isikbay	isikbay	PROPN
chd-169	586	2	,	,	PUNCT
chd-169	586	3	m.	m.	NOUN
chd-169	586	4	,	,	PUNCT
chd-169	586	5	otto	otto	PROPN
chd-169	586	6	,	,	PUNCT
chd-169	586	7	k.	k.	PROPN
chd-169	586	8	,	,	PUNCT
chd-169	586	9	kregel	kregel	PROPN
chd-169	586	10	,	,	PUNCT
chd-169	586	11	s.	s.	PROPN
chd-169	586	12	,	,	PUNCT
chd-169	586	13	kach	kach	PROPN
chd-169	586	14	,	,	PUNCT
chd-169	586	15	j.	j.	PROPN
chd-169	586	16	,	,	PUNCT
chd-169	586	17	cai	cai	PROPN
chd-169	586	18	,	,	PUNCT
chd-169	586	19	y.	y.	PROPN
chd-169	586	20	,	,	PUNCT
chd-169	586	21	vander	vander	PROPN
chd-169	586	22	griend	griend	PROPN
chd-169	586	23	,	,	PUNCT
chd-169	586	24	d.j	d.j	PROPN
chd-169	586	25	.	.	PROPN
chd-169	586	26	,	,	PUNCT
chd-169	586	27	conzen	conzen	PROPN
chd-169	586	28	,	,	PUNCT
chd-169	586	29	s.d	s.d	PROPN
chd-169	586	30	.	.	PROPN
chd-169	586	31	,	,	PUNCT
chd-169	586	32	and	and	CCONJ
chd-169	586	33	szmulewitz	szmulewitz	PROPN
chd-169	586	34	,	,	PUNCT
chd-169	586	35	r.z	r.z	PROPN
chd-169	586	36	.	.	PUNCT
chd-169	586	37	(	(	PUNCT
chd-169	586	38	2014	2014	NUM
chd-169	586	39	)	)	PUNCT
chd-169	586	40	.	.	PUNCT
chd-169	587	1	glucocorticoid	glucocorticoid	ADJ
chd-169	587	2	receptor	receptor	NOUN
chd-169	587	3	activity	activity	NOUN
chd-169	587	4	contributes	contribute	VERB
chd-169	587	5	to	to	ADP
chd-169	587	6	resistance	resistance	NOUN
chd-169	587	7	to	to	ADP
chd-169	587	8	androgen	androgen	NOUN
chd-169	587	9	-	-	PUNCT
chd-169	587	10	targeted	target	VERB
chd-169	587	11	therapy	therapy	NOUN
chd-169	587	12	in	in	ADP
chd-169	587	13	prostate	prostate	NOUN
chd-169	587	14	cancer	cancer	NOUN
chd-169	587	15	.	.	PUNCT
chd-169	588	1	horm	horm	NOUN
chd-169	588	2	cancer	cancer	PROPN
chd-169	588	3	5	5	NUM
chd-169	588	4	,	,	PUNCT
chd-169	588	5	72	72	NUM
chd-169	588	6	-	-	SYM
chd-169	588	7	89	89	NUM
chd-169	588	8	.	.	PUNCT
chd-169	589	1	ito	ito	PROPN
chd-169	589	2	,	,	PUNCT
chd-169	589	3	k.	k.	PROPN
chd-169	589	4	,	,	PUNCT
chd-169	589	5	chung	chung	PROPN
chd-169	589	6	,	,	PUNCT
chd-169	589	7	k.f	k.f	PROPN
chd-169	589	8	.	.	PROPN
chd-169	589	9	,	,	PUNCT
chd-169	589	10	and	and	CCONJ
chd-169	589	11	adcock	adcock	NOUN
chd-169	589	12	,	,	PUNCT
chd-169	589	13	i.m	i.m	PROPN
chd-169	589	14	.	.	PUNCT
chd-169	589	15	(	(	PUNCT
chd-169	589	16	2006	2006	NUM
chd-169	589	17	)	)	PUNCT
chd-169	589	18	.	.	PUNCT
chd-169	590	1	update	update	NOUN
chd-169	590	2	on	on	ADP
chd-169	590	3	glucocorticoid	glucocorticoid	ADJ
chd-169	590	4	action	action	NOUN
chd-169	590	5	and	and	CCONJ
chd-169	590	6	resistance	resistance	NOUN
chd-169	590	7	.	.	PUNCT
chd-169	591	1	j	j	PROPN
chd-169	591	2	allergy	allergy	PROPN
chd-169	591	3	clin	clin	PROPN
chd-169	591	4	immunol	immunol	PROPN
chd-169	591	5	117	117	NUM
chd-169	591	6	,	,	PUNCT
chd-169	591	7	522	522	NUM
chd-169	591	8	-	-	SYM
chd-169	591	9	543	543	NUM
chd-169	591	10	.	.	PUNCT
chd-169	592	1	james	james	PROPN
chd-169	592	2	,	,	PUNCT
chd-169	592	3	n.d	n.d	PROPN
chd-169	592	4	.	.	PROPN
chd-169	592	5	,	,	PUNCT
chd-169	592	6	pirrie	pirrie	PROPN
chd-169	592	7	,	,	PUNCT
chd-169	592	8	s.j	s.j	PROPN
chd-169	592	9	.	.	PROPN
chd-169	592	10	,	,	PUNCT
chd-169	592	11	pope	pope	PROPN
chd-169	592	12	,	,	PUNCT
chd-169	592	13	a.m.	a.m.	ADV
chd-169	592	14	,	,	PUNCT
chd-169	592	15	barton	barton	PROPN
chd-169	592	16	,	,	PUNCT
chd-169	592	17	d.	d.	PROPN
chd-169	592	18	,	,	PUNCT
chd-169	592	19	andronis	andronis	PROPN
chd-169	592	20	,	,	PUNCT
chd-169	592	21	l.	l.	PROPN
chd-169	592	22	,	,	PUNCT
chd-169	592	23	goranitis	goranitis	PROPN
chd-169	592	24	,	,	PUNCT
chd-169	592	25	i.	i.	PROPN
chd-169	592	26	,	,	PUNCT
chd-169	592	27	collins	collins	PROPN
chd-169	592	28	,	,	PUNCT
chd-169	592	29	s.	s.	PROPN
chd-169	592	30	,	,	PUNCT
chd-169	592	31	daunton	daunton	PROPN
chd-169	592	32	,	,	PUNCT
chd-169	592	33	a.	a.	PROPN
chd-169	592	34	,	,	PUNCT
chd-169	592	35	mclaren	mclaren	PROPN
chd-169	592	36	,	,	PUNCT
chd-169	592	37	d.	d.	PROPN
chd-169	592	38	,	,	PUNCT
chd-169	592	39	o'sullivan	o'sullivan	PROPN
chd-169	592	40	,	,	PUNCT
chd-169	592	41	j.	j.	PROPN
chd-169	592	42	,	,	PUNCT
chd-169	592	43	et	et	PROPN
chd-169	592	44	al	al	PROPN
chd-169	592	45	.	.	PUNCT
chd-169	593	1	(	(	PUNCT
chd-169	593	2	2016	2016	NUM
chd-169	593	3	)	)	PUNCT
chd-169	593	4	.	.	PUNCT
chd-169	594	1	clinical	clinical	ADJ
chd-169	594	2	outcomes	outcome	NOUN
chd-169	594	3	and	and	CCONJ
chd-169	594	4	survival	survival	NOUN
chd-169	594	5	following	follow	VERB
chd-169	594	6	treatment	treatment	NOUN
chd-169	594	7	of	of	ADP
chd-169	594	8	metastatic	metastatic	ADJ
chd-169	594	9	castrate	castrate	NOUN
chd-169	594	10	-	-	PUNCT
chd-169	594	11	refractory	refractory	NOUN
chd-169	594	12	prostate	prostate	NOUN
chd-169	594	13	cancer	cancer	NOUN
chd-169	594	14	with	with	ADP
chd-169	594	15	docetaxel	docetaxel	NOUN
chd-169	594	16	alone	alone	ADJ
chd-169	594	17	or	or	CCONJ
chd-169	594	18	with	with	ADP
chd-169	594	19	strontium-89	strontium-89	PROPN
chd-169	594	20	,	,	PUNCT
chd-169	594	21	zoledronic	zoledronic	ADJ
chd-169	594	22	acid	acid	NOUN
chd-169	594	23	,	,	PUNCT
chd-169	594	24	or	or	CCONJ
chd-169	594	25	both	both	PRON
chd-169	594	26	:	:	PUNCT
chd-169	594	27	the	the	DET
chd-169	594	28	trapeze	trapeze	NOUN
chd-169	594	29	randomized	randomize	VERB
chd-169	594	30	clinical	clinical	ADJ
chd-169	594	31	trial	trial	NOUN
chd-169	594	32	.	.	PUNCT
chd-169	595	1	jama	jama	PROPN
chd-169	595	2	oncol	oncol	ADJ
chd-169	595	3	2	2	NUM
chd-169	595	4	,	,	PUNCT
chd-169	595	5	493	493	NUM
chd-169	595	6	-	-	SYM
chd-169	595	7	499	499	NUM
chd-169	595	8	.	.	PUNCT
chd-169	596	1	jaratlerdsiri	jaratlerdsiri	PROPN
chd-169	596	2	,	,	PUNCT
chd-169	596	3	w.	w.	PROPN
chd-169	596	4	,	,	PUNCT
chd-169	596	5	chan	chan	PROPN
chd-169	596	6	,	,	PUNCT
chd-169	596	7	e.k.f	e.k.f	PROPN
chd-169	596	8	.	.	PROPN
chd-169	596	9	,	,	PUNCT
chd-169	596	10	gong	gong	PROPN
chd-169	596	11	,	,	PUNCT
chd-169	596	12	t.	t.	PROPN
chd-169	596	13	,	,	PUNCT
chd-169	596	14	petersen	petersen	PROPN
chd-169	596	15	,	,	PUNCT
chd-169	596	16	d.c	d.c	PROPN
chd-169	596	17	.	.	PROPN
chd-169	596	18	,	,	PUNCT
chd-169	596	19	kalsbeek	kalsbeek	PROPN
chd-169	596	20	,	,	PUNCT
chd-169	596	21	a.m.f	a.m.f	NOUN
chd-169	596	22	.	.	PROPN
chd-169	596	23	,	,	PUNCT
chd-169	596	24	venter	venter	PROPN
chd-169	596	25	,	,	PUNCT
chd-169	596	26	p.a	p.a	PROPN
chd-169	596	27	.	.	PROPN
chd-169	596	28	,	,	PUNCT
chd-169	596	29	stricker	stricker	PROPN
chd-169	596	30	,	,	PUNCT
chd-169	596	31	p.d	p.d	PROPN
chd-169	596	32	.	.	PROPN
chd-169	596	33	,	,	PUNCT
chd-169	596	34	bornman	bornman	NOUN
chd-169	596	35	,	,	PUNCT
chd-169	596	36	m.s.r	m.s.r	PROPN
chd-169	596	37	.	.	PROPN
chd-169	596	38	,	,	PUNCT
chd-169	596	39	and	and	CCONJ
chd-169	596	40	hayes	hayes	PROPN
chd-169	596	41	,	,	PUNCT
chd-169	596	42	v.m	v.m	PROPN
chd-169	596	43	.	.	PUNCT
chd-169	596	44	(	(	PUNCT
chd-169	596	45	2018	2018	NUM
chd-169	596	46	)	)	PUNCT
chd-169	596	47	.	.	PUNCT
chd-169	597	1	whole	whole	ADJ
chd-169	597	2	-	-	PUNCT
chd-169	597	3	genome	genome	NOUN
chd-169	597	4	sequencing	sequencing	NOUN
chd-169	597	5	reveals	reveal	NOUN
chd-169	597	6	elevated	elevate	VERB
chd-169	597	7	tumor	tumor	NOUN
chd-169	597	8	mutational	mutational	ADJ
chd-169	597	9	burden	burden	NOUN
chd-169	597	10	and	and	CCONJ
chd-169	597	11	initiating	initiate	VERB
chd-169	597	12	driver	driver	NOUN
chd-169	597	13	mutations	mutation	NOUN
chd-169	597	14	in	in	ADP
chd-169	597	15	african	african	ADJ
chd-169	597	16	men	man	NOUN
chd-169	597	17	with	with	ADP
chd-169	597	18	treatment	treatment	NOUN
chd-169	597	19	-	-	PUNCT
chd-169	597	20	naive	naive	ADJ
chd-169	597	21	,	,	PUNCT
chd-169	597	22	high	high	ADJ
chd-169	597	23	-	-	PUNCT
chd-169	597	24	risk	risk	NOUN
chd-169	597	25	prostate	prostate	NOUN
chd-169	597	26	cancer	cancer	NOUN
chd-169	597	27	.	.	PUNCT
chd-169	598	1	cancer	cancer	NOUN
chd-169	598	2	res	re	NOUN
chd-169	598	3	78	78	NUM
chd-169	598	4	,	,	PUNCT
chd-169	598	5	6736	6736	NUM
chd-169	598	6	-	-	SYM
chd-169	598	7	6746	6746	NUM
chd-169	598	8	.	.	PUNCT
chd-169	599	1	jemal	jemal	ADJ
chd-169	599	2	,	,	PUNCT
chd-169	599	3	a.	a.	PROPN
chd-169	599	4	,	,	PUNCT
chd-169	599	5	siegel	siegel	PROPN
chd-169	599	6	,	,	PUNCT
chd-169	599	7	r.	r.	PROPN
chd-169	599	8	,	,	PUNCT
chd-169	599	9	ward	ward	PROPN
chd-169	599	10	,	,	PUNCT
chd-169	599	11	e.	e.	PROPN
chd-169	599	12	,	,	PUNCT
chd-169	599	13	murray	murray	PROPN
chd-169	599	14	,	,	PUNCT
chd-169	599	15	t.	t.	PROPN
chd-169	599	16	,	,	PUNCT
chd-169	599	17	xu	xu	PROPN
chd-169	599	18	,	,	PUNCT
chd-169	599	19	j.	j.	PROPN
chd-169	599	20	,	,	PUNCT
chd-169	599	21	smigal	smigal	PROPN
chd-169	599	22	,	,	PUNCT
chd-169	599	23	c.	c.	NOUN
chd-169	599	24	,	,	PUNCT
chd-169	599	25	and	and	CCONJ
chd-169	599	26	thun	thun	PROPN
chd-169	599	27	,	,	PUNCT
chd-169	599	28	m.j	m.j	PROPN
chd-169	599	29	.	.	PROPN
chd-169	599	30	(	(	PUNCT
chd-169	599	31	2006	2006	NUM
chd-169	599	32	)	)	PUNCT
chd-169	599	33	.	.	PUNCT
chd-169	600	1	cancer	cancer	NOUN
chd-169	600	2	statistics	statistic	NOUN
chd-169	600	3	,	,	PUNCT
chd-169	600	4	2006	2006	NUM
chd-169	600	5	.	.	PUNCT
chd-169	601	1	ca	ca	NOUN
chd-169	601	2	:	:	PUNCT
chd-169	601	3	a	a	DET
chd-169	601	4	cancer	cancer	NOUN
chd-169	601	5	journal	journal	NOUN
chd-169	601	6	for	for	ADP
chd-169	601	7	clinicians	clinician	NOUN
chd-169	601	8	56	56	NUM
chd-169	601	9	,	,	PUNCT
chd-169	601	10	106	106	NUM
chd-169	601	11	-	-	SYM
chd-169	601	12	130	130	NUM
chd-169	601	13	.	.	PUNCT
chd-169	602	1	jia	jia	PROPN
chd-169	602	2	,	,	PUNCT
chd-169	602	3	l.	l.	PROPN
chd-169	602	4	,	,	PUNCT
chd-169	602	5	choong	choong	PROPN
chd-169	602	6	,	,	PUNCT
chd-169	602	7	c.s	c.s	PROPN
chd-169	602	8	.	.	PROPN
chd-169	602	9	,	,	PUNCT
chd-169	602	10	ricciardelli	ricciardelli	PROPN
chd-169	602	11	,	,	PUNCT
chd-169	602	12	c.	c.	PROPN
chd-169	602	13	,	,	PUNCT
chd-169	602	14	kim	kim	PROPN
chd-169	602	15	,	,	PUNCT
chd-169	602	16	j.	j.	PROPN
chd-169	602	17	,	,	PUNCT
chd-169	602	18	tilley	tilley	PROPN
chd-169	602	19	,	,	PUNCT
chd-169	602	20	w.d	w.d	PROPN
chd-169	602	21	.	.	PROPN
chd-169	602	22	,	,	PUNCT
chd-169	602	23	and	and	CCONJ
chd-169	602	24	coetzee	coetzee	PROPN
chd-169	602	25	,	,	PUNCT
chd-169	602	26	g.a	g.a	PROPN
chd-169	602	27	.	.	PROPN
chd-169	602	28	(	(	PUNCT
chd-169	602	29	2004	2004	NUM
chd-169	602	30	)	)	PUNCT
chd-169	602	31	.	.	PUNCT
chd-169	603	1	androgen	androgen	NOUN
chd-169	603	2	receptor	receptor	NOUN
chd-169	603	3	signaling	signal	VERB
chd-169	603	4	:	:	PUNCT
chd-169	603	5	mechanism	mechanism	NOUN
chd-169	603	6	of	of	ADP
chd-169	603	7	interleukin-6	interleukin-6	NUM
chd-169	603	8	inhibition	inhibition	NOUN
chd-169	603	9	.	.	PUNCT
chd-169	604	1	cancer	cancer	NOUN
chd-169	604	2	research	research	NOUN
chd-169	604	3	64	64	NUM
chd-169	604	4	,	,	PUNCT
chd-169	604	5	2619	2619	NUM
chd-169	604	6	-	-	SYM
chd-169	604	7	2626	2626	NUM
chd-169	604	8	.	.	PUNCT
chd-169	605	1	joseph	joseph	PROPN
chd-169	605	2	,	,	PUNCT
chd-169	605	3	d.n	d.n	PROPN
chd-169	605	4	.	.	PROPN
chd-169	605	5	,	,	PUNCT
chd-169	605	6	and	and	CCONJ
chd-169	605	7	whirledge	whirledge	VERB
chd-169	605	8	,	,	PUNCT
chd-169	605	9	s.	s.	PROPN
chd-169	605	10	(	(	PUNCT
chd-169	605	11	2017	2017	NUM
chd-169	605	12	)	)	PUNCT
chd-169	605	13	.	.	PUNCT
chd-169	606	1	stress	stress	NOUN
chd-169	606	2	and	and	CCONJ
chd-169	606	3	the	the	DET
chd-169	606	4	hpa	hpa	NOUN
chd-169	606	5	axis	axis	NOUN
chd-169	606	6	:	:	PUNCT
chd-169	606	7	balancing	balance	VERB
chd-169	606	8	homeostasis	homeostasis	NOUN
chd-169	606	9	and	and	CCONJ
chd-169	606	10	fertility	fertility	NOUN
chd-169	606	11	.	.	PUNCT
chd-169	607	1	int	int	PROPN
chd-169	607	2	j	j	PROPN
chd-169	607	3	mol	mol	ADP
chd-169	607	4	sci	sci	PROPN
chd-169	607	5	18	18	NUM
chd-169	607	6	.	.	PUNCT
chd-169	608	1	july	july	PROPN
chd-169	608	2	,	,	PUNCT
chd-169	608	3	l.v	l.v	PROPN
chd-169	608	4	.	.	PROPN
chd-169	608	5	,	,	PUNCT
chd-169	608	6	akbari	akbari	PROPN
chd-169	608	7	,	,	PUNCT
chd-169	608	8	m.	m.	NOUN
chd-169	608	9	,	,	PUNCT
chd-169	608	10	zellweger	zellweger	PROPN
chd-169	608	11	,	,	PUNCT
chd-169	608	12	t.	t.	PROPN
chd-169	608	13	,	,	PUNCT
chd-169	608	14	jones	jones	PROPN
chd-169	608	15	,	,	PUNCT
chd-169	608	16	e.c	e.c	PROPN
chd-169	608	17	.	.	PROPN
chd-169	608	18	,	,	PUNCT
chd-169	608	19	goldenberg	goldenberg	PROPN
chd-169	608	20	,	,	PUNCT
chd-169	608	21	s.l	s.l	PROPN
chd-169	608	22	.	.	PROPN
chd-169	608	23	,	,	PUNCT
chd-169	608	24	and	and	CCONJ
chd-169	608	25	gleave	gleave	PROPN
chd-169	608	26	,	,	PUNCT
chd-169	608	27	m.e	m.e	PROPN
chd-169	608	28	.	.	PROPN
chd-169	608	29	(	(	PUNCT
chd-169	608	30	2002	2002	NUM
chd-169	608	31	)	)	PUNCT
chd-169	608	32	.	.	PUNCT
chd-169	609	1	clusterin	clusterin	ADJ
chd-169	609	2	expression	expression	NOUN
chd-169	609	3	is	be	AUX
chd-169	609	4	significantly	significantly	ADV
chd-169	609	5	enhanced	enhance	VERB
chd-169	609	6	in	in	ADP
chd-169	609	7	prostate	prostate	NOUN
chd-169	609	8	cancer	cancer	NOUN
chd-169	609	9	cells	cell	NOUN
chd-169	609	10	following	follow	VERB
chd-169	609	11	androgen	androgen	NOUN
chd-169	609	12	withdrawal	withdrawal	NOUN
chd-169	609	13	therapy	therapy	NOUN
chd-169	609	14	.	.	PUNCT
chd-169	610	1	prostate	prostate	NOUN
chd-169	610	2	50	50	NUM
chd-169	610	3	,	,	PUNCT
chd-169	610	4	179	179	NUM
chd-169	610	5	-	-	SYM
chd-169	610	6	188	188	NUM
chd-169	610	7	.	.	PUNCT
chd-169	611	1	kach	kach	PROPN
chd-169	611	2	,	,	PUNCT
chd-169	611	3	j.	j.	PROPN
chd-169	611	4	,	,	PUNCT
chd-169	611	5	long	long	ADV
chd-169	611	6	,	,	PUNCT
chd-169	611	7	t.m	t.m	PROPN
chd-169	611	8	.	.	PROPN
chd-169	611	9	,	,	PUNCT
chd-169	611	10	selman	selman	PROPN
chd-169	611	11	,	,	PUNCT
chd-169	611	12	p.	p.	PROPN
chd-169	611	13	,	,	PUNCT
chd-169	611	14	tonsing	tonse	VERB
chd-169	611	15	-	-	PUNCT
chd-169	611	16	carter	carter	NOUN
chd-169	611	17	,	,	PUNCT
chd-169	611	18	e.y	e.y	PROPN
chd-169	611	19	.	.	PROPN
chd-169	611	20	,	,	PUNCT
chd-169	611	21	bacalao	bacalao	PROPN
chd-169	611	22	,	,	PUNCT
chd-169	611	23	m.a	m.a	PROPN
chd-169	611	24	.	.	PROPN
chd-169	611	25	,	,	PUNCT
chd-169	611	26	lastra	lastra	PROPN
chd-169	611	27	,	,	PUNCT
chd-169	611	28	r.r	r.r	PROPN
chd-169	611	29	.	.	PROPN
chd-169	611	30	,	,	PUNCT
chd-169	611	31	de	de	ADP
chd-169	611	32	wet	wet	PROPN
chd-169	611	33	,	,	PUNCT
chd-169	611	34	l.	l.	PROPN
chd-169	611	35	,	,	PUNCT
chd-169	611	36	comiskey	comiskey	PROPN
chd-169	611	37	,	,	PUNCT
chd-169	611	38	s.	s.	PROPN
chd-169	611	39	,	,	PUNCT
chd-169	611	40	gillard	gillard	PROPN
chd-169	611	41	,	,	PUNCT
chd-169	611	42	m.	m.	NOUN
chd-169	611	43	,	,	PUNCT
chd-169	611	44	vanopstall	vanopstall	NOUN
chd-169	611	45	,	,	PUNCT
chd-169	611	46	c.	c.	PROPN
chd-169	611	47	,	,	PUNCT
chd-169	611	48	et	et	PROPN
chd-169	611	49	al	al	PROPN
chd-169	611	50	.	.	PUNCT
chd-169	611	51	(	(	PUNCT
chd-169	611	52	2017	2017	NUM
chd-169	611	53	)	)	PUNCT
chd-169	611	54	.	.	PUNCT
chd-169	612	1	selective	selective	ADJ
chd-169	612	2	glucocorticoid	glucocorticoid	ADJ
chd-169	612	3	receptor	receptor	NOUN
chd-169	612	4	modulators	modulator	NOUN
chd-169	612	5	(	(	PUNCT
chd-169	612	6	sgrms	sgrm	NOUN
chd-169	612	7	)	)	PUNCT
chd-169	612	8	delay	delay	NOUN
chd-169	612	9	castrate	castrate	NOUN
chd-169	612	10	-	-	PUNCT
chd-169	612	11	resistant	resistant	ADJ
chd-169	612	12	prostate	prostate	NOUN
chd-169	612	13	cancer	cancer	NOUN
chd-169	612	14	growth	growth	NOUN
chd-169	612	15	.	.	PUNCT
chd-169	613	1	molecular	molecular	ADJ
chd-169	613	2	cancer	cancer	NOUN
chd-169	613	3	therapeutics	therapeutic	NOUN
chd-169	613	4	16	16	NUM
chd-169	613	5	,	,	PUNCT
chd-169	613	6	1680	1680	NUM
chd-169	613	7	-	-	SYM
chd-169	613	8	1692	1692	NUM
chd-169	613	9	.	.	PUNCT
chd-169	614	1	kadmiel	kadmiel	PROPN
chd-169	614	2	,	,	PUNCT
chd-169	614	3	m.	m.	NOUN
chd-169	614	4	,	,	PUNCT
chd-169	614	5	and	and	CCONJ
chd-169	614	6	cidlowski	cidlowski	VERB
chd-169	614	7	,	,	PUNCT
chd-169	614	8	j.a	j.a	PROPN
chd-169	614	9	.	.	PROPN
chd-169	614	10	(	(	PUNCT
chd-169	614	11	2013	2013	NUM
chd-169	614	12	)	)	PUNCT
chd-169	614	13	.	.	PUNCT
chd-169	615	1	glucocorticoid	glucocorticoid	ADJ
chd-169	615	2	receptor	receptor	NOUN
chd-169	615	3	signaling	signal	VERB
chd-169	615	4	in	in	ADP
chd-169	615	5	health	health	NOUN
chd-169	615	6	and	and	CCONJ
chd-169	615	7	disease	disease	NOUN
chd-169	615	8	.	.	PUNCT
chd-169	616	1	trends	trend	NOUN
chd-169	616	2	pharmacol	pharmacol	PROPN
chd-169	616	3	sci	sci	PROPN
chd-169	616	4	34	34	NUM
chd-169	616	5	,	,	PUNCT
chd-169	616	6	518	518	NUM
chd-169	616	7	-	-	SYM
chd-169	616	8	530	530	NUM
chd-169	616	9	.	.	PUNCT
chd-169	617	1	kantor	kantor	PROPN
chd-169	617	2	,	,	PUNCT
chd-169	617	3	e.d	e.d	PROPN
chd-169	617	4	.	.	PROPN
chd-169	617	5	,	,	PUNCT
chd-169	617	6	haneuse	haneuse	PROPN
chd-169	617	7	,	,	PUNCT
chd-169	617	8	s.	s.	PROPN
chd-169	617	9	,	,	PUNCT
chd-169	617	10	valdimarsdottir	valdimarsdottir	PROPN
chd-169	617	11	,	,	PUNCT
chd-169	617	12	u.a	u.a	PROPN
chd-169	617	13	.	.	PROPN
chd-169	617	14	,	,	PUNCT
chd-169	617	15	williams	williams	PROPN
chd-169	617	16	,	,	PUNCT
chd-169	617	17	d.r	d.r	PROPN
chd-169	617	18	.	.	PROPN
chd-169	617	19	,	,	PUNCT
chd-169	617	20	signorello	signorello	PROPN
chd-169	617	21	,	,	PUNCT
chd-169	617	22	l.b	l.b	PROPN
chd-169	617	23	.	.	PROPN
chd-169	617	24	,	,	PUNCT
chd-169	617	25	and	and	CCONJ
chd-169	617	26	rider	rider	NOUN
chd-169	617	27	,	,	PUNCT
chd-169	617	28	j.r	j.r	PROPN
chd-169	617	29	.	.	PROPN
chd-169	617	30	(	(	PUNCT
chd-169	617	31	2019	2019	NUM
chd-169	617	32	)	)	PUNCT
chd-169	617	33	.	.	PUNCT
chd-169	618	1	socioenvironmental	socioenvironmental	ADJ
chd-169	618	2	adversity	adversity	NOUN
chd-169	618	3	and	and	CCONJ
chd-169	618	4	risk	risk	NOUN
chd-169	618	5	of	of	ADP
chd-169	618	6	prostate	prostate	NOUN
chd-169	618	7	cancer	cancer	NOUN
chd-169	618	8	in	in	ADP
chd-169	618	9	non	non	ADJ
chd-169	618	10	-	-	ADJ
chd-169	618	11	hispanic	hispanic	ADJ
chd-169	618	12	black	black	ADJ
chd-169	618	13	and	and	CCONJ
chd-169	618	14	white	white	ADJ
chd-169	618	15	men	man	NOUN
chd-169	618	16	.	.	PUNCT
chd-169	619	1	cancer	cancer	NOUN
chd-169	619	2	causes	cause	VERB
chd-169	619	3	control	control	NOUN
chd-169	619	4	30	30	NUM
chd-169	619	5	,	,	PUNCT
chd-169	619	6	9971007	9971007	NUM
chd-169	619	7	.	.	PUNCT
chd-169	620	1	karakas	karakas	PROPN
chd-169	620	2	,	,	PUNCT
chd-169	620	3	c.	c.	PROPN
chd-169	620	4	,	,	PUNCT
chd-169	620	5	wang	wang	PROPN
chd-169	620	6	,	,	PUNCT
chd-169	620	7	c.	c.	PROPN
chd-169	620	8	,	,	PUNCT
chd-169	620	9	deng	deng	PROPN
chd-169	620	10	,	,	PUNCT
chd-169	620	11	f.	f.	PROPN
chd-169	620	12	,	,	PUNCT
chd-169	620	13	huang	huang	PROPN
chd-169	620	14	,	,	PUNCT
chd-169	620	15	h.	h.	PROPN
chd-169	620	16	,	,	PUNCT
chd-169	620	17	wang	wang	PROPN
chd-169	620	18	,	,	PUNCT
chd-169	620	19	d.	d.	PROPN
chd-169	620	20	,	,	PUNCT
chd-169	620	21	and	and	CCONJ
chd-169	620	22	lee	lee	PROPN
chd-169	620	23	,	,	PUNCT
chd-169	620	24	p.	p.	NOUN
chd-169	620	25	(	(	PUNCT
chd-169	620	26	2017	2017	NUM
chd-169	620	27	)	)	PUNCT
chd-169	620	28	.	.	PUNCT
chd-169	621	1	molecular	molecular	ADJ
chd-169	621	2	mechanisms	mechanism	NOUN
chd-169	621	3	involving	involve	VERB
chd-169	621	4	prostate	prostate	NOUN
chd-169	621	5	cancer	cancer	NOUN
chd-169	621	6	racial	racial	ADJ
chd-169	621	7	disparity	disparity	NOUN
chd-169	621	8	.	.	PUNCT
chd-169	622	1	am	be	AUX
chd-169	622	2	j	j	PROPN
chd-169	622	3	clin	clin	PROPN
chd-169	622	4	exp	exp	PROPN
chd-169	622	5	urol	urol	PROPN
chd-169	622	6	5	5	NUM
chd-169	622	7	,	,	PUNCT
chd-169	622	8	34	34	NUM
chd-169	622	9	-	-	SYM
chd-169	622	10	48	48	NUM
chd-169	622	11	.	.	PUNCT
chd-169	623	1	kassel	kassel	PROPN
chd-169	623	2	,	,	PUNCT
chd-169	623	3	o.	o.	PROPN
chd-169	623	4	,	,	PUNCT
chd-169	623	5	and	and	CCONJ
chd-169	623	6	herrlich	herrlich	NOUN
chd-169	623	7	,	,	PUNCT
chd-169	623	8	p.	p.	NOUN
chd-169	623	9	(	(	PUNCT
chd-169	623	10	2007	2007	NUM
chd-169	623	11	)	)	PUNCT
chd-169	623	12	.	.	PUNCT
chd-169	623	13	crosstalk	crosstalk	VERB
chd-169	623	14	between	between	ADP
chd-169	623	15	the	the	DET
chd-169	623	16	glucocorticoid	glucocorticoid	ADJ
chd-169	623	17	receptor	receptor	NOUN
chd-169	623	18	and	and	CCONJ
chd-169	623	19	other	other	ADJ
chd-169	623	20	transcription	transcription	NOUN
chd-169	623	21	factors	factor	NOUN
chd-169	623	22	:	:	PUNCT
chd-169	623	23	molecular	molecular	ADJ
chd-169	623	24	aspects	aspect	NOUN
chd-169	623	25	.	.	PUNCT
chd-169	624	1	mol	mol	ADP
chd-169	624	2	cell	cell	NOUN
chd-169	624	3	endocrinol	endocrinol	NOUN
chd-169	624	4	275	275	NUM
chd-169	624	5	,	,	PUNCT
chd-169	624	6	13	13	NUM
chd-169	624	7	-	-	SYM
chd-169	624	8	29	29	NUM
chd-169	624	9	.	.	PUNCT
chd-169	625	1	kaufman	kaufman	PROPN
chd-169	625	2	,	,	PUNCT
chd-169	625	3	j.s	j.s	PROPN
chd-169	625	4	.	.	PROPN
chd-169	625	5	,	,	PUNCT
chd-169	625	6	cooper	cooper	PROPN
chd-169	625	7	,	,	PUNCT
chd-169	625	8	r.s	r.s	PROPN
chd-169	625	9	.	.	PROPN
chd-169	625	10	,	,	PUNCT
chd-169	625	11	and	and	CCONJ
chd-169	625	12	mcgee	mcgee	PROPN
chd-169	625	13	,	,	PUNCT
chd-169	625	14	d.l	d.l	PROPN
chd-169	625	15	.	.	PROPN
chd-169	625	16	(	(	PUNCT
chd-169	625	17	1997	1997	NUM
chd-169	625	18	)	)	PUNCT
chd-169	625	19	.	.	PUNCT
chd-169	626	1	socioeconomic	socioeconomic	ADJ
chd-169	626	2	status	status	NOUN
chd-169	626	3	and	and	CCONJ
chd-169	626	4	health	health	NOUN
chd-169	626	5	in	in	ADP
chd-169	626	6	blacks	black	NOUN
chd-169	626	7	and	and	CCONJ
chd-169	626	8	whites	white	NOUN
chd-169	626	9	:	:	PUNCT
chd-169	626	10	the	the	DET
chd-169	626	11	problem	problem	NOUN
chd-169	626	12	of	of	ADP
chd-169	626	13	residual	residual	ADJ
chd-169	626	14	confounding	confounding	NOUN
chd-169	626	15	and	and	CCONJ
chd-169	626	16	the	the	DET
chd-169	626	17	resiliency	resiliency	NOUN
chd-169	626	18	of	of	ADP
chd-169	626	19	race	race	NOUN
chd-169	626	20	.	.	PUNCT
chd-169	627	1	epidemiology	epidemiology	NOUN
chd-169	627	2	8	8	NUM
chd-169	627	3	,	,	PUNCT
chd-169	627	4	621	621	NUM
chd-169	627	5	-	-	SYM
chd-169	627	6	628	628	NUM
chd-169	627	7	.	.	PUNCT
chd-169	628	1	kelly	kelly	PROPN
chd-169	628	2	,	,	PUNCT
chd-169	628	3	s.p	s.p	PROPN
chd-169	628	4	.	.	PROPN
chd-169	628	5	,	,	PUNCT
chd-169	628	6	rosenberg	rosenberg	PROPN
chd-169	628	7	,	,	PUNCT
chd-169	628	8	p.s	p.s	PROPN
chd-169	628	9	.	.	PROPN
chd-169	628	10	,	,	PUNCT
chd-169	628	11	anderson	anderson	PROPN
chd-169	628	12	,	,	PUNCT
chd-169	628	13	w.f	w.f	PROPN
chd-169	628	14	.	.	PROPN
chd-169	628	15	,	,	PUNCT
chd-169	628	16	andreotti	andreotti	PROPN
chd-169	628	17	,	,	PUNCT
chd-169	628	18	g.	g.	PROPN
chd-169	628	19	,	,	PUNCT
chd-169	628	20	younes	younes	PROPN
chd-169	628	21	,	,	PUNCT
chd-169	628	22	n.	n.	NOUN
chd-169	628	23	,	,	PUNCT
chd-169	628	24	cleary	cleary	PROPN
chd-169	628	25	,	,	PUNCT
chd-169	628	26	s.d	s.d	PROPN
chd-169	628	27	.	.	PROPN
chd-169	628	28	,	,	PUNCT
chd-169	628	29	and	and	CCONJ
chd-169	628	30	cook	cook	VERB
chd-169	628	31	,	,	PUNCT
chd-169	628	32	m.b	m.b	PROPN
chd-169	628	33	.	.	PROPN
chd-169	628	34	(	(	PUNCT
chd-169	628	35	2017	2017	NUM
chd-169	628	36	)	)	PUNCT
chd-169	628	37	.	.	PUNCT
chd-169	629	1	trends	trend	NOUN
chd-169	629	2	in	in	ADP
chd-169	629	3	the	the	DET
chd-169	629	4	incidence	incidence	NOUN
chd-169	629	5	of	of	ADP
chd-169	629	6	fatal	fatal	ADJ
chd-169	629	7	prostate	prostate	NOUN
chd-169	629	8	cancer	cancer	NOUN
chd-169	629	9	in	in	ADP
chd-169	629	10	the	the	DET
chd-169	629	11	united	united	PROPN
chd-169	629	12	states	states	PROPN
chd-169	629	13	by	by	ADP
chd-169	629	14	race	race	NOUN
chd-169	629	15	.	.	PUNCT
chd-169	630	1	eur	eur	PROPN
chd-169	630	2	urol	urol	ADJ
chd-169	630	3	71	71	NUM
chd-169	630	4	,	,	PUNCT
chd-169	630	5	195	195	NUM
chd-169	630	6	-	-	PUNCT
chd-169	630	7	201	201	NUM
chd-169	630	8	.	.	PUNCT
chd-169	631	1	kheirandish	kheirandish	PROPN
chd-169	631	2	,	,	PUNCT
chd-169	631	3	p.	p.	NOUN
chd-169	631	4	,	,	PUNCT
chd-169	631	5	and	and	CCONJ
chd-169	631	6	chinegwundoh	chinegwundoh	PROPN
chd-169	631	7	,	,	PUNCT
chd-169	631	8	f.	f.	PROPN
chd-169	631	9	(	(	PUNCT
chd-169	631	10	2011	2011	NUM
chd-169	631	11	)	)	PUNCT
chd-169	631	12	.	.	PUNCT
chd-169	632	1	ethnic	ethnic	ADJ
chd-169	632	2	differences	difference	NOUN
chd-169	632	3	in	in	ADP
chd-169	632	4	prostate	prostate	NOUN
chd-169	632	5	cancer	cancer	NOUN
chd-169	632	6	.	.	PUNCT
chd-169	633	1	br	br	PROPN
chd-169	633	2	j	j	PROPN
chd-169	633	3	cancer	cancer	PROPN
chd-169	633	4	105	105	NUM
chd-169	633	5	,	,	PUNCT
chd-169	633	6	481	481	NUM
chd-169	633	7	-	-	SYM
chd-169	633	8	485	485	NUM
chd-169	633	9	.	.	PUNCT
chd-169	634	1	kinlock	kinlock	PROPN
chd-169	634	2	,	,	PUNCT
chd-169	634	3	b.l	b.l	PROPN
chd-169	634	4	.	.	PROPN
chd-169	634	5	,	,	PUNCT
chd-169	634	6	thorpe	thorpe	PROPN
chd-169	634	7	,	,	PUNCT
chd-169	634	8	r.j	r.j	PROPN
chd-169	634	9	.	.	PROPN
chd-169	634	10	,	,	PUNCT
chd-169	634	11	jr	jr	PROPN
chd-169	634	12	.	.	PROPN
chd-169	634	13	,	,	PUNCT
chd-169	634	14	howard	howard	PROPN
chd-169	634	15	,	,	PUNCT
chd-169	634	16	d.l	d.l	PROPN
chd-169	634	17	.	.	PROPN
chd-169	634	18	,	,	PUNCT
chd-169	634	19	bowie	bowie	PROPN
chd-169	634	20	,	,	PUNCT
chd-169	634	21	j.v	j.v	PROPN
chd-169	634	22	.	.	PROPN
chd-169	634	23	,	,	PUNCT
chd-169	634	24	ross	ross	PROPN
chd-169	634	25	,	,	PUNCT
chd-169	634	26	l.e	l.e	PROPN
chd-169	634	27	.	.	PROPN
chd-169	634	28	,	,	PUNCT
chd-169	634	29	fakunle	fakunle	PROPN
chd-169	634	30	,	,	PUNCT
chd-169	634	31	d.o	d.o	PROPN
chd-169	634	32	.	.	PROPN
chd-169	634	33	,	,	PUNCT
chd-169	634	34	and	and	CCONJ
chd-169	634	35	laveist	laveist	PROPN
chd-169	634	36	,	,	PUNCT
chd-169	634	37	t.a	t.a	PROPN
chd-169	634	38	.	.	PROPN
chd-169	634	39	(	(	PUNCT
chd-169	634	40	2016	2016	NUM
chd-169	634	41	)	)	PUNCT
chd-169	634	42	.	.	PUNCT
chd-169	635	1	racial	racial	ADJ
chd-169	635	2	disparity	disparity	NOUN
chd-169	635	3	in	in	ADP
chd-169	635	4	time	time	NOUN
chd-169	635	5	between	between	ADP
chd-169	635	6	first	first	ADJ
chd-169	635	7	diagnosis	diagnosis	NOUN
chd-169	635	8	and	and	CCONJ
chd-169	635	9	initial	initial	ADJ
chd-169	635	10	treatment	treatment	NOUN
chd-169	635	11	of	of	ADP
chd-169	635	12	prostate	prostate	NOUN
chd-169	635	13	cancer	cancer	NOUN
chd-169	635	14	.	.	PUNCT
chd-169	636	1	cancer	cancer	NOUN
chd-169	636	2	control	control	NOUN
chd-169	636	3	23	23	NUM
chd-169	636	4	,	,	PUNCT
chd-169	636	5	47	47	NUM
chd-169	636	6	-	-	SYM
chd-169	636	7	51	51	NUM
chd-169	636	8	.	.	PUNCT
chd-169	637	1	kish	kish	PROPN
chd-169	637	2	,	,	PUNCT
chd-169	637	3	j.k	j.k	PROPN
chd-169	637	4	.	.	PROPN
chd-169	637	5	,	,	PUNCT
chd-169	637	6	yu	yu	PROPN
chd-169	637	7	,	,	PUNCT
chd-169	637	8	m.	m.	NOUN
chd-169	637	9	,	,	PUNCT
chd-169	637	10	percy	percy	PROPN
chd-169	637	11	-	-	PUNCT
chd-169	637	12	laurry	laurry	PROPN
chd-169	637	13	,	,	PUNCT
chd-169	637	14	a.	a.	NOUN
chd-169	637	15	,	,	PUNCT
chd-169	637	16	and	and	CCONJ
chd-169	637	17	altekruse	altekruse	PROPN
chd-169	637	18	,	,	PUNCT
chd-169	637	19	s.f	s.f	PROPN
chd-169	637	20	.	.	PROPN
chd-169	637	21	(	(	PUNCT
chd-169	637	22	2014	2014	NUM
chd-169	637	23	)	)	PUNCT
chd-169	637	24	.	.	PUNCT
chd-169	638	1	racial	racial	ADJ
chd-169	638	2	and	and	CCONJ
chd-169	638	3	ethnic	ethnic	ADJ
chd-169	638	4	disparities	disparity	NOUN
chd-169	638	5	in	in	ADP
chd-169	638	6	cancer	cancer	NOUN
chd-169	638	7	survival	survival	NOUN
chd-169	638	8	by	by	ADP
chd-169	638	9	neighborhood	neighborhood	NOUN
chd-169	638	10	socioeconomic	socioeconomic	ADJ
chd-169	638	11	status	status	NOUN
chd-169	638	12	in	in	ADP
chd-169	638	13	surveillance	surveillance	NOUN
chd-169	638	14	,	,	PUNCT
chd-169	638	15	epidemiology	epidemiology	NOUN
chd-169	638	16	,	,	PUNCT
chd-169	638	17	and	and	CCONJ
chd-169	638	18	end	end	VERB
chd-169	638	19	results	result	NOUN
chd-169	638	20	(	(	PUNCT
chd-169	638	21	seer	seer	NOUN
chd-169	638	22	)	)	PUNCT
chd-169	638	23	registries	registry	NOUN
chd-169	638	24	.	.	PUNCT
chd-169	639	1	journal	journal	NOUN
chd-169	639	2	of	of	ADP
chd-169	639	3	the	the	DET
chd-169	639	4	national	national	PROPN
chd-169	639	5	cancer	cancer	PROPN
chd-169	639	6	institute	institute	PROPN
chd-169	639	7	monographs	monograph	NOUN
chd-169	639	8	2014	2014	NUM
chd-169	639	9	,	,	PUNCT
chd-169	639	10	236243	236243	NUM
chd-169	639	11	.	.	PUNCT
chd-169	640	1	klengel	klengel	PROPN
chd-169	640	2	,	,	PUNCT
chd-169	640	3	t.	t.	PROPN
chd-169	640	4	,	,	PUNCT
chd-169	640	5	mehta	mehta	PROPN
chd-169	640	6	,	,	PUNCT
chd-169	640	7	d.	d.	PROPN
chd-169	640	8	,	,	PUNCT
chd-169	640	9	anacker	anacker	PROPN
chd-169	640	10	,	,	PUNCT
chd-169	640	11	c.	c.	PROPN
chd-169	640	12	,	,	PUNCT
chd-169	640	13	rex	rex	PROPN
chd-169	640	14	-	-	PUNCT
chd-169	640	15	haffner	haffner	PROPN
chd-169	640	16	,	,	PUNCT
chd-169	640	17	m.	m.	NOUN
chd-169	640	18	,	,	PUNCT
chd-169	640	19	pruessner	pruessner	NOUN
chd-169	640	20	,	,	PUNCT
chd-169	640	21	j.c	j.c	PROPN
chd-169	640	22	.	.	PROPN
chd-169	640	23	,	,	PUNCT
chd-169	640	24	pariante	pariante	PROPN
chd-169	640	25	,	,	PUNCT
chd-169	640	26	c.m	c.m	PROPN
chd-169	640	27	.	.	PROPN
chd-169	640	28	,	,	PUNCT
chd-169	640	29	pace	pace	NOUN
chd-169	640	30	,	,	PUNCT
chd-169	640	31	t.w	t.w	PROPN
chd-169	640	32	.	.	PROPN
chd-169	640	33	,	,	PUNCT
chd-169	640	34	mercer	mercer	PROPN
chd-169	640	35	,	,	PUNCT
chd-169	640	36	k.b	k.b	PROPN
chd-169	640	37	.	.	PROPN
chd-169	640	38	,	,	PUNCT
chd-169	640	39	mayberg	mayberg	PROPN
chd-169	640	40	,	,	PUNCT
chd-169	640	41	h.s	h.s	PROPN
chd-169	640	42	.	.	PROPN
chd-169	640	43	,	,	PUNCT
chd-169	640	44	bradley	bradley	PROPN
chd-169	640	45	,	,	PUNCT
chd-169	640	46	b.	b.	PROPN
chd-169	640	47	,	,	PUNCT
chd-169	640	48	et	et	PROPN
chd-169	640	49	al	al	PROPN
chd-169	640	50	.	.	PROPN
chd-169	640	51	(	(	PUNCT
chd-169	640	52	2013	2013	NUM
chd-169	640	53	)	)	PUNCT
chd-169	640	54	.	.	PUNCT
chd-169	641	1	allele	allele	NOUN
chd-169	641	2	-	-	PUNCT
chd-169	641	3	specific	specific	ADJ
chd-169	641	4	fkbp5	fkbp5	NOUN
chd-169	641	5	dna	dna	PROPN
chd-169	641	6	demethylation	demethylation	NOUN
chd-169	641	7	mediates	mediate	NOUN
chd-169	641	8	gene	gene	NOUN
chd-169	641	9	-	-	PUNCT
chd-169	641	10	childhood	childhood	NOUN
chd-169	641	11	trauma	trauma	NOUN
chd-169	641	12	interactions	interaction	NOUN
chd-169	641	13	.	.	PUNCT
chd-169	642	1	nat	nat	PROPN
chd-169	642	2	neurosci	neurosci	PROPN
chd-169	642	3	16	16	NUM
chd-169	642	4	,	,	PUNCT
chd-169	642	5	33	33	NUM
chd-169	642	6	-	-	SYM
chd-169	642	7	41	41	NUM
chd-169	642	8	.	.	PUNCT
chd-169	643	1	knox	knox	PROPN
chd-169	643	2	,	,	PUNCT
chd-169	643	3	s.s	s.s	PROPN
chd-169	643	4	.	.	PROPN
chd-169	643	5	,	,	PUNCT
chd-169	643	6	jacobs	jacobs	PROPN
chd-169	643	7	,	,	PUNCT
chd-169	643	8	d.r	d.r	PROPN
chd-169	643	9	.	.	PROPN
chd-169	643	10	,	,	PUNCT
chd-169	643	11	jr	jr	PROPN
chd-169	643	12	.	.	PROPN
chd-169	643	13	,	,	PUNCT
chd-169	643	14	chesney	chesney	PROPN
chd-169	643	15	,	,	PUNCT
chd-169	643	16	m.a	m.a	PROPN
chd-169	643	17	.	.	PROPN
chd-169	643	18	,	,	PUNCT
chd-169	643	19	raczynski	raczynski	PROPN
chd-169	643	20	,	,	PUNCT
chd-169	643	21	j.	j.	PROPN
chd-169	643	22	,	,	PUNCT
chd-169	643	23	and	and	CCONJ
chd-169	643	24	mccreath	mccreath	NOUN
chd-169	643	25	,	,	PUNCT
chd-169	643	26	h.	h.	PROPN
chd-169	643	27	(	(	PUNCT
chd-169	643	28	1996	1996	NUM
chd-169	643	29	)	)	PUNCT
chd-169	643	30	.	.	PUNCT
chd-169	644	1	psychosocial	psychosocial	ADJ
chd-169	644	2	factors	factor	NOUN
chd-169	644	3	and	and	CCONJ
chd-169	644	4	plasma	plasma	NOUN
chd-169	644	5	lipids	lipid	NOUN
chd-169	644	6	in	in	ADP
chd-169	644	7	black	black	ADJ
chd-169	644	8	and	and	CCONJ
chd-169	644	9	white	white	ADJ
chd-169	644	10	young	young	ADJ
chd-169	644	11	adults	adult	NOUN
chd-169	644	12	:	:	PUNCT
chd-169	644	13	the	the	DET
chd-169	644	14	coronary	coronary	ADJ
chd-169	644	15	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-169	644	16	e25	e25	PROPN
chd-169	644	17	cancer	cancer	NOUN
chd-169	644	18	health	health	NOUN
chd-169	644	19	disparities	disparity	NOUN
chd-169	644	20	research	research	NOUN
chd-169	644	21	artery	artery	NOUN
chd-169	644	22	risk	risk	NOUN
chd-169	644	23	development	development	NOUN
chd-169	644	24	in	in	ADP
chd-169	644	25	young	young	ADJ
chd-169	644	26	adults	adult	NOUN
chd-169	644	27	study	study	NOUN
chd-169	644	28	data	datum	NOUN
chd-169	644	29	.	.	PUNCT
chd-169	645	1	psychosom	psychosom	PROPN
chd-169	645	2	med	med	PROPN
chd-169	645	3	58	58	NUM
chd-169	645	4	,	,	PUNCT
chd-169	645	5	365	365	NUM
chd-169	645	6	-	-	SYM
chd-169	645	7	373	373	NUM
chd-169	645	8	.	.	PUNCT
chd-169	646	1	koltai	koltai	PROPN
chd-169	646	2	,	,	PUNCT
chd-169	646	3	t.	t.	PROPN
chd-169	646	4	(	(	PUNCT
chd-169	646	5	2014	2014	NUM
chd-169	646	6	)	)	PUNCT
chd-169	646	7	.	.	PUNCT
chd-169	647	1	clusterin	clusterin	NOUN
chd-169	647	2	:	:	PUNCT
chd-169	647	3	a	a	DET
chd-169	647	4	key	key	ADJ
chd-169	647	5	player	player	NOUN
chd-169	647	6	in	in	ADP
chd-169	647	7	cancer	cancer	NOUN
chd-169	647	8	chemoresistance	chemoresistance	NOUN
chd-169	647	9	and	and	CCONJ
chd-169	647	10	its	its	PRON
chd-169	647	11	inhibition	inhibition	NOUN
chd-169	647	12	.	.	PUNCT
chd-169	648	1	onco	onco	NOUN
chd-169	648	2	targets	target	NOUN
chd-169	648	3	ther	ther	ADV
chd-169	648	4	7	7	NUM
chd-169	648	5	,	,	PUNCT
chd-169	648	6	447	447	NUM
chd-169	648	7	-	-	NOUN
chd-169	648	8	456	456	NUM
chd-169	648	9	.	.	PUNCT
chd-169	649	1	kolvenbag	kolvenbag	PROPN
chd-169	649	2	,	,	PUNCT
chd-169	649	3	g.j	g.j	PROPN
chd-169	649	4	.	.	PROPN
chd-169	649	5	,	,	PUNCT
chd-169	649	6	and	and	CCONJ
chd-169	649	7	nash	nash	NOUN
chd-169	649	8	,	,	PUNCT
chd-169	649	9	a.	a.	NOUN
chd-169	649	10	(	(	PUNCT
chd-169	649	11	1999	1999	NUM
chd-169	649	12	)	)	PUNCT
chd-169	649	13	.	.	PUNCT
chd-169	650	1	bicalutamide	bicalutamide	VERB
chd-169	650	2	dosages	dosage	NOUN
chd-169	650	3	used	use	VERB
chd-169	650	4	in	in	ADP
chd-169	650	5	the	the	DET
chd-169	650	6	treatment	treatment	NOUN
chd-169	650	7	of	of	ADP
chd-169	650	8	prostate	prostate	NOUN
chd-169	650	9	cancer	cancer	NOUN
chd-169	650	10	.	.	PUNCT
chd-169	651	1	prostate	prostate	NOUN
chd-169	651	2	39	39	NUM
chd-169	651	3	,	,	PUNCT
chd-169	651	4	4753	4753	NUM
chd-169	651	5	.	.	PUNCT
chd-169	652	1	kote	kote	VERB
chd-169	652	2	-	-	PUNCT
chd-169	652	3	jarai	jarai	PROPN
chd-169	652	4	,	,	PUNCT
chd-169	652	5	z.	z.	PROPN
chd-169	652	6	,	,	PUNCT
chd-169	652	7	olama	olama	PROPN
chd-169	652	8	,	,	PUNCT
chd-169	652	9	a.a	a.a	PROPN
chd-169	652	10	.	.	PROPN
chd-169	652	11	,	,	PUNCT
chd-169	652	12	giles	giles	PROPN
chd-169	652	13	,	,	PUNCT
chd-169	652	14	g.g	g.g	PROPN
chd-169	652	15	.	.	PROPN
chd-169	652	16	,	,	PUNCT
chd-169	652	17	severi	severi	PROPN
chd-169	652	18	,	,	PUNCT
chd-169	652	19	g.	g.	NOUN
chd-169	652	20	,	,	PUNCT
chd-169	652	21	schleutker	schleutker	NOUN
chd-169	652	22	,	,	PUNCT
chd-169	652	23	j.	j.	PROPN
chd-169	652	24	,	,	PUNCT
chd-169	652	25	weischer	weischer	NOUN
chd-169	652	26	,	,	PUNCT
chd-169	652	27	m.	m.	NOUN
chd-169	652	28	,	,	PUNCT
chd-169	652	29	campa	campa	PROPN
chd-169	652	30	,	,	PUNCT
chd-169	652	31	d.	d.	PROPN
chd-169	652	32	,	,	PUNCT
chd-169	652	33	riboli	riboli	ADV
chd-169	652	34	,	,	PUNCT
chd-169	652	35	e.	e.	PROPN
chd-169	652	36	,	,	PUNCT
chd-169	652	37	key	key	NOUN
chd-169	652	38	,	,	PUNCT
chd-169	652	39	t.	t.	PROPN
chd-169	652	40	,	,	PUNCT
chd-169	652	41	gronberg	gronberg	PROPN
chd-169	652	42	,	,	PUNCT
chd-169	652	43	h.	h.	PROPN
chd-169	652	44	,	,	PUNCT
chd-169	652	45	et	et	PROPN
chd-169	652	46	al	al	PROPN
chd-169	652	47	.	.	PUNCT
chd-169	653	1	(	(	PUNCT
chd-169	653	2	2011	2011	NUM
chd-169	653	3	)	)	PUNCT
chd-169	653	4	.	.	PUNCT
chd-169	654	1	seven	seven	NUM
chd-169	654	2	prostate	prostate	NOUN
chd-169	654	3	cancer	cancer	NOUN
chd-169	654	4	susceptibility	susceptibility	NOUN
chd-169	654	5	loci	locus	NOUN
chd-169	654	6	identified	identify	VERB
chd-169	654	7	by	by	ADP
chd-169	654	8	a	a	DET
chd-169	654	9	multi	multi	ADJ
chd-169	654	10	-	-	ADJ
chd-169	654	11	stage	stage	ADJ
chd-169	654	12	genome	genome	NOUN
chd-169	654	13	-	-	PUNCT
chd-169	654	14	wide	wide	ADJ
chd-169	654	15	association	association	NOUN
chd-169	654	16	study	study	NOUN
chd-169	654	17	.	.	PUNCT
chd-169	655	1	nat	nat	PROPN
chd-169	655	2	genet	genet	PROPN
chd-169	655	3	43	43	NUM
chd-169	655	4	,	,	PUNCT
chd-169	655	5	785	785	NUM
chd-169	655	6	-	-	SYM
chd-169	655	7	791	791	NUM
chd-169	655	8	.	.	PUNCT
chd-169	656	1	kratochwil	kratochwil	PROPN
chd-169	656	2	,	,	PUNCT
chd-169	656	3	c.	c.	NOUN
chd-169	656	4	,	,	PUNCT
chd-169	656	5	fendler	fendler	PROPN
chd-169	656	6	,	,	PUNCT
chd-169	656	7	w.p	w.p	PROPN
chd-169	656	8	.	.	PROPN
chd-169	656	9	,	,	PUNCT
chd-169	656	10	eiber	eiber	PROPN
chd-169	656	11	,	,	PUNCT
chd-169	656	12	m.	m.	NOUN
chd-169	656	13	,	,	PUNCT
chd-169	656	14	baum	baum	PROPN
chd-169	656	15	,	,	PUNCT
chd-169	656	16	r.	r.	PROPN
chd-169	656	17	,	,	PUNCT
chd-169	656	18	bozkurt	bozkurt	PROPN
chd-169	656	19	,	,	PUNCT
chd-169	656	20	m.f	m.f	PROPN
chd-169	656	21	.	.	PROPN
chd-169	656	22	,	,	PUNCT
chd-169	656	23	czernin	czernin	PROPN
chd-169	656	24	,	,	PUNCT
chd-169	656	25	j.	j.	PROPN
chd-169	656	26	,	,	PUNCT
chd-169	656	27	delgado	delgado	VERB
chd-169	656	28	bolton	bolton	PROPN
chd-169	656	29	,	,	PUNCT
chd-169	656	30	r.c	r.c	PROPN
chd-169	656	31	.	.	PROPN
chd-169	656	32	,	,	PUNCT
chd-169	656	33	ezziddin	ezziddin	PROPN
chd-169	656	34	,	,	PUNCT
chd-169	656	35	s.	s.	PROPN
chd-169	656	36	,	,	PUNCT
chd-169	656	37	forrer	forrer	PROPN
chd-169	656	38	,	,	PUNCT
chd-169	656	39	f.	f.	PROPN
chd-169	656	40	,	,	PUNCT
chd-169	656	41	hicks	hicks	PROPN
chd-169	656	42	,	,	PUNCT
chd-169	656	43	r.j	r.j	PROPN
chd-169	656	44	.	.	PROPN
chd-169	656	45	,	,	PUNCT
chd-169	656	46	et	et	PROPN
chd-169	656	47	al	al	PROPN
chd-169	656	48	.	.	PROPN
chd-169	657	1	(	(	PUNCT
chd-169	657	2	2019	2019	NUM
chd-169	657	3	)	)	PUNCT
chd-169	657	4	.	.	PUNCT
chd-169	658	1	eanm	eanm	ADJ
chd-169	658	2	procedure	procedure	NOUN
chd-169	658	3	guidelines	guideline	NOUN
chd-169	658	4	for	for	ADP
chd-169	658	5	radionuclide	radionuclide	NOUN
chd-169	658	6	therapy	therapy	NOUN
chd-169	658	7	with	with	ADP
chd-169	658	8	(	(	PUNCT
chd-169	658	9	177)lu	177)lu	ADV
chd-169	658	10	-	-	PUNCT
chd-169	658	11	labelled	label	VERB
chd-169	658	12	psma	psma	NOUN
chd-169	658	13	-	-	PUNCT
chd-169	658	14	ligands	ligand	NOUN
chd-169	658	15	(	(	PUNCT
chd-169	658	16	(	(	PUNCT
chd-169	658	17	177)lu	177)lu	NUM
chd-169	658	18	-	-	PUNCT
chd-169	658	19	psma	psma	NOUN
chd-169	658	20	-	-	PUNCT
chd-169	658	21	rlt	rlt	NOUN
chd-169	658	22	)	)	PUNCT
chd-169	658	23	.	.	PUNCT
chd-169	659	1	eur	eur	PROPN
chd-169	659	2	j	j	PROPN
chd-169	659	3	nucl	nucl	PROPN
chd-169	659	4	med	me	VERB
chd-169	659	5	mol	mol	ADP
chd-169	659	6	imaging	image	VERB
chd-169	659	7	46	46	NUM
chd-169	659	8	,	,	PUNCT
chd-169	659	9	2536	2536	NUM
chd-169	659	10	-	-	SYM
chd-169	659	11	2544	2544	NUM
chd-169	659	12	.	.	PUNCT
chd-169	660	1	krieger	krieger	PROPN
chd-169	660	2	,	,	PUNCT
chd-169	660	3	n.	n.	PROPN
chd-169	660	4	,	,	PUNCT
chd-169	660	5	kosheleva	kosheleva	PROPN
chd-169	660	6	,	,	PUNCT
chd-169	660	7	a.	a.	PROPN
chd-169	660	8	,	,	PUNCT
chd-169	660	9	waterman	waterman	PROPN
chd-169	660	10	,	,	PUNCT
chd-169	660	11	p.d	p.d	PROPN
chd-169	660	12	.	.	PROPN
chd-169	660	13	,	,	PUNCT
chd-169	660	14	chen	chen	PROPN
chd-169	660	15	,	,	PUNCT
chd-169	660	16	j.t	j.t	PROPN
chd-169	660	17	.	.	PROPN
chd-169	660	18	,	,	PUNCT
chd-169	660	19	and	and	CCONJ
chd-169	660	20	koenen	koenen	PROPN
chd-169	660	21	,	,	PUNCT
chd-169	660	22	k.	k.	PROPN
chd-169	660	23	(	(	PUNCT
chd-169	660	24	2011	2011	NUM
chd-169	660	25	)	)	PUNCT
chd-169	660	26	.	.	PUNCT
chd-169	661	1	racial	racial	ADJ
chd-169	661	2	discrimination	discrimination	NOUN
chd-169	661	3	,	,	PUNCT
chd-169	661	4	psychological	psychological	ADJ
chd-169	661	5	distress	distress	NOUN
chd-169	661	6	,	,	PUNCT
chd-169	661	7	and	and	CCONJ
chd-169	661	8	self	self	NOUN
chd-169	661	9	-	-	PUNCT
chd-169	661	10	rated	rate	VERB
chd-169	661	11	health	health	NOUN
chd-169	661	12	among	among	ADP
chd-169	661	13	us	we	PRON
chd-169	661	14	-	-	PUNCT
chd-169	661	15	born	bear	VERB
chd-169	661	16	and	and	CCONJ
chd-169	661	17	foreign	foreign	ADJ
chd-169	661	18	-	-	PUNCT
chd-169	661	19	born	bear	VERB
chd-169	661	20	black	black	ADJ
chd-169	661	21	americans	americans	PROPN
chd-169	661	22	.	.	PUNCT
chd-169	662	1	american	american	PROPN
chd-169	662	2	journal	journal	PROPN
chd-169	662	3	of	of	ADP
chd-169	662	4	public	public	ADJ
chd-169	662	5	health	health	NOUN
chd-169	662	6	101	101	NUM
chd-169	662	7	,	,	PUNCT
chd-169	662	8	1704	1704	NUM
chd-169	662	9	-	-	SYM
chd-169	662	10	1713	1713	NUM
chd-169	662	11	.	.	PUNCT
chd-169	663	1	krok	krok	PROPN
chd-169	663	2	-	-	PUNCT
chd-169	663	3	schoen	schoen	PROPN
chd-169	663	4	,	,	PUNCT
chd-169	663	5	j.l	j.l	PROPN
chd-169	663	6	.	.	PROPN
chd-169	663	7	,	,	PUNCT
chd-169	663	8	fisher	fisher	PROPN
chd-169	663	9	,	,	PUNCT
chd-169	663	10	j.l	j.l	PROPN
chd-169	663	11	.	.	PROPN
chd-169	663	12	,	,	PUNCT
chd-169	663	13	baltic	baltic	PROPN
chd-169	663	14	,	,	PUNCT
chd-169	663	15	r.d	r.d	PROPN
chd-169	663	16	.	.	PROPN
chd-169	663	17	,	,	PUNCT
chd-169	663	18	and	and	CCONJ
chd-169	663	19	paskett	paskett	PROPN
chd-169	663	20	,	,	PUNCT
chd-169	663	21	e.d	e.d	PROPN
chd-169	663	22	.	.	PROPN
chd-169	663	23	(	(	PUNCT
chd-169	663	24	2017	2017	NUM
chd-169	663	25	)	)	PUNCT
chd-169	663	26	.	.	PUNCT
chd-169	664	1	white	white	ADJ
chd-169	664	2	-	-	PUNCT
chd-169	664	3	black	black	ADJ
chd-169	664	4	differences	difference	NOUN
chd-169	664	5	in	in	ADP
chd-169	664	6	cancer	cancer	NOUN
chd-169	664	7	incidence	incidence	NOUN
chd-169	664	8	,	,	PUNCT
chd-169	664	9	stage	stage	NOUN
chd-169	664	10	at	at	ADP
chd-169	664	11	diagnosis	diagnosis	NOUN
chd-169	664	12	,	,	PUNCT
chd-169	664	13	and	and	CCONJ
chd-169	664	14	survival	survival	NOUN
chd-169	664	15	among	among	ADP
chd-169	664	16	older	old	ADJ
chd-169	664	17	adults	adult	NOUN
chd-169	664	18	.	.	PUNCT
chd-169	665	1	journal	journal	NOUN
chd-169	665	2	of	of	ADP
chd-169	665	3	aging	aging	NOUN
chd-169	665	4	and	and	CCONJ
chd-169	665	5	health	health	NOUN
chd-169	665	6	,	,	PUNCT
chd-169	665	7	898264317696777	898264317696777	NUM
chd-169	665	8	.	.	PUNCT
chd-169	666	1	kroon	kroon	PROPN
chd-169	666	2	,	,	PUNCT
chd-169	666	3	j.	j.	PROPN
chd-169	666	4	,	,	PUNCT
chd-169	666	5	puhr	puhr	NOUN
chd-169	666	6	,	,	PUNCT
chd-169	666	7	m.	m.	NOUN
chd-169	666	8	,	,	PUNCT
chd-169	666	9	buijs	buijs	PROPN
chd-169	666	10	,	,	PUNCT
chd-169	666	11	j.t	j.t	PROPN
chd-169	666	12	.	.	PROPN
chd-169	666	13	,	,	PUNCT
chd-169	666	14	van	van	PROPN
chd-169	666	15	der	der	PROPN
chd-169	666	16	horst	horst	PROPN
chd-169	666	17	,	,	PUNCT
chd-169	666	18	g.	g.	PROPN
chd-169	666	19	,	,	PUNCT
chd-169	666	20	hemmer	hemmer	PROPN
chd-169	666	21	,	,	PUNCT
chd-169	666	22	d.m	d.m	PROPN
chd-169	666	23	.	.	PROPN
chd-169	666	24	,	,	PUNCT
chd-169	666	25	marijt	marijt	ADJ
chd-169	666	26	,	,	PUNCT
chd-169	666	27	k.a	k.a	PROPN
chd-169	666	28	.	.	PROPN
chd-169	666	29	,	,	PUNCT
chd-169	666	30	hwang	hwang	PROPN
chd-169	666	31	,	,	PUNCT
chd-169	666	32	m.s	m.s	PROPN
chd-169	666	33	.	.	PROPN
chd-169	666	34	,	,	PUNCT
chd-169	666	35	masood	masood	PROPN
chd-169	666	36	,	,	PUNCT
chd-169	666	37	m.	m.	NOUN
chd-169	666	38	,	,	PUNCT
chd-169	666	39	grimm	grimm	NOUN
chd-169	666	40	,	,	PUNCT
chd-169	666	41	s.	s.	PROPN
chd-169	666	42	,	,	PUNCT
chd-169	666	43	storm	storm	NOUN
chd-169	666	44	,	,	PUNCT
chd-169	666	45	g.	g.	PROPN
chd-169	666	46	,	,	PUNCT
chd-169	666	47	et	et	PROPN
chd-169	666	48	al	al	PROPN
chd-169	666	49	.	.	PUNCT
chd-169	666	50	(	(	PUNCT
chd-169	666	51	2016	2016	NUM
chd-169	666	52	)	)	PUNCT
chd-169	666	53	.	.	PUNCT
chd-169	667	1	glucocorticoid	glucocorticoid	ADJ
chd-169	667	2	receptor	receptor	NOUN
chd-169	667	3	antagonism	antagonism	NOUN
chd-169	667	4	reverts	revert	VERB
chd-169	667	5	docetaxel	docetaxel	NOUN
chd-169	667	6	resistance	resistance	NOUN
chd-169	667	7	in	in	ADP
chd-169	667	8	human	human	ADJ
chd-169	667	9	prostate	prostate	NOUN
chd-169	667	10	cancer	cancer	NOUN
chd-169	667	11	.	.	PUNCT
chd-169	668	1	endocr	endocr	PROPN
chd-169	668	2	relat	relat	PROPN
chd-169	668	3	cancer	cancer	NOUN
chd-169	668	4	23	23	NUM
chd-169	668	5	,	,	PUNCT
chd-169	668	6	35	35	NUM
chd-169	668	7	-	-	SYM
chd-169	668	8	45	45	NUM
chd-169	668	9	.	.	PUNCT
chd-169	669	1	ku	ku	PROPN
chd-169	669	2	,	,	PUNCT
chd-169	669	3	s.y	s.y	PROPN
chd-169	669	4	.	.	PROPN
chd-169	669	5	,	,	PUNCT
chd-169	669	6	gleave	gleave	PROPN
chd-169	669	7	,	,	PUNCT
chd-169	669	8	m.e	m.e	PROPN
chd-169	669	9	.	.	PROPN
chd-169	669	10	,	,	PUNCT
chd-169	669	11	and	and	CCONJ
chd-169	669	12	beltran	beltran	PROPN
chd-169	669	13	,	,	PUNCT
chd-169	669	14	h.	h.	PROPN
chd-169	669	15	(	(	PUNCT
chd-169	669	16	2019	2019	NUM
chd-169	669	17	)	)	PUNCT
chd-169	669	18	.	.	PUNCT
chd-169	670	1	towards	towards	ADP
chd-169	670	2	precision	precision	NOUN
chd-169	670	3	oncology	oncology	NOUN
chd-169	670	4	in	in	ADP
chd-169	670	5	advanced	advanced	ADJ
chd-169	670	6	prostate	prostate	NOUN
chd-169	670	7	cancer	cancer	NOUN
chd-169	670	8	.	.	PUNCT
chd-169	671	1	nat	nat	PROPN
chd-169	671	2	rev	rev	VERB
chd-169	671	3	urol	urol	PROPN
chd-169	671	4	16	16	NUM
chd-169	671	5	,	,	PUNCT
chd-169	671	6	645	645	NUM
chd-169	671	7	-	-	SYM
chd-169	671	8	654	654	NUM
chd-169	671	9	.	.	PUNCT
chd-169	672	1	kyriakopoulos	kyriakopoulo	NOUN
chd-169	672	2	,	,	PUNCT
chd-169	672	3	c.e	c.e	PROPN
chd-169	672	4	.	.	PROPN
chd-169	672	5	,	,	PUNCT
chd-169	672	6	chen	chen	PROPN
chd-169	672	7	,	,	PUNCT
chd-169	672	8	y.h	y.h	PROPN
chd-169	672	9	.	.	PROPN
chd-169	672	10	,	,	PUNCT
chd-169	672	11	carducci	carducci	PROPN
chd-169	672	12	,	,	PUNCT
chd-169	672	13	m.a	m.a	PROPN
chd-169	672	14	.	.	PROPN
chd-169	672	15	,	,	PUNCT
chd-169	672	16	liu	liu	PROPN
chd-169	672	17	,	,	PUNCT
chd-169	672	18	g.	g.	PROPN
chd-169	672	19	,	,	PUNCT
chd-169	672	20	jarrard	jarrard	PROPN
chd-169	672	21	,	,	PUNCT
chd-169	672	22	d.f	d.f	PROPN
chd-169	672	23	.	.	PROPN
chd-169	672	24	,	,	PUNCT
chd-169	672	25	hahn	hahn	PROPN
chd-169	672	26	,	,	PUNCT
chd-169	672	27	n.m	n.m	PROPN
chd-169	672	28	.	.	PROPN
chd-169	672	29	,	,	PUNCT
chd-169	672	30	shevrin	shevrin	PROPN
chd-169	672	31	,	,	PUNCT
chd-169	672	32	d.h	d.h	PROPN
chd-169	672	33	.	.	PROPN
chd-169	672	34	,	,	PUNCT
chd-169	672	35	dreicer	dreicer	PROPN
chd-169	672	36	,	,	PUNCT
chd-169	672	37	r.	r.	PROPN
chd-169	672	38	,	,	PUNCT
chd-169	672	39	hussain	hussain	PROPN
chd-169	672	40	,	,	PUNCT
chd-169	672	41	m.	m.	NOUN
chd-169	672	42	,	,	PUNCT
chd-169	672	43	eisenberger	eisenberger	NOUN
chd-169	672	44	,	,	PUNCT
chd-169	672	45	m.	m.	NOUN
chd-169	672	46	,	,	PUNCT
chd-169	672	47	et	et	PROPN
chd-169	672	48	al	al	PROPN
chd-169	672	49	.	.	PUNCT
chd-169	672	50	(	(	PUNCT
chd-169	672	51	2018	2018	NUM
chd-169	672	52	)	)	PUNCT
chd-169	672	53	.	.	PUNCT
chd-169	673	1	chemohormonal	chemohormonal	ADJ
chd-169	673	2	therapy	therapy	NOUN
chd-169	673	3	in	in	ADP
chd-169	673	4	metastatic	metastatic	ADJ
chd-169	673	5	hormone	hormone	NOUN
chd-169	673	6	-	-	PUNCT
chd-169	673	7	sensitive	sensitive	ADJ
chd-169	673	8	prostate	prostate	NOUN
chd-169	673	9	cancer	cancer	NOUN
chd-169	673	10	:	:	PUNCT
chd-169	673	11	longterm	longterm	VERB
chd-169	673	12	survival	survival	NOUN
chd-169	673	13	analysis	analysis	NOUN
chd-169	673	14	of	of	ADP
chd-169	673	15	the	the	DET
chd-169	673	16	randomized	randomized	ADJ
chd-169	673	17	phase	phase	NOUN
chd-169	673	18	iii	iii	NOUN
chd-169	673	19	e3805	e3805	PROPN
chd-169	673	20	chaarted	chaarte	VERB
chd-169	673	21	trial	trial	NOUN
chd-169	673	22	.	.	PUNCT
chd-169	674	1	journal	journal	NOUN
chd-169	674	2	of	of	ADP
chd-169	674	3	clinical	clinical	ADJ
chd-169	674	4	oncology	oncology	NOUN
chd-169	674	5	:	:	PUNCT
chd-169	674	6	official	official	ADJ
chd-169	674	7	journal	journal	NOUN
chd-169	674	8	of	of	ADP
chd-169	674	9	the	the	DET
chd-169	674	10	american	american	ADJ
chd-169	674	11	society	society	NOUN
chd-169	674	12	of	of	ADP
chd-169	674	13	clinical	clinical	ADJ
chd-169	674	14	oncology	oncology	NOUN
chd-169	674	15	36	36	NUM
chd-169	674	16	,	,	PUNCT
chd-169	674	17	1080	1080	NUM
chd-169	674	18	-	-	SYM
chd-169	674	19	1087	1087	NUM
chd-169	674	20	.	.	PUNCT
chd-169	675	1	lachize	lachize	VERB
chd-169	675	2	,	,	PUNCT
chd-169	675	3	s.	s.	PROPN
chd-169	675	4	,	,	PUNCT
chd-169	675	5	apostolakis	apostolakis	PROPN
chd-169	675	6	,	,	PUNCT
chd-169	675	7	e.m	e.m	PROPN
chd-169	675	8	.	.	PROPN
chd-169	675	9	,	,	PUNCT
chd-169	675	10	van	van	PROPN
chd-169	675	11	der	der	PROPN
chd-169	675	12	laan	laan	PROPN
chd-169	675	13	,	,	PUNCT
chd-169	675	14	s.	s.	PROPN
chd-169	675	15	,	,	PUNCT
chd-169	675	16	tijssen	tijssen	PROPN
chd-169	675	17	,	,	PUNCT
chd-169	675	18	a.m.	a.m.	ADV
chd-169	675	19	,	,	PUNCT
chd-169	675	20	xu	xu	PROPN
chd-169	675	21	,	,	PUNCT
chd-169	675	22	j.	j.	PROPN
chd-169	675	23	,	,	PUNCT
chd-169	675	24	de	de	PROPN
chd-169	675	25	kloet	kloet	NOUN
chd-169	675	26	,	,	PUNCT
chd-169	675	27	e.r	e.r	PROPN
chd-169	675	28	.	.	PROPN
chd-169	675	29	,	,	PUNCT
chd-169	675	30	and	and	CCONJ
chd-169	675	31	meijer	meijer	NOUN
chd-169	675	32	,	,	PUNCT
chd-169	675	33	o.c	o.c	PROPN
chd-169	675	34	.	.	PROPN
chd-169	675	35	(	(	PUNCT
chd-169	675	36	2009	2009	NUM
chd-169	675	37	)	)	PUNCT
chd-169	675	38	.	.	PUNCT
chd-169	676	1	steroid	steroid	NOUN
chd-169	676	2	receptor	receptor	NOUN
chd-169	676	3	coactivator-1	coactivator-1	NUM
chd-169	676	4	is	be	AUX
chd-169	676	5	necessary	necessary	ADJ
chd-169	676	6	for	for	ADP
chd-169	676	7	regulation	regulation	NOUN
chd-169	676	8	of	of	ADP
chd-169	676	9	corticotropin	corticotropin	NOUN
chd-169	676	10	-	-	PUNCT
chd-169	676	11	releasing	release	VERB
chd-169	676	12	hormone	hormone	NOUN
chd-169	676	13	by	by	ADP
chd-169	676	14	chronic	chronic	ADJ
chd-169	676	15	stress	stress	NOUN
chd-169	676	16	and	and	CCONJ
chd-169	676	17	glucocorticoids	glucocorticoid	NOUN
chd-169	676	18	.	.	PUNCT
chd-169	677	1	proceedings	proceeding	NOUN
chd-169	677	2	of	of	ADP
chd-169	677	3	the	the	DET
chd-169	677	4	national	national	PROPN
chd-169	677	5	academy	academy	PROPN
chd-169	677	6	of	of	ADP
chd-169	677	7	sciences	sciences	PROPN
chd-169	677	8	of	of	ADP
chd-169	677	9	the	the	DET
chd-169	677	10	united	united	PROPN
chd-169	677	11	states	states	PROPN
chd-169	677	12	of	of	ADP
chd-169	677	13	america	america	PROPN
chd-169	677	14	106	106	NUM
chd-169	677	15	,	,	PUNCT
chd-169	677	16	8038	8038	NUM
chd-169	677	17	-	-	SYM
chd-169	677	18	8042	8042	NUM
chd-169	677	19	.	.	PUNCT
chd-169	678	1	lafeuille	lafeuille	PROPN
chd-169	678	2	,	,	PUNCT
chd-169	678	3	m.h	m.h	PROPN
chd-169	678	4	.	.	PROPN
chd-169	678	5	,	,	PUNCT
chd-169	678	6	gravel	gravel	PROPN
chd-169	678	7	,	,	PUNCT
chd-169	678	8	j.	j.	PROPN
chd-169	678	9	,	,	PUNCT
chd-169	678	10	grittner	grittner	NOUN
chd-169	678	11	,	,	PUNCT
chd-169	678	12	a.	a.	NOUN
chd-169	678	13	,	,	PUNCT
chd-169	678	14	lefebvre	lefebvre	PROPN
chd-169	678	15	,	,	PUNCT
chd-169	678	16	p.	p.	PROPN
chd-169	678	17	,	,	PUNCT
chd-169	678	18	ellis	ellis	PROPN
chd-169	678	19	,	,	PUNCT
chd-169	678	20	l.	l.	PROPN
chd-169	678	21	,	,	PUNCT
chd-169	678	22	and	and	CCONJ
chd-169	678	23	mckenzie	mckenzie	PROPN
chd-169	678	24	,	,	PUNCT
chd-169	678	25	r.s	r.s	PROPN
chd-169	678	26	.	.	PROPN
chd-169	678	27	(	(	PUNCT
chd-169	678	28	2013	2013	NUM
chd-169	678	29	)	)	PUNCT
chd-169	678	30	.	.	PUNCT
chd-169	679	1	real	real	ADJ
chd-169	679	2	-	-	PUNCT
chd-169	679	3	world	world	NOUN
chd-169	679	4	corticosteroid	corticosteroid	ADJ
chd-169	679	5	utilization	utilization	NOUN
chd-169	679	6	patterns	pattern	NOUN
chd-169	679	7	in	in	ADP
chd-169	679	8	patients	patient	NOUN
chd-169	679	9	with	with	ADP
chd-169	679	10	metastatic	metastatic	ADJ
chd-169	679	11	castrationresistant	castrationresistant	NOUN
chd-169	679	12	prostate	prostate	NOUN
chd-169	679	13	cancer	cancer	NOUN
chd-169	679	14	in	in	ADP
chd-169	679	15	2	2	NUM
chd-169	679	16	large	large	ADJ
chd-169	679	17	us	us	PROPN
chd-169	679	18	administrative	administrative	ADJ
chd-169	679	19	claims	claim	NOUN
chd-169	679	20	databases	database	NOUN
chd-169	679	21	.	.	PUNCT
chd-169	680	1	am	be	AUX
chd-169	680	2	health	health	NOUN
chd-169	680	3	drug	drug	NOUN
chd-169	680	4	benefits	benefit	NOUN
chd-169	680	5	6	6	NUM
chd-169	680	6	,	,	PUNCT
chd-169	680	7	307	307	NUM
chd-169	680	8	-	-	SYM
chd-169	680	9	316	316	NUM
chd-169	680	10	.	.	PUNCT
chd-169	681	1	lamont	lamont	PROPN
chd-169	681	2	,	,	PUNCT
chd-169	681	3	k.r	k.r	PROPN
chd-169	681	4	.	.	PROPN
chd-169	681	5	,	,	PUNCT
chd-169	681	6	and	and	CCONJ
chd-169	681	7	tindall	tindall	PROPN
chd-169	681	8	,	,	PUNCT
chd-169	681	9	d.j	d.j	PROPN
chd-169	681	10	.	.	PROPN
chd-169	681	11	(	(	PUNCT
chd-169	681	12	2011	2011	NUM
chd-169	681	13	)	)	PUNCT
chd-169	681	14	.	.	PUNCT
chd-169	682	1	minireview	minireview	NOUN
chd-169	682	2	:	:	PUNCT
chd-169	682	3	alternative	alternative	ADJ
chd-169	682	4	activation	activation	NOUN
chd-169	682	5	pathways	pathway	NOUN
chd-169	682	6	for	for	ADP
chd-169	682	7	the	the	DET
chd-169	682	8	androgen	androgen	NOUN
chd-169	682	9	receptor	receptor	NOUN
chd-169	682	10	in	in	ADP
chd-169	682	11	prostate	prostate	NOUN
chd-169	682	12	cancer	cancer	NOUN
chd-169	682	13	.	.	PUNCT
chd-169	683	1	mol	mol	ADP
chd-169	683	2	endocrinol	endocrinol	NOUN
chd-169	683	3	25	25	NUM
chd-169	683	4	,	,	PUNCT
chd-169	683	5	897	897	NUM
chd-169	683	6	-	-	SYM
chd-169	683	7	907	907	NUM
chd-169	683	8	.	.	PUNCT
chd-169	684	1	lempiainen	lempiainen	PROPN
chd-169	684	2	,	,	PUNCT
chd-169	684	3	j.k	j.k	PROPN
chd-169	684	4	.	.	PROPN
chd-169	684	5	,	,	PUNCT
chd-169	684	6	niskanen	niskanen	PROPN
chd-169	684	7	,	,	PUNCT
chd-169	684	8	e.a	e.a	PROPN
chd-169	684	9	.	.	PROPN
chd-169	684	10	,	,	PUNCT
chd-169	684	11	vuoti	vuoti	PROPN
chd-169	684	12	,	,	PUNCT
chd-169	684	13	k.m	k.m	PROPN
chd-169	684	14	.	.	PROPN
chd-169	684	15	,	,	PUNCT
chd-169	684	16	lampinen	lampinen	PROPN
chd-169	684	17	,	,	PUNCT
chd-169	684	18	r.e	r.e	PROPN
chd-169	684	19	.	.	PROPN
chd-169	684	20	,	,	PUNCT
chd-169	684	21	goos	goos	PROPN
chd-169	684	22	,	,	PUNCT
chd-169	684	23	h.	h.	PROPN
chd-169	684	24	,	,	PUNCT
chd-169	684	25	varjosalo	varjosalo	PROPN
chd-169	684	26	,	,	PUNCT
chd-169	684	27	m.	m.	NOUN
chd-169	684	28	,	,	PUNCT
chd-169	684	29	and	and	CCONJ
chd-169	684	30	palvimo	palvimo	NOUN
chd-169	684	31	,	,	PUNCT
chd-169	684	32	j.j	j.j	PROPN
chd-169	684	33	.	.	PROPN
chd-169	684	34	(	(	PUNCT
chd-169	684	35	2017	2017	NUM
chd-169	684	36	)	)	PUNCT
chd-169	684	37	.	.	PUNCT
chd-169	685	1	agonistspecific	agonistspecific	NOUN
chd-169	685	2	protein	protein	NOUN
chd-169	685	3	interactomes	interactome	NOUN
chd-169	685	4	of	of	ADP
chd-169	685	5	glucocorticoid	glucocorticoid	ADJ
chd-169	685	6	and	and	CCONJ
chd-169	685	7	androgen	androgen	NOUN
chd-169	685	8	receptor	receptor	NOUN
chd-169	685	9	as	as	SCONJ
chd-169	685	10	revealed	reveal	VERB
chd-169	685	11	by	by	ADP
chd-169	685	12	proximity	proximity	NOUN
chd-169	685	13	mapping	mapping	NOUN
chd-169	685	14	.	.	PUNCT
chd-169	686	1	mol	mol	ADP
chd-169	686	2	cell	cell	NOUN
chd-169	686	3	proteomics	proteomic	NOUN
chd-169	686	4	16	16	NUM
chd-169	686	5	,	,	PUNCT
chd-169	686	6	1462	1462	NUM
chd-169	686	7	-	-	SYM
chd-169	686	8	1474	1474	NUM
chd-169	686	9	.	.	PUNCT
chd-169	687	1	leproult	leproult	PROPN
chd-169	687	2	,	,	PUNCT
chd-169	687	3	r.	r.	PROPN
chd-169	687	4	,	,	PUNCT
chd-169	687	5	copinschi	copinschi	NOUN
chd-169	687	6	,	,	PUNCT
chd-169	687	7	g.	g.	PROPN
chd-169	687	8	,	,	PUNCT
chd-169	687	9	buxton	buxton	PROPN
chd-169	687	10	,	,	PUNCT
chd-169	687	11	o.	o.	PROPN
chd-169	687	12	,	,	PUNCT
chd-169	687	13	and	and	CCONJ
chd-169	687	14	van	van	PROPN
chd-169	687	15	cauter	cauter	NOUN
chd-169	687	16	,	,	PUNCT
chd-169	687	17	e.	e.	PROPN
chd-169	687	18	(	(	PUNCT
chd-169	687	19	1997	1997	NUM
chd-169	687	20	)	)	PUNCT
chd-169	687	21	.	.	PUNCT
chd-169	688	1	sleep	sleep	VERB
chd-169	688	2	loss	loss	NOUN
chd-169	688	3	results	result	NOUN
chd-169	688	4	in	in	ADP
chd-169	688	5	an	an	DET
chd-169	688	6	elevation	elevation	NOUN
chd-169	688	7	of	of	ADP
chd-169	688	8	cortisol	cortisol	ADJ
chd-169	688	9	levels	level	NOUN
chd-169	688	10	the	the	DET
chd-169	688	11	next	next	ADJ
chd-169	688	12	evening	evening	NOUN
chd-169	688	13	.	.	PUNCT
chd-169	689	1	sleep	sleep	NOUN
chd-169	689	2	20	20	NUM
chd-169	689	3	,	,	PUNCT
chd-169	689	4	865	865	NUM
chd-169	689	5	-	-	SYM
chd-169	689	6	870	870	NUM
chd-169	689	7	.	.	PUNCT
chd-169	690	1	li	li	PROPN
chd-169	690	2	,	,	PUNCT
chd-169	690	3	j.	j.	PROPN
chd-169	690	4	,	,	PUNCT
chd-169	690	5	alyamani	alyamani	PROPN
chd-169	690	6	,	,	PUNCT
chd-169	690	7	m.	m.	NOUN
chd-169	690	8	,	,	PUNCT
chd-169	690	9	zhang	zhang	PROPN
chd-169	690	10	,	,	PUNCT
chd-169	690	11	a.	a.	PROPN
chd-169	690	12	,	,	PUNCT
chd-169	690	13	chang	chang	PROPN
chd-169	690	14	,	,	PUNCT
chd-169	690	15	k.h	k.h	PROPN
chd-169	690	16	.	.	PROPN
chd-169	690	17	,	,	PUNCT
chd-169	690	18	berk	berk	PROPN
chd-169	690	19	,	,	PUNCT
chd-169	690	20	m.	m.	NOUN
chd-169	690	21	,	,	PUNCT
chd-169	690	22	li	li	PROPN
chd-169	690	23	,	,	PUNCT
chd-169	690	24	z.	z.	PROPN
chd-169	690	25	,	,	PUNCT
chd-169	690	26	zhu	zhu	PROPN
chd-169	690	27	,	,	PUNCT
chd-169	690	28	z.	z.	PROPN
chd-169	690	29	,	,	PUNCT
chd-169	690	30	petro	petro	PROPN
chd-169	690	31	,	,	PUNCT
chd-169	690	32	m.	m.	NOUN
chd-169	690	33	,	,	PUNCT
chd-169	690	34	magi	magi	NOUN
chd-169	690	35	-	-	PUNCT
chd-169	690	36	galluzzi	galluzzi	NOUN
chd-169	690	37	,	,	PUNCT
chd-169	690	38	c.	c.	PROPN
chd-169	690	39	,	,	PUNCT
chd-169	690	40	taplin	taplin	PROPN
chd-169	690	41	,	,	PUNCT
chd-169	690	42	m.e	m.e	PROPN
chd-169	690	43	.	.	PROPN
chd-169	690	44	,	,	PUNCT
chd-169	690	45	et	et	PROPN
chd-169	690	46	al	al	PROPN
chd-169	690	47	.	.	PUNCT
chd-169	690	48	(	(	PUNCT
chd-169	690	49	2017	2017	NUM
chd-169	690	50	)	)	PUNCT
chd-169	690	51	.	.	PUNCT
chd-169	691	1	aberrant	aberrant	ADJ
chd-169	691	2	corticosteroid	corticosteroid	ADJ
chd-169	691	3	metabolism	metabolism	NOUN
chd-169	691	4	in	in	ADP
chd-169	691	5	tumor	tumor	NOUN
chd-169	691	6	cells	cell	NOUN
chd-169	691	7	enables	enable	VERB
chd-169	691	8	gr	gr	NOUN
chd-169	691	9	takeover	takeover	NOUN
chd-169	691	10	in	in	ADP
chd-169	691	11	enzalutamide	enzalutamide	ADJ
chd-169	691	12	resistant	resistant	ADJ
chd-169	691	13	prostate	prostate	NOUN
chd-169	691	14	cancer	cancer	NOUN
chd-169	691	15	.	.	PUNCT
chd-169	692	1	elife	elife	NOUN
chd-169	692	2	6	6	NUM
chd-169	692	3	.	.	PUNCT
chd-169	693	1	li	li	PROPN
chd-169	693	2	,	,	PUNCT
chd-169	693	3	y.	y.	PROPN
chd-169	693	4	,	,	PUNCT
chd-169	693	5	li	li	PROPN
chd-169	693	6	,	,	PUNCT
chd-169	693	7	c.x	c.x	PROPN
chd-169	693	8	.	.	PROPN
chd-169	693	9	,	,	PUNCT
chd-169	693	10	ye	ye	PROPN
chd-169	693	11	,	,	PUNCT
chd-169	693	12	h.	h.	PROPN
chd-169	693	13	,	,	PUNCT
chd-169	693	14	chen	chen	PROPN
chd-169	693	15	,	,	PUNCT
chd-169	693	16	f.	f.	PROPN
chd-169	693	17	,	,	PUNCT
chd-169	693	18	melamed	melamed	PROPN
chd-169	693	19	,	,	PUNCT
chd-169	693	20	j.	j.	PROPN
chd-169	693	21	,	,	PUNCT
chd-169	693	22	peng	peng	PROPN
chd-169	693	23	,	,	PUNCT
chd-169	693	24	y.	y.	PROPN
chd-169	693	25	,	,	PUNCT
chd-169	693	26	liu	liu	PROPN
chd-169	693	27	,	,	PUNCT
chd-169	693	28	j.	j.	PROPN
chd-169	693	29	,	,	PUNCT
chd-169	693	30	wang	wang	PROPN
chd-169	693	31	,	,	PUNCT
chd-169	693	32	z.	z.	PROPN
chd-169	693	33	,	,	PUNCT
chd-169	693	34	tsou	tsou	PROPN
chd-169	693	35	,	,	PUNCT
chd-169	693	36	h.c	h.c	PROPN
chd-169	693	37	.	.	PROPN
chd-169	693	38	,	,	PUNCT
chd-169	693	39	wei	wei	PROPN
chd-169	693	40	,	,	PUNCT
chd-169	693	41	j.	j.	PROPN
chd-169	693	42	,	,	PUNCT
chd-169	693	43	et	et	PROPN
chd-169	693	44	al	al	PROPN
chd-169	693	45	.	.	PUNCT
chd-169	694	1	(	(	PUNCT
chd-169	694	2	2008	2008	NUM
chd-169	694	3	)	)	PUNCT
chd-169	694	4	.	.	PUNCT
chd-169	695	1	decrease	decrease	NOUN
chd-169	695	2	in	in	ADP
chd-169	695	3	stromal	stromal	ADJ
chd-169	695	4	androgen	androgen	NOUN
chd-169	695	5	receptor	receptor	NOUN
chd-169	695	6	associates	associate	NOUN
chd-169	695	7	with	with	ADP
chd-169	695	8	androgenindependent	androgenindependent	NOUN
chd-169	695	9	disease	disease	NOUN
chd-169	695	10	and	and	CCONJ
chd-169	695	11	promotes	promote	VERB
chd-169	695	12	prostate	prostate	NOUN
chd-169	695	13	cancer	cancer	NOUN
chd-169	695	14	cell	cell	NOUN
chd-169	695	15	proliferation	proliferation	NOUN
chd-169	695	16	and	and	CCONJ
chd-169	695	17	invasion	invasion	NOUN
chd-169	695	18	.	.	PUNCT
chd-169	696	1	j	j	PROPN
chd-169	696	2	cell	cell	NOUN
chd-169	696	3	mol	mol	ADP
chd-169	696	4	med	med	PROPN
chd-169	696	5	12	12	NUM
chd-169	696	6	,	,	PUNCT
chd-169	696	7	2790	2790	NUM
chd-169	696	8	-	-	SYM
chd-169	696	9	2798	2798	NUM
chd-169	696	10	.	.	PUNCT
chd-169	697	1	lonard	lonard	NOUN
chd-169	697	2	,	,	PUNCT
chd-169	697	3	d.m	d.m	PROPN
chd-169	697	4	.	.	PROPN
chd-169	697	5	,	,	PUNCT
chd-169	697	6	and	and	CCONJ
chd-169	697	7	o'malley	o'malley	PROPN
chd-169	697	8	,	,	PUNCT
chd-169	697	9	b.w	b.w	PROPN
chd-169	697	10	.	.	PROPN
chd-169	697	11	(	(	PUNCT
chd-169	697	12	2012	2012	NUM
chd-169	697	13	)	)	PUNCT
chd-169	697	14	.	.	PUNCT
chd-169	698	1	nuclear	nuclear	ADJ
chd-169	698	2	receptor	receptor	NOUN
chd-169	698	3	coregulators	coregulator	NOUN
chd-169	698	4	:	:	PUNCT
chd-169	698	5	modulators	modulator	NOUN
chd-169	698	6	of	of	ADP
chd-169	698	7	pathology	pathology	NOUN
chd-169	698	8	and	and	CCONJ
chd-169	698	9	therapeutic	therapeutic	ADJ
chd-169	698	10	targets	target	NOUN
chd-169	698	11	.	.	PUNCT
chd-169	699	1	nat	nat	PROPN
chd-169	699	2	rev	rev	VERB
chd-169	699	3	endocrinol	endocrinol	NOUN
chd-169	699	4	8	8	NUM
chd-169	699	5	,	,	PUNCT
chd-169	699	6	598	598	NUM
chd-169	699	7	-	-	SYM
chd-169	699	8	604	604	NUM
chd-169	699	9	.	.	PUNCT
chd-169	700	1	luisi	luisi	VERB
chd-169	700	2	,	,	PUNCT
chd-169	700	3	b.f	b.f	PROPN
chd-169	700	4	.	.	PROPN
chd-169	700	5	,	,	PUNCT
chd-169	700	6	xu	xu	PROPN
chd-169	700	7	,	,	PUNCT
chd-169	700	8	w.x	w.x	PROPN
chd-169	700	9	.	.	PROPN
chd-169	700	10	,	,	PUNCT
chd-169	700	11	otwinowski	otwinowski	PROPN
chd-169	700	12	,	,	PUNCT
chd-169	700	13	z.	z.	PROPN
chd-169	700	14	,	,	PUNCT
chd-169	700	15	freedman	freedman	PROPN
chd-169	700	16	,	,	PUNCT
chd-169	700	17	l.p	l.p	PROPN
chd-169	700	18	.	.	PROPN
chd-169	700	19	,	,	PUNCT
chd-169	700	20	yamamoto	yamamoto	PROPN
chd-169	700	21	,	,	PUNCT
chd-169	700	22	k.r	k.r	PROPN
chd-169	700	23	.	.	PROPN
chd-169	700	24	,	,	PUNCT
chd-169	700	25	and	and	CCONJ
chd-169	700	26	sigler	sigler	PROPN
chd-169	700	27	,	,	PUNCT
chd-169	700	28	p.b	p.b	PROPN
chd-169	700	29	.	.	PROPN
chd-169	700	30	(	(	PUNCT
chd-169	700	31	1991	1991	NUM
chd-169	700	32	)	)	PUNCT
chd-169	700	33	.	.	PUNCT
chd-169	701	1	crystallographic	crystallographic	ADJ
chd-169	701	2	analysis	analysis	NOUN
chd-169	701	3	of	of	ADP
chd-169	701	4	the	the	DET
chd-169	701	5	interaction	interaction	NOUN
chd-169	701	6	of	of	ADP
chd-169	701	7	the	the	DET
chd-169	701	8	glucocorticoid	glucocorticoid	ADJ
chd-169	701	9	receptor	receptor	NOUN
chd-169	701	10	with	with	ADP
chd-169	701	11	dna	dna	PROPN
chd-169	701	12	.	.	PUNCT
chd-169	702	1	nature	nature	NOUN
chd-169	702	2	352	352	NUM
chd-169	702	3	,	,	PUNCT
chd-169	702	4	497	497	NUM
chd-169	702	5	-	-	SYM
chd-169	702	6	505	505	NUM
chd-169	702	7	.	.	PUNCT
chd-169	703	1	mahal	mahal	PROPN
chd-169	703	2	,	,	PUNCT
chd-169	703	3	b.a	b.a	PROPN
chd-169	703	4	.	.	PROPN
chd-169	703	5	,	,	PUNCT
chd-169	703	6	chen	chen	PROPN
chd-169	703	7	,	,	PUNCT
chd-169	703	8	y.w	y.w	PROPN
chd-169	703	9	.	.	PROPN
chd-169	703	10	,	,	PUNCT
chd-169	703	11	muralidhar	muralidhar	PROPN
chd-169	703	12	,	,	PUNCT
chd-169	703	13	v.	v.	PROPN
chd-169	703	14	,	,	PUNCT
chd-169	703	15	mahal	mahal	PROPN
chd-169	703	16	,	,	PUNCT
chd-169	703	17	a.r	a.r	PROPN
chd-169	703	18	.	.	PROPN
chd-169	703	19	,	,	PUNCT
chd-169	703	20	choueiri	choueiri	NOUN
chd-169	703	21	,	,	PUNCT
chd-169	703	22	t.k	t.k	PROPN
chd-169	703	23	.	.	PROPN
chd-169	703	24	,	,	PUNCT
chd-169	703	25	hoffman	hoffman	PROPN
chd-169	703	26	,	,	PUNCT
chd-169	703	27	k.e	k.e	PROPN
chd-169	703	28	.	.	PROPN
chd-169	703	29	,	,	PUNCT
chd-169	703	30	hu	hu	PROPN
chd-169	703	31	,	,	PUNCT
chd-169	703	32	j.c	j.c	PROPN
chd-169	703	33	.	.	PROPN
chd-169	703	34	,	,	PUNCT
chd-169	703	35	sweeney	sweeney	PROPN
chd-169	703	36	,	,	PUNCT
chd-169	703	37	c.j	c.j	PROPN
chd-169	703	38	.	.	PROPN
chd-169	703	39	,	,	PUNCT
chd-169	703	40	yu	yu	PROPN
chd-169	703	41	,	,	PUNCT
chd-169	703	42	j.b	j.b	PROPN
chd-169	703	43	.	.	PROPN
chd-169	703	44	,	,	PUNCT
chd-169	703	45	feng	feng	PROPN
chd-169	703	46	,	,	PUNCT
chd-169	703	47	f.y	f.y	PROPN
chd-169	703	48	.	.	PROPN
chd-169	703	49	,	,	PUNCT
chd-169	703	50	et	et	PROPN
chd-169	703	51	al	al	PROPN
chd-169	703	52	.	.	PUNCT
chd-169	703	53	(	(	PUNCT
chd-169	703	54	2017	2017	NUM
chd-169	703	55	)	)	PUNCT
chd-169	703	56	.	.	PUNCT
chd-169	704	1	racial	racial	ADJ
chd-169	704	2	disparities	disparity	NOUN
chd-169	704	3	in	in	ADP
chd-169	704	4	prostate	prostate	NOUN
chd-169	704	5	cancer	cancer	NOUN
chd-169	704	6	outcome	outcome	NOUN
chd-169	704	7	among	among	ADP
chd-169	704	8	prostate	prostate	NOUN
chd-169	704	9	-	-	PUNCT
chd-169	704	10	specific	specific	ADJ
chd-169	704	11	antigen	antigen	NOUN
chd-169	704	12	screening	screen	VERB
chd-169	704	13	eligible	eligible	ADJ
chd-169	704	14	populations	population	NOUN
chd-169	704	15	in	in	ADP
chd-169	704	16	the	the	DET
chd-169	704	17	united	united	PROPN
chd-169	704	18	states	states	PROPN
chd-169	704	19	.	.	PUNCT
chd-169	705	1	ann	ann	PROPN
chd-169	705	2	oncol	oncol	PROPN
chd-169	705	3	28	28	NUM
chd-169	705	4	,	,	PUNCT
chd-169	705	5	1098	1098	NUM
chd-169	705	6	-	-	SYM
chd-169	705	7	1104	1104	NUM
chd-169	705	8	.	.	PUNCT
chd-169	706	1	maitland	maitland	PROPN
chd-169	706	2	,	,	PUNCT
chd-169	706	3	n.j	n.j	PROPN
chd-169	706	4	.	.	PROPN
chd-169	706	5	,	,	PUNCT
chd-169	706	6	frame	frame	NOUN
chd-169	706	7	,	,	PUNCT
chd-169	706	8	f.m	f.m	PROPN
chd-169	706	9	.	.	PROPN
chd-169	706	10	,	,	PUNCT
chd-169	706	11	rane	rane	PROPN
chd-169	706	12	,	,	PUNCT
chd-169	706	13	j.k	j.k	PROPN
chd-169	706	14	.	.	PROPN
chd-169	706	15	,	,	PUNCT
chd-169	706	16	erb	erb	PROPN
chd-169	706	17	,	,	PUNCT
chd-169	706	18	h.h	h.h	PROPN
chd-169	706	19	.	.	PROPN
chd-169	706	20	,	,	PUNCT
chd-169	706	21	packer	packer	PROPN
chd-169	706	22	,	,	PUNCT
chd-169	706	23	j.r	j.r	PROPN
chd-169	706	24	.	.	PROPN
chd-169	706	25	,	,	PUNCT
chd-169	706	26	archer	archer	PROPN
chd-169	706	27	,	,	PUNCT
chd-169	706	28	l.k	l.k	PROPN
chd-169	706	29	.	.	PROPN
chd-169	706	30	,	,	PUNCT
chd-169	706	31	and	and	CCONJ
chd-169	706	32	pellacani	pellacani	PROPN
chd-169	706	33	,	,	PUNCT
chd-169	706	34	d.	d.	PROPN
chd-169	706	35	(	(	PUNCT
chd-169	706	36	2019	2019	NUM
chd-169	706	37	)	)	PUNCT
chd-169	706	38	.	.	PUNCT
chd-169	707	1	resolution	resolution	NOUN
chd-169	707	2	of	of	ADP
chd-169	707	3	cellular	cellular	ADJ
chd-169	707	4	heterogeneity	heterogeneity	NOUN
chd-169	707	5	in	in	ADP
chd-169	707	6	human	human	ADJ
chd-169	707	7	prostate	prostate	NOUN
chd-169	707	8	cancers	cancer	NOUN
chd-169	707	9	:	:	PUNCT
chd-169	707	10	implications	implication	NOUN
chd-169	707	11	for	for	ADP
chd-169	707	12	diagnosis	diagnosis	NOUN
chd-169	707	13	and	and	CCONJ
chd-169	707	14	treatment	treatment	NOUN
chd-169	707	15	.	.	PUNCT
chd-169	708	1	adv	adv	PROPN
chd-169	708	2	exp	exp	NOUN
chd-169	708	3	med	med	ADJ
chd-169	708	4	biol	biol	PROPN
chd-169	708	5	1164	1164	NUM
chd-169	708	6	,	,	PUNCT
chd-169	708	7	207	207	NUM
chd-169	708	8	-	-	SYM
chd-169	708	9	224	224	NUM
chd-169	708	10	.	.	PUNCT
chd-169	709	1	mangelsdorf	mangelsdorf	PROPN
chd-169	709	2	,	,	PUNCT
chd-169	709	3	d.j	d.j	PROPN
chd-169	709	4	.	.	PROPN
chd-169	709	5	,	,	PUNCT
chd-169	709	6	thummel	thummel	PROPN
chd-169	709	7	,	,	PUNCT
chd-169	709	8	c.	c.	PROPN
chd-169	709	9	,	,	PUNCT
chd-169	709	10	beato	beato	PROPN
chd-169	709	11	,	,	PUNCT
chd-169	709	12	m.	m.	NOUN
chd-169	709	13	,	,	PUNCT
chd-169	709	14	herrlich	herrlich	NOUN
chd-169	709	15	,	,	PUNCT
chd-169	709	16	p.	p.	NOUN
chd-169	709	17	,	,	PUNCT
chd-169	709	18	schutz	schutz	PROPN
chd-169	709	19	,	,	PUNCT
chd-169	709	20	g.	g.	PROPN
chd-169	709	21	,	,	PUNCT
chd-169	709	22	umesono	umesono	PROPN
chd-169	709	23	,	,	PUNCT
chd-169	709	24	k.	k.	PROPN
chd-169	709	25	,	,	PUNCT
chd-169	709	26	blumberg	blumberg	PROPN
chd-169	709	27	,	,	PUNCT
chd-169	709	28	b.	b.	PROPN
chd-169	709	29	,	,	PUNCT
chd-169	709	30	kastner	kastner	PROPN
chd-169	709	31	,	,	PUNCT
chd-169	709	32	p.	p.	PROPN
chd-169	709	33	,	,	PUNCT
chd-169	709	34	mark	mark	NOUN
chd-169	709	35	,	,	PUNCT
chd-169	709	36	m.	m.	NOUN
chd-169	709	37	,	,	PUNCT
chd-169	709	38	chambon	chambon	NOUN
chd-169	709	39	,	,	PUNCT
chd-169	709	40	p.	p.	PROPN
chd-169	709	41	,	,	PUNCT
chd-169	709	42	et	et	PROPN
chd-169	709	43	al	al	PROPN
chd-169	709	44	.	.	PROPN
chd-169	709	45	(	(	PUNCT
chd-169	709	46	1995	1995	NUM
chd-169	709	47	)	)	PUNCT
chd-169	709	48	.	.	PUNCT
chd-169	710	1	the	the	DET
chd-169	710	2	nuclear	nuclear	ADJ
chd-169	710	3	receptor	receptor	NOUN
chd-169	710	4	superfamily	superfamily	ADV
chd-169	710	5	:	:	PUNCT
chd-169	710	6	the	the	DET
chd-169	710	7	second	second	ADJ
chd-169	710	8	decade	decade	NOUN
chd-169	710	9	.	.	PUNCT
chd-169	711	1	cell	cell	NOUN
chd-169	711	2	83	83	NUM
chd-169	711	3	,	,	PUNCT
chd-169	711	4	835	835	NUM
chd-169	711	5	-	-	SYM
chd-169	711	6	839	839	NUM
chd-169	711	7	.	.	PUNCT
chd-169	711	8	marioni	marioni	NOUN
chd-169	711	9	,	,	PUNCT
chd-169	711	10	r.e	r.e	PROPN
chd-169	711	11	.	.	PROPN
chd-169	711	12	,	,	PUNCT
chd-169	711	13	shah	shah	PROPN
chd-169	711	14	,	,	PUNCT
chd-169	711	15	s.	s.	PROPN
chd-169	711	16	,	,	PUNCT
chd-169	711	17	mcrae	mcrae	PROPN
chd-169	711	18	,	,	PUNCT
chd-169	711	19	a.f	a.f	PROPN
chd-169	711	20	.	.	PROPN
chd-169	711	21	,	,	PUNCT
chd-169	711	22	chen	chen	PROPN
chd-169	711	23	,	,	PUNCT
chd-169	711	24	b.h	b.h	PROPN
chd-169	711	25	.	.	PROPN
chd-169	711	26	,	,	PUNCT
chd-169	711	27	colicino	colicino	PROPN
chd-169	711	28	,	,	PUNCT
chd-169	711	29	e.	e.	PROPN
chd-169	711	30	,	,	PUNCT
chd-169	711	31	harris	harris	PROPN
chd-169	711	32	,	,	PUNCT
chd-169	711	33	s.e	s.e	PROPN
chd-169	711	34	.	.	PROPN
chd-169	711	35	,	,	PUNCT
chd-169	711	36	gibson	gibson	PROPN
chd-169	711	37	,	,	PUNCT
chd-169	711	38	j.	j.	PROPN
chd-169	711	39	,	,	PUNCT
chd-169	711	40	henders	hender	NOUN
chd-169	711	41	,	,	PUNCT
chd-169	711	42	a.k	a.k	PROPN
chd-169	711	43	.	.	PROPN
chd-169	711	44	,	,	PUNCT
chd-169	711	45	redmond	redmond	PROPN
chd-169	711	46	,	,	PUNCT
chd-169	711	47	p.	p.	PROPN
chd-169	711	48	,	,	PUNCT
chd-169	711	49	cox	cox	PROPN
chd-169	711	50	,	,	PUNCT
chd-169	711	51	s.r	s.r	PROPN
chd-169	711	52	.	.	PROPN
chd-169	711	53	,	,	PUNCT
chd-169	711	54	et	et	PROPN
chd-169	711	55	al	al	PROPN
chd-169	711	56	.	.	PROPN
chd-169	712	1	(	(	PUNCT
chd-169	712	2	2015a	2015a	NUM
chd-169	712	3	)	)	PUNCT
chd-169	712	4	.	.	PUNCT
chd-169	713	1	dna	dna	PROPN
chd-169	713	2	methylation	methylation	NOUN
chd-169	713	3	age	age	NOUN
chd-169	713	4	of	of	ADP
chd-169	713	5	blood	blood	NOUN
chd-169	713	6	predicts	predict	VERB
chd-169	713	7	all	all	DET
chd-169	713	8	-	-	PUNCT
chd-169	713	9	cause	cause	NOUN
chd-169	713	10	mortality	mortality	NOUN
chd-169	713	11	in	in	ADP
chd-169	713	12	later	later	ADJ
chd-169	713	13	life	life	NOUN
chd-169	713	14	.	.	PUNCT
chd-169	714	1	genome	genome	NOUN
chd-169	714	2	biol	biol	NOUN
chd-169	714	3	16	16	NUM
chd-169	714	4	,	,	PUNCT
chd-169	714	5	25	25	NUM
chd-169	714	6	.	.	PUNCT
chd-169	714	7	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-169	714	8	e26	e26	PROPN
chd-169	714	9	cancer	cancer	NOUN
chd-169	714	10	health	health	NOUN
chd-169	714	11	disparities	disparity	NOUN
chd-169	714	12	research	research	NOUN
chd-169	714	13	marioni	marioni	NOUN
chd-169	714	14	,	,	PUNCT
chd-169	714	15	r.e	r.e	PROPN
chd-169	714	16	.	.	PROPN
chd-169	714	17	,	,	PUNCT
chd-169	714	18	shah	shah	PROPN
chd-169	714	19	,	,	PUNCT
chd-169	714	20	s.	s.	PROPN
chd-169	714	21	,	,	PUNCT
chd-169	714	22	mcrae	mcrae	PROPN
chd-169	714	23	,	,	PUNCT
chd-169	714	24	a.f	a.f	PROPN
chd-169	714	25	.	.	PROPN
chd-169	714	26	,	,	PUNCT
chd-169	714	27	ritchie	ritchie	PROPN
chd-169	714	28	,	,	PUNCT
chd-169	714	29	s.j	s.j	PROPN
chd-169	714	30	.	.	PROPN
chd-169	714	31	,	,	PUNCT
chd-169	714	32	munizterrera	munizterrera	PROPN
chd-169	714	33	,	,	PUNCT
chd-169	714	34	g.	g.	PROPN
chd-169	714	35	,	,	PUNCT
chd-169	714	36	harris	harris	PROPN
chd-169	714	37	,	,	PUNCT
chd-169	714	38	s.e	s.e	PROPN
chd-169	714	39	.	.	PROPN
chd-169	714	40	,	,	PUNCT
chd-169	714	41	gibson	gibson	PROPN
chd-169	714	42	,	,	PUNCT
chd-169	714	43	j.	j.	PROPN
chd-169	714	44	,	,	PUNCT
chd-169	714	45	redmond	redmond	PROPN
chd-169	714	46	,	,	PUNCT
chd-169	714	47	p.	p.	PROPN
chd-169	714	48	,	,	PUNCT
chd-169	714	49	cox	cox	PROPN
chd-169	714	50	,	,	PUNCT
chd-169	714	51	s.r	s.r	PROPN
chd-169	714	52	.	.	PROPN
chd-169	714	53	,	,	PUNCT
chd-169	714	54	pattie	pattie	NOUN
chd-169	714	55	,	,	PUNCT
chd-169	714	56	a.	a.	NOUN
chd-169	714	57	,	,	PUNCT
chd-169	714	58	et	et	PROPN
chd-169	714	59	al	al	PROPN
chd-169	714	60	.	.	PUNCT
chd-169	714	61	(	(	PUNCT
chd-169	714	62	2015b	2015b	NUM
chd-169	714	63	)	)	PUNCT
chd-169	714	64	.	.	PUNCT
chd-169	715	1	the	the	DET
chd-169	715	2	epigenetic	epigenetic	ADJ
chd-169	715	3	clock	clock	NOUN
chd-169	715	4	is	be	AUX
chd-169	715	5	correlated	correlate	VERB
chd-169	715	6	with	with	ADP
chd-169	715	7	physical	physical	ADJ
chd-169	715	8	and	and	CCONJ
chd-169	715	9	cognitive	cognitive	ADJ
chd-169	715	10	fitness	fitness	NOUN
chd-169	715	11	in	in	ADP
chd-169	715	12	the	the	DET
chd-169	715	13	lothian	lothian	ADJ
chd-169	715	14	birth	birth	NOUN
chd-169	715	15	cohort	cohort	NOUN
chd-169	715	16	1936	1936	NUM
chd-169	715	17	.	.	PUNCT
chd-169	716	1	international	international	ADJ
chd-169	716	2	journal	journal	NOUN
chd-169	716	3	of	of	ADP
chd-169	716	4	epidemiology	epidemiology	NOUN
chd-169	716	5	44	44	NUM
chd-169	716	6	,	,	PUNCT
chd-169	716	7	1388	1388	NUM
chd-169	716	8	-	-	SYM
chd-169	716	9	1396	1396	NUM
chd-169	716	10	.	.	PUNCT
chd-169	717	1	massengill	massengill	NOUN
chd-169	717	2	,	,	PUNCT
chd-169	717	3	j.c	j.c	PROPN
chd-169	717	4	.	.	PROPN
chd-169	717	5	,	,	PUNCT
chd-169	717	6	sun	sun	PROPN
chd-169	717	7	,	,	PUNCT
chd-169	717	8	l.	l.	PROPN
chd-169	717	9	,	,	PUNCT
chd-169	717	10	moul	moul	PROPN
chd-169	717	11	,	,	PUNCT
chd-169	717	12	j.w	j.w	PROPN
chd-169	717	13	.	.	PROPN
chd-169	717	14	,	,	PUNCT
chd-169	717	15	wu	wu	PROPN
chd-169	717	16	,	,	PUNCT
chd-169	717	17	h.	h.	PROPN
chd-169	717	18	,	,	PUNCT
chd-169	717	19	mcleod	mcleod	PROPN
chd-169	717	20	,	,	PUNCT
chd-169	717	21	d.g	d.g	PROPN
chd-169	717	22	.	.	PROPN
chd-169	717	23	,	,	PUNCT
chd-169	717	24	amling	amling	NOUN
chd-169	717	25	,	,	PUNCT
chd-169	717	26	c.	c.	NOUN
chd-169	717	27	,	,	PUNCT
chd-169	717	28	lance	lance	NOUN
chd-169	717	29	,	,	PUNCT
chd-169	717	30	r.	r.	PROPN
chd-169	717	31	,	,	PUNCT
chd-169	717	32	foley	foley	PROPN
chd-169	717	33	,	,	PUNCT
chd-169	717	34	j.	j.	PROPN
chd-169	717	35	,	,	PUNCT
chd-169	717	36	sexton	sexton	PROPN
chd-169	717	37	,	,	PUNCT
chd-169	717	38	w.	w.	PROPN
chd-169	717	39	,	,	PUNCT
chd-169	717	40	kusuda	kusuda	PROPN
chd-169	717	41	,	,	PUNCT
chd-169	717	42	l.	l.	PROPN
chd-169	717	43	,	,	PUNCT
chd-169	717	44	et	et	PROPN
chd-169	717	45	al	al	PROPN
chd-169	717	46	.	.	PUNCT
chd-169	717	47	(	(	PUNCT
chd-169	717	48	2003	2003	NUM
chd-169	717	49	)	)	PUNCT
chd-169	717	50	.	.	PUNCT
chd-169	718	1	pretreatment	pretreatment	NOUN
chd-169	718	2	total	total	ADJ
chd-169	718	3	testosterone	testosterone	NOUN
chd-169	718	4	level	level	NOUN
chd-169	718	5	predicts	predict	VERB
chd-169	718	6	pathological	pathological	ADJ
chd-169	718	7	stage	stage	NOUN
chd-169	718	8	in	in	ADP
chd-169	718	9	patients	patient	NOUN
chd-169	718	10	with	with	ADP
chd-169	718	11	localized	localized	ADJ
chd-169	718	12	prostate	prostate	NOUN
chd-169	718	13	cancer	cancer	NOUN
chd-169	718	14	treated	treat	VERB
chd-169	718	15	with	with	ADP
chd-169	718	16	radical	radical	ADJ
chd-169	718	17	prostatectomy	prostatectomy	NOUN
chd-169	718	18	.	.	PUNCT
chd-169	719	1	j	j	PROPN
chd-169	719	2	urol	urol	PROPN
chd-169	719	3	169	169	NUM
chd-169	719	4	,	,	PUNCT
chd-169	719	5	1670	1670	NUM
chd-169	719	6	-	-	SYM
chd-169	719	7	1675	1675	NUM
chd-169	719	8	.	.	PUNCT
chd-169	720	1	mata	mata	PROPN
chd-169	720	2	-	-	PUNCT
chd-169	720	3	greenwood	greenwood	PROPN
chd-169	720	4	,	,	PUNCT
chd-169	720	5	e.	e.	PROPN
chd-169	720	6	,	,	PUNCT
chd-169	720	7	jackson	jackson	PROPN
chd-169	720	8	,	,	PUNCT
chd-169	720	9	p.n	p.n	PROPN
chd-169	720	10	.	.	PROPN
chd-169	720	11	,	,	PUNCT
chd-169	720	12	pearce	pearce	PROPN
chd-169	720	13	,	,	PUNCT
chd-169	720	14	w.j	w.j	PROPN
chd-169	720	15	.	.	PROPN
chd-169	720	16	,	,	PUNCT
chd-169	720	17	and	and	CCONJ
chd-169	720	18	zhang	zhang	PROPN
chd-169	720	19	,	,	PUNCT
chd-169	720	20	l.	l.	PROPN
chd-169	720	21	(	(	PUNCT
chd-169	720	22	2015	2015	NUM
chd-169	720	23	)	)	PUNCT
chd-169	720	24	.	.	PUNCT
chd-169	721	1	endothelial	endothelial	ADJ
chd-169	721	2	glucocorticoid	glucocorticoid	ADJ
chd-169	721	3	receptor	receptor	NOUN
chd-169	721	4	promoter	promoter	NOUN
chd-169	721	5	methylation	methylation	NOUN
chd-169	721	6	according	accord	VERB
chd-169	721	7	to	to	ADP
chd-169	721	8	dexamethasone	dexamethasone	NOUN
chd-169	721	9	sensitivity	sensitivity	NOUN
chd-169	721	10	.	.	PUNCT
chd-169	722	1	j	j	PROPN
chd-169	722	2	mol	mol	ADP
chd-169	722	3	endocrinol	endocrinol	PROPN
chd-169	722	4	55	55	NUM
chd-169	722	5	,	,	PUNCT
chd-169	722	6	133	133	NUM
chd-169	722	7	-	-	SYM
chd-169	722	8	146	146	NUM
chd-169	722	9	.	.	PUNCT
chd-169	722	10	matsumoto	matsumoto	PROPN
chd-169	722	11	,	,	PUNCT
chd-169	722	12	h.	h.	PROPN
chd-169	722	13	,	,	PUNCT
chd-169	722	14	yamamoto	yamamoto	PROPN
chd-169	722	15	,	,	PUNCT
chd-169	722	16	y.	y.	PROPN
chd-169	722	17	,	,	PUNCT
chd-169	722	18	shiota	shiota	NOUN
chd-169	722	19	,	,	PUNCT
chd-169	722	20	m.	m.	NOUN
chd-169	722	21	,	,	PUNCT
chd-169	722	22	kuruma	kuruma	PROPN
chd-169	722	23	,	,	PUNCT
chd-169	722	24	h.	h.	PROPN
chd-169	722	25	,	,	PUNCT
chd-169	722	26	beraldi	beraldi	PROPN
chd-169	722	27	,	,	PUNCT
chd-169	722	28	e.	e.	PROPN
chd-169	722	29	,	,	PUNCT
chd-169	722	30	matsuyama	matsuyama	PROPN
chd-169	722	31	,	,	PUNCT
chd-169	722	32	h.	h.	PROPN
chd-169	722	33	,	,	PUNCT
chd-169	722	34	zoubeidi	zoubeidi	NOUN
chd-169	722	35	,	,	PUNCT
chd-169	722	36	a.	a.	NOUN
chd-169	722	37	,	,	PUNCT
chd-169	722	38	and	and	CCONJ
chd-169	722	39	gleave	gleave	PROPN
chd-169	722	40	,	,	PUNCT
chd-169	722	41	m.	m.	NOUN
chd-169	722	42	(	(	PUNCT
chd-169	722	43	2013	2013	NUM
chd-169	722	44	)	)	PUNCT
chd-169	722	45	.	.	PUNCT
chd-169	723	1	cotargeting	cotargete	VERB
chd-169	723	2	androgen	androgen	NOUN
chd-169	723	3	receptor	receptor	NOUN
chd-169	723	4	and	and	CCONJ
chd-169	723	5	clusterin	clusterin	NOUN
chd-169	723	6	delays	delay	NOUN
chd-169	723	7	castrate	castrate	VERB
chd-169	723	8	-	-	PUNCT
chd-169	723	9	resistant	resistant	ADJ
chd-169	723	10	prostate	prostate	NOUN
chd-169	723	11	cancer	cancer	NOUN
chd-169	723	12	progression	progression	NOUN
chd-169	723	13	by	by	ADP
chd-169	723	14	inhibiting	inhibit	VERB
chd-169	723	15	adaptive	adaptive	ADJ
chd-169	723	16	stress	stress	NOUN
chd-169	723	17	response	response	NOUN
chd-169	723	18	and	and	CCONJ
chd-169	723	19	ar	ar	NOUN
chd-169	723	20	stability	stability	NOUN
chd-169	723	21	.	.	PUNCT
chd-169	724	1	cancer	cancer	NOUN
chd-169	724	2	research	research	NOUN
chd-169	724	3	73	73	NUM
chd-169	724	4	,	,	PUNCT
chd-169	724	5	5206	5206	NUM
chd-169	724	6	-	-	SYM
chd-169	724	7	5217	5217	NUM
chd-169	724	8	.	.	PUNCT
chd-169	725	1	mccoy	mccoy	PROPN
chd-169	725	2	,	,	PUNCT
chd-169	725	3	j.	j.	PROPN
chd-169	725	4	,	,	PUNCT
chd-169	725	5	wambier	wambier	NOUN
chd-169	725	6	,	,	PUNCT
chd-169	725	7	c.g	c.g	PROPN
chd-169	725	8	.	.	PROPN
chd-169	725	9	,	,	PUNCT
chd-169	725	10	vano	vano	PROPN
chd-169	725	11	-	-	NOUN
chd-169	725	12	galvan	galvan	NOUN
chd-169	725	13	,	,	PUNCT
chd-169	725	14	s.	s.	PROPN
chd-169	725	15	,	,	PUNCT
chd-169	725	16	shapiro	shapiro	PROPN
chd-169	725	17	,	,	PUNCT
chd-169	725	18	j.	j.	PROPN
chd-169	725	19	,	,	PUNCT
chd-169	725	20	sinclair	sinclair	PROPN
chd-169	725	21	,	,	PUNCT
chd-169	725	22	r.	r.	PROPN
chd-169	725	23	,	,	PUNCT
chd-169	725	24	ramos	ramos	PROPN
chd-169	725	25	,	,	PUNCT
chd-169	725	26	p.m.	p.m.	ADV
chd-169	725	27	,	,	PUNCT
chd-169	725	28	washenik	washenik	ADV
chd-169	725	29	,	,	PUNCT
chd-169	725	30	k.	k.	PROPN
chd-169	725	31	,	,	PUNCT
chd-169	725	32	andrade	andrade	PROPN
chd-169	725	33	,	,	PUNCT
chd-169	725	34	m.	m.	NOUN
chd-169	725	35	,	,	PUNCT
chd-169	725	36	herrera	herrera	NOUN
chd-169	725	37	,	,	PUNCT
chd-169	725	38	s.	s.	PROPN
chd-169	725	39	,	,	PUNCT
chd-169	725	40	and	and	CCONJ
chd-169	725	41	goren	goren	PROPN
chd-169	725	42	,	,	PUNCT
chd-169	725	43	a.	a.	NOUN
chd-169	725	44	(	(	PUNCT
chd-169	725	45	2020	2020	NUM
chd-169	725	46	)	)	PUNCT
chd-169	725	47	.	.	PUNCT
chd-169	726	1	racial	racial	ADJ
chd-169	726	2	variations	variation	NOUN
chd-169	726	3	in	in	ADP
chd-169	726	4	covid-19	covid-19	PROPN
chd-169	726	5	deaths	death	NOUN
chd-169	726	6	may	may	AUX
chd-169	726	7	be	be	AUX
chd-169	726	8	due	due	ADJ
chd-169	726	9	to	to	ADP
chd-169	726	10	androgen	androgen	NOUN
chd-169	726	11	receptor	receptor	NOUN
chd-169	726	12	genetic	genetic	ADJ
chd-169	726	13	variants	variant	NOUN
chd-169	726	14	associated	associate	VERB
chd-169	726	15	with	with	ADP
chd-169	726	16	prostate	prostate	NOUN
chd-169	726	17	cancer	cancer	NOUN
chd-169	726	18	and	and	CCONJ
chd-169	726	19	androgenetic	androgenetic	ADJ
chd-169	726	20	alopecia	alopecia	NOUN
chd-169	726	21	.	.	PUNCT
chd-169	727	1	are	be	AUX
chd-169	727	2	anti	anti	ADJ
chd-169	727	3	-	-	ADJ
chd-169	727	4	androgens	androgens	ADJ
chd-169	727	5	a	a	DET
chd-169	727	6	potential	potential	ADJ
chd-169	727	7	treatment	treatment	NOUN
chd-169	727	8	for	for	ADP
chd-169	727	9	covid-19	covid-19	PROPN
chd-169	727	10	?	?	PUNCT
chd-169	728	1	j	j	PROPN
chd-169	728	2	cosmet	cosmet	VERB
chd-169	728	3	dermatol	dermatol	NOUN
chd-169	728	4	19	19	NUM
chd-169	728	5	,	,	PUNCT
chd-169	728	6	15421543	15421543	NUM
chd-169	728	7	.	.	PUNCT
chd-169	729	1	mcewen	mcewen	PROPN
chd-169	729	2	,	,	PUNCT
chd-169	729	3	b.s	b.s	PROPN
chd-169	729	4	.	.	PROPN
chd-169	729	5	(	(	PUNCT
chd-169	729	6	1998	1998	NUM
chd-169	729	7	)	)	PUNCT
chd-169	729	8	.	.	PUNCT
chd-169	730	1	protective	protective	ADJ
chd-169	730	2	and	and	CCONJ
chd-169	730	3	damaging	damaging	ADJ
chd-169	730	4	effects	effect	NOUN
chd-169	730	5	of	of	ADP
chd-169	730	6	stress	stress	ADJ
chd-169	730	7	mediators	mediator	NOUN
chd-169	730	8	.	.	PUNCT
chd-169	731	1	n	n	PROPN
chd-169	731	2	engl	engl	PROPN
chd-169	731	3	j	j	PROPN
chd-169	731	4	med	me	VERB
chd-169	731	5	338	338	NUM
chd-169	731	6	,	,	PUNCT
chd-169	731	7	171	171	NUM
chd-169	731	8	-	-	SYM
chd-169	731	9	179	179	NUM
chd-169	731	10	.	.	PUNCT
chd-169	732	1	mediavilla	mediavilla	PROPN
chd-169	732	2	-	-	PUNCT
chd-169	732	3	varela	varela	PROPN
chd-169	732	4	,	,	PUNCT
chd-169	732	5	m.	m.	NOUN
chd-169	732	6	,	,	PUNCT
chd-169	732	7	pacheco	pacheco	PROPN
chd-169	732	8	,	,	PUNCT
chd-169	732	9	f.j	f.j	PROPN
chd-169	732	10	.	.	PROPN
chd-169	732	11	,	,	PUNCT
chd-169	732	12	almaguel	almaguel	PROPN
chd-169	732	13	,	,	PUNCT
chd-169	732	14	f.	f.	PROPN
chd-169	732	15	,	,	PUNCT
chd-169	732	16	perez	perez	PROPN
chd-169	732	17	,	,	PUNCT
chd-169	732	18	j.	j.	PROPN
chd-169	732	19	,	,	PUNCT
chd-169	732	20	sahakian	sahakian	PROPN
chd-169	732	21	,	,	PUNCT
chd-169	732	22	e.	e.	PROPN
chd-169	732	23	,	,	PUNCT
chd-169	732	24	daniels	daniels	PROPN
chd-169	732	25	,	,	PUNCT
chd-169	732	26	t.r	t.r	PROPN
chd-169	732	27	.	.	PROPN
chd-169	732	28	,	,	PUNCT
chd-169	732	29	leoh	leoh	PROPN
chd-169	732	30	,	,	PUNCT
chd-169	732	31	l.s	l.s	PROPN
chd-169	732	32	.	.	PROPN
chd-169	732	33	,	,	PUNCT
chd-169	732	34	padilla	padilla	PROPN
chd-169	732	35	,	,	PUNCT
chd-169	732	36	a.	a.	PROPN
chd-169	732	37	,	,	PUNCT
chd-169	732	38	wall	wall	PROPN
chd-169	732	39	,	,	PUNCT
chd-169	732	40	n.r	n.r	PROPN
chd-169	732	41	.	.	PROPN
chd-169	732	42	,	,	PUNCT
chd-169	732	43	lilly	lilly	PROPN
chd-169	732	44	,	,	PUNCT
chd-169	732	45	m.b	m.b	PROPN
chd-169	732	46	.	.	PROPN
chd-169	732	47	,	,	PUNCT
chd-169	732	48	et	et	PROPN
chd-169	732	49	al	al	PROPN
chd-169	732	50	.	.	PUNCT
chd-169	733	1	(	(	PUNCT
chd-169	733	2	2009	2009	NUM
chd-169	733	3	)	)	PUNCT
chd-169	733	4	.	.	PUNCT
chd-169	734	1	docetaxel	docetaxel	NOUN
chd-169	734	2	-	-	PUNCT
chd-169	734	3	induced	induce	VERB
chd-169	734	4	prostate	prostate	NOUN
chd-169	734	5	cancer	cancer	NOUN
chd-169	734	6	cell	cell	NOUN
chd-169	734	7	death	death	NOUN
chd-169	734	8	involves	involve	VERB
chd-169	734	9	concomitant	concomitant	ADJ
chd-169	734	10	activation	activation	NOUN
chd-169	734	11	of	of	ADP
chd-169	734	12	caspase	caspase	NOUN
chd-169	734	13	and	and	CCONJ
chd-169	734	14	lysosomal	lysosomal	ADJ
chd-169	734	15	pathways	pathway	NOUN
chd-169	734	16	and	and	CCONJ
chd-169	734	17	is	be	AUX
chd-169	734	18	attenuated	attenuate	VERB
chd-169	734	19	by	by	ADP
chd-169	734	20	ledgf	ledgf	NOUN
chd-169	734	21	/	/	SYM
chd-169	734	22	p75	p75	NOUN
chd-169	734	23	.	.	PUNCT
chd-169	735	1	molecular	molecular	ADJ
chd-169	735	2	cancer	cancer	NOUN
chd-169	735	3	8	8	NUM
chd-169	735	4	,	,	PUNCT
chd-169	735	5	68	68	NUM
chd-169	735	6	.	.	PUNCT
chd-169	736	1	meijer	meijer	PROPN
chd-169	736	2	,	,	PUNCT
chd-169	736	3	o.c	o.c	PROPN
chd-169	736	4	.	.	PROPN
chd-169	736	5	,	,	PUNCT
chd-169	736	6	koorneef	koorneef	PROPN
chd-169	736	7	,	,	PUNCT
chd-169	736	8	l.l	l.l	PROPN
chd-169	736	9	.	.	PROPN
chd-169	736	10	,	,	PUNCT
chd-169	736	11	and	and	CCONJ
chd-169	736	12	kroon	kroon	PROPN
chd-169	736	13	,	,	PUNCT
chd-169	736	14	j.	j.	PROPN
chd-169	736	15	(	(	PUNCT
chd-169	736	16	2018	2018	NUM
chd-169	736	17	)	)	PUNCT
chd-169	736	18	.	.	PUNCT
chd-169	737	1	glucocorticoid	glucocorticoid	ADJ
chd-169	737	2	receptor	receptor	NOUN
chd-169	737	3	modulators	modulator	NOUN
chd-169	737	4	.	.	PUNCT
chd-169	738	1	ann	ann	PROPN
chd-169	738	2	endocrinol	endocrinol	PROPN
chd-169	738	3	(	(	PUNCT
chd-169	738	4	paris	paris	PROPN
chd-169	738	5	)	)	PUNCT
chd-169	738	6	79	79	NUM
chd-169	738	7	,	,	PUNCT
chd-169	738	8	107	107	NUM
chd-169	738	9	-	-	SYM
chd-169	738	10	111	111	NUM
chd-169	738	11	.	.	PUNCT
chd-169	738	12	misra	misra	ADJ
chd-169	738	13	-	-	PUNCT
chd-169	738	14	hebert	hebert	NOUN
chd-169	738	15	,	,	PUNCT
chd-169	738	16	a.d	a.d	PROPN
chd-169	738	17	.	.	PROPN
chd-169	738	18	,	,	PUNCT
chd-169	738	19	hu	hu	PROPN
chd-169	738	20	,	,	PUNCT
chd-169	738	21	b.	b.	PROPN
chd-169	738	22	,	,	PUNCT
chd-169	738	23	klein	klein	PROPN
chd-169	738	24	,	,	PUNCT
chd-169	738	25	e.a	e.a	PROPN
chd-169	738	26	.	.	PROPN
chd-169	738	27	,	,	PUNCT
chd-169	738	28	stephenson	stephenson	PROPN
chd-169	738	29	,	,	PUNCT
chd-169	738	30	a.	a.	NOUN
chd-169	738	31	,	,	PUNCT
chd-169	738	32	taksler	taksler	NOUN
chd-169	738	33	,	,	PUNCT
chd-169	738	34	g.b	g.b	PROPN
chd-169	738	35	.	.	PROPN
chd-169	738	36	,	,	PUNCT
chd-169	738	37	kattan	kattan	PROPN
chd-169	738	38	,	,	PUNCT
chd-169	738	39	m.w	m.w	PROPN
chd-169	738	40	.	.	PROPN
chd-169	738	41	,	,	PUNCT
chd-169	738	42	and	and	CCONJ
chd-169	738	43	rothberg	rothberg	PROPN
chd-169	738	44	,	,	PUNCT
chd-169	738	45	m.b	m.b	PROPN
chd-169	738	46	.	.	PROPN
chd-169	738	47	(	(	PUNCT
chd-169	738	48	2017	2017	NUM
chd-169	738	49	)	)	PUNCT
chd-169	738	50	.	.	PUNCT
chd-169	739	1	prostate	prostate	NOUN
chd-169	739	2	cancer	cancer	NOUN
chd-169	739	3	screening	screening	NOUN
chd-169	739	4	practices	practice	NOUN
chd-169	739	5	in	in	ADP
chd-169	739	6	a	a	DET
chd-169	739	7	large	large	ADJ
chd-169	739	8	,	,	PUNCT
chd-169	739	9	integrated	integrated	ADJ
chd-169	739	10	health	health	NOUN
chd-169	739	11	system	system	NOUN
chd-169	739	12	:	:	PUNCT
chd-169	739	13	2007	2007	NUM
chd-169	739	14	-	-	SYM
chd-169	739	15	2014	2014	NUM
chd-169	739	16	.	.	PUNCT
chd-169	740	1	bju	bju	NOUN
chd-169	740	2	int	int	PROPN
chd-169	740	3	120	120	NUM
chd-169	740	4	,	,	PUNCT
chd-169	740	5	257	257	NUM
chd-169	740	6	-	-	SYM
chd-169	740	7	264	264	NUM
chd-169	740	8	.	.	PUNCT
chd-169	741	1	montgomery	montgomery	PROPN
chd-169	741	2	,	,	PUNCT
chd-169	741	3	b.	b.	PROPN
chd-169	741	4	,	,	PUNCT
chd-169	741	5	cheng	cheng	PROPN
chd-169	741	6	,	,	PUNCT
chd-169	741	7	h.h	h.h	PROPN
chd-169	741	8	.	.	PROPN
chd-169	741	9	,	,	PUNCT
chd-169	741	10	drechsler	drechsler	PROPN
chd-169	741	11	,	,	PUNCT
chd-169	741	12	j.	j.	PROPN
chd-169	741	13	,	,	PUNCT
chd-169	741	14	and	and	CCONJ
chd-169	741	15	mostaghel	mostaghel	PROPN
chd-169	741	16	,	,	PUNCT
chd-169	741	17	e.a	e.a	PROPN
chd-169	741	18	.	.	PROPN
chd-169	741	19	(	(	PUNCT
chd-169	741	20	2014	2014	NUM
chd-169	741	21	)	)	PUNCT
chd-169	741	22	.	.	PUNCT
chd-169	742	1	glucocorticoids	glucocorticoid	NOUN
chd-169	742	2	and	and	CCONJ
chd-169	742	3	prostate	prostate	NOUN
chd-169	742	4	cancer	cancer	NOUN
chd-169	742	5	treatment	treatment	NOUN
chd-169	742	6	:	:	PUNCT
chd-169	742	7	friend	friend	NOUN
chd-169	742	8	or	or	CCONJ
chd-169	742	9	foe	foe	NOUN
chd-169	742	10	?	?	PUNCT
chd-169	743	1	asian	asian	PROPN
chd-169	743	2	j	j	PROPN
chd-169	743	3	androl	androl	PROPN
chd-169	743	4	16	16	NUM
chd-169	743	5	,	,	PUNCT
chd-169	743	6	354	354	NUM
chd-169	743	7	-	-	SYM
chd-169	743	8	358	358	NUM
chd-169	743	9	.	.	PUNCT
chd-169	744	1	montgomery	montgomery	PROPN
chd-169	744	2	,	,	PUNCT
chd-169	744	3	b.	b.	PROPN
chd-169	744	4	,	,	PUNCT
chd-169	744	5	kheoh	kheoh	PROPN
chd-169	744	6	,	,	PUNCT
chd-169	744	7	t.	t.	PROPN
chd-169	744	8	,	,	PUNCT
chd-169	744	9	molina	molina	PROPN
chd-169	744	10	,	,	PUNCT
chd-169	744	11	a.	a.	PROPN
chd-169	744	12	,	,	PUNCT
chd-169	744	13	li	li	PROPN
chd-169	744	14	,	,	PUNCT
chd-169	744	15	j.	j.	PROPN
chd-169	744	16	,	,	PUNCT
chd-169	744	17	bellmunt	bellmunt	NOUN
chd-169	744	18	,	,	PUNCT
chd-169	744	19	j.	j.	PROPN
chd-169	744	20	,	,	PUNCT
chd-169	744	21	tran	tran	PROPN
chd-169	744	22	,	,	PUNCT
chd-169	744	23	n.	n.	NOUN
chd-169	744	24	,	,	PUNCT
chd-169	744	25	loriot	loriot	PROPN
chd-169	744	26	,	,	PUNCT
chd-169	744	27	y.	y.	PROPN
chd-169	744	28	,	,	PUNCT
chd-169	744	29	efstathiou	efstathiou	PROPN
chd-169	744	30	,	,	PUNCT
chd-169	744	31	e.	e.	PROPN
chd-169	744	32	,	,	PUNCT
chd-169	744	33	ryan	ryan	PROPN
chd-169	744	34	,	,	PUNCT
chd-169	744	35	c.j	c.j	PROPN
chd-169	744	36	.	.	PROPN
chd-169	744	37	,	,	PUNCT
chd-169	744	38	scher	scher	PROPN
chd-169	744	39	,	,	PUNCT
chd-169	744	40	h.i	h.i	PROPN
chd-169	744	41	.	.	PROPN
chd-169	744	42	,	,	PUNCT
chd-169	744	43	et	et	PROPN
chd-169	744	44	al	al	PROPN
chd-169	744	45	.	.	PUNCT
chd-169	744	46	(	(	PUNCT
chd-169	744	47	2015	2015	NUM
chd-169	744	48	)	)	PUNCT
chd-169	744	49	.	.	PUNCT
chd-169	745	1	impact	impact	NOUN
chd-169	745	2	of	of	ADP
chd-169	745	3	baseline	baseline	ADJ
chd-169	745	4	corticosteroids	corticosteroid	NOUN
chd-169	745	5	on	on	ADP
chd-169	745	6	survival	survival	NOUN
chd-169	745	7	and	and	CCONJ
chd-169	745	8	steroid	steroid	NOUN
chd-169	745	9	androgens	androgen	NOUN
chd-169	745	10	in	in	ADP
chd-169	745	11	metastatic	metastatic	ADJ
chd-169	745	12	castration	castration	NOUN
chd-169	745	13	-	-	PUNCT
chd-169	745	14	resistant	resistant	ADJ
chd-169	745	15	prostate	prostate	NOUN
chd-169	745	16	cancer	cancer	NOUN
chd-169	745	17	:	:	PUNCT
chd-169	745	18	exploratory	exploratory	ADJ
chd-169	745	19	analysis	analysis	NOUN
chd-169	745	20	from	from	ADP
chd-169	745	21	cou	cou	PROPN
chd-169	745	22	-	-	PUNCT
chd-169	745	23	aa-301	aa-301	PROPN
chd-169	745	24	.	.	PUNCT
chd-169	746	1	eur	eur	PROPN
chd-169	746	2	urol	urol	PROPN
chd-169	746	3	67	67	NUM
chd-169	746	4	,	,	PUNCT
chd-169	746	5	866	866	NUM
chd-169	746	6	-	-	SYM
chd-169	746	7	873	873	NUM
chd-169	746	8	.	.	PUNCT
chd-169	747	1	morgan	morgan	PROPN
chd-169	747	2	,	,	PUNCT
chd-169	747	3	d.j	d.j	PROPN
chd-169	747	4	.	.	PROPN
chd-169	747	5	,	,	PUNCT
chd-169	747	6	poolman	poolman	PROPN
chd-169	747	7	,	,	PUNCT
chd-169	747	8	t.m	t.m	PROPN
chd-169	747	9	.	.	PROPN
chd-169	747	10	,	,	PUNCT
chd-169	747	11	williamson	williamson	PROPN
chd-169	747	12	,	,	PUNCT
chd-169	747	13	a.j	a.j	PROPN
chd-169	747	14	.	.	PROPN
chd-169	747	15	,	,	PUNCT
chd-169	747	16	wang	wang	PROPN
chd-169	747	17	,	,	PUNCT
chd-169	747	18	z.	z.	PROPN
chd-169	747	19	,	,	PUNCT
chd-169	747	20	clark	clark	PROPN
chd-169	747	21	,	,	PUNCT
chd-169	747	22	n.r	n.r	PROPN
chd-169	747	23	.	.	PROPN
chd-169	747	24	,	,	PUNCT
chd-169	747	25	ma'ayan	ma'ayan	PROPN
chd-169	747	26	,	,	PUNCT
chd-169	747	27	a.	a.	PROPN
chd-169	747	28	,	,	PUNCT
chd-169	747	29	whetton	whetton	PROPN
chd-169	747	30	,	,	PUNCT
chd-169	747	31	a.d	a.d	PROPN
chd-169	747	32	.	.	PROPN
chd-169	747	33	,	,	PUNCT
chd-169	747	34	brass	brass	NOUN
chd-169	747	35	,	,	PUNCT
chd-169	747	36	a.	a.	NOUN
chd-169	747	37	,	,	PUNCT
chd-169	747	38	matthews	matthews	PROPN
chd-169	747	39	,	,	PUNCT
chd-169	747	40	l.c	l.c	PROPN
chd-169	747	41	.	.	PROPN
chd-169	747	42	,	,	PUNCT
chd-169	747	43	and	and	CCONJ
chd-169	747	44	ray	ray	NOUN
chd-169	747	45	,	,	PUNCT
chd-169	747	46	d.w	d.w	PROPN
chd-169	747	47	.	.	PUNCT
chd-169	747	48	(	(	PUNCT
chd-169	747	49	2016	2016	NUM
chd-169	747	50	)	)	PUNCT
chd-169	747	51	.	.	PUNCT
chd-169	748	1	glucocorticoid	glucocorticoid	ADJ
chd-169	748	2	receptor	receptor	NOUN
chd-169	748	3	isoforms	isoform	VERB
chd-169	748	4	direct	direct	ADJ
chd-169	748	5	distinct	distinct	ADJ
chd-169	748	6	mitochondrial	mitochondrial	ADJ
chd-169	748	7	programs	program	NOUN
chd-169	748	8	to	to	PART
chd-169	748	9	regulate	regulate	VERB
chd-169	748	10	atp	atp	NOUN
chd-169	748	11	production	production	NOUN
chd-169	748	12	.	.	PUNCT
chd-169	749	1	sci	sci	PROPN
chd-169	749	2	rep	rep	PROPN
chd-169	749	3	6	6	NUM
chd-169	749	4	,	,	PUNCT
chd-169	749	5	26419	26419	NUM
chd-169	749	6	.	.	PUNCT
chd-169	750	1	moul	moul	PROPN
chd-169	750	2	,	,	PUNCT
chd-169	750	3	j.w	j.w	PROPN
chd-169	750	4	.	.	PROPN
chd-169	750	5	,	,	PUNCT
chd-169	750	6	sesterhenn	sesterhenn	PROPN
chd-169	750	7	,	,	PUNCT
chd-169	750	8	i.a	i.a	PROPN
chd-169	750	9	.	.	PROPN
chd-169	750	10	,	,	PUNCT
chd-169	750	11	connelly	connelly	PROPN
chd-169	750	12	,	,	PUNCT
chd-169	750	13	r.r	r.r	PROPN
chd-169	750	14	.	.	PROPN
chd-169	750	15	,	,	PUNCT
chd-169	750	16	douglas	douglas	PROPN
chd-169	750	17	,	,	PUNCT
chd-169	750	18	t.	t.	PROPN
chd-169	750	19	,	,	PUNCT
chd-169	750	20	srivastava	srivastava	PROPN
chd-169	750	21	,	,	PUNCT
chd-169	750	22	s.	s.	PROPN
chd-169	750	23	,	,	PUNCT
chd-169	750	24	mostofi	mostofi	NOUN
chd-169	750	25	,	,	PUNCT
chd-169	750	26	f.k	f.k	PROPN
chd-169	750	27	.	.	PROPN
chd-169	750	28	,	,	PUNCT
chd-169	750	29	and	and	CCONJ
chd-169	750	30	mcleod	mcleod	PROPN
chd-169	750	31	,	,	PUNCT
chd-169	750	32	d.g	d.g	PROPN
chd-169	750	33	.	.	PROPN
chd-169	750	34	(	(	PUNCT
chd-169	750	35	1995	1995	NUM
chd-169	750	36	)	)	PUNCT
chd-169	750	37	.	.	PUNCT
chd-169	751	1	prostate	prostate	NOUN
chd-169	751	2	-	-	PUNCT
chd-169	751	3	specific	specific	ADJ
chd-169	751	4	antigen	antigen	ADJ
chd-169	751	5	values	value	NOUN
chd-169	751	6	at	at	ADP
chd-169	751	7	the	the	DET
chd-169	751	8	time	time	NOUN
chd-169	751	9	of	of	ADP
chd-169	751	10	prostate	prostate	NOUN
chd-169	751	11	cancer	cancer	NOUN
chd-169	751	12	diagnosis	diagnosis	NOUN
chd-169	751	13	in	in	ADP
chd-169	751	14	african	african	ADJ
chd-169	751	15	-	-	PUNCT
chd-169	751	16	american	american	ADJ
chd-169	751	17	men	man	NOUN
chd-169	751	18	.	.	PUNCT
chd-169	752	1	jama	jama	PROPN
chd-169	752	2	274	274	NUM
chd-169	752	3	,	,	PUNCT
chd-169	752	4	1277	1277	NUM
chd-169	752	5	-	-	SYM
chd-169	752	6	1281	1281	NUM
chd-169	752	7	.	.	PUNCT
chd-169	753	1	multani	multani	PROPN
chd-169	753	2	,	,	PUNCT
chd-169	753	3	p.s	p.s	PROPN
chd-169	753	4	.	.	PROPN
chd-169	753	5	(	(	PUNCT
chd-169	753	6	2019	2019	NUM
chd-169	753	7	)	)	PUNCT
chd-169	753	8	.	.	PUNCT
chd-169	754	1	study	study	NOUN
chd-169	754	2	of	of	ADP
chd-169	754	3	oric-101	oric-101	NOUN
chd-169	754	4	in	in	ADP
chd-169	754	5	combination	combination	NOUN
chd-169	754	6	with	with	ADP
chd-169	754	7	enzalutamide	enzalutamide	NOUN
chd-169	754	8	.	.	PUNCT
chd-169	755	1	murthy	murthy	ADJ
chd-169	755	2	,	,	PUNCT
chd-169	755	3	v.h	v.h	PROPN
chd-169	755	4	.	.	PROPN
chd-169	755	5	,	,	PUNCT
chd-169	755	6	krumholz	krumholz	PROPN
chd-169	755	7	,	,	PUNCT
chd-169	755	8	h.m	h.m	PROPN
chd-169	755	9	.	.	PROPN
chd-169	755	10	,	,	PUNCT
chd-169	755	11	and	and	CCONJ
chd-169	755	12	gross	gross	ADJ
chd-169	755	13	,	,	PUNCT
chd-169	755	14	c.p	c.p	PROPN
chd-169	755	15	.	.	PROPN
chd-169	755	16	(	(	PUNCT
chd-169	755	17	2004	2004	NUM
chd-169	755	18	)	)	PUNCT
chd-169	755	19	.	.	PUNCT
chd-169	756	1	participation	participation	NOUN
chd-169	756	2	in	in	ADP
chd-169	756	3	cancer	cancer	NOUN
chd-169	756	4	clinical	clinical	ADJ
chd-169	756	5	trials	trial	NOUN
chd-169	756	6	:	:	PUNCT
chd-169	756	7	race-	race-	ADJ
chd-169	756	8	,	,	PUNCT
chd-169	756	9	sex-	sex-	INTJ
chd-169	756	10	,	,	PUNCT
chd-169	756	11	and	and	CCONJ
chd-169	756	12	agebased	agebase	VERB
chd-169	756	13	disparities	disparity	NOUN
chd-169	756	14	.	.	PUNCT
chd-169	757	1	jama	jama	PROPN
chd-169	757	2	291	291	NUM
chd-169	757	3	,	,	PUNCT
chd-169	757	4	2720	2720	NUM
chd-169	757	5	-	-	SYM
chd-169	757	6	2726	2726	NUM
chd-169	757	7	.	.	PUNCT
chd-169	758	1	narayanan	narayanan	PROPN
chd-169	758	2	,	,	PUNCT
chd-169	758	3	s.	s.	PROPN
chd-169	758	4	,	,	PUNCT
chd-169	758	5	srinivas	srinivas	PROPN
chd-169	758	6	,	,	PUNCT
chd-169	758	7	s.	s.	PROPN
chd-169	758	8	,	,	PUNCT
chd-169	758	9	and	and	CCONJ
chd-169	758	10	feldman	feldman	PROPN
chd-169	758	11	,	,	PUNCT
chd-169	758	12	d.	d.	PROPN
chd-169	758	13	(	(	PUNCT
chd-169	758	14	2016	2016	NUM
chd-169	758	15	)	)	PUNCT
chd-169	758	16	.	.	PUNCT
chd-169	759	1	androgenglucocorticoid	androgenglucocorticoid	NOUN
chd-169	759	2	interactions	interaction	NOUN
chd-169	759	3	in	in	ADP
chd-169	759	4	the	the	DET
chd-169	759	5	era	era	NOUN
chd-169	759	6	of	of	ADP
chd-169	759	7	novel	novel	ADJ
chd-169	759	8	prostate	prostate	NOUN
chd-169	759	9	cancer	cancer	NOUN
chd-169	759	10	therapy	therapy	NOUN
chd-169	759	11	.	.	PUNCT
chd-169	760	1	nature	nature	NOUN
chd-169	760	2	reviews	review	VERB
chd-169	760	3	urology	urology	NOUN
chd-169	760	4	13	13	NUM
chd-169	760	5	,	,	PUNCT
chd-169	760	6	47	47	NUM
chd-169	760	7	-	-	SYM
chd-169	760	8	60	60	NUM
chd-169	760	9	.	.	PUNCT
chd-169	761	1	nettey	nettey	PROPN
chd-169	761	2	,	,	PUNCT
chd-169	761	3	o.s	o.s	PROPN
chd-169	761	4	.	.	PROPN
chd-169	761	5	,	,	PUNCT
chd-169	761	6	walker	walker	PROPN
chd-169	761	7	,	,	PUNCT
chd-169	761	8	a.j	a.j	PROPN
chd-169	761	9	.	.	PROPN
chd-169	761	10	,	,	PUNCT
chd-169	761	11	keeter	keeter	PROPN
chd-169	761	12	,	,	PUNCT
chd-169	761	13	m.k	m.k	PROPN
chd-169	761	14	.	.	PROPN
chd-169	761	15	,	,	PUNCT
chd-169	761	16	singal	singal	PROPN
chd-169	761	17	,	,	PUNCT
chd-169	761	18	a.	a.	NOUN
chd-169	761	19	,	,	PUNCT
chd-169	761	20	nugooru	nugooru	NOUN
chd-169	761	21	,	,	PUNCT
chd-169	761	22	a.	a.	PROPN
chd-169	761	23	,	,	PUNCT
chd-169	761	24	martin	martin	PROPN
chd-169	761	25	,	,	PUNCT
chd-169	761	26	i.k	i.k	PROPN
chd-169	761	27	.	.	PROPN
chd-169	761	28	,	,	PUNCT
chd-169	761	29	ruden	ruden	ADJ
chd-169	761	30	,	,	PUNCT
chd-169	761	31	m.	m.	NOUN
chd-169	761	32	,	,	PUNCT
chd-169	761	33	gogana	gogana	PROPN
chd-169	761	34	,	,	PUNCT
chd-169	761	35	p.	p.	PROPN
chd-169	761	36	,	,	PUNCT
chd-169	761	37	dixon	dixon	PROPN
chd-169	761	38	,	,	PUNCT
chd-169	761	39	m.a	m.a	PROPN
chd-169	761	40	.	.	PROPN
chd-169	761	41	,	,	PUNCT
chd-169	761	42	osuma	osuma	PROPN
chd-169	761	43	,	,	PUNCT
chd-169	761	44	t.	t.	PROPN
chd-169	761	45	,	,	PUNCT
chd-169	761	46	et	et	PROPN
chd-169	761	47	al	al	PROPN
chd-169	761	48	.	.	PUNCT
chd-169	761	49	(	(	PUNCT
chd-169	761	50	2018	2018	NUM
chd-169	761	51	)	)	PUNCT
chd-169	761	52	.	.	PUNCT
chd-169	762	1	self	self	NOUN
chd-169	762	2	-	-	PUNCT
chd-169	762	3	reported	report	VERB
chd-169	762	4	black	black	ADJ
chd-169	762	5	race	race	NOUN
chd-169	762	6	predicts	predict	VERB
chd-169	762	7	significant	significant	ADJ
chd-169	762	8	prostate	prostate	NOUN
chd-169	762	9	cancer	cancer	NOUN
chd-169	762	10	independent	independent	ADJ
chd-169	762	11	of	of	ADP
chd-169	762	12	clinical	clinical	ADJ
chd-169	762	13	setting	setting	NOUN
chd-169	762	14	and	and	CCONJ
chd-169	762	15	clinical	clinical	ADJ
chd-169	762	16	and	and	CCONJ
chd-169	762	17	socioeconomic	socioeconomic	ADJ
chd-169	762	18	risk	risk	NOUN
chd-169	762	19	factors	factor	NOUN
chd-169	762	20	.	.	PUNCT
chd-169	763	1	urol	urol	ADJ
chd-169	763	2	oncol	oncol	PROPN
chd-169	763	3	36	36	NUM
chd-169	763	4	,	,	PUNCT
chd-169	763	5	501	501	NUM
chd-169	763	6	e501	e501	PROPN
chd-169	763	7	-	-	PUNCT
chd-169	763	8	501	501	NUM
chd-169	763	9	e508	e508	PROPN
chd-169	763	10	.	.	PUNCT
chd-169	763	11	netto	netto	PROPN
chd-169	763	12	,	,	PUNCT
chd-169	763	13	g.j	g.j	PROPN
chd-169	763	14	.	.	PROPN
chd-169	764	1	(	(	PUNCT
chd-169	764	2	2013	2013	NUM
chd-169	764	3	)	)	PUNCT
chd-169	764	4	.	.	PUNCT
chd-169	765	1	clinical	clinical	ADJ
chd-169	765	2	applications	application	NOUN
chd-169	765	3	of	of	ADP
chd-169	765	4	recent	recent	ADJ
chd-169	765	5	molecular	molecular	ADJ
chd-169	765	6	advances	advance	NOUN
chd-169	765	7	in	in	ADP
chd-169	765	8	urologic	urologic	ADJ
chd-169	765	9	malignancies	malignancy	NOUN
chd-169	765	10	:	:	PUNCT
chd-169	765	11	no	no	ADV
chd-169	765	12	longer	long	ADV
chd-169	765	13	chasing	chase	VERB
chd-169	765	14	a	a	DET
chd-169	765	15	"	"	PUNCT
chd-169	765	16	mirage	mirage	NOUN
chd-169	765	17	"	"	PUNCT
chd-169	765	18	?	?	PUNCT
chd-169	766	1	advances	advance	NOUN
chd-169	766	2	in	in	ADP
chd-169	766	3	anatomic	anatomic	ADJ
chd-169	766	4	pathology	pathology	NOUN
chd-169	766	5	20	20	NUM
chd-169	766	6	,	,	PUNCT
chd-169	766	7	175	175	NUM
chd-169	766	8	-	-	SYM
chd-169	766	9	203	203	NUM
chd-169	766	10	.	.	PUNCT
chd-169	767	1	nguyen	nguyen	NOUN
chd-169	767	2	,	,	PUNCT
chd-169	767	3	e.t	e.t	PROPN
chd-169	767	4	.	.	PROPN
chd-169	767	5	,	,	PUNCT
chd-169	767	6	streicher	streicher	PROPN
chd-169	767	7	,	,	PUNCT
chd-169	767	8	j.	j.	PROPN
chd-169	767	9	,	,	PUNCT
chd-169	767	10	berman	berman	PROPN
chd-169	767	11	,	,	PUNCT
chd-169	767	12	s.	s.	PROPN
chd-169	767	13	,	,	PUNCT
chd-169	767	14	caldwell	caldwell	PROPN
chd-169	767	15	,	,	PUNCT
chd-169	767	16	j.l	j.l	PROPN
chd-169	767	17	.	.	PROPN
chd-169	767	18	,	,	PUNCT
chd-169	767	19	ghisays	ghisay	NOUN
chd-169	767	20	,	,	PUNCT
chd-169	767	21	v.	v.	PROPN
chd-169	767	22	,	,	PUNCT
chd-169	767	23	estrada	estrada	PROPN
chd-169	767	24	,	,	PUNCT
chd-169	767	25	c.m	c.m	PROPN
chd-169	767	26	.	.	PROPN
chd-169	767	27	,	,	PUNCT
chd-169	767	28	wulsin	wulsin	PROPN
chd-169	767	29	,	,	PUNCT
chd-169	767	30	a.c	a.c	PROPN
chd-169	767	31	.	.	PROPN
chd-169	767	32	,	,	PUNCT
chd-169	767	33	and	and	CCONJ
chd-169	767	34	solomon	solomon	PROPN
chd-169	767	35	,	,	PUNCT
chd-169	767	36	m.b	m.b	PROPN
chd-169	767	37	.	.	PROPN
chd-169	767	38	(	(	PUNCT
chd-169	767	39	2017	2017	NUM
chd-169	767	40	)	)	PUNCT
chd-169	767	41	.	.	PUNCT
chd-169	768	1	a	a	DET
chd-169	768	2	mixed	mixed	ADJ
chd-169	768	3	glucocorticoid	glucocorticoid	NOUN
chd-169	768	4	/	/	SYM
chd-169	768	5	mineralocorticoid	mineralocorticoid	NOUN
chd-169	768	6	receptor	receptor	NOUN
chd-169	768	7	modulator	modulator	NOUN
chd-169	768	8	dampens	dampen	VERB
chd-169	768	9	endocrine	endocrine	NOUN
chd-169	768	10	and	and	CCONJ
chd-169	768	11	hippocampal	hippocampal	VERB
chd-169	768	12	stress	stress	NOUN
chd-169	768	13	responsivity	responsivity	NOUN
chd-169	768	14	in	in	ADP
chd-169	768	15	male	male	ADJ
chd-169	768	16	rats	rat	NOUN
chd-169	768	17	.	.	PUNCT
chd-169	769	1	physiol	physiol	PROPN
chd-169	769	2	behav	behav	PROPN
chd-169	769	3	178	178	NUM
chd-169	769	4	,	,	PUNCT
chd-169	769	5	82	82	NUM
chd-169	769	6	-	-	SYM
chd-169	769	7	92	92	NUM
chd-169	769	8	.	.	PUNCT
chd-169	770	1	nguyen	nguyen	NOUN
chd-169	770	2	,	,	PUNCT
chd-169	770	3	p.l	p.l	PROPN
chd-169	770	4	.	.	PROPN
chd-169	770	5	,	,	PUNCT
chd-169	770	6	ma	ma	PROPN
chd-169	770	7	,	,	PUNCT
chd-169	770	8	j.	j.	PROPN
chd-169	770	9	,	,	PUNCT
chd-169	770	10	chavarro	chavarro	PROPN
chd-169	770	11	,	,	PUNCT
chd-169	770	12	j.e	j.e	PROPN
chd-169	770	13	.	.	PROPN
chd-169	770	14	,	,	PUNCT
chd-169	770	15	freedman	freedman	PROPN
chd-169	770	16	,	,	PUNCT
chd-169	770	17	m.l	m.l	PROPN
chd-169	770	18	.	.	PROPN
chd-169	770	19	,	,	PUNCT
chd-169	770	20	lis	lis	PROPN
chd-169	770	21	,	,	PUNCT
chd-169	770	22	r.	r.	PROPN
chd-169	770	23	,	,	PUNCT
chd-169	770	24	fedele	fedele	PROPN
chd-169	770	25	,	,	PUNCT
chd-169	770	26	g.	g.	PROPN
chd-169	770	27	,	,	PUNCT
chd-169	770	28	fiore	fiore	NOUN
chd-169	770	29	,	,	PUNCT
chd-169	770	30	c.	c.	PROPN
chd-169	770	31	,	,	PUNCT
chd-169	770	32	qiu	qiu	PROPN
chd-169	770	33	,	,	PUNCT
chd-169	770	34	w.	w.	PROPN
chd-169	770	35	,	,	PUNCT
chd-169	770	36	fiorentino	fiorentino	PROPN
chd-169	770	37	,	,	PUNCT
chd-169	770	38	m.	m.	NOUN
chd-169	770	39	,	,	PUNCT
chd-169	770	40	finn	finn	PROPN
chd-169	770	41	,	,	PUNCT
chd-169	770	42	s.	s.	PROPN
chd-169	770	43	,	,	PUNCT
chd-169	770	44	et	et	PROPN
chd-169	770	45	al	al	PROPN
chd-169	770	46	.	.	PUNCT
chd-169	771	1	(	(	PUNCT
chd-169	771	2	2010	2010	NUM
chd-169	771	3	)	)	PUNCT
chd-169	771	4	.	.	PUNCT
chd-169	772	1	fatty	fatty	NOUN
chd-169	772	2	acid	acid	ADJ
chd-169	772	3	synthase	synthase	NOUN
chd-169	772	4	polymorphisms	polymorphism	NOUN
chd-169	772	5	,	,	PUNCT
chd-169	772	6	tumor	tumor	NOUN
chd-169	772	7	expression	expression	NOUN
chd-169	772	8	,	,	PUNCT
chd-169	772	9	body	body	NOUN
chd-169	772	10	mass	mass	PROPN
chd-169	772	11	index	index	NOUN
chd-169	772	12	,	,	PUNCT
chd-169	772	13	prostate	prostate	NOUN
chd-169	772	14	cancer	cancer	NOUN
chd-169	772	15	risk	risk	NOUN
chd-169	772	16	,	,	PUNCT
chd-169	772	17	and	and	CCONJ
chd-169	772	18	survival	survival	NOUN
chd-169	772	19	.	.	PUNCT
chd-169	773	1	j	j	PROPN
chd-169	773	2	clin	clin	PROPN
chd-169	773	3	oncol	oncol	PROPN
chd-169	773	4	28	28	NUM
chd-169	773	5	,	,	PUNCT
chd-169	773	6	3958	3958	NUM
chd-169	773	7	-	-	SYM
chd-169	773	8	3964	3964	NUM
chd-169	773	9	.	.	PUNCT
chd-169	774	1	nicolaides	nicolaides	PROPN
chd-169	774	2	,	,	PUNCT
chd-169	774	3	n.c	n.c	PROPN
chd-169	774	4	.	.	PROPN
chd-169	774	5	,	,	PUNCT
chd-169	774	6	galata	galata	PROPN
chd-169	774	7	,	,	PUNCT
chd-169	774	8	z.	z.	PROPN
chd-169	774	9	,	,	PUNCT
chd-169	774	10	kino	kino	PROPN
chd-169	774	11	,	,	PUNCT
chd-169	774	12	t.	t.	PROPN
chd-169	774	13	,	,	PUNCT
chd-169	774	14	chrousos	chrouso	NOUN
chd-169	774	15	,	,	PUNCT
chd-169	774	16	g.p	g.p	PROPN
chd-169	774	17	.	.	PROPN
chd-169	774	18	,	,	PUNCT
chd-169	774	19	and	and	CCONJ
chd-169	774	20	charmandari	charmandari	PROPN
chd-169	774	21	,	,	PUNCT
chd-169	774	22	e.	e.	PROPN
chd-169	774	23	(	(	PUNCT
chd-169	774	24	2010	2010	NUM
chd-169	774	25	)	)	PUNCT
chd-169	774	26	.	.	PUNCT
chd-169	775	1	the	the	DET
chd-169	775	2	human	human	ADJ
chd-169	775	3	glucocorticoid	glucocorticoid	ADJ
chd-169	775	4	receptor	receptor	NOUN
chd-169	775	5	:	:	PUNCT
chd-169	775	6	molecular	molecular	ADJ
chd-169	775	7	basis	basis	NOUN
chd-169	775	8	of	of	ADP
chd-169	775	9	biologic	biologic	ADJ
chd-169	775	10	function	function	NOUN
chd-169	775	11	.	.	PUNCT
chd-169	776	1	steroids	steroid	NOUN
chd-169	776	2	75	75	NUM
chd-169	776	3	,	,	PUNCT
chd-169	776	4	1	1	NUM
chd-169	776	5	-	-	SYM
chd-169	776	6	12	12	NUM
chd-169	776	7	.	.	PUNCT
chd-169	777	1	oakley	oakley	PROPN
chd-169	777	2	,	,	PUNCT
chd-169	777	3	r.h	r.h	PROPN
chd-169	777	4	.	.	PROPN
chd-169	777	5	,	,	PUNCT
chd-169	777	6	and	and	CCONJ
chd-169	777	7	cidlowski	cidlowski	VERB
chd-169	777	8	,	,	PUNCT
chd-169	777	9	j.a	j.a	PROPN
chd-169	777	10	.	.	PROPN
chd-169	777	11	(	(	PUNCT
chd-169	777	12	2011	2011	NUM
chd-169	777	13	)	)	PUNCT
chd-169	777	14	.	.	PUNCT
chd-169	778	1	cellular	cellular	ADJ
chd-169	778	2	processing	processing	NOUN
chd-169	778	3	of	of	ADP
chd-169	778	4	the	the	DET
chd-169	778	5	glucocorticoid	glucocorticoid	ADJ
chd-169	778	6	receptor	receptor	NOUN
chd-169	778	7	gene	gene	NOUN
chd-169	778	8	and	and	CCONJ
chd-169	778	9	protein	protein	NOUN
chd-169	778	10	:	:	PUNCT
chd-169	778	11	new	new	ADJ
chd-169	778	12	mechanisms	mechanism	NOUN
chd-169	778	13	for	for	ADP
chd-169	778	14	generating	generate	VERB
chd-169	778	15	tissue	tissue	NOUN
chd-169	778	16	-	-	PUNCT
chd-169	778	17	specific	specific	ADJ
chd-169	778	18	actions	action	NOUN
chd-169	778	19	of	of	ADP
chd-169	778	20	glucocorticoids	glucocorticoid	NOUN
chd-169	778	21	.	.	PUNCT
chd-169	779	1	j	j	PROPN
chd-169	779	2	biol	biol	PROPN
chd-169	779	3	chem	chem	NOUN
chd-169	779	4	286	286	NUM
chd-169	779	5	,	,	PUNCT
chd-169	779	6	3177	3177	NUM
chd-169	779	7	-	-	SYM
chd-169	779	8	3184	3184	NUM
chd-169	779	9	.	.	PUNCT
chd-169	780	1	oakley	oakley	PROPN
chd-169	780	2	,	,	PUNCT
chd-169	780	3	r.h	r.h	PROPN
chd-169	780	4	.	.	PROPN
chd-169	780	5	,	,	PUNCT
chd-169	780	6	and	and	CCONJ
chd-169	780	7	cidlowski	cidlowski	VERB
chd-169	780	8	,	,	PUNCT
chd-169	780	9	j.a	j.a	PROPN
chd-169	780	10	.	.	PROPN
chd-169	780	11	(	(	PUNCT
chd-169	780	12	2013	2013	NUM
chd-169	780	13	)	)	PUNCT
chd-169	780	14	.	.	PUNCT
chd-169	781	1	the	the	DET
chd-169	781	2	biology	biology	NOUN
chd-169	781	3	of	of	ADP
chd-169	781	4	the	the	DET
chd-169	781	5	glucocorticoid	glucocorticoid	ADJ
chd-169	781	6	receptor	receptor	NOUN
chd-169	781	7	:	:	PUNCT
chd-169	781	8	new	new	ADJ
chd-169	781	9	signaling	signal	VERB
chd-169	781	10	mechanisms	mechanism	NOUN
chd-169	781	11	in	in	ADP
chd-169	781	12	health	health	NOUN
chd-169	781	13	and	and	CCONJ
chd-169	781	14	disease	disease	NOUN
chd-169	781	15	.	.	PUNCT
chd-169	782	1	j	j	PROPN
chd-169	782	2	allergy	allergy	PROPN
chd-169	782	3	clin	clin	PROPN
chd-169	782	4	immunol	immunol	PROPN
chd-169	782	5	132	132	NUM
chd-169	782	6	,	,	PUNCT
chd-169	782	7	10331044	10331044	NUM
chd-169	782	8	.	.	PUNCT
chd-169	783	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	783	2	e27	e27	PROPN
chd-169	783	3	cancer	cancer	NOUN
chd-169	783	4	health	health	NOUN
chd-169	783	5	disparities	disparity	NOUN
chd-169	783	6	research	research	NOUN
chd-169	783	7	olender	olender	NOUN
chd-169	783	8	,	,	PUNCT
chd-169	783	9	j.	j.	PROPN
chd-169	783	10	,	,	PUNCT
chd-169	783	11	and	and	CCONJ
chd-169	783	12	lee	lee	PROPN
chd-169	783	13	,	,	PUNCT
chd-169	783	14	n.h	n.h	PROPN
chd-169	783	15	.	.	PUNCT
chd-169	784	1	(	(	PUNCT
chd-169	784	2	2019	2019	NUM
chd-169	784	3	)	)	PUNCT
chd-169	784	4	.	.	PUNCT
chd-169	785	1	role	role	NOUN
chd-169	785	2	of	of	ADP
chd-169	785	3	alternative	alternative	ADJ
chd-169	785	4	splicing	splicing	NOUN
chd-169	785	5	in	in	ADP
chd-169	785	6	prostate	prostate	NOUN
chd-169	785	7	cancer	cancer	NOUN
chd-169	785	8	aggressiveness	aggressiveness	NOUN
chd-169	785	9	and	and	CCONJ
chd-169	785	10	drug	drug	NOUN
chd-169	785	11	resistance	resistance	NOUN
chd-169	785	12	in	in	ADP
chd-169	785	13	african	african	ADJ
chd-169	785	14	americans	americans	PROPN
chd-169	785	15	.	.	PUNCT
chd-169	786	1	adv	adv	PROPN
chd-169	786	2	exp	exp	NOUN
chd-169	786	3	med	med	ADJ
chd-169	786	4	biol	biol	PROPN
chd-169	786	5	1164	1164	NUM
chd-169	786	6	,	,	PUNCT
chd-169	786	7	119	119	NUM
chd-169	786	8	-	-	SYM
chd-169	786	9	139	139	NUM
chd-169	786	10	.	.	PUNCT
chd-169	787	1	petersen	petersen	PROPN
chd-169	787	2	,	,	PUNCT
chd-169	787	3	d.c	d.c	PROPN
chd-169	787	4	.	.	PROPN
chd-169	787	5	,	,	PUNCT
chd-169	787	6	jaratlerdsiri	jaratlerdsiri	PROPN
chd-169	787	7	,	,	PUNCT
chd-169	787	8	w.	w.	PROPN
chd-169	787	9	,	,	PUNCT
chd-169	787	10	van	van	PROPN
chd-169	787	11	wyk	wyk	PROPN
chd-169	787	12	,	,	PUNCT
chd-169	787	13	a.	a.	PROPN
chd-169	787	14	,	,	PUNCT
chd-169	787	15	chan	chan	PROPN
chd-169	787	16	,	,	PUNCT
chd-169	787	17	e.k.f	e.k.f	PROPN
chd-169	787	18	.	.	PROPN
chd-169	787	19	,	,	PUNCT
chd-169	787	20	fernandez	fernandez	PROPN
chd-169	787	21	,	,	PUNCT
chd-169	787	22	p.	p.	PROPN
chd-169	787	23	,	,	PUNCT
chd-169	787	24	lyons	lyons	PROPN
chd-169	787	25	,	,	PUNCT
chd-169	787	26	r.j	r.j	PROPN
chd-169	787	27	.	.	PROPN
chd-169	787	28	,	,	PUNCT
chd-169	787	29	mutambirw	mutambirw	PROPN
chd-169	787	30	,	,	PUNCT
chd-169	787	31	s.b.a	s.b.a	PROPN
chd-169	787	32	.	.	PROPN
chd-169	787	33	,	,	PUNCT
chd-169	787	34	van	van	PROPN
chd-169	787	35	der	der	PROPN
chd-169	787	36	merwe	merwe	PROPN
chd-169	787	37	,	,	PUNCT
chd-169	787	38	a.	a.	PROPN
chd-169	787	39	,	,	PUNCT
chd-169	787	40	venter	venter	PROPN
chd-169	787	41	,	,	PUNCT
chd-169	787	42	p.a	p.a	PROPN
chd-169	787	43	.	.	PROPN
chd-169	787	44	,	,	PUNCT
chd-169	787	45	bates	bates	PROPN
chd-169	787	46	,	,	PUNCT
chd-169	787	47	w.	w.	PROPN
chd-169	787	48	,	,	PUNCT
chd-169	787	49	et	et	PROPN
chd-169	787	50	al	al	PROPN
chd-169	787	51	.	.	PROPN
chd-169	787	52	(	(	PUNCT
chd-169	787	53	2019	2019	NUM
chd-169	787	54	)	)	PUNCT
chd-169	787	55	.	.	PUNCT
chd-169	788	1	african	african	PROPN
chd-169	788	2	khoesan	khoesan	PROPN
chd-169	788	3	ancestry	ancestry	PROPN
chd-169	788	4	linked	link	VERB
chd-169	788	5	to	to	ADP
chd-169	788	6	high	high	ADJ
chd-169	788	7	-	-	PUNCT
chd-169	788	8	risk	risk	NOUN
chd-169	788	9	prostate	prostate	NOUN
chd-169	788	10	cancer	cancer	NOUN
chd-169	788	11	.	.	PUNCT
chd-169	789	1	bmc	bmc	ADJ
chd-169	789	2	med	med	ADJ
chd-169	789	3	genomics	genomic	NOUN
chd-169	789	4	12	12	NUM
chd-169	789	5	,	,	PUNCT
chd-169	789	6	82	82	NUM
chd-169	789	7	.	.	PUNCT
chd-169	790	1	petrovics	petrovic	NOUN
chd-169	790	2	,	,	PUNCT
chd-169	790	3	g.	g.	NOUN
chd-169	790	4	,	,	PUNCT
chd-169	790	5	price	price	NOUN
chd-169	790	6	,	,	PUNCT
chd-169	790	7	d.k	d.k	PROPN
chd-169	790	8	.	.	PROPN
chd-169	790	9	,	,	PUNCT
chd-169	790	10	lou	lou	PROPN
chd-169	790	11	,	,	PUNCT
chd-169	790	12	h.	h.	PROPN
chd-169	790	13	,	,	PUNCT
chd-169	790	14	chen	chen	PROPN
chd-169	790	15	,	,	PUNCT
chd-169	790	16	y.	y.	PROPN
chd-169	790	17	,	,	PUNCT
chd-169	790	18	garland	garland	PROPN
chd-169	790	19	,	,	PUNCT
chd-169	790	20	l.	l.	PROPN
chd-169	790	21	,	,	PUNCT
chd-169	790	22	bass	bass	PROPN
chd-169	790	23	,	,	PUNCT
chd-169	790	24	s.	s.	PROPN
chd-169	790	25	,	,	PUNCT
chd-169	790	26	jones	jones	PROPN
chd-169	790	27	,	,	PUNCT
chd-169	790	28	k.	k.	PROPN
chd-169	790	29	,	,	PUNCT
chd-169	790	30	kohaar	kohaar	PROPN
chd-169	790	31	,	,	PUNCT
chd-169	790	32	i.	i.	PROPN
chd-169	790	33	,	,	PUNCT
chd-169	790	34	ali	ali	PROPN
chd-169	790	35	,	,	PUNCT
chd-169	790	36	a.	a.	PROPN
chd-169	790	37	,	,	PUNCT
chd-169	790	38	ravindranath	ravindranath	NOUN
chd-169	790	39	,	,	PUNCT
chd-169	790	40	l.	l.	PROPN
chd-169	790	41	,	,	PUNCT
chd-169	790	42	et	et	PROPN
chd-169	790	43	al	al	PROPN
chd-169	790	44	.	.	PROPN
chd-169	791	1	(	(	PUNCT
chd-169	791	2	2019	2019	NUM
chd-169	791	3	)	)	PUNCT
chd-169	791	4	.	.	PUNCT
chd-169	792	1	increased	increase	VERB
chd-169	792	2	frequency	frequency	NOUN
chd-169	792	3	of	of	ADP
chd-169	792	4	germline	germline	NOUN
chd-169	792	5	brca2	brca2	PROPN
chd-169	792	6	mutations	mutation	NOUN
chd-169	792	7	associates	associate	NOUN
chd-169	792	8	with	with	ADP
chd-169	792	9	prostate	prostate	NOUN
chd-169	792	10	cancer	cancer	NOUN
chd-169	792	11	metastasis	metastasis	NOUN
chd-169	792	12	in	in	ADP
chd-169	792	13	a	a	DET
chd-169	792	14	racially	racially	ADV
chd-169	792	15	diverse	diverse	ADJ
chd-169	792	16	patient	patient	ADJ
chd-169	792	17	population	population	NOUN
chd-169	792	18	.	.	PUNCT
chd-169	793	1	prostate	prostate	NOUN
chd-169	793	2	cancer	cancer	NOUN
chd-169	793	3	prostatic	prostatic	ADJ
chd-169	793	4	dis	dis	PROPN
chd-169	793	5	22	22	NUM
chd-169	793	6	,	,	PUNCT
chd-169	793	7	406	406	NUM
chd-169	793	8	-	-	SYM
chd-169	793	9	410	410	NUM
chd-169	793	10	.	.	PUNCT
chd-169	794	1	pettersson	pettersson	NOUN
chd-169	794	2	,	,	PUNCT
chd-169	794	3	a.	a.	NOUN
chd-169	794	4	,	,	PUNCT
chd-169	794	5	lis	lis	PROPN
chd-169	794	6	,	,	PUNCT
chd-169	794	7	r.t	r.t	PROPN
chd-169	794	8	.	.	PROPN
chd-169	794	9	,	,	PUNCT
chd-169	794	10	meisner	meisner	PROPN
chd-169	794	11	,	,	PUNCT
chd-169	794	12	a.	a.	NOUN
chd-169	794	13	,	,	PUNCT
chd-169	794	14	flavin	flavin	PROPN
chd-169	794	15	,	,	PUNCT
chd-169	794	16	r.	r.	PROPN
chd-169	794	17	,	,	PUNCT
chd-169	794	18	stack	stack	NOUN
chd-169	794	19	,	,	PUNCT
chd-169	794	20	e.c	e.c	PROPN
chd-169	794	21	.	.	PROPN
chd-169	794	22	,	,	PUNCT
chd-169	794	23	fiorentino	fiorentino	PROPN
chd-169	794	24	,	,	PUNCT
chd-169	794	25	m.	m.	NOUN
chd-169	794	26	,	,	PUNCT
chd-169	794	27	finn	finn	PROPN
chd-169	794	28	,	,	PUNCT
chd-169	794	29	s.	s.	PROPN
chd-169	794	30	,	,	PUNCT
chd-169	794	31	graff	graff	PROPN
chd-169	794	32	,	,	PUNCT
chd-169	794	33	r.e	r.e	PROPN
chd-169	794	34	.	.	PROPN
chd-169	794	35	,	,	PUNCT
chd-169	794	36	penney	penney	PROPN
chd-169	794	37	,	,	PUNCT
chd-169	794	38	k.l	k.l	PROPN
chd-169	794	39	.	.	PROPN
chd-169	794	40	,	,	PUNCT
chd-169	794	41	rider	rider	NOUN
chd-169	794	42	,	,	PUNCT
chd-169	794	43	j.r	j.r	PROPN
chd-169	794	44	.	.	PROPN
chd-169	794	45	,	,	PUNCT
chd-169	794	46	et	et	PROPN
chd-169	794	47	al	al	PROPN
chd-169	794	48	.	.	PROPN
chd-169	794	49	(	(	PUNCT
chd-169	794	50	2013	2013	NUM
chd-169	794	51	)	)	PUNCT
chd-169	794	52	.	.	PUNCT
chd-169	795	1	modification	modification	NOUN
chd-169	795	2	of	of	ADP
chd-169	795	3	the	the	DET
chd-169	795	4	association	association	NOUN
chd-169	795	5	between	between	ADP
chd-169	795	6	obesity	obesity	NOUN
chd-169	795	7	and	and	CCONJ
chd-169	795	8	lethal	lethal	ADJ
chd-169	795	9	prostate	prostate	NOUN
chd-169	795	10	cancer	cancer	NOUN
chd-169	795	11	by	by	ADP
chd-169	795	12	tmprss2	tmprss2	NOUN
chd-169	795	13	:	:	PUNCT
chd-169	795	14	erg	erg	PROPN
chd-169	795	15	.	.	PROPN
chd-169	795	16	journal	journal	PROPN
chd-169	795	17	of	of	ADP
chd-169	795	18	the	the	DET
chd-169	795	19	national	national	PROPN
chd-169	795	20	cancer	cancer	PROPN
chd-169	795	21	institute	institute	PROPN
chd-169	795	22	105	105	NUM
chd-169	795	23	,	,	PUNCT
chd-169	795	24	1881	1881	NUM
chd-169	795	25	-	-	SYM
chd-169	795	26	1890	1890	NUM
chd-169	795	27	.	.	PUNCT
chd-169	796	1	polk	polk	PROPN
chd-169	796	2	,	,	PUNCT
chd-169	796	3	d.e	d.e	PROPN
chd-169	796	4	.	.	PROPN
chd-169	796	5	,	,	PUNCT
chd-169	796	6	cohen	cohen	PROPN
chd-169	796	7	,	,	PUNCT
chd-169	796	8	s.	s.	PROPN
chd-169	796	9	,	,	PUNCT
chd-169	796	10	doyle	doyle	PROPN
chd-169	796	11	,	,	PUNCT
chd-169	796	12	w.j	w.j	PROPN
chd-169	796	13	.	.	PROPN
chd-169	796	14	,	,	PUNCT
chd-169	796	15	skoner	skoner	PROPN
chd-169	796	16	,	,	PUNCT
chd-169	796	17	d.p	d.p	PROPN
chd-169	796	18	.	.	PROPN
chd-169	796	19	,	,	PUNCT
chd-169	796	20	and	and	CCONJ
chd-169	796	21	kirschbaum	kirschbaum	PROPN
chd-169	796	22	,	,	PUNCT
chd-169	796	23	c.	c.	PROPN
chd-169	796	24	(	(	PUNCT
chd-169	796	25	2005	2005	NUM
chd-169	796	26	)	)	PUNCT
chd-169	796	27	.	.	PUNCT
chd-169	797	1	state	state	NOUN
chd-169	797	2	and	and	CCONJ
chd-169	797	3	trait	trait	NOUN
chd-169	797	4	affect	affect	VERB
chd-169	797	5	as	as	ADP
chd-169	797	6	predictors	predictor	NOUN
chd-169	797	7	of	of	ADP
chd-169	797	8	salivary	salivary	ADJ
chd-169	797	9	cortisol	cortisol	NOUN
chd-169	797	10	in	in	ADP
chd-169	797	11	healthy	healthy	ADJ
chd-169	797	12	adults	adult	NOUN
chd-169	797	13	.	.	PUNCT
chd-169	798	1	psychoneuroendocrinology	psychoneuroendocrinology	NOUN
chd-169	798	2	30	30	NUM
chd-169	798	3	,	,	PUNCT
chd-169	798	4	261	261	NUM
chd-169	798	5	-	-	SYM
chd-169	798	6	272	272	NUM
chd-169	798	7	.	.	PUNCT
chd-169	799	1	powell	powell	PROPN
chd-169	799	2	,	,	PUNCT
chd-169	799	3	i.j	i.j	PROPN
chd-169	799	4	.	.	PROPN
chd-169	799	5	,	,	PUNCT
chd-169	799	6	dyson	dyson	PROPN
chd-169	799	7	,	,	PUNCT
chd-169	799	8	g.	g.	PROPN
chd-169	799	9	,	,	PUNCT
chd-169	799	10	land	land	NOUN
chd-169	799	11	,	,	PUNCT
chd-169	799	12	s.	s.	PROPN
chd-169	799	13	,	,	PUNCT
chd-169	799	14	ruterbusch	ruterbusch	PROPN
chd-169	799	15	,	,	PUNCT
chd-169	799	16	j.	j.	PROPN
chd-169	799	17	,	,	PUNCT
chd-169	799	18	bock	bock	NOUN
chd-169	799	19	,	,	PUNCT
chd-169	799	20	c.h	c.h	PROPN
chd-169	799	21	.	.	PROPN
chd-169	799	22	,	,	PUNCT
chd-169	799	23	lenk	lenk	PROPN
chd-169	799	24	,	,	PUNCT
chd-169	799	25	s.	s.	PROPN
chd-169	799	26	,	,	PUNCT
chd-169	799	27	herawi	herawi	PROPN
chd-169	799	28	,	,	PUNCT
chd-169	799	29	m.	m.	NOUN
chd-169	799	30	,	,	PUNCT
chd-169	799	31	everson	everson	PROPN
chd-169	799	32	,	,	PUNCT
chd-169	799	33	r.	r.	PROPN
chd-169	799	34	,	,	PUNCT
chd-169	799	35	giroux	giroux	NOUN
chd-169	799	36	,	,	PUNCT
chd-169	799	37	c.n	c.n	PROPN
chd-169	799	38	.	.	PROPN
chd-169	799	39	,	,	PUNCT
chd-169	799	40	schwartz	schwartz	PROPN
chd-169	799	41	,	,	PUNCT
chd-169	799	42	a.g	a.g	PROPN
chd-169	799	43	.	.	PROPN
chd-169	799	44	,	,	PUNCT
chd-169	799	45	et	et	PROPN
chd-169	799	46	al	al	PROPN
chd-169	799	47	.	.	PROPN
chd-169	800	1	(	(	PUNCT
chd-169	800	2	2013	2013	NUM
chd-169	800	3	)	)	PUNCT
chd-169	800	4	.	.	PUNCT
chd-169	801	1	genes	gene	NOUN
chd-169	801	2	associated	associate	VERB
chd-169	801	3	with	with	ADP
chd-169	801	4	prostate	prostate	NOUN
chd-169	801	5	cancer	cancer	NOUN
chd-169	801	6	are	be	AUX
chd-169	801	7	differentially	differentially	ADV
chd-169	801	8	expressed	express	VERB
chd-169	801	9	in	in	ADP
chd-169	801	10	african	african	ADJ
chd-169	801	11	american	american	ADJ
chd-169	801	12	and	and	CCONJ
chd-169	801	13	european	european	ADJ
chd-169	801	14	american	american	ADJ
chd-169	801	15	men	man	NOUN
chd-169	801	16	.	.	PUNCT
chd-169	802	1	cancer	cancer	NOUN
chd-169	802	2	epidemiol	epidemiol	PROPN
chd-169	802	3	biomarkers	biomarkers	PROPN
chd-169	802	4	prev	prev	VERB
chd-169	802	5	22	22	NUM
chd-169	802	6	,	,	PUNCT
chd-169	802	7	891	891	NUM
chd-169	802	8	-	-	SYM
chd-169	802	9	897	897	NUM
chd-169	802	10	.	.	PUNCT
chd-169	803	1	pratt	pratt	PROPN
chd-169	803	2	,	,	PUNCT
chd-169	803	3	w.b	w.b	PROPN
chd-169	803	4	.	.	PROPN
chd-169	803	5	,	,	PUNCT
chd-169	803	6	and	and	CCONJ
chd-169	803	7	toft	toft	NOUN
chd-169	803	8	,	,	PUNCT
chd-169	803	9	d.o	d.o	PROPN
chd-169	803	10	.	.	PROPN
chd-169	803	11	(	(	PUNCT
chd-169	803	12	1997	1997	NUM
chd-169	803	13	)	)	PUNCT
chd-169	803	14	.	.	PUNCT
chd-169	804	1	steroid	steroid	NOUN
chd-169	804	2	receptor	receptor	NOUN
chd-169	804	3	interactions	interaction	NOUN
chd-169	804	4	with	with	ADP
chd-169	804	5	heat	heat	NOUN
chd-169	804	6	shock	shock	NOUN
chd-169	804	7	protein	protein	NOUN
chd-169	804	8	and	and	CCONJ
chd-169	804	9	immunophilin	immunophilin	PROPN
chd-169	804	10	chaperones	chaperone	NOUN
chd-169	804	11	.	.	PUNCT
chd-169	805	1	endocr	endocr	PROPN
chd-169	805	2	rev	rev	PROPN
chd-169	805	3	18	18	NUM
chd-169	805	4	,	,	PUNCT
chd-169	805	5	306	306	NUM
chd-169	805	6	-	-	SYM
chd-169	805	7	360	360	NUM
chd-169	805	8	.	.	PUNCT
chd-169	806	1	pruessner	pruessner	NOUN
chd-169	806	2	,	,	PUNCT
chd-169	806	3	m.	m.	NOUN
chd-169	806	4	,	,	PUNCT
chd-169	806	5	hellhammer	hellhammer	PROPN
chd-169	806	6	,	,	PUNCT
chd-169	806	7	d.h	d.h	PROPN
chd-169	806	8	.	.	PROPN
chd-169	806	9	,	,	PUNCT
chd-169	806	10	pruessner	pruessner	PROPN
chd-169	806	11	,	,	PUNCT
chd-169	806	12	j.c	j.c	PROPN
chd-169	806	13	.	.	PROPN
chd-169	806	14	,	,	PUNCT
chd-169	806	15	and	and	CCONJ
chd-169	806	16	lupien	lupien	PROPN
chd-169	806	17	,	,	PUNCT
chd-169	806	18	s.j	s.j	PROPN
chd-169	806	19	.	.	PROPN
chd-169	806	20	(	(	PUNCT
chd-169	806	21	2003	2003	NUM
chd-169	806	22	)	)	PUNCT
chd-169	806	23	.	.	PUNCT
chd-169	807	1	self	self	NOUN
chd-169	807	2	-	-	PUNCT
chd-169	807	3	reported	report	VERB
chd-169	807	4	depressive	depressive	ADJ
chd-169	807	5	symptoms	symptom	NOUN
chd-169	807	6	and	and	CCONJ
chd-169	807	7	stress	stress	NOUN
chd-169	807	8	levels	level	NOUN
chd-169	807	9	in	in	ADP
chd-169	807	10	healthy	healthy	ADJ
chd-169	807	11	young	young	ADJ
chd-169	807	12	men	man	NOUN
chd-169	807	13	:	:	PUNCT
chd-169	807	14	associations	association	NOUN
chd-169	807	15	with	with	ADP
chd-169	807	16	the	the	DET
chd-169	807	17	cortisol	cortisol	ADJ
chd-169	807	18	response	response	NOUN
chd-169	807	19	to	to	ADP
chd-169	807	20	awakening	awakening	NOUN
chd-169	807	21	.	.	PUNCT
chd-169	808	1	psychosom	psychosom	PROPN
chd-169	808	2	med	med	PROPN
chd-169	808	3	65	65	NUM
chd-169	808	4	,	,	PUNCT
chd-169	808	5	92	92	NUM
chd-169	808	6	-	-	SYM
chd-169	808	7	99	99	NUM
chd-169	808	8	.	.	PUNCT
chd-169	809	1	puhr	puhr	PROPN
chd-169	809	2	,	,	PUNCT
chd-169	809	3	m.	m.	NOUN
chd-169	809	4	,	,	PUNCT
chd-169	809	5	hoefer	hoefer	NOUN
chd-169	809	6	,	,	PUNCT
chd-169	809	7	j.	j.	PROPN
chd-169	809	8	,	,	PUNCT
chd-169	809	9	eigentler	eigentler	NOUN
chd-169	809	10	,	,	PUNCT
chd-169	809	11	a.	a.	NOUN
chd-169	809	12	,	,	PUNCT
chd-169	809	13	ploner	ploner	NOUN
chd-169	809	14	,	,	PUNCT
chd-169	809	15	c.	c.	PROPN
chd-169	809	16	,	,	PUNCT
chd-169	809	17	handle	handle	PROPN
chd-169	809	18	,	,	PUNCT
chd-169	809	19	f.	f.	PROPN
chd-169	809	20	,	,	PUNCT
chd-169	809	21	schaefer	schaefer	PROPN
chd-169	809	22	,	,	PUNCT
chd-169	809	23	g.	g.	PROPN
chd-169	809	24	,	,	PUNCT
chd-169	809	25	kroon	kroon	PROPN
chd-169	809	26	,	,	PUNCT
chd-169	809	27	j.	j.	PROPN
chd-169	809	28	,	,	PUNCT
chd-169	809	29	leo	leo	PROPN
chd-169	809	30	,	,	PUNCT
chd-169	809	31	a.	a.	PROPN
chd-169	809	32	,	,	PUNCT
chd-169	809	33	heidegger	heidegger	PROPN
chd-169	809	34	,	,	PUNCT
chd-169	809	35	i.	i.	NOUN
chd-169	809	36	,	,	PUNCT
chd-169	809	37	eder	eder	NOUN
chd-169	809	38	,	,	PUNCT
chd-169	809	39	i.	i.	NOUN
chd-169	809	40	,	,	PUNCT
chd-169	809	41	et	et	PROPN
chd-169	809	42	al	al	PROPN
chd-169	809	43	.	.	PUNCT
chd-169	809	44	(	(	PUNCT
chd-169	809	45	2018	2018	NUM
chd-169	809	46	)	)	PUNCT
chd-169	809	47	.	.	PUNCT
chd-169	810	1	the	the	DET
chd-169	810	2	glucocorticoid	glucocorticoid	ADJ
chd-169	810	3	receptor	receptor	NOUN
chd-169	810	4	is	be	AUX
chd-169	810	5	a	a	DET
chd-169	810	6	key	key	ADJ
chd-169	810	7	player	player	NOUN
chd-169	810	8	for	for	ADP
chd-169	810	9	prostate	prostate	NOUN
chd-169	810	10	cancer	cancer	NOUN
chd-169	810	11	cell	cell	NOUN
chd-169	810	12	survival	survival	NOUN
chd-169	810	13	and	and	CCONJ
chd-169	810	14	a	a	DET
chd-169	810	15	target	target	NOUN
chd-169	810	16	for	for	ADP
chd-169	810	17	improved	improved	ADJ
chd-169	810	18	antiandrogen	antiandrogen	NOUN
chd-169	810	19	therapy	therapy	NOUN
chd-169	810	20	.	.	PUNCT
chd-169	811	1	clinical	clinical	ADJ
chd-169	811	2	cancer	cancer	NOUN
chd-169	811	3	research	research	NOUN
chd-169	811	4	:	:	PUNCT
chd-169	811	5	an	an	DET
chd-169	811	6	official	official	ADJ
chd-169	811	7	journal	journal	NOUN
chd-169	811	8	of	of	ADP
chd-169	811	9	the	the	DET
chd-169	811	10	american	american	PROPN
chd-169	811	11	association	association	PROPN
chd-169	811	12	for	for	ADP
chd-169	811	13	cancer	cancer	NOUN
chd-169	811	14	research	research	NOUN
chd-169	811	15	24	24	NUM
chd-169	811	16	,	,	PUNCT
chd-169	811	17	927	927	NUM
chd-169	811	18	-	-	SYM
chd-169	811	19	938	938	NUM
chd-169	811	20	.	.	PUNCT
chd-169	812	1	rakyan	rakyan	PROPN
chd-169	812	2	,	,	PUNCT
chd-169	812	3	v.k	v.k	PROPN
chd-169	812	4	.	.	PROPN
chd-169	812	5	,	,	PUNCT
chd-169	812	6	down	down	ADV
chd-169	812	7	,	,	PUNCT
chd-169	812	8	t.a	t.a	PROPN
chd-169	812	9	.	.	PROPN
chd-169	812	10	,	,	PUNCT
chd-169	812	11	maslau	maslau	PROPN
chd-169	812	12	,	,	PUNCT
chd-169	812	13	s.	s.	PROPN
chd-169	812	14	,	,	PUNCT
chd-169	812	15	andrew	andrew	PROPN
chd-169	812	16	,	,	PUNCT
chd-169	812	17	t.	t.	PROPN
chd-169	812	18	,	,	PUNCT
chd-169	812	19	yang	yang	PROPN
chd-169	812	20	,	,	PUNCT
chd-169	812	21	t.p	t.p	PROPN
chd-169	812	22	.	.	PROPN
chd-169	812	23	,	,	PUNCT
chd-169	812	24	beyan	beyan	PROPN
chd-169	812	25	,	,	PUNCT
chd-169	812	26	h.	h.	PROPN
chd-169	812	27	,	,	PUNCT
chd-169	812	28	whittaker	whittaker	PROPN
chd-169	812	29	,	,	PUNCT
chd-169	812	30	p.	p.	PROPN
chd-169	812	31	,	,	PUNCT
chd-169	812	32	mccann	mccann	PROPN
chd-169	812	33	,	,	PUNCT
chd-169	812	34	o.t	o.t	PROPN
chd-169	812	35	.	.	PROPN
chd-169	812	36	,	,	PUNCT
chd-169	812	37	finer	finer	PROPN
chd-169	812	38	,	,	PUNCT
chd-169	812	39	s.	s.	PROPN
chd-169	812	40	,	,	PUNCT
chd-169	812	41	valdes	valde	NOUN
chd-169	812	42	,	,	PUNCT
chd-169	812	43	a.m.	a.m.	ADV
chd-169	812	44	,	,	PUNCT
chd-169	812	45	et	et	PROPN
chd-169	812	46	al	al	PROPN
chd-169	812	47	.	.	PUNCT
chd-169	813	1	(	(	PUNCT
chd-169	813	2	2010	2010	NUM
chd-169	813	3	)	)	PUNCT
chd-169	813	4	.	.	PUNCT
chd-169	814	1	human	human	ADJ
chd-169	814	2	aging	age	VERB
chd-169	814	3	-	-	PUNCT
chd-169	814	4	associated	associate	VERB
chd-169	814	5	dna	dna	PROPN
chd-169	814	6	hypermethylation	hypermethylation	NOUN
chd-169	814	7	occurs	occur	VERB
chd-169	814	8	preferentially	preferentially	ADV
chd-169	814	9	at	at	ADP
chd-169	814	10	bivalent	bivalent	ADJ
chd-169	814	11	chromatin	chromatin	NOUN
chd-169	814	12	domains	domain	NOUN
chd-169	814	13	.	.	PUNCT
chd-169	815	1	genome	genome	NOUN
chd-169	815	2	research	research	NOUN
chd-169	815	3	20	20	NUM
chd-169	815	4	,	,	PUNCT
chd-169	815	5	434	434	NUM
chd-169	815	6	-	-	SYM
chd-169	815	7	439	439	NUM
chd-169	815	8	.	.	PUNCT
chd-169	816	1	rand	rand	NOUN
chd-169	816	2	,	,	PUNCT
chd-169	816	3	k.a	k.a	PROPN
chd-169	816	4	.	.	PROPN
chd-169	816	5	,	,	PUNCT
chd-169	816	6	rohland	rohland	PROPN
chd-169	816	7	,	,	PUNCT
chd-169	816	8	n.	n.	NOUN
chd-169	816	9	,	,	PUNCT
chd-169	816	10	tandon	tandon	PROPN
chd-169	816	11	,	,	PUNCT
chd-169	816	12	a.	a.	PROPN
chd-169	816	13	,	,	PUNCT
chd-169	816	14	stram	stram	PROPN
chd-169	816	15	,	,	PUNCT
chd-169	816	16	a.	a.	PROPN
chd-169	816	17	,	,	PUNCT
chd-169	816	18	sheng	sheng	PROPN
chd-169	816	19	,	,	PUNCT
chd-169	816	20	x.	x.	PROPN
chd-169	816	21	,	,	PUNCT
chd-169	816	22	do	do	VERB
chd-169	816	23	,	,	PUNCT
chd-169	816	24	r.	r.	PROPN
chd-169	816	25	,	,	PUNCT
chd-169	816	26	pasaniuc	pasaniuc	NOUN
chd-169	816	27	,	,	PUNCT
chd-169	816	28	b.	b.	PROPN
chd-169	816	29	,	,	PUNCT
chd-169	816	30	allen	allen	PROPN
chd-169	816	31	,	,	PUNCT
chd-169	816	32	a.	a.	NOUN
chd-169	816	33	,	,	PUNCT
chd-169	816	34	quinque	quinque	NOUN
chd-169	816	35	,	,	PUNCT
chd-169	816	36	d.	d.	PROPN
chd-169	816	37	,	,	PUNCT
chd-169	816	38	mallick	mallick	PROPN
chd-169	816	39	,	,	PUNCT
chd-169	816	40	s.	s.	PROPN
chd-169	816	41	,	,	PUNCT
chd-169	816	42	et	et	PROPN
chd-169	816	43	al	al	PROPN
chd-169	816	44	.	.	PUNCT
chd-169	817	1	(	(	PUNCT
chd-169	817	2	2016	2016	NUM
chd-169	817	3	)	)	PUNCT
chd-169	817	4	.	.	PUNCT
chd-169	818	1	whole	whole	ADJ
chd-169	818	2	-	-	PUNCT
chd-169	818	3	exome	exome	NOUN
chd-169	818	4	sequencing	sequencing	NOUN
chd-169	818	5	of	of	ADP
chd-169	818	6	over	over	ADP
chd-169	818	7	4100	4100	NUM
chd-169	818	8	men	man	NOUN
chd-169	818	9	of	of	ADP
chd-169	818	10	african	african	ADJ
chd-169	818	11	ancestry	ancestry	NOUN
chd-169	818	12	and	and	CCONJ
chd-169	818	13	prostate	prostate	NOUN
chd-169	818	14	cancer	cancer	NOUN
chd-169	818	15	risk	risk	NOUN
chd-169	818	16	.	.	PUNCT
chd-169	819	1	hum	hum	PROPN
chd-169	819	2	mol	mol	ADP
chd-169	819	3	genet	genet	PROPN
chd-169	819	4	25	25	NUM
chd-169	819	5	,	,	PUNCT
chd-169	819	6	371	371	NUM
chd-169	819	7	-	-	SYM
chd-169	819	8	381	381	NUM
chd-169	819	9	.	.	PUNCT
chd-169	820	1	reams	ream	NOUN
chd-169	820	2	,	,	PUNCT
chd-169	820	3	r.r	r.r	PROPN
chd-169	820	4	.	.	PROPN
chd-169	820	5	,	,	PUNCT
chd-169	820	6	agrawal	agrawal	PROPN
chd-169	820	7	,	,	PUNCT
chd-169	820	8	d.	d.	PROPN
chd-169	820	9	,	,	PUNCT
chd-169	820	10	davis	davis	PROPN
chd-169	820	11	,	,	PUNCT
chd-169	820	12	m.b	m.b	PROPN
chd-169	820	13	.	.	PROPN
chd-169	820	14	,	,	PUNCT
chd-169	820	15	yoder	yoder	PROPN
chd-169	820	16	,	,	PUNCT
chd-169	820	17	s.	s.	PROPN
chd-169	820	18	,	,	PUNCT
chd-169	820	19	odedina	odedina	PROPN
chd-169	820	20	,	,	PUNCT
chd-169	820	21	f.t	f.t	PROPN
chd-169	820	22	.	.	PROPN
chd-169	820	23	,	,	PUNCT
chd-169	820	24	kumar	kumar	PROPN
chd-169	820	25	,	,	PUNCT
chd-169	820	26	n.	n.	PROPN
chd-169	820	27	,	,	PUNCT
chd-169	820	28	higginbotham	higginbotham	PROPN
chd-169	820	29	,	,	PUNCT
chd-169	820	30	j.m	j.m	PROPN
chd-169	820	31	.	.	PROPN
chd-169	820	32	,	,	PUNCT
chd-169	820	33	akinremi	akinremi	ADV
chd-169	820	34	,	,	PUNCT
chd-169	820	35	t.	t.	PROPN
chd-169	820	36	,	,	PUNCT
chd-169	820	37	suther	suther	ADV
chd-169	820	38	,	,	PUNCT
chd-169	820	39	s.	s.	PROPN
chd-169	820	40	,	,	PUNCT
chd-169	820	41	and	and	CCONJ
chd-169	820	42	soliman	soliman	NOUN
chd-169	820	43	,	,	PUNCT
chd-169	820	44	k.f	k.f	PROPN
chd-169	820	45	.	.	PROPN
chd-169	820	46	(	(	PUNCT
chd-169	820	47	2009	2009	NUM
chd-169	820	48	)	)	PUNCT
chd-169	820	49	.	.	PUNCT
chd-169	821	1	microarray	microarray	PROPN
chd-169	821	2	comparison	comparison	NOUN
chd-169	821	3	of	of	ADP
chd-169	821	4	prostate	prostate	NOUN
chd-169	821	5	tumor	tumor	NOUN
chd-169	821	6	gene	gene	NOUN
chd-169	821	7	expression	expression	NOUN
chd-169	821	8	in	in	ADP
chd-169	821	9	african	african	ADJ
chd-169	821	10	-	-	PUNCT
chd-169	821	11	american	american	ADJ
chd-169	821	12	and	and	CCONJ
chd-169	821	13	caucasian	caucasian	ADJ
chd-169	821	14	american	american	ADJ
chd-169	821	15	males	male	NOUN
chd-169	821	16	:	:	PUNCT
chd-169	821	17	a	a	DET
chd-169	821	18	pilot	pilot	NOUN
chd-169	821	19	project	project	NOUN
chd-169	821	20	study	study	NOUN
chd-169	821	21	.	.	PUNCT
chd-169	822	1	infect	infect	VERB
chd-169	822	2	agent	agent	NOUN
chd-169	822	3	cancer	cancer	NOUN
chd-169	822	4	4	4	NUM
chd-169	822	5	suppl	suppl	ADJ
chd-169	822	6	1	1	NUM
chd-169	822	7	,	,	PUNCT
chd-169	822	8	s3	s3	PROPN
chd-169	822	9	.	.	PROPN
chd-169	822	10	rebbeck	rebbeck	PROPN
chd-169	822	11	,	,	PUNCT
chd-169	822	12	t.r	t.r	PROPN
chd-169	822	13	.	.	PROPN
chd-169	822	14	(	(	PUNCT
chd-169	822	15	2017	2017	NUM
chd-169	822	16	)	)	PUNCT
chd-169	822	17	.	.	PUNCT
chd-169	823	1	prostate	prostate	NOUN
chd-169	823	2	cancer	cancer	NOUN
chd-169	823	3	genetics	genetic	NOUN
chd-169	823	4	:	:	PUNCT
chd-169	823	5	variation	variation	NOUN
chd-169	823	6	by	by	ADP
chd-169	823	7	race	race	NOUN
chd-169	823	8	,	,	PUNCT
chd-169	823	9	ethnicity	ethnicity	NOUN
chd-169	823	10	,	,	PUNCT
chd-169	823	11	and	and	CCONJ
chd-169	823	12	geography	geography	NOUN
chd-169	823	13	.	.	PUNCT
chd-169	824	1	semin	semin	PROPN
chd-169	824	2	radiat	radiat	PROPN
chd-169	824	3	oncol	oncol	PROPN
chd-169	824	4	27	27	NUM
chd-169	824	5	,	,	PUNCT
chd-169	824	6	3	3	NUM
chd-169	824	7	-	-	SYM
chd-169	824	8	10	10	NUM
chd-169	824	9	.	.	PUNCT
chd-169	825	1	rehman	rehman	NOUN
chd-169	825	2	,	,	PUNCT
chd-169	825	3	y.	y.	PROPN
chd-169	825	4	,	,	PUNCT
chd-169	825	5	and	and	CCONJ
chd-169	825	6	rosenberg	rosenberg	PROPN
chd-169	825	7	,	,	PUNCT
chd-169	825	8	j.e	j.e	PROPN
chd-169	825	9	.	.	PROPN
chd-169	825	10	(	(	PUNCT
chd-169	825	11	2012	2012	NUM
chd-169	825	12	)	)	PUNCT
chd-169	825	13	.	.	PUNCT
chd-169	826	1	abiraterone	abiraterone	NOUN
chd-169	826	2	acetate	acetate	NOUN
chd-169	826	3	:	:	PUNCT
chd-169	826	4	oral	oral	ADJ
chd-169	826	5	androgen	androgen	NOUN
chd-169	826	6	biosynthesis	biosynthesis	NOUN
chd-169	826	7	inhibitor	inhibitor	NOUN
chd-169	826	8	for	for	ADP
chd-169	826	9	treatment	treatment	NOUN
chd-169	826	10	of	of	ADP
chd-169	826	11	castration	castration	NOUN
chd-169	826	12	-	-	PUNCT
chd-169	826	13	resistant	resistant	ADJ
chd-169	826	14	prostate	prostate	NOUN
chd-169	826	15	cancer	cancer	NOUN
chd-169	826	16	.	.	PUNCT
chd-169	827	1	drug	drug	NOUN
chd-169	827	2	des	des	PROPN
chd-169	827	3	devel	devel	NOUN
chd-169	827	4	ther	ther	ADJ
chd-169	827	5	6	6	NUM
chd-169	827	6	,	,	PUNCT
chd-169	827	7	13	13	NUM
chd-169	827	8	-	-	SYM
chd-169	827	9	18	18	NUM
chd-169	827	10	.	.	PUNCT
chd-169	828	1	rios	rio	NOUN
chd-169	828	2	-	-	PUNCT
chd-169	828	3	colon	colon	NOUN
chd-169	828	4	,	,	PUNCT
chd-169	828	5	l.	l.	PROPN
chd-169	828	6	,	,	PUNCT
chd-169	828	7	cajigas	cajigas	PROPN
chd-169	828	8	-	-	PUNCT
chd-169	828	9	du	du	PROPN
chd-169	828	10	ross	ross	PROPN
chd-169	828	11	,	,	PUNCT
chd-169	828	12	c.k	c.k	PROPN
chd-169	828	13	.	.	PROPN
chd-169	828	14	,	,	PUNCT
chd-169	828	15	basu	basu	PROPN
chd-169	828	16	,	,	PUNCT
chd-169	828	17	a.	a.	PROPN
chd-169	828	18	,	,	PUNCT
chd-169	828	19	elix	elix	PROPN
chd-169	828	20	,	,	PUNCT
chd-169	828	21	c.	c.	PROPN
chd-169	828	22	,	,	PUNCT
chd-169	828	23	aliceapolanco	aliceapolanco	PROPN
chd-169	828	24	,	,	PUNCT
chd-169	828	25	i.	i.	PROPN
chd-169	828	26	,	,	PUNCT
chd-169	828	27	sanchez	sanchez	PROPN
chd-169	828	28	,	,	PUNCT
chd-169	828	29	t.w	t.w	PROPN
chd-169	828	30	.	.	PROPN
chd-169	828	31	,	,	PUNCT
chd-169	828	32	radhakrishnan	radhakrishnan	PROPN
chd-169	828	33	,	,	PUNCT
chd-169	828	34	v.	v.	PROPN
chd-169	828	35	,	,	PUNCT
chd-169	828	36	chen	chen	PROPN
chd-169	828	37	,	,	PUNCT
chd-169	828	38	c.s	c.s	PROPN
chd-169	828	39	.	.	PROPN
chd-169	828	40	,	,	PUNCT
chd-169	828	41	and	and	CCONJ
chd-169	828	42	casiano	casiano	PROPN
chd-169	828	43	,	,	PUNCT
chd-169	828	44	c.a	c.a	PROPN
chd-169	828	45	.	.	PROPN
chd-169	828	46	(	(	PUNCT
chd-169	828	47	2017	2017	NUM
chd-169	828	48	)	)	PUNCT
chd-169	828	49	.	.	PUNCT
chd-169	829	1	targeting	target	VERB
chd-169	829	2	the	the	DET
chd-169	829	3	stress	stress	NOUN
chd-169	829	4	oncoprotein	oncoprotein	VERB
chd-169	829	5	ledgf	ledgf	PROPN
chd-169	829	6	/	/	SYM
chd-169	829	7	p75	p75	ADJ
chd-169	829	8	to	to	PART
chd-169	829	9	sensitize	sensitize	VERB
chd-169	829	10	chemoresistant	chemoresistant	ADJ
chd-169	829	11	prostate	prostate	NOUN
chd-169	829	12	cancer	cancer	NOUN
chd-169	829	13	cells	cell	NOUN
chd-169	829	14	to	to	ADP
chd-169	829	15	taxanes	taxane	NOUN
chd-169	829	16	.	.	PUNCT
chd-169	830	1	oncotarget	oncotarget	VERB
chd-169	830	2	8	8	NUM
chd-169	830	3	,	,	PUNCT
chd-169	830	4	2491524931	2491524931	NUM
chd-169	830	5	.	.	PUNCT
chd-169	831	1	riviere	riviere	PROPN
chd-169	831	2	,	,	PUNCT
chd-169	831	3	p.	p.	NOUN
chd-169	831	4	,	,	PUNCT
chd-169	831	5	luterstein	luterstein	PROPN
chd-169	831	6	,	,	PUNCT
chd-169	831	7	e.	e.	PROPN
chd-169	831	8	,	,	PUNCT
chd-169	831	9	kumar	kumar	PROPN
chd-169	831	10	,	,	PUNCT
chd-169	831	11	a.	a.	NOUN
chd-169	831	12	,	,	PUNCT
chd-169	831	13	vitzthum	vitzthum	NOUN
chd-169	831	14	,	,	PUNCT
chd-169	831	15	l.k	l.k	PROPN
chd-169	831	16	.	.	PROPN
chd-169	831	17	,	,	PUNCT
chd-169	831	18	deka	deka	PROPN
chd-169	831	19	,	,	PUNCT
chd-169	831	20	r.	r.	PROPN
chd-169	831	21	,	,	PUNCT
chd-169	831	22	sarkar	sarkar	PROPN
chd-169	831	23	,	,	PUNCT
chd-169	831	24	r.r	r.r	PROPN
chd-169	831	25	.	.	PROPN
chd-169	831	26	,	,	PUNCT
chd-169	831	27	bryant	bryant	PROPN
chd-169	831	28	,	,	PUNCT
chd-169	831	29	a.k	a.k	PROPN
chd-169	831	30	.	.	PROPN
chd-169	831	31	,	,	PUNCT
chd-169	831	32	bruggeman	bruggeman	PROPN
chd-169	831	33	,	,	PUNCT
chd-169	831	34	a.	a.	NOUN
chd-169	831	35	,	,	PUNCT
chd-169	831	36	einck	einck	NOUN
chd-169	831	37	,	,	PUNCT
chd-169	831	38	j.p	j.p	PROPN
chd-169	831	39	.	.	PROPN
chd-169	831	40	,	,	PUNCT
chd-169	831	41	murphy	murphy	PROPN
chd-169	831	42	,	,	PUNCT
chd-169	831	43	j.d	j.d	PROPN
chd-169	831	44	.	.	PROPN
chd-169	831	45	,	,	PUNCT
chd-169	831	46	et	et	PROPN
chd-169	831	47	al	al	PROPN
chd-169	831	48	.	.	PROPN
chd-169	831	49	(	(	PUNCT
chd-169	831	50	2020	2020	NUM
chd-169	831	51	)	)	PUNCT
chd-169	831	52	.	.	PUNCT
chd-169	832	1	survival	survival	NOUN
chd-169	832	2	of	of	ADP
chd-169	832	3	african	african	ADJ
chd-169	832	4	american	american	ADJ
chd-169	832	5	and	and	CCONJ
chd-169	832	6	non	non	ADJ
chd-169	832	7	-	-	ADJ
chd-169	832	8	hispanic	hispanic	ADJ
chd-169	832	9	white	white	ADJ
chd-169	832	10	men	man	NOUN
chd-169	832	11	with	with	ADP
chd-169	832	12	prostate	prostate	NOUN
chd-169	832	13	cancer	cancer	NOUN
chd-169	832	14	in	in	ADP
chd-169	832	15	an	an	DET
chd-169	832	16	equal	equal	ADJ
chd-169	832	17	-	-	PUNCT
chd-169	832	18	access	access	NOUN
chd-169	832	19	health	health	NOUN
chd-169	832	20	care	care	NOUN
chd-169	832	21	system	system	NOUN
chd-169	832	22	.	.	PUNCT
chd-169	833	1	cancer	cancer	NOUN
chd-169	833	2	.	.	PUNCT
chd-169	834	1	roberts	roberts	PROPN
chd-169	834	2	,	,	PUNCT
chd-169	834	3	l.r	l.r	PROPN
chd-169	834	4	.	.	PROPN
chd-169	834	5	,	,	PUNCT
chd-169	834	6	wilson	wilson	PROPN
chd-169	834	7	,	,	PUNCT
chd-169	834	8	c.m	c.m	PROPN
chd-169	834	9	.	.	PROPN
chd-169	834	10	,	,	PUNCT
chd-169	834	11	stiel	stiel	PROPN
chd-169	834	12	,	,	PUNCT
chd-169	834	13	l.	l.	PROPN
chd-169	834	14	,	,	PUNCT
chd-169	834	15	casiano	casiano	PROPN
chd-169	834	16	,	,	PUNCT
chd-169	834	17	c.a	c.a	PROPN
chd-169	834	18	.	.	PROPN
chd-169	834	19	,	,	PUNCT
chd-169	834	20	and	and	CCONJ
chd-169	834	21	montgomery	montgomery	PROPN
chd-169	834	22	,	,	PUNCT
chd-169	834	23	s.b	s.b	PROPN
chd-169	834	24	.	.	PROPN
chd-169	834	25	(	(	PUNCT
chd-169	834	26	2018	2018	NUM
chd-169	834	27	)	)	PUNCT
chd-169	834	28	.	.	PUNCT
chd-169	835	1	prostate	prostate	NOUN
chd-169	835	2	cancer	cancer	NOUN
chd-169	835	3	screening	screening	NOUN
chd-169	835	4	among	among	ADP
chd-169	835	5	high	high	ADJ
chd-169	835	6	-	-	PUNCT
chd-169	835	7	risk	risk	NOUN
chd-169	835	8	black	black	ADJ
chd-169	835	9	men	man	NOUN
chd-169	835	10	.	.	PUNCT
chd-169	836	1	j	j	PROPN
chd-169	836	2	nurse	nurse	PROPN
chd-169	836	3	pract	pract	PROPN
chd-169	836	4	14	14	NUM
chd-169	836	5	,	,	PUNCT
chd-169	836	6	677	677	NUM
chd-169	836	7	-	-	SYM
chd-169	836	8	682	682	NUM
chd-169	836	9	e672	e672	NUM
chd-169	836	10	.	.	PUNCT
chd-169	837	1	romero	romero	PROPN
chd-169	837	2	-	-	PUNCT
chd-169	837	3	laorden	laorden	PROPN
chd-169	837	4	,	,	PUNCT
chd-169	837	5	n.	n.	PROPN
chd-169	837	6	,	,	PUNCT
chd-169	837	7	lozano	lozano	PROPN
chd-169	837	8	,	,	PUNCT
chd-169	837	9	r.	r.	PROPN
chd-169	837	10	,	,	PUNCT
chd-169	837	11	jayaram	jayaram	PROPN
chd-169	837	12	,	,	PUNCT
chd-169	837	13	a.	a.	PROPN
chd-169	837	14	,	,	PUNCT
chd-169	837	15	lopez	lopez	PROPN
chd-169	837	16	-	-	PUNCT
chd-169	837	17	campos	campos	PROPN
chd-169	837	18	,	,	PUNCT
chd-169	837	19	f.	f.	PROPN
chd-169	837	20	,	,	PUNCT
chd-169	837	21	saez	saez	PROPN
chd-169	837	22	,	,	PUNCT
chd-169	837	23	m.i	m.i	PROPN
chd-169	837	24	.	.	PROPN
chd-169	837	25	,	,	PUNCT
chd-169	837	26	montesa	montesa	PROPN
chd-169	837	27	,	,	PUNCT
chd-169	837	28	a.	a.	NOUN
chd-169	837	29	,	,	PUNCT
chd-169	837	30	gutierrez	gutierrez	NOUN
chd-169	837	31	-	-	PUNCT
chd-169	837	32	pecharoman	pecharoman	NOUN
chd-169	837	33	,	,	PUNCT
chd-169	837	34	a.	a.	NOUN
chd-169	837	35	,	,	PUNCT
chd-169	837	36	villatoro	villatoro	PROPN
chd-169	837	37	,	,	PUNCT
chd-169	837	38	r.	r.	PROPN
chd-169	837	39	,	,	PUNCT
chd-169	837	40	herrera	herrera	PROPN
chd-169	837	41	,	,	PUNCT
chd-169	837	42	b.	b.	PROPN
chd-169	837	43	,	,	PUNCT
chd-169	837	44	correa	correa	PROPN
chd-169	837	45	,	,	PUNCT
chd-169	837	46	r.	r.	PROPN
chd-169	837	47	,	,	PUNCT
chd-169	837	48	et	et	PROPN
chd-169	837	49	al	al	PROPN
chd-169	837	50	.	.	PUNCT
chd-169	837	51	(	(	PUNCT
chd-169	837	52	2018	2018	NUM
chd-169	837	53	)	)	PUNCT
chd-169	837	54	.	.	PUNCT
chd-169	838	1	phase	phase	NOUN
chd-169	838	2	ii	ii	PROPN
chd-169	838	3	pilot	pilot	NOUN
chd-169	838	4	study	study	NOUN
chd-169	838	5	of	of	ADP
chd-169	838	6	the	the	DET
chd-169	838	7	prednisone	prednisone	NOUN
chd-169	838	8	to	to	ADP
chd-169	838	9	dexamethasone	dexamethasone	NOUN
chd-169	838	10	switch	switch	NOUN
chd-169	838	11	in	in	ADP
chd-169	838	12	metastatic	metastatic	ADJ
chd-169	838	13	castration	castration	NOUN
chd-169	838	14	-	-	PUNCT
chd-169	838	15	resistant	resistant	ADJ
chd-169	838	16	prostate	prostate	NOUN
chd-169	838	17	cancer	cancer	NOUN
chd-169	838	18	(	(	PUNCT
chd-169	838	19	mcrpc	mcrpc	NOUN
chd-169	838	20	)	)	PUNCT
chd-169	838	21	patients	patient	NOUN
chd-169	838	22	with	with	ADP
chd-169	838	23	limited	limited	ADJ
chd-169	838	24	progression	progression	NOUN
chd-169	838	25	on	on	ADP
chd-169	838	26	abiraterone	abiraterone	NOUN
chd-169	838	27	plus	plus	CCONJ
chd-169	838	28	prednisone	prednisone	NOUN
chd-169	838	29	(	(	PUNCT
chd-169	838	30	switch	switch	NOUN
chd-169	838	31	study	study	NOUN
chd-169	838	32	)	)	PUNCT
chd-169	838	33	.	.	PUNCT
chd-169	839	1	br	br	PROPN
chd-169	839	2	j	j	PROPN
chd-169	839	3	cancer	cancer	PROPN
chd-169	839	4	119	119	NUM
chd-169	839	5	,	,	PUNCT
chd-169	839	6	1052	1052	NUM
chd-169	839	7	-	-	SYM
chd-169	839	8	1059	1059	NUM
chd-169	839	9	.	.	PUNCT
chd-169	840	1	ross	ross	PROPN
chd-169	840	2	,	,	PUNCT
chd-169	840	3	r.k	r.k	PROPN
chd-169	840	4	.	.	PROPN
chd-169	840	5	,	,	PUNCT
chd-169	840	6	bernstein	bernstein	PROPN
chd-169	840	7	,	,	PUNCT
chd-169	840	8	l.	l.	PROPN
chd-169	840	9	,	,	PUNCT
chd-169	840	10	lobo	lobo	PROPN
chd-169	840	11	,	,	PUNCT
chd-169	840	12	r.a	r.a	PROPN
chd-169	840	13	.	.	PROPN
chd-169	840	14	,	,	PUNCT
chd-169	840	15	shimizu	shimizu	PROPN
chd-169	840	16	,	,	PUNCT
chd-169	840	17	h.	h.	PROPN
chd-169	840	18	,	,	PUNCT
chd-169	840	19	stanczyk	stanczyk	VERB
chd-169	840	20	,	,	PUNCT
chd-169	840	21	f.z	f.z	PROPN
chd-169	840	22	.	.	PROPN
chd-169	840	23	,	,	PUNCT
chd-169	840	24	pike	pike	PROPN
chd-169	840	25	,	,	PUNCT
chd-169	840	26	m.c	m.c	PROPN
chd-169	840	27	.	.	PROPN
chd-169	840	28	,	,	PUNCT
chd-169	840	29	and	and	CCONJ
chd-169	840	30	henderson	henderson	PROPN
chd-169	840	31	,	,	PUNCT
chd-169	840	32	b.e	b.e	PROPN
chd-169	840	33	.	.	PROPN
chd-169	840	34	(	(	PUNCT
chd-169	840	35	1992	1992	NUM
chd-169	840	36	)	)	PUNCT
chd-169	840	37	.	.	PUNCT
chd-169	841	1	5	5	NUM
chd-169	841	2	-	-	PUNCT
chd-169	841	3	alpha	alpha	NOUN
chd-169	841	4	-	-	PUNCT
chd-169	841	5	reductase	reductase	NOUN
chd-169	841	6	activity	activity	NOUN
chd-169	841	7	and	and	CCONJ
chd-169	841	8	risk	risk	NOUN
chd-169	841	9	of	of	ADP
chd-169	841	10	prostate	prostate	NOUN
chd-169	841	11	cancer	cancer	NOUN
chd-169	841	12	among	among	ADP
chd-169	841	13	japanese	japanese	PROPN
chd-169	841	14	and	and	CCONJ
chd-169	841	15	us	we	PRON
chd-169	841	16	white	white	ADJ
chd-169	841	17	and	and	CCONJ
chd-169	841	18	black	black	ADJ
chd-169	841	19	males	male	NOUN
chd-169	841	20	.	.	PUNCT
chd-169	842	1	lancet	lancet	PROPN
chd-169	842	2	339	339	NUM
chd-169	842	3	,	,	PUNCT
chd-169	842	4	887	887	NUM
chd-169	842	5	-	-	SYM
chd-169	842	6	889	889	NUM
chd-169	842	7	.	.	PUNCT
chd-169	843	1	rundlett	rundlett	PROPN
chd-169	843	2	,	,	PUNCT
chd-169	843	3	s.e	s.e	PROPN
chd-169	843	4	.	.	PROPN
chd-169	843	5	,	,	PUNCT
chd-169	843	6	and	and	CCONJ
chd-169	843	7	miesfeld	miesfeld	NOUN
chd-169	843	8	,	,	PUNCT
chd-169	843	9	r.l	r.l	PROPN
chd-169	843	10	.	.	PROPN
chd-169	843	11	(	(	PUNCT
chd-169	843	12	1995	1995	NUM
chd-169	843	13	)	)	PUNCT
chd-169	843	14	.	.	PUNCT
chd-169	844	1	quantitative	quantitative	ADJ
chd-169	844	2	differences	difference	NOUN
chd-169	844	3	in	in	ADP
chd-169	844	4	androgen	androgen	NOUN
chd-169	844	5	and	and	CCONJ
chd-169	844	6	glucocorticoid	glucocorticoid	ADJ
chd-169	844	7	receptor	receptor	NOUN
chd-169	844	8	dna	dna	NOUN
chd-169	844	9	binding	bind	VERB
chd-169	844	10	properties	property	NOUN
chd-169	844	11	contribute	contribute	VERB
chd-169	844	12	to	to	ADP
chd-169	844	13	receptor	receptor	NOUN
chd-169	844	14	-	-	PUNCT
chd-169	844	15	selective	selective	ADJ
chd-169	844	16	transcriptional	transcriptional	NOUN
chd-169	844	17	regulation	regulation	NOUN
chd-169	844	18	.	.	PUNCT
chd-169	845	1	mol	mol	ADP
chd-169	845	2	cell	cell	NOUN
chd-169	845	3	endocrinol	endocrinol	NOUN
chd-169	845	4	109	109	NUM
chd-169	845	5	,	,	PUNCT
chd-169	845	6	1	1	NUM
chd-169	845	7	-	-	SYM
chd-169	845	8	10	10	NUM
chd-169	845	9	.	.	PUNCT
chd-169	846	1	sahu	sahu	PROPN
chd-169	846	2	,	,	PUNCT
chd-169	846	3	b.	b.	PROPN
chd-169	846	4	,	,	PUNCT
chd-169	846	5	laakso	laakso	NOUN
chd-169	846	6	,	,	PUNCT
chd-169	846	7	m.	m.	NOUN
chd-169	846	8	,	,	PUNCT
chd-169	846	9	pihlajamaa	pihlajamaa	ADJ
chd-169	846	10	,	,	PUNCT
chd-169	846	11	p.	p.	NOUN
chd-169	846	12	,	,	PUNCT
chd-169	846	13	ovaska	ovaska	PROPN
chd-169	846	14	,	,	PUNCT
chd-169	846	15	k.	k.	PROPN
chd-169	846	16	,	,	PUNCT
chd-169	846	17	sinielnikov	sinielnikov	PROPN
chd-169	846	18	,	,	PUNCT
chd-169	846	19	i.	i.	PROPN
chd-169	846	20	,	,	PUNCT
chd-169	846	21	hautaniemi	hautaniemi	PROPN
chd-169	846	22	,	,	PUNCT
chd-169	846	23	s.	s.	PROPN
chd-169	846	24	,	,	PUNCT
chd-169	846	25	and	and	CCONJ
chd-169	846	26	janne	janne	PROPN
chd-169	846	27	,	,	PUNCT
chd-169	846	28	o.a	o.a	PROPN
chd-169	846	29	.	.	PROPN
chd-169	846	30	(	(	PUNCT
chd-169	846	31	2013	2013	NUM
chd-169	846	32	)	)	PUNCT
chd-169	846	33	.	.	PUNCT
chd-169	847	1	foxa1	foxa1	NOUN
chd-169	847	2	specifies	specifie	NOUN
chd-169	847	3	unique	unique	ADJ
chd-169	847	4	androgen	androgen	NOUN
chd-169	847	5	and	and	CCONJ
chd-169	847	6	glucocorticoid	glucocorticoid	ADJ
chd-169	847	7	receptor	receptor	NOUN
chd-169	847	8	binding	bind	VERB
chd-169	847	9	events	event	NOUN
chd-169	847	10	in	in	ADP
chd-169	847	11	prostate	prostate	NOUN
chd-169	847	12	cancer	cancer	NOUN
chd-169	847	13	cells	cell	NOUN
chd-169	847	14	.	.	PUNCT
chd-169	848	1	cancer	cancer	NOUN
chd-169	848	2	res	re	VERB
chd-169	848	3	73	73	NUM
chd-169	848	4	,	,	PUNCT
chd-169	848	5	1570	1570	NUM
chd-169	848	6	-	-	SYM
chd-169	848	7	1580	1580	NUM
chd-169	848	8	.	.	PUNCT
chd-169	849	1	sanchez	sanchez	PROPN
chd-169	849	2	,	,	PUNCT
chd-169	849	3	t.w	t.w	PROPN
chd-169	849	4	.	.	PROPN
chd-169	849	5	,	,	PUNCT
chd-169	849	6	zhang	zhang	PROPN
chd-169	849	7	,	,	PUNCT
chd-169	849	8	g.	g.	PROPN
chd-169	849	9	,	,	PUNCT
chd-169	849	10	li	li	PROPN
chd-169	849	11	,	,	PUNCT
chd-169	849	12	j.	j.	PROPN
chd-169	849	13	,	,	PUNCT
chd-169	849	14	dai	dai	PROPN
chd-169	849	15	,	,	PUNCT
chd-169	849	16	l.	l.	PROPN
chd-169	849	17	,	,	PUNCT
chd-169	849	18	mirshahidi	mirshahidi	PROPN
chd-169	849	19	,	,	PUNCT
chd-169	849	20	s.	s.	PROPN
chd-169	849	21	,	,	PUNCT
chd-169	849	22	wall	wall	PROPN
chd-169	849	23	,	,	PUNCT
chd-169	849	24	n.r	n.r	PROPN
chd-169	849	25	.	.	PROPN
chd-169	849	26	,	,	PUNCT
chd-169	849	27	yates	yates	PROPN
chd-169	849	28	,	,	PUNCT
chd-169	849	29	c.	c.	PROPN
chd-169	849	30	,	,	PUNCT
chd-169	849	31	wilson	wilson	PROPN
chd-169	849	32	,	,	PUNCT
chd-169	849	33	c.	c.	PROPN
chd-169	849	34	,	,	PUNCT
chd-169	849	35	montgomery	montgomery	PROPN
chd-169	849	36	,	,	PUNCT
chd-169	849	37	s.	s.	PROPN
chd-169	849	38	,	,	PUNCT
chd-169	849	39	zhang	zhang	PROPN
chd-169	849	40	,	,	PUNCT
chd-169	849	41	j.y	j.y	PROPN
chd-169	849	42	.	.	PROPN
chd-169	849	43	,	,	PUNCT
chd-169	849	44	et	et	PROPN
chd-169	849	45	al	al	PROPN
chd-169	849	46	.	.	PUNCT
chd-169	849	47	(	(	PUNCT
chd-169	849	48	2016	2016	NUM
chd-169	849	49	)	)	PUNCT
chd-169	849	50	.	.	PUNCT
chd-169	850	1	immunoseroproteomic	immunoseroproteomic	ADJ
chd-169	850	2	profiling	profiling	NOUN
chd-169	850	3	in	in	ADP
chd-169	850	4	african	african	ADJ
chd-169	850	5	american	american	ADJ
chd-169	850	6	men	man	NOUN
chd-169	850	7	with	with	ADP
chd-169	850	8	prostate	prostate	NOUN
chd-169	850	9	cancer	cancer	NOUN
chd-169	850	10	:	:	PUNCT
chd-169	850	11	evidence	evidence	NOUN
chd-169	850	12	for	for	ADP
chd-169	850	13	an	an	DET
chd-169	850	14	autoantibody	autoantibody	ADJ
chd-169	850	15	response	response	NOUN
chd-169	850	16	to	to	ADP
chd-169	850	17	glycolysis	glycolysis	NOUN
chd-169	850	18	and	and	CCONJ
chd-169	850	19	plasminogenassociated	plasminogenassociate	VERB
chd-169	850	20	proteins	protein	NOUN
chd-169	850	21	.	.	PUNCT
chd-169	851	1	mol	mol	ADP
chd-169	851	2	cell	cell	NOUN
chd-169	851	3	proteomics	proteomic	NOUN
chd-169	851	4	15	15	NUM
chd-169	851	5	,	,	PUNCT
chd-169	851	6	3564	3564	NUM
chd-169	851	7	-	-	SYM
chd-169	851	8	3580	3580	NUM
chd-169	851	9	.	.	PUNCT
chd-169	852	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	852	2	e28	e28	PROPN
chd-169	852	3	cancer	cancer	NOUN
chd-169	852	4	health	health	NOUN
chd-169	852	5	disparities	disparity	NOUN
chd-169	852	6	research	research	PROPN
chd-169	852	7	sanchez	sanchez	PROPN
chd-169	852	8	-	-	PUNCT
chd-169	852	9	ortiz	ortiz	PROPN
chd-169	852	10	,	,	PUNCT
chd-169	852	11	r.f	r.f	PROPN
chd-169	852	12	.	.	PROPN
chd-169	852	13	,	,	PUNCT
chd-169	852	14	troncoso	troncoso	NOUN
chd-169	852	15	,	,	PUNCT
chd-169	852	16	p.	p.	NOUN
chd-169	852	17	,	,	PUNCT
chd-169	852	18	babaian	babaian	PROPN
chd-169	852	19	,	,	PUNCT
chd-169	852	20	r.j	r.j	PROPN
chd-169	852	21	.	.	PROPN
chd-169	852	22	,	,	PUNCT
chd-169	852	23	lloreta	lloreta	PROPN
chd-169	852	24	,	,	PUNCT
chd-169	852	25	j.	j.	PROPN
chd-169	852	26	,	,	PUNCT
chd-169	852	27	johnston	johnston	PROPN
chd-169	852	28	,	,	PUNCT
chd-169	852	29	d.a	d.a	PROPN
chd-169	852	30	.	.	PROPN
chd-169	852	31	,	,	PUNCT
chd-169	852	32	and	and	CCONJ
chd-169	852	33	pettaway	pettaway	NOUN
chd-169	852	34	,	,	PUNCT
chd-169	852	35	c.a	c.a	PROPN
chd-169	852	36	.	.	PROPN
chd-169	852	37	(	(	PUNCT
chd-169	852	38	2006	2006	NUM
chd-169	852	39	)	)	PUNCT
chd-169	852	40	.	.	PUNCT
chd-169	853	1	africanamerican	africanamerican	ADJ
chd-169	853	2	men	man	NOUN
chd-169	853	3	with	with	ADP
chd-169	853	4	nonpalpable	nonpalpable	ADJ
chd-169	853	5	prostate	prostate	NOUN
chd-169	853	6	cancer	cancer	NOUN
chd-169	853	7	exhibit	exhibit	VERB
chd-169	853	8	greater	great	ADJ
chd-169	853	9	tumor	tumor	NOUN
chd-169	853	10	volume	volume	NOUN
chd-169	853	11	than	than	SCONJ
chd-169	853	12	matched	match	VERB
chd-169	853	13	white	white	ADJ
chd-169	853	14	men	man	NOUN
chd-169	853	15	.	.	PUNCT
chd-169	854	1	cancer	cancer	NOUN
chd-169	854	2	107	107	NUM
chd-169	854	3	,	,	PUNCT
chd-169	854	4	75	75	NUM
chd-169	854	5	-	-	SYM
chd-169	854	6	82	82	NUM
chd-169	854	7	.	.	PUNCT
chd-169	854	8	sartor	sartor	NOUN
chd-169	854	9	,	,	PUNCT
chd-169	854	10	o.	o.	PROPN
chd-169	854	11	,	,	PUNCT
chd-169	854	12	parker	parker	PROPN
chd-169	854	13	,	,	PUNCT
chd-169	854	14	c.c	c.c	PROPN
chd-169	854	15	.	.	PROPN
chd-169	854	16	,	,	PUNCT
chd-169	854	17	and	and	CCONJ
chd-169	854	18	de	de	X
chd-169	854	19	bono	bono	X
chd-169	854	20	,	,	PUNCT
chd-169	854	21	j.	j.	PROPN
chd-169	854	22	(	(	PUNCT
chd-169	854	23	2014	2014	NUM
chd-169	854	24	)	)	PUNCT
chd-169	854	25	.	.	PUNCT
chd-169	855	1	reappraisal	reappraisal	NOUN
chd-169	855	2	of	of	ADP
chd-169	855	3	glucocorticoids	glucocorticoid	NOUN
chd-169	855	4	in	in	ADP
chd-169	855	5	castrate	castrate	NOUN
chd-169	855	6	-	-	PUNCT
chd-169	855	7	resistant	resistant	ADJ
chd-169	855	8	prostate	prostate	NOUN
chd-169	855	9	cancer	cancer	NOUN
chd-169	855	10	.	.	PUNCT
chd-169	856	1	asian	asian	PROPN
chd-169	856	2	j	j	PROPN
chd-169	856	3	androl	androl	PROPN
chd-169	856	4	16	16	NUM
chd-169	856	5	,	,	PUNCT
chd-169	856	6	666	666	NUM
chd-169	856	7	.	.	PUNCT
chd-169	856	8	sartor	sartor	NOUN
chd-169	856	9	,	,	PUNCT
chd-169	856	10	o.	o.	PROPN
chd-169	856	11	,	,	PUNCT
chd-169	856	12	yang	yang	PROPN
chd-169	856	13	,	,	PUNCT
chd-169	856	14	s.	s.	PROPN
chd-169	856	15	,	,	PUNCT
chd-169	856	16	ledet	ledet	PROPN
chd-169	856	17	,	,	PUNCT
chd-169	856	18	e.	e.	PROPN
chd-169	856	19	,	,	PUNCT
chd-169	856	20	moses	moses	PROPN
chd-169	856	21	,	,	PUNCT
chd-169	856	22	m.	m.	NOUN
chd-169	856	23	,	,	PUNCT
chd-169	856	24	and	and	CCONJ
chd-169	856	25	nicolosi	nicolosi	NOUN
chd-169	856	26	,	,	PUNCT
chd-169	856	27	p.	p.	NOUN
chd-169	856	28	(	(	PUNCT
chd-169	856	29	2020	2020	NUM
chd-169	856	30	)	)	PUNCT
chd-169	856	31	.	.	PUNCT
chd-169	857	1	inherited	inherit	VERB
chd-169	857	2	dna	dna	NOUN
chd-169	857	3	-	-	PUNCT
chd-169	857	4	repair	repair	NOUN
chd-169	857	5	gene	gene	NOUN
chd-169	857	6	mutations	mutation	NOUN
chd-169	857	7	in	in	ADP
chd-169	857	8	african	african	ADJ
chd-169	857	9	american	american	ADJ
chd-169	857	10	men	man	NOUN
chd-169	857	11	with	with	ADP
chd-169	857	12	prostate	prostate	NOUN
chd-169	857	13	cancer	cancer	NOUN
chd-169	857	14	.	.	PUNCT
chd-169	858	1	oncotarget	oncotarget	NOUN
chd-169	858	2	11	11	NUM
chd-169	858	3	,	,	PUNCT
chd-169	858	4	440442	440442	NUM
chd-169	858	5	.	.	PUNCT
chd-169	859	1	schatzl	schatzl	PROPN
chd-169	859	2	,	,	PUNCT
chd-169	859	3	g.	g.	PROPN
chd-169	859	4	,	,	PUNCT
chd-169	859	5	madersbacher	madersbacher	NOUN
chd-169	859	6	,	,	PUNCT
chd-169	859	7	s.	s.	PROPN
chd-169	859	8	,	,	PUNCT
chd-169	859	9	haitel	haitel	PROPN
chd-169	859	10	,	,	PUNCT
chd-169	859	11	a.	a.	PROPN
chd-169	859	12	,	,	PUNCT
chd-169	859	13	gsur	gsur	PROPN
chd-169	859	14	,	,	PUNCT
chd-169	859	15	a.	a.	PROPN
chd-169	859	16	,	,	PUNCT
chd-169	859	17	preyer	preyer	NOUN
chd-169	859	18	,	,	PUNCT
chd-169	859	19	m.	m.	NOUN
chd-169	859	20	,	,	PUNCT
chd-169	859	21	haidinger	haidinger	NOUN
chd-169	859	22	,	,	PUNCT
chd-169	859	23	g.	g.	PROPN
chd-169	859	24	,	,	PUNCT
chd-169	859	25	gassner	gassner	NOUN
chd-169	859	26	,	,	PUNCT
chd-169	859	27	c.	c.	NOUN
chd-169	859	28	,	,	PUNCT
chd-169	859	29	ochsner	ochsner	NOUN
chd-169	859	30	,	,	PUNCT
chd-169	859	31	m.	m.	NOUN
chd-169	859	32	,	,	PUNCT
chd-169	859	33	and	and	CCONJ
chd-169	859	34	marberger	marberger	NOUN
chd-169	859	35	,	,	PUNCT
chd-169	859	36	m.	m.	NOUN
chd-169	859	37	(	(	PUNCT
chd-169	859	38	2003	2003	NUM
chd-169	859	39	)	)	PUNCT
chd-169	859	40	.	.	PUNCT
chd-169	860	1	associations	association	NOUN
chd-169	860	2	of	of	ADP
chd-169	860	3	serum	serum	NOUN
chd-169	860	4	testosterone	testosterone	NOUN
chd-169	860	5	with	with	ADP
chd-169	860	6	microvessel	microvessel	NOUN
chd-169	860	7	density	density	NOUN
chd-169	860	8	,	,	PUNCT
chd-169	860	9	androgen	androgen	NOUN
chd-169	860	10	receptor	receptor	NOUN
chd-169	860	11	density	density	NOUN
chd-169	860	12	and	and	CCONJ
chd-169	860	13	androgen	androgen	NOUN
chd-169	860	14	receptor	receptor	NOUN
chd-169	860	15	gene	gene	NOUN
chd-169	860	16	polymorphism	polymorphism	NOUN
chd-169	860	17	in	in	ADP
chd-169	860	18	prostate	prostate	NOUN
chd-169	860	19	cancer	cancer	NOUN
chd-169	860	20	.	.	PUNCT
chd-169	861	1	j	j	PROPN
chd-169	861	2	urol	urol	PROPN
chd-169	861	3	169	169	NUM
chd-169	861	4	,	,	PUNCT
chd-169	861	5	1312	1312	NUM
chd-169	861	6	-	-	SYM
chd-169	861	7	1315	1315	NUM
chd-169	861	8	.	.	PUNCT
chd-169	862	1	scher	scher	PROPN
chd-169	862	2	,	,	PUNCT
chd-169	862	3	h.i	h.i	PROPN
chd-169	862	4	.	.	PROPN
chd-169	862	5	,	,	PUNCT
chd-169	862	6	buchanan	buchanan	PROPN
chd-169	862	7	,	,	PUNCT
chd-169	862	8	g.	g.	PROPN
chd-169	862	9	,	,	PUNCT
chd-169	862	10	gerald	gerald	PROPN
chd-169	862	11	,	,	PUNCT
chd-169	862	12	w.	w.	PROPN
chd-169	862	13	,	,	PUNCT
chd-169	862	14	butler	butler	PROPN
chd-169	862	15	,	,	PUNCT
chd-169	862	16	l.m	l.m	PROPN
chd-169	862	17	.	.	PROPN
chd-169	862	18	,	,	PUNCT
chd-169	862	19	and	and	CCONJ
chd-169	862	20	tilley	tilley	PROPN
chd-169	862	21	,	,	PUNCT
chd-169	862	22	w.d	w.d	PROPN
chd-169	862	23	.	.	PROPN
chd-169	862	24	(	(	PUNCT
chd-169	862	25	2004	2004	NUM
chd-169	862	26	)	)	PUNCT
chd-169	862	27	.	.	PUNCT
chd-169	863	1	targeting	target	VERB
chd-169	863	2	the	the	DET
chd-169	863	3	androgen	androgen	NOUN
chd-169	863	4	receptor	receptor	NOUN
chd-169	863	5	:	:	PUNCT
chd-169	863	6	improving	improve	VERB
chd-169	863	7	outcomes	outcome	NOUN
chd-169	863	8	for	for	ADP
chd-169	863	9	castration	castration	NOUN
chd-169	863	10	-	-	PUNCT
chd-169	863	11	resistant	resistant	ADJ
chd-169	863	12	prostate	prostate	NOUN
chd-169	863	13	cancer	cancer	NOUN
chd-169	863	14	.	.	PUNCT
chd-169	864	1	endocr	endocr	PROPN
chd-169	864	2	relat	relat	PROPN
chd-169	864	3	cancer	cancer	NOUN
chd-169	864	4	11	11	NUM
chd-169	864	5	,	,	PUNCT
chd-169	864	6	459	459	NUM
chd-169	864	7	-	-	SYM
chd-169	864	8	476	476	NUM
chd-169	864	9	.	.	PUNCT
chd-169	865	1	schmid	schmid	PROPN
chd-169	865	2	,	,	PUNCT
chd-169	865	3	m.	m.	NOUN
chd-169	865	4	,	,	PUNCT
chd-169	865	5	meyer	meyer	PROPN
chd-169	865	6	,	,	PUNCT
chd-169	865	7	c.p	c.p	PROPN
chd-169	865	8	.	.	PROPN
chd-169	865	9	,	,	PUNCT
chd-169	865	10	reznor	reznor	PROPN
chd-169	865	11	,	,	PUNCT
chd-169	865	12	g.	g.	NOUN
chd-169	865	13	,	,	PUNCT
chd-169	865	14	choueiri	choueiri	NOUN
chd-169	865	15	,	,	PUNCT
chd-169	865	16	t.k	t.k	PROPN
chd-169	865	17	.	.	PROPN
chd-169	865	18	,	,	PUNCT
chd-169	865	19	hanske	hanske	PROPN
chd-169	865	20	,	,	PUNCT
chd-169	865	21	j.	j.	PROPN
chd-169	865	22	,	,	PUNCT
chd-169	865	23	sammon	sammon	PROPN
chd-169	865	24	,	,	PUNCT
chd-169	865	25	j.d	j.d	PROPN
chd-169	865	26	.	.	PROPN
chd-169	865	27	,	,	PUNCT
chd-169	865	28	abdollah	abdollah	PROPN
chd-169	865	29	,	,	PUNCT
chd-169	865	30	f.	f.	PROPN
chd-169	865	31	,	,	PUNCT
chd-169	865	32	chun	chun	PROPN
chd-169	865	33	,	,	PUNCT
chd-169	865	34	f.k	f.k	PROPN
chd-169	865	35	.	.	PROPN
chd-169	865	36	,	,	PUNCT
chd-169	865	37	kibel	kibel	PROPN
chd-169	865	38	,	,	PUNCT
chd-169	865	39	a.s	a.s	PROPN
chd-169	865	40	.	.	PROPN
chd-169	865	41	,	,	PUNCT
chd-169	865	42	tuckerseeley	tuckerseeley	NOUN
chd-169	865	43	,	,	PUNCT
chd-169	865	44	r.d	r.d	PROPN
chd-169	865	45	.	.	PROPN
chd-169	865	46	,	,	PUNCT
chd-169	865	47	et	et	PROPN
chd-169	865	48	al	al	PROPN
chd-169	865	49	.	.	PUNCT
chd-169	866	1	(	(	PUNCT
chd-169	866	2	2016	2016	NUM
chd-169	866	3	)	)	PUNCT
chd-169	866	4	.	.	PUNCT
chd-169	867	1	racial	racial	ADJ
chd-169	867	2	differences	difference	NOUN
chd-169	867	3	in	in	ADP
chd-169	867	4	the	the	DET
chd-169	867	5	surgical	surgical	ADJ
chd-169	867	6	care	care	NOUN
chd-169	867	7	of	of	ADP
chd-169	867	8	medicare	medicare	PROPN
chd-169	867	9	beneficiaries	beneficiary	NOUN
chd-169	867	10	with	with	ADP
chd-169	867	11	localized	localized	ADJ
chd-169	867	12	prostate	prostate	NOUN
chd-169	867	13	cancer	cancer	NOUN
chd-169	867	14	.	.	PUNCT
chd-169	868	1	jama	jama	PROPN
chd-169	868	2	oncol	oncol	ADJ
chd-169	868	3	2	2	NUM
chd-169	868	4	,	,	PUNCT
chd-169	868	5	85	85	NUM
chd-169	868	6	-	-	SYM
chd-169	868	7	93	93	NUM
chd-169	868	8	.	.	PUNCT
chd-169	869	1	schmid	schmid	PROPN
chd-169	869	2	,	,	PUNCT
chd-169	869	3	s.	s.	PROPN
chd-169	869	4	,	,	PUNCT
chd-169	869	5	and	and	CCONJ
chd-169	869	6	omlin	omlin	NOUN
chd-169	869	7	,	,	PUNCT
chd-169	869	8	a.	a.	NOUN
chd-169	869	9	(	(	PUNCT
chd-169	869	10	2020	2020	NUM
chd-169	869	11	)	)	PUNCT
chd-169	869	12	.	.	PUNCT
chd-169	870	1	progress	progress	NOUN
chd-169	870	2	in	in	ADP
chd-169	870	3	therapy	therapy	NOUN
chd-169	870	4	across	across	ADP
chd-169	870	5	the	the	DET
chd-169	870	6	spectrum	spectrum	NOUN
chd-169	870	7	of	of	ADP
chd-169	870	8	advanced	advanced	ADJ
chd-169	870	9	prostate	prostate	NOUN
chd-169	870	10	cancer	cancer	NOUN
chd-169	870	11	.	.	PUNCT
chd-169	871	1	nat	nat	PROPN
chd-169	871	2	rev	rev	VERB
chd-169	871	3	urol	urol	PROPN
chd-169	871	4	17	17	NUM
chd-169	871	5	,	,	PUNCT
chd-169	871	6	71	71	NUM
chd-169	871	7	-	-	SYM
chd-169	871	8	72	72	NUM
chd-169	871	9	.	.	PUNCT
chd-169	872	1	schrecengost	schrecengost	ADJ
chd-169	872	2	,	,	PUNCT
chd-169	872	3	r.	r.	PROPN
chd-169	872	4	,	,	PUNCT
chd-169	872	5	and	and	CCONJ
chd-169	872	6	knudsen	knudsen	PROPN
chd-169	872	7	,	,	PUNCT
chd-169	872	8	k.e	k.e	PROPN
chd-169	872	9	.	.	PROPN
chd-169	872	10	(	(	PUNCT
chd-169	872	11	2013	2013	NUM
chd-169	872	12	)	)	PUNCT
chd-169	872	13	.	.	PUNCT
chd-169	873	1	molecular	molecular	ADJ
chd-169	873	2	pathogenesis	pathogenesis	NOUN
chd-169	873	3	and	and	CCONJ
chd-169	873	4	progression	progression	NOUN
chd-169	873	5	of	of	ADP
chd-169	873	6	prostate	prostate	NOUN
chd-169	873	7	cancer	cancer	NOUN
chd-169	873	8	.	.	PUNCT
chd-169	874	1	semin	semin	PROPN
chd-169	874	2	oncol	oncol	PROPN
chd-169	874	3	40	40	NUM
chd-169	874	4	,	,	PUNCT
chd-169	874	5	244	244	NUM
chd-169	874	6	-	-	SYM
chd-169	874	7	258	258	NUM
chd-169	874	8	.	.	PUNCT
chd-169	875	1	schulz	schulz	PROPN
chd-169	875	2	,	,	PUNCT
chd-169	875	3	a.j	a.j	PROPN
chd-169	875	4	.	.	PROPN
chd-169	875	5	,	,	PUNCT
chd-169	875	6	williams	williams	PROPN
chd-169	875	7	,	,	PUNCT
chd-169	875	8	d.r	d.r	PROPN
chd-169	875	9	.	.	PROPN
chd-169	875	10	,	,	PUNCT
chd-169	875	11	israel	israel	PROPN
chd-169	875	12	,	,	PUNCT
chd-169	875	13	b.a	b.a	PROPN
chd-169	875	14	.	.	PROPN
chd-169	875	15	,	,	PUNCT
chd-169	875	16	and	and	CCONJ
chd-169	875	17	lempert	lempert	ADJ
chd-169	875	18	,	,	PUNCT
chd-169	875	19	l.b	l.b	PROPN
chd-169	875	20	.	.	PROPN
chd-169	875	21	(	(	PUNCT
chd-169	875	22	2002	2002	NUM
chd-169	875	23	)	)	PUNCT
chd-169	875	24	.	.	PUNCT
chd-169	876	1	racial	racial	ADJ
chd-169	876	2	and	and	CCONJ
chd-169	876	3	spatial	spatial	ADJ
chd-169	876	4	relations	relation	NOUN
chd-169	876	5	as	as	ADP
chd-169	876	6	fundamental	fundamental	ADJ
chd-169	876	7	determinants	determinant	NOUN
chd-169	876	8	of	of	ADP
chd-169	876	9	health	health	NOUN
chd-169	876	10	in	in	ADP
chd-169	876	11	detroit	detroit	PROPN
chd-169	876	12	.	.	PUNCT
chd-169	877	1	the	the	DET
chd-169	877	2	milbank	milbank	PROPN
chd-169	877	3	quarterly	quarterly	PROPN
chd-169	877	4	80	80	NUM
chd-169	877	5	,	,	PUNCT
chd-169	877	6	677	677	NUM
chd-169	877	7	-	-	SYM
chd-169	877	8	707	707	NUM
chd-169	877	9	,	,	PUNCT
chd-169	877	10	iv	iv	PROPN
chd-169	877	11	.	.	PUNCT
chd-169	877	12	schwartz	schwartz	PROPN
chd-169	877	13	,	,	PUNCT
chd-169	877	14	j.r	j.r	PROPN
chd-169	877	15	.	.	PROPN
chd-169	877	16	(	(	PUNCT
chd-169	877	17	2012	2012	NUM
chd-169	877	18	)	)	PUNCT
chd-169	877	19	.	.	PUNCT
chd-169	878	1	dexamethasone	dexamethasone	NOUN
chd-169	878	2	premedication	premedication	NOUN
chd-169	878	3	for	for	ADP
chd-169	878	4	prophylaxis	prophylaxis	NOUN
chd-169	878	5	of	of	ADP
chd-169	878	6	taxane	taxane	NOUN
chd-169	878	7	toxicities	toxicity	NOUN
chd-169	878	8	:	:	PUNCT
chd-169	878	9	can	can	AUX
chd-169	878	10	the	the	DET
chd-169	878	11	doses	dose	NOUN
chd-169	878	12	be	be	AUX
chd-169	878	13	reduced	reduce	VERB
chd-169	878	14	when	when	SCONJ
chd-169	878	15	paclitaxel	paclitaxel	PROPN
chd-169	878	16	or	or	CCONJ
chd-169	878	17	docetaxel	docetaxel	NOUN
chd-169	878	18	are	be	AUX
chd-169	878	19	given	give	VERB
chd-169	878	20	weekly	weekly	ADV
chd-169	878	21	?	?	PUNCT
chd-169	879	1	j	j	PROPN
chd-169	879	2	oncol	oncol	ADJ
chd-169	879	3	pharm	pharm	NOUN
chd-169	879	4	pract	pract	PROPN
chd-169	879	5	18	18	NUM
chd-169	879	6	,	,	PUNCT
chd-169	879	7	250	250	NUM
chd-169	879	8	-	-	SYM
chd-169	879	9	256	256	NUM
chd-169	879	10	.	.	PUNCT
chd-169	880	1	seeman	seeman	PROPN
chd-169	880	2	,	,	PUNCT
chd-169	880	3	t.e	t.e	PROPN
chd-169	880	4	.	.	PROPN
chd-169	880	5	,	,	PUNCT
chd-169	880	6	lusignolo	lusignolo	PROPN
chd-169	880	7	,	,	PUNCT
chd-169	880	8	t.m	t.m	PROPN
chd-169	880	9	.	.	PROPN
chd-169	880	10	,	,	PUNCT
chd-169	880	11	albert	albert	PROPN
chd-169	880	12	,	,	PUNCT
chd-169	880	13	m.	m.	NOUN
chd-169	880	14	,	,	PUNCT
chd-169	880	15	and	and	CCONJ
chd-169	880	16	berkman	berkman	NOUN
chd-169	880	17	,	,	PUNCT
chd-169	880	18	l.	l.	PROPN
chd-169	880	19	(	(	PUNCT
chd-169	880	20	2001	2001	NUM
chd-169	880	21	)	)	PUNCT
chd-169	880	22	.	.	PUNCT
chd-169	881	1	social	social	ADJ
chd-169	881	2	relationships	relationship	NOUN
chd-169	881	3	,	,	PUNCT
chd-169	881	4	social	social	ADJ
chd-169	881	5	support	support	NOUN
chd-169	881	6	,	,	PUNCT
chd-169	881	7	and	and	CCONJ
chd-169	881	8	patterns	pattern	NOUN
chd-169	881	9	of	of	ADP
chd-169	881	10	cognitive	cognitive	ADJ
chd-169	881	11	aging	aging	NOUN
chd-169	881	12	in	in	ADP
chd-169	881	13	healthy	healthy	ADJ
chd-169	881	14	,	,	PUNCT
chd-169	881	15	high	high	ADJ
chd-169	881	16	-	-	PUNCT
chd-169	881	17	functioning	function	VERB
chd-169	881	18	older	old	ADJ
chd-169	881	19	adults	adult	NOUN
chd-169	881	20	:	:	PUNCT
chd-169	881	21	macarthur	macarthur	NOUN
chd-169	881	22	studies	study	NOUN
chd-169	881	23	of	of	ADP
chd-169	881	24	successful	successful	ADJ
chd-169	881	25	aging	aging	NOUN
chd-169	881	26	.	.	PUNCT
chd-169	882	1	health	health	NOUN
chd-169	882	2	psychology	psychology	NOUN
chd-169	882	3	:	:	PUNCT
chd-169	882	4	official	official	ADJ
chd-169	882	5	journal	journal	NOUN
chd-169	882	6	of	of	ADP
chd-169	882	7	the	the	DET
chd-169	882	8	division	division	NOUN
chd-169	882	9	of	of	ADP
chd-169	882	10	health	health	NOUN
chd-169	882	11	psychology	psychology	NOUN
chd-169	882	12	,	,	PUNCT
chd-169	882	13	american	american	PROPN
chd-169	882	14	psychological	psychological	PROPN
chd-169	882	15	association	association	NOUN
chd-169	882	16	20	20	NUM
chd-169	882	17	,	,	PUNCT
chd-169	882	18	243255	243255	NUM
chd-169	882	19	.	.	PUNCT
chd-169	883	1	sharifi	sharifi	NOUN
chd-169	883	2	,	,	PUNCT
chd-169	883	3	n.	n.	NOUN
chd-169	883	4	(	(	PUNCT
chd-169	883	5	2013	2013	NUM
chd-169	883	6	)	)	PUNCT
chd-169	883	7	.	.	PUNCT
chd-169	884	1	mechanisms	mechanism	NOUN
chd-169	884	2	of	of	ADP
chd-169	884	3	androgen	androgen	NOUN
chd-169	884	4	receptor	receptor	NOUN
chd-169	884	5	activation	activation	NOUN
chd-169	884	6	in	in	ADP
chd-169	884	7	castration	castration	NOUN
chd-169	884	8	-	-	PUNCT
chd-169	884	9	resistant	resistant	ADJ
chd-169	884	10	prostate	prostate	NOUN
chd-169	884	11	cancer	cancer	NOUN
chd-169	884	12	.	.	PUNCT
chd-169	885	1	endocrinology	endocrinology	NOUN
chd-169	885	2	154	154	NUM
chd-169	885	3	,	,	PUNCT
chd-169	885	4	4010	4010	NUM
chd-169	885	5	-	-	SYM
chd-169	885	6	4017	4017	NUM
chd-169	885	7	.	.	PUNCT
chd-169	886	1	shavers	shaver	NOUN
chd-169	886	2	,	,	PUNCT
chd-169	886	3	v.l	v.l	PROPN
chd-169	886	4	.	.	PROPN
chd-169	886	5	,	,	PUNCT
chd-169	886	6	and	and	CCONJ
chd-169	886	7	brown	brown	ADJ
chd-169	886	8	,	,	PUNCT
chd-169	886	9	m.l	m.l	PROPN
chd-169	886	10	.	.	PUNCT
chd-169	886	11	(	(	PUNCT
chd-169	886	12	2002	2002	NUM
chd-169	886	13	)	)	PUNCT
chd-169	886	14	.	.	PUNCT
chd-169	887	1	racial	racial	ADJ
chd-169	887	2	and	and	CCONJ
chd-169	887	3	ethnic	ethnic	ADJ
chd-169	887	4	disparities	disparity	NOUN
chd-169	887	5	in	in	ADP
chd-169	887	6	the	the	DET
chd-169	887	7	receipt	receipt	NOUN
chd-169	887	8	of	of	ADP
chd-169	887	9	cancer	cancer	NOUN
chd-169	887	10	treatment	treatment	NOUN
chd-169	887	11	.	.	PUNCT
chd-169	888	1	journal	journal	NOUN
chd-169	888	2	of	of	ADP
chd-169	888	3	the	the	DET
chd-169	888	4	national	national	PROPN
chd-169	888	5	cancer	cancer	PROPN
chd-169	888	6	institute	institute	PROPN
chd-169	888	7	94	94	NUM
chd-169	888	8	,	,	PUNCT
chd-169	888	9	334	334	NUM
chd-169	888	10	-	-	SYM
chd-169	888	11	357	357	NUM
chd-169	888	12	.	.	PUNCT
chd-169	889	1	shepherd	shepherd	NOUN
chd-169	889	2	,	,	PUNCT
chd-169	889	3	s.	s.	PROPN
chd-169	889	4	(	(	PUNCT
chd-169	889	5	2018	2018	NUM
chd-169	889	6	)	)	PUNCT
chd-169	889	7	.	.	PUNCT
chd-169	890	1	study	study	NOUN
chd-169	890	2	to	to	PART
chd-169	890	3	evaluate	evaluate	VERB
chd-169	890	4	cort125281	cort125281	PROPN
chd-169	890	5	in	in	ADP
chd-169	890	6	combination	combination	NOUN
chd-169	890	7	with	with	ADP
chd-169	890	8	enzalutamide	enzalutamide	NOUN
chd-169	890	9	in	in	ADP
chd-169	890	10	patients	patient	NOUN
chd-169	890	11	with	with	ADP
chd-169	890	12	mcrpc	mcrpc	PROPN
chd-169	890	13	.	.	PUNCT
chd-169	891	1	siegel	siegel	PROPN
chd-169	891	2	,	,	PUNCT
chd-169	891	3	r.l	r.l	PROPN
chd-169	891	4	.	.	PROPN
chd-169	891	5	,	,	PUNCT
chd-169	891	6	miller	miller	PROPN
chd-169	891	7	,	,	PUNCT
chd-169	891	8	k.d	k.d	PROPN
chd-169	891	9	.	.	PROPN
chd-169	891	10	,	,	PUNCT
chd-169	891	11	and	and	CCONJ
chd-169	891	12	jemal	jemal	ADJ
chd-169	891	13	,	,	PUNCT
chd-169	891	14	a.	a.	NOUN
chd-169	891	15	(	(	PUNCT
chd-169	891	16	2020	2020	NUM
chd-169	891	17	)	)	PUNCT
chd-169	891	18	.	.	PUNCT
chd-169	892	1	cancer	cancer	NOUN
chd-169	892	2	statistics	statistic	NOUN
chd-169	892	3	,	,	PUNCT
chd-169	892	4	2020	2020	NUM
chd-169	892	5	.	.	PUNCT
chd-169	893	1	ca	can	AUX
chd-169	893	2	cancer	cancer	PROPN
chd-169	893	3	j	j	PROPN
chd-169	893	4	clin	clin	PROPN
chd-169	893	5	70	70	NUM
chd-169	893	6	,	,	PUNCT
chd-169	893	7	7	7	NUM
chd-169	893	8	-	-	SYM
chd-169	893	9	30	30	NUM
chd-169	893	10	.	.	PUNCT
chd-169	894	1	silver	silver	NOUN
chd-169	894	2	,	,	PUNCT
chd-169	894	3	d.a	d.a	PROPN
chd-169	894	4	.	.	PROPN
chd-169	894	5	,	,	PUNCT
chd-169	894	6	pellicer	pellicer	PROPN
chd-169	894	7	,	,	PUNCT
chd-169	894	8	i.	i.	NOUN
chd-169	894	9	,	,	PUNCT
chd-169	894	10	fair	fair	ADJ
chd-169	894	11	,	,	PUNCT
chd-169	894	12	w.r	w.r	PROPN
chd-169	894	13	.	.	PROPN
chd-169	894	14	,	,	PUNCT
chd-169	894	15	heston	heston	PROPN
chd-169	894	16	,	,	PUNCT
chd-169	894	17	w.d	w.d	PROPN
chd-169	894	18	.	.	PROPN
chd-169	894	19	,	,	PUNCT
chd-169	894	20	and	and	CCONJ
chd-169	894	21	cordoncardo	cordoncardo	PROPN
chd-169	894	22	,	,	PUNCT
chd-169	894	23	c.	c.	PROPN
chd-169	894	24	(	(	PUNCT
chd-169	894	25	1997	1997	NUM
chd-169	894	26	)	)	PUNCT
chd-169	894	27	.	.	PUNCT
chd-169	895	1	prostate	prostate	NOUN
chd-169	895	2	-	-	PUNCT
chd-169	895	3	specific	specific	ADJ
chd-169	895	4	membrane	membrane	NOUN
chd-169	895	5	antigen	antigen	NOUN
chd-169	895	6	expression	expression	NOUN
chd-169	895	7	in	in	ADP
chd-169	895	8	normal	normal	ADJ
chd-169	895	9	and	and	CCONJ
chd-169	895	10	malignant	malignant	ADJ
chd-169	895	11	human	human	ADJ
chd-169	895	12	tissues	tissue	NOUN
chd-169	895	13	.	.	PUNCT
chd-169	896	1	clinical	clinical	ADJ
chd-169	896	2	cancer	cancer	NOUN
chd-169	896	3	research	research	NOUN
chd-169	896	4	:	:	PUNCT
chd-169	896	5	an	an	DET
chd-169	896	6	official	official	ADJ
chd-169	896	7	journal	journal	NOUN
chd-169	896	8	of	of	ADP
chd-169	896	9	the	the	DET
chd-169	896	10	american	american	PROPN
chd-169	896	11	association	association	PROPN
chd-169	896	12	for	for	ADP
chd-169	896	13	cancer	cancer	NOUN
chd-169	896	14	research	research	NOUN
chd-169	896	15	3	3	NUM
chd-169	896	16	,	,	PUNCT
chd-169	896	17	81	81	NUM
chd-169	896	18	-	-	SYM
chd-169	896	19	85	85	NUM
chd-169	896	20	.	.	PUNCT
chd-169	897	1	singh	singh	PROPN
chd-169	897	2	,	,	PUNCT
chd-169	897	3	g.k	g.k	PROPN
chd-169	897	4	.	.	PROPN
chd-169	897	5	,	,	PUNCT
chd-169	897	6	and	and	CCONJ
chd-169	897	7	jemal	jemal	ADJ
chd-169	897	8	,	,	PUNCT
chd-169	897	9	a.	a.	NOUN
chd-169	897	10	(	(	PUNCT
chd-169	897	11	2017	2017	NUM
chd-169	897	12	)	)	PUNCT
chd-169	897	13	.	.	PUNCT
chd-169	898	1	socioeconomic	socioeconomic	ADJ
chd-169	898	2	and	and	CCONJ
chd-169	898	3	racial	racial	ADJ
chd-169	898	4	/	/	SYM
chd-169	898	5	ethnic	ethnic	ADJ
chd-169	898	6	disparities	disparity	NOUN
chd-169	898	7	in	in	ADP
chd-169	898	8	cancer	cancer	NOUN
chd-169	898	9	mortality	mortality	NOUN
chd-169	898	10	,	,	PUNCT
chd-169	898	11	incidence	incidence	NOUN
chd-169	898	12	,	,	PUNCT
chd-169	898	13	and	and	CCONJ
chd-169	898	14	survival	survival	NOUN
chd-169	898	15	in	in	ADP
chd-169	898	16	the	the	DET
chd-169	898	17	united	united	PROPN
chd-169	898	18	states	states	PROPN
chd-169	898	19	,	,	PUNCT
chd-169	898	20	1950	1950	NUM
chd-169	898	21	-	-	SYM
chd-169	898	22	2014	2014	NUM
chd-169	898	23	:	:	PUNCT
chd-169	898	24	over	over	ADP
chd-169	898	25	six	six	NUM
chd-169	898	26	decades	decade	NOUN
chd-169	898	27	of	of	ADP
chd-169	898	28	changing	change	VERB
chd-169	898	29	patterns	pattern	NOUN
chd-169	898	30	and	and	CCONJ
chd-169	898	31	widening	widen	VERB
chd-169	898	32	inequalities	inequality	NOUN
chd-169	898	33	.	.	PUNCT
chd-169	899	1	j	j	PROPN
chd-169	899	2	environ	environ	PROPN
chd-169	899	3	public	public	PROPN
chd-169	899	4	health	health	PROPN
chd-169	899	5	2017	2017	NUM
chd-169	899	6	,	,	PUNCT
chd-169	899	7	2819372	2819372	NUM
chd-169	899	8	.	.	PUNCT
chd-169	900	1	singh	singh	PROPN
chd-169	900	2	,	,	PUNCT
chd-169	900	3	m.	m.	NOUN
chd-169	900	4	,	,	PUNCT
chd-169	900	5	jha	jha	PROPN
chd-169	900	6	,	,	PUNCT
chd-169	900	7	r.	r.	PROPN
chd-169	900	8	,	,	PUNCT
chd-169	900	9	melamed	melamed	PROPN
chd-169	900	10	,	,	PUNCT
chd-169	900	11	j.	j.	PROPN
chd-169	900	12	,	,	PUNCT
chd-169	900	13	shapiro	shapiro	PROPN
chd-169	900	14	,	,	PUNCT
chd-169	900	15	e.	e.	PROPN
chd-169	900	16	,	,	PUNCT
chd-169	900	17	hayward	hayward	PROPN
chd-169	900	18	,	,	PUNCT
chd-169	900	19	s.w	s.w	PROPN
chd-169	900	20	.	.	PROPN
chd-169	900	21	,	,	PUNCT
chd-169	900	22	and	and	CCONJ
chd-169	900	23	lee	lee	PROPN
chd-169	900	24	,	,	PUNCT
chd-169	900	25	p.	p.	PROPN
chd-169	900	26	(	(	PUNCT
chd-169	900	27	2014	2014	NUM
chd-169	900	28	)	)	PUNCT
chd-169	900	29	.	.	PUNCT
chd-169	901	1	stromal	stromal	ADJ
chd-169	901	2	androgen	androgen	NOUN
chd-169	901	3	receptor	receptor	NOUN
chd-169	901	4	in	in	ADP
chd-169	901	5	prostate	prostate	NOUN
chd-169	901	6	development	development	NOUN
chd-169	901	7	and	and	CCONJ
chd-169	901	8	cancer	cancer	NOUN
chd-169	901	9	.	.	PUNCT
chd-169	902	1	am	be	AUX
chd-169	902	2	j	j	PROPN
chd-169	902	3	pathol	pathol	NOUN
chd-169	902	4	184	184	NUM
chd-169	902	5	,	,	PUNCT
chd-169	902	6	2598	2598	NUM
chd-169	902	7	-	-	SYM
chd-169	902	8	2607	2607	NUM
chd-169	902	9	.	.	PUNCT
chd-169	903	1	singh	singh	PROPN
chd-169	903	2	,	,	PUNCT
chd-169	903	3	s.k	s.k	PROPN
chd-169	903	4	.	.	PROPN
chd-169	903	5	,	,	PUNCT
chd-169	903	6	lillard	lillard	PROPN
chd-169	903	7	,	,	PUNCT
chd-169	903	8	j.w	j.w	PROPN
chd-169	903	9	.	.	PROPN
chd-169	903	10	,	,	PUNCT
chd-169	903	11	jr	jr	PROPN
chd-169	903	12	.	.	PROPN
chd-169	903	13	,	,	PUNCT
chd-169	903	14	and	and	CCONJ
chd-169	903	15	singh	singh	PROPN
chd-169	903	16	,	,	PUNCT
chd-169	903	17	r.	r.	PROPN
chd-169	903	18	(	(	PUNCT
chd-169	903	19	2017	2017	NUM
chd-169	903	20	)	)	PUNCT
chd-169	903	21	.	.	PUNCT
chd-169	904	1	molecular	molecular	ADJ
chd-169	904	2	basis	basis	NOUN
chd-169	904	3	for	for	ADP
chd-169	904	4	prostate	prostate	NOUN
chd-169	904	5	cancer	cancer	NOUN
chd-169	904	6	racial	racial	ADJ
chd-169	904	7	disparities	disparity	NOUN
chd-169	904	8	.	.	PUNCT
chd-169	905	1	front	front	ADJ
chd-169	905	2	biosci	biosci	PROPN
chd-169	905	3	(	(	PUNCT
chd-169	905	4	landmark	landmark	PROPN
chd-169	905	5	ed	ed	NOUN
chd-169	905	6	)	)	PUNCT
chd-169	905	7	22	22	NUM
chd-169	905	8	,	,	PUNCT
chd-169	905	9	428	428	NUM
chd-169	905	10	-	-	SYM
chd-169	905	11	450	450	NUM
chd-169	905	12	.	.	PUNCT
chd-169	906	1	stephens	stephens	PROPN
chd-169	906	2	,	,	PUNCT
chd-169	906	3	m.a	m.a	PROPN
chd-169	906	4	.	.	PROPN
chd-169	906	5	,	,	PUNCT
chd-169	906	6	and	and	CCONJ
chd-169	906	7	wand	wand	NOUN
chd-169	906	8	,	,	PUNCT
chd-169	906	9	g.	g.	PROPN
chd-169	906	10	(	(	PUNCT
chd-169	906	11	2012	2012	NUM
chd-169	906	12	)	)	PUNCT
chd-169	906	13	.	.	PUNCT
chd-169	907	1	stress	stress	NOUN
chd-169	907	2	and	and	CCONJ
chd-169	907	3	the	the	DET
chd-169	907	4	hpa	hpa	NOUN
chd-169	907	5	axis	axis	NOUN
chd-169	907	6	:	:	PUNCT
chd-169	907	7	role	role	NOUN
chd-169	907	8	of	of	ADP
chd-169	907	9	glucocorticoids	glucocorticoid	NOUN
chd-169	907	10	in	in	ADP
chd-169	907	11	alcohol	alcohol	NOUN
chd-169	907	12	dependence	dependence	NOUN
chd-169	907	13	.	.	PUNCT
chd-169	908	1	alcohol	alcohol	NOUN
chd-169	908	2	res	re	NOUN
chd-169	908	3	34	34	NUM
chd-169	908	4	,	,	PUNCT
chd-169	908	5	468	468	NUM
chd-169	908	6	-	-	SYM
chd-169	908	7	483	483	NUM
chd-169	908	8	.	.	PUNCT
chd-169	909	1	steptoe	steptoe	PROPN
chd-169	909	2	,	,	PUNCT
chd-169	909	3	a.	a.	NOUN
chd-169	909	4	,	,	PUNCT
chd-169	909	5	cropley	cropley	NOUN
chd-169	909	6	,	,	PUNCT
chd-169	909	7	m.	m.	NOUN
chd-169	909	8	,	,	PUNCT
chd-169	909	9	griffith	griffith	PROPN
chd-169	909	10	,	,	PUNCT
chd-169	909	11	j.	j.	PROPN
chd-169	909	12	,	,	PUNCT
chd-169	909	13	and	and	CCONJ
chd-169	909	14	kirschbaum	kirschbaum	PROPN
chd-169	909	15	,	,	PUNCT
chd-169	909	16	c.	c.	PROPN
chd-169	909	17	(	(	PUNCT
chd-169	909	18	2000	2000	NUM
chd-169	909	19	)	)	PUNCT
chd-169	909	20	.	.	PUNCT
chd-169	910	1	job	job	NOUN
chd-169	910	2	strain	strain	NOUN
chd-169	910	3	and	and	CCONJ
chd-169	910	4	anger	anger	NOUN
chd-169	910	5	expression	expression	NOUN
chd-169	910	6	predict	predict	VERB
chd-169	910	7	early	early	ADJ
chd-169	910	8	morning	morning	NOUN
chd-169	910	9	elevations	elevation	NOUN
chd-169	910	10	in	in	ADP
chd-169	910	11	salivary	salivary	ADJ
chd-169	910	12	cortisol	cortisol	NOUN
chd-169	910	13	.	.	PUNCT
chd-169	911	1	psychosom	psychosom	PROPN
chd-169	911	2	med	med	PROPN
chd-169	911	3	62	62	NUM
chd-169	911	4	,	,	PUNCT
chd-169	911	5	286292	286292	NUM
chd-169	911	6	.	.	PUNCT
chd-169	912	1	strahle	strahle	PROPN
chd-169	912	2	,	,	PUNCT
chd-169	912	3	u.	u.	PROPN
chd-169	912	4	,	,	PUNCT
chd-169	912	5	klock	klock	PROPN
chd-169	912	6	,	,	PUNCT
chd-169	912	7	g.	g.	PROPN
chd-169	912	8	,	,	PUNCT
chd-169	912	9	and	and	CCONJ
chd-169	912	10	schutz	schutz	ADJ
chd-169	912	11	,	,	PUNCT
chd-169	912	12	g.	g.	PROPN
chd-169	912	13	(	(	PUNCT
chd-169	912	14	1987	1987	NUM
chd-169	912	15	)	)	PUNCT
chd-169	912	16	.	.	PUNCT
chd-169	913	1	a	a	DET
chd-169	913	2	dna	dna	PROPN
chd-169	913	3	sequence	sequence	NOUN
chd-169	913	4	of	of	ADP
chd-169	913	5	15	15	NUM
chd-169	913	6	base	base	NOUN
chd-169	913	7	pairs	pair	NOUN
chd-169	913	8	is	be	AUX
chd-169	913	9	sufficient	sufficient	ADJ
chd-169	913	10	to	to	PART
chd-169	913	11	mediate	mediate	VERB
chd-169	913	12	both	both	CCONJ
chd-169	913	13	glucocorticoid	glucocorticoid	ADJ
chd-169	913	14	and	and	CCONJ
chd-169	913	15	progesterone	progesterone	NOUN
chd-169	913	16	induction	induction	NOUN
chd-169	913	17	of	of	ADP
chd-169	913	18	gene	gene	NOUN
chd-169	913	19	expression	expression	NOUN
chd-169	913	20	.	.	PUNCT
chd-169	914	1	proceedings	proceeding	NOUN
chd-169	914	2	of	of	ADP
chd-169	914	3	the	the	DET
chd-169	914	4	national	national	PROPN
chd-169	914	5	academy	academy	PROPN
chd-169	914	6	of	of	ADP
chd-169	914	7	sciences	sciences	PROPN
chd-169	914	8	of	of	ADP
chd-169	914	9	the	the	DET
chd-169	914	10	united	united	PROPN
chd-169	914	11	states	states	PROPN
chd-169	914	12	of	of	ADP
chd-169	914	13	america	america	PROPN
chd-169	914	14	84	84	NUM
chd-169	914	15	,	,	PUNCT
chd-169	914	16	7871	7871	NUM
chd-169	914	17	-	-	SYM
chd-169	914	18	7875	7875	NUM
chd-169	914	19	.	.	PUNCT
chd-169	915	1	sundi	sundi	PROPN
chd-169	915	2	,	,	PUNCT
chd-169	915	3	d.	d.	PROPN
chd-169	915	4	,	,	PUNCT
chd-169	915	5	ross	ross	PROPN
chd-169	915	6	,	,	PUNCT
chd-169	915	7	a.e	a.e	PROPN
chd-169	915	8	.	.	PROPN
chd-169	915	9	,	,	PUNCT
chd-169	915	10	humphreys	humphreys	PROPN
chd-169	915	11	,	,	PUNCT
chd-169	915	12	e.b	e.b	PROPN
chd-169	915	13	.	.	PROPN
chd-169	915	14	,	,	PUNCT
chd-169	915	15	han	han	PROPN
chd-169	915	16	,	,	PUNCT
chd-169	915	17	m.	m.	NOUN
chd-169	915	18	,	,	PUNCT
chd-169	915	19	partin	partin	PROPN
chd-169	915	20	,	,	PUNCT
chd-169	915	21	a.w	a.w	PROPN
chd-169	915	22	.	.	PROPN
chd-169	915	23	,	,	PUNCT
chd-169	915	24	carter	carter	PROPN
chd-169	915	25	,	,	PUNCT
chd-169	915	26	h.b	h.b	PROPN
chd-169	915	27	.	.	PROPN
chd-169	915	28	,	,	PUNCT
chd-169	915	29	and	and	CCONJ
chd-169	915	30	schaeffer	schaeffer	PROPN
chd-169	915	31	,	,	PUNCT
chd-169	915	32	e.m	e.m	PROPN
chd-169	915	33	.	.	PROPN
chd-169	915	34	(	(	PUNCT
chd-169	915	35	2013	2013	NUM
chd-169	915	36	)	)	PUNCT
chd-169	915	37	.	.	PUNCT
chd-169	916	1	african	african	ADJ
chd-169	916	2	american	american	ADJ
chd-169	916	3	men	man	NOUN
chd-169	916	4	with	with	ADP
chd-169	916	5	very	very	ADV
chd-169	916	6	low	low	ADJ
chd-169	916	7	-	-	PUNCT
chd-169	916	8	risk	risk	NOUN
chd-169	916	9	prostate	prostate	NOUN
chd-169	916	10	cancer	cancer	NOUN
chd-169	916	11	exhibit	exhibit	VERB
chd-169	916	12	adverse	adverse	ADJ
chd-169	916	13	oncologic	oncologic	NOUN
chd-169	916	14	outcomes	outcome	NOUN
chd-169	916	15	after	after	ADP
chd-169	916	16	radical	radical	ADJ
chd-169	916	17	prostatectomy	prostatectomy	NOUN
chd-169	916	18	:	:	PUNCT
chd-169	916	19	should	should	AUX
chd-169	916	20	active	active	ADJ
chd-169	916	21	surveillance	surveillance	NOUN
chd-169	916	22	still	still	ADV
chd-169	916	23	be	be	VERB
chd-169	916	24	an	an	DET
chd-169	916	25	option	option	NOUN
chd-169	916	26	for	for	ADP
chd-169	916	27	them	they	PRON
chd-169	916	28	?	?	PUNCT
chd-169	917	1	journal	journal	NOUN
chd-169	917	2	of	of	ADP
chd-169	917	3	clinical	clinical	ADJ
chd-169	917	4	oncology	oncology	NOUN
chd-169	917	5	:	:	PUNCT
chd-169	917	6	official	official	ADJ
chd-169	917	7	journal	journal	NOUN
chd-169	917	8	of	of	ADP
chd-169	917	9	the	the	DET
chd-169	917	10	american	american	ADJ
chd-169	917	11	society	society	NOUN
chd-169	917	12	of	of	ADP
chd-169	917	13	clinical	clinical	ADJ
chd-169	917	14	oncology	oncology	NOUN
chd-169	917	15	31	31	NUM
chd-169	917	16	,	,	PUNCT
chd-169	917	17	2991	2991	NUM
chd-169	917	18	-	-	SYM
chd-169	917	19	2997	2997	NUM
chd-169	917	20	.	.	PUNCT
chd-169	918	1	surjit	surjit	PROPN
chd-169	918	2	,	,	PUNCT
chd-169	918	3	m.	m.	NOUN
chd-169	918	4	,	,	PUNCT
chd-169	918	5	ganti	ganti	PROPN
chd-169	918	6	,	,	PUNCT
chd-169	918	7	k.p	k.p	PROPN
chd-169	918	8	.	.	PROPN
chd-169	918	9	,	,	PUNCT
chd-169	918	10	mukherji	mukherji	PROPN
chd-169	918	11	,	,	PUNCT
chd-169	918	12	a.	a.	NOUN
chd-169	918	13	,	,	PUNCT
chd-169	918	14	ye	ye	PRON
chd-169	918	15	,	,	PUNCT
chd-169	918	16	t.	t.	PROPN
chd-169	918	17	,	,	PUNCT
chd-169	918	18	hua	hua	PROPN
chd-169	918	19	,	,	PUNCT
chd-169	918	20	g.	g.	PROPN
chd-169	918	21	,	,	PUNCT
chd-169	918	22	metzger	metzger	PROPN
chd-169	918	23	,	,	PUNCT
chd-169	918	24	d.	d.	PROPN
chd-169	918	25	,	,	PUNCT
chd-169	918	26	li	li	PROPN
chd-169	918	27	,	,	PUNCT
chd-169	918	28	m.	m.	NOUN
chd-169	918	29	,	,	PUNCT
chd-169	918	30	and	and	CCONJ
chd-169	918	31	chambon	chambon	NOUN
chd-169	918	32	,	,	PUNCT
chd-169	918	33	p.	p.	NOUN
chd-169	918	34	(	(	PUNCT
chd-169	918	35	2011	2011	NUM
chd-169	918	36	)	)	PUNCT
chd-169	918	37	.	.	PUNCT
chd-169	919	1	widespread	widespread	ADJ
chd-169	919	2	negative	negative	ADJ
chd-169	919	3	response	response	NOUN
chd-169	919	4	elements	element	NOUN
chd-169	919	5	mediate	mediate	VERB
chd-169	919	6	direct	direct	ADJ
chd-169	919	7	repression	repression	NOUN
chd-169	919	8	by	by	ADP
chd-169	919	9	agonistliganded	agonistligande	VERB
chd-169	919	10	glucocorticoid	glucocorticoid	ADJ
chd-169	919	11	receptor	receptor	NOUN
chd-169	919	12	.	.	PUNCT
chd-169	920	1	cell	cell	NOUN
chd-169	920	2	145	145	NUM
chd-169	920	3	,	,	PUNCT
chd-169	920	4	224	224	NUM
chd-169	920	5	-	-	SYM
chd-169	920	6	241	241	NUM
chd-169	920	7	.	.	PUNCT
chd-169	921	1	tammemagi	tammemagi	PROPN
chd-169	921	2	,	,	PUNCT
chd-169	921	3	c.m	c.m	PROPN
chd-169	921	4	.	.	PROPN
chd-169	921	5	,	,	PUNCT
chd-169	921	6	nerenz	nerenz	PROPN
chd-169	921	7	,	,	PUNCT
chd-169	921	8	d.	d.	PROPN
chd-169	921	9	,	,	PUNCT
chd-169	921	10	neslund	neslund	NOUN
chd-169	921	11	-	-	PUNCT
chd-169	921	12	dudas	dudas	PROPN
chd-169	921	13	,	,	PUNCT
chd-169	921	14	c.	c.	PROPN
chd-169	921	15	,	,	PUNCT
chd-169	921	16	feldkamp	feldkamp	PROPN
chd-169	921	17	,	,	PUNCT
chd-169	921	18	c.	c.	NOUN
chd-169	921	19	,	,	PUNCT
chd-169	921	20	and	and	CCONJ
chd-169	921	21	nathanson	nathanson	PROPN
chd-169	921	22	,	,	PUNCT
chd-169	921	23	d.	d.	PROPN
chd-169	921	24	(	(	PUNCT
chd-169	921	25	2005	2005	NUM
chd-169	921	26	)	)	PUNCT
chd-169	921	27	.	.	PUNCT
chd-169	922	1	comorbidity	comorbidity	NOUN
chd-169	922	2	and	and	CCONJ
chd-169	922	3	survival	survival	NOUN
chd-169	922	4	disparities	disparity	NOUN
chd-169	922	5	among	among	ADP
chd-169	922	6	black	black	ADJ
chd-169	922	7	and	and	CCONJ
chd-169	922	8	white	white	ADJ
chd-169	922	9	patients	patient	NOUN
chd-169	922	10	with	with	ADP
chd-169	922	11	breast	breast	NOUN
chd-169	922	12	cancer	cancer	NOUN
chd-169	922	13	.	.	PUNCT
chd-169	923	1	jama	jama	PROPN
chd-169	923	2	294	294	NUM
chd-169	923	3	,	,	PUNCT
chd-169	923	4	1765	1765	NUM
chd-169	923	5	-	-	SYM
chd-169	923	6	1772	1772	NUM
chd-169	923	7	.	.	PUNCT
chd-169	924	1	tannock	tannock	PROPN
chd-169	924	2	,	,	PUNCT
chd-169	924	3	i.	i.	PROPN
chd-169	924	4	,	,	PUNCT
chd-169	924	5	gospodarowicz	gospodarowicz	NOUN
chd-169	924	6	,	,	PUNCT
chd-169	924	7	m.	m.	NOUN
chd-169	924	8	,	,	PUNCT
chd-169	924	9	meakin	meakin	PROPN
chd-169	924	10	,	,	PUNCT
chd-169	924	11	w.	w.	PROPN
chd-169	924	12	,	,	PUNCT
chd-169	924	13	panzarella	panzarella	PROPN
chd-169	924	14	,	,	PUNCT
chd-169	924	15	t.	t.	PROPN
chd-169	924	16	,	,	PUNCT
chd-169	924	17	stewart	stewart	PROPN
chd-169	924	18	,	,	PUNCT
chd-169	924	19	l.	l.	PROPN
chd-169	924	20	,	,	PUNCT
chd-169	924	21	and	and	CCONJ
chd-169	924	22	rider	rider	NOUN
chd-169	924	23	,	,	PUNCT
chd-169	924	24	w.	w.	NOUN
chd-169	924	25	(	(	PUNCT
chd-169	924	26	1989	1989	NUM
chd-169	924	27	)	)	PUNCT
chd-169	924	28	.	.	PUNCT
chd-169	925	1	treatment	treatment	NOUN
chd-169	925	2	of	of	ADP
chd-169	925	3	metastatic	metastatic	ADJ
chd-169	925	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PUNCT
chd-169	925	5	e29	e29	PROPN
chd-169	925	6	cancer	cancer	NOUN
chd-169	925	7	health	health	NOUN
chd-169	925	8	disparities	disparity	NOUN
chd-169	925	9	research	research	VERB
chd-169	925	10	prostatic	prostatic	ADJ
chd-169	925	11	cancer	cancer	NOUN
chd-169	925	12	with	with	ADP
chd-169	925	13	low	low	ADJ
chd-169	925	14	-	-	PUNCT
chd-169	925	15	dose	dose	NOUN
chd-169	925	16	prednisone	prednisone	NOUN
chd-169	925	17	:	:	PUNCT
chd-169	925	18	evaluation	evaluation	NOUN
chd-169	925	19	of	of	ADP
chd-169	925	20	pain	pain	NOUN
chd-169	925	21	and	and	CCONJ
chd-169	925	22	quality	quality	NOUN
chd-169	925	23	of	of	ADP
chd-169	925	24	life	life	NOUN
chd-169	925	25	as	as	ADP
chd-169	925	26	pragmatic	pragmatic	ADJ
chd-169	925	27	indices	index	NOUN
chd-169	925	28	of	of	ADP
chd-169	925	29	response	response	NOUN
chd-169	925	30	.	.	PUNCT
chd-169	926	1	j	j	PROPN
chd-169	926	2	clin	clin	PROPN
chd-169	926	3	oncol	oncol	PROPN
chd-169	926	4	7	7	NUM
chd-169	926	5	,	,	PUNCT
chd-169	926	6	590	590	NUM
chd-169	926	7	-	-	SYM
chd-169	926	8	597	597	NUM
chd-169	926	9	.	.	PUNCT
chd-169	926	10	tannock	tannock	PROPN
chd-169	926	11	,	,	PUNCT
chd-169	926	12	i.f	i.f	PROPN
chd-169	926	13	.	.	PROPN
chd-169	926	14	,	,	PUNCT
chd-169	926	15	de	de	PROPN
chd-169	926	16	wit	wit	PROPN
chd-169	926	17	,	,	PUNCT
chd-169	926	18	r.	r.	PROPN
chd-169	926	19	,	,	PUNCT
chd-169	926	20	berry	berry	NOUN
chd-169	926	21	,	,	PUNCT
chd-169	926	22	w.r	w.r	PROPN
chd-169	926	23	.	.	PROPN
chd-169	926	24	,	,	PUNCT
chd-169	926	25	horti	horti	PROPN
chd-169	926	26	,	,	PUNCT
chd-169	926	27	j.	j.	PROPN
chd-169	926	28	,	,	PUNCT
chd-169	926	29	pluzanska	pluzanska	PROPN
chd-169	926	30	,	,	PUNCT
chd-169	926	31	a.	a.	NOUN
chd-169	926	32	,	,	PUNCT
chd-169	926	33	chi	chi	PROPN
chd-169	926	34	,	,	PUNCT
chd-169	926	35	k.n	k.n	PROPN
chd-169	926	36	.	.	PROPN
chd-169	926	37	,	,	PUNCT
chd-169	926	38	oudard	oudard	ADJ
chd-169	926	39	,	,	PUNCT
chd-169	926	40	s.	s.	PROPN
chd-169	926	41	,	,	PUNCT
chd-169	926	42	theodore	theodore	PROPN
chd-169	926	43	,	,	PUNCT
chd-169	926	44	c.	c.	PROPN
chd-169	926	45	,	,	PUNCT
chd-169	926	46	james	james	PROPN
chd-169	926	47	,	,	PUNCT
chd-169	926	48	n.d	n.d	PROPN
chd-169	926	49	.	.	PROPN
chd-169	926	50	,	,	PUNCT
chd-169	926	51	turesson	turesson	PROPN
chd-169	926	52	,	,	PUNCT
chd-169	926	53	i.	i.	PROPN
chd-169	926	54	,	,	PUNCT
chd-169	926	55	et	et	PROPN
chd-169	926	56	al	al	PROPN
chd-169	926	57	.	.	PROPN
chd-169	927	1	(	(	PUNCT
chd-169	927	2	2004	2004	NUM
chd-169	927	3	)	)	PUNCT
chd-169	927	4	.	.	PUNCT
chd-169	928	1	docetaxel	docetaxel	PROPN
chd-169	928	2	plus	plus	CCONJ
chd-169	928	3	prednisone	prednisone	PROPN
chd-169	928	4	or	or	CCONJ
chd-169	928	5	mitoxantrone	mitoxantrone	NOUN
chd-169	928	6	plus	plus	CCONJ
chd-169	928	7	prednisone	prednisone	NOUN
chd-169	928	8	for	for	ADP
chd-169	928	9	advanced	advanced	ADJ
chd-169	928	10	prostate	prostate	NOUN
chd-169	928	11	cancer	cancer	NOUN
chd-169	928	12	.	.	PUNCT
chd-169	929	1	n	n	PROPN
chd-169	929	2	engl	engl	PROPN
chd-169	929	3	j	j	PROPN
chd-169	929	4	med	med	PROPN
chd-169	929	5	351	351	NUM
chd-169	929	6	,	,	PUNCT
chd-169	929	7	1502	1502	NUM
chd-169	929	8	-	-	SYM
chd-169	929	9	1512	1512	NUM
chd-169	929	10	.	.	PUNCT
chd-169	930	1	taylor	taylor	PROPN
chd-169	930	2	,	,	PUNCT
chd-169	930	3	r.a	r.a	PROPN
chd-169	930	4	.	.	PROPN
chd-169	930	5	,	,	PUNCT
chd-169	930	6	and	and	CCONJ
chd-169	930	7	risbridger	risbridger	NOUN
chd-169	930	8	,	,	PUNCT
chd-169	930	9	g.p	g.p	PROPN
chd-169	930	10	.	.	PROPN
chd-169	930	11	(	(	PUNCT
chd-169	930	12	2008	2008	NUM
chd-169	930	13	)	)	PUNCT
chd-169	930	14	.	.	PUNCT
chd-169	931	1	prostatic	prostatic	ADJ
chd-169	931	2	tumor	tumor	NOUN
chd-169	931	3	stroma	stroma	NOUN
chd-169	931	4	:	:	PUNCT
chd-169	931	5	a	a	DET
chd-169	931	6	key	key	ADJ
chd-169	931	7	player	player	NOUN
chd-169	931	8	in	in	ADP
chd-169	931	9	cancer	cancer	NOUN
chd-169	931	10	progression	progression	NOUN
chd-169	931	11	.	.	PUNCT
chd-169	932	1	curr	curr	PROPN
chd-169	932	2	cancer	cancer	NOUN
chd-169	932	3	drug	drug	NOUN
chd-169	932	4	targets	target	NOUN
chd-169	932	5	8	8	NUM
chd-169	932	6	,	,	PUNCT
chd-169	932	7	490	490	NUM
chd-169	932	8	-	-	SYM
chd-169	932	9	497	497	NUM
chd-169	932	10	.	.	PUNCT
chd-169	933	1	thames	thames	PROPN
chd-169	933	2	,	,	PUNCT
chd-169	933	3	a.d	a.d	PROPN
chd-169	933	4	.	.	PROPN
chd-169	933	5	,	,	PUNCT
chd-169	933	6	irwin	irwin	PROPN
chd-169	933	7	,	,	PUNCT
chd-169	933	8	m.r	m.r	PROPN
chd-169	933	9	.	.	PROPN
chd-169	933	10	,	,	PUNCT
chd-169	933	11	breen	breen	PROPN
chd-169	933	12	,	,	PUNCT
chd-169	933	13	e.c	e.c	PROPN
chd-169	933	14	.	.	PROPN
chd-169	933	15	,	,	PUNCT
chd-169	933	16	and	and	CCONJ
chd-169	933	17	cole	cole	PROPN
chd-169	933	18	,	,	PUNCT
chd-169	933	19	s.w	s.w	PROPN
chd-169	933	20	.	.	PROPN
chd-169	933	21	(	(	PUNCT
chd-169	933	22	2019	2019	NUM
chd-169	933	23	)	)	PUNCT
chd-169	933	24	.	.	PUNCT
chd-169	934	1	experienced	experience	VERB
chd-169	934	2	discrimination	discrimination	NOUN
chd-169	934	3	and	and	CCONJ
chd-169	934	4	racial	racial	ADJ
chd-169	934	5	differences	difference	NOUN
chd-169	934	6	in	in	ADP
chd-169	934	7	leukocyte	leukocyte	ADJ
chd-169	934	8	gene	gene	NOUN
chd-169	934	9	expression	expression	NOUN
chd-169	934	10	.	.	PUNCT
chd-169	935	1	psychoneuroendocrinology	psychoneuroendocrinology	NOUN
chd-169	935	2	106	106	NUM
chd-169	935	3	,	,	PUNCT
chd-169	935	4	277	277	NUM
chd-169	935	5	-	-	SYM
chd-169	935	6	283	283	NUM
chd-169	935	7	.	.	PUNCT
chd-169	936	1	thomassin	thomassin	PROPN
chd-169	936	2	,	,	PUNCT
chd-169	936	3	h.	h.	PROPN
chd-169	936	4	,	,	PUNCT
chd-169	936	5	flavin	flavin	NOUN
chd-169	936	6	,	,	PUNCT
chd-169	936	7	m.	m.	NOUN
chd-169	936	8	,	,	PUNCT
chd-169	936	9	espinas	espinas	PROPN
chd-169	936	10	,	,	PUNCT
chd-169	936	11	m.l	m.l	PROPN
chd-169	936	12	.	.	PROPN
chd-169	936	13	,	,	PUNCT
chd-169	936	14	and	and	CCONJ
chd-169	936	15	grange	grange	PROPN
chd-169	936	16	,	,	PUNCT
chd-169	936	17	t.	t.	PROPN
chd-169	936	18	(	(	PUNCT
chd-169	936	19	2001	2001	NUM
chd-169	936	20	)	)	PUNCT
chd-169	936	21	.	.	PUNCT
chd-169	937	1	glucocorticoid	glucocorticoid	NOUN
chd-169	937	2	-	-	PUNCT
chd-169	937	3	induced	induce	VERB
chd-169	937	4	dna	dna	NOUN
chd-169	937	5	demethylation	demethylation	NOUN
chd-169	937	6	and	and	CCONJ
chd-169	937	7	gene	gene	NOUN
chd-169	937	8	memory	memory	NOUN
chd-169	937	9	during	during	ADP
chd-169	937	10	development	development	NOUN
chd-169	937	11	.	.	PUNCT
chd-169	938	1	embo	embo	PROPN
chd-169	938	2	j	j	PROPN
chd-169	938	3	20	20	NUM
chd-169	938	4	,	,	PUNCT
chd-169	938	5	1974	1974	NUM
chd-169	938	6	-	-	SYM
chd-169	938	7	1983	1983	NUM
chd-169	938	8	.	.	PUNCT
chd-169	939	1	thoreson	thoreson	PROPN
chd-169	939	2	,	,	PUNCT
chd-169	939	3	g.r	g.r	PROPN
chd-169	939	4	.	.	PROPN
chd-169	939	5	,	,	PUNCT
chd-169	939	6	gayed	gaye	VERB
chd-169	939	7	,	,	PUNCT
chd-169	939	8	b.a	b.a	PROPN
chd-169	939	9	.	.	PROPN
chd-169	939	10	,	,	PUNCT
chd-169	939	11	chung	chung	PROPN
chd-169	939	12	,	,	PUNCT
chd-169	939	13	p.h	p.h	PROPN
chd-169	939	14	.	.	PROPN
chd-169	939	15	,	,	PUNCT
chd-169	939	16	and	and	CCONJ
chd-169	939	17	raj	raj	PROPN
chd-169	939	18	,	,	PUNCT
chd-169	939	19	g.v	g.v	PROPN
chd-169	939	20	.	.	PROPN
chd-169	939	21	(	(	PUNCT
chd-169	939	22	2014	2014	NUM
chd-169	939	23	)	)	PUNCT
chd-169	939	24	.	.	PUNCT
chd-169	940	1	emerging	emerge	VERB
chd-169	940	2	therapies	therapy	NOUN
chd-169	940	3	in	in	ADP
chd-169	940	4	castration	castration	NOUN
chd-169	940	5	resistant	resistant	ADJ
chd-169	940	6	prostate	prostate	NOUN
chd-169	940	7	cancer	cancer	NOUN
chd-169	940	8	.	.	PUNCT
chd-169	941	1	can	can	AUX
chd-169	941	2	j	j	PROPN
chd-169	941	3	urol	urol	PROPN
chd-169	941	4	21	21	NUM
chd-169	941	5	,	,	PUNCT
chd-169	941	6	98	98	NUM
chd-169	941	7	-	-	SYM
chd-169	941	8	105	105	NUM
chd-169	941	9	.	.	PUNCT
chd-169	942	1	todd	todd	PROPN
chd-169	942	2	,	,	PUNCT
chd-169	942	3	n.f	n.f	PROPN
chd-169	942	4	.	.	PROPN
chd-169	942	5	,	,	PUNCT
chd-169	942	6	lieberman	lieberman	PROPN
chd-169	942	7	,	,	PUNCT
chd-169	942	8	r.	r.	PROPN
chd-169	942	9	,	,	PUNCT
chd-169	942	10	gulley	gulley	NOUN
chd-169	942	11	,	,	PUNCT
chd-169	942	12	j.l	j.l	PROPN
chd-169	942	13	.	.	PROPN
chd-169	942	14	,	,	PUNCT
chd-169	942	15	dahut	dahut	VERB
chd-169	942	16	,	,	PUNCT
chd-169	942	17	w.	w.	PROPN
chd-169	942	18	,	,	PUNCT
chd-169	942	19	and	and	CCONJ
chd-169	942	20	arlen	arlen	PROPN
chd-169	942	21	,	,	PUNCT
chd-169	942	22	p.m.	p.m.	NOUN
chd-169	942	23	(	(	PUNCT
chd-169	942	24	2005	2005	NUM
chd-169	942	25	)	)	PUNCT
chd-169	942	26	.	.	PUNCT
chd-169	943	1	prolonged	prolonged	ADJ
chd-169	943	2	response	response	NOUN
chd-169	943	3	to	to	ADP
chd-169	943	4	nilutamide	nilutamide	ADV
chd-169	943	5	in	in	ADP
chd-169	943	6	a	a	DET
chd-169	943	7	patient	patient	NOUN
chd-169	943	8	with	with	ADP
chd-169	943	9	stage	stage	NOUN
chd-169	943	10	d0.5	d0.5	ADJ
chd-169	943	11	prostate	prostate	NOUN
chd-169	943	12	cancer	cancer	NOUN
chd-169	943	13	who	who	PRON
chd-169	943	14	previously	previously	ADV
chd-169	943	15	failed	fail	VERB
chd-169	943	16	androgen	androgen	NOUN
chd-169	943	17	deprivation	deprivation	NOUN
chd-169	943	18	therapy	therapy	NOUN
chd-169	943	19	.	.	PUNCT
chd-169	944	1	am	be	AUX
chd-169	944	2	j	j	PROPN
chd-169	944	3	ther	ther	ADJ
chd-169	944	4	12	12	NUM
chd-169	944	5	,	,	PUNCT
chd-169	944	6	172174	172174	NUM
chd-169	944	7	.	.	PUNCT
chd-169	945	1	tsodikov	tsodikov	PROPN
chd-169	945	2	,	,	PUNCT
chd-169	945	3	a.	a.	PROPN
chd-169	945	4	,	,	PUNCT
chd-169	945	5	gulati	gulati	PROPN
chd-169	945	6	,	,	PUNCT
chd-169	945	7	r.	r.	PROPN
chd-169	945	8	,	,	PUNCT
chd-169	945	9	de	de	PROPN
chd-169	945	10	carvalho	carvalho	PROPN
chd-169	945	11	,	,	PUNCT
chd-169	945	12	t.m	t.m	PROPN
chd-169	945	13	.	.	PROPN
chd-169	945	14	,	,	PUNCT
chd-169	945	15	heijnsdijk	heijnsdijk	PROPN
chd-169	945	16	,	,	PUNCT
chd-169	945	17	e.a.m	e.a.m	X
chd-169	945	18	.	.	PROPN
chd-169	945	19	,	,	PUNCT
chd-169	945	20	hunter	hunter	NOUN
chd-169	945	21	-	-	PUNCT
chd-169	945	22	merrill	merrill	NOUN
chd-169	945	23	,	,	PUNCT
chd-169	945	24	r.a	r.a	PROPN
chd-169	945	25	.	.	PROPN
chd-169	945	26	,	,	PUNCT
chd-169	945	27	mariotto	mariotto	NOUN
chd-169	945	28	,	,	PUNCT
chd-169	945	29	a.b	a.b	PROPN
chd-169	945	30	.	.	PROPN
chd-169	945	31	,	,	PUNCT
chd-169	945	32	de	de	PROPN
chd-169	945	33	koning	koning	PROPN
chd-169	945	34	,	,	PUNCT
chd-169	945	35	h.j	h.j	PROPN
chd-169	945	36	.	.	PROPN
chd-169	945	37	,	,	PUNCT
chd-169	945	38	and	and	CCONJ
chd-169	945	39	etzioni	etzioni	PROPN
chd-169	945	40	,	,	PUNCT
chd-169	945	41	r.	r.	PROPN
chd-169	945	42	(	(	PUNCT
chd-169	945	43	2017	2017	NUM
chd-169	945	44	)	)	PUNCT
chd-169	945	45	.	.	PUNCT
chd-169	945	46	is	be	AUX
chd-169	945	47	prostate	prostate	NOUN
chd-169	945	48	cancer	cancer	NOUN
chd-169	945	49	different	different	ADJ
chd-169	945	50	in	in	ADP
chd-169	945	51	black	black	ADJ
chd-169	945	52	men	man	NOUN
chd-169	945	53	?	?	PUNCT
chd-169	946	1	answers	answer	NOUN
chd-169	946	2	from	from	ADP
chd-169	946	3	3	3	NUM
chd-169	946	4	natural	natural	ADJ
chd-169	946	5	history	history	NOUN
chd-169	946	6	models	model	NOUN
chd-169	946	7	.	.	PUNCT
chd-169	947	1	cancer	cancer	NOUN
chd-169	947	2	123	123	NUM
chd-169	947	3	,	,	PUNCT
chd-169	947	4	2312	2312	NUM
chd-169	947	5	-	-	SYM
chd-169	947	6	2319	2319	NUM
chd-169	947	7	.	.	PUNCT
chd-169	948	1	turner	turner	PROPN
chd-169	948	2	,	,	PUNCT
chd-169	948	3	j.d	j.d	PROPN
chd-169	948	4	.	.	PROPN
chd-169	948	5	,	,	PUNCT
chd-169	948	6	and	and	CCONJ
chd-169	948	7	muller	muller	NOUN
chd-169	948	8	,	,	PUNCT
chd-169	948	9	c.p	c.p	PROPN
chd-169	948	10	.	.	PROPN
chd-169	948	11	(	(	PUNCT
chd-169	948	12	2005	2005	NUM
chd-169	948	13	)	)	PUNCT
chd-169	948	14	.	.	PUNCT
chd-169	949	1	structure	structure	NOUN
chd-169	949	2	of	of	ADP
chd-169	949	3	the	the	DET
chd-169	949	4	glucocorticoid	glucocorticoid	ADJ
chd-169	949	5	receptor	receptor	NOUN
chd-169	949	6	(	(	PUNCT
chd-169	949	7	nr3c1	nr3c1	NOUN
chd-169	949	8	)	)	PUNCT
chd-169	949	9	gene	gene	NOUN
chd-169	949	10	5	5	NUM
chd-169	949	11	'	'	PART
chd-169	949	12	untranslated	untranslated	ADJ
chd-169	949	13	region	region	NOUN
chd-169	949	14	:	:	PUNCT
chd-169	949	15	identification	identification	NOUN
chd-169	949	16	,	,	PUNCT
chd-169	949	17	and	and	CCONJ
chd-169	949	18	tissue	tissue	NOUN
chd-169	949	19	distribution	distribution	NOUN
chd-169	949	20	of	of	ADP
chd-169	949	21	multiple	multiple	ADJ
chd-169	949	22	new	new	ADJ
chd-169	949	23	human	human	ADJ
chd-169	949	24	exon	exon	PROPN
chd-169	949	25	1	1	NUM
chd-169	949	26	.	.	PUNCT
chd-169	950	1	j	j	PROPN
chd-169	950	2	mol	mol	ADP
chd-169	950	3	endocrinol	endocrinol	PROPN
chd-169	950	4	35	35	NUM
chd-169	950	5	,	,	PUNCT
chd-169	950	6	283	283	NUM
chd-169	950	7	-	-	SYM
chd-169	950	8	292	292	NUM
chd-169	950	9	.	.	PUNCT
chd-169	951	1	vandevyver	vandevyver	PROPN
chd-169	951	2	,	,	PUNCT
chd-169	951	3	s.	s.	PROPN
chd-169	951	4	,	,	PUNCT
chd-169	951	5	dejager	dejager	NOUN
chd-169	951	6	,	,	PUNCT
chd-169	951	7	l.	l.	PROPN
chd-169	951	8	,	,	PUNCT
chd-169	951	9	and	and	CCONJ
chd-169	951	10	libert	libert	NOUN
chd-169	951	11	,	,	PUNCT
chd-169	951	12	c.	c.	PROPN
chd-169	951	13	(	(	PUNCT
chd-169	951	14	2014	2014	NUM
chd-169	951	15	)	)	PUNCT
chd-169	951	16	.	.	PUNCT
chd-169	952	1	comprehensive	comprehensive	ADJ
chd-169	952	2	overview	overview	NOUN
chd-169	952	3	of	of	ADP
chd-169	952	4	the	the	DET
chd-169	952	5	structure	structure	NOUN
chd-169	952	6	and	and	CCONJ
chd-169	952	7	regulation	regulation	NOUN
chd-169	952	8	of	of	ADP
chd-169	952	9	the	the	DET
chd-169	952	10	glucocorticoid	glucocorticoid	ADJ
chd-169	952	11	receptor	receptor	NOUN
chd-169	952	12	.	.	PUNCT
chd-169	953	1	endocr	endocr	PROPN
chd-169	953	2	rev	rev	PROPN
chd-169	953	3	35	35	NUM
chd-169	953	4	,	,	PUNCT
chd-169	953	5	671	671	NUM
chd-169	953	6	-	-	PUNCT
chd-169	953	7	693	693	NUM
chd-169	953	8	.	.	PUNCT
chd-169	953	9	vandewalle	vandewalle	PROPN
chd-169	953	10	,	,	PUNCT
chd-169	953	11	j.	j.	PROPN
chd-169	953	12	,	,	PUNCT
chd-169	953	13	luypaert	luypaert	PROPN
chd-169	953	14	,	,	PUNCT
chd-169	953	15	a.	a.	NOUN
chd-169	953	16	,	,	PUNCT
chd-169	953	17	de	de	PROPN
chd-169	953	18	bosscher	bosscher	PROPN
chd-169	953	19	,	,	PUNCT
chd-169	953	20	k.	k.	PROPN
chd-169	953	21	,	,	PUNCT
chd-169	953	22	and	and	CCONJ
chd-169	953	23	libert	libert	NOUN
chd-169	953	24	,	,	PUNCT
chd-169	953	25	c.	c.	PROPN
chd-169	953	26	(	(	PUNCT
chd-169	953	27	2018	2018	NUM
chd-169	953	28	)	)	PUNCT
chd-169	953	29	.	.	PUNCT
chd-169	954	1	therapeutic	therapeutic	ADJ
chd-169	954	2	mechanisms	mechanism	NOUN
chd-169	954	3	of	of	ADP
chd-169	954	4	glucocorticoids	glucocorticoid	NOUN
chd-169	954	5	.	.	PUNCT
chd-169	955	1	trends	trend	NOUN
chd-169	955	2	endocrinol	endocrinol	VERB
chd-169	955	3	metab	metab	NOUN
chd-169	955	4	29	29	NUM
chd-169	955	5	,	,	PUNCT
chd-169	955	6	42	42	NUM
chd-169	955	7	-	-	SYM
chd-169	955	8	54	54	NUM
chd-169	955	9	.	.	PUNCT
chd-169	956	1	vedhara	vedhara	PROPN
chd-169	956	2	,	,	PUNCT
chd-169	956	3	k.	k.	PROPN
chd-169	956	4	,	,	PUNCT
chd-169	956	5	cox	cox	PROPN
chd-169	956	6	,	,	PUNCT
chd-169	956	7	n.k	n.k	PROPN
chd-169	956	8	.	.	PROPN
chd-169	956	9	,	,	PUNCT
chd-169	956	10	wilcock	wilcock	PROPN
chd-169	956	11	,	,	PUNCT
chd-169	956	12	g.k	g.k	PROPN
chd-169	956	13	.	.	PROPN
chd-169	956	14	,	,	PUNCT
chd-169	956	15	perks	perk	NOUN
chd-169	956	16	,	,	PUNCT
chd-169	956	17	p.	p.	NOUN
chd-169	956	18	,	,	PUNCT
chd-169	956	19	hunt	hunt	NOUN
chd-169	956	20	,	,	PUNCT
chd-169	956	21	m.	m.	NOUN
chd-169	956	22	,	,	PUNCT
chd-169	956	23	anderson	anderson	PROPN
chd-169	956	24	,	,	PUNCT
chd-169	956	25	s.	s.	PROPN
chd-169	956	26	,	,	PUNCT
chd-169	956	27	lightman	lightman	PROPN
chd-169	956	28	,	,	PUNCT
chd-169	956	29	s.l	s.l	PROPN
chd-169	956	30	.	.	PROPN
chd-169	956	31	,	,	PUNCT
chd-169	956	32	and	and	CCONJ
chd-169	956	33	shanks	shank	NOUN
chd-169	956	34	,	,	PUNCT
chd-169	956	35	n.m	n.m	PROPN
chd-169	956	36	.	.	PROPN
chd-169	956	37	(	(	PUNCT
chd-169	956	38	1999	1999	NUM
chd-169	956	39	)	)	PUNCT
chd-169	956	40	.	.	PUNCT
chd-169	957	1	chronic	chronic	ADJ
chd-169	957	2	stress	stress	NOUN
chd-169	957	3	in	in	ADP
chd-169	957	4	elderly	elderly	ADJ
chd-169	957	5	carers	carer	NOUN
chd-169	957	6	of	of	ADP
chd-169	957	7	dementia	dementia	NOUN
chd-169	957	8	patients	patient	NOUN
chd-169	957	9	and	and	CCONJ
chd-169	957	10	antibody	antibody	NOUN
chd-169	957	11	response	response	NOUN
chd-169	957	12	to	to	ADP
chd-169	957	13	influenza	influenza	NOUN
chd-169	957	14	vaccination	vaccination	NOUN
chd-169	957	15	.	.	PUNCT
chd-169	958	1	lancet	lancet	PROPN
chd-169	958	2	353	353	NUM
chd-169	958	3	,	,	PUNCT
chd-169	958	4	627	627	NUM
chd-169	958	5	-	-	SYM
chd-169	958	6	631	631	NUM
chd-169	958	7	.	.	PUNCT
chd-169	959	1	wallace	wallace	PROPN
chd-169	959	2	,	,	PUNCT
chd-169	959	3	t.a	t.a	PROPN
chd-169	959	4	.	.	PROPN
chd-169	959	5	,	,	PUNCT
chd-169	959	6	martin	martin	PROPN
chd-169	959	7	,	,	PUNCT
chd-169	959	8	d.n	d.n	PROPN
chd-169	959	9	.	.	PROPN
chd-169	959	10	,	,	PUNCT
chd-169	959	11	and	and	CCONJ
chd-169	959	12	ambs	amb	NOUN
chd-169	959	13	,	,	PUNCT
chd-169	959	14	s.	s.	PROPN
chd-169	959	15	(	(	PUNCT
chd-169	959	16	2011	2011	NUM
chd-169	959	17	)	)	PUNCT
chd-169	959	18	.	.	PUNCT
chd-169	960	1	interactions	interaction	NOUN
chd-169	960	2	among	among	ADP
chd-169	960	3	genes	gene	NOUN
chd-169	960	4	,	,	PUNCT
chd-169	960	5	tumor	tumor	NOUN
chd-169	960	6	biology	biology	NOUN
chd-169	960	7	and	and	CCONJ
chd-169	960	8	the	the	DET
chd-169	960	9	environment	environment	NOUN
chd-169	960	10	in	in	ADP
chd-169	960	11	cancer	cancer	NOUN
chd-169	960	12	health	health	NOUN
chd-169	960	13	disparities	disparity	NOUN
chd-169	960	14	:	:	PUNCT
chd-169	960	15	examining	examine	VERB
chd-169	960	16	the	the	DET
chd-169	960	17	evidence	evidence	NOUN
chd-169	960	18	on	on	ADP
chd-169	960	19	a	a	DET
chd-169	960	20	national	national	ADJ
chd-169	960	21	and	and	CCONJ
chd-169	960	22	global	global	ADJ
chd-169	960	23	scale	scale	NOUN
chd-169	960	24	.	.	PUNCT
chd-169	961	1	carcinogenesis	carcinogenesis	NOUN
chd-169	961	2	32	32	NUM
chd-169	961	3	,	,	PUNCT
chd-169	961	4	1107	1107	NUM
chd-169	961	5	-	-	SYM
chd-169	961	6	1121	1121	NUM
chd-169	961	7	.	.	PUNCT
chd-169	962	1	wallace	wallace	PROPN
chd-169	962	2	,	,	PUNCT
chd-169	962	3	t.a	t.a	PROPN
chd-169	962	4	.	.	PROPN
chd-169	962	5	,	,	PUNCT
chd-169	962	6	prueitt	prueitt	VERB
chd-169	962	7	,	,	PUNCT
chd-169	962	8	r.l	r.l	PROPN
chd-169	962	9	.	.	PROPN
chd-169	962	10	,	,	PUNCT
chd-169	962	11	yi	yi	PROPN
chd-169	962	12	,	,	PUNCT
chd-169	962	13	m.	m.	NOUN
chd-169	962	14	,	,	PUNCT
chd-169	962	15	howe	howe	NOUN
chd-169	962	16	,	,	PUNCT
chd-169	962	17	t.m	t.m	PROPN
chd-169	962	18	.	.	PROPN
chd-169	962	19	,	,	PUNCT
chd-169	962	20	gillespie	gillespie	PROPN
chd-169	962	21	,	,	PUNCT
chd-169	962	22	j.w	j.w	PROPN
chd-169	962	23	.	.	PROPN
chd-169	962	24	,	,	PUNCT
chd-169	962	25	yfantis	yfantis	PROPN
chd-169	962	26	,	,	PUNCT
chd-169	962	27	h.g	h.g	PROPN
chd-169	962	28	.	.	PROPN
chd-169	962	29	,	,	PUNCT
chd-169	962	30	stephens	stephens	PROPN
chd-169	962	31	,	,	PUNCT
chd-169	962	32	r.m	r.m	PROPN
chd-169	962	33	.	.	PROPN
chd-169	962	34	,	,	PUNCT
chd-169	962	35	caporaso	caporaso	PROPN
chd-169	962	36	,	,	PUNCT
chd-169	962	37	n.e	n.e	PROPN
chd-169	962	38	.	.	PROPN
chd-169	962	39	,	,	PUNCT
chd-169	962	40	loffredo	loffredo	PROPN
chd-169	962	41	,	,	PUNCT
chd-169	962	42	c.a	c.a	PROPN
chd-169	962	43	.	.	PROPN
chd-169	962	44	,	,	PUNCT
chd-169	962	45	and	and	CCONJ
chd-169	962	46	ambs	amb	NOUN
chd-169	962	47	,	,	PUNCT
chd-169	962	48	s.	s.	PROPN
chd-169	962	49	(	(	PUNCT
chd-169	962	50	2008	2008	NUM
chd-169	962	51	)	)	PUNCT
chd-169	962	52	.	.	PUNCT
chd-169	963	1	tumor	tumor	NOUN
chd-169	963	2	immunobiological	immunobiological	ADJ
chd-169	963	3	differences	difference	NOUN
chd-169	963	4	in	in	ADP
chd-169	963	5	prostate	prostate	NOUN
chd-169	963	6	cancer	cancer	NOUN
chd-169	963	7	between	between	ADP
chd-169	963	8	african	african	ADJ
chd-169	963	9	-	-	PUNCT
chd-169	963	10	american	american	ADJ
chd-169	963	11	and	and	CCONJ
chd-169	963	12	european	european	ADJ
chd-169	963	13	-	-	PUNCT
chd-169	963	14	american	american	ADJ
chd-169	963	15	men	man	NOUN
chd-169	963	16	.	.	PUNCT
chd-169	964	1	cancer	cancer	NOUN
chd-169	964	2	research	research	NOUN
chd-169	964	3	68	68	NUM
chd-169	964	4	,	,	PUNCT
chd-169	964	5	927936	927936	NUM
chd-169	964	6	.	.	PUNCT
chd-169	965	1	wang	wang	PROPN
chd-169	965	2	,	,	PUNCT
chd-169	965	3	b.d	b.d	PROPN
chd-169	965	4	.	.	PROPN
chd-169	965	5	,	,	PUNCT
chd-169	965	6	ceniccola	ceniccola	PROPN
chd-169	965	7	,	,	PUNCT
chd-169	965	8	k.	k.	PROPN
chd-169	965	9	,	,	PUNCT
chd-169	965	10	hwang	hwang	PROPN
chd-169	965	11	,	,	PUNCT
chd-169	965	12	s.	s.	PROPN
chd-169	965	13	,	,	PUNCT
chd-169	965	14	andrawis	andrawis	PROPN
chd-169	965	15	,	,	PUNCT
chd-169	965	16	r.	r.	PROPN
chd-169	965	17	,	,	PUNCT
chd-169	965	18	horvath	horvath	PROPN
chd-169	965	19	,	,	PUNCT
chd-169	965	20	a.	a.	PROPN
chd-169	965	21	,	,	PUNCT
chd-169	965	22	freedman	freedman	PROPN
chd-169	965	23	,	,	PUNCT
chd-169	965	24	j.a	j.a	PROPN
chd-169	965	25	.	.	PROPN
chd-169	965	26	,	,	PUNCT
chd-169	965	27	olender	olender	PROPN
chd-169	965	28	,	,	PUNCT
chd-169	965	29	j.	j.	PROPN
chd-169	965	30	,	,	PUNCT
chd-169	965	31	knapp	knapp	PROPN
chd-169	965	32	,	,	PUNCT
chd-169	965	33	s.	s.	PROPN
chd-169	965	34	,	,	PUNCT
chd-169	965	35	ching	ching	PROPN
chd-169	965	36	,	,	PUNCT
chd-169	965	37	t.	t.	PROPN
chd-169	965	38	,	,	PUNCT
chd-169	965	39	garmire	garmire	NOUN
chd-169	965	40	,	,	PUNCT
chd-169	965	41	l.	l.	PROPN
chd-169	965	42	,	,	PUNCT
chd-169	965	43	et	et	PROPN
chd-169	965	44	al	al	PROPN
chd-169	965	45	.	.	PUNCT
chd-169	965	46	(	(	PUNCT
chd-169	965	47	2017	2017	NUM
chd-169	965	48	)	)	PUNCT
chd-169	965	49	.	.	PUNCT
chd-169	966	1	alternative	alternative	ADJ
chd-169	966	2	splicing	splicing	NOUN
chd-169	966	3	promotes	promote	VERB
chd-169	966	4	tumour	tumour	ADJ
chd-169	966	5	aggressiveness	aggressiveness	NOUN
chd-169	966	6	and	and	CCONJ
chd-169	966	7	drug	drug	NOUN
chd-169	966	8	resistance	resistance	NOUN
chd-169	966	9	in	in	ADP
chd-169	966	10	african	african	ADJ
chd-169	966	11	american	american	ADJ
chd-169	966	12	prostate	prostate	NOUN
chd-169	966	13	cancer	cancer	NOUN
chd-169	966	14	.	.	PUNCT
chd-169	967	1	nat	nat	PROPN
chd-169	967	2	commun	commun	PROPN
chd-169	967	3	8	8	NUM
chd-169	967	4	,	,	PUNCT
chd-169	967	5	15921	15921	NUM
chd-169	967	6	.	.	PUNCT
chd-169	968	1	wang	wang	PROPN
chd-169	968	2	,	,	PUNCT
chd-169	968	3	y.	y.	PROPN
chd-169	968	4	,	,	PUNCT
chd-169	968	5	and	and	CCONJ
chd-169	968	6	chen	chen	PROPN
chd-169	968	7	,	,	PUNCT
chd-169	968	8	x.	x.	NOUN
chd-169	968	9	(	(	PUNCT
chd-169	968	10	2011	2011	NUM
chd-169	968	11	)	)	PUNCT
chd-169	968	12	.	.	PUNCT
chd-169	969	1	how	how	SCONJ
chd-169	969	2	much	much	ADJ
chd-169	969	3	of	of	ADP
chd-169	969	4	racial	racial	ADJ
chd-169	969	5	/	/	SYM
chd-169	969	6	ethnic	ethnic	ADJ
chd-169	969	7	disparities	disparity	NOUN
chd-169	969	8	in	in	ADP
chd-169	969	9	dietary	dietary	ADJ
chd-169	969	10	intakes	intake	NOUN
chd-169	969	11	,	,	PUNCT
chd-169	969	12	exercise	exercise	NOUN
chd-169	969	13	,	,	PUNCT
chd-169	969	14	and	and	CCONJ
chd-169	969	15	weight	weight	NOUN
chd-169	969	16	status	status	NOUN
chd-169	969	17	can	can	AUX
chd-169	969	18	be	be	AUX
chd-169	969	19	explained	explain	VERB
chd-169	969	20	by	by	ADP
chd-169	969	21	nutritionand	nutritionand	NOUN
chd-169	969	22	health	health	NOUN
chd-169	969	23	-	-	PUNCT
chd-169	969	24	related	relate	VERB
chd-169	969	25	psychosocial	psychosocial	ADJ
chd-169	969	26	factors	factor	NOUN
chd-169	969	27	and	and	CCONJ
chd-169	969	28	socioeconomic	socioeconomic	ADJ
chd-169	969	29	status	status	NOUN
chd-169	969	30	among	among	ADP
chd-169	969	31	us	us	PROPN
chd-169	969	32	adults	adult	NOUN
chd-169	969	33	?	?	PUNCT
chd-169	970	1	j	j	PROPN
chd-169	970	2	am	be	AUX
chd-169	970	3	diet	diet	PROPN
chd-169	970	4	assoc	assoc	PROPN
chd-169	970	5	111	111	NUM
chd-169	970	6	,	,	PUNCT
chd-169	970	7	1904	1904	NUM
chd-169	970	8	-	-	SYM
chd-169	970	9	1911	1911	NUM
chd-169	970	10	.	.	PUNCT
chd-169	971	1	ward	ward	PROPN
chd-169	971	2	,	,	PUNCT
chd-169	971	3	e.	e.	PROPN
chd-169	971	4	,	,	PUNCT
chd-169	971	5	halpern	halpern	PROPN
chd-169	971	6	,	,	PUNCT
chd-169	971	7	m.	m.	NOUN
chd-169	971	8	,	,	PUNCT
chd-169	971	9	schrag	schrag	NOUN
chd-169	971	10	,	,	PUNCT
chd-169	971	11	n.	n.	NOUN
chd-169	971	12	,	,	PUNCT
chd-169	971	13	cokkinides	cokkinide	NOUN
chd-169	971	14	,	,	PUNCT
chd-169	971	15	v.	v.	ADV
chd-169	971	16	,	,	PUNCT
chd-169	971	17	desantis	desantis	PROPN
chd-169	971	18	,	,	PUNCT
chd-169	971	19	c.	c.	PROPN
chd-169	971	20	,	,	PUNCT
chd-169	971	21	bandi	bandi	PROPN
chd-169	971	22	,	,	PUNCT
chd-169	971	23	p.	p.	PROPN
chd-169	971	24	,	,	PUNCT
chd-169	971	25	siegel	siegel	PROPN
chd-169	971	26	,	,	PUNCT
chd-169	971	27	r.	r.	PROPN
chd-169	971	28	,	,	PUNCT
chd-169	971	29	stewart	stewart	PROPN
chd-169	971	30	,	,	PUNCT
chd-169	971	31	a.	a.	NOUN
chd-169	971	32	,	,	PUNCT
chd-169	971	33	and	and	CCONJ
chd-169	971	34	jemal	jemal	ADJ
chd-169	971	35	,	,	PUNCT
chd-169	971	36	a.	a.	NOUN
chd-169	971	37	(	(	PUNCT
chd-169	971	38	2008	2008	NUM
chd-169	971	39	)	)	PUNCT
chd-169	971	40	.	.	PUNCT
chd-169	972	1	association	association	NOUN
chd-169	972	2	of	of	ADP
chd-169	972	3	insurance	insurance	NOUN
chd-169	972	4	with	with	ADP
chd-169	972	5	cancer	cancer	NOUN
chd-169	972	6	care	care	NOUN
chd-169	972	7	utilization	utilization	NOUN
chd-169	972	8	and	and	CCONJ
chd-169	972	9	outcomes	outcome	NOUN
chd-169	972	10	.	.	PUNCT
chd-169	973	1	ca	can	AUX
chd-169	973	2	:	:	PUNCT
chd-169	973	3	a	a	DET
chd-169	973	4	cancer	cancer	NOUN
chd-169	973	5	journal	journal	NOUN
chd-169	973	6	for	for	ADP
chd-169	973	7	clinicians	clinician	NOUN
chd-169	973	8	58	58	NUM
chd-169	973	9	,	,	PUNCT
chd-169	973	10	9	9	NUM
chd-169	973	11	-	-	SYM
chd-169	973	12	31	31	NUM
chd-169	973	13	.	.	PUNCT
chd-169	974	1	ward	ward	PROPN
chd-169	974	2	,	,	PUNCT
chd-169	974	3	e.	e.	PROPN
chd-169	974	4	,	,	PUNCT
chd-169	974	5	jemal	jemal	PROPN
chd-169	974	6	,	,	PUNCT
chd-169	974	7	a.	a.	NOUN
chd-169	974	8	,	,	PUNCT
chd-169	974	9	cokkinides	cokkinide	NOUN
chd-169	974	10	,	,	PUNCT
chd-169	974	11	v.	v.	ADV
chd-169	974	12	,	,	PUNCT
chd-169	974	13	singh	singh	PROPN
chd-169	974	14	,	,	PUNCT
chd-169	974	15	g.k	g.k	PROPN
chd-169	974	16	.	.	PROPN
chd-169	974	17	,	,	PUNCT
chd-169	974	18	cardinez	cardinez	PROPN
chd-169	974	19	,	,	PUNCT
chd-169	974	20	c.	c.	NOUN
chd-169	974	21	,	,	PUNCT
chd-169	974	22	ghafoor	ghafoor	PROPN
chd-169	974	23	,	,	PUNCT
chd-169	974	24	a.	a.	NOUN
chd-169	974	25	,	,	PUNCT
chd-169	974	26	and	and	CCONJ
chd-169	974	27	thun	thun	PROPN
chd-169	974	28	,	,	PUNCT
chd-169	974	29	m.	m.	NOUN
chd-169	974	30	(	(	PUNCT
chd-169	974	31	2004	2004	NUM
chd-169	974	32	)	)	PUNCT
chd-169	974	33	.	.	PUNCT
chd-169	975	1	cancer	cancer	NOUN
chd-169	975	2	disparities	disparity	NOUN
chd-169	975	3	by	by	ADP
chd-169	975	4	race	race	NOUN
chd-169	975	5	/	/	SYM
chd-169	975	6	ethnicity	ethnicity	NOUN
chd-169	975	7	and	and	CCONJ
chd-169	975	8	socioeconomic	socioeconomic	ADJ
chd-169	975	9	status	status	NOUN
chd-169	975	10	.	.	PUNCT
chd-169	976	1	ca	can	AUX
chd-169	976	2	:	:	PUNCT
chd-169	976	3	a	a	DET
chd-169	976	4	cancer	cancer	NOUN
chd-169	976	5	journal	journal	NOUN
chd-169	976	6	for	for	ADP
chd-169	976	7	clinicians	clinician	NOUN
chd-169	976	8	54	54	NUM
chd-169	976	9	,	,	PUNCT
chd-169	976	10	78	78	NUM
chd-169	976	11	-	-	SYM
chd-169	976	12	93	93	NUM
chd-169	976	13	.	.	PUNCT
chd-169	977	1	warner	warner	PROPN
chd-169	977	2	,	,	PUNCT
chd-169	977	3	e.w	e.w	PROPN
chd-169	977	4	.	.	PROPN
chd-169	977	5	,	,	PUNCT
chd-169	977	6	yip	yip	PROPN
chd-169	977	7	,	,	PUNCT
chd-169	977	8	s.m	s.m	PROPN
chd-169	977	9	.	.	PROPN
chd-169	977	10	,	,	PUNCT
chd-169	977	11	chi	chi	PROPN
chd-169	977	12	,	,	PUNCT
chd-169	977	13	k.n	k.n	PROPN
chd-169	977	14	.	.	PROPN
chd-169	977	15	,	,	PUNCT
chd-169	977	16	and	and	CCONJ
chd-169	977	17	wyatt	wyatt	PROPN
chd-169	977	18	,	,	PUNCT
chd-169	977	19	a.w	a.w	PROPN
chd-169	977	20	.	.	PROPN
chd-169	977	21	(	(	PUNCT
chd-169	977	22	2019	2019	NUM
chd-169	977	23	)	)	PUNCT
chd-169	977	24	.	.	PUNCT
chd-169	978	1	dna	dna	PROPN
chd-169	978	2	repair	repair	VERB
chd-169	978	3	defects	defect	NOUN
chd-169	978	4	in	in	ADP
chd-169	978	5	prostate	prostate	NOUN
chd-169	978	6	cancer	cancer	NOUN
chd-169	978	7	:	:	PUNCT
chd-169	978	8	impact	impact	NOUN
chd-169	978	9	for	for	ADP
chd-169	978	10	screening	screening	NOUN
chd-169	978	11	,	,	PUNCT
chd-169	978	12	prognostication	prognostication	NOUN
chd-169	978	13	and	and	CCONJ
chd-169	978	14	treatment	treatment	NOUN
chd-169	978	15	.	.	PUNCT
chd-169	979	1	bju	bju	NOUN
chd-169	979	2	int	int	PROPN
chd-169	979	3	123	123	NUM
chd-169	979	4	,	,	PUNCT
chd-169	979	5	769	769	NUM
chd-169	979	6	-	-	SYM
chd-169	979	7	776	776	NUM
chd-169	979	8	.	.	PUNCT
chd-169	980	1	weidner	weidner	PROPN
chd-169	980	2	,	,	PUNCT
chd-169	980	3	c.i	c.i	PROPN
chd-169	980	4	.	.	PROPN
chd-169	980	5	,	,	PUNCT
chd-169	980	6	lin	lin	PROPN
chd-169	980	7	,	,	PUNCT
chd-169	980	8	q.	q.	PROPN
chd-169	980	9	,	,	PUNCT
chd-169	980	10	koch	koch	PROPN
chd-169	980	11	,	,	PUNCT
chd-169	980	12	c.m	c.m	PROPN
chd-169	980	13	.	.	PROPN
chd-169	980	14	,	,	PUNCT
chd-169	980	15	eisele	eisele	PROPN
chd-169	980	16	,	,	PUNCT
chd-169	980	17	l.	l.	PROPN
chd-169	980	18	,	,	PUNCT
chd-169	980	19	beier	beier	PROPN
chd-169	980	20	,	,	PUNCT
chd-169	980	21	f.	f.	PROPN
chd-169	980	22	,	,	PUNCT
chd-169	980	23	ziegler	ziegler	PROPN
chd-169	980	24	,	,	PUNCT
chd-169	980	25	p.	p.	NOUN
chd-169	980	26	,	,	PUNCT
chd-169	980	27	bauerschlag	bauerschlag	NOUN
chd-169	980	28	,	,	PUNCT
chd-169	980	29	d.o	d.o	PROPN
chd-169	980	30	.	.	PROPN
chd-169	980	31	,	,	PUNCT
chd-169	980	32	jockel	jockel	NOUN
chd-169	980	33	,	,	PUNCT
chd-169	980	34	k.h	k.h	PROPN
chd-169	980	35	.	.	PROPN
chd-169	980	36	,	,	PUNCT
chd-169	980	37	erbel	erbel	PROPN
chd-169	980	38	,	,	PUNCT
chd-169	980	39	r.	r.	PROPN
chd-169	980	40	,	,	PUNCT
chd-169	980	41	muhleisen	muhleisen	PROPN
chd-169	980	42	,	,	PUNCT
chd-169	980	43	t.w	t.w	PROPN
chd-169	980	44	.	.	PROPN
chd-169	980	45	,	,	PUNCT
chd-169	980	46	et	et	PROPN
chd-169	980	47	al	al	PROPN
chd-169	980	48	.	.	PUNCT
chd-169	980	49	(	(	PUNCT
chd-169	980	50	2014	2014	NUM
chd-169	980	51	)	)	PUNCT
chd-169	980	52	.	.	PUNCT
chd-169	981	1	aging	aging	NOUN
chd-169	981	2	of	of	ADP
chd-169	981	3	blood	blood	NOUN
chd-169	981	4	can	can	AUX
chd-169	981	5	be	be	AUX
chd-169	981	6	tracked	track	VERB
chd-169	981	7	by	by	ADP
chd-169	981	8	dna	dna	PROPN
chd-169	981	9	methylation	methylation	NOUN
chd-169	981	10	changes	change	NOUN
chd-169	981	11	at	at	ADP
chd-169	981	12	just	just	ADV
chd-169	981	13	three	three	NUM
chd-169	981	14	cpg	cpg	NOUN
chd-169	981	15	sites	site	NOUN
chd-169	981	16	.	.	PUNCT
chd-169	982	1	genome	genome	NOUN
chd-169	982	2	biol	biol	NOUN
chd-169	982	3	15	15	NUM
chd-169	982	4	,	,	PUNCT
chd-169	982	5	r24	r24	PROPN
chd-169	982	6	.	.	PROPN
chd-169	982	7	weprin	weprin	PROPN
chd-169	982	8	,	,	PUNCT
chd-169	982	9	s.a	s.a	PROPN
chd-169	982	10	.	.	PROPN
chd-169	982	11	,	,	PUNCT
chd-169	982	12	parker	parker	PROPN
chd-169	982	13	,	,	PUNCT
chd-169	982	14	d.c	d.c	PROPN
chd-169	982	15	.	.	PROPN
chd-169	982	16	,	,	PUNCT
chd-169	982	17	jones	jones	PROPN
chd-169	982	18	,	,	PUNCT
chd-169	982	19	j.d	j.d	PROPN
chd-169	982	20	.	.	PROPN
chd-169	982	21	,	,	PUNCT
chd-169	982	22	kaplan	kaplan	PROPN
chd-169	982	23	,	,	PUNCT
chd-169	982	24	j.r	j.r	PROPN
chd-169	982	25	.	.	PROPN
chd-169	982	26	,	,	PUNCT
chd-169	982	27	giusto	giusto	PROPN
chd-169	982	28	,	,	PUNCT
chd-169	982	29	l.l	l.l	PROPN
chd-169	982	30	.	.	PROPN
chd-169	982	31	,	,	PUNCT
chd-169	982	32	mydlo	mydlo	PROPN
chd-169	982	33	,	,	PUNCT
chd-169	982	34	j.h	j.h	PROPN
chd-169	982	35	.	.	PROPN
chd-169	982	36	,	,	PUNCT
chd-169	982	37	yu	yu	PROPN
chd-169	982	38	,	,	PUNCT
chd-169	982	39	s.s	s.s	PROPN
chd-169	982	40	.	.	PROPN
chd-169	982	41	,	,	PUNCT
chd-169	982	42	lee	lee	PROPN
chd-169	982	43	,	,	PUNCT
chd-169	982	44	d.i	d.i	PROPN
chd-169	982	45	.	.	PROPN
chd-169	982	46	,	,	PUNCT
chd-169	982	47	eun	eun	PROPN
chd-169	982	48	,	,	PUNCT
chd-169	982	49	d.d	d.d	PROPN
chd-169	982	50	.	.	PROPN
chd-169	982	51	,	,	PUNCT
chd-169	982	52	and	and	CCONJ
chd-169	982	53	reese	reese	PROPN
chd-169	982	54	,	,	PUNCT
chd-169	982	55	a.c	a.c	PROPN
chd-169	982	56	.	.	PROPN
chd-169	982	57	(	(	PUNCT
chd-169	982	58	2019	2019	NUM
chd-169	982	59	)	)	PUNCT
chd-169	982	60	.	.	PUNCT
chd-169	983	1	association	association	NOUN
chd-169	983	2	of	of	ADP
chd-169	983	3	low	low	ADJ
chd-169	983	4	socioeconomic	socioeconomic	ADJ
chd-169	983	5	status	status	NOUN
chd-169	983	6	with	with	ADP
chd-169	983	7	adverse	adverse	ADJ
chd-169	983	8	prostate	prostate	NOUN
chd-169	983	9	cancer	cancer	NOUN
chd-169	983	10	pathology	pathology	NOUN
chd-169	983	11	among	among	ADP
chd-169	983	12	african	african	ADJ
chd-169	983	13	american	american	ADJ
chd-169	983	14	men	man	NOUN
chd-169	983	15	who	who	PRON
chd-169	983	16	underwent	undergo	VERB
chd-169	983	17	radical	radical	ADJ
chd-169	983	18	prostatectomy	prostatectomy	NOUN
chd-169	983	19	.	.	PUNCT
chd-169	984	1	clin	clin	PROPN
chd-169	984	2	genitourin	genitourin	PROPN
chd-169	984	3	cancer	cancer	PROPN
chd-169	984	4	17	17	NUM
chd-169	984	5	,	,	PUNCT
chd-169	984	6	e1054	e1054	NOUN
chd-169	984	7	-	-	PUNCT
chd-169	984	8	e1059	e1059	NOUN
chd-169	984	9	.	.	PUNCT
chd-169	985	1	wiench	wiench	NOUN
chd-169	985	2	,	,	PUNCT
chd-169	985	3	m.	m.	NOUN
chd-169	985	4	,	,	PUNCT
chd-169	985	5	john	john	PROPN
chd-169	985	6	,	,	PUNCT
chd-169	985	7	s.	s.	PROPN
chd-169	985	8	,	,	PUNCT
chd-169	985	9	baek	baek	PROPN
chd-169	985	10	,	,	PUNCT
chd-169	985	11	s.	s.	PROPN
chd-169	985	12	,	,	PUNCT
chd-169	985	13	johnson	johnson	PROPN
chd-169	985	14	,	,	PUNCT
chd-169	985	15	t.a	t.a	PROPN
chd-169	985	16	.	.	PROPN
chd-169	985	17	,	,	PUNCT
chd-169	985	18	sung	sung	PROPN
chd-169	985	19	,	,	PUNCT
chd-169	985	20	m.h	m.h	PROPN
chd-169	985	21	.	.	PROPN
chd-169	985	22	,	,	PUNCT
chd-169	985	23	escobar	escobar	PROPN
chd-169	985	24	,	,	PUNCT
chd-169	985	25	t.	t.	PROPN
chd-169	985	26	,	,	PUNCT
chd-169	985	27	simmons	simmon	NOUN
chd-169	985	28	,	,	PUNCT
chd-169	985	29	c.a	c.a	PROPN
chd-169	985	30	.	.	PROPN
chd-169	985	31	,	,	PUNCT
chd-169	985	32	pearce	pearce	PROPN
chd-169	985	33	,	,	PUNCT
chd-169	985	34	k.h	k.h	PROPN
chd-169	985	35	.	.	PROPN
chd-169	985	36	,	,	PUNCT
chd-169	985	37	biddie	biddie	PROPN
chd-169	985	38	,	,	PUNCT
chd-169	985	39	s.c	s.c	PROPN
chd-169	985	40	.	.	PROPN
chd-169	985	41	,	,	PUNCT
chd-169	985	42	sabo	sabo	PROPN
chd-169	985	43	,	,	PUNCT
chd-169	985	44	p.j	p.j	PROPN
chd-169	985	45	.	.	PROPN
chd-169	985	46	,	,	PUNCT
chd-169	985	47	et	et	PROPN
chd-169	985	48	al	al	PROPN
chd-169	985	49	.	.	PROPN
chd-169	985	50	(	(	PUNCT
chd-169	985	51	2011a	2011a	NUM
chd-169	985	52	)	)	PUNCT
chd-169	985	53	.	.	PUNCT
chd-169	986	1	dna	dna	PROPN
chd-169	986	2	methylation	methylation	NOUN
chd-169	986	3	status	status	NOUN
chd-169	986	4	predicts	predict	VERB
chd-169	986	5	cell	cell	NOUN
chd-169	986	6	type	type	NOUN
chd-169	986	7	-	-	PUNCT
chd-169	986	8	specific	specific	ADJ
chd-169	986	9	enhancer	enhancer	NOUN
chd-169	986	10	activity	activity	NOUN
chd-169	986	11	.	.	PUNCT
chd-169	987	1	embo	embo	PROPN
chd-169	987	2	j	j	PROPN
chd-169	987	3	30	30	NUM
chd-169	987	4	,	,	PUNCT
chd-169	987	5	30283039	30283039	NUM
chd-169	987	6	.	.	PUNCT
chd-169	988	1	wiench	wiench	NOUN
chd-169	988	2	,	,	PUNCT
chd-169	988	3	m.	m.	NOUN
chd-169	988	4	,	,	PUNCT
chd-169	988	5	miranda	miranda	PROPN
chd-169	988	6	,	,	PUNCT
chd-169	988	7	t.b	t.b	PROPN
chd-169	988	8	.	.	PROPN
chd-169	988	9	,	,	PUNCT
chd-169	988	10	and	and	CCONJ
chd-169	988	11	hager	hager	NOUN
chd-169	988	12	,	,	PUNCT
chd-169	988	13	g.l	g.l	PROPN
chd-169	988	14	.	.	PROPN
chd-169	988	15	(	(	PUNCT
chd-169	988	16	2011b	2011b	NUM
chd-169	988	17	)	)	PUNCT
chd-169	988	18	.	.	PUNCT
chd-169	989	1	control	control	NOUN
chd-169	989	2	of	of	ADP
chd-169	989	3	nuclear	nuclear	ADJ
chd-169	989	4	receptor	receptor	NOUN
chd-169	989	5	function	function	NOUN
chd-169	989	6	by	by	ADP
chd-169	989	7	local	local	ADJ
chd-169	989	8	chromatin	chromatin	NOUN
chd-169	989	9	structure	structure	NOUN
chd-169	989	10	.	.	PUNCT
chd-169	990	1	febs	febs	PROPN
chd-169	990	2	j	j	PROPN
chd-169	990	3	278	278	NUM
chd-169	990	4	,	,	PUNCT
chd-169	990	5	2211	2211	NUM
chd-169	990	6	-	-	SYM
chd-169	990	7	2230	2230	NUM
chd-169	990	8	.	.	PUNCT
chd-169	991	1	williams	williams	PROPN
chd-169	991	2	,	,	PUNCT
chd-169	991	3	d.r	d.r	PROPN
chd-169	991	4	.	.	PROPN
chd-169	991	5	(	(	PUNCT
chd-169	991	6	2003	2003	NUM
chd-169	991	7	)	)	PUNCT
chd-169	991	8	.	.	PUNCT
chd-169	992	1	the	the	DET
chd-169	992	2	health	health	NOUN
chd-169	992	3	of	of	ADP
chd-169	992	4	men	man	NOUN
chd-169	992	5	:	:	PUNCT
chd-169	992	6	structured	structured	ADJ
chd-169	992	7	inequalities	inequality	NOUN
chd-169	992	8	and	and	CCONJ
chd-169	992	9	opportunities	opportunity	NOUN
chd-169	992	10	.	.	PUNCT
chd-169	993	1	am	be	AUX
chd-169	993	2	j	j	PROPN
chd-169	993	3	public	public	ADJ
chd-169	993	4	health	health	NOUN
chd-169	993	5	93	93	NUM
chd-169	993	6	,	,	PUNCT
chd-169	993	7	724	724	NUM
chd-169	993	8	-	-	SYM
chd-169	993	9	731	731	NUM
chd-169	993	10	.	.	PUNCT
chd-169	994	1	williams	williams	PROPN
chd-169	994	2	,	,	PUNCT
chd-169	994	3	d.r	d.r	PROPN
chd-169	994	4	.	.	PROPN
chd-169	994	5	,	,	PUNCT
chd-169	994	6	and	and	CCONJ
chd-169	994	7	collins	collins	PROPN
chd-169	994	8	,	,	PUNCT
chd-169	994	9	c.	c.	PROPN
chd-169	994	10	(	(	PUNCT
chd-169	994	11	2001	2001	NUM
chd-169	994	12	)	)	PUNCT
chd-169	994	13	.	.	PUNCT
chd-169	995	1	racial	racial	ADJ
chd-169	995	2	residential	residential	ADJ
chd-169	995	3	segregation	segregation	NOUN
chd-169	995	4	:	:	PUNCT
chd-169	995	5	a	a	DET
chd-169	995	6	fundamental	fundamental	ADJ
chd-169	995	7	cause	cause	NOUN
chd-169	995	8	of	of	ADP
chd-169	995	9	racial	racial	ADJ
chd-169	995	10	disparities	disparity	NOUN
chd-169	995	11	in	in	ADP
chd-169	995	12	health	health	NOUN
chd-169	995	13	.	.	PUNCT
chd-169	996	1	public	public	ADJ
chd-169	996	2	health	health	NOUN
chd-169	996	3	reports	report	NOUN
chd-169	996	4	(	(	PUNCT
chd-169	996	5	washington	washington	PROPN
chd-169	996	6	,	,	PUNCT
chd-169	996	7	dc	dc	PROPN
chd-169	996	8	:	:	PUNCT
chd-169	996	9	1974	1974	NUM
chd-169	996	10	)	)	PUNCT
chd-169	996	11	116	116	NUM
chd-169	996	12	,	,	PUNCT
chd-169	996	13	404	404	NUM
chd-169	996	14	-	-	SYM
chd-169	996	15	416	416	NUM
chd-169	996	16	.	.	PUNCT
chd-169	997	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-169	997	2	e30	e30	PROPN
chd-169	997	3	cancer	cancer	NOUN
chd-169	997	4	health	health	NOUN
chd-169	997	5	disparities	disparity	NOUN
chd-169	997	6	research	research	PROPN
chd-169	997	7	williams	williams	PROPN
chd-169	997	8	,	,	PUNCT
chd-169	997	9	d.r	d.r	PROPN
chd-169	997	10	.	.	PROPN
chd-169	997	11	,	,	PUNCT
chd-169	997	12	mohammed	mohammed	PROPN
chd-169	997	13	,	,	PUNCT
chd-169	997	14	s.a	s.a	PROPN
chd-169	997	15	.	.	PROPN
chd-169	997	16	,	,	PUNCT
chd-169	997	17	leavell	leavell	PROPN
chd-169	997	18	,	,	PUNCT
chd-169	997	19	j.	j.	PROPN
chd-169	997	20	,	,	PUNCT
chd-169	997	21	and	and	CCONJ
chd-169	997	22	collins	collins	PROPN
chd-169	997	23	,	,	PUNCT
chd-169	997	24	c.	c.	PROPN
chd-169	997	25	(	(	PUNCT
chd-169	997	26	2010	2010	NUM
chd-169	997	27	)	)	PUNCT
chd-169	997	28	.	.	PUNCT
chd-169	998	1	race	race	NOUN
chd-169	998	2	,	,	PUNCT
chd-169	998	3	socioeconomic	socioeconomic	ADJ
chd-169	998	4	status	status	NOUN
chd-169	998	5	,	,	PUNCT
chd-169	998	6	and	and	CCONJ
chd-169	998	7	health	health	NOUN
chd-169	998	8	:	:	PUNCT
chd-169	998	9	complexities	complexity	NOUN
chd-169	998	10	,	,	PUNCT
chd-169	998	11	ongoing	ongoing	ADJ
chd-169	998	12	challenges	challenge	NOUN
chd-169	998	13	,	,	PUNCT
chd-169	998	14	and	and	CCONJ
chd-169	998	15	research	research	NOUN
chd-169	998	16	opportunities	opportunity	NOUN
chd-169	998	17	.	.	PUNCT
chd-169	999	1	ann	ann	PROPN
chd-169	999	2	n	n	PROPN
chd-169	999	3	y	y	PROPN
chd-169	999	4	acad	acad	PROPN
chd-169	999	5	sci	sci	PROPN
chd-169	999	6	1186	1186	NUM
chd-169	999	7	,	,	PUNCT
chd-169	999	8	69	69	NUM
chd-169	999	9	-	-	SYM
chd-169	999	10	101	101	NUM
chd-169	999	11	.	.	PUNCT
chd-169	1000	1	williams	williams	PROPN
chd-169	1000	2	,	,	PUNCT
chd-169	1000	3	d.r	d.r	PROPN
chd-169	1000	4	.	.	PROPN
chd-169	1000	5	,	,	PUNCT
chd-169	1000	6	and	and	CCONJ
chd-169	1000	7	sternthal	sternthal	ADJ
chd-169	1000	8	,	,	PUNCT
chd-169	1000	9	m.	m.	NOUN
chd-169	1000	10	(	(	PUNCT
chd-169	1000	11	2010	2010	NUM
chd-169	1000	12	)	)	PUNCT
chd-169	1000	13	.	.	PUNCT
chd-169	1001	1	understanding	understand	VERB
chd-169	1001	2	racialethnic	racialethnic	ADJ
chd-169	1001	3	disparities	disparity	NOUN
chd-169	1001	4	in	in	ADP
chd-169	1001	5	health	health	NOUN
chd-169	1001	6	:	:	PUNCT
chd-169	1001	7	sociological	sociological	ADJ
chd-169	1001	8	contributions	contribution	NOUN
chd-169	1001	9	.	.	PUNCT
chd-169	1002	1	j	j	PROPN
chd-169	1002	2	health	health	PROPN
chd-169	1002	3	soc	soc	NOUN
chd-169	1002	4	behav	behav	VERB
chd-169	1002	5	51	51	NUM
chd-169	1002	6	suppl	suppl	PROPN
chd-169	1002	7	,	,	PUNCT
chd-169	1002	8	s15	s15	PROPN
chd-169	1002	9	-	-	PUNCT
chd-169	1002	10	27	27	NUM
chd-169	1002	11	.	.	PUNCT
chd-169	1003	1	williamson	williamson	PROPN
chd-169	1003	2	,	,	PUNCT
chd-169	1003	3	m.	m.	NOUN
chd-169	1003	4	,	,	PUNCT
chd-169	1003	5	garg	garg	PROPN
chd-169	1003	6	,	,	PUNCT
chd-169	1003	7	r.	r.	PROPN
chd-169	1003	8	,	,	PUNCT
chd-169	1003	9	and	and	CCONJ
chd-169	1003	10	wells	wells	PROPN
chd-169	1003	11	,	,	PUNCT
chd-169	1003	12	c.m	c.m	PROPN
chd-169	1003	13	.	.	PROPN
chd-169	1003	14	(	(	PUNCT
chd-169	1003	15	2019	2019	NUM
chd-169	1003	16	)	)	PUNCT
chd-169	1003	17	.	.	PUNCT
chd-169	1004	1	plexinb1	plexinb1	PROPN
chd-169	1004	2	promotes	promote	VERB
chd-169	1004	3	nuclear	nuclear	ADJ
chd-169	1004	4	translocation	translocation	NOUN
chd-169	1004	5	of	of	ADP
chd-169	1004	6	the	the	DET
chd-169	1004	7	glucocorticoid	glucocorticoid	ADJ
chd-169	1004	8	receptor	receptor	NOUN
chd-169	1004	9	.	.	PUNCT
chd-169	1005	1	cells	cell	NOUN
chd-169	1005	2	9	9	NUM
chd-169	1005	3	.	.	PUNCT
chd-169	1006	1	woods	wood	NOUN
chd-169	1006	2	-	-	PUNCT
chd-169	1006	3	burnham	burnham	PROPN
chd-169	1006	4	,	,	PUNCT
chd-169	1006	5	l.	l.	PROPN
chd-169	1006	6	,	,	PUNCT
chd-169	1006	7	cajigas	cajigas	PROPN
chd-169	1006	8	-	-	PUNCT
chd-169	1006	9	du	du	PROPN
chd-169	1006	10	ross	ross	PROPN
chd-169	1006	11	,	,	PUNCT
chd-169	1006	12	c.k	c.k	PROPN
chd-169	1006	13	.	.	PROPN
chd-169	1006	14	,	,	PUNCT
chd-169	1006	15	love	love	PROPN
chd-169	1006	16	,	,	PUNCT
chd-169	1006	17	a.	a.	PROPN
chd-169	1006	18	,	,	PUNCT
chd-169	1006	19	basu	basu	PROPN
chd-169	1006	20	,	,	PUNCT
chd-169	1006	21	a.	a.	PROPN
chd-169	1006	22	,	,	PUNCT
chd-169	1006	23	sanchez	sanchez	PROPN
chd-169	1006	24	-	-	PUNCT
chd-169	1006	25	hernandez	hernandez	PROPN
chd-169	1006	26	,	,	PUNCT
chd-169	1006	27	e.s	e.s	PROPN
chd-169	1006	28	.	.	PROPN
chd-169	1006	29	,	,	PUNCT
chd-169	1006	30	martinez	martinez	PROPN
chd-169	1006	31	,	,	PUNCT
chd-169	1006	32	s.r	s.r	PROPN
chd-169	1006	33	.	.	PROPN
chd-169	1006	34	,	,	PUNCT
chd-169	1006	35	ortizhernandez	ortizhernandez	PROPN
chd-169	1006	36	,	,	PUNCT
chd-169	1006	37	g.l	g.l	PROPN
chd-169	1006	38	.	.	PROPN
chd-169	1006	39	,	,	PUNCT
chd-169	1006	40	stiel	stiel	PROPN
chd-169	1006	41	,	,	PUNCT
chd-169	1006	42	l.	l.	PROPN
chd-169	1006	43	,	,	PUNCT
chd-169	1006	44	duran	duran	PROPN
chd-169	1006	45	,	,	PUNCT
chd-169	1006	46	a.m.	a.m.	ADV
chd-169	1006	47	,	,	PUNCT
chd-169	1006	48	wilson	wilson	PROPN
chd-169	1006	49	,	,	PUNCT
chd-169	1006	50	c.	c.	PROPN
chd-169	1006	51	,	,	PUNCT
chd-169	1006	52	et	et	PROPN
chd-169	1006	53	al	al	PROPN
chd-169	1006	54	.	.	PUNCT
chd-169	1006	55	(	(	PUNCT
chd-169	1006	56	2018a	2018a	NUM
chd-169	1006	57	)	)	PUNCT
chd-169	1006	58	.	.	PUNCT
chd-169	1007	1	glucocorticoids	glucocorticoid	NOUN
chd-169	1007	2	induce	induce	VERB
chd-169	1007	3	stress	stress	ADJ
chd-169	1007	4	oncoproteins	oncoprotein	NOUN
chd-169	1007	5	associated	associate	VERB
chd-169	1007	6	with	with	ADP
chd-169	1007	7	therapy	therapy	NOUN
chd-169	1007	8	-	-	PUNCT
chd-169	1007	9	resistance	resistance	NOUN
chd-169	1007	10	in	in	ADP
chd-169	1007	11	african	african	ADJ
chd-169	1007	12	american	american	ADJ
chd-169	1007	13	and	and	CCONJ
chd-169	1007	14	european	european	ADJ
chd-169	1007	15	american	american	ADJ
chd-169	1007	16	prostate	prostate	NOUN
chd-169	1007	17	cancer	cancer	NOUN
chd-169	1007	18	cells	cell	NOUN
chd-169	1007	19	.	.	PUNCT
chd-169	1008	1	sci	sci	PROPN
chd-169	1008	2	rep	rep	PROPN
chd-169	1008	3	.	.	PROPN
chd-169	1008	4	woods	woods	PROPN
chd-169	1008	5	-	-	PUNCT
chd-169	1008	6	burnham	burnham	PROPN
chd-169	1008	7	,	,	PUNCT
chd-169	1008	8	l.	l.	PROPN
chd-169	1008	9	,	,	PUNCT
chd-169	1008	10	stiel	stiel	PROPN
chd-169	1008	11	,	,	PUNCT
chd-169	1008	12	l.	l.	PROPN
chd-169	1008	13	,	,	PUNCT
chd-169	1008	14	wilson	wilson	PROPN
chd-169	1008	15	,	,	PUNCT
chd-169	1008	16	c.	c.	PROPN
chd-169	1008	17	,	,	PUNCT
chd-169	1008	18	montgomery	montgomery	PROPN
chd-169	1008	19	,	,	PUNCT
chd-169	1008	20	s.	s.	PROPN
chd-169	1008	21	,	,	PUNCT
chd-169	1008	22	duran	duran	PROPN
chd-169	1008	23	,	,	PUNCT
chd-169	1008	24	a.m.	a.m.	ADV
chd-169	1008	25	,	,	PUNCT
chd-169	1008	26	ruckle	ruckle	NOUN
chd-169	1008	27	,	,	PUNCT
chd-169	1008	28	h.r	h.r	PROPN
chd-169	1008	29	.	.	PROPN
chd-169	1008	30	,	,	PUNCT
chd-169	1008	31	thompson	thompson	PROPN
chd-169	1008	32	,	,	PUNCT
chd-169	1008	33	r.a	r.a	PROPN
chd-169	1008	34	.	.	PROPN
chd-169	1008	35	,	,	PUNCT
chd-169	1008	36	de	de	PROPN
chd-169	1008	37	leon	leon	PROPN
chd-169	1008	38	,	,	PUNCT
chd-169	1008	39	m.	m.	NOUN
chd-169	1008	40	,	,	PUNCT
chd-169	1008	41	and	and	CCONJ
chd-169	1008	42	casiano	casiano	PROPN
chd-169	1008	43	,	,	PUNCT
chd-169	1008	44	c.a	c.a	PROPN
chd-169	1008	45	.	.	PROPN
chd-169	1008	46	(	(	PUNCT
chd-169	1008	47	2018b	2018b	NUM
chd-169	1008	48	)	)	PUNCT
chd-169	1008	49	.	.	PUNCT
chd-169	1009	1	physician	physician	NOUN
chd-169	1009	2	consultations	consultation	NOUN
chd-169	1009	3	,	,	PUNCT
chd-169	1009	4	prostate	prostate	NOUN
chd-169	1009	5	cancer	cancer	NOUN
chd-169	1009	6	knowledge	knowledge	NOUN
chd-169	1009	7	,	,	PUNCT
chd-169	1009	8	and	and	CCONJ
chd-169	1009	9	psa	psa	VERB
chd-169	1009	10	screening	screening	NOUN
chd-169	1009	11	of	of	ADP
chd-169	1009	12	african	african	ADJ
chd-169	1009	13	american	american	ADJ
chd-169	1009	14	men	man	NOUN
chd-169	1009	15	in	in	ADP
chd-169	1009	16	the	the	DET
chd-169	1009	17	era	era	NOUN
chd-169	1009	18	of	of	ADP
chd-169	1009	19	shared	shared	ADJ
chd-169	1009	20	decisionmaking	decisionmaking	NOUN
chd-169	1009	21	.	.	PUNCT
chd-169	1009	22	am	be	AUX
chd-169	1009	23	j	j	PROPN
chd-169	1009	24	mens	mens	PROPN
chd-169	1009	25	health	health	PROPN
chd-169	1009	26	,	,	PUNCT
chd-169	1009	27	1557988318763673	1557988318763673	NUM
chd-169	1009	28	.	.	PUNCT
chd-169	1010	1	yamoah	yamoah	PROPN
chd-169	1010	2	,	,	PUNCT
chd-169	1010	3	k.	k.	PROPN
chd-169	1010	4	,	,	PUNCT
chd-169	1010	5	johnson	johnson	PROPN
chd-169	1010	6	,	,	PUNCT
chd-169	1010	7	m.h	m.h	PROPN
chd-169	1010	8	.	.	PROPN
chd-169	1010	9	,	,	PUNCT
chd-169	1010	10	choeurng	choeurng	PROPN
chd-169	1010	11	,	,	PUNCT
chd-169	1010	12	v.	v.	ADV
chd-169	1010	13	,	,	PUNCT
chd-169	1010	14	faisal	faisal	NOUN
chd-169	1010	15	,	,	PUNCT
chd-169	1010	16	f.a	f.a	PROPN
chd-169	1010	17	.	.	PROPN
chd-169	1010	18	,	,	PUNCT
chd-169	1010	19	yousefi	yousefi	PROPN
chd-169	1010	20	,	,	PUNCT
chd-169	1010	21	k.	k.	PROPN
chd-169	1010	22	,	,	PUNCT
chd-169	1010	23	haddad	haddad	PROPN
chd-169	1010	24	,	,	PUNCT
chd-169	1010	25	z.	z.	PROPN
chd-169	1010	26	,	,	PUNCT
chd-169	1010	27	ross	ross	PROPN
chd-169	1010	28	,	,	PUNCT
chd-169	1010	29	a.e	a.e	PROPN
chd-169	1010	30	.	.	PROPN
chd-169	1010	31	,	,	PUNCT
chd-169	1010	32	alshalafa	alshalafa	PROPN
chd-169	1010	33	,	,	PUNCT
chd-169	1010	34	m.	m.	NOUN
chd-169	1010	35	,	,	PUNCT
chd-169	1010	36	den	den	PROPN
chd-169	1010	37	,	,	PUNCT
chd-169	1010	38	r.	r.	PROPN
chd-169	1010	39	,	,	PUNCT
chd-169	1010	40	lal	lal	PROPN
chd-169	1010	41	,	,	PUNCT
chd-169	1010	42	p.	p.	PROPN
chd-169	1010	43	,	,	PUNCT
chd-169	1010	44	et	et	PROPN
chd-169	1010	45	al	al	PROPN
chd-169	1010	46	.	.	PUNCT
chd-169	1011	1	(	(	PUNCT
chd-169	1011	2	2015	2015	NUM
chd-169	1011	3	)	)	PUNCT
chd-169	1011	4	.	.	PUNCT
chd-169	1012	1	novel	novel	NOUN
chd-169	1012	2	biomarker	biomarker	NOUN
chd-169	1012	3	signature	signature	NOUN
chd-169	1012	4	that	that	PRON
chd-169	1012	5	may	may	AUX
chd-169	1012	6	predict	predict	VERB
chd-169	1012	7	aggressive	aggressive	ADJ
chd-169	1012	8	disease	disease	NOUN
chd-169	1012	9	in	in	ADP
chd-169	1012	10	african	african	ADJ
chd-169	1012	11	american	american	ADJ
chd-169	1012	12	men	man	NOUN
chd-169	1012	13	with	with	ADP
chd-169	1012	14	prostate	prostate	NOUN
chd-169	1012	15	cancer	cancer	NOUN
chd-169	1012	16	.	.	PUNCT
chd-169	1013	1	j	j	PROPN
chd-169	1013	2	clin	clin	PROPN
chd-169	1013	3	oncol	oncol	PROPN
chd-169	1013	4	33	33	NUM
chd-169	1013	5	,	,	PUNCT
chd-169	1013	6	2789	2789	NUM
chd-169	1013	7	-	-	SYM
chd-169	1013	8	2796	2796	NUM
chd-169	1013	9	.	.	PUNCT
chd-169	1014	1	yancik	yancik	PROPN
chd-169	1014	2	,	,	PUNCT
chd-169	1014	3	r.	r.	PROPN
chd-169	1014	4	,	,	PUNCT
chd-169	1014	5	wesley	wesley	PROPN
chd-169	1014	6	,	,	PUNCT
chd-169	1014	7	m.n	m.n	PROPN
chd-169	1014	8	.	.	PROPN
chd-169	1014	9	,	,	PUNCT
chd-169	1014	10	ries	ries	PROPN
chd-169	1014	11	,	,	PUNCT
chd-169	1014	12	l.a	l.a	PROPN
chd-169	1014	13	.	.	PROPN
chd-169	1014	14	,	,	PUNCT
chd-169	1014	15	havlik	havlik	PROPN
chd-169	1014	16	,	,	PUNCT
chd-169	1014	17	r.j	r.j	PROPN
chd-169	1014	18	.	.	PROPN
chd-169	1014	19	,	,	PUNCT
chd-169	1014	20	long	long	ADV
chd-169	1014	21	,	,	PUNCT
chd-169	1014	22	s.	s.	PROPN
chd-169	1014	23	,	,	PUNCT
chd-169	1014	24	edwards	edwards	PROPN
chd-169	1014	25	,	,	PUNCT
chd-169	1014	26	b.k	b.k	PROPN
chd-169	1014	27	.	.	PROPN
chd-169	1014	28	,	,	PUNCT
chd-169	1014	29	and	and	CCONJ
chd-169	1014	30	yates	yates	PROPN
chd-169	1014	31	,	,	PUNCT
chd-169	1014	32	j.w	j.w	PROPN
chd-169	1014	33	.	.	PROPN
chd-169	1014	34	(	(	PUNCT
chd-169	1014	35	1998	1998	NUM
chd-169	1014	36	)	)	PUNCT
chd-169	1014	37	.	.	PUNCT
chd-169	1015	1	comorbidity	comorbidity	NOUN
chd-169	1015	2	and	and	CCONJ
chd-169	1015	3	age	age	NOUN
chd-169	1015	4	as	as	ADP
chd-169	1015	5	predictors	predictor	NOUN
chd-169	1015	6	of	of	ADP
chd-169	1015	7	risk	risk	NOUN
chd-169	1015	8	for	for	ADP
chd-169	1015	9	early	early	ADJ
chd-169	1015	10	mortality	mortality	NOUN
chd-169	1015	11	of	of	ADP
chd-169	1015	12	male	male	ADJ
chd-169	1015	13	and	and	CCONJ
chd-169	1015	14	female	female	ADJ
chd-169	1015	15	colon	colon	NOUN
chd-169	1015	16	carcinoma	carcinoma	NOUN
chd-169	1015	17	patients	patient	NOUN
chd-169	1015	18	:	:	PUNCT
chd-169	1015	19	a	a	DET
chd-169	1015	20	population	population	NOUN
chd-169	1015	21	-	-	PUNCT
chd-169	1015	22	based	base	VERB
chd-169	1015	23	study	study	NOUN
chd-169	1015	24	.	.	PUNCT
chd-169	1016	1	cancer	cancer	NOUN
chd-169	1016	2	82	82	NUM
chd-169	1016	3	,	,	PUNCT
chd-169	1016	4	2123	2123	NUM
chd-169	1016	5	-	-	SYM
chd-169	1016	6	2134	2134	NUM
chd-169	1016	7	.	.	PUNCT
chd-169	1017	1	yang	yang	PROPN
chd-169	1017	2	,	,	PUNCT
chd-169	1017	3	l.	l.	PROPN
chd-169	1017	4	,	,	PUNCT
chd-169	1017	5	yeh	yeh	PROPN
chd-169	1017	6	,	,	PUNCT
chd-169	1017	7	s.d	s.d	PROPN
chd-169	1017	8	.	.	PROPN
chd-169	1017	9	,	,	PUNCT
chd-169	1017	10	xie	xie	PROPN
chd-169	1017	11	,	,	PUNCT
chd-169	1017	12	s.	s.	PROPN
chd-169	1017	13	,	,	PUNCT
chd-169	1017	14	altuwaijri	altuwaijri	VERB
chd-169	1017	15	,	,	PUNCT
chd-169	1017	16	s.	s.	PROPN
chd-169	1017	17	,	,	PUNCT
chd-169	1017	18	ni	ni	PROPN
chd-169	1017	19	,	,	PUNCT
chd-169	1017	20	j.	j.	PROPN
chd-169	1017	21	,	,	PUNCT
chd-169	1017	22	hu	hu	PROPN
chd-169	1017	23	,	,	PUNCT
chd-169	1017	24	y.c	y.c	PROPN
chd-169	1017	25	.	.	PROPN
chd-169	1017	26	,	,	PUNCT
chd-169	1017	27	chen	chen	PROPN
chd-169	1017	28	,	,	PUNCT
chd-169	1017	29	y.t	y.t	PROPN
chd-169	1017	30	.	.	PROPN
chd-169	1017	31	,	,	PUNCT
chd-169	1017	32	bao	bao	PROPN
chd-169	1017	33	,	,	PUNCT
chd-169	1017	34	b.y	b.y	PROPN
chd-169	1017	35	.	.	PROPN
chd-169	1017	36	,	,	PUNCT
chd-169	1017	37	su	su	PROPN
chd-169	1017	38	,	,	PUNCT
chd-169	1017	39	c.h	c.h	PROPN
chd-169	1017	40	.	.	PROPN
chd-169	1017	41	,	,	PUNCT
chd-169	1017	42	and	and	CCONJ
chd-169	1017	43	chang	chang	PROPN
chd-169	1017	44	,	,	PUNCT
chd-169	1017	45	c.	c.	PROPN
chd-169	1017	46	(	(	PUNCT
chd-169	1017	47	2004	2004	NUM
chd-169	1017	48	)	)	PUNCT
chd-169	1017	49	.	.	PUNCT
chd-169	1018	1	androgen	androgen	NOUN
chd-169	1018	2	suppresses	suppress	VERB
chd-169	1018	3	pml	pml	NOUN
chd-169	1018	4	protein	protein	NOUN
chd-169	1018	5	expression	expression	NOUN
chd-169	1018	6	in	in	ADP
chd-169	1018	7	prostate	prostate	NOUN
chd-169	1018	8	cancer	cancer	NOUN
chd-169	1018	9	cwr22r	cwr22r	NOUN
chd-169	1018	10	cells	cell	NOUN
chd-169	1018	11	.	.	PUNCT
chd-169	1019	1	biochem	biochem	PROPN
chd-169	1019	2	biophys	biophys	PROPN
chd-169	1019	3	res	res	PROPN
chd-169	1019	4	commun	commun	PROPN
chd-169	1019	5	314	314	NUM
chd-169	1019	6	,	,	PUNCT
chd-169	1019	7	6975	6975	NUM
chd-169	1019	8	.	.	PUNCT
chd-169	1020	1	yeager	yeager	PROPN
chd-169	1020	2	,	,	PUNCT
chd-169	1020	3	m.	m.	PROPN
chd-169	1020	4	,	,	PUNCT
chd-169	1020	5	orr	orr	PROPN
chd-169	1020	6	,	,	PUNCT
chd-169	1020	7	n.	n.	PROPN
chd-169	1020	8	,	,	PUNCT
chd-169	1020	9	hayes	hayes	PROPN
chd-169	1020	10	,	,	PUNCT
chd-169	1020	11	r.b	r.b	PROPN
chd-169	1020	12	.	.	PROPN
chd-169	1020	13	,	,	PUNCT
chd-169	1020	14	jacobs	jacobs	PROPN
chd-169	1020	15	,	,	PUNCT
chd-169	1020	16	k.b	k.b	PROPN
chd-169	1020	17	.	.	PROPN
chd-169	1020	18	,	,	PUNCT
chd-169	1020	19	kraft	kraft	PROPN
chd-169	1020	20	,	,	PUNCT
chd-169	1020	21	p.	p.	NOUN
chd-169	1020	22	,	,	PUNCT
chd-169	1020	23	wacholder	wacholder	NOUN
chd-169	1020	24	,	,	PUNCT
chd-169	1020	25	s.	s.	PROPN
chd-169	1020	26	,	,	PUNCT
chd-169	1020	27	minichiello	minichiello	PROPN
chd-169	1020	28	,	,	PUNCT
chd-169	1020	29	m.j	m.j	PROPN
chd-169	1020	30	.	.	PROPN
chd-169	1020	31	,	,	PUNCT
chd-169	1020	32	fearnhead	fearnhead	NOUN
chd-169	1020	33	,	,	PUNCT
chd-169	1020	34	p.	p.	PROPN
chd-169	1020	35	,	,	PUNCT
chd-169	1020	36	yu	yu	PROPN
chd-169	1020	37	,	,	PUNCT
chd-169	1020	38	k.	k.	PROPN
chd-169	1020	39	,	,	PUNCT
chd-169	1020	40	chatterjee	chatterjee	PROPN
chd-169	1020	41	,	,	PUNCT
chd-169	1020	42	n.	n.	PROPN
chd-169	1020	43	,	,	PUNCT
chd-169	1020	44	et	et	PROPN
chd-169	1020	45	al	al	PROPN
chd-169	1020	46	.	.	PUNCT
chd-169	1020	47	(	(	PUNCT
chd-169	1020	48	2007	2007	NUM
chd-169	1020	49	)	)	PUNCT
chd-169	1020	50	.	.	PUNCT
chd-169	1021	1	genome	genome	NOUN
chd-169	1021	2	-	-	PUNCT
chd-169	1021	3	wide	wide	ADJ
chd-169	1021	4	association	association	NOUN
chd-169	1021	5	study	study	NOUN
chd-169	1021	6	of	of	ADP
chd-169	1021	7	prostate	prostate	NOUN
chd-169	1021	8	cancer	cancer	NOUN
chd-169	1021	9	identifies	identify	VERB
chd-169	1021	10	a	a	DET
chd-169	1021	11	second	second	ADJ
chd-169	1021	12	risk	risk	NOUN
chd-169	1021	13	locus	locus	NOUN
chd-169	1021	14	at	at	ADP
chd-169	1021	15	8q24	8q24	NOUN
chd-169	1021	16	.	.	PUNCT
chd-169	1022	1	nat	nat	PROPN
chd-169	1022	2	genet	genet	PROPN
chd-169	1022	3	39	39	NUM
chd-169	1022	4	,	,	PUNCT
chd-169	1022	5	645	645	NUM
chd-169	1022	6	-	-	SYM
chd-169	1022	7	649	649	NUM
chd-169	1022	8	.	.	PUNCT
chd-169	1023	1	young	young	ADJ
chd-169	1023	2	,	,	PUNCT
chd-169	1023	3	r.f	r.f	PROPN
chd-169	1023	4	.	.	PROPN
chd-169	1023	5	,	,	PUNCT
chd-169	1023	6	waller	waller	PROPN
chd-169	1023	7	,	,	PUNCT
chd-169	1023	8	j.b	j.b	PROPN
chd-169	1023	9	.	.	PROPN
chd-169	1023	10	,	,	PUNCT
chd-169	1023	11	jr	jr	PROPN
chd-169	1023	12	.	.	PROPN
chd-169	1023	13	,	,	PUNCT
chd-169	1023	14	and	and	CCONJ
chd-169	1023	15	kahana	kahana	PROPN
chd-169	1023	16	,	,	PUNCT
chd-169	1023	17	e.	e.	PROPN
chd-169	1023	18	(	(	PUNCT
chd-169	1023	19	1991	1991	NUM
chd-169	1023	20	)	)	PUNCT
chd-169	1023	21	.	.	PUNCT
chd-169	1024	1	racial	racial	ADJ
chd-169	1024	2	and	and	CCONJ
chd-169	1024	3	socioeconomic	socioeconomic	ADJ
chd-169	1024	4	aspects	aspect	NOUN
chd-169	1024	5	of	of	ADP
chd-169	1024	6	myocardial	myocardial	ADJ
chd-169	1024	7	infarction	infarction	NOUN
chd-169	1024	8	recovery	recovery	NOUN
chd-169	1024	9	:	:	PUNCT
chd-169	1024	10	studying	study	VERB
chd-169	1024	11	confounds	confound	VERB
chd-169	1024	12	.	.	PUNCT
chd-169	1025	1	am	be	AUX
chd-169	1025	2	j	j	PROPN
chd-169	1025	3	prev	prev	X
chd-169	1025	4	med	me	VERB
chd-169	1025	5	7	7	NUM
chd-169	1025	6	,	,	PUNCT
chd-169	1025	7	438	438	NUM
chd-169	1025	8	-	-	SYM
chd-169	1025	9	444	444	NUM
chd-169	1025	10	.	.	PUNCT
chd-169	1026	1	yuan	yuan	NOUN
chd-169	1026	2	,	,	PUNCT
chd-169	1026	3	j.	j.	PROPN
chd-169	1026	4	,	,	PUNCT
chd-169	1026	5	kensler	kensler	PROPN
chd-169	1026	6	,	,	PUNCT
chd-169	1026	7	k.h	k.h	PROPN
chd-169	1026	8	.	.	PROPN
chd-169	1026	9	,	,	PUNCT
chd-169	1026	10	hu	hu	PROPN
chd-169	1026	11	,	,	PUNCT
chd-169	1026	12	z.	z.	PROPN
chd-169	1026	13	,	,	PUNCT
chd-169	1026	14	zhang	zhang	PROPN
chd-169	1026	15	,	,	PUNCT
chd-169	1026	16	y.	y.	PROPN
chd-169	1026	17	,	,	PUNCT
chd-169	1026	18	zhang	zhang	PROPN
chd-169	1026	19	,	,	PUNCT
chd-169	1026	20	t.	t.	PROPN
chd-169	1026	21	,	,	PUNCT
chd-169	1026	22	jiang	jiang	PROPN
chd-169	1026	23	,	,	PUNCT
chd-169	1026	24	j.	j.	PROPN
chd-169	1026	25	,	,	PUNCT
chd-169	1026	26	xu	xu	PROPN
chd-169	1026	27	,	,	PUNCT
chd-169	1026	28	m.	m.	NOUN
chd-169	1026	29	,	,	PUNCT
chd-169	1026	30	pan	pan	PROPN
chd-169	1026	31	,	,	PUNCT
chd-169	1026	32	y.	y.	PROPN
chd-169	1026	33	,	,	PUNCT
chd-169	1026	34	long	long	ADV
chd-169	1026	35	,	,	PUNCT
chd-169	1026	36	m.	m.	NOUN
chd-169	1026	37	,	,	PUNCT
chd-169	1026	38	montone	montone	PROPN
chd-169	1026	39	,	,	PUNCT
chd-169	1026	40	k.t	k.t	PROPN
chd-169	1026	41	.	.	PROPN
chd-169	1026	42	,	,	PUNCT
chd-169	1026	43	et	et	PROPN
chd-169	1026	44	al	al	PROPN
chd-169	1026	45	.	.	PROPN
chd-169	1026	46	(	(	PUNCT
chd-169	1026	47	2020	2020	NUM
chd-169	1026	48	)	)	PUNCT
chd-169	1026	49	.	.	PUNCT
chd-169	1027	1	integrative	integrative	ADJ
chd-169	1027	2	comparison	comparison	NOUN
chd-169	1027	3	of	of	ADP
chd-169	1027	4	the	the	DET
chd-169	1027	5	genomic	genomic	NOUN
chd-169	1027	6	and	and	CCONJ
chd-169	1027	7	transcriptomic	transcriptomic	ADJ
chd-169	1027	8	landscape	landscape	NOUN
chd-169	1027	9	between	between	ADP
chd-169	1027	10	prostate	prostate	NOUN
chd-169	1027	11	cancer	cancer	NOUN
chd-169	1027	12	patients	patient	NOUN
chd-169	1027	13	of	of	ADP
chd-169	1027	14	predominantly	predominantly	ADV
chd-169	1027	15	african	african	ADJ
chd-169	1027	16	or	or	CCONJ
chd-169	1027	17	european	european	ADJ
chd-169	1027	18	genetic	genetic	ADJ
chd-169	1027	19	ancestry	ancestry	NOUN
chd-169	1027	20	.	.	PUNCT
chd-169	1028	1	plos	plos	PROPN
chd-169	1028	2	genet	genet	PROPN
chd-169	1028	3	16	16	NUM
chd-169	1028	4	,	,	PUNCT
chd-169	1028	5	e1008641	e1008641	PROPN
chd-169	1028	6	.	.	PROPN
chd-169	1028	7	zalachoras	zalachoras	PROPN
chd-169	1028	8	,	,	PUNCT
chd-169	1028	9	i.	i.	PROPN
chd-169	1028	10	,	,	PUNCT
chd-169	1028	11	verhoeve	verhoeve	INTJ
chd-169	1028	12	,	,	PUNCT
chd-169	1028	13	s.l	s.l	PROPN
chd-169	1028	14	.	.	PROPN
chd-169	1028	15	,	,	PUNCT
chd-169	1028	16	toonen	toonen	PROPN
chd-169	1028	17	,	,	PUNCT
chd-169	1028	18	l.j	l.j	PROPN
chd-169	1028	19	.	.	PROPN
chd-169	1028	20	,	,	PUNCT
chd-169	1028	21	van	van	PROPN
chd-169	1028	22	weert	weert	PROPN
chd-169	1028	23	,	,	PUNCT
chd-169	1028	24	l.t	l.t	PROPN
chd-169	1028	25	.	.	PROPN
chd-169	1028	26	,	,	PUNCT
chd-169	1028	27	van	van	PROPN
chd-169	1028	28	vlodrop	vlodrop	NOUN
chd-169	1028	29	,	,	PUNCT
chd-169	1028	30	a.m.	a.m.	ADV
chd-169	1028	31	,	,	PUNCT
chd-169	1028	32	mol	mol	PROPN
chd-169	1028	33	,	,	PUNCT
chd-169	1028	34	i.m	i.m	PROPN
chd-169	1028	35	.	.	PROPN
chd-169	1028	36	,	,	PUNCT
chd-169	1028	37	meelis	meelis	PROPN
chd-169	1028	38	,	,	PUNCT
chd-169	1028	39	w.	w.	PROPN
chd-169	1028	40	,	,	PUNCT
chd-169	1028	41	de	de	PROPN
chd-169	1028	42	kloet	kloet	NOUN
chd-169	1028	43	,	,	PUNCT
chd-169	1028	44	e.r	e.r	PROPN
chd-169	1028	45	.	.	PROPN
chd-169	1028	46	,	,	PUNCT
chd-169	1028	47	and	and	CCONJ
chd-169	1028	48	meijer	meijer	NOUN
chd-169	1028	49	,	,	PUNCT
chd-169	1028	50	o.c	o.c	PROPN
chd-169	1028	51	.	.	PROPN
chd-169	1028	52	(	(	PUNCT
chd-169	1028	53	2016	2016	NUM
chd-169	1028	54	)	)	PUNCT
chd-169	1028	55	.	.	PUNCT
chd-169	1029	1	isoform	isoform	NOUN
chd-169	1029	2	switching	switching	NOUN
chd-169	1029	3	of	of	ADP
chd-169	1029	4	steroid	steroid	NOUN
chd-169	1029	5	receptor	receptor	NOUN
chd-169	1029	6	co	co	VERB
chd-169	1029	7	-	-	NOUN
chd-169	1029	8	activator-1	activator-1	NUM
chd-169	1029	9	attenuates	attenuate	VERB
chd-169	1029	10	glucocorticoid	glucocorticoid	NOUN
chd-169	1029	11	-	-	PUNCT
chd-169	1029	12	induced	induce	VERB
chd-169	1029	13	anxiogenic	anxiogenic	ADJ
chd-169	1029	14	amygdala	amygdala	NOUN
chd-169	1029	15	crh	crh	PROPN
chd-169	1029	16	expression	expression	NOUN
chd-169	1029	17	.	.	PUNCT
chd-169	1030	1	mol	mol	ADP
chd-169	1030	2	psychiatry	psychiatry	NOUN
chd-169	1030	3	21	21	NUM
chd-169	1030	4	,	,	PUNCT
chd-169	1030	5	1733	1733	NUM
chd-169	1030	6	-	-	SYM
chd-169	1030	7	1739	1739	NUM
chd-169	1030	8	.	.	PUNCT
chd-169	1031	1	zannas	zannas	PROPN
chd-169	1031	2	,	,	PUNCT
chd-169	1031	3	a.s	a.s	PROPN
chd-169	1031	4	.	.	PROPN
chd-169	1031	5	,	,	PUNCT
chd-169	1031	6	arloth	arloth	PROPN
chd-169	1031	7	,	,	PUNCT
chd-169	1031	8	j.	j.	PROPN
chd-169	1031	9	,	,	PUNCT
chd-169	1031	10	carrillo	carrillo	PROPN
chd-169	1031	11	-	-	PUNCT
chd-169	1031	12	roa	roa	PROPN
chd-169	1031	13	,	,	PUNCT
chd-169	1031	14	t.	t.	PROPN
chd-169	1031	15	,	,	PUNCT
chd-169	1031	16	iurato	iurato	PROPN
chd-169	1031	17	,	,	PUNCT
chd-169	1031	18	s.	s.	PROPN
chd-169	1031	19	,	,	PUNCT
chd-169	1031	20	roh	roh	PROPN
chd-169	1031	21	,	,	PUNCT
chd-169	1031	22	s.	s.	PROPN
chd-169	1031	23	,	,	PUNCT
chd-169	1031	24	ressler	ressler	PROPN
chd-169	1031	25	,	,	PUNCT
chd-169	1031	26	k.j	k.j	PROPN
chd-169	1031	27	.	.	PROPN
chd-169	1031	28	,	,	PUNCT
chd-169	1031	29	nemeroff	nemeroff	PROPN
chd-169	1031	30	,	,	PUNCT
chd-169	1031	31	c.b	c.b	PROPN
chd-169	1031	32	.	.	PROPN
chd-169	1031	33	,	,	PUNCT
chd-169	1031	34	smith	smith	PROPN
chd-169	1031	35	,	,	PUNCT
chd-169	1031	36	a.k	a.k	PROPN
chd-169	1031	37	.	.	PROPN
chd-169	1031	38	,	,	PUNCT
chd-169	1031	39	bradley	bradley	PROPN
chd-169	1031	40	,	,	PUNCT
chd-169	1031	41	b.	b.	PROPN
chd-169	1031	42	,	,	PUNCT
chd-169	1031	43	heim	heim	PROPN
chd-169	1031	44	,	,	PUNCT
chd-169	1031	45	c.	c.	PROPN
chd-169	1031	46	,	,	PUNCT
chd-169	1031	47	et	et	PROPN
chd-169	1031	48	al	al	PROPN
chd-169	1031	49	.	.	PUNCT
chd-169	1031	50	(	(	PUNCT
chd-169	1031	51	2015	2015	NUM
chd-169	1031	52	)	)	PUNCT
chd-169	1031	53	.	.	PUNCT
chd-169	1032	1	lifetime	lifetime	NOUN
chd-169	1032	2	stress	stress	NOUN
chd-169	1032	3	accelerates	accelerate	VERB
chd-169	1032	4	epigenetic	epigenetic	ADJ
chd-169	1032	5	aging	aging	NOUN
chd-169	1032	6	in	in	ADP
chd-169	1032	7	an	an	DET
chd-169	1032	8	urban	urban	ADJ
chd-169	1032	9	,	,	PUNCT
chd-169	1032	10	african	african	ADJ
chd-169	1032	11	american	american	ADJ
chd-169	1032	12	cohort	cohort	NOUN
chd-169	1032	13	:	:	PUNCT
chd-169	1032	14	relevance	relevance	NOUN
chd-169	1032	15	of	of	ADP
chd-169	1032	16	glucocorticoid	glucocorticoid	ADJ
chd-169	1032	17	signaling	signaling	NOUN
chd-169	1032	18	.	.	PUNCT
chd-169	1033	1	genome	genome	NOUN
chd-169	1033	2	biol	biol	NOUN
chd-169	1033	3	16	16	NUM
chd-169	1033	4	,	,	PUNCT
chd-169	1033	5	266	266	NUM
chd-169	1033	6	.	.	PUNCT
chd-169	1034	1	zannas	zannas	PROPN
chd-169	1034	2	,	,	PUNCT
chd-169	1034	3	a.s	a.s	PROPN
chd-169	1034	4	.	.	PROPN
chd-169	1034	5	,	,	PUNCT
chd-169	1034	6	and	and	CCONJ
chd-169	1034	7	west	west	PROPN
chd-169	1034	8	,	,	PUNCT
chd-169	1034	9	a.e	a.e	PROPN
chd-169	1034	10	.	.	PROPN
chd-169	1034	11	(	(	PUNCT
chd-169	1034	12	2014	2014	NUM
chd-169	1034	13	)	)	PUNCT
chd-169	1034	14	.	.	PUNCT
chd-169	1035	1	epigenetics	epigenetic	NOUN
chd-169	1035	2	and	and	CCONJ
chd-169	1035	3	the	the	DET
chd-169	1035	4	regulation	regulation	NOUN
chd-169	1035	5	of	of	ADP
chd-169	1035	6	stress	stress	NOUN
chd-169	1035	7	vulnerability	vulnerability	NOUN
chd-169	1035	8	and	and	CCONJ
chd-169	1035	9	resilience	resilience	NOUN
chd-169	1035	10	.	.	PUNCT
chd-169	1036	1	neuroscience	neuroscience	NOUN
chd-169	1036	2	264	264	NUM
chd-169	1036	3	,	,	PUNCT
chd-169	1036	4	157	157	NUM
chd-169	1036	5	-	-	SYM
chd-169	1036	6	170	170	NUM
chd-169	1036	7	.	.	PUNCT
chd-169	1037	1	zeng	zeng	PROPN
chd-169	1037	2	,	,	PUNCT
chd-169	1037	3	c.	c.	PROPN
chd-169	1037	4	,	,	PUNCT
chd-169	1037	5	wen	wen	PROPN
chd-169	1037	6	,	,	PUNCT
chd-169	1037	7	w.	w.	PROPN
chd-169	1037	8	,	,	PUNCT
chd-169	1037	9	morgans	morgans	PROPN
chd-169	1037	10	,	,	PUNCT
chd-169	1037	11	a.k	a.k	PROPN
chd-169	1037	12	.	.	PROPN
chd-169	1037	13	,	,	PUNCT
chd-169	1037	14	pao	pao	PROPN
chd-169	1037	15	,	,	PUNCT
chd-169	1037	16	w.	w.	PROPN
chd-169	1037	17	,	,	PUNCT
chd-169	1037	18	shu	shu	PROPN
chd-169	1037	19	,	,	PUNCT
chd-169	1037	20	x.o	x.o	PROPN
chd-169	1037	21	.	.	PROPN
chd-169	1037	22	,	,	PUNCT
chd-169	1037	23	and	and	CCONJ
chd-169	1037	24	zheng	zheng	PROPN
chd-169	1037	25	,	,	PUNCT
chd-169	1037	26	w.	w.	PROPN
chd-169	1037	27	(	(	PUNCT
chd-169	1037	28	2015	2015	NUM
chd-169	1037	29	)	)	PUNCT
chd-169	1037	30	.	.	PUNCT
chd-169	1038	1	disparities	disparity	NOUN
chd-169	1038	2	by	by	ADP
chd-169	1038	3	race	race	NOUN
chd-169	1038	4	,	,	PUNCT
chd-169	1038	5	age	age	NOUN
chd-169	1038	6	,	,	PUNCT
chd-169	1038	7	and	and	CCONJ
chd-169	1038	8	sex	sex	NOUN
chd-169	1038	9	in	in	ADP
chd-169	1038	10	the	the	DET
chd-169	1038	11	improvement	improvement	NOUN
chd-169	1038	12	of	of	ADP
chd-169	1038	13	survival	survival	NOUN
chd-169	1038	14	for	for	ADP
chd-169	1038	15	major	major	ADJ
chd-169	1038	16	cancers	cancer	NOUN
chd-169	1038	17	:	:	PUNCT
chd-169	1038	18	results	result	NOUN
chd-169	1038	19	from	from	ADP
chd-169	1038	20	the	the	DET
chd-169	1038	21	national	national	PROPN
chd-169	1038	22	cancer	cancer	PROPN
chd-169	1038	23	institute	institute	PROPN
chd-169	1038	24	surveillance	surveillance	NOUN
chd-169	1038	25	,	,	PUNCT
chd-169	1038	26	epidemiology	epidemiology	NOUN
chd-169	1038	27	,	,	PUNCT
chd-169	1038	28	and	and	CCONJ
chd-169	1038	29	end	end	VERB
chd-169	1038	30	results	result	NOUN
chd-169	1038	31	(	(	PUNCT
chd-169	1038	32	seer	seer	NOUN
chd-169	1038	33	)	)	PUNCT
chd-169	1038	34	program	program	NOUN
chd-169	1038	35	in	in	ADP
chd-169	1038	36	the	the	DET
chd-169	1038	37	united	united	PROPN
chd-169	1038	38	states	states	PROPN
chd-169	1038	39	,	,	PUNCT
chd-169	1038	40	1990	1990	NUM
chd-169	1038	41	to	to	ADP
chd-169	1038	42	2010	2010	NUM
chd-169	1038	43	.	.	PUNCT
chd-169	1039	1	jama	jama	PROPN
chd-169	1039	2	oncol	oncol	ADJ
chd-169	1039	3	1	1	NUM
chd-169	1039	4	,	,	PUNCT
chd-169	1039	5	88	88	NUM
chd-169	1039	6	-	-	SYM
chd-169	1039	7	96	96	NUM
chd-169	1039	8	.	.	PUNCT
chd-169	1040	1	zhao	zhao	PROPN
chd-169	1040	2	,	,	PUNCT
chd-169	1040	3	b.	b.	PROPN
chd-169	1040	4	,	,	PUNCT
chd-169	1040	5	choi	choi	PROPN
chd-169	1040	6	,	,	PUNCT
chd-169	1040	7	j.p	j.p	PROPN
chd-169	1040	8	.	.	PROPN
chd-169	1040	9	,	,	PUNCT
chd-169	1040	10	jaehne	jaehne	PROPN
chd-169	1040	11	,	,	PUNCT
chd-169	1040	12	m.	m.	NOUN
chd-169	1040	13	,	,	PUNCT
chd-169	1040	14	gao	gao	PROPN
chd-169	1040	15	,	,	PUNCT
chd-169	1040	16	y.r	y.r	PROPN
chd-169	1040	17	.	.	PROPN
chd-169	1040	18	,	,	PUNCT
chd-169	1040	19	desai	desai	PROPN
chd-169	1040	20	,	,	PUNCT
chd-169	1040	21	r.	r.	PROPN
chd-169	1040	22	,	,	PUNCT
chd-169	1040	23	tuckermann	tuckermann	PROPN
chd-169	1040	24	,	,	PUNCT
chd-169	1040	25	j.	j.	PROPN
chd-169	1040	26	,	,	PUNCT
chd-169	1040	27	zhou	zhou	PROPN
chd-169	1040	28	,	,	PUNCT
chd-169	1040	29	h.	h.	PROPN
chd-169	1040	30	,	,	PUNCT
chd-169	1040	31	handelsman	handelsman	PROPN
chd-169	1040	32	,	,	PUNCT
chd-169	1040	33	d.j	d.j	PROPN
chd-169	1040	34	.	.	PROPN
chd-169	1040	35	,	,	PUNCT
chd-169	1040	36	and	and	CCONJ
chd-169	1040	37	simanainen	simanainen	NOUN
chd-169	1040	38	,	,	PUNCT
chd-169	1040	39	u.	u.	PROPN
chd-169	1040	40	(	(	PUNCT
chd-169	1040	41	2014	2014	NUM
chd-169	1040	42	)	)	PUNCT
chd-169	1040	43	.	.	PUNCT
chd-169	1041	1	glucocorticoid	glucocorticoid	ADJ
chd-169	1041	2	receptor	receptor	NOUN
chd-169	1041	3	in	in	ADP
chd-169	1041	4	prostate	prostate	NOUN
chd-169	1041	5	epithelia	epithelium	NOUN
chd-169	1041	6	is	be	AUX
chd-169	1041	7	not	not	PART
chd-169	1041	8	required	require	VERB
chd-169	1041	9	for	for	ADP
chd-169	1041	10	corticosteroidinduced	corticosteroidinduce	VERB
chd-169	1041	11	epithelial	epithelial	ADJ
chd-169	1041	12	hyperproliferation	hyperproliferation	NOUN
chd-169	1041	13	in	in	ADP
chd-169	1041	14	the	the	DET
chd-169	1041	15	mouse	mouse	NOUN
chd-169	1041	16	prostate	prostate	NOUN
chd-169	1041	17	.	.	PUNCT
chd-169	1042	1	prostate	prostate	NOUN
chd-169	1042	2	74	74	NUM
chd-169	1042	3	,	,	PUNCT
chd-169	1042	4	1068	1068	NUM
chd-169	1042	5	-	-	SYM
chd-169	1042	6	1078	1078	NUM
chd-169	1042	7	.	.	PUNCT